0001561032-23-000020.txt : 20231113 0001561032-23-000020.hdr.sgml : 20231113 20231113071647 ACCESSION NUMBER: 0001561032-23-000020 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Trust, Inc. CENTRAL INDEX KEY: 0001561032 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383888962 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39153 FILM NUMBER: 231395075 BUSINESS ADDRESS: STREET 1: 222 BELLEVUE AVENUE CITY: NEWPORT STATE: RI ZIP: 02840 BUSINESS PHONE: 212-415-6500 MAIL ADDRESS: STREET 1: 222 BELLEVUE AVENUE CITY: NEWPORT STATE: RI ZIP: 02840 FORMER COMPANY: FORMER CONFORMED NAME: American Realty Capital Healthcare Trust II, Inc. DATE OF NAME CHANGE: 20121025 10-Q 1 hct-20230930.htm 10-Q hct-20230930
000156103212/312023Q3FALSEP6M0.0833P3Yhttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent00015610322023-01-012023-09-300001561032dei:FormerAddressMember2023-01-012023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2023-01-012023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2023-01-012023-09-3000015610322023-11-06xbrli:shares00015610322023-09-30iso4217:USD00015610322022-12-310001561032us-gaap:RelatedPartyMember2023-09-300001561032us-gaap:RelatedPartyMember2022-12-31xbrli:pure0001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-12-31iso4217:USDxbrli:shares0001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-12-3100015610322023-07-012023-09-3000015610322022-07-012022-09-3000015610322022-01-012022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-12-310001561032us-gaap:CommonStockMember2022-12-310001561032us-gaap:AdditionalPaidInCapitalMember2022-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001561032us-gaap:RetainedEarningsMember2022-12-310001561032us-gaap:ParentMember2022-12-310001561032us-gaap:NoncontrollingInterestMember2022-12-310001561032us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001561032us-gaap:ParentMember2023-01-012023-09-300001561032us-gaap:CommonStockMember2023-01-012023-09-300001561032us-gaap:RetainedEarningsMember2023-01-012023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2023-01-012023-09-300001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2023-01-012023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2023-01-012023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:ParentMember2023-01-012023-09-300001561032us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2023-09-300001561032us-gaap:CommonStockMember2023-09-300001561032us-gaap:AdditionalPaidInCapitalMember2023-09-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001561032us-gaap:RetainedEarningsMember2023-09-300001561032us-gaap:ParentMember2023-09-300001561032us-gaap:NoncontrollingInterestMember2023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2023-06-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2023-06-300001561032us-gaap:CommonStockMember2023-06-300001561032us-gaap:AdditionalPaidInCapitalMember2023-06-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001561032us-gaap:RetainedEarningsMember2023-06-300001561032us-gaap:ParentMember2023-06-300001561032us-gaap:NoncontrollingInterestMember2023-06-3000015610322023-06-300001561032us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001561032us-gaap:ParentMember2023-07-012023-09-300001561032us-gaap:CommonStockMember2023-07-012023-09-300001561032us-gaap:RetainedEarningsMember2023-07-012023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2023-07-012023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2023-07-012023-09-300001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2023-07-012023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2023-07-012023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2023-07-012023-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:ParentMember2023-07-012023-09-300001561032us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2021-12-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2021-12-310001561032us-gaap:CommonStockMember2021-12-310001561032us-gaap:AdditionalPaidInCapitalMember2021-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001561032us-gaap:RetainedEarningsMember2021-12-310001561032us-gaap:ParentMember2021-12-310001561032us-gaap:NoncontrollingInterestMember2021-12-3100015610322021-12-310001561032us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001561032us-gaap:ParentMember2022-01-012022-09-300001561032us-gaap:CommonStockMember2022-01-012022-09-300001561032us-gaap:RetainedEarningsMember2022-01-012022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2022-01-012022-09-300001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-01-012022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2022-01-012022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:ParentMember2022-01-012022-09-300001561032us-gaap:NoncontrollingInterestMember2022-01-012022-09-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-09-300001561032us-gaap:CommonStockMember2022-09-300001561032us-gaap:AdditionalPaidInCapitalMember2022-09-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001561032us-gaap:RetainedEarningsMember2022-09-300001561032us-gaap:ParentMember2022-09-300001561032us-gaap:NoncontrollingInterestMember2022-09-3000015610322022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-06-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2022-06-300001561032us-gaap:CommonStockMember2022-06-300001561032us-gaap:AdditionalPaidInCapitalMember2022-06-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001561032us-gaap:RetainedEarningsMember2022-06-300001561032us-gaap:ParentMember2022-06-300001561032us-gaap:NoncontrollingInterestMember2022-06-3000015610322022-06-300001561032us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001561032us-gaap:ParentMember2022-07-012022-09-300001561032us-gaap:CommonStockMember2022-07-012022-09-300001561032us-gaap:RetainedEarningsMember2022-07-012022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-07-012022-09-300001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2022-07-012022-09-300001561032us-gaap:ParentMemberhct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2022-07-012022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2022-07-012022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:RetainedEarningsMember2022-07-012022-09-300001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:ParentMember2022-07-012022-09-300001561032us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-30hct:propertyhct:stateutr:sqfthct:segmenthct:contractor00015610322020-10-012023-09-3000015610322022-01-012022-12-3100015610322021-01-012021-12-3100015610322020-01-012020-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-09-300001561032srt:MinimumMember2023-01-012023-09-300001561032srt:MaximumMember2023-01-012023-09-300001561032us-gaap:BuildingMember2023-09-300001561032us-gaap:LandImprovementsMember2023-09-300001561032us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-09-300001561032srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-09-30hct:lease0001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-09-300001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-09-300001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-09-300001561032us-gaap:AboveMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-09-300001561032us-gaap:AboveMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-09-300001561032stpr:FLus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001561032stpr:FLus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300001561032us-gaap:SalesRevenueNetMemberstpr:PAus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001561032hct:InplaceLeasesandOtherIntangibleAssetsMemberhct:DepreciationandAmortizationExpenseMember2023-07-012023-09-300001561032hct:InplaceLeasesandOtherIntangibleAssetsMemberhct:DepreciationandAmortizationExpenseMember2022-07-012022-09-300001561032hct:InplaceLeasesandOtherIntangibleAssetsMemberhct:DepreciationandAmortizationExpenseMember2023-01-012023-09-300001561032hct:InplaceLeasesandOtherIntangibleAssetsMemberhct:DepreciationandAmortizationExpenseMember2022-01-012022-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:RentalIncomeMember2023-07-012023-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:RentalIncomeMember2022-07-012022-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:RentalIncomeMember2023-01-012023-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:RentalIncomeMember2022-01-012022-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:PropertyOperatingandMaintenanceExpenseMember2023-07-012023-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:PropertyOperatingandMaintenanceExpenseMember2022-07-012022-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:PropertyOperatingandMaintenanceExpenseMember2023-01-012023-09-300001561032hct:AboveandBelowMarketLeasesMemberhct:PropertyOperatingandMaintenanceExpenseMember2022-01-012022-09-300001561032us-gaap:LeasesAcquiredInPlaceMemberhct:AmortizationExpenseMember2023-09-300001561032us-gaap:OtherIntangibleAssetsMemberhct:AmortizationExpenseMember2023-09-300001561032hct:AmortizationExpenseMember2023-09-300001561032hct:RentalIncomeMemberus-gaap:AboveMarketLeasesMember2023-09-300001561032hct:RentalIncomeMemberhct:BelowMarketLeaseMember2023-09-300001561032hct:RentalIncomeMember2023-09-300001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2023-07-012023-09-300001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2023-01-012023-09-300001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2023-01-012023-09-300001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2023-09-300001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2022-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-01-012023-09-300001561032hct:TripleNetLeasedHealthcareFacilitiesMemberstpr:TXus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-07-010001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMember2021-12-310001561032stpr:TX2021-01-012021-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMember2022-01-012022-03-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:LaSallePropertiesMember2022-07-012022-09-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-09-300001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-07-012023-09-300001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-01-012023-09-300001561032hct:MOBPropertyIllinoisSkilledNursingFacilitiesMemberhct:MedicalOfficeBuildingsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-07-012022-09-300001561032hct:MOBPropertyIllinoisSkilledNursingFacilitiesMemberhct:MedicalOfficeBuildingsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-09-300001561032hct:MedicalOfficeBuildingsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-07-012022-09-300001561032hct:MedicalOfficeBuildingsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-09-300001561032hct:VariousSeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2022-07-012022-09-300001561032hct:VariousSeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-09-300001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2022-07-012022-09-300001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-09-300001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-07-012022-09-300001561032us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-09-300001561032hct:MOBPropertyIllinoisSkilledNursingFacilitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-09-300001561032hct:VariousSeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-09-300001561032hct:VariousSeniorsHousingCommunitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2023-01-012023-09-300001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatBryantBryantMember2023-09-300001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatBryantBryantMember2022-12-310001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatChenalLittleRockMember2023-09-300001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatChenalLittleRockMember2022-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMemberus-gaap:MortgagesMember2023-09-300001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMemberus-gaap:MortgagesMember2022-12-310001561032us-gaap:MortgagesMemberhct:MOBLoanMember2023-09-300001561032us-gaap:MortgagesMemberhct:MOBLoanMember2022-12-310001561032hct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2023-09-300001561032hct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2022-12-310001561032us-gaap:MortgagesMemberhct:ShilohIllinoisMember2023-09-300001561032us-gaap:MortgagesMemberhct:ShilohIllinoisMember2022-12-310001561032us-gaap:MortgagesMemberhct:BMOMOBLoanMember2023-09-300001561032us-gaap:MortgagesMemberhct:BMOMOBLoanMember2022-12-310001561032us-gaap:MortgagesMemberhct:BarclaysMOBLoanMember2023-09-300001561032us-gaap:MortgagesMemberhct:BarclaysMOBLoanMember2022-12-310001561032us-gaap:MortgagesMember2023-09-300001561032us-gaap:MortgagesMember2022-12-310001561032hct:LIBORBasedInterestRateSwapMemberhct:MOBLoanMember2022-12-310001561032hct:LIBORBasedInterestRateSwapMemberhct:MOBLoanMember2023-09-300001561032us-gaap:MortgagesMemberhct:BarclaysMOBLoanMember2023-05-240001561032us-gaap:MortgagesMemberhct:BarclaysMOBLoanMember2023-05-242023-05-240001561032us-gaap:RevolvingCreditFacilityMember2023-05-242023-05-240001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-09-300001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2022-12-310001561032us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-09-300001561032us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2022-12-310001561032us-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-09-30hct:encumberedProperty0001561032hct:PriorCreditFacilityMember2023-09-300001561032hct:PriorCreditFacilityMember2022-12-310001561032hct:CapitalOneFacilityMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-09-300001561032hct:CapitalOneFacilityMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:KeyBankFacilityMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-09-300001561032hct:KeyBankFacilityMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-09-300001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:CapitalOneFacilityMemberhct:MasterCreditFacilityMember2023-09-300001561032hct:KeyBankFacilityMemberhct:MasterCreditFacilityMember2023-09-300001561032us-gaap:InterestRateCapMemberhct:MasterCreditFacilityMember2023-09-30hct:instrument0001561032us-gaap:InterestRateCapMemberhct:CapitalOneFacilityMemberhct:MasterCreditFacilityMember2023-09-300001561032hct:KeyBankFacilityMemberus-gaap:InterestRateCapMemberhct:MasterCreditFacilityMember2023-09-300001561032us-gaap:InterestRateCapMemberhct:CapitalOneFacilityMemberhct:MasterCreditFacilityMember2022-12-310001561032hct:KeyBankFacilityMemberus-gaap:InterestRateCapMemberhct:MasterCreditFacilityMember2022-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2022-01-012022-12-310001561032us-gaap:SecuredDebtMemberhct:SOFRBasedInterestRateSwapMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:CapitalOneFacilityMemberhct:MasterCreditFacilityMemberhct:LIBORBasedInterestRateSwapMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:MortgageNotePayableMemberhct:SOFRBasedInterestRateSwapMember2023-09-300001561032hct:MasterCreditFacilityMember2023-09-300001561032hct:UnencumberedPropertiesMember2023-09-300001561032hct:SecuredOvernightFinancingRateSOFRMembersrt:MinimumMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-01-012023-09-300001561032srt:MaximumMemberhct:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-01-012023-09-300001561032us-gaap:BaseRateMembersrt:MinimumMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-01-012023-09-300001561032srt:MaximumMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-01-012023-09-300001561032us-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-07-012023-09-300001561032us-gaap:LineOfCreditMemberhct:PriorCreditFacilityMember2023-01-012023-09-30hct:derivative0001561032hct:LondonInterbankOfferedRateOneMonthMemberhct:CapitalOneFacilityMemberhct:MasterCreditFacilityMember2023-01-012023-09-300001561032hct:KeyBankFacilityMemberhct:LondonInterbankOfferedRateOneMonthMemberhct:MasterCreditFacilityMember2023-01-012023-09-300001561032hct:CapitalOneFacilityMemberhct:MasterCreditFacilityMemberhct:SecuredOvernightFinancingRateOneMonthMember2023-01-012023-09-300001561032hct:KeyBankFacilityMemberhct:MasterCreditFacilityMemberhct:SecuredOvernightFinancingRateOneMonthMember2023-01-012023-09-300001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-07-012023-09-300001561032hct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-07-012023-07-310001561032us-gaap:SubsequentEventMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-10-012023-11-130001561032us-gaap:SubsequentEventMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-11-130001561032us-gaap:LineOfCreditMember2023-09-300001561032hct:MasterCreditFacilityMemberhct:SOFRBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:InterestRateCapMemberus-gaap:NondesignatedMember2023-09-300001561032us-gaap:SecuredDebtMemberhct:LIBORBasedInterestRateSwapMemberus-gaap:LineOfCreditMember2022-12-310001561032hct:LIBORBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001561032us-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001561032us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001561032us-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001561032us-gaap:FairValueMeasurementsRecurringMember2023-09-300001561032us-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032us-gaap:FairValueMeasurementsRecurringMember2022-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2023-09-300001561032hct:MedicalOfficeBuildingsMemberhct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2023-09-300001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001561032hct:FannieCreditFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001561032hct:FannieCreditFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001561032hct:FannieCreditFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001561032hct:FannieCreditFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001561032us-gaap:InterestRateSwapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:InterestRateSwapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:InterestRateCapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:NondesignatedMember2023-09-300001561032us-gaap:InterestRateCapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:NondesignatedMember2022-12-310001561032hct:SOFRBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032hct:SOFRBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032hct:LIBORBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032hct:LIBORBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001561032us-gaap:InterestRateSwapMember2023-07-012023-09-300001561032us-gaap:InterestRateSwapMember2022-07-012022-09-300001561032us-gaap:InterestRateSwapMember2023-01-012023-09-300001561032us-gaap:InterestRateSwapMember2022-01-012022-09-300001561032us-gaap:MortgagesMemberhct:MOBLoanMember2017-06-300001561032us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-10-012019-12-310001561032us-gaap:InterestRateSwapMemberhct:MOBLoanMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-10-012019-12-310001561032us-gaap:InterestExpenseMemberhct:MOBLoanMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-10-012019-12-310001561032us-gaap:InterestExpenseMemberhct:MOBLoanMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001561032hct:SOFRBasedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001561032us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001561032us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001561032us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001561032us-gaap:InterestRateCapMemberus-gaap:NondesignatedMember2022-12-310001561032us-gaap:InterestRateCapMemberhct:MasterCreditFacilityMember2023-01-012023-09-300001561032us-gaap:InterestRateCapMemberus-gaap:SubsequentEventMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-11-100001561032hct:InterestRateCapMaturingApril2024Member2023-09-300001561032us-gaap:InterestRateCapMemberhct:MasterCreditFacilityMember2022-12-3100015610322012-10-152022-12-3100015610322012-10-152023-09-3000015610322020-12-310001561032srt:MaximumMember2019-12-310001561032hct:PublicStockOfferingMember2019-12-3100015610322020-09-300001561032hct:PublicStockOfferingMember2021-05-310001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMemberhct:PublicStockOfferingMember2021-10-0400015610322018-03-012018-03-0100015610322020-10-012020-10-0100015610322021-01-042021-01-0400015610322021-04-022021-04-0200015610322021-07-012021-07-0100015610322021-10-012021-10-0100015610322022-01-032022-01-0300015610322022-04-012022-04-0100015610322022-07-012022-07-0100015610322022-10-032022-10-0300015610322023-01-032023-01-0300015610322023-04-032023-04-0300015610322023-07-032023-07-030001561032us-gaap:SubsequentEventMember2023-10-022023-10-020001561032hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMembersrt:AffiliatedEntityMemberhct:SpecialLimitedPartnerMember2023-09-300001561032hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMembersrt:AffiliatedEntityMemberhct:SpecialLimitedPartnerMember2022-12-310001561032hct:TaxDepreciationDeductionMembersrt:AffiliatedEntityMemberhct:AdvisorMember2023-09-3000015610322017-02-172017-02-170001561032hct:SecondAmendedandRestatedAdvisoryAgreementMember2017-02-172017-02-170001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2017-02-172017-02-170001561032hct:AdvanceOnLoanOrOtherInvestmentMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMemberhct:PreTaxNonCompoundedReturnOnCapitalContributionMemberhct:SpecialLimitedPartnerMemberhct:AnnualTargetedInvestorReturnMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ContractPurchasePriceMemberhct:AdvisorMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:AdvisorMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:MonthlyBaseManagementFeeMember2017-02-172017-02-170001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:QuarterlyVariableManagementFeeBenchmarkOneMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:QuarterlyVariableManagementFeeBenchmarkTwoMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMember2023-09-300001561032hct:GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMember2023-09-300001561032srt:MaximumMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:GrossRevenueManagedPropertiesMemberhct:AdvisorMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:AmendedandRestatedPropertyManagementandLeasingAgreementMember2017-02-172017-02-170001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvisorMember2023-01-012023-09-300001561032hct:ReimbursementsofAdministrativeServicesMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2023-07-012023-09-300001561032hct:ReimbursementsofAdministrativeServicesMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2023-01-012023-09-300001561032hct:ReimbursementsofAdministrativeServicesMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2022-07-012022-09-300001561032hct:ReimbursementsofAdministrativeServicesMemberus-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2022-01-012022-09-300001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMemberhct:ConsumerPriceIndexMember2019-07-252019-07-250001561032us-gaap:RelatedPartyMemberhct:CappedReimbursementAmountMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032us-gaap:RelatedPartyMemberhct:CappedReimbursementAmountMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:RealEstateCostMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032us-gaap:RelatedPartyMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMemberhct:AdvisorMember2019-07-252019-07-250001561032us-gaap:RelatedPartyMemberhct:AdvisorAndCompanyMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032us-gaap:RelatedPartyMemberhct:AcquisitionCostsReimbursementsMember2023-07-012023-09-300001561032us-gaap:RelatedPartyMemberhct:AcquisitionCostsReimbursementsMember2022-07-012022-09-300001561032us-gaap:RelatedPartyMemberhct:AcquisitionCostsReimbursementsMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:AcquisitionCostsReimbursementsMember2022-01-012022-09-300001561032us-gaap:RelatedPartyMemberhct:AcquisitionCostsReimbursementsMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:AcquisitionCostsReimbursementsMember2022-12-310001561032hct:AssetManagementFeesMemberus-gaap:RelatedPartyMember2023-07-012023-09-300001561032hct:AssetManagementFeesMemberus-gaap:RelatedPartyMember2022-07-012022-09-300001561032hct:AssetManagementFeesMemberus-gaap:RelatedPartyMember2023-01-012023-09-300001561032hct:AssetManagementFeesMemberus-gaap:RelatedPartyMember2022-01-012022-09-300001561032hct:AssetManagementFeesMemberus-gaap:RelatedPartyMember2023-09-300001561032hct:AssetManagementFeesMemberus-gaap:RelatedPartyMember2022-12-310001561032us-gaap:RelatedPartyMemberhct:PropertyManagementFeesMember2023-07-012023-09-300001561032us-gaap:RelatedPartyMemberhct:PropertyManagementFeesMember2022-07-012022-09-300001561032us-gaap:RelatedPartyMemberhct:PropertyManagementFeesMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:PropertyManagementFeesMember2022-01-012022-09-300001561032us-gaap:RelatedPartyMemberhct:PropertyManagementFeesMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:PropertyManagementFeesMember2022-12-310001561032us-gaap:RelatedPartyMemberhct:TransferAgentandOtherProfessionalFeesMember2023-07-012023-09-300001561032us-gaap:RelatedPartyMemberhct:TransferAgentandOtherProfessionalFeesMember2022-07-012022-09-300001561032us-gaap:RelatedPartyMemberhct:TransferAgentandOtherProfessionalFeesMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:TransferAgentandOtherProfessionalFeesMember2022-01-012022-09-300001561032us-gaap:RelatedPartyMemberhct:TransferAgentandOtherProfessionalFeesMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:TransferAgentandOtherProfessionalFeesMember2022-12-310001561032us-gaap:RelatedPartyMemberhct:OperationFeesAndReimbursementsMember2023-07-012023-09-300001561032us-gaap:RelatedPartyMemberhct:OperationFeesAndReimbursementsMember2022-07-012022-09-300001561032us-gaap:RelatedPartyMemberhct:OperationFeesAndReimbursementsMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:OperationFeesAndReimbursementsMember2022-01-012022-09-300001561032us-gaap:RelatedPartyMemberhct:OperationFeesAndReimbursementsMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:OperationFeesAndReimbursementsMember2022-12-310001561032us-gaap:RelatedPartyMemberhct:CappedReimbursementAmountMember2023-07-012023-09-300001561032us-gaap:RelatedPartyMemberhct:CappedReimbursementAmountMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:CappedReimbursementAmountMember2022-07-012022-09-300001561032us-gaap:RelatedPartyMemberhct:CappedReimbursementAmountMember2022-01-012022-09-300001561032us-gaap:RelatedPartyMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMemberhct:SpecialLimitedPartnerMemberhct:ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember2023-09-300001561032us-gaap:RelatedPartyMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMemberhct:NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMemberhct:SpecialLimitedPartnerMember2023-09-300001561032hct:SecondAmendedandRestatedAdvisoryAgreementMemberus-gaap:RelatedPartyMemberhct:AdvisorMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:TransitionFeeMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:SubjectFeesTransitionFeeNotinExcessoftheProductMember2023-01-012023-09-300001561032srt:MaximumMemberus-gaap:RelatedPartyMemberhct:SubjectFeesTransitionFeeNotinExcessoftheProductMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:ChangeinControlFeeMember2023-01-012023-09-300001561032us-gaap:RelatedPartyMemberhct:VariableManagementIncentiveFeeMember2023-01-012023-09-300001561032hct:MonthlyBaseManagementFeeMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2017-02-172017-02-170001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2023-01-012023-09-300001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2023-09-300001561032hct:RestrictedSharePlanMembersrt:MinimumMemberus-gaap:RestrictedStockMember2023-01-012023-09-300001561032srt:MaximumMemberhct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2023-01-012023-09-300001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2023-07-012023-09-300001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-07-012022-09-300001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-01-012022-09-300001561032srt:DirectorMember2023-01-012023-09-300001561032srt:DirectorMember2022-01-012022-09-300001561032hct:SeriesAPreferredUnitMember2023-09-300001561032hct:SeriesAPreferredUnitMember2022-12-310001561032hct:CommonOperatingPartnershipUnitMember2023-09-300001561032hct:CommonOperatingPartnershipUnitMember2022-12-310001561032us-gaap:NoncontrollingInterestMember2021-09-300001561032us-gaap:NoncontrollingInterestMember2014-11-300001561032hct:OpUnitsMember2023-01-012023-09-300001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2023-09-300001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMemberhct:HealthcareTrustOperatingPartnershipL.P.Member2023-09-300001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2022-12-310001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2023-07-012023-09-300001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2022-07-012022-09-300001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMember2023-01-012023-09-300001561032hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMemberus-gaap:NoncontrollingInterestMemberhct:HealthcareTrustOperatingPartnershipL.P.Member2022-12-310001561032us-gaap:RestrictedStockMember2023-07-012023-09-300001561032us-gaap:RestrictedStockMember2022-07-012022-09-300001561032us-gaap:RestrictedStockMember2023-01-012023-09-300001561032us-gaap:RestrictedStockMember2022-01-012022-09-300001561032hct:OpUnitsMember2023-07-012023-09-300001561032hct:OpUnitsMember2022-07-012022-09-300001561032hct:OpUnitsMember2022-01-012022-09-300001561032hct:ClassBUnitsMember2023-07-012023-09-300001561032hct:ClassBUnitsMember2022-07-012022-09-300001561032hct:ClassBUnitsMember2023-01-012023-09-300001561032hct:ClassBUnitsMember2022-01-012022-09-300001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2022-09-300001561032hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMemberhct:AdvisorMember2023-09-300001561032hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMemberhct:AdvisorMember2022-09-300001561032hct:MedicalOfficeBuildingsMember2023-07-012023-09-300001561032hct:SeniorsHousingCommunitiesMember2023-07-012023-09-300001561032hct:MedicalOfficeBuildingsMember2022-07-012022-09-300001561032hct:SeniorsHousingCommunitiesMember2022-07-012022-09-300001561032hct:MedicalOfficeBuildingsMember2023-01-012023-09-300001561032hct:SeniorsHousingCommunitiesMember2023-01-012023-09-300001561032hct:MedicalOfficeBuildingsMember2022-01-012022-09-300001561032hct:SeniorsHousingCommunitiesMember2022-01-012022-09-300001561032hct:MedicalOfficeBuildingsMember2023-09-300001561032hct:MedicalOfficeBuildingsMember2022-12-310001561032hct:SeniorsHousingCommunitiesMember2023-09-300001561032hct:SeniorsHousingCommunitiesMember2022-12-310001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2023-07-012023-09-300001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2022-07-012022-09-300001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2023-01-012023-09-300001561032us-gaap:OperatingSegmentsMemberhct:MedicalOfficeBuildingsMember2022-01-012022-09-300001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2023-07-012023-09-300001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2022-07-012022-09-300001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2023-01-012023-09-300001561032us-gaap:OperatingSegmentsMemberhct:SeniorsHousingCommunitiesMember2022-01-012022-09-300001561032us-gaap:OperatingSegmentsMember2023-07-012023-09-300001561032us-gaap:OperatingSegmentsMember2022-07-012022-09-300001561032us-gaap:OperatingSegmentsMember2023-01-012023-09-300001561032us-gaap:OperatingSegmentsMember2022-01-012022-09-300001561032us-gaap:InterestRateCapMemberus-gaap:SubsequentEventMemberhct:MasterCreditFacilityMemberus-gaap:LineOfCreditMember2023-10-012023-11-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to __________
Commission file number: 001-39153
hti2a18.jpg
Healthcare Trust, Inc.
(Exact name of registrant as specified in its charter)
Maryland38-3888962
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
222 Bellevue Ave., Newport, RI
02840
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (212) 415-6500
650 Fifth Ave., 30th Floor, New York, NY
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per shareHTIAThe Nasdaq Global Market
7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per shareHTIBPThe Nasdaq Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
1


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes No
As of November 6, 2023, the registrant had 111,545,038 shares of common stock outstanding.
2

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
`
Page

2




Part I — FINANCIAL INFORMATION

Item 1. Financial Statements.

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
September 30,
2023
December 31, 2022
ASSETS(Unaudited)(Unaudited)
Real estate investments, at cost:
Land$208,594 $206,454 
Buildings, fixtures and improvements2,119,797 2,089,133 
Acquired intangible assets293,295 292,034 
Total real estate investments, at cost2,621,686 2,587,621 
Less: accumulated depreciation and amortization(663,534)(609,324)
Total real estate investments, net1,958,152 1,978,297 
Cash and cash equivalents51,041 53,654 
Restricted cash40,245 22,884 
Derivative assets, at fair value37,547 40,647 
Straight-line rent receivable, net26,214 25,276 
Operating lease right-of-use assets7,739 7,814 
Prepaid expenses and other assets36,019 34,554 
Deferred costs, net15,300 17,223 
Total assets$2,172,257 $2,180,349 
LIABILITIES AND EQUITY  
Mortgage notes payable, net$808,752 $578,700 
Credit facilities, net347,720 530,297 
Market lease intangible liabilities, net8,519 9,407 
Accounts payable and accrued expenses (including $665 and $47, respectively, due to related parties as of September 30, 2023 and December 31, 2022)
48,234 45,247 
Operating lease liabilities8,051 8,087 
Deferred rent6,904 5,925 
Distributions payable3,496 3,496 
Total liabilities1,231,676 1,181,159 
Stockholders’ Equity
7.375% Series A cumulative redeemable perpetual preferred stock, $0.01 par value, 4,740,000 authorized; 3,977,144 issued and outstanding as of September 30, 2023 and December 31, 2022
40 40 
7.125% Series B cumulative redeemable perpetual preferred stock, $0.01 par value, 3,680,000 authorized; 3,630,000 issued and outstanding as of September 30, 2023 and December 31, 2022
36 36 
Common stock, $0.01 par value, 300,000,000 shares authorized, 109,877,212 shares and 105,080,531 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
1,098 1,051 
Additional paid-in capital2,485,745 2,417,059 
Accumulated other comprehensive income35,340 36,910 
Distributions in excess of accumulated earnings(1,588,261)(1,462,457)
Total stockholders’ equity933,998 992,639 
Non-controlling interests6,583 6,551 
Total equity940,581 999,190 
Total liabilities and equity$2,172,257 $2,180,349 

The accompanying notes are an integral part of these consolidated financial statements.
3

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
(Unaudited)


 Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Revenue from tenants$85,686 $83,460 $259,145 $250,936 
Operating expenses:   
Property operating and maintenance54,326 51,198 161,778 156,880 
Impairment charges 8,949  25,786 
Operating fees to related parties6,397 6,333 19,153 19,003 
Acquisition and transaction related173 199 384 1,153 
General and administrative4,753 4,471 14,105 13,369 
Depreciation and amortization20,776 20,854 61,520 61,525 
Total expenses
86,425 92,004 256,940 277,716 
Operating (loss) income before loss (gain) on sale of real estate investments(739)(8,544)2,205 (26,780)
(Loss) gain on sale of real estate investments(173)194 (364)(109)
Operating (loss) income(912)(8,350)1,841 (26,889)
Other income (expense):
Interest expense(15,720)(13,284)(50,208)(37,098)
Interest and other income
258 10 576 24 
Gain on non-designated derivatives406 1,826 510 3,212 
Total other expenses
(15,056)(11,448)(49,122)(33,862)
Loss before income taxes(15,968)(19,798)(47,281)(60,751)
Income tax expense(157)(77)(244)(159)
Net loss(16,125)(19,875)(47,525)(60,910)
Net loss attributable to non-controlling interests14 22 45 100 
Allocation for preferred stock(3,450)(3,450)(10,349)(10,349)
Net loss attributable to common stockholders(19,561)(23,303)(57,829)(71,159)
Other comprehensive income (loss):
   Unrealized gain (loss) on designated derivatives395 16,948 (1,570)53,384 
Comprehensive loss attributable to common stockholders$(19,166)$(6,355)$(59,399)$(17,775)
Weighted-average shares outstanding — Basic and Diluted (1)
111,426,241 111,365,461 111,404,655 111,333,801 
Net loss per common share attributable to common stockholders — Basic and Diluted (1)
$(0.18)$(0.21)$(0.52)$(0.64)
_____
(1)Retroactively adjusted for the effects of the stock dividends (see Note 1).

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands, except share data)
(Unaudited)


Nine Months Ended September 30, 2023
Series A Preferred StockSeries B Preferred StockCommon StockAccumulated Other Comprehensive Income
Number of
Shares
Par Value
Number of
Shares
Par ValueNumber of
Shares
Par Value Additional
Paid-in
Capital
Distributions in excess of accumulated earningsTotal Stockholders EquityNon-controlling InterestsTotal Equity
Balance, December 31, 20223,977,144 40 3,630,000 $36 105,080,531 $1,051 $2,417,059 $36,910 $(1,462,457)$992,639 $6,551 $999,190 
Share-based compensation, net— — — — — — 689 — — 689 — 689 
Distributions declared in common stock, $0.42 per share
— — — — 4,796,681 47 67,928 — (67,975) —  
Distributions declared on Series A Preferred Stock, $0.92 per share
— — — — — — — — (5,500)(5,500)— (5,500)
Distributions declared on Series B Preferred Stock, $0.90 per share
— — — — — — — — (4,849)(4,849)— (4,849)
Distributions to non-controlling interest holders— — — — — — — — — — (138)(138)
Net loss— — — — — — — — (47,480)(47,480)(45)(47,525)
Unrealized loss on designated derivatives— — — — — — — (1,570)— (1,570)— (1,570)
Contributions from minority interests— — — — — — — — — — 284 284 
Rebalancing of ownership percentage— — — — — — 69 — — 69 (69) 
Balance, September 30, 20233,977,144 $40 3,630,000 $36 109,877,212 $1,098 $2,485,745 $35,340 $(1,588,261)$933,998 $6,583 $940,581 




Three Months Ended September 30, 2023
Series A Preferred StockSeries B Preferred StockCommon StockAccumulated Other Comprehensive Income
Number of
Shares
Par Value
Number of
Shares
Par ValueNumber of
Shares
Par Value Additional
Paid-in
Capital
Distributions in excess of accumulated earningsTotal Stockholders EquityNon-controlling InterestsTotal Equity
Balance, June 30, 20233,977,144 $40 3,630,000 $36 108,284,434 $1,082 $2,462,523 $34,945 $(1,545,708)$952,918 $6,660 $959,578 
Share-based compensation, net— — — — — — 229 — — 229 — 229 
Distributions declared in common stock, $0.21 per share
— — — — 1,592,778 16 22,976 — (22,992) —  
Distributions declared on Series A Preferred Stock, $0.46 per share
— — — — — — — — (1,834)(1,834)— (1,834)
Distributions declared on Series B Preferred Stock, $0.45 per share
— — — — — — — — (1,616)(1,616)— (1,616)
Distributions to non-controlling interest holders— — — — — — — — — — (46)(46)
Net loss— — — — — — — — (16,111)(16,111)(14)(16,125)
Unrealized gain on designated derivatives— — — — — — — 395 — 395 — 395 
Rebalancing of ownership percentage— — — — — — 17 — — 17 (17) 
Balance, September 30, 20233,977,144 $40 3,630,000 $36 109,877,212 $1,098 $2,485,745 $35,340 $(1,588,261)$933,998 $6,583 $940,581 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
5

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands, except share data)
(Unaudited)


Nine Months Ended September 30, 2022
Series A Preferred StockSeries B Preferred StockCommon StockAccumulated Other Comprehensive (Loss) Income
Number of
Shares
Par ValueNumber of
Shares
Par ValueNumber of
Shares
Par ValueAdditional
Paid-in
Capital
Distributions in Excess of Accumulated EarningsTotal Stockholders EquityNon-controlling InterestsTotal Equity
Balance, December 31, 20213,977,144 $40 3,630,000 $36 99,281,754 $993 $2,329,839 $(14,341)$(1,282,871)$1,033,696 $6,704 $1,040,400 
Issuance of Preferred Stock, net— — — — — — (39)— — (39)— (39)
Share-based compensation, net— — — — — — 955 — — 955 — 955 
Distributions declared in common stock, $0.42 per share
— — — — 4,330,590 43 64,237 — (64,280) —  
Distributions declared on Series A Preferred Stock, $0.92 per share
— — — — — — — — (5,500)(5,500)— (5,500)
Distributions declared on Series B Preferred Stock, $0.90 per share
— — — — — — — — (4,850)(4,850)— (4,850)
Distributions to non-controlling interest holders— — — — — — — — — — (138)(138)
Net loss— — — — — — — — (60,810)(60,810)(100)(60,910)
Unrealized gain on designated derivatives— — — — — — — 53,384 — 53,384 — 53,384 
Rebalancing of ownership percentage— — — — — — (202)— — (202)202  
Balance, September 30, 20223,977,144 $40 3,630,000 $36 103,612,344 $1,036 $2,394,790 $39,043 $(1,418,311)$1,016,634 $6,668 $1,023,302 



Three Months Ended September 30, 2022
Series A Preferred StockSeries B Preferred StockCommon StockAccumulated Other Comprehensive Income
Number of
Shares
Par ValueNumber of
Shares
Par ValueNumber of
Shares
Par Value Additional
Paid-in
Capital
Distributions in Excess of Accumulated EarningsTotal Stockholders EquityNon-controlling InterestsTotal Equity
Balance, June 30, 20223,977,144 $40 3,630,000 $36 102,164,671 $1,022 $2,372,889 $22,095 $(1,373,296)$1,022,786 $6,677 $1,029,463 
Issuance of Preferred Stock, net— — — — — — (28)— — (28)— (28)
Share-based compensation, net— — — — — — 291 — — 291 — 291 
Distributions declared in common stock, $0.21 per share
— — — — 1,447,673 14 21,697 — (21,711) —  
Distributions declared on Series A Preferred Stock, $0.46 per share
— — — — — — — — (1,834)(1,834)— (1,834)
Distributions declared on Series B Preferred Stock, $0.45 per share
— — — — — — — — (1,617)(1,617)— (1,617)
Distributions to non-controlling interest holders— — — — — — — — — — (46)(46)
Net loss— — — — — — — — (19,853)(19,853)(22)(19,875)
Unrealized gain on designated derivatives— — — — — — — 16,948 — 16,948 — 16,948 
Rebalancing of ownership percentage— — — — — — (59)— — (59)59  
Balance, September 30, 20223,977,144 $40 3,630,000 $36 103,612,344 $1,036 $2,394,790 $39,043 $(1,418,311)$1,016,634 $6,668 $1,023,302 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
6

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
  
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended September 30,
20232022
Cash flows from operating activities: 
Net loss$(47,525)$(60,910)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization61,520 61,525 
Amortization of deferred financing costs5,954 3,542 
(Accretion) amortization of terminated swap (2,660)423 
Amortization of mortgage premiums and discounts, net69 28 
Accretion of market lease and other intangibles, net(675)(421)
Bad debt expense909 2,559 
Equity-based compensation689 955 
Loss on sale of real estate investments, net364 109 
Cash received from non-designated derivative instruments3,866  
Gain on non-designated derivative instruments(510)(3,212)
Impairment charges 25,786 
Changes in assets and liabilities:
Straight-line rent receivable(938)(1,236)
Prepaid expenses and other assets(4,180)(986)
Accounts payable, accrued expenses and other liabilities(1,504)(4,855)
Deferred rent979 (2,212)
Net cash provided by operating activities16,358 21,095 
Cash flows from investing activities:
Property acquisitions(35,261)(17,799)
Capital expenditures(13,998)(16,707)
Investments in non-designated interest rate caps(4,580) 
Proceeds from sales of real estate investments4,803 11,759 
Net cash used in investing activities(49,036)(22,747)
Cash flows from financing activities:
Payments on credit facilities(199,160) 
Proceeds from credit facilities20,000  
Proceeds from mortgage notes payable240,000  
Payments on mortgage notes payable(850)(8,329)
Proceeds from termination of derivative instruments5,413  
Payments of deferred financing costs(7,774)(858)
Payments for derivative instruments (39)
Preferred stock issuance costs (39)
Contributions from non-controlling interests284  
Dividends paid on Series A Preferred stock (5,500)(5,500)
Dividends paid on Series B Preferred stock(4,849)(4,849)
Distributions to non-controlling interest holders(138)(138)
Net cash provided by (used in) financing activities47,426 (19,752)
Net change in cash, cash equivalents and restricted cash14,748 (21,404)
Cash, cash equivalents and restricted cash, beginning of period76,538 85,382 
Cash, cash equivalents and restricted cash, end of period$91,286 $63,978 
7

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
  
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended September 30,
20232022
Cash and cash equivalents, end of period$51,041 $40,120 
Restricted cash, end of period40,245 23,858 
Cash, cash equivalents and restricted cash, end of period$91,286 $63,978 
Supplemental disclosures of cash flow information:
Cash paid for interest$46,905 $32,448 
Cash paid for income and franchise taxes416 566 
Non-cash investing and financing activities:
Common stock issued through stock dividends$67,975 $64,280 
Proceeds from real estate sales used to repay mortgage notes payable$2,663 $ 
Mortgage notes payable repaid with proceeds from real estate sales$(2,663)$ 
Proceeds from real estate sales used to repay amounts outstanding under the Prior Credit Facility$5,167 $ 
Amounts outstanding under the Prior Credit Facility repaid with proceeds from real estate sales$(5,167)$ 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

8

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)

Note 1 — Organization
Healthcare Trust, Inc. (including, as required by context, Healthcare Trust Operating Partnership, L.P. (the “OP”) and its subsidiaries, the “Company”), is an externally managed entity that for U.S. federal income tax purposes has qualified as a real estate investment trust (“REIT”). The Company acquires, owns and manages a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”) and senior housing operating properties (“SHOPs”).
As of September 30, 2023, the Company owned 204 properties located in 33 states and comprised of 9.0 million rentable square feet.
Substantially all of the Company’s business is conducted through the OP and its wholly-owned subsidiaries including taxable REIT subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages its day-to-day business with the assistance of its property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to the Company. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP. As of September 30, 2023, the Company owned 46 seniors housing properties using the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure in its SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor.
The Company operates in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. All of the Company’s properties across both business segments are located throughout the United States. In its MOB operating segment, the Company owns, manages, and leases single- and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. The Property Manager or third-party managers manage the Company’s MOBs. In its SHOP segment, the Company invests in seniors housing properties through the RIDEA structure. As of September 30, 2023, the Company had four eligible independent contractors operating 46 SHOPs, although effective on September 30, 2023, the Company terminated its contract with one independent contractor which managed 20 SHOPs. The Company is in the process of transferring the management of these 20 SHOPs to a new independent contractor, which the Company expects to be completed before December 31, 2023. The Company incurred $0.3 million of costs directly related to the termination in the three and nine months ended September 30, 2023.
The Company has declared quarterly dividends entirely in shares of its common stock since October 2020. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. Since October 2020, the Company has issued an aggregate of approximately 17.3 million shares as stock dividends. No other additional shares of common stock have been issued since October 2020. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding resulting from the stock dividends since October 2020 and through October 2023, and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. Please see Note 8 — Stockholder’s Equity for additional information on the stock dividends.
On March 31, 2023, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2022. The Estimated Per-Share NAV published on March 31, 2023 has not been adjusted since publication and will not be adjusted until the Company’s board of directors (the “Board”) determines a new Estimated Per-Share NAV. Issuing dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a stock dividend; however, because each stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
9

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Note 2 — Summary of Significant Accounting Policies
The accompanying unaudited consolidated financial statements of the Company included herein were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to this Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished includes all adjustments and accruals of a normal recurring nature, which, in the opinion of management, are necessary for a fair statement of results for the interim periods. The results of operations for the nine months ended September 30, 2023 and 2022 are not necessarily indicative of the results for the entire year or any subsequent interim periods.
These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2023. Except for those required by new accounting pronouncements discussed below, there have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2023.
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Continuing Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic commenced. The pandemic and its aftermath has had, and could continue to have, adverse impacts on economic and market conditions. The Company’s tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted, and may continue to impact, the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants which may further impact the ability of the Company’s tenants to pay their rent obligations to the Company when due.
The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy as could the rates charged to residents at its SHOPs. Moreover, the demand for leasing space at the Company’s MOB properties could decline, negatively impacting occupancy percentage, revenue and earnings. Additionally, downturns or stagnation in the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs.
Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates have had, and may continue to have, adverse impacts on the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing wars in Ukraine, Israel and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants to pay rent and hence the Company’s results of operations and liquidity.
Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:

10

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
COVID-19 Impact — MOB Segment
The financial stability and overall health of the Company’s tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its tenants in this segment, and all amounts previously deferred under prior rent deferral agreements have been collected.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases were modified, the Financial Accounting Standards Board (“FASB”) and SEC provided relief that allowed companies to elect whether they treated COVID-19 related lease amendments as provisions included in the pre-concession arrangements, and therefore, not lease modifications, or to treat lease amendments as modifications. In order to be considered COVID-19 related, cash flows had to be substantially the same or less than those prior to the concessions. For COVID-19 relief qualified changes, there were two methods to potentially account for such rent deferrals or abatements under the relief: (i) as if the changes were originally contemplated in the lease contract or (ii) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company was required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualified for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there was no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact was recognized ratably over the remaining life of the leases. For leases not qualifying for this relief, the Company applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
COVID-19 Impact — SHOP Segment
In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and then stabilized until June 2022. Since then, SHOP occupancy has trended downward. The Company also experienced lower inquiry volumes and reduced in-person tours during the COVID-19 pandemic compared to pre-pandemic periods. In addition, beginning in March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See “CARES Act Grants” below for additional information on the CARES Act.
During the year ended December 31, 2022, the Company relied more on the use of temporary contract labor and agencies than it had historically. The Company has since reduced its reliance on this labor source in the nine months ended September 30, 2023. However, the wage expenses (including overtime, training and bonus wages) incurred by the Company from employees of its third party operators has increased due to, among other things, inflation raising the cost of labor generally, a lack of qualified personnel that the Company’s third party operators are able to employ on a permanent basis and training hours and other onboarding costs for permanent staff which replaced previously utilized contract and agency labor.
The persistence of high inflation, labor shortages and supply chain disruptions have caused adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have a material adverse effect on its operations in future periods.
The adverse financial impacts of the COVID-19 pandemic on the Company were partially offset by funds received by the Company under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million under the CARES Act during the years ended December 31, 2022, 2021, and 2020, respectively. The Company did not receive any such funds during the three and nine months ended September 30, 2023 and it received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the Company treated these funds as grant contributions from the government. The full amounts received were recognized as reductions of property operating and maintenance expenses in the Company’s consolidated statements of operations and comprehensive loss
11

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
for the periods in which the funds were received, to partially offset the incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of September 30, 2023, these leases had a weighted average remaining lease term of 4.8 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with any increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short term in nature.
As of September 30, 2023:
(In thousands)Future 
Base Rent Payments
2023 (remainder)$27,566 
2024108,291 
202598,378 
202690,299 
202771,439 
Thereafter240,452 
Total$636,425 
The Company continually reviews receivables related to rent and unbilled rent and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments
12

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive loss in the period the related costs are incurred, as applicable.
The Company recorded reductions in revenue of $0.2 million and $0.9 million, respectively, for uncollectable amounts during the three and nine months ended September 30, 2023, and $1.7 million and $2.6 million, respectively, during the three and nine months ended September 30, 2022.
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the three months ended September 30, 2023 and 2022. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of September 30, 2023 or December 31, 2022.
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the nine months ended September 30, 2023 were asset acquisitions. The Company acquired seven properties during the nine months ended September 30, 2023.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
13

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationships, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the nine months ended September 30, 2023 or 2022.
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of September 30, 2023 and December 31, 2022, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (i) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Lessee Accounting
The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheets as of September 30, 2023 and December 31, 2022, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023 and 2022.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a
14

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see Note 16Commitments and Contingencies.
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statements of operations and comprehensive income to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held for use. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see Note 15 — Segment Reporting.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress is not depreciated until the project has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
15

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of September 30, 2023, the Company owned 46 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of September 30, 2023 and December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the COVID-19 pandemic. During the three months ended September 30, 2023, the Company modified 26 intercompany leases with the TRS which reduced intercompany rent.
Because of the TRS's recent operating history of losses and the impact of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $7.6 million as of September 30, 2023. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive loss. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance.
CARES Act Grants
On March 27, 2020, the CARES Act was signed into law and provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designed to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company did not receive any funding from the CARES Act during the three and nine months ended September 30, 2023 and the Company received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. Any funding that the Company would receive is recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2022:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.
Not yet Fully Adopted as of September 30, 2023:
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform
16

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
Note 3 — Real Estate Investments, Net
Property Acquisitions
The Company invests in healthcare-related facilities, primarily MOBs and seniors housing properties which expand and diversify its portfolio and revenue base. The Company owned 204 properties as of September 30, 2023. During the nine months ended September 30, 2023 and 2022, the Company acquired seven and three properties, respectively. All acquisitions in the nine months ended September 30, 2023 and 2022 were considered asset acquisitions for accounting purposes.
The following table presents the allocation of real estate assets acquired and liabilities assumed during the nine months ended September 30, 2023 and 2022:
Nine Months Ended September 30,
(In thousands)20232022
Real estate investments, at cost:
Land$3,373 $4,199 
Buildings, fixtures and improvements27,069 10,662 
Total tangible assets30,442 14,861 
Acquired intangibles:
In-place leases and other intangible assets5,057 2,670 
Market lease and other intangible assets33 268 
Market lease liabilities(271) 
Total intangible assets and liabilities4,819 2,938 
Cash paid for real estate investments, including acquisitions$35,261 $17,799 
Number of properties purchased7 3 

Significant Tenants
As of September 30, 2023 and 2022, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income for the portfolio on a straight-line basis. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of September 30, 2023 and 2022:
September 30,
State20232022
Florida19.8%19.0%
Pennsylvania10.6%*
_________
* The annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the date specified.
17

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Intangible Assets and Liabilities
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above- and below-market lease assets and liabilities, net and the amortization and accretion of above- and below-market ground leases, net, for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Amortization of in-place leases and other intangible assets (1)
$3,455 $3,815 $10,414 $11,502 
Accretion of above -and below-market leases, net (2)
$(244)$(219)$(795)$(549)
Amortization of above -and below-market ground leases, net (3)
$40 $40 $120 $120 
________
(1)Reflected within depreciation and amortization expense.
(2)Reflected within rental income.
(3)Reflected within property operating and maintenance expense.
The following table provides the projected amortization expense and adjustments to revenues for the next five years:
(In thousands)2023 (remainder)2024202520262027
In-place lease assets$3,157 $11,812 $10,224 $8,979 $5,468 
Other intangible assets10 10 10 10 10 
Total to be added to amortization expense$3,167 $11,822 $10,234 $8,989 $5,478 
Above-market lease assets$(101)$(419)$(366)$(331)$(243)
Below-market lease liabilities309 1,297 1,127 972 654 
Total to be added to revenue from tenants
$208 $878 $761 $641 $411 
Dispositions
Three and Nine Months Ended September 30, 2023
During the three months ended September 30, 2023, the Company did not dispose of any properties. During the nine months ended September 30, 2023, the Company disposed of four SHOPs and one MOB for an aggregate contract sales price of $13.8 million. Two of the four disposed SHOPs were impaired by $15.1 million in the year ended December 31, 2022 (see below). As a result, the Company recorded an aggregate loss on sale of $0.4 million, which is presented in the Company’s consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2023.
Three and Nine Months Ended September 30, 2022
On July 1, 2020, the Company transitioned four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) from the former triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties were leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. During the third quarter of 2021, the Company began to actively market the LaSalle Properties for sale, and a non-binding letter of intent was signed in the fourth quarter of 2021 for an aggregate contract sales price of $12.4 million. The Company had previously recorded $34.0 million of impairment charges on the LaSalle Properties in the year ended December 31, 2021. The Company completed the sale of the LaSalle Properties in the first quarter of 2022 and recorded a loss on sale of $0.3 million in the first quarter of 2022, which is presented in the Company’s consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2022.The Company recorded a gain on sale of $0.2 million in the three months ended September 30, 2022 related to the settlement of a lien on formerly disposed properties.
18

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Assets Held for Sale
When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.
There were no assets held for sale as of September 30, 2023 and December 31, 2022.
Assets Held for Use
When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single-tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.
Impairment Charges
There were no impairment charges recorded in the three and nine months ended September 30, 2023. The following table presents impairment charges by segment recorded during the nine months ended September 30, 2022:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20222022
MOB Segment:
Illinois skilled nursing facilities (1)
$ $10,644 
Total MOB impairment charges 10,644 
SHOP Segment:
Various held for use SHOPs (2)
8,949 15,142 
Total SHOP impairment charges8,949 15,142 
Total impairment charges$8,949 $25,786 
(1)These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of September 30, 2023, these properties were not disposed of, nor were any under contract for disposal.
(2)Consists of eight total properties that were impaired as a result of the Company reassessing the holding period for the properties. Two of these properties were sold in the nine months ended September 30, 2023.
19

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Note 4 — Mortgage Notes Payable, Net
The following table reflects the Company’s mortgage notes payable as of September 30, 2023 and December 31, 2022:
Outstanding Loan Amount as of
Effective Interest Rate (1) as of
PortfolioEncumbered PropertiesSeptember 30,
2023
December 31, 2022September 30,
2023
December 31, 2022Interest RateMaturity
(In thousands)(In thousands)
Fox Ridge Bryant - Bryant, AR1$6,689 $6,817 3.98 %3.98 %FixedMay 2047
Fox Ridge Chenal - Little Rock, AR115,344 15,639 2.95 %2.95 %FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR19,520 9,704 2.95 %2.95 %FixedMay 2049
Capital One MOB Loan (2)
41378,500 378,500 3.71 %3.73 %Fixed(2)Dec. 2026
Multi-Property CMBS Loan20116,037 118,700 4.60 %4.60 %FixedMay 2028
Shiloh - Illinois
112,828 13,071 4.34 %4.34 %FixedJan. 2025
BMO CMBS Loan942,750 42,750 2.89 %2.89 %FixedDec. 2031
Barclays MOB Loan62240,000  6.45 % %FixedJune 2033
Gross mortgage notes payable136821,668 585,181 4.58 %3.83 %
Deferred financing costs, net of accumulated amortization (3)
(11,620)(5,117)
Mortgage premiums and discounts, net(1,296)(1,364)
Mortgage notes payable, net$808,752 $578,700 
_____________
(1)Calculated on a weighted average basis for all mortgages outstanding as of September 30, 2023 and December 31, 2022. For the SOFR (defined in Note 5 — Credit Facilities)/LIBOR based loans, the Company used the applicable SOFR/LIBOR rate index in effect at the balance sheet date. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(2)Variable rate loan, based on daily SOFR as of September 30, 2023 and December 31, 2022, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of September 30, 2023 and December 31, 2022.
(3)Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close or result in a definitive agreement.

As of September 30, 2023, the Company had pledged $1.3 billion in total real estate investments, at cost, as collateral for its $0.8 billion of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.
Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants, including debt service coverage ratios. As of September 30, 2023, the Company was in compliance with these financial covenants.
See Note 5 — Credit Facilities - Future Principal Payment and LIBOR Transition for a schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and discussion of the cessation of LIBOR publication.
Barclays MOB Loan
On May 24, 2023, the Company, through certain subsidiaries of the OP), entered into a non-recourse loan agreement (the “Barclays MOB Loan Agreement”), with (i) Barclays Capital Real Estate Inc., (ii) Société Générale Financial Corporation and (iii) KeyBank National Association (each individually, a “Lender,” and collectively, the “Lenders”), in the aggregate amount of $240.0 million (the “Barclay’s MOB Loan”). In connection with the Barclay’s MOB Loan Agreement, the OP entered into a Guaranty Agreement (the “Guaranty”) and an Environmental Indemnity Agreement (the “Environmental Indemnity”) for the benefit of the Lenders.
The Barclays MOB Loan is secured by, among other things, first priority mortgages on the Company’s interests in 62 MOBs with an aggregate gross asset value of $416.8 million. The Barclays MOB Loan has a 10-year term and is interest-only at a fixed rate of 6.453% per year. Under the Barclays MOB Loan Agreement, the Company is required to make interest-only
20

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
payments on a monthly basis with the principal balance due on the maturity date of June 6, 2033. The Barclays MOB Loan Agreement requires the OP to comply with certain covenants, including, maintaining combined cash and cash equivalents totaling at least $12.5 million at all times.
Subject to certain conditions, the Company may prepay the Barclays MOB Loan in whole or in part at any time after one year from closing with a pre-payment premium equal to the Yield Maintenance Program (as defined in the Barclays MOB Loan Agreement) by providing the lenders thereunder with prior written notice of prepayment no less than thirty days before prepayment, subject to a pre-payment premium equal to the Yield Maintenance Premium (as defined in the Barclay’s MOB Loan Agreement). Following the earlier of May 24, 2026 and the date that is two years after the securitization of the Barclay’s MOB Loan, the Company may prepay the Barclays MOB Loan through defeasance, Notwithstanding the foregoing, the Barclays MOB Loan may be prepaid at par during the final six months of the term. The Company paid $7.8 million in deferred financing costs related to the Barclay’s MOB Loan, which is amortized into interest expense over the term of the loan.
At the closing of the Barclays MOB Loan, the Company applied $194.8 million of the Barclays MOB Loan proceeds to repay and terminate the Company’s then-existing credit facility (the “Prior Credit Facility”). The Company also terminated its interest rate swap contracts that formerly hedged interest rate changes under the Prior Credit Facility (see Note 7 — Derivatives and Hedging Activities for additional information). The remaining proceeds of approximately $39.0 million (after the payment of Barclays MOB Loan closing costs and reimbursement of deposits) are available for general corporate purposes, subject to the terms of the Barclays MOB Loan Agreement. Additionally, by terminating the Prior Credit Facility, the Company is no longer subject to certain restrictive covenants previously imposed by the Prior Credit Facility (see Note 5 — Credit Facilities for additional information).
Under the Guaranty, the OP has (i) guaranteed the full repayment of the Barclays MOB Loan in the case of certain major defaults by the Company or the OP, including bankruptcy, and (ii) indemnified the Lenders against losses, costs or liabilities related to certain other “bad boy” acts of the Company or the OP, including fraud, willful misconduct, bad faith, and gross negligence. Pursuant to the Environmental Indemnity, the OP and the Company have indemnified the Lenders against losses, costs or liabilities related to certain environmental matters.
Note 5 — Credit Facilities
    The Company had the following credit facilities outstanding as of September 30, 2023 and December 31, 2022:
Outstanding Facility
Amount as of
Effective Interest Rate (8)
Credit Facilities
Encumbered Properties (1)
September 30,
2023
December 31, 2022September 30,
2023
December 31, 2022Interest RateMaturity
(In thousands)(In thousands)
Prior Credit Facility:
   Revolving Credit Facility$ $30,000  %7.26 %VariableMar. 2024(7)
   Term Loan
 150,000  %5.11 %Fixed(5)Mar. 2024
   Deferred financing costs (1,750)
   Term Loan, net
 148,250 
Total Prior Credit Facility$ $178,250 
Fannie Mae Master Credit Facilities:
Capital One Facility
11(2)$207,829 $210,483 7.84 %5.90 %Variable(6)Nov. 2026
KeyBank Facility
10(3)139,891 141,564 7.89 %6.60 %Variable(6)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$347,720 $352,047 
Total Credit Facilities21$347,720 $530,297 7.86 %(4)5.94 %(4)
________
(1)Encumbered properties are as of September 30, 2023.
(2)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $350.5 million.
21

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
(3)Secured by first-priority mortgages on ten of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $261.9 million.
(4)Calculated on a weighted average basis for all credit facilities outstanding as of September 30, 2023 and December 31, 2022, respectively.
(5)Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see Note 7 — Derivatives and Hedging Activities for additional details).
(6)The effective rates above only include the impact of designated hedging instruments. The Company has seven non-designated interest rate cap agreements with an aggregate notional amount of $351.6 million which limited 30-day LIBOR (until June 30, 2023, and SOFR thereafter) to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see Note 7 — Derivatives and Hedging Activities for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility and KeyBank Fannie Mae Facility was 5.89% and 5.93%, respectively, as of September 30, 2023, and 5.26%, and 5.96%, respectively, as of December 31, 2022.
(7)During the year ended December 31 2022, the Company exercised its option to extend the maturity one year to March 2024 subject to certain conditions.
(8)Effective interest rate below for variable rate debt gives effect to any outstanding “pay-fixed” swaps entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of September 30, 2023 and December 31, 2022. The Company allocated $150.0 million of its SOFR-based interest rate swaps to the Term Loan $50.0 million of its LIBOR-based interest rate swaps to the Capital One Facility as of December 31, 2022. The interest rate swaps allocated to the Prior Credit Facility were all terminated in the nine months ended September 30, 2023. Upon termination, the fair values of terminated swaps are recorded within AOCI, and are amortized into interest expense over the original term of the then-existing swap. These amortized amounts from terminated swaps are not included in the calculation of effective interest. The Company continues to have $378.5 million of SOFR-based “pay-fixed” interest rate swaps allocated to a variable-rate mortgage note payable as of September 30, 2023. See Note 7 — Derivatives and Hedging Activities for additional details.
As of September 30, 2023, the carrying value of the Company’s real estate investments, at cost was $2.6 billion, with $1.3 billion of this asset value pledged as collateral for mortgage notes payable and $0.6 billion of this asset value pledged to secure advances under the Fannie Mae Master Credit Facilities. All of the real estate assets pledged to secure debt or to secure the Fannie Mae Master Credit Facilities are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the pledged collateral.
Unencumbered real estate investments, at cost as of September 30, 2023 were $0.7 billion, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for future mortgage loans, future advances under the Fannie Mae Master Credit Facilities, or other future financings.
Prior Credit Facility
The Prior Credit Facility consisted of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”). The Revolving Credit Facility and Term Loan were interest-only and would have matured on March 13, 2024. The Prior Credit Facility was fully repaid in May 2023 with net proceeds provided by the Barclays MOB Loan (see Note 4 — Mortgage Notes Payable, Net for details) and the Prior Credit Facility was terminated.
Amounts outstanding under the Prior Credit Facility bore interest at the Company’s option of either (i) Secured Overnight Financing Rate (“SOFR”), plus an applicable margin that ranges, depending on the Company’s leverage, from 2.10% to 2.85% or (ii) the Base Rate (as defined in the Prior Credit Facility), plus an applicable margin that ranged, depending on the Company’s leverage, from 0.85% to 1.60%. For the period from January 1, 2023 through the termination of the Prior Credit Facility in May 2023, the Company elected to use the SOFR option for all of its borrowings under the Prior Credit Facility. At termination, the Company wrote off the remaining deferred financing costs associated with the Prior Credit Facility of $2.6 million which is included in interest expense in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023.
The Prior Credit Facility contained various restrictions which no longer apply, that limited the Company’s ability to incur additional debt, maintain certain cash balances or pay dividends, among other things.
Fannie Mae Master Credit Facilities
22

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually as a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements were assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.
In connection with the Fannie Mae Master Credit Facilities, the Company was required to enter into interest rate cap agreements which the Company periodically renews upon their expiration. During the three months ended September 30, 2023, the Company paid premiums of $4.6 million to renew three caps which matured in the three months ended September 30, 2023.
As of September 30, 2023 the Company had six non-designated interest rate cap agreements with an aggregate current effective notional amount of $351.6 million which caps SOFR at 3.50% and various maturities through April 2024. The existing caps were transitioned to SOFR-based contracts effective July 1, 2023. The Company does not apply hedge accounting to these non-designated interest cap agreements and changes in value are reflected in earnings (see Note 7Derivatives and Hedging Activities for additional information regarding the Company’s derivatives).
As of September 30, 2023, $347.7 million was outstanding under the Fannie Mae Master Credit Facilities. The Company may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. Borrowings under the Fannie Mae Master Credit Facilities bore annual interest at a rate that varied on a monthly basis and was equal to the sum of the current LIBOR for one month U.S. dollar-denominated deposits and a spread (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively). Effective July 1, 2023, the Fannie Mae Master Credit Facilities automatically transitioned to SOFR-based borrowings with monthly interest equal to the sum of the current SOFR for one-month denominated deposits and a spread of (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively). The Fannie Mae Master Credit Facilities mature on November 1, 2026.
As of December 31, 2022, the Company had $150.0 million of SOFR-based interest swap agreements, which were allocated to the Term Loan, and $50.0 million of LIBOR-based interest swap agreements which were allocated to the Capital One Facility. These swaps were all terminated in the six months ended June 30, 2023. The Term Loan was fully repaid in the three months ended June 30, 2023, but the Capital One Facility remained outstanding.
In the three months ended September 30, 2023, the Company provided a $5.1 million cash deposit to Fannie Mae because the debt service coverage ratios of the underlying properties of each facility were below the minimum required amount per the debt agreements. This amount will be recorded as restricted cash and is pledged as additional collateral for the Fannie Mae Master Credit Facilities. This deposit will be refunded the earlier of the Company’s achievement of a debt service coverage ratio above the minimum required amount of 1.40 or the maturity of the Fannie Mae Master Credit Facilities. Subsequent to September 30, 2023, the Company provided an additional deposit of $6.7 million, which brought the total deposit to $11.8 million (see Note 17 — Subsequent Events for additional information).
23

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Future Principal Payments
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to September 30, 2023 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2023 (remainder)$289 $1,442 $1,731 
20241,178 5,769 6,947 
202513,270 5,769 19,039 
2026379,393 334,740 714,133 
2027922  922 
Thereafter426,616  426,616 
Total$821,668 $347,720 $1,169,388 
LIBOR Transition
In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the SOFR as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings were published through June 30, 2023.
The Company had no LIBOR-based borrowings or derivative instruments as of September 30, 2023. As of September 30, 2023, the Company had $347.7 million of variable-rate, SOFR-based borrowings under the Fannie Mae Master Credit Facilities, which automatically transitioned from variable-rate, LIBOR-based borrowings on July 1, 2023. As of September 30, 2023, the Company had SOFR-based interest rate caps with notional amounts of $351.6 million which are not designated as hedging instruments which also transitioned from LIBOR-based contracts effective July 1, 2023.
During the year ended December 31, 2022, the Company converted $150.0 million of its “pay-fixed” swaps on its Prior Credit Facility from LIBOR to SOFR, as well as its $378.5 million Capital One MOB Loan and the related “pay-fixed” swap from LIBOR to SOFR. During the nine months ended September 30, 2023, the Company terminated its remaining $50.0 million of LIBOR-based “pay-fixed” swaps. The “pay-fixed” swaps were terminated in an asset position and the Company received $5.4 million in cash following the termination. This amount was included in accumulated other comprehensive income (“AOCI”), and will amortize into earnings as a reduction to interest expense through March 2024 (the original term of the swap and variable hedged debt). See Note 7 — Derivatives and Hedging Activities for additional details.
Note 6 — Fair Value of Financial Instruments
GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring assets and liabilities at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below:
Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.
Level 3 — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.
24

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.
Financial Instruments Measured at Fair Value on a Recurring Basis
Derivative Instruments
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of September 30, 2023, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.
The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.

25

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
The following table presents information about the Company’s assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
September 30, 2023
Derivative assets, at fair value (non-designated)$ $4,946 $ $4,946 
Derivative assets, at fair value (designated) 32,601  32,601 
Total $ $37,547 $ $37,547 
December 31, 2022
Derivative assets, at fair value (non-designated)$ $3,737 $ $3,737 
Derivative assets, at fair value (designated) 36,910  36,910 
Total $ $40,647 $ $40,647 
A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2023.
Real Estate Investments Measured at Fair Value on a Non-Recurring Basis
Real Estate Investments - Held for Use
The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheets as of September 30, 2023 and December 31, 2022.
As of September 30, 2023, the Company owned 16 held for use properties (10 MOBs and six SHOPs) for which the Company had reconsidered their expected holding periods, of which six properties (three MOB and three SHOPs) are being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying values of the respective properties, and has previously recorded impairment charges on 10 properties (eight MOBs and two SHOPs) to reduce the carrying values to their estimated fair values during the year ended December 31, 2022.
See Note 3 — Real Estate Investments, Net - “Assets Held for Use and Related Impairments” for additional details.
Real Estate Investments - Held for Sale
Real estate investments held for sale are carried at net realizable value on a non-recurring basis and are generally classified in Level 3 of the fair value hierarchy. The Company did not have any real estate investments classified as held for sale as of September 30, 2023 and December 31, 2022.
Financial Instruments Not Measured at Fair Value
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.

26

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
September 30, 2023December 31, 2022
(In thousands)LevelCarrying Amount Fair Value Carrying AmountFair Value 
Gross mortgage notes payable and mortgage premium and discounts, net
3$820,372 $766,584 $583,817 $550,626 
Prior Credit Facility3$ $ $180,000 $179,496 
Fannie Mae Master Credit Facilities
3$347,720 $348,120 $352,047 $353,034 

The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives.
Note 7 — Derivatives and Hedging Activities
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings.
The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of September 30, 2023 and December 31, 2022:
(In thousands)Balance Sheet LocationSeptember 30,
2023
December 31, 2022
Derivatives designated as hedging instruments:
    Interest rate “pay-fixed” swapsDerivative assets, at fair value$32,601 $36,910 
Derivatives not designated as hedging instruments:
    Interest rate capsDerivative assets, at fair value$4,946 $3,737 
Cash Flow Hedges of Interest Rate Risk
As of September 30, 2023 and December 31, 2022, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
September 30, 2023December 31, 2022
Interest Rate DerivativesNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
SOFR-based interest rate “pay-fixed” swaps1 $378,500 7 $528,500 
LIBOR-based interest rate “pay-fixed” swaps  2 50,000 
Total interest rate “pay-fixed” swaps1 $378,500 9 $578,500 
27

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
The table below details the location in the financial statements of the gain (loss) recognized on interest rate derivatives designated as cash flow hedges for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives$5,418 $17,513 $12,078 $49,522 
Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense$5,023 $565 $13,648 $(3,862)
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$(15,720)$(13,284)$(50,208)$(37,098)
As of September 30, 2023, the Company had one SOFR-based “pay-fixed” interest rate swap that is designated as a cash flow hedge. The Company uses its interest rate swap as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for fixed-rate payments by the Company over the life of the agreement without exchange of the underlying notional amount. During the nine months ended September 30, 2023 and the year ended December 31, 2022, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. The remaining interest rate “pay-fixed” swap has a base interest rate of 1.61% and matures December 2026.
The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in AOCI and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.
MOB Loan Swap Termination
In connection with the refinancing of the $250.0 million loan made by Capital One, National Association and certain other lenders to certain subsidiaries of the OP on June 30, 2017 (the “MOB Loan”), during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and was reclassified as an increase to interest expense over the original term of the two terminated swaps and the MOB Loan prior to its refinancing. For the nine months ended September 30, 2022, the Company reclassified $0.4 million from AOCI as an increase to interest expense. No amounts remained in AOCI related to this swap termination designated to the MOB Loan as of December 31, 2022.
Prior Credit Facility Swap Terminations
During the nine months ended September 30, 2023, the Company terminated two LIBOR-based interest rate swap agreements with an aggregate notional amount of $50.0 million and six SOFR-based interest rate swap agreements with an aggregate notional amount of $150.0 million. The swaps were terminated in asset positions, and the Company received $1.9 million in cash from the LIBOR-based swap terminations, and $3.5 million in cash from the SOFR-based swap terminations. These amounts were included in AOCI and will be amortized into earnings as a reduction to interest expense from the termination dates of the swaps through March 2024 (the original term of the swap and the Prior Credit Facility). For the three and nine months ended September 30, 2023, the Company reclassified $1.5 million and $2.7 million, respectively, from AOCI as decreases to interest expense, and $2.7 million remained in AOCI as of September 30, 2023.
Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from October 1, 2023 through September 30, 2024, the Company estimates that $16.5 million will be reclassified from AOCI as a decrease to interest expense or other comprehensive income relating to the “pay-fixed” swaps designated as derivatives.
28

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Non-Designated Derivatives
The Company had the following outstanding interest rate derivatives with current effective notional amounts that were not designated as hedges in qualified hedging relationships as of September 30, 2023 and December 31, 2022:
September 30, 2023December 31, 2022
Interest Rate DerivativesNumber of Instruments
Notional Amount (1)
Number of Instruments
Notional Amount (1)
(In thousands)(In thousands)
Interest rate caps (2)
6 $351,572 7 $354,624 
(1)Notional amount represents the currently active interest rate cap contracts.
(2)All of the Company’s interest rate cap agreements limited 30-day LIBOR through June 30, 2023 (and SOFR, thereafter) to 3.50% with terms through July 2025. The actual 30-day LIBOR rates during the six months ended June 30, 2023, and the SOFR rates during the three months ended September 30, 2023, exceeded the strike price rate of 3.50% and the Company received payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.
These derivatives are used to limit the Company’s exposure to interest rate movements for economic purposes, however, the Company has not elected to apply hedge accounting. As of September 30, 2023 and December 31, 2022, the Company had entered into six SOFR-based and seven LIBOR-based interest rate caps, respectively, with notional amounts of $351.6 million and $354.6 million, respectively, which limited 30-day SOFR/LIBOR borrowings to 3.50% and have varying maturities through July 2025.
The Company paid premiums of $4.6 million to renew three caps with an aggregate notional amount of $138.5 million which matured in the nine months ended September 30, 2023. Subsequent to September 30, 2023, the Company paid premiums of $5.0 million to renew two maturing interest rate caps with an aggregate notional amount of $150.9 million (see Note 17 — Subsequent Events for additional information). One interest rate cap with a notional amount of $60.0 million matures in April 2024, which represents the next interest rate cap maturity excluding those renewed subsequent to September 30, 2023. All of the Company’s LIBOR-based interest rate caps were transitioned to SOFR-based contracts effective July 1, 2023.
Beginning in the year ended December 31, 2022, LIBOR exceeded 3.50% and the Company began receiving payments under these interest rate caps. While the Company does not apply hedge accounting for these interest rate caps, they are economically hedging the Capital One Facility and KeyBank Facility. Changes in the fair value of, and any cash received from, derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net loss and are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive loss.
The gains on non-designated derivatives were $0.4 million and $0.5 million, respectively, for the three and nine months ended September 30, 2023, and were $1.8 million and $3.2 million, respectively, for the three and nine months ended September 30, 2022. During the nine months ended September 30, 2023, the Company received aggregate payments of $3.9 million related to its effective interest rate caps as LIBOR/SOFR exceeded the effective rates of the capped debt. No such amounts were received during the nine months ended September 30, 2022.
Offsetting Derivatives
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives (both designated and non-designated) as of September 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.
29

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
September 30, 2023$37,547 $ $ $37,547 $ $ $37,547 
December 31, 2022$40,647 $ $ $40,647 $ $ $40,647 


Credit-risk-related Contingent Features
The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.
As of September 30, 2023, there were no derivatives in a net liability position. The Company is not required to post any collateral related to these agreements and was not in breach of any agreement provisions.
Note 8 — Stockholders’ Equity
Common Stock
As of September 30, 2023 and December 31, 2022, the Company had 109,877,212 and 105,080,531 shares of common stock outstanding, respectively, including unvested restricted shares, shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases, and shares issued as stock dividends since October 2020. Since October 2020, the Company has issued an aggregate of approximately 17.3 million shares in respect to the stock dividends. Except for shares issued as dividends, no additional shares of common stock were issued during the nine months ended September 30, 2023 or the year ended December 31, 2022. References made to weighted-average shares and per-share amounts in the consolidated statements of operations and comprehensive loss have been retroactively adjusted to reflect the cumulative increase in shares outstanding due to the stock dividends (including the October 2023 stock dividend) and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. See Note 1 — Organization for additional information.
On March 31, 2023, the Company published a new Estimated Per-Share NAV as of December 31, 2022, which was approved by the Board on March 31, 2023. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
Share Repurchase Program
Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.
Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
The Board suspended the SRP in August 2020 and rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated.
30

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.
The table below reflects the number of shares repurchased and the average price per share, under the SRP and does not include any repurchases under tender offers, cumulatively through September 30, 2023.
Number of Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 20224,896,620 $20.60 
Nine months ended September 30, 2023  
Cumulative repurchases as of September 30, 20234,896,620 20.60 
Distribution Reinvestment Plan
Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheets in the period distributions are declared. During the nine months ended September 30, 2023 and the year ended December 31, 2022, the Company did not issue any shares of common stock pursuant to the DRIP. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.
Stockholder Rights Plan
In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its Board in its discretion.
Preferred Stock and Preferred Units
The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019, the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC, (the “Preferred Stock Equity Line”) and in May 2021, the Board authorized the classification of 2,530,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the offering in May 2021. Also, in connection with an underwritten offering in October 2021, the Company classified and designated 3,680,000 shares of its authorized preferred stock on October 4, 2021 as authorized shares of its Series B Preferred Stock.
The Company had 3,977,144 shares of Series A Preferred Stock issued and outstanding as of September 30, 2023 and December 31, 2022.
The Company had 3,630,000 shares of Series B Preferred Stock issued and outstanding as of September 30, 2023 and December 31, 2022.
The Company also had 100,000 Series A Preferred Units outstanding as of September 30, 2023 and December 31, 2022, which were accounted for as a component of non-controlling interests. See Note 13 — Non-controlling Interests for additional information.
Distributions and Dividends
Common Stock
From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock.
31

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
On August 13, 2020, the Board changed the Company’s common stock distribution policy to preserve the Company’s liquidity and maintain additional financial flexibility. Under the policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s Estimated Per Share NAV of common stock in effect on the applicable date:
Stock Dividend Declaration DateStock Dividend Issue DateQuarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 20200.013492
January 4, 2021January 15, 20210.013492
April 2, 2021April 15, 20210.014655
July 1, 2021July 15, 20210.014655
October 1, 2021October 15, 20210.014655
January 3, 2022January 15, 20220.014655
April 1, 2022April 18, 20220.014167
July 1, 2022July 15, 20220.014167
October 3, 2022October 17, 20220.014167
January 3, 2023January 18, 20230.014167
April 3, 2023April 17, 20230.015179
July 3, 2023July 17, 20230.015179
October 2, 2023October 16, 20230.015179
Note 9 — Related Party Transactions and Arrangements
As of September 30, 2023 and December 31, 2022, the Special Limited Partner owned 10,550 and 10,094 shares (assuming conversion of its partnership interests), respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of September 30, 2023 and December 31, 2022, the Advisor held 90 partnership units in the OP designated as “Common OP Units”.
The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP.  In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.
Fees Incurred in Connection with the Operations of the Company
The Second Amended and Restated Advisory Agreement by and among the Company, the OP and the Advisor (as amended the “Second A&R Advisory Agreement”) took effect on February 17, 2017 and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days’ prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&R Advisory Agreement or (b) any material breach of the Second A&R Advisory Agreement of any nature whatsoever by the Company.
On July 25, 2019, the Company entered into Amendment No. 1 to the Second A&R Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “—Professional Fees and Other Reimbursements.”
Acquisition Expense Reimbursements
The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for
32

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
third-party acquisition expenses. Under the Second A&R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through September 30, 2023.
33

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Asset Management Fees and Variable Management/Incentive Fees
Under the LPA and the advisory agreement that was superseded by the original amended and restated advisory agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the “Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).
Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.
Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of September 30, 2023, the Company determined that achieving the Performance Condition was not yet considered probable for accounting purposes. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any, on the Company’s common stock. These cash distributions on Class B Units are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss until the Performance Condition is considered probable to occur. stock dividends do not cause the OP to issue additional Class B Units, rather, the redemption ratio to common stock is adjusted. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that the Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units.
On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.
Effective February 17, 2017, the Second A&R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. There are no variable management fees earned from the issuance of common stock dividends. The base management fee is payable to the Advisor or its assignees in cash, Common OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any Common OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.
In addition, the Second A&R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted shares of common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt
34

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No incentive fee was incurred for the three and nine months ended September 30, 2023 or 2022.
Property Management Fees
Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by the Company’s Board (including a majority of the independent directors).
If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.
On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&R Property Management Agreement”) with the OP and the Property Manager. The A&R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&R Property Management Agreement at least 90 days prior to the end of the term. Neither party has provided notice of intent to terminate. The current term of the A&R Property Management Agreement expires February 17, 2024. The Property Manager may assign the A&R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.
On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&R Property Management Agreement. See the Mortgage Notes Payable table included in Note 4 — Mortgage Notes Payable, Net for additional information on the Multi-Property CMBS Loan.
Professional Fees and Other Reimbursements
The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the three and nine months ended September 30, 2023, the Company incurred $2.5 million and $6.4 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. During the three and nine months ended September 30, 2022, the Company incurred $2.4 million and $6.7 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive loss.
35

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Advisory Agreement Amendment, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.
The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.
Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), is limited to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”).
Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the Advisory Agreement Amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2020; (a) the Fixed Component was equal to $6.8 million (currently $7.7 million) and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.
If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the Advisory Agreement Amendment requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the Advisory Agreement Amendment requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.
Summary of fees, expenses and related payables
The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,Payable (Prepayments) as of
 2023202220232022
(In thousands)IncurredIncurred
Incurred
IncurredSeptember 30,
2023
December 31, 2022
Non-recurring fees and reimbursements:
Acquisition cost reimbursements$10 $ $31 $18 $10 $5 
Ongoing fees and reimbursements:
Asset management fees 5,458 5,458 16,374 16,374   
Property management and fees (2)
1,155 1,101 3,132 3,058 161 3 
Professional fees and other reimbursements (1)
2,824 2,398 7,584 6,748 

494 39 
Total related party operation fees and reimbursements$9,447 $8,957 $27,121 $26,198 $665 $47 
___________
(1)Included in general and administrative expenses in the consolidated statements of operations. Includes $2.0 million and $5.2 million, respectively, for the three and nine months ended September 30, 2023, and $1.7 million and $4.6 million, respectively, for the three and nine months ended September 30, 2022, subject to the Capped Reimbursement.
(2)The three and nine months ended September 30, 2023 includes $0.2 million and $0.4 million of leasing commissions, respectively, which are capitalized and included in prepaid expenses and other assets as of September 30, 2023.
36

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets
Fees Incurred in Connection with a Listing
If the common stock of the Company is listed on a national securities exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the nine months ended September 30, 2023 or 2022. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.
Subordinated Participation in Net Sales Proceeds
Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the nine months ended September 30, 2023 or 2022. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.
Termination Fees
Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.
Under the Advisory Agreement Amendment, upon the termination or non-renewal of the agreement, the Advisor will be entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination or non-renewal of the Advisory Agreement Amendment.
Upon a termination by either party in connection with a change of control (as defined in the Advisory Agreement Amendment), the Company would be required to pay the Advisor a change of control fee equal to the product of four and the “Subject Fees” described below.
Upon a termination by the Company in connection with a transition to self-management, the Company would be required to pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.
The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.
37

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Note 10 — Economic Dependency
Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.
As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.
Note 11 — Equity-Based Compensation
Restricted Share Plan
The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.6 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).
Restricted shares vest on a straight-line basis over periods of three to five years and may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.
The following table reflects the amount of restricted shares outstanding as of September 30, 2023 and activity for the period presented:
Number of Shares of Common StockWeighted Average Issue Price
Unvested, December 31, 202297,343 $18.89 
Stock dividend4,399 14.32 
Vested(50,871)20.40 
Unvested, September 30, 202350,871 $16.98 
As of September 30, 2023, the Company had $0.8 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. This cost will be recognized over a weighted-average period of 0.9 years. Compensation expense related to restricted shares was $0.2 million and $0.7 million, respectively, for the three and nine months ended September 30, 2023, and $0.3 million and $1.0 million, respectively, for the three and nine months ended September 30, 2022.
Other Share-Based Compensation
The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the nine months ended September 30, 2023 or 2022.
38

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Note 12 — Accumulated Other Comprehensive Income
    The following table illustrates the changes in accumulated other comprehensive income as of and for the period presented:
(In thousands)Unrealized Gain (loss) on Designated Derivative
Balance, December 31, 2022$36,910 
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives12,078 
Amount of gain reclassified from accumulated other comprehensive income(13,648)
Rebalancing of ownership percentage  
Balance, September 30, 2023$35,340 
Accumulated other comprehensive income predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in Note 7 — Derivatives and Hedging Activities, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item.
Note 13 — Non-controlling Interests
Non-controlling interests on the Company’s consolidated balance sheets is comprised of the following:
Balance as of
(In thousands)September 30, 2023December 31, 2022
Series A Preferred Units held by third parties$2,578 $2,578 
Common OP Units held by third parties3,316 3,584 
 Total Non-controlling Interests in the OP5,894 6,162 
Non-controlling Interests in property owning subsidiaries689 389 
Total Non-controlling interests$6,583 $6,551 
Non-Controlling Interests in the OP
For preferred and common shares issued by the Company, the Company typically issues mirror securities with substantially equivalent economic rights between the Company and the OP. The securities held by the Company are eliminated in consolidation.
Series A Preferred Units
The Company is the sole general partner and holds substantially all of the Series A Preferred Units (except as discussed below). All common and preferred units in the OP held by the Company are eliminated in consolidation.
In September 2021, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 100,000 Series A Preferred Units to the unaffiliated third party, with a face value of $25.00 per unit, which were recorded at issuance at a then fair value of $2.6 million, or $25.78 per unit, to the unaffiliated third party.
A holder of Series A Preferred Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s Series A Preferred Stock, which earn dividends at a rate equal to 7.375% of its face value. After holding the Series A Preferred Units for a period of one year, a holder of Series A Preferred Units has the right to redeem Series A Preferred Units for, at the option of the OP, the corresponding number of shares of the Company’s Series A Preferred Stock, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During both the three months ended September 30, 2023 and 2022, Series A Preferred Unit holders were paid $0.1 million.
Common OP Units
The Company is the sole general partner and holds substantially all of the Common OP Units. As of September 30, 2023 and December 31, 2022, the Advisor held 90 Common OP Units, which represents a nominal percentage of the aggregate ownership in the OP.
39

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 Common OP Units, with a value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.
A holder of Common OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the stock dividends, other stock dividends and other similar events. After holding the Common OP Units for a period of one year, a holder of Common OP Units has the right to redeem Common OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock, as retroactively adjusted for the stock dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the nine months ended September 30, 2023 and 2022, Common OP Unit non-controlling interest holders were not paid any cash distributions.
Stock dividends do not cause the OP to issue additional Common OP Units, rather, the redemption ratio to common stock is adjusted. The 405,998 Common OP Units outstanding as of September 30, 2023 would be redeemable for 489,233 shares of common stock, giving effect to adjustments for the impact of the stock dividends through October 2023.
Non-Controlling Interests in Property Owning Subsidiaries
The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.
The following table summarizes the activity related to investment arrangements with the unaffiliated third parties:
Distributions
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementThree Months Ended September 30,
Property Name
(Dollar amounts in thousands)
Investment DateSeptember 30, 2023September 30, 2023September 30, 2023As of December 31, 202220232022
Plaza Del Rio Medical Office Campus Portfolio (1)
May 2015
$689 4.4 %$12,426 $12,455   
_______
(1)One property within the Plaza Del Rio Medical Office Campus Portfolio was pledged to secure the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable, net for additional information. In the nine months ended September 30, 2023, the unaffiliated third party contributed $0.3 million to increase its ownership from 2.6% to 4.4%.
Note 14 — Net Loss Per Share
The following is a summary of the basic and diluted net loss per share computation for the periods presented and has been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss attributable to common stockholders (in thousands)
$(19,561)$(23,303)$(57,829)$(71,159)
Basic and diluted weighted-average shares outstanding (1)
111,426,241 111,365,461 111,404,655 111,333,801 
Basic and diluted net loss per share (1)
$(0.18)$(0.21)$(0.52)$(0.64)
(1)Retroactively adjusted for the effects of the stock dividends (see Note 1 — Organization and Note 8 — Stockholders’ Equity for additional information).
40

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, Common OP Units and Class B Units to be common share equivalents. Series A Preferred Units are non-participating. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Unvested restricted shares (1)
70,730 131,279 92,316 162,938 
Common OP Units (2)
489,233 489,233 489,233 489,233 
Class B Units (3)
432,901 432,901 432,901 432,901 
Total weighted average antidilutive common stock equivalents
992,864 1,053,413 1,014,450 1,085,072 
________
(1)Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 50,871 and 95,983 unvested restricted shares outstanding, respectively, as of September 30, 2023 and 2022.
(2)Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see Note 1 — Organization for additional details). There were 405,998 Common OP Units outstanding as of September 30, 2023 and 2022. The securities held by the Company are eliminated in consolidation.
(3)Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see Note 1 — Organization for additional details). There were 359,250 Class B Units outstanding as of September 30, 2023 and 2022. These Class B Units were unvested as of September 30, 2023 and 2022 (see Note 9 — Related Party Transactions for additional information).
Note 15 — Segment Reporting
The disclosures below for the three and nine months ended September 30, 2023 and 2022 are presented for the Company’s two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs.
The Company evaluates performance and makes resource allocations based on its two business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses as well as seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.
Net Operating Income
The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net loss. The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net loss.
NOI excludes certain components from net loss in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net loss as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net loss as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.
41

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)

The following tables reconcile the segment activity to consolidated net loss for the periods presented:
Three Months Ended September 30,Three Months Ended September 30,
20232022
(In thousands)Medical Office BuildingsSeniors Housing — Operating Properties ConsolidatedMedical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants
$33,657 $52,029 $85,686 $33,185 $50,275 $83,460 
Property operating and maintenance
9,379 44,947 54,326 9,377 41,821 51,198 
NOI
$24,278 $7,082 31,360 $23,808 $8,454 32,262 
Impairment charges
 (8,949)
Operating fees to related parties
(6,397)(6,333)
Acquisition and transaction related
(173)(199)
General and administrative
(4,753)(4,471)
Depreciation and amortization
(20,776)(20,854)
Interest expense
(15,720)(13,284)
Interest and other income
258 10 
(Loss) gain on sale of real estate investments(173)194 
Gain on non-designated derivatives406 1,826 
Income tax expense(157)(77)
Net loss attributable to non-controlling interests14 22 
Allocation for preferred stock (3,450)(3,450)
Net loss attributable to common stockholders$(19,561)$(23,303)


Nine Months Ended September 30,Nine Months Ended September 30,
20232022
(In thousands)Medical Office BuildingsSeniors Housing — Operating Properties ConsolidatedMedical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants
$101,187 $157,958 $259,145 $98,026 $152,910 $250,936 
Property operating and maintenance
27,772 134,006 161,778 26,417 130,463 156,880 
NOI
$73,415 $23,952 97,367 $71,609 $22,447 94,056 
Impairment charges
 (25,786)
Operating fees to related parties
(19,153)(19,003)
Acquisition and transaction related
(384)(1,153)
General and administrative
(14,105)(13,369)
Depreciation and amortization
(61,520)(61,525)
Interest expense
(50,208)(37,098)
Interest and other income
576 24 
Loss on sale of real estate investments(364)(109)
Gain on non-designated derivatives510 3,212 
Income tax expense(244)(159)
Net loss attributable to non-controlling interests45 100 
Allocation for preferred stock (10,349)(10,349)
Net loss attributable to common stockholders$(57,829)$(71,159)


42

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
(In thousands)September 30, 2023December 31, 2022
ASSETS
Investments in real estate, net:
MOB Segment$1,126,677 $1,121,857 
SHOP Segment831,475 856,440 
Total investments in real estate, net
1,958,152 1,978,297 
Cash and cash equivalents51,041 53,654 
Restricted cash40,245 22,884 
Derivative assets, at fair value37,547 40,647 
Straight-line rent receivable, net26,214 25,276 
Operating lease right-of-use assets7,739 7,814 
Prepaid expenses and other assets36,019 34,554 
Deferred costs, net15,300 17,223 
Total assets$2,172,257 $2,180,349 
The following table reconciles capital expenditures by reportable business segment, excluding corporate non-real estate expenditures, for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
MOB Segment$1,686 $2,309 $4,650 $5,981 
SHOP Segment3,172 5,323 9,348 10,726 
Total capital expenditures$4,858 $7,632 $13,998 $16,707 
Note 16 — Commitments and Contingencies
As of September 30, 2023, the Company had seven operating and six direct financing lease agreements. The seven operating leases have durations, including assumed renewals, ranging from 19.1 years to 84.0 years, excluding an adjacent parking lot lease with a term of 1.0 year. The Company did not enter into any additional ground leases during the nine months ended September 30, 2023.
As of September 30, 2023, the Company’s balance sheet included ROU assets and liabilities of $7.7 million and $8.1 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the lease guidance issued in 2019, as well as for new operating leases in the current period, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Because the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment.
The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 33.6 years and a weighted-average discount rate of 7.37% as of September 30, 2023. For each of the three months ended September 30, 2023 and 2022, the Company paid cash of $0.2 million for amounts included in the measurement of lease liabilities and recorded expense of $0.2 million on a straight-line basis in accordance with the current accounting guidance. For the nine months ended September 30, 2023, the Company paid cash of $0.6 million for amounts included in the measurement of lease liabilities and recorded expense of $0.6 million. For the nine months ended September 30, 2022, the Company paid cash of $0.7 million for amounts included in the measurement of lease liabilities and recorded expense of $0.7 million. The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss.
The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:
43

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023 (remainder)$162 $22 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,943 7,215 
Total minimum lease payments24,541 7,612 
Less: amounts representing interest(16,490)(2,778)
Total present value of minimum lease payments$8,051 $4,834 
_______
(1)The direct finance lease liability is included in accounts payable and accrued expenses on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Litigation and Regulatory Matters
In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.
Environmental Matters
In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of September 30, 2023, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.
Note 17 — Subsequent Events
The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except for the following:
Dividend Declaration
On October 2, 2023, the Company announced the declaration of a stock dividend of 0.015179 shares of the Company’s common stock, on each share of the Company’s outstanding common stock. The stock dividend was issued on October 16, 2023 to holders of record of the Company’s common stock at the close of business on October 12, 2023.
Other Subsequent Events
Subsequent to September 30, 2023, the Company renewed two interest rate caps, which matured on November 1, 2023, with an aggregate notional amount of $150.9 million and a strike price of 3.50% for $5.0 million. Additionally, the Company provided a $6.7 million cash deposit to Fannie Mae. This deposit was provided because the debt service coverage ratio of the underlying properties of each facility were below the minimum required amount per the debt agreements. This deposit will be refunded at the earlier of the Company’s achievement of a debt service coverage ratio above the minimum required amount of 1.40 or the maturity of the Fannie Mae Master Credit Facilities.
44


Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with the accompanying consolidated financial statements of Healthcare Trust, Inc. and the notes thereto. As used herein, the terms the “Company,” “we,” “our” and “us” refer to Healthcare Trust, Inc., a Maryland corporation, including, as required by context, Healthcare Trust Operating Partnership, LP (our “OP”), a Delaware limited partnership, and its subsidiaries. The Company is externally managed by Healthcare Trust Advisors, LLC (our “Advisor”), a Delaware limited liability company. Capitalized terms used herein, but not otherwise defined, have the meaning ascribed to those terms in “Part I — Financial Information” included in the notes to the consolidated financial statements and contained herein.
Forward-Looking Statements
Certain statements included in this Quarterly Report on Form 10-Q that are not historical facts may be forward-looking statements. Such forward-looking statements include the intent, belief or current expectations of Healthcare Trust, Inc. (“we,” “our” or “us”) and members of our management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,”, “projects,” “potential,” “predicts,” “intends,” “would,” “could,” “should” or similar expressions, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those contemplated by such forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.
These forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the risks associated with the geopolitical instability due to the ongoing military conflicts between Russia and Ukraine and Israel and Hamas, including related sanctions and other penalties imposed by the U.S. and European Union, and the related impact on us, our tenants and the global economy and financial markets; that any potential future acquisition by the Company is subject to market conditions and capital availability and may not be identified or completed on favorable terms, or at all. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause our actual results to differ materially from those presented in our forward-looking statements are set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022 as well as Part II — Other Information, Item IA — Risk Factors below.
Overview
We are an externally managed entity that for U.S. federal income tax purposes has qualified as a real estate investment trust (“REIT”). We acquire, own and manage a diversified portfolio of healthcare-related real estate focused on medical office and other healthcare-related buildings and senior housing operating properties. As of September 30, 2023, we owned 204 properties located in 33 states and comprised of 9.0 million rentable square feet.
Substantially all of our business is conducted through the OP, a Delaware limited partnership, and its wholly-owned subsidiaries. Our Advisor manages our day-to-day business with the assistance of Healthcare Trust Properties, LLC (our “Property Manager”). Our Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”) and these related parties receive compensation and fees for providing services to us. We also reimburse these entities for certain expenses they incur in providing these services to us. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in us through ownership of interests in our OP.
We operate in two reportable business segments for management and financial reporting purposes: medical office and other health-care related buildings (“MOBs”) and senior housing operating properties (“SHOPs”). All of our properties across both business segments are located throughout the United States. In our MOB operating segment, we own, manage, and lease single- and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. Our Property Manager or third-party managers manage our MOBs. In our SHOP segment, we invest in seniors housing properties through the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure. As of September 30, 2023, we had four eligible independent contractors operating 46 SHOPs, although effective on September 30, 2023, we terminated our contract with one independent contractor which managed 20 SHOPs. We are in the process of transferring the management of these 20 SHOPs to a new independent contractor, which we expect to be completed before December 31, 2023. There were no material costs incurred by this termination in the three or nine months ended September 30, 2023.
We have declared and paid quarterly dividends entirely in shares of our common stock since October 2020.
On March 31, 2023, we published a new Estimated Per-Share NAV equal to $14.00 as of December 31, 2022. Our previous Estimated Per-Share NAV was equal to $15.00 as of December 31, 2021. The Estimated Per-Share NAV has not been
45


adjusted since publication and will not be adjusted until the Board determines a new Estimated Per-Share NAV. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when dividends paid in stock are issued; however, because each stockholder will receive the same number of new shares, the total value of our common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. We intend to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless and until we list our common stock.
Management Update on the Continuing Impacts of the COVID-19 Pandemic
The COVID-19 global pandemic created several risks and uncertainties that have impacted our business, including our financial condition, future results of operations and our liquidity.
Seniors Housing Properties
Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect us in a number of ways. Occupancy in our SHOP portfolio trended lower from 85.1% as of December 31, 2019 to a low of 72.0% as of March 31, 2021, and stabilized until December 31, 2022. As of September 30, 2023, occupancy in this segment reached 74.1%, representing a decline from December 31, 2022 of 1.0%. The below table presents SHOP occupancy since the onset of our downward occupancy trends, which was exacerbated by the COVID-19 pandemic in March 2020:
As of
Number of Properties(1)
Rentable UnitsPercentage Leased
December 31, 2019594,92685.1%
March 31, 2020635,19884.4%
June 30, 2020635,19879.2%
September 30, 2020675,35077.4%
December 31, 2020594,87874.5%
March 31, 2021554,68272.0%
June 30, 2021544,53073.2%
September 30, 2021544,49474.3%
December 31, 2021544,49474.1%
March 31, 2022504,37875.9%
June 30, 2022504,37476.3%
September 30, 2022504,37475.8%
December 31, 2022504,37475.1%
March 31, 2023504,37473.3%
June 30, 2023 (2)
464,16473.3%
September 30, 2023 (2)
464,16474.1%
________
(1)Exclusive of two land parcels.
(2)Inclusive of one SHOP with 39 rentable units which was closed in May 2023.
Contract Labor and Wage Expenses
Beginning with the second quarter of 2021, our occupancy and operating costs in our SHOP portfolio were relatively stable. During the year ended December 31, 2022, our third party operators needed to increase their use of temporary contract labor and agencies, and the amount paid for overtime, training and bonus wages, in response to a shortage of workers, the cost of labor generally, lack of qualified personnel that our third party operators are able to employ on a permanent basis and training hours and other onboarding costs for permanent staff which replaced previously utilized contract and agency labor. During the nine months ended September 30, 2023, these contract and agency costs declined. In particular, costs incurred from contract labor and agencies for care providers decreased in our SHOP segment by $2.9 million and $5.1 million, from $3.2 million and $6.7 million, respectively, in the three and nine months ended September 30, 2022, to $0.3 million and $1.6 million, respectively, as compared to the three and nine months ended September 30, 2023.
46


However, these costs were offset by increased wage costs for direct employees of our third party operators of $0.8 million and $4.9 million, respectively, in the three and nine months ended September 30, 2023 compared to the three and nine months ended September 30, 2022. Likewise, occupancy levels have not recovered to their pre-pandemic rates (as noted in the table above), thus the results of operations in our SHOP segment have been significantly adversely affected by the increase in labor costs even though resident fees have increased.
Rent Concessions
We have also granted rent concessions since the onset of the COVID-19 pandemic which serve to reduce revenue in our SHOP segment. We offered $0.8 million and $2.3 million rent concessions during the three and nine months ended September 30, 2023, and $0.7 million and $2.7 million during the three and nine months ended September 30, 2022.
The CARES Act
The adverse financial impacts of the COVID-19 pandemic were partially offset by funds we received under the CARES Act in prior years, however, no such funds have been received or are expected in 2023. On March 27, 2020, the CARES Act was signed into law and it provided funding to Medicare providers in order to alleviate financial hardship during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designed to reimburse providers for healthcare-related expenses and lost revenues attributable to COVID-19. We did not receive any funding from the CARES Act during the three and nine months ended September 30, 2023. We received $4.3 million and $4.5 million, respectively, of funds through the CARES Act for the three and nine months ended September 30, 2022. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. We recognized funding under this program as a reduction of property operating and maintenance expenses in our consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Future developments in the course of inflation increases, labor shortages and supply chain disruptions may cause further adverse impacts on our occupancy and cost levels.
Significant Accounting Estimates and Critical Accounting Policies
For a discussion about our significant accounting estimates and critical accounting policies, see the “Significant Accounting Estimates and Critical Accounting Policies” section of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 17, 2023. Except for those required by new accounting pronouncements discussed below, there have been no material changes from these significant accounting estimates and critical accounting policies.
Recently Issued Accounting Pronouncements
Please see Note 2 — Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements to our consolidated financial statements in this Quarterly Report on Form 10-Q for further discussion.
Properties
The following table presents certain additional information about the properties we owned as of September 30, 2023:
PortfolioNumber
of Properties
Rentable
Square Feet
Percentage Leased(1)
Weighted Average Remaining
Lease Term in Years (2)
Gross Asset Value (3)
(In thousands)
MOB Segment1565,153,419 90.9%4.8$1,465,516 
SHOP Segment48(4)3,857,652 74.1%(5)N/A1,132,650 
Total Portfolio2049,011,071 $2,598,166 
________
(1)Inclusive of leases signed but not yet commenced as of September 30, 2023.
(2)Weighted-average remaining lease term in years is calculated based on square feet as of September 30, 2023.
(3)Gross asset value represents total real estate investments, at cost ($2.6 billion total as of September 30, 2023) net of gross market lease intangible liabilities ($23.5 million total as of September 30, 2023). Impairment charges are already reflected within gross asset value.
(4)Includes two parcels of land
(5)Weighted by unit count as of September 30, 2023. As of September 30, 2023, we had 4,164 rentable units in our SHOP segment. The SHOP segment includes one closed SHOP with 30 rentable units, and excludes land parcels.
N/A    Not applicable.

47

Same Store Properties
Information based on Same Store Properties, Acquired Properties and Disposed Properties (as each are defined below) allows us to evaluate the performance of our portfolio based on a consistent population of properties owned for the entire period of time covered. As of September 30, 2023, we owned 204 properties. There were 193 properties owned for the entire year ended December 31, 2022 and the nine months ended September 30, 2023 (our “Same Store Properties), including two vacant land parcels. Since January 1, 2022, we acquired eleven properties (our “Acquired Properties”) and disposed of nine properties (our “Disposed Properties”).
The following table presents a roll-forward of our properties owned from January 1, 2022 to September 30, 2023:
MOBSHOPTotal
Number of properties, January 1, 2022146 56 202 
Acquisition activity during the year ended December 31, 2022— 
Disposition activity during the year ended December 31, 2022— (4)(4)
Number of properties, December 31, 2022150 52 202 
Acquisition activity during the nine months ended September 30, 2023— 
Disposition activity during the nine months ended September 30, 2023(1)(4)(5)
Number of properties, September 30, 2023156 48 204 
Number of Same Store Properties145 48 193 
Number of Acquired Properties11  11 
Number of Disposed Properties1 8 9 
48


Results of Operations
Comparison of the Three Months Ended September 30, 2023 and 2022
Net loss attributable to common stockholders was $19.6 million and $23.3 million, respectively, for the three months ended September 30, 2023, and 2022. The following table shows our results of operations for the three months ended September 30, 2023 and 2022 and the period to period change by line item of the consolidated statements of operations:
 Three Months Ended September 30,Increase (Decrease)
(Dollars in thousands)20232022$
Revenue from tenants$85,686 $83,460 $2,226 
Operating expenses: 
Property operating and maintenance54,326 51,198 3,128 
Impairment charges— 8,949 (8,949)
Operating fees to related parties6,397 6,333 64 
Acquisition and transaction related173 199 (26)
General and administrative4,753 4,471 282 
Depreciation and amortization20,776 20,854 (78)
Total expenses
86,425 92,004 (5,579)
Operating loss before (loss) gain on sale of real estate investments(739)(8,544)7,805 
(Loss) gain on sale of real estate investments(173)194 (367)
Operating loss(912)(8,350)7,438 
Other income (expense):
Interest expense(15,720)(13,284)(2,436)
Interest and other income258 10 248 
Gain on non-designated derivatives406 1,826 (1,420)
Total other expenses
(15,056)(11,448)(3,608)
Loss before income taxes(15,968)(19,798)3,830 
Income tax expense(157)(77)(80)
Net loss(16,125)(19,875)3,750 
Net loss attributable to non-controlling interests14 22 (8)
Allocation for preferred stock(3,450)(3,450)— 
Net loss attributable to common stockholders$(19,561)$(23,303)$3,742 
Net Operating Income
NOI is a non-GAAP financial measure used by us to evaluate the operating performance of our real estate portfolio. NOI is equal to revenue from tenants less property operating and maintenance expenses. NOI excludes all other items of expense and income included in the financial statements in calculating net loss attributable to common stockholders.
We believe NOI provides useful and relevant information because it reflects only those income and expense items that are incurred at the property-level and presents such items on an unlevered basis. We use NOI to assess and compare property-level performance and to make decisions concerning the operation of the properties. Further, we believe NOI is useful to investors as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net loss attributable to common stockholders.
NOI excludes certain components from net loss to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property-level.
NOI presented by us may not be comparable to NOI reported by other REITs that define NOI differently. We believe that in order to facilitate a clear understanding of our operating results, NOI should be examined in conjunction with net loss to common stockholders as presented in our consolidated statements of operations. NOI should not be considered as an alternative
49


to net loss attributable to common stockholders as an indication of our performance, or to cash flows as a measure of our liquidity or ability to pay distributions.
The following table reflects the items deducted from or added to net loss attributable to stockholders in our calculation of Same Store Properties, Acquired Properties and Disposed Properties NOI for the three months ended September 30, 2023:
(In thousands)Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
MOBsSHOPsMOBsSHOPsMOBsSHOPs
Net income (loss) attributable to common stockholders (in accordance with GAAP)$11,119 $(1,423)$492 $— $(4)$(141)$(29,604)$(19,561)
Operating fees to related parties— — — — — — 6,397 6,397 
Acquisition and transaction related— — — — — — 173 173 
General and administrative21 — — — — — 4,732 4,753 
Depreciation and amortization12,152 8,146 478 — — — — 20,776 
Interest expense21 329 — — — — 15,370 15,720 
Interest and other income(1)(2)— — — — (255)(258)
Gain on sale of real estate investments— 55 — — — 118 — 173 
Loss on non-designated derivative instruments— — — — — — (406)(406)
Income tax (benefit) expense— — — — — — 157 157 
Allocation for preferred stock— — — — — — 3,450 3,450 
Net loss attributable to non-controlling interests— — — — — — (14)(14)
NOI$23,312 $7,105 $970 $— $(4)$(23)$— $31,360 
The following table reflects the items deducted from or added to net loss attributable to stockholders in our calculation of Same Store Properties, Acquired Properties and Disposed Properties NOI for the three months ended September 30, 2022:
(In thousands)Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
MOBsSHOPsMOBsSHOPsMOBsSHOPs
Net income (loss) attributable to common stockholders (in accordance with GAAP)$10,696 $(2,970)$170 $— $(79)$(5,545)$(25,575)$(23,303)
Impairment charges— 4,108 — — — 4,841 — 8,949 
Operating fees to related parties— — — — — — 6,333 6,333 
Acquisition and transaction related— — — — — 198 199 
General and administrative22 — — — — — 4,449 4,471 
Depreciation and amortization12,753 7,668 194 — 31 208 — 20,854 
Interest expense21 338 — — — — 12,925 13,284 
Interest and other income(1)— — — — — (9)(10)
Loss on sale of real estate investments— — — — — (194)— (194)
Gain on non-designated derivative instruments— — — — — — (1,826)(1,826)
Income tax (benefit) expense— — — — — — 77 77 
Allocation for preferred stock— — — — — — 3,450 3,450 
Net income attributable to non-controlling interests— — — — — — (22)(22)
NOI$23,491 $9,144 $365 $— $(48)$(690)$— $32,262 
50


Segment Results — Medical Office Buildings
The following table presents the revenue and property operating and maintenance expense and the period to period change within our MOB segment for the three months ended September 30, 2023 and 2022:
Same Store (1)
Acquisitions (2)
Dispositions (3)
Segment Total (4)
 Three Months Ended September 30,Increase (Decrease)Three Months Ended September 30,Increase (Decrease)Three Months Ended September 30,Increase (Decrease)Three Months Ended September 30,Increase (Decrease)
(Dollars in thousands)20232022$20232022$20232022$20232022$
Revenue from tenants$32,594 $32,779 $(185)$1,063 $403 $660 $— $$(3)$33,657 $33,185 $472 
Less: Property operating and maintenance
9,282 9,288 (6)93 38 55 51 (47)9,379 9,377 
      NOI$23,312 $23,491 $(179)$970 $365 $605 $(4)$(48)$44 $24,278 $23,808 $470 
_______________
(1)Our MOB segment included 145 Same Store Properties.
(2)Our MOB segment included 11 Acquired Properties.
(3)Our MOB segment included one Disposed Property.
(4)Our MOB segment included 156 total properties.
Revenue from tenants primarily reflects contractual rent received from tenants in our MOBs and operating expense reimbursements. These reimbursements generally increase in proportion with the increase in property operating and maintenance expenses in our MOB segment. Pursuant to many of our lease agreements in our MOBs, tenants are required to pay their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors, in addition to base rent.
Revenue from Tenants
During the three months ended September 30, 2023, revenue from tenants increased by $0.5 million in our MOB segment as compared to the three months ended September 30, 2022, which was primarily driven by an increase in revenue from tenants of $0.7 million due to our Acquired Properties, partially offset by a decrease in revenue from tenants of $0.2 million due to our Same Store Properties.
The decrease in our Same Store properties revenue from tenants was primarily due to marginally lower occupancy in these properties in the three months ended September 30, 2023 as compared to the three months ended September 30, 2022.
Property Operating and Maintenance
Property operating and maintenance expenses reflect the costs associated with our properties, including real estate taxes, utilities, repairs, maintenance, and unaffiliated third-party property management fees. Our MOB segment had consistent property operating and maintenance expenses of $9.4 million in each of the three months ended September 30, 2023 and 2022.
Segment Results — Seniors Housing Operating Properties
The following table presents the revenue and property operating and maintenance expenses and the period to period change within our SHOP segment for the three months ended September 30, 2023 and 2022:
Same Store (1)
Acquisitions (2)
Dispositions (3)
Segment Total (4)
 Three Months Ended September 30,Increase (Decrease)Three Months Ended September 30,Increase (Decrease)Three Months Ended September 30,Increase (Decrease)Three Months Ended September 30,Increase (Decrease)
(Dollars in thousands)20232022$20232022$20232022$20232022$
Revenue from tenants$52,034 $49,667 $2,367 $— $— $— $(5)$608 $(613)$52,029 $50,275 $1,754 
Less: Property operating and maintenance
44,929 40,523 4,406 — — — 18 1,298 (1,280)44,947 41,821 3,126 
NOI
$7,105 $9,144 $(2,039)$— $— $— $(23)$(690)$667 $7,082 $8,454 $(1,372)
________
(1)Our SHOP segment included 48 Same Store Properties (including two land parcels).
(2)Our SHOP segment did not include any Acquired Properties.
(3)Our SHOP segment included eight Disposed Properties.
(4)Our SHOP segment included 48 total properties (including two land parcels).
Revenue from tenants within our SHOP segment are generated in connection with rent and services offered to residents in our SHOPs depending on the level of care required, as well as fees associated with other ancillary services. Property operating and maintenance expenses relate to the costs associated with staffing to provide care for the residents in our SHOPs, as well as food, marketing, real estate taxes, management fees paid to our third-party operators, and costs associated with maintaining the physical site.
Revenue from Tenants
51


During the three months ended September 30, 2023, revenue from tenants increased by $1.8 million in our SHOP segment as compared to the three months ended September 30, 2022, which was due to an increase in revenue from tenants of $2.4 million from our Same Store Properties, partially offset by a decrease in revenue from tenants of $0.6 million from our Disposed Properties.
The increase to our Same Store properties revenue from tenants was primarily driven by higher leasing rates during the three months ended September 30, 2023 as compared to the three months ended September 30, 2022, partially offset by marginally lower occupancy in the three months ended September 30, 2023 as compared to the three months ended September 30, 2022. Additionally, we offered more rent concessions during the three months ended September 30, 2023, which amounted to $0.8 million as compared to $0.7 million of rent concessions offered during the three months ended September 30, 2022.
Property Operating and Maintenance
During the three months ended September 30, 2023, property operating and maintenance expenses increased $3.1 million in our SHOP segment as compared to the three months ended September 30, 2022, primarily due to an increase in property operating and maintenance expenses of $4.4 million in our Same Store Properties, partially offset by a decrease of $1.3 million from our Disposed Properties.
Our Same Store Properties property operating and maintenance expenses increased in the quarter ended September 30, 2023 compared to the same period last year, primarily from $3.5 million of funds received through the CARES Act in the three months ended September 30, 2022 (of a total $4.3 million received from the CARES Act during that period), which serve to reduce property operating expenses in the period received. There were no such receipts from the CARES Act in the three months ended September 30, 2023. The increase was also due to (i) $1.6 million of increased costs for overtime, training and bonus wages paid to employees of our third party operators, (ii) $1.1 million of increased management fees paid to our third party operators, (iii) $0.7 million of higher insurance expense, (iv) $0.3 million of costs directly related to the termination of one SHOP operator effective September 30, 2023 and (v) the effects of inflation which raised the general costs of food, supplies, and utilities generally. These increases to property operating and maintenance expenses were partially offset by decreased costs for contract labor of $2.8 million.
Other Results of Operations
Impairment Charges
We did not record any impairment charges during the quarter ended September 30, 2023.
During the three months ended September 30, 2022, we incurred $8.9 million of impairment charges which related to six held for use SHOP properties of eight total properties that we were actively marketing for sale. These impairment charges were recorded to reduce the carrying value of these six properties to their fair values, respectively, as determined by estimated discounted cash flows over our intended holding period.
See Note 3 — Real Estate Investments to our consolidated financial statements in this Quarterly Report on Form 10-Q for additional information on the impairment charges.
Operating Fees to Related Parties
Operating fees to related parties were consistent at $6.4 million and $6.3 million, respectively, for the three months ended September 30, 2023 and 2022, respectively.
Our Advisor and Property Manager are paid for asset management and property management services for managing our properties on a day-to-day basis. We pay a fixed base management fee equal to $1.6 million per month, while the variable portion of the base management fee is equal, per month, to one-twelfth of 1.25% of the cumulative net proceeds of any equity raised subsequent to February 17, 2017. Asset management fees were $5.5 million for both the three months ended September 30, 2023 and 2022. Variable asset management fees will increase if we issue additional equity securities in the future. There were no incentive fees incurred in either of the three months ended September 30, 2023 or 2022.
Property management fees were consistent at $0.9 million for the three months ended September 30, 2023 and 2022. Property management fees increase or decrease in direct correlation with gross revenues of the properties managed and depending on the mix of properties managed, as the fee payable for different types of properties varies.
See Note 9 Related Party Transactions and Arrangements to our consolidated financial statements in this Quarterly Report on Form 10-Q which provides detail on our fees and expense reimbursements.
Acquisition and Transaction Related Expenses
Acquisition and transaction related expenses were consistent at $0.2 million for the three months ended September 30, 2023 and 2022.
52


General and Administrative Expenses
General and administrative expenses increased by $0.3 million to $4.8 million for the three months ended September 30, 2023 compared to $4.5 million for the three months ended September 30, 2022, which includes $2.8 million and $2.4 million, respectively, for the three months ended September 30, 2023 and September 30, 2022, incurred in expense reimbursements. The increase in general and administrative expenses was primarily attributable to $0.3 million of severance payments incurred in the three months ended September 30, 2023 made to former employees of the Advisor.
Depreciation and Amortization Expenses
Depreciation and amortization expense increased $0.1 million to $20.8 million for the three months ended September 30, 2023 from $20.9 million for the three months ended September 30, 2022.
Loss on Sale of Real Estate Investments
During the three months ended September 30, 2023 and 2022, we did not dispose of any properties. However, we did record a loss on sale of $0.2 million during the three months ended September 30, 2023 and gain on sale of $0.2 million in the three months ended September 30, 2022, related to various settlements of liens and accruals on formerly disposed properties.
Interest Expense
Interest expense increased by $2.4 million to $15.7 million for the three months ended September 30, 2023 from $13.3 million for the three months ended September 30, 2022. The increase in interest expense mainly resulted from higher average rates and higher average balances of our indebtedness during the three months ended September 30, 2023 as compared to the three months ended September 30, 2022. These increases were partially offset by the amortization of our terminated swaps, which reduced interest expense in the three months ended September 30, 2023 by $1.5 million as well as by a decrease in deferred financing cost amortization of $0.5 million in the three months ended September 30, 2023 as compared to the three months ended September 30, 2022.
As of September 30, 2023, our outstanding debt obligations were $1.2 billion at a weighted average interest rate of 5.56% per year. As of September 30, 2022, we had total borrowings of $1.1 billion, at a weighted average interest rate of 4.29% per year. The weighted-average interest rates include the impact of our “pay-fixed” interest rate swaps which are designated as hedges on a portion of our variable-rate borrowings.
Our interest expense in future periods will vary based on our level of future borrowings and the cost of borrowings, among other factors (including the impact of variable rates to the extent such borrowings are not hedged). Recent and continuing increases in interest rates may adversely impact the terms on which we may borrow in the future and thus our results of operations.
Interest and Other Income
Interest and other income includes income from our investment securities and interest income earned on cash and cash equivalents held during the period. Interest and other income was approximately $0.3 million and $10,000, respectively, for the three months ended September 30, 2023 and 2022. Interest income increased in the three months ended September 30, 2023 due to a higher balance of cash (including restricted cash) as well as higher interest rates on our cash accounts.
Gains (Losses) on Non-Designated Derivatives
The loss in the three months ended September 30, 2023 and September 30, 2022 on non-designated derivative instruments related to interest rate caps that are designed to protect us from adverse interest rate changes in connection with our Fannie Mae Master Credit Facilities, which have floating interest rates. The relevant amounts in each period represent the change in value and any cash received on the non-designated derivatives.
Income Tax Expense
Income taxes generally relate to our SHOPs, which are leased to our TRS. We recorded an income tax expense of $0.2 million and $0.1 million, respectively, for the three months ended September 30, 2023 and 2022.
Because of our TRS’s recent operating history of losses and the continuing impacts of the COVID-19 pandemic on the results of operations of our SHOP assets, in the third quarter of 2020, we were not able to conclude that it is more likely than not we will realize the future benefit of our deferred tax assets and recorded a full valuation allowance. Since that time, our TRS’s operating performance has not significantly improved and thus we have recorded a 100% valuation allowance on our net deferred tax assets as of September 30, 2023. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our consolidated statements of comprehensive loss.
53


Net Loss Attributable to Non-Controlling Interests
Net loss attributable to non-controlling interests was approximately $14,000 for the three months ended September 30, 2023 and net loss attributable to non-controlling interests was approximately $22,000 for the three months ended September 30, 2022. These amounts represent the portion of our net loss that is related to the Series A Preferred Units held by third parties, Common OP Units held by third parties, and non-controlling interest holders in our subsidiaries that own certain properties.
Allocation for Preferred Stock Dividends
Allocation for preferred stock was $3.5 million for the three months ended September 30, 2023 and 2022. These amounts represent the allocation of our net loss that is attributable to holders of Series A Preferred Stock and holders of Series B Preferred Stock.
Comparison of the Nine Months Ended September 30, 2023 and 2022
Information based on Same Store, Acquisitions and Dispositions allows us to evaluate the performance of our portfolio based on a consistent population of properties. Net loss attributable to common stockholders was $57.8 million and $71.2 million, respectively, for the nine months ended September 30, 2023 and 2022. The following table shows our results of operations for the nine months ended September 30, 2023 and 2022 and the period to period change by line item of the consolidated statements of operations:
 Nine Months Ended September 30,Increase (Decrease)
(Dollars in thousands)20232022$
Revenue from tenants$259,145 $250,936 $8,209 
Operating expenses:  
Property operating and maintenance161,778 156,880 4,898 
Impairment charges— 25,786 (25,786)
Operating fees to related parties19,153 19,003 150 
Acquisition and transaction related384 1,153 (769)
General and administrative14,105 13,369 736 
Depreciation and amortization61,520 61,525 (5)
Total expenses
256,940 277,716 (20,776)
Operating income (loss) before loss on sale of real estate investments2,205 (26,780)28,985 
Loss on sale of real estate investments(364)(109)(255)
Operating income (loss)1,841 (26,889)28,730 
Other income (expense):
Interest expense(50,208)(37,098)(13,110)
Interest and other income
576 24 552 
Gain on non-designated derivatives510 3,212 (2,702)
Total other expenses
(49,122)(33,862)(15,260)
Loss before income taxes(47,281)(60,751)13,470 
Income tax expense(244)(159)(85)
Net loss(47,525)(60,910)13,385 
Net loss attributable to non-controlling interests45 100 (55)
Allocation for preferred stock (10,349)(10,349)— 
Net loss attributable to common stockholders$(57,829)$(71,159)$13,330 

54


Net Operating Income
The following table reflects the items deducted from or added to net income (loss) attributable to stockholders in our calculation of Same Store, Acquisitions and Dispositions NOI for the nine months ended September 30, 2023:
(In thousands)Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
MOBsSHOPsMOBsSHOPsMOBsSHOPs
Net income (loss) attributable to common stockholders (in accordance with GAAP)$34,463 $(349)$1,324 $— $(352)$(511)$(92,404)$(57,829)
Operating fees to related parties— — — — — — 19,153 19,153 
Acquisition and transaction related— — — — — — 384 384 
General and administrative97 26 — — — — 13,982 14,105 
Depreciation and amortization36,208 23,744 1,292 — 63 213 — 61,520 
Interest expense64 995 — — — — 49,149 50,208 
Interest and other income(4)(270)— — — — (302)(576)
Loss on sale of real estate investments— 43 — — 260 61 — 364 
Gain on non-designated derivative instruments— — — — — — (510)(510)
Income tax (benefit) expense— — — — — — 244 244 
Allocation for preferred stock— — — — — — 10,349 10,349 
Net loss attributable to non-controlling interests— — — — — — (45)(45)
NOI$70,828 $24,189 $2,616 $— $(29)$(237)$— $97,367 
The following table reflects the items deducted from or added to net income (loss) attributable to stockholders in our calculation of Same Store, Acquisitions and Dispositions NOI for the nine months ended September 30, 2022:
(In thousands)Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
MOBsSHOPsMOBsSHOPsMOBsSHOPs
Net income (loss) attributable to common stockholders (in accordance with GAAP)$22,870 $(3,861)$218 $— $(249)$(13,755)$(76,382)$(71,159)
Impairment charges10,644 4,108 — — — 11,034 — 25,786 
Operating fees to related parties— — — — — — 19,003 19,003 
Acquisition and transaction related212 — — — — 940 1,153 
General and administrative65 — — — 13,300 13,369 
Depreciation and amortization37,450 22,785 224 — 92 974 — 61,525 
Interest expense95 1,050 — — — — 35,953 37,098 
Interest and other income(4)(1)— — (9)— (10)(24)
Loss on sale of real estate investments— — — — — 109 — 109 
Gain on non-designated derivative instruments— — — — — — (3,212)(3,212)
Income tax (benefit) expense— — — — — — 159 159 
Allocation for preferred stock— — — — — — 10,349 10,349 
Net loss attributable to non-controlling interests— — — — — — (100)(100)
NOI$71,332 $24,083 $443 $— $(166)$(1,636)$— $94,056 

55


Segment Results — Medical Office Buildings
The following table presents the components of NOI and the period to period change within our MOB segment for the nine months ended September 30, 2023 and 2022:
Same Store(1)
Acquisitions(2)
Dispositions(3)
Segment Total
 Nine Months Ended September 30,Increase (Decrease)Nine Months Ended September 30,Increase (Decrease)Nine Months Ended September 30,Increase (Decrease)Nine Months Ended September 30,Increase (Decrease)
(Dollars in thousands)20232022$20232022$20232022$20232022$
Revenue from tenants
$98,282 $97,557 $725 $2,844 $485 $2,359 $61 $(16)$77 $101,187 $98,026 $3,161 
Less: Property operating and maintenance27,454 26,225 1,229 228 42 186 90 150 (60)27,772 26,417 1,355 
NOI$70,828 $71,332 $(504)$2,616 $443 $2,173 $(29)$(166)$137 $73,415 $71,609 $1,806 
_______________
(1)Our MOB segment included 145 Same Store properties.
(2)Our MOB segment included 11 Acquisition properties.
(3)Our MOB segment included one Disposition property.
(4)Our MOB segment included 156 properties.
Revenue from tenants primarily reflects contractual rent received from tenants in our MOBs and operating expense reimbursements. These reimbursements generally increase in proportion with the increase in property operating and maintenance expenses in our MOB segment. Pursuant to many of our lease agreements in our MOBs, tenants are required to pay their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors, in addition to base rent.
Revenue from Tenants
During the nine months ended September 30, 2023, revenue from tenants increased by $3.2 million in our MOB segment as compared to the nine months ended September 30, 2022, primarily as a result of increased revenue from tenants of $2.4 million due to our Acquired Properties and an increase in revenue from tenants of $0.7 million from our Same Store Properties, and an increase in revenue from tenants of $0.1 million due to our Disposed Properties.
The increase in our Same Store Properties revenue from tenants was primarily driven by an increase of operating expense reimbursement revenue from increased property, operating and maintenance expenses, as well as from marginally higher occupancy in the nine months ended September 30, 2023, as compared to September 30, 2022.
Property Operating and Maintenance
Property operating and maintenance expenses reflect the costs associated with our properties, including real estate taxes, utilities, repairs, maintenance, and unaffiliated third-party property management fees. During the nine months ended September 30, 2023, property operating and maintenance costs in our MOB segment increased by $1.4 million as compared to the same period last year, primarily as a result of increased costs from our Same Store Properties of $1.2 million.
The increase in property operating and maintenance expenses from our Same Store properties is primarily the result of the impacts of inflation on utility and maintenance costs, which are largely reimbursed by tenants.
Segment Results — Seniors Housing - Operating Properties
The following table presents the components of NOI and the period to period change within our SHOP segment for the nine months ended September 30, 2023 and 2022:
Same Store (1)
Acquisitions (2)
Dispositions (3)
Segment Total
 Nine Months Ended September 30,Increase (Decrease)Nine Months Ended September 30,Increase (Decrease)Nine Months Ended September 30,Increase (Decrease)Nine Months Ended September 30,Increase (Decrease)
(Dollars in thousands)20232022$20232022$20232022$20232022$
Revenue from tenants
$155,197 $147,057 $8,140 $— $— $— $2,761 $5,853 $(3,092)$157,958 $152,910 $5,048 
Less: Property operating and maintenance131,008 122,974 8,034 — — — 2,998 7,489 (4,491)134,006 130,463 3,543 
NOI
$24,189 $24,083 $106 $— $— $— $(237)$(1,636)$1,399 $23,952 $22,447 $1,505 
_______________
(1)Our SHOP segment included 48 Same Store properties (including two land parcels.
(2)Our SHOP segment did not include any Acquired Properties.
(3) Our SHOP segment included eight Disposed Properties.
(4)Our SHOP segment included 48 total properties (including two land parcels).

Revenues from tenants within our SHOP segment are generated in connection with rent and services offered to residents in our SHOPs depending on the level of care required, as well as fees associated with other ancillary services. Property operating
56


and maintenance expenses relate to the costs associated with staffing to provide care for the residents in our SHOPs, as well as food, marketing, real estate taxes, management fees paid to our third-party operators, and costs associated with maintaining the physical site.
Revenue from Tenants
During the nine months ended September 30, 2023, revenue from tenants increased by $5.0 million in our SHOP segment as compared to the nine months ended September 30, 2022, which was primarily driven by an increase in revenue from tenants of $8.1 million due to our Same Store Properties, partially offset by a decrease in revenue from tenants of $3.1 million due to our Disposed Properties.
The increase to our Same Store properties revenue from tenants was primarily driven by higher leasing rates during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, as well as by $1.6 million of less rent concessions offered during the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022. These increases were partially offset by marginally lower occupancy in the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022.
Property Operating and Maintenance
During the nine months ended September 30, 2023, property operating and maintenance expenses increased $3.5 million in our SHOP segment as compared to the nine months ended September 30, 2022, primarily due to an increase in property operating and maintenance expenses of $8.0 million from our Same Store Properties, partially offset by a decrease of $4.5 million from our Disposed Properties.
Our Same Store properties operating and maintenance expenses increased in the nine months ended September 30, 2023 compared to the same period last year, primarily from $3.7 million of funds received through the CARES Act in the nine months ended September 30, 2022 (of a total $4.5 million received from the CARES Act in that period), which serve to reduce property operating expenses in the period received. There were no such receipts from the CARES Act in the nine months ended September 30, 2023. The increase was also due to (i) $6.6 million of increased costs for overtime, training and bonus wages paid to employees of our third party operators, (ii) $1.3 million of increased management fees paid to our third party operators, (iii) $0.4 million of higher insurance expense, (iv) $0.3 million of costs directly related to the termination of one SHOP operator effective September 30, 2023 and (v) the effects of inflation which raised the general costs of food, supplies, and utilities generally. These increases to property operating and maintenance expenses were partially offset by decreased costs for contract labor of $4.9 million.
Other Results of Operations
Impairment Charges
We did not record any impairment charges during the nine months ended September 30, 2023. We recorded impairment charges of $25.8 million during the nine months ended September 30, 2022, of which $10.6 million related to seven skilled nursing facilities in our MOB segment located in Illinois, and $15.1 million related to six held for use SHOP properties of eight total properties that we were actively marketing for sale. All of these impairment charges were recorded to reduce the carrying value of the properties to their fair values, respectively, as determined by estimated discounted cash flows over our intended holding periods.
See Note 3 — Real Estate Investments to our consolidated financial statements in this Quarterly Report on Form 10-Q for additional information on the impairment charges for the nine months ended September 30, 2023 and 2022.
Operating Fees to Related Parties
Operating fees to related parties were $19.2 million and $19.0 million, respectively, for the nine months ended September 30, 2023 and 2022.
Our Advisor and Property Manager are paid for asset management and property management services for managing our properties on a day-to-day basis (see — Results of Operations Comparison of the Three Months Ended September 30, 2023 and 2022 for additional information). Asset management fees were $16.4 million for both the nine months ended September 30, 2023 and 2022. Variable asset management fees will further increase if we issue additional equity securities in the future. There were no incentive fees incurred in either of the nine months ended September 30, 2023 or 2022.
Property management fees were consistent at $2.8 million and $2.6 million, respectively, for the nine months ended September 30, 2023 and 2022. Property management fees increase or decrease in direct correlation with gross revenues of the properties managed and depending on the mix of properties managed, as the fee payable for different types of properties varies.
See Note 9 Related Party Transactions and Arrangements to our consolidated financial statements in this Quarterly Report on Form 10-Q which provides detail on our fees and expense reimbursements.
57


Acquisition and Transaction Related Expenses
Acquisition and transaction related expenses decreased by $0.8 million, to $0.4 million for the nine months ended September 30, 2023 from $1.2 million for the nine months ended September 30, 2022. This decrease was due to $0.6 million of less dead deal costs, $0.1 million of less legal costs from terminated SHOP operators and $0.1 million of less mortgage prepayment penalties.
General and Administrative Expenses
General and administrative expenses increased $0.7 million to $14.1 million for the nine months ended September 30, 2023 compared to $13.4 million for the nine months ended September 30, 2022, which includes $7.6 million and $6.7 million, respectively, for the nine months ended September 30, 2023 and 2022, incurred in expense reimbursements. The increase in general and administrative expenses was primarily attributable to $0.3 million of severance payments incurred in the nine months ended September 30, 2023 made to former employees of the Advisor.
Depreciation and Amortization Expenses
Depreciation and amortization expense was consistent at $61.5 million for the nine months ended September 30, 2023 and 2022.
Gain (Loss) on Sale of Real Estate Investments
During the nine months ended September 30, 2023, we disposed of four SHOPs and one MOB for an aggregate contract sales price of $13.8 million. Two of the four disposed SHOPs were impaired by $15.1 million in the nine months ended September 30, 2022 (see above). As a result, the Company recorded an aggregate loss on sale of $0.4 million in the nine months ended September 30, 2023.
During the nine months ended September 30, 2022, we recorded a loss on sale of real estate investments of $0.1 million. This was comprised of a loss on sale of $0.3 million for the sale of the LaSalle Properties, partially offset by a gain of $0.2 million related to the settlement of a lien on formerly disposed properties. We had previously recorded $34.0 million of impairment charges on the LaSalle Properties in the year ended December 31, 2021.
Interest Expense
Interest expense increased $13.1 million to $50.2 million for the nine months ended September 30, 2023 from $37.1 million for the nine months ended September 30, 2022. The increase in interest expense mainly resulted from the acceleration of deferred financing costs of $2.6 million from the termination of our Prior Credit Facility, as well as from higher average rates and higher average balances of amounts outstanding under our indebtedness during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. These increases were partially offset by the amortization of our terminated swaps, which reduced interest expense in the nine months ended September 30, 2023 by $1.1 million but increased interest expense by $0.4 million in the nine months ended September 30, 2022.
As of September 30, 2023, our outstanding debt obligations were $1.2 billion, at a weighted average interest rate of 5.56% per year. As of September 30, 2022, we had total borrowings of $1.1 billion, at a weighted average interest rate of 4.29% per year. The weighted-average interest rates include the impact of our “pay-fixed” interest rate swaps which are designated as hedges on a portion of our variable-rate borrowings.
Our interest expense in future periods will vary based on our level of future borrowings and the cost of borrowings, among other factors (including the impact of variable rates to the extent such borrowings are not hedged). Recent and continuing increases in interest rates may adversely impact the terms on which we may borrow in the future and thus our results of operations.
Interest and Other Income
Interest and other income includes income from our investment securities and interest income earned on cash and cash equivalents held during the period. Interest and other income was approximately $0.6 million for the nine months ended September 30, 2023 and approximately $24,000 for the nine months ended September 30, 2022. Interest income increased in the nine months ended September 30, 2023 due to a higher balance of cash (including restricted cash) as well as higher interest rates on our cash accounts.
Gain (Loss) on Non-Designated Derivatives
Gain (loss) on non-designated derivative instruments for the nine months ended September 30, 2023 and 2022 related to interest rate caps that are designed to protect us from adverse interest rate changes in connection with the Fannie Mae Master Credit Facilities, which have floating interest rates. The gain recorded in the nine months ended September 30, 2023 was due to significant increases in interest rates during the period.
58


Income Tax Benefit (Expense)
Income taxes generally relate to our SHOPs, which are leased to our TRS. We recorded an income tax expense of approximately $0.2 million for the nine months ended September 30, 2023 and 2022.
Because of our TRS’s recent operating history of losses and the impacts of the COVID-19 pandemic on the results of operations of our SHOP assets, in the third quarter of 2020, we were not able to conclude that it is more likely than not we will realize the future benefit of our deferred tax assets and recorded a full valuation allowance. Since that time, our TRS’s operating performance has not significantly improved and thus we have recorded a 100% valuation allowance on our net deferred tax assets through September 30, 2023. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our consolidated statements of comprehensive income (loss).
Net Loss (Income) Attributable to Non-Controlling Interests
Net loss attributable to non-controlling interests was approximately $45,000 for the nine months ended September 30, 2023 and net loss attributable to non-controlling interests was approximately $0.1 million for the nine months ended September 30, 2022, which represents the portion of our net income that is related to the Series A Preferred Units held by third parties (issued in connection with a property acquisition in September, 2021), Common OP Units held by third parties, and other non-controlling interest holders in our subsidiaries that own certain properties.
Allocation for Preferred Stock
Allocation for preferred stock was $10.3 million for the nine months ended September 30, 2023 and 2022. These amounts represent the allocation of our net loss that is attributable to holders of Series A Preferred Stock and holders of Series B Preferred Stock.
Cash Flows from Operating Activities
The level of cash flows used in or provided by operating activities is affected by, among other things, the number of properties owned, the performance of those properties, the timing of interest payments and the amount of borrowings outstanding during the period, as well as the receipt of scheduled rent payments and the level of operating expenses.
During the nine months ended September 30, 2023, net cash provided by operating activities was $16.4 million. Cash inflows included non-cash items of $18.1 million (net loss of $47.5 million adjusted for non-cash items including: (i) depreciation and amortization of tangible and intangible assets, (ii) amortization of deferred financing costs, (iii) accretion of terminated swaps, (iv) net amortization of mortgage premiums and discounts, (v) accretion of market lease intangibles, (vi) bad debt expense, (vii) equity-based compensation, (viii) loss on sale of real estate investments, (ix) gain on non-designated derivatives and (x) impairment charges), cash received from non-designated derivative instruments of $3.9 million, and a decrease in prepaid expenses and other assets of $4.2 million. These cash inflows were partially offset by a decrease in accounts payable and accrued expenses of $1.5 million, an increase in unbilled receivables recorded in accordance with straight-line basis accounting of $0.9 million and a decrease in deferred rent and other liabilities of $1.0 million.
During the nine months ended September 30, 2022, net cash provided by operating activities was $21.1 million. Cash inflows included non-cash items of $30.4 million (net loss of $60.9 million adjusted for non-cash items including depreciation and amortization of tangible and identifiable intangible real estate assets, deferred financing costs and mortgage premiums and discounts, bad debt expense, equity-based compensation, gain on non-designated derivatives and impairment charges) and, a decrease in prepaid expenses and other assets of $1.0 million. These cash inflows were partially offset by a decrease in accounts payable and accrued expenses of $4.9 million related to timing of payments for real estate taxes, property operating expenses and professional and legal fees, a decrease in deferred rent and other liabilities of $2.2 million and by a net increase in unbilled receivables recorded in accordance with straight-line basis accounting of $1.2 million.
Cash Flows from Investing Activities
Net cash used in investing activities during the nine months ended September 30, 2023 was $49.0 million. The cash used in investing activities included (i) $35.3 million for the acquisition of seven properties, (ii) $14.0 million in capital expenditures and (iii) payments for non-designated derivative instruments of $4.6 million. These outflows were partially offset by $4.8 million of proceeds from real estate dispositions.
Net cash used in investing activities during the nine months ended September 30, 2022 was $22.7 million. The cash used in investing activities included $17.8 million for the acquisition of three properties and $16.7 million in capital expenditures, partially offset by $11.8 million from the sale of the four LaSalle Properties.
Cash Flows from Financing Activities
Net cash provided by financing activities during the nine months ended September 30, 2023 was $47.4 million. Cash inflows consisted of (i) proceeds from mortgage notes payable of $240.0 million, (ii) proceeds from borrowings under our
59


Revolving Credit Facility of $20.0 million, (iii) proceeds from terminated “pay-fixed” interest rate swaps of $5.4 million and (iv) contributions from non-controlling interests of $0.3 million. Cash outflows consisted of (i) payments our credit facilities of $199.2 million, (ii) payments for deferred financing costs of $7.8 million, (iii) dividends paid to holders of Series A Preferred Stock of $5.5 million, (iv) dividends paid to holders of Series B Preferred Stock of $4.8 million, (v) principal payments on our mortgages of $0.9 million and (vi) distributions to our non-controlling interests of $0.1 million.
Net cash used in financing activities of $19.8 million during the nine months ended September 30, 2022 was comprised of cash outflows of payments of deferred financing costs of $0.9 million, dividends paid to holders of Series A Preferred Stock of $5.5 million, dividends to paid holders of Series B Preferred Stock of $4.8 million, payments for derivative instruments of $39,000 and principal payments on mortgages of $8.3 million.
Liquidity and Capital Resources
Our existing principal demands for cash are to fund acquisitions, capital expenditures, the payment of our operating and administrative expenses, debt service obligations (including principal repayment), and dividends to holders of our Series A Preferred Stock and holders of our Series B Preferred Stock. We monitor our current and anticipated liquidity position relative to our current and anticipated demands for cash and believe that we have sufficient current liquidity to meet our financial obligations for at least the next 12 months. Our future liquidity requirements, and available liquidity, however, depend on many factors. Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates may adversely impact our results of operations and thus ultimately our liquidity. Supply chain disruptions and increases in interest rates may also impact our tenants’ ability to pay rent and hence our results of operations and liquidity.
We expect to fund our future short-term operating liquidity requirements, including dividends to holders of Series A Preferred Stock and holders of Series B Preferred Stock, through a combination of current cash on hand, net cash provided by our property operations, potential borrowings secured by currently unencumbered real estate assets (see below), potential future advances under our Fannie Mae Master Credit Facilities and net cash provided by our dispositions.
The Barclays MOB Loan Agreement requires us to maintain a minimum balance of cash and cash equivalents of $12.5 million at all times. As of September 30, 2023, we had $51.0 million of cash and cash equivalents.
At the closing of the Barclays MOB Loan (see below), we applied $194.8 million of the Barclays MOB Loan proceeds to repay and terminate our then-existing credit facility (the “Prior Credit Facility”). We also terminated the interest rate swap contracts that formerly hedged interest rate changes under the Prior Credit Facility (see Note 7 — Derivatives and Hedging Activities to our consolidated financial statements in this Quarterly Report on Form 10-Q for additional information). The remaining proceeds of approximately $39.0 million (after the payment of Barclays MOB Loan closing costs and reimbursement of deposits) were available for general corporate purposes, subject to the terms of the Barclays MOB Loan Agreement. Additionally, by terminating the Prior Credit Facility, we are no longer subject to certain restrictive covenants previously imposed by the Prior Credit Facility (see Note 5 — Credit Facilities to our consolidated financial statements in this Quarterly Report on Form 10-Q for additional information).
Financings
On May 24, 2023, we, through certain subsidiaries of our OP, entered into a non-recourse loan agreement (the “Barclays MOB Loan Agreement”), with (i) Barclays Capital Real Estate Inc., (ii) Société Générale Financial Corporation and (iii) KeyBank National Association (each individually, a “Lender,” and collectively, the “Lenders”), in the aggregate amount of $240.0 million (the “Barclays MOB Loan”). In connection with the Barclays MOB Loan Agreement, we entered into a Guaranty Agreement (the “Guaranty”) and an Environmental Indemnity Agreement (the “Environmental Indemnity”) for the benefit of the Lenders.
The Barclays MOB Loan is secured by, among other things, first priority mortgages on the Company’s interests in 62 MOBs, which had a carrying value of $416.8 million as of September 30, 2023. The Barclays MOB Loan has a 10-year term and is interest-only at a fixed rate of 6.453% per year. The Barclays MOB Loan Agreement requires us to pay interest on a monthly basis with the principal balance due on the maturity date of June 6, 2033. The Barclays MOB Loan Agreement requires us to comply with certain covenants, including, among other things, a requirement to maintain at all times a combination of cash and cash equivalents totaling at least $12.5 million.
As of September 30, 2023, our total debt leverage ratio (total debt divided by total gross asset value) was approximately 43.0%. Net debt totaled $1.1 billion, which represents gross debt ($1.2 billion) less cash and cash equivalents ($51.0 million). Gross asset value totaled $2.6 billion, which represents total real estate investments, at cost ($2.6 billion) net of gross market lease intangible liabilities ($23.5 million). Cumulative impairment charges are reflected within gross asset value.
As of September 30, 2023, we had total gross borrowings of $1.2 billion, at a weighted-average interest rate of 5.56%. The weighted-average interest rates in both periods include the impact of “pay-fixed” swaps that are designated as hedging
60


instruments on a portion of our variable-rate debt, but does not include the impact of our non-designated interest rate caps (discussed below).
As of September 30, 2023, the carrying value of our real estate investments, at cost was $2.6 billion, with $1.3 billion of this asset value pledged as collateral for mortgage notes payable and $0.6 billion of this asset value pledged to secure advances under the Fannie Mae Master Credit Facilities. These real estate assets are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, as applicable, unless the existing indebtedness is repaid or the collateral is released from the pledge associated with the secured debt.
Unencumbered real estate investments, at cost as of September 30, 2023 was $0.7 billion. There can be no assurance as to the amount of liquidity we would be able to generate from using these unencumbered assets as collateral for future mortgage loans, future advances under the Fannie Mae Master Credit Facilities, or other future financings.
Non-Designated Interest Rate Caps
Our interest rate caps are used to limit our exposure to interest rate movements on our Fannie Mae Master Credit Facilities for economic purposes, however, we do not elect to apply hedge accounting to these instruments. As of September 30, 2023, we had six SOFR-based interest rate caps with an aggregate notional amount of $351.6 million, which limits 30-day SOFR to 3.50% and have varying maturities through July 2025.
As SOFR has increased beyond 3.50%, we have received cash payments of $3.9 million in the nine months ended September 30, 2023. We did not receive such payments in the nine months ended September 30, 2022.
We paid premiums of $4.6 million to renew three caps with an aggregate notional amount of $138.5 million which matured in the nine months ended September 30, 2023. Subsequent to September 30, 2023, we paid premiums of $5.0 million to renew two maturing interest rate caps with an aggregate notional amount of $150.9 million. We have one interest rate cap with a notional amount of $60.0 million which matures in April 2024, which represents the next maturing interest rate cap, excluding those renewed subsequent to September 30, 2023.
Upon the maturity and renewal of our interest rate caps, we have been obligated to provide a cash deposit to Fannie Mae because the debt service coverage ratios of the underlying properties of each facility were below those of the minimum required amounts per the debt agreements. In the nine months ended September 30, 2023, we provided a cash deposit of $5.1 million, and we provided another cash deposit of $6.7 million subsequent to September 30, 2023, bringing the total deposit to $11.8 million. We expect to provide another deposit upon the maturity of one interest rate cap in April 2024. Please see Fannie Mae Master Credit Facilities section below for additional information.
Mortgage Notes Payable
As of September 30, 2023, we had $821.7 million in mortgage notes payable outstanding, all of which is either fixed-rate or effectively fixed through our interest rate swap contracts. Future scheduled principal payments on our mortgage notes payable for the remainder of 2023 and 2024 are $0.3 million and $1.2 million, respectively.
On May 24, 2023, we, through certain subsidiaries of our OP, entered into the Barclay’s MOB Loan Agreement, with the Lenders, in the aggregate amount of $240.0 million. In connection with the Barclay’s MOB Loan Agreement, our OP entered into the “Guaranty and the “Environmental Indemnity for the benefit of the Lenders.
The Barclay’s MOB Loan is secured by, among other things, first priority mortgages on the Company’s interests in 62 MOBs, which had a carrying value of $0.4 billion as of June 30, 2023. The Barclay’s MOB Loan has a 10-year term and is interest-only at a fixed rate of 6.453% per year. Under the Barclays MOB Loan Agreement requires to pay interest on a monthly basis with the principal balance due on the maturity date of June 6, 2033. The Barclay’s MOB Loan Agreement requires our OP to comply with certain covenants, including, among other things, a requirement to maintain at all times a combination of cash and cash equivalents totaling at least $12.5 million at all times.
Prior Credit Facility
Our Prior Credit Facility consisted of two components, the Revolving Credit Facility and our Term Loan. The Revolving Credit Facility and Term Loan were interest-only and would have matured on March 13, 2024. The Prior Credit Facility was fully repaid in May 2023 with net proceeds provided by the Barclay’s MOB Loan (see Note 4 — Mortgage Notes Payable, Net to our consolidated financial statements in this Quarterly Report on Form 10-Q for details).
The Prior Credit Facility contained various restrictions which are no longer in affect since its repayment. These restrictions included, but were not limited to, (i) a minimum cash and cash equivalents balance, (ii) maintaining a certain fixed charge coverage ratio, (iii) dividend restrictions (on both common stock and preferred stock), (iv) share repurchases and (v) use of net proceeds from real estate dispositions.
Fannie Mae Master Credit Facilities
As of September 30, 2023, $347.7 million was outstanding under the Fannie Mae Master Credit Facilities. We may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool subject to
61


customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. We do not expect to draw any further amounts on the Fannie Mae Master Credit Facilities. Borrowings under the Fannie Mae Master Credit Facilities bear annual interest at a rate that varies on a monthly basis and is equal to the sum of the current SOFR for one month U.S. dollar-denominated deposits and a spread (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively) with a combined floor of 2.62%. The Fannie Mae Master Credit Facilities mature on November 1, 2026. Future scheduled principal payments on our Fannie Mae Master Credit Facilities for the remainder of 2023 and 2024 are $1.4 million and $5.8 million, respectively.
In July 2023, we provided a $5.1 million cash deposit to Fannie Mae. This deposit was provided because the debt service coverage ratios of the underlying properties of each facility were below those of the minimum required amounts per the debt agreements. This deposit will be refunded if we achieve debt service coverage ratios above those of the minimum required amounts. Subsequent to September 30, 2023, we provided an additional $6.7 million deposit to Fannie Mae which brought the total deposit to $11.8 million.
Capital Expenditures
During the nine months ended September 30, 2023, our capital expenditures were $14.0 million, of which $4.7 million related to our MOB segment and $9.3 million related to our SHOP segment. We anticipate this rate of capital expenditures for the MOB and SHOP segments throughout 2023.
Acquisitions — Three and Nine Months Ended September 30, 2023
During the three months ended September 30, 2023, we acquired two single-tenant MOBs for an aggregate contract purchase price of $9.8 million, funded with cash on hand.
During the nine months ended September 30, 2023, we acquired seven single-tenant MOBs for an aggregate contract purchase price of $34.9 million. These acquisitions were funded with $20.0 million of borrowings from our Prior Credit Facility and the remainder with cash on hand.
Acquisitions — Subsequent to September 30, 2023
We have not acquired any properties subsequent to September 30, 2023. We have signed one letter of intent to acquire four properties for a contract purchase of $12.6 million. There can be no assurance we will complete this acquisition on its contemplated terms, or at all. We anticipate primarily using cash on hand to fund the consideration required to complete this acquisition.
Dispositions — Three and Nine Months Ended September 30, 2023
We did not dispose of any properties during the three months ended September 30, 2023. During the nine months ended September 30, 2023, we disposed of four SHOPs and one MOB for an aggregate contract sales price of $13.8 million. Pursuant to the terms of the Prior Credit Facility, $5.2 million of net proceeds were used to repay amounts then outstanding, and $2.7 million of net proceeds were used to partially repay the Multi-Property CMBS Loan mortgage note.
Dispositions — Subsequent to September 30, 2023
We have not disposed of any properties subsequent to September 30, 2023.
Share Repurchase Program
We did not repurchase any shares during the three and nine months ended September 30, 2023 and 2022.
Non-GAAP Financial Measures
This section discusses the non-GAAP financial measures we use to evaluate our performance including Funds from Operations (“FFO”) and Modified Funds from Operations (“MFFO”). For additional information on Net Operating Income, another non-GAAP financial measure we use to evaluate our performance, see Results of Operations — Net Operating Income above. While NOI is a property-level measure, MFFO is based on our total performance as a company and therefore reflects the impact of other items not specifically associated with NOI such as, interest expense, general and administrative expenses and operating fees to related parties. Additionally, NOI as defined herein, includes straight-line rent adjustments which are excluded from MFFO.
Funds from Operations and Modified Funds from Operations
The historical accounting convention used for real estate assets requires straight-line depreciation of buildings, improvements, and straight-line amortization of intangibles, which implies that the value of a real estate asset diminishes predictably over time. We believe that, because real estate values historically rise and fall with market conditions, including, but not limited to, inflation, interest rates, the business cycle, unemployment and consumer spending, presentations of operating results for a REIT using the historical accounting convention for depreciation and certain other items may be less informative.
62


Because of these factors, the National Association of Real Estate Investment Trusts (“NAREIT”), an industry trade group, has published a standardized measure of performance known as FFO, which is used in the REIT industry as a supplemental performance measure. We believe FFO, which excludes certain items such as real estate-related depreciation and amortization, is an appropriate supplemental measure of a REIT’s operating performance. FFO is not equivalent to our net income or loss as determined under GAAP.
We calculate FFO, a non-GAAP measure, consistent with the standards established over time by the Board of Governors of NAREIT, as restated in a White Paper approved by the Board of Governors of NAREIT effective in December 2018 (the “White Paper”). The White Paper defines FFO as net income or loss computed in accordance with GAAP, excluding depreciation and amortization related to real estate, gains and losses from the sales of certain real estate assets, gains and losses from changes in control and impairment charges of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. Adjustments for unconsolidated partnerships and joint ventures are calculated to reflect our proportionate share of FFO attributable to our stockholders. Our FFO calculation complies with NAREIT’s definition.
We believe that the use of FFO provides a more complete understanding of our operating performance to investors and to management, and reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income.
Changes in the accounting and reporting promulgations under GAAP that were put into effect in 2009 subsequent to the establishment of NAREIT’s definition of FFO, such as the change to expense as incurred rather than capitalize and depreciate acquisition fees and expenses incurred for business combinations, have prompted an increase in cash-settled expenses, specifically acquisition fees and expenses, as items that are expensed under GAAP across all industries. These changes had a particularly significant impact on publicly registered, non-listed REITs, which typically have a significant amount of acquisition activity in the early part of their existence, particularly during the period when they are raising capital through ongoing initial public offerings.
Because of these factors, the Institute of Portfolio Alternatives (“IPA”), an industry trade group, has published a standardized measure of performance known as MFFO, which the IPA has recommended as a supplemental measure for publicly registered, non-listed REITs. MFFO is designed to be reflective of the ongoing operating performance of publicly registered, non-listed REITs by adjusting for those costs that are more reflective of acquisitions and investment activity, along with other items the IPA believes are not indicative of the ongoing operating performance of a publicly registered, non-listed REIT, such as straight-lining of rents as required by GAAP. We believe it is appropriate to use MFFO as a supplemental measure of operating performance because we believe that, when compared year-over-year it reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income. MFFO is not equivalent to our net income or loss as determined under GAAP.
We calculate MFFO, a non-GAAP measure, consistent with the IPA’s Guideline 2010-01, Supplemental Performance Measure for Publicly Registered, Non-Listed REITs: Modified Funds from Operations (the “Practice Guideline”) issued by the IPA in November 2010, except that we adjust for deferred tax asset allowances based on management’s determination. The Practice Guideline defines MFFO as FFO further adjusted for acquisition fees and expenses and other items. In calculating MFFO, we follow the Practice Guideline (with the added adjustment for deferred tax asset allowances based on management’s determination as noted above) and exclude acquisition fees and expenses, amortization of above- and below-market leases and other intangible lease assets and liabilities, amounts relating to straight-line rent adjustments (in order to reflect such payments from a GAAP accrual basis to a cash basis of disclosing the lease and rental payments), contingent purchase price consideration, accretion of discounts and amortization of premiums on debt, mark-to-market adjustments included in net loss, gains or losses included in net loss from the extinguishment or sale of debt, hedges, foreign exchange, derivatives or securities holdings where trading of such holdings is not a fundamental attribute of the business plan, unrealized gains or losses resulting from consolidation from, or deconsolidation to, equity accounting, and adjustments for unconsolidated partnerships and joint ventures, with such adjustments calculated to reflect MFFO on the same basis. We also exclude other non-operating items in calculating MFFO, such as transaction-related fees and expenses and capitalized interest.
We believe that, because MFFO excludes costs that we consider more reflective of acquisition activities and other non-operating items, MFFO can provide, on a going-forward basis, an indication of the sustainability (that is, the capacity to continue to be maintained) of our operating performance. We also believe that MFFO is a recognized measure of sustainable operating performance by the non-listed REIT industry and allows for an evaluation of our performance against other publicly registered, non-listed REITs.
63


Not all REITs, including publicly registered, non-listed REITs, calculate FFO and MFFO the same way. Accordingly, comparisons with other REITs, including publicly registered, non-listed REITs, may not be meaningful. Furthermore, FFO and MFFO are not indicative of cash flow available to fund cash needs and should not be considered as an alternative to net income (loss) or income (loss) from continuing operations as determined under GAAP as an indication of our performance, as an alternative to cash flows from operations as an indication of our liquidity, or indicative of funds available to fund our cash needs including our ability to pay dividends and other distributions to our stockholders. FFO and MFFO should be reviewed in conjunction with GAAP measurements as an indication of our performance. The methods utilized to evaluate the performance of a publicly registered, non-listed REIT under GAAP should be construed as more relevant measures of operational performance and considered more prominently than the non-GAAP measures, FFO and MFFO, and the adjustments to GAAP in calculating FFO and MFFO.
Neither the SEC, NAREIT, the IPA nor any other regulatory body or industry trade group has passed judgment on the acceptability of the adjustments that we use to calculate FFO or MFFO. In the future, updates to the White Paper or the Practice Guideline may be published or the SEC or another regulatory body could standardize the allowable adjustments across the publicly registered, non-listed REIT industry and we would have to adjust our calculation and characterization of FFO or MFFO accordingly.
The table below reflects the items deducted from or added to net loss attributable to stockholders in our calculation of FFO and MFFO for the periods indicated. In calculating our FFO and MFFO, we exclude the impact of amounts attributable to our non-controlling interests.
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Net loss attributable to common stockholders (in accordance with GAAP)
$(19,561)$(23,303)$(57,829)$(71,159)
Depreciation and amortization (1)
19,960 20,361 59,483 60,308 
Impairment charges— 8,949 — 25,786 
Loss (gain) on sale of real estate investment173 (194)364 109 
Adjustments for non-controlling interests (3)
(97)(124)(298)(386)
FFO (as defined by NAREIT) attributable to stockholders
475 5,689 1,720 14,658 
Acquisition and transaction related173 199 384 1,153 
Accretion of market lease and other intangibles, net(204)(176)(675)(421)
Straight-line rent adjustments
(352)(183)(938)(1,236)
Amortization (accretion) of mortgage premiums and discounts, net23 23 69 28 
Gain on non-designated derivatives(406)(1,826)(510)(3,212)
Cash received from non-designated derivative instruments1,565 — 3,866 — 
Deferred tax asset valuation allowance (2)
(265)216 726 1,358 
Adjustments for non-controlling interests (3)
16 14 
MFFO attributable to stockholders
$1,011 $3,951 $4,658 $12,342 
_______
(1)Excludes non-real estate depreciation and amortization.
(2)This is a non-cash item and is added back as it is not considered a part of operating performance.
(3)Represents the portion of the adjustments allocable to non-controlling interests.
Dividends and Other Distributions
Dividends on our Series A Preferred Stock are declared quarterly in an amount equal to $1.84375 per share each year ($0.460938 per share per quarter) to holders of Series A Preferred Stock, which is equivalent to 7.375% of per annum in the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.
Dividends on our Series B Preferred Stock are declared quarterly in an amount equal to $1.78125 per share each year ($0.445313 per share per quarter) to holders of Series B Preferred Stock, which is equivalent to 7.125% of per annum in the $25.00 liquidation preference per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the
64


next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.
Since mid-2020, we have not paid cash dividends on our shares of common stock but have issues stock dividends to the holders. The stock dividends have been declared quarterly using a rate of $0.85 per share per year. The number of shares issued with each dividend is based on the estimated per share asset value in effect on the applicable date.
The amount of dividends and other distributions payable to our stockholders is determined by the Board and is dependent on a number of factors, including funds available for distribution, our financial condition, capital expenditure requirements, as applicable, requirements of Maryland law and annual distribution requirements needed to maintain our status as a REIT under the Internal Revenue Code of 1986 (the “Code”). Distribution payments are dependent on the availability of funds. The Board may reduce the amount of dividends or distributions paid or suspend dividend or distribution payments at any time and therefore dividend and distribution payments are not assured. Any accrued and unpaid dividends payable with respect to the Series A Preferred Stock or Series B Preferred Stock become part of the liquidation preference thereof.
The following table shows the sources for the payment of distributions to preferred stockholders, including distributions on unvested restricted shares and Common OP Units, but excluding distributions related to Class B Units as these distributions are recorded as an expense in our consolidated statements of operations and comprehensive loss, for the periods indicated. No cash distributions were made to common stockholders, restricted shareholders, holders of Common OP Units or holders of Class B Units in the six months ended June 30, 2023.
Three Months EndedYear-To-Date
March 31, 2023June 30, 2023September 30, 2023September 30, 2023
(In thousands)AmountsPercentage of DistributionsAmountsPercentage of DistributionsAmountsPercentage of DistributionsAmountsPercentage of Distributions
Distributions:
Dividends to holders of Series A Preferred Stock $1,832 52.4%$1,834 52.5%$1,834 52.5%$5,500 52.5%
Dividends to holders of Series B Preferred Stock1,616 46.3%1,617 46.2%1,616 46.2%4,849 46.2%
Distributions paid to holders of Series A Preferred Units46 1.3%46 1.3%46 1.3%138 1.3%
Total cash distributions$3,494 100.0%$3,497 100.0%$3,496 100.0%$10,487 100.0%
Source of distribution coverage:
Cash flows provided by operations (1)
$3,494 100.0%$3,497 100.0%$3,496 100.0%$10,487 100.0%
Available cash on hand
— —%— —%— —%— —%
Total source of distribution coverage$3,494 100.0%$3,497 100.0%$3,496 100.0%$10,487 100.0%
Cash flows provided by operations (in accordance with GAAP)
$4,989 $5,688 $5,681 $16,358 
Net loss (in accordance with GAAP)$(14,068)$(17,332)$(16,125)$(47,525)
______
(1)Assumes the use of available cash flows from operations before any other sources.
For the nine months ended September 30, 2023, cash flows provided by operations were $16.4 million. We had not historically generated sufficient cash flows from operations to fund the payment of dividends and other distributions at the current rate prior to switching from paying cash dividends to stock dividends on our common stock. As shown in the table above, we funded dividends to holders of Series A Preferred Stock, Series B Preferred Stock and Series A Preferred Units with cash flows provided by operations. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as we pay distributions in stock instead of cash.
65


Our ability to pay dividends on our Series A Preferred Stock, Series B Preferred Stock and Series A Preferred Units and other distributions depends on our ability to increase the amount of cash we generate from property operations which in turn depends on a variety of factors, including the duration and scope of the COVID-19 pandemic and its impact on our tenants and properties, our ability to complete acquisitions of new properties and our ability to improve operations at our existing properties. There can be no assurance that we will complete acquisitions on a timely basis or on acceptable terms and conditions, if at all. Our ability to improve operations at our existing properties is also subject to a variety of risks and uncertainties, many of which are beyond our control, and there can be no assurance we will be successful in achieving this objective.
Election as a REIT 
We elected to be taxed as a REIT under Sections 856 through 860 of the Code, effective for our taxable year ended December 31, 2013. Commencing with that taxable year, we have been organized and operated in a manner so that we qualify as a REIT under the Code. We intend to continue to operate in such a manner but we can provide no assurances that we will operate in a manner so as to remain qualified for taxation as a REIT. To continue to qualify as a REIT, we must distribute annually at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP) determined without regard to the deduction for dividends paid and excluding net capital gains, and comply with a number of other organizational and operational requirements. If we continue to qualify as a REIT, we generally will not be subject to U.S. federal corporate income tax on the portion of our REIT taxable income that we distribute to our stockholders. Even if we continue to qualify for taxation as a REIT, we may be subject to certain state and local taxes on our income and properties as well as U.S. federal income and excise taxes on our undistributed income.
Inflation
We may be adversely impacted by inflation on the leases with tenants in our MOB segment that do not contain indexed escalation provisions, or those leases which have escalations at rates which do not exceed or approximate current inflation rates. As of September 30, 2023, the increase to the 12-month CPI for all items, as published by the Bureau of Labor Statistics, was 3.7%. To help mitigate the adverse impact of inflation, most of our leases with our tenants in our MOB segment contain rent escalation provisions which increase the cash that is due under these leases over time. These provisions generally increase rental rates during the terms of the leases either at fixed rates or indexed escalations (based on the Consumer Price Index or other measures). Although most of our leases with tenants in our MOB segment contain rent escalation provisions, these rates are generally below the current rate of inflation.
In addition to base rent, depending on the specific lease, MOB tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Property operating and maintenance expenses include common area maintenance costs, real estate taxes and insurance. Increased operating costs paid by our tenants under these net leases could have an adverse impact on our tenants if increases in their operating expenses exceed increases in their revenue, which may adversely affect our tenants’ ability to pay rent owed to us or property expenses to be paid, or reimbursed to us, by our tenants. Renewals of leases or future leases for our net lease properties may not be negotiated on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, in which event we may have to pay those costs. If we are unable to lease properties on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, or if tenants fail to pay required tax, utility and other impositions, we could be required to pay those costs.
Leases with residents at our SHOPs typically do not have rent escalations, however, we are able to renew leases at market rates as they mature due to their short-term nature. As inflation rates increase or persist at high levels, the cost of providing medical care at our SHOPs, particularly labor costs, will increase. If we are unable to admit new residents or renew resident leases at market rates, while bearing these increased costs from providing services to our residents, our results of operations may be affected.
Related-Party Transactions and Agreements
Please see Note 9 — Related Party Transactions and Arrangements to our consolidated financial statements included in this Quarterly Report on Form 10-Q for a discussion of the various related party transactions, agreements and fees.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
There has been no material change in our exposure to market risk during the nine months ended September 30, 2023. For a discussion of our exposure to market risk, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 17, 2023.
66


Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
In accordance with Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q and determined that our disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
No change occurred in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
67


PART II — OTHER INFORMATION
Item 1. Legal Proceedings.
We are not a party to, and none of our properties are subject to, any material pending legal proceedings.
Item 1A. Risk Factors.
    There have been no material changes to the risk factors disclosed in Part I — Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 17, 2023, and we direct your attention to those risk factors.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Trading Plans
During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408.
Indemnification Agreement
On November 9, 2023, we entered into an indemnification agreement with our Chief Executive Officer (the “Indemnification Agreement”). The Indemnification Agreement is in the same form as the indemnification agreements we have entered into with our directors and officers, which forms have been filed with the SEC.
Change of Corporate Address
Effective November 8, 2023, we changed the address of our principal executive corporate office. The new address is 222 Bellevue Ave., Newport, RI 02840.

68


Item 6. Exhibits.
The following exhibits are included, or incorporated by reference, in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (and are numbered in accordance with Item 601 of Regulation S-K):
Exhibit No.  Description
3.1 (1)
Articles of Amendment and Restatement for Healthcare Trust, Inc.
3.2 (2)
Second Amended and Restated Bylaws of Healthcare Trust, Inc.
3.3 (3)
Articles Supplementary of Healthcare Trust, Inc. relating to election to be subject to Section 3-803 of the Maryland General Corporation Law, dated November 9, 2017.
3.4 (4)
Articles Supplementary relating to the designation of shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, dated December 6, 2019.
3.5 (5)
Articles Supplementary designating additional shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, dated September 15, 2020.
3.6 (6)
Articles Supplementary relating to the designation of shares of 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, dated October 4, 2021.
4.1 (6)
Sixth Amendment, dated October 4, 2021, to the Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P., dated February 14, 2013.
Certification of the Principal Executive Officer of the Company pursuant to Securities Exchange Act Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of the Principal Financial Officer of the Company pursuant to Securities Exchange Act Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 *
Written statements of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS *
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH *Inline XBRL Taxonomy Extension Schema Document.
101.CAL *Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF *Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB *Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE *Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 *
Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
______
*    Filed herewith.
(1)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 11, 2016, and incorporated by reference herein.
(2)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on August 11, 2023, and incorporated by reference herein.
(3)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the SEC on November 14, 2017, and incorporated by reference herein.
(4)Filed as an exhibit to the Company’s Registration Statement on Form 8-A filed with the SEC on December 6, 2019, and incorporated by reference herein.
(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 15, 2020, and incorporated by reference herein.
(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2021, and incorporated by reference herein.
69


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 HEALTHCARE TRUST, INC.
 By:/s/ Michael Anderson
  Michael Anderson
  Chief Executive Officer
(Principal Executive Officer)
By:/s/ Scott M. Lappetito
 Scott M. Lappetito
 Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)

Dated: November 13, 2023
70
EX-31.1 2 ex311hti9302023.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Michael Anderson, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated this 13th day of November, 2023/s/ Michael Anderson
Michael Anderson
Chief Executive Officer
(Principal Executive Officer)



EX-31.2 3 ex312hti9302023.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Scott M. Lappetito, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated this 13th day of November, 2023/s/ Scott M. Lappetito
Scott M. Lappetito
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)




EX-32 4 ex32hti9302023.htm EX-32 Document

Exhibit 32

SECTION 1350 CERTIFICATIONS
This Certificate is being delivered pursuant to the requirements of Section 1350 of Chapter 63 (Mail Fraud) of Title 18 (Crimes and Criminal Procedures) of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
The undersigned, who are the Chief Executive Officer and Chief Financial Officer of Healthcare Trust, Inc. (the “Company”), each hereby certify as follows:
The Quarterly report on Form 10-Q of the Company, which accompanies this Certificate, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and all information contained in this quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated this 13th day of November, 2023
/s/ Michael Anderson
Michael Anderson
Chief Executive Officer
(Principal Executive Officer)
/s/ Scott M. Lappetito
Scott M. Lappetito
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)


EX-101.SCH 5 hct-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Mortgage Notes Payable, Net link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Credit Facilities link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Derivatives and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Related Party Transactions and Arrangements link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Economic Dependency link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Non-controlling Interests link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Mortgage Notes Payable, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Credit Facilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Derivatives and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Related Party Transactions and Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Non-controlling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Summary of Significant Accounting Policies - Lessor Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Real Estate Investments, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Real Estate Investments, Net - Acquired Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Real Estate Investments, Net - Geographic Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Real Estate Investments, Net - Summary of Amortization and Accretion Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Real Estate Investments, Net - Summary of Intangible Assets and Liabilities Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Real Estate Investments, Net - Impairments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Mortgage Notes Payable, Net - Mortgage Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Mortgage Notes Payable, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Credit Facilities - Summary of Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Credit Facilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Credit Facilities - Future Principal Payments of Outstanding Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Fair Value of Financial Instruments - Assets Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Fair Value of Financial Instruments - Carrying Amounts and Fair Values of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Derivatives and Hedging Activities - Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Derivatives and Hedging Activities - Summary of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Derivatives and Hedging Activities - Derivatives Included in AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Derivatives and Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Derivatives and Hedging Activities - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Stockholders' Equity - Cumulative Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Stockholders' Equity - Stock Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Related Party Transactions and Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Related Party Transactions and Arrangements - Fees and Participations Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Equity-Based Compensation - Summary of Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Non-controlling Interests - Balance Sheet Breakdown (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Non-controlling Interests - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Non-controlling Interests - Summary of Non-controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Computation (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Segment Reporting - Reconciliation of Segment Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Segment Reporting - Reconciliation of Segment Activity to Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Segment Reporting - Reconciliation of Capital Expenditures by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hct-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hct-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hct-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Economic Dependency [Abstract] Economic Dependency [Abstract] Economic Dependency [Abstract] Class B units (in shares) Common Share Equivalents, Shares Outstanding Common Share Equivalents, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Schedule of Revenue Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Below market leases, amortization income, 2024 Below Market Lease, Amortization Income, Year One Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Ownership [Axis] Ownership [Axis] Number of independent contractors Number Of Independent Contractors Number Of Independent Contractors Director Director [Member] Below market leases, amortization income, 2026 Below Market Lease, Amortization Income, Year Three Noncontrolling Interest [Table] Noncontrolling Interest [Table] Preferred stock Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Change in Control Fee Change in Control Fee [Member] Change in Control Fee [Member] Number of senior housing communities managed by terminated contractor Number Of Senior Housing Communities Managed By Terminated Contractor Number Of Senior Housing Communities Managed By Terminated Contractor Net loss per common share attributable to common stockholders - Diluted (in usd per share) Diluted net loss per share (in usd per share) Earnings Per Share, Diluted Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Texas TEXAS Unrealized gain (loss) on designated derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Credit Facilities Line of Credit [Member] Trading Symbol Trading Symbol Shares approved for issuance (in shares) Common Share Equivalents, Shares Approved for Issuance Common Share Equivalents, Shares Approved for Issuance Equity instruments, net of selling commissions (in usd per share) Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] SOFR SOFR Based Interest Rate Swap [Member] SOFR Based Interest Rate Swap Gross Revenue, Stand-alone Single-tenant Net Leased Properties Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member] Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member] Below market leases, amortization income, 2027 Below Market Lease, Amortization Income, Year Four Total Lessor, Operating Lease, Payment to be Received Amortization of mortgage premiums and discounts, net Amortization of Debt Discount (Premium) Reimbursed fees to related party, percentage of benchmark Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs American Realty Capital Healthcare II Special Limited Partnership, LLC American Realty Capital Healthcare II Special Limited Partnership, LLC [Member] American Realty Capital Healthcare II Special Limited Partnership, LLC [Member] Other intangible assets Other Intangible Assets [Member] Summary of Basic and Diluted Net Loss Per Share Computation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Variable Management - Incentive Fee Variable Management - Incentive Fee [Member] Variable Management - Incentive Fee [Member] Reduction of real estate cost percent Related Party Transaction Reduction of Real Estate Cost Percent Related Party Transaction Reduction of Real Estate Cost Percent Transaction amount Related Party Transaction, Amounts of Transaction Executive Category: Executive Category [Axis] Capped Reimbursement Amount Capped Reimbursement Amount [Member] Capped Reimbursement Amount [Member] 2027 Lessor, Operating Lease, Payment to be Received, Year Four Number of Shares of Common Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Subordinated performance fee as a percentage of benchmark Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark Monthly Base Management Fee Monthly Base Management Fee [Member] Monthly Base Management Fee [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets Level 1 Fair Value, Inputs, Level 1 [Member] Deferred tax asset Deferred Tax Assets, Net of Valuation Allowance Carrying Amount Reported Value Measurement [Member] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] 2025 Long-Term Debt, Maturity, Year Two Entity Small Business Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Notional amount Notional Amount Derivative, Notional Amount Measurement Frequency [Axis] Measurement Frequency [Axis] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Encumbered Properties Number of Real Estate Properties, Encumbered Number of Real Estate Properties, Encumbered Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] American Realty Capital Healthcare Advisors, LLC American Realty Capital Healthcare Advisors, LLC [Member] American Realty Capital Healthcare Advisors, LLC [Member] Schedule of Business Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Mortgages Mortgage Notes Payable Gross mortgage notes payable and mortgage premium and discounts, net Mortgages [Member] Revenue from tenants Revenues Summary of Antidilutive Securities Excluded from Computation of Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Acquisition and transaction related Acquisition and transaction related Business Combination, Acquisition Related Costs Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Mortgage Note Payable Mortgage Note Payable [Member] Mortgage Note Payable Document Quarterly Report Document Quarterly Report Units issued Common Unit, Issuance Value Non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Common stock issued through distribution reinvestment plan (in shares) Stock Issued During Period, Shares, Dividend Reinvestment Plan Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Schedule of Stock Dividends Dividends Declared [Table Text Block] Related Party Transactions and Arrangements Related Party Transactions Disclosure [Text Block] Less: amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Bad debt expense Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Payable (Prepayment) Accounts Payable (Prepayments) Accounts Payable (Prepayments) Real Estate [Domain] Real Estate [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Acquired intangible assets Finite-Lived Intangible Assets, Net Average Price per Share (in usd per share) Shares Acquired, Average Cost Per Share Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Debt instrument, fair value disclosure Debt Instrument, Fair Value Disclosure Number of contractors terminated Number Of Contractors Terminated Number Of Contractors Terminated Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] NOI Gross Profit Real estate investment, at cost relating to notes payable Real Estate Investment, At Cost Relating to Notes Payable Real Estate Investment, At Cost Relating to Notes Payable Security Exchange Name Security Exchange Name Fixed component Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Employee Stock Option Employee Stock Option [Member] Derivatives and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Total related party operation fees and reimbursements Operation Fees and Reimbursements [Member] Operation Fees and Reimbursements [Member] Distribution upon nonrenewal of advisory agreement Related Party Transaction, Distribution Upon Nonrenewal of Advisory Agreement, Percentage of Benchmark Related Party Transaction, Distribution Upon Nonrenewal of Advisory Agreement, Percentage of Benchmark Maximum Maximum [Member] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Buildings, fixtures and improvements Buildings, Fixtures and Improvements Buildings, Fixtures and Improvements Quarterly asset management earned by related party, percentage of benchmark Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark Geographic Concentration Risk Geographic Concentration Risk [Member] Tabular List, Table Tabular List [Table Text Block] Number of properties impaired Disposal Group Including Discontinued Operation, Number Of Properties Impaired Disposal Group Including Discontinued Operation, Number Of Properties Impaired Barclays MOB Loan Barclay’s MOB Loan [Member] Barclay’s MOB Loan 2026 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Fee payment period Related Party Transaction, Fee Payment Period Related Party Transaction, Fee Payment Period Dividends paid on preferred stock Payments of Ordinary Dividends, Preferred Stock and Preference Stock Property management and fees Property Management Fees [Member] Property Management Fees [Member] 2023 (remainder) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Credit Facilities Schedule of Line of Credit Facilities [Table Text Block] Derivative [Table] Derivative [Table] Advance on Loan or Other Investment Advance on Loan or Other Investment [Member] Advance on Loan or Other Investment [Member] Variable Rate [Axis] Variable Rate [Axis] Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities (Loss) gain on sale of real estate investments Loss on sale of real estate investments, net Gain (loss) on sale of real estate investments Gains (Losses) on Sales of Investment Real Estate Interest rate Debt Instrument, Interest Rate, Economic Percentage Debt Instrument, Interest Rate, Economic Percentage Period after closing required before prepayment Debt Instrument, Period Required After Closing Before Prepayment Debt Instrument, Period Required After Closing Before Prepayment 2024 Lessor, Operating Lease, Payment to be Received, Year One Title of 12(b) Security Title of 12(b) Security Related Party [Domain] Related Party, Type [Domain] Number or rights per share (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Distributions to non-controlling interest holders Distributions to non-controlling interest holders Payments of Ordinary Dividends, Noncontrolling Interest Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Non-Controlling Ownership Percentage Subsidiary, Ownership Percentage, Noncontrolling Owner Contract Purchase Price Contract Purchase Price [Member] Contract Purchase Price [Member] Operating Segments Operating Segments [Member] Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Payments to noncontrolling interests Payments to Noncontrolling Interests Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Less: accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation KeyBank Facility KeyBank Facility [Member] KeyBank Facility [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Allocation for preferred stock Distributions declared on preferred stock Dividends, Preferred Stock Third Amended And Restated Advisory Agreement Third Amended And Restated Advisory Agreement [Member] Third Amended And Restated Advisory Agreement [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Impairment charges Impairment charges Impairment of Real Estate Below market leases, amortization income, 2025 Below Market Lease, Amortization Income, Year Two Preferred unit, face value (in usd per share) Preferred Unit, Face Value, Share Price Preferred Unit, Face Value, Share Price Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Excess depreciation deductions maximum Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum Measure: Measure [Axis] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Triple-Net Leased Properties Triple-Net Leased Healthcare Facilities [Member] Triple-Net Leased Healthcare Facilities [Member] Stock dividends (in shares) Stock Dividends, Shares Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Assets held for sale Disposal Group, Including Discontinued Operation, Assets Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating lease payments Operating Lease, Payments Common stock, shares outstanding (in shares) Common stock, shares outstanding beginning balance (in shares) Common stock, shares outstanding ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Schedule of Future Base Rent Payments Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Valuation allowance, percentage Deferred Tax Asset, Valuation Allowance, Percentage Deferred Tax Asset, Valuation Allowance, Percentage Economic Dependency Economic Dependency [Text Block] Matters related to services provided by affiliate. Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Rental Income Rental Income [Member] Rental Income [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Stock dividend (in usd per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value Interest rate “pay-fixed” swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Lease intangibles, lease-up period Lease Intangibles, Lease-up Period Lease Intangibles, Lease-up Period 2023 (remainder) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Real Estate Cost Real Estate Cost [Member] Real Estate Cost [Member] Credit Facility [Axis] Credit Facility [Axis] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Stock dividend (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend Measurement Frequency [Domain] Measurement Frequency [Domain] Transition Fee Transition Fee [Member] Transition Fee [Member] Limited Partners' Capital Account, Class [Domain] Limited Partners' Capital Account, Class [Domain] Title of Individual [Axis] Title of Individual [Axis] 2026 Lessor, Operating Lease, Payment to be Received, Year Three Distributions declared on preferred stock (in usd per share) Preferred Stock, Dividends Per Share, Declared Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] MOB Loan MOB Loan [Member] MOB Loan [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Cost Of Living Consumer Price Index [Member] Consumer Price Index [Member] Affiliated Entity Affiliated Entity [Member] General and administrative General and administrative General and Administrative Expense Former Address Former Address [Member] Common OP Unit Common Operating Partnership Unit [Member] Common Operating Partnership Unit Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] In-place Leases and Other Intangible Assets In-place Leases and Other Intangible Assets [Member] In-place Leases and Other Intangible Assets [Member] Number of properties held for use Disposal Group Including Discontinued Operation, Number Of Properties Held For Use Disposal Group Including Discontinued Operation, Number Of Properties Held For Use Reportable Segments Segment Reporting, Policy [Policy Text Block] Preferred Stock Preferred Stock [Member] Impairment charges Asset Impairment Charges Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Above and Below Market Leases Above and Below Market Leases [Member] Above and Below Market Leases [Member] Fannie Mae Master Credit Facilities Master Credit Facility [Member] Master Credit Facility [Member] Interest rate caps Interest Rate Cap [Member] Payments for escrow deposit Payments For Escrow Deposit Payments For Escrow Deposit Concentration risk, percentage Concentration Risk, Percentage Contingent good faith negotiations of fixed component, term Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term Schedule of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Number of preferred OP units issued (in shares) Preferred Units, Issued Capital One Facility Capital One Facility [Member] Capital One Facility [Member] LIBOR LIBOR Based Interest Rate Swap [Member] LIBOR Based Interest Rate Swap SHOP Segment: SHOP Segment Seniors Housing Communities [Member] Seniors Housing Communities [Member] 2027 Finance Lease, Liability, to be Paid, Year Four Second Amended and Restated Advisory Agreement Second Amended and Restated Advisory Agreement [Member] Second Amended and Restated Advisory Agreement [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Projected Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Preferred stock, additional shares authorized (in shares) Preferred Stock, Additional Shares Authorized Preferred Stock, Additional Shares Authorized Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Depreciation and amortization Depreciation, Depletion and Amortization Deferred costs, net Deferred Costs Furniture and Fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Derivative assets, at fair value Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral Consolidation Items [Axis] Consolidation Items [Axis] Professional fees and other reimbursements Transfer Agent and Other Professional Fees [Member] Transfer Agent and other professional fees [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Direct Financing Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Period of notice of termination Related Party Transaction, Period of Notice for Termination Related Party Transaction, Period of Notice for Termination Fox Ridge Chenal - Little Rock, AR Fox Ridge Senior Living at Chenal - Little Rock [Member] Fox Ridge Senior Living at Chenal - Little Rock [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Entity Emerging Growth Company Entity Emerging Growth Company Proceeds from sale of interest rate cash flow hedge Proceeds From Sale of Interest Rate Cash Flow Hedge Proceeds From Sale of Interest Rate Cash Flow Hedge Debt prepayment, written notice requirement Debt Instrument, Prepayment, Written Notice Requirement Debt Instrument, Prepayment, Written Notice Requirement Deferred financing costs, net of accumulated amortization Deferred financing costs Debt Issuance Costs, Net Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Common Stock Common Stock [Member] Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Deferred rent Deferred Rent Credit Income Statement Location [Domain] Income Statement Location [Domain] Mortgage premiums and discounts, net Debt Instrument, Unamortized Discount (Premium), Net Payments on mortgage notes payable Repayments of Secured Debt Summary of Recurring Fair Value Measurements Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Distributions to non-controlling interest holders Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Total intangible assets and liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net Minimum Minimum [Member] Rentable square feet Area of Real Estate Property Number of properties owned Encumbered properties Number of Real Estate Properties Unrealized gain (loss) on designated derivatives Other Comprehensive Income (Loss), Net of Tax Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] In-place lease assets Leases, Acquired-in-Place [Member] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Four Lessor, Operating Lease, Payment to be Received, after Year Four Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Basis of core earnings, percent Related Party Transaction, Basis of Core Earnings, Percent Related Party Transaction, Basis of Core Earnings, Percent Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Distributions in excess of accumulated earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Other income (expense): Nonoperating Income (Expense) [Abstract] Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net loss per common share attributable to common stockholders - Basic (in usd per share) Basic net loss per share (in usd per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Below market leases, amortization income, remainder 2023 (reminder) Below Market Lease, Amortization Income, Remainder of Fiscal Year Common stock issued through stock dividends Stock Issued Cash paid for income and franchise taxes Income Taxes Paid Principles of Consolidation and Basis of Presentation Consolidation, Policy [Policy Text Block] Renewal term of lease excluded Lessee, Operating Lease, Renewal Term, Excluded Lessee, Operating Lease, Renewal Term, Excluded Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest Expense Interest Expense [Member] Total real estate investments, net Net Real Estate Assets Subject to Investment Arrangement Total investments in real estate, net Real Estate Investment Property, Net Payments on credit facilities Payments on credit facilities Repayments of Lines of Credit Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Outstanding loan amount Total Long-Term Debt, Gross All Trading Arrangements All Trading Arrangements [Member] Disposal group, gain (loss) on disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Additional CARES Act funding Proceeds From Government Assistance, CARES Act Proceeds From Government Assistance, CARES Act All Adjustments to Compensation All Adjustments to Compensation [Member] Percent of board approval required for early termination Related Party Transaction, Voting Percentage Required to Alter Agreement Related Party Transaction, Voting Percentage Required to Alter Agreement Compensation Amount Outstanding Recovery Compensation Amount Interest and other income Interest and Other Income Number of senior housing communities Number of Senior Housing Communities Number of Senior Housing Communities Derivative assets, at fair value Net Amounts of Assets presented in the Consolidated Balance Sheet Derivative Asset Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Balance Sheet Location Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Total present value of minimum lease payments Finance Lease, Liability Operating fees to related parties Affiliate Costs 2024 Long-Term Debt, Maturity, Year One Proceeds from real estate sales used to repay mortgage notes payable Noncash, Or Part Noncash, Proceeds From Sale And Collection Of Mortgage Notes Payable Noncash, Or Part Noncash, Proceeds From Sale And Collection Of Mortgage Notes Payable Basis of core earnings, share basis (in usd per share) Related Party Transaction, Basis of Core Earnings, Per Share Basis Related Party Transaction, Basis of Core Earnings, Per Share Basis Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Number of properties disposed Disposal Group Including Discontinued Operation, Number Of Properties Disposed Disposal Group Including Discontinued Operation, Number Of Properties Disposed Interest and other income Other Nonoperating Income Debt instrument, collateral amount Debt Instrument, Collateral Amount Straight-line rent receivable, net Deferred Rent Receivables, Net, Noncurrent Cash from termination Payments for (Proceeds from) Derivative Instrument, Financing Activities Debt service coverage ratio Debt Instrument, Covenants, Debt Service Coverage Ratio Debt Instrument, Covenants, Debt Service Coverage Ratio Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Renewal period Related Party Agreement, Term of Agreement, Renewal Period Related Party Agreement, Term of Agreement, Renewal Period Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Income tax expense Income tax expense Income Tax Expense (Benefit) Derivatives designated as hedging instruments: Designated as Hedging Instrument Designated as Hedging Instrument [Member] Limited partner units (in shares) Limited Partners' Capital Account, Units Outstanding Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Amount of gain reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Debt financing wrote off Deferred Debt Issuance Cost, Writeoff Lender Name [Axis] Lender Name [Axis] American Realty Capital Healthcare III Advisors, LLC American Realty Capital Healthcare III Advisors, LLC [Member] American Realty Capital Healthcare III Advisors, LLC [Member] Equity [Abstract] Equity [Abstract] Remaining lease term Operating Lease, Weighted Average Remaining Lease Term Healthcare Trust Special Limited Partnership, LLC Healthcare Trust Special Limited Partnership, LLC [Member] Healthcare Trust Special Limited Partnership, LLC [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Summary of Non-controlling Interest Redeemable Noncontrolling Interest [Table Text Block] 2025 Lessor, Operating Lease, Payment to be Received, Year Two Number of finance lease contracts Lessee, Finance Lease, Number Of Contracts Lessee, Finance Lease, Number Of Contracts Cash and cash equivalents Cash and cash equivalents, end of period Cash and Cash Equivalents, at Carrying Value Remaining lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Credit Facility [Domain] Credit Facility [Domain] Number of Shares Repurchased (in shares) Treasury Stock, Shares, Acquired Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Secured Overnight Financing Rate One Month Secured Overnight Financing Rate One Month [Member] Secured Overnight Financing Rate One Month DRIP period of notice to alter agreement DRIP, Period of Notice to Alter Agreement DRIP, Period of Notice to Alter Agreement Number of Instruments Number of instruments Derivative, Number of Instruments Held Interest Rate Contract Interest Rate Contract [Member] Less: amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Cover [Abstract] Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Amortization of deferred financing costs Amortization of Debt Issuance Costs Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Number of properties purchased Number of Businesses Acquired Preferred units outstanding (in shares) Preferred Units, Outstanding Investments in non-designated interest rate caps Payments for Derivative Instrument, Investing Activities Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Market lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired Total expenses Expenses incurred Operating Expenses Segment Reporting Segment Reporting Disclosure [Text Block] Healthcare Trust Operating Partnership, L.P. Healthcare Trust Operating Partnership, L.P. [Member] Healthcare Trust Operating Partnership, L.P. [Member] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Average variable interest rate Derivative, Average Variable Interest Rate Secured Debt Secured Debt [Member] Equity Component [Domain] Equity Component [Domain] Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Related Party Fees, by Benchmark [Axis] Related Party Fees, by Benchmark [Axis] Related Party Fees, by Benchmark [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Plaza Del Rio Medical Office Campus Portfolio - Peoria, AZ Plaza Del Rio Medical Office Campus Portfolio AZ [Member] Plaza Del Rio Medical Office Campus Portfolio AZ [Member] Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Quarterly Variable Management Fee, Benchmark One Quarterly Variable Management Fee, Benchmark One [Member] Quarterly Variable Management Fee, Benchmark One [Member] Operating (loss) income Operating Income (Loss) Accounting for Leases, Lessor Accounting Lessor, Leases [Policy Text Block] Preferred units, redemption period Preferred Units, Redemption Period Preferred Units, Redemption Period Mortgage notes payable repaid with proceeds from real estate sales Noncash, Or Part Noncash, Mortgage Notes Payable Repaid With Proceeds From Real Estate Sales Noncash, Or Part Noncash, Mortgage Notes Payable Repaid With Proceeds From Real Estate Sales Prepaid expenses and other assets Prepaid expenses and other assets Prepaid Expense and Other Assets Preferred units issued (in usd per share) Preferred Unit, Issuance Value, Share Price Preferred Unit, Issuance Value, Share Price Distributions declared in common stock (in shares) Share increase from stock dividends (in shares) Common Stock Dividends, Shares Interest rate cap Derivative, Cap Interest Rate Segments [Axis] Segments [Axis] Special Limited Partner Special Limited Partner [Member] Special Limited Partner [Member] Proceeds from real estate sales used to repay amounts outstanding under the Prior Credit Facility Noncash, Or Part Noncash, Proceeds From Real Estate Sales Used To Repay Amounts Outstanding Under Prior Credit Facility Noncash, Or Part Noncash, Proceeds From Real Estate Sales Used To Repay Amounts Outstanding Under Prior Credit Facility Fair Value  Estimate of Fair Value Measurement [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Below-market lease liabilities Below Market Lease [Member] Below Market Lease [Member] Credit facilities, net Outstanding balance Long-Term Line of Credit Real estate investments Real Estate Properties [Line Items] Number of instruments terminated Derivative, Number of Instruments Terminated Derivative, Number of Instruments Terminated Limited Partners' Capital Account by Class [Axis] Limited Partners' Capital Account by Class [Axis] Stockholders’ Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member] Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Variable Rate [Domain] Variable Rate [Domain] Net loss attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent LIBOR One Month London Interbank Offered Rate One Month [Member] London Interbank Offered Rate One Month Credit Facilities Debt Disclosure [Text Block] Base management fee of net proceeds Related Party Transaction, Base Management Fee of Net Proceeds, Percent Related Party Transaction, Base Management Fee of Net Proceeds, Percent Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Subordinated incentive listing distribution Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Cash received from non-designated derivative instruments Derivative Instruments Not Designated As Hedging Instruments, Cash Received Derivative Instruments Not Designated As Hedging Instruments, Cash Received Restatement Determination Date: Restatement Determination Date [Axis] Total other expenses Nonoperating Income (Expense) Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Oversight fees earned by related party Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark Multi-Property CMBS Loan Multi-Property CMBS Loan [Member] Multi-Property CMBS Loan [Member] Geographical [Axis] Geographical [Axis] Total real estate investments, at cost Total real estate investments, at cost Real Estate Investment Property, at Cost Units issued (in usd per share) Common Unit, Issuance Value Share Price Common Unit, Issuance Value Share Price Concentration Risk [Line Items] Concentration Risk [Line Items] Asset management fees Asset Management Fees [Member] Asset Management Fees [Member] Accounting for Leases, Lessee Accounting Lessee, Leases [Policy Text Block] CARES Act Grants Revenue [Policy Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Weighted Average Issue Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accretion of market lease and other intangibles, net Accretion of above-and below-market leases, net Accretion of Below-Market Lease Liabilities and Amortization of Above-Market Lease Assets, Net Adjustment for noncash decrease (increase) in rental revenue related to assets (liabilities) associated with the acquisition of an off-market lease when the terms of the lease are favorable (unfavorable) to the market terms for the lease at the date of acquisition. Advisor And Company Advisor And Company [Member] Advisor And Company [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Gross Amounts of Recognized (Liabilities) Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Mortgage notes payable, net Secured Debt Property Operating and Maintenance Expense Property Operating and Maintenance Expense [Member] Property Operating and Maintenance Expense [Member] Future  Base Rent Payments Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Land Land Property management fees Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs Level 3 Fair Value, Inputs, Level 3 [Member] Non-controlling Interests in property owning subsidiaries Noncontrolling Interests In Property Owning Subsidiaries Noncontrolling Interests In Property Owning Subsidiaries Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member] Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net Income (Loss) Net Income (Loss) Derivative Contract [Domain] Derivative Contract [Domain] 2025 Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Commitments and Contingencies Lessee, Operating Leases [Text Block] Number of intercompany leases modified Number Of Intercompany Leases Modified Number Of Intercompany Leases Modified LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Restricted share vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Schedule of Restricted Share Award Activity Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Name Measure Name Name Forgone Recovery, Individual Name Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Illinois skilled nursing facilities M O B Property Illinois Skilled Nursing Facilities [Member] M O B Property Illinois Skilled Nursing Facilities [Member] Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Straight-line rent receivable Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Distribution declared on common stock (in usd per share) Common Stock, Dividends, Per Share, Declared 2023 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Fee multiplier Related Party Transaction, Fee Multiplier Related Party Transaction, Fee Multiplier Term Debt Instrument, Term Preferred stock issuance costs Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period Related Party Fees, Benchmark [Domain] Related Party Fees, Benchmark [Domain] Related Party Fees, Benchmark [Domain] Payments of deferred financing costs Payments of Debt Issuance Costs Disposal Group, Held-for-use, Not Discontinued Operations Disposal Group, Held-for-use, Not Discontinued Operations [Member] Disposal Group, Held-for-use, Not Discontinued Operations [Member] Payment for termination of swap Payment For Sale Of Interest Rate Cash Flow Hedge Payment For Sale Of Interest Rate Cash Flow Hedge Property acquisitions Payments to Acquire Real Estate Income Statement Location [Axis] Income Statement Location [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Summary of Operating Lease Maturities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Financing advance fees as a percentage of benchmark, expected company portfolio cost Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs Summary of Fair Value by Balance Sheet Fair Value, by Balance Sheet Grouping [Table Text Block] Tax Depreciation Deduction Tax Depreciation Deduction [Member] Tax Depreciation Deduction [Member] Other Performance Measure, Amount Other Performance Measure, Amount Payments for derivative instruments Payments for Derivative Instrument, Financing Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Investments in Real Estate Real Estate, Policy [Policy Text Block] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Plan Name [Domain] Plan Name [Domain] Long-term debt, covenant requirements, amount Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity Interest expense Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss Interest Expense Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized 2023 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Buildings, fixtures and improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number 2026 Long-Term Debt, Maturity, Year Three Amortization of market least intangibles Amortization of Intangible Assets Entity Shell Company Entity Shell Company Thereafter Finance Lease, Liability, to be Paid, Due after Year Four Finance Lease, Liability, to be Paid, Due after Year Four Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Restricted Share Plan Restricted Share Plan [Member] Restricted Share Plan [Member] Derivative, premium paid Derivative, premium paid Derivative, Premium Paid Deferred rent Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accounts payable and accrued expenses (including $665 and $47, respectively, due to related parties as of September 30, 2023 and December 31, 2022) Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities Subject Fees (Transition Fee Not in Excess of the Product) Subject Fees (Transition Fee Not in Excess of the Product) [Member] Subject Fees (Transition Fee Not in Excess of the Product) [Member] Operating lease liability Operating Lease, Cost Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Limited partner units, redemption period Limited Partners' Capital Account, Units, Redemption Period Limited Partners' Capital Account, Units, Redemption Period Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Cost of living percent multiplier Related Party Transaction Basis Cost Of Living Percent Related Party Transaction Basis Cost Of Living Percent Mortgage notes payable, net Long-Term Debt 2027 Long-Term Debt, Maturity, Year Four Dividends Payable [Line Items] Dividends Payable [Line Items] Fannie Mae Master Credit Facilities Fannie Credit Facility [Member] Fannie Credit Facility [Member] Weighted-average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-controlling Interests Noncontrolling Interest Disclosure [Text Block] Gross Revenue, Managed Properties Gross Revenue, Managed Properties [Member] Gross Revenue, Managed Properties [Member] Comprehensive loss attributable to common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Proceeds from loans Proceeds from Loans Class B Units Class B Units [Member] Class B Units [Member] Beginning balance (in shares) Ending balance (in shares) Unvested restricted stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number In-place leases, market leases, and other intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Subsequent Event [Table] Subsequent Event [Table] 2024 Finance Lease, Liability, to be Paid, Year One Unencumbered Properties Unencumbered Properties [Member] Unencumbered Properties [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Subsequent Event Subsequent Event [Member] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Noncontrolling Interest on Balance Sheet Noncontrolling Interest [Table Text Block] Noncontrolling Interest Value of preferred OP Units Preferred Unit, Issuance Value Preferred Unit, Issuance Value Income Statement [Abstract] Income Statement [Abstract] Stock issued during period, shares, new issues (in shares) Stock Issued During Period, Shares, New Issues Notional amount renewed Derivative, Notional Amount Renewed Derivative, Notional Amount Renewed Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Share-based compensation, net Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Class of Stock [Line Items] Class of Stock [Line Items] Dividends Payable [Table] Dividends Payable [Table] Distributions declared in common stock (in usd per share) Common Stock, Stock Dividends, Per Share, Declared Common Stock, Stock Dividends, Per Share, Declared Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Real Estate Investments, Net Real Estate Disclosure [Text Block] Schedule of Impairments Recorded Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Total Stockholders Equity Parent [Member] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Debt instrument, face amount Debt Instrument, Face Amount Leases [Abstract] Leases [Abstract] Market lease intangible liabilities, net Off-Market Lease, Unfavorable Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Redeemable amount of shares (in shares) Limited Partners' Capital Account, Potentially Redeemable Amount Limited Partners' Capital Account, Potentially Redeemable Amount Total minimum lease payments Finance Lease, Liability, to be Paid Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and Amortization Expense Depreciation and Amortization Expense [Member] Depreciation and Amortization Expense [Member] BMO CMBS Loan BMO MOB Loan [Member] BMO MOB Loan Disposal Group Name [Domain] Disposal Group Name [Domain] Distributions in excess of accumulated earnings Accumulated Distributions in Excess of Net Income Individual business acquisitions Series of Individually Immaterial Business Acquisitions [Member] Derivatives terminated in period Derivative, Notional Amount, Terminated In Period Derivative, Notional Amount, Terminated In Period Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative assets, at fair value Gross Amounts of Recognized Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Class of Stock [Domain] Class of Stock [Domain] Net loss attributable to common stockholders Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Name of Property [Domain] Name of Property [Domain] Operating lease liabilities Total present value of minimum lease payments Operating Lease, Liability Real Estate Investments, Net [Abstract] Real Estate Investments, Net [Abstract] Contributions from minority interests Noncontrolling Interest, Increase from Subsidiary Equity Issuance Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Aggregate contract sale price Disposal Group, Including Discontinued Operation, Consideration Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive (Loss) Income Unrealized Gain (loss) on Designated Derivative AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount MOB Segment MOB Segment: Medical Office Buildings [Member] Medical Office Buildings [Member] Rebalancing of ownership percentage Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage Capital expenditures Payments to Acquire Other Property, Plant, and Equipment All Executive Categories All Executive Categories [Member] Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period Base management fee of net proceeds, variable portion factor, percent Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent (Accretion) amortization of terminated swap Amortization (Accretion) Of Terminated Swap Payment Amortization (Accretion) Of Terminated Swap Payment Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Gross Amounts Not Offset in the Consolidated Balance Sheet, Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset Number of operating lease contracts Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Proceeds from termination of derivative instruments Proceeds from Derivative Instrument, Financing Activities Common stock, $0.01 par value, 300,000,000 shares authorized, 109,877,212 shares and 105,080,531 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Cash paid for real estate investments, including acquisitions Business Acquisition Cost Of Acquired Entity Cash Paid In Period Business Acquisition Cost Of Acquired Entity Cash Paid In Period Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Quarterly Variable Management Fee, Benchmark Two Quarterly Variable Management Fee, Benchmark Two [Member] Quarterly Variable Management Fee, Benchmark Two [Member] Acquired intangibles: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired Intangibles [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired Intangibles [Abstract] Series A Preferred Stock Series A Cumulative Redeemable Perpetual Preferred Stock [Member] Series A Cumulative Redeemable Perpetual Preferred Stock Summary of Finance Lease Maturities Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Restricted cash Restricted cash, end of period Restricted Cash All Individuals All Individuals [Member] Fox Ridge Bryant - Bryant, AR Fox Ridge Senior Living at Bryant - Bryant [Member] Fox Ridge Senior Living at Bryant - Bryant [Member] Advisor Advisor [Member] Advisor [Member] Entity Filer Category Entity Filer Category Florida FLORIDA Proceeds from mortgage notes payable Proceeds from Issuance of Secured Debt Schedule of Cumulative Share Repurchases Class of Treasury Stock [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Proceeds from sales of real estate investments Proceeds from Sale, Real Estate, Held-for-Investment Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member] Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member] Schedule of Derivatives Included in AOCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Term Loan, net Long-term Line of Credit, Including Financing Costs Long-term Line of Credit, Including Financing Costs Address Type [Domain] Address Type [Domain] PEO Name PEO Name Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Building Building [Member] Cash flow hedge reclassification current Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Preferred stock, shares outstanding (in shares) Preferred stock, shares outstanding beginning balance (in shares) Preferred stock, shares outstanding Ending balance (in shares) Preferred Stock, Shares Outstanding Pre-tax Non-compounded Return on Capital Contribution Pre-tax Non-compounded Return on Capital Contribution [Member] Pre-tax Non-compounded Return on Capital Contribution [Member] Maturity extension Long Term Line Of Credit, Maturity, Extension Term Long Term Line Of Credit, Maturity, Extension Term Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Depreciation and Amortization Depreciation, Depletion, and Amortization [Policy Text Block] Total stockholders’ equity Equity, Attributable to Parent Number of properties held for sale Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Unvested Restricted Stock Unvested restricted shares Restricted Stock [Member] Total Fair Value, Net Asset (Liability) Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Fox Ridge North Little Rock - North Little Rock, AR Fox Ridge Senior Living at Parkstone - North Little Rock [Member] Fox Ridge Senior Living at Parkstone - North Little Rock [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Derivatives not designated as hedging instruments: Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Hedging Designation [Domain] Hedging Designation [Domain] Significant Other Observable Inputs Level 2 Fair Value, Inputs, Level 2 [Member] Series B Preferred Stock Series B Cumulative Redeemable Perpetual Preferred Stock [Member] Series B Cumulative Redeemable Perpetual Preferred Stock Distributions declared in common stock Stock Issued During Period, Value, Stock Dividend Real estate cost percent multiplier Related Party Transaction Basis of Real Estate Cost Percent Related Party Transaction Basis of Real Estate Cost Percent Disposal Group Classification [Domain] Disposal Group Classification [Domain] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Property operating and maintenance Operating Lease, Expense City Area Code City Area Code Net Loss Per Share Earnings Per Share [Text Block] Finance Lease, Liability, Statement of Financial Position [Extensible List] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Operating (loss) income before loss (gain) on sale of real estate investments Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments Land Improvements Land Improvements [Member] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Gain on non-designated derivatives Gain on non-designated derivative instruments Gain on non-designated derivatives Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative assets, at fair value Derivative Financial Instruments, Assets [Member] Interest Rate Cap Maturing April 2024 Interest Rate Cap Maturing April 2024 [Member] Interest Rate Cap Maturing April 2024 Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest LaSalle Properties LaSalle Properties [Member] LaSalle Properties Series A Preferred Unit Series A Preferred Unit [Member] Series A Preferred Unit Total liabilities and equity Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] 2023 (remainder) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Related Party Related Party [Member] Operating fees to related parties Costs and Expenses, Related Party Reimbursements of Administrative Services Reimbursements of Administrative Services [Member] Reimbursements of Administrative Services [Member] Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block] Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Document Information [Table] Document Information [Table] Contributions from non-controlling interests Proceeds from Noncontrolling Interests Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Various held for use SHOPs Various Seniors Housing Communities [Member] Various Seniors Housing Communities [Member] Cash flow hedge reclassification in next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Maximum authorized amount as a percentage of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Title of Individual [Domain] Title of Individual [Domain] Distributions payable Dividends Payable Shiloh - Illinois Shiloh - Illinois [Member] Shiloh - Illinois [Member] Strike price percentage Derivative, Strike Price, Percentage Derivative, Strike Price, Percentage Period to terminate early with board approval Related Party Transaction, Period of Notice to Alter Agreement Related Party Transaction, Period of Notice to Alter Agreement Gross Amounts Not Offset in the Consolidated Balance Sheet, Cash Collateral Received Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Escrow deposit Escrow Deposit Additional paid-in capital Additional Paid in Capital Document Information [Line Items] Document Information [Line Items] Pennsylvania PENNSYLVANIA Income Taxes Income Tax, Policy [Policy Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three OP Units Common OP Units OP Units [Member] OP Units [Member] Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Number of properties marketed for sale Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale Related Party [Axis] Related Party, Type [Axis] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Leasing commissions Leasing Commissions Expense Adjustment to Compensation, Amount Adjustment to Compensation Amount Prior Credit Facility Prior Credit Facility [Member] Prior Credit Facility Non-controlling interests Total Non-controlling interests Third Party Net Investment Amount Equity, Attributable to Noncontrolling Interest Proceeds from credit facilities Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Preferred stock, dividend rate, percentage Preferred Stock, Dividend Rate, Percentage Disposal Group Name [Axis] Disposal Group Name [Axis] Entity Central Index Key Entity Central Index Key Share-based payment arrangement, expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Purchase Price Allocation Purchase Price Allocation Policy [Policy Text Block] Purchase Price Allocation Policy [Policy Text Block] Payments of deferred financing costs Payments of Financing Costs Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Issuance of Preferred Stock, net Stock Issued During Period, Value, New Issues Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Repurchase price per share, percentage of estimated per-share NAV Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV Legal Entity [Axis] Legal Entity [Axis] Amended and Restated Property Management and Leasing Agreement Amended and Restated Property Management and Leasing Agreement [Member] Amended and Restated Property Management and Leasing Agreement [Member] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Stock issued during period, issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Weighted-average shares outstanding - Diluted (in shares) Diluted weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Amounts outstanding under the Prior Credit Facility repaid with proceeds from real estate sales Noncash, Or Part Noncash, Amounts Outstanding Under Prior Credit Facility Repaid With Proceeds From Real Estate Sales Noncash, Or Part Noncash, Amounts Outstanding Under Prior Credit Facility Repaid With Proceeds From Real Estate Sales Acquisition cost reimbursements Acquisition Costs Reimbursements [Member] Acquisition Costs Reimbursements [Member] Operating expenses: Operating Expenses [Abstract] Total capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Above-market lease assets Above Market Leases [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Number of real estate properties impaired Number Of Real Estate Properties, Failed To Recover Carrying Value Number Of Real Estate Properties, Failed To Recover Carrying Value Number of states properties are located in Number of States in which Entity Operates Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Termination costs incurred Contract Termination Costs Contract Termination Costs Cumulative capital investment return to investors as a percentage of benchmark Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark Annual Targeted Investor Return Annual Targeted Investor Return [Member] Annual Targeted Investor Return [Member] Mortgage Notes Payable, Net Mortgage Notes Payable Disclosure [Text Block] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Renewal term Lessee, Lease, Renewal Term Lessee, Lease, Renewal Term Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Assets under management threshold Related Party Transaction, Asset Threshold Qualifying Management Related Party Transaction, Asset Threshold Qualifying Management Gross Amounts Offset in the Consolidated Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted-average shares outstanding - Basic (in shares) Basic weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Real estate investments, at cost: Investments in real estate, net: Real Estate Investment Property, at Cost [Abstract] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Number of instruments held, renew Derivative, Number Of Instruments Renewed Derivative, Number Of Instruments Renewed Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Summary of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Total Non-controlling Interests in the OP Noncontrolling Interest in Operating Partnerships Name of Property [Axis] Name of Property [Axis] Non-controlling Interests Noncontrolling Interest [Member] Amortization Expense Amortization Expense [Member] Amortization Expense [Member] EX-101.PRE 9 hct-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 hct-20230930_g1.jpg begin 644 hct-20230930_g1.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_X1""17AI9@ 34T *@ @ ! $[ ( M % (2H=I 0 ! (4)R= $ * 0<.H< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \ M/WAP86-K970@96YD/2=W)S\^_]L 0P " 0$" 0$" @(" @(" @,% P,# P,& M! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L M0P$" @(# P,& P,&# @'" P,# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,_\ $0@$S0EM P$B (1 0,1 ?_$ !\ M $% 0$! 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ M !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?( MR;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! M 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ _?RBBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHSBC- !11FB@ HHHH **** M"BBC- !11FC- !11FB@ HHHH **** "BBB@ HHSBC.: "BC.*,T %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1106Q0 449XH!S0 4449H **,YHH **,T9 MH **,T;J "BC-&<4 %%,:XC3[SJ/J:Y[Q%\8O"7A#=_:WBCP_I>WK]KU"*'' M_?3"KC3G+X4V9RK4X_%)+YG29IK$YKQ_Q'_P4&^!?A1F%]\8/AK"Z]4'B*UD MD'_ %CZ>)_R:"W^17Q;K?\ P7^_9CTE6\CQEJNI8[6^@WBY^GF1I7%Z MY_P?Y=#XJT?O/T&! MSW_6C/%?F?JW_!SS\)X<_8? 7Q"N/3SQ:0Y^N)6KE]8_X.CO#,1/V'X2ZY<> MGGZU%#G\HGK:/#69O:D_P_S.>7%65K_E\G]Y^K/-+TK\@=1_X.FKF3<+7X*P MQ^AE\5;OT%H/YUAW_P#P=&>+&S]E^$^@0^GFZQ+)_P"@QK71'A3,VO@MZM'/ M+C#*U]N_R/V:HK\2K_\ X.?OB=(Q^S_#SP/#Z"22YD_DXK,N?^#G3XS-_J?! M7PTC/;?;7K?^W K1<'YE_*OO1C+C;*U]I_8]E]Y/^O66=Y?-<C8?:/ OPZD]?+CO$_G.:E\&YE_*O MO1:XXRM_:?W'[A4'FOQ4M/\ @Z$^(BG]_P##7P?)Z[+NX3/ZFM>P_P"#I#Q) M&ZFZ^$>BS#N(=6/_ &H?%(?]#:C^==-I/_!T3X*EQ]N^%OB>'U\C4H)+,K?_+U+[S]2R?Q_&C=CTK\V=)_X.;8.?P58_>CZ1S17 ME_AG]MGX.^, /[+^*OPZU!FZ+;^([21A[8$F?PKO-#\::/XFA\S3=5T_4(_[ MUM<)*/S4FN>5"K'XHO[F=4<51E\,U]Z-2BFK,K=&4_C3LUEL;*2>P449HS0, M**,T9H **,\T4 %%&<49H ***,T %%&:,YH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M***,T %%&ZC/- !11F@G% !11G%&: "BC.*-W- !37ZTV:[CMT+22*BJ,DDX MQ7DOQ1_;S^"_P8,J^)/B?X*TN>'A[9M5BDN0?^N*%I/_ !VM*=&I-VIQ;]$8 MU,12IK]Y)+U9ZYT'^--WX%?#OQ*_X.$_V;_ 9E73M:\1>+I$.-FDZ/(H)]FN M/)4_4$U\]_$K_@Z+TN R)X1^$]]==H[C5]76WV^YBBC?\@]>I0X?S"M\-)_/ M0\?$<39;1TE57RU/UH#?2C.1_A7X,_$;_@Y'^/?BL/'HNG^!_"\1/[LVFGR7 M,P^K3R,A^NP?2O"/B)_P5P_:0^)WF+J'Q:\46JOU72W33 /;_1UC/ZU[%'@G M'3_B.,?G<\:OQY@(.U-2E\K']*]YJ=OIUNTLUQ##&@RSR.%51[DUY?X[_;E^ M#?PRW_V]\4O .F21]89=F8[ MB^H:A+K1X#C_R]J_/^-O^#FGX+Z-N M31/"7Q!UJ9.C26UK:PM_P(S,W_CM?AK17IT>"/HWEE_P!:\Q\5?\%*OC_XR+?;?C!\0E5^ MJ6NMSVJG_@,;**\0HKT*>5X.GI&DON1Y]3-L94^.J_O9U'BGXV^,O'!?^VO% MGB75O,^]]LU.:?/_ 'TQ_G7,^:S=68_B3^/:FT5T1HTHZ15CDE6J2^*3?W@3 MGU_Q_*@-116JTV,OF%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *,[EHHH 4$CIQ^/6I;?4)[257AFEBD7D,CL"/QS_ %J& MBH<8O=%1J26S.X\-?M-_$GP8RG1_B!XVTDI]TV6MW,&SZ;)%KTSPA_P5=_:, M\$;?L?Q?\8S>7P/M]W]N'_D=7_E7SW16$\#AI_%33^2.BGC\1#X:C^]GVKX/ M_P"#@/\ :8\,%?M7BK1M<5?X;[0[5=WU,*H?Y&O4_!__ HQ^6C/0I\19E3^&K+[S]A/!/_ M =(Z7<,B^(_A'?VN/OR:=KJSY^B/"GY;OQKV#P3_P ')7P!\2%%U+3_ !]X M>;^)KK3(IHU^AAF=B/\ @.>.E?@W17GU.#\MGM%KT9ZE'C3,X;S3]5^I_2+X M&_X+1_LS_$!E6U^*FDV4C_PZE:7-@%/NTT:K^.<5[9X _:;^'/Q3V?\ ",^/ M?!OB R?=&G:S;W+'\$I M1\0,0OXE)/T;1_7.)5D^ZV?H:=NQC^M?RG^ ?VH?B5\*@G_"-?$#QIH"Q\*F MGZS<6Z@>F%8#\Q7N'P]_X+7_ +3'PY=!!\2[[5((\ Q:I9VU[O\ J\B%_P 0 MU>76X%Q,=:51/UNCUJ/B!A7I5IM>FI_2 S8':@'(K\._AO\ \'-?Q!_$D*=7MUN-/GD]R=\B9^B"O?_AK_ ,'0'@'4UC3Q;\-?%FBL?OMI=Y!J M*@_1S#Q],UY%?A7,J>U/F]&>SA^,,KJ;U.7U5C]0\\4Z,Y6OCOX9?\%VOV:? MB6\<;^.9O#MS)C$.L:9<6^WZR*C1C_ONOHSX8_M+_#SXR(#X3\<>$_$A8;@N MFZM!=.![JCDC\0*\BM@,32TJ0:^1[-#,L+6UI5$_F=U134E5_NL#]#3LURG< MG?5!11G-&: "B@'(HH **,T4 %%&/=+^2U\?_ !G_ M .#E3X-^"#-#X/T#Q9XWNE)\N7RDTVSDZ_\ +20F4?C%_P#6[\-E.-Q#_7B\YP6'_BU$OF?HTG#4COM7)88_WNM?AE\:/^#E?XQ>.!-#X0\.>$O!=K M,?EE>-]2NXQ_OR;8R>G6'']/DWXP_P#!17XX_'AYO^$F^*'BZ\AF_P!9;07S M6=JX/8PP[(\>VVOHL+P3C:GO56H_BSYO%<=X"GI2BY?@C^CSXM_M_M32<^@]AT%>[A>!< M-'6O)R]'8^=Q7'V+EI0A&*[[L_6/XL_\'1&K77G0^!_A;I]IC_5W6N:F]QN_ MWH8E3'X2&OF3XK_\%Y/VDOB?YB0^+['PO:R]8-%TR&$ >TD@DE&/9A]:^-Z* M^@P_#V7T?AI)^;U?XGSN)XDS&N_?K-+LM$=Q\2_VF?B+\9W8^+O'?BWQ('.Y MEU/5I[E/H%9B!]!Q7$,S.P^8\?=))X_"DHKUJ=&%-6@DOD>14K5*CO.3?S#_ M "****T,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** _EZ&GPW#6[*T;-&5.5(8_+]/2F44I)-6 M8U)K5'K?PP_;T^-'P9,:^&_B?XUTVWAX6U_M666UXZ?N7+1_^.FOI+X3?\'$ MG[1'P]\M=8O/"_C2%>&_M72EAE(]FMC%S[D'_=KX2HKSJV4X.M_$I)_(]'#Y MQC*+_=U6OF?L9\)/^#HC0;ORXO'7POU?3^SW.B:C'>;_ '$4JQ;?^^S7T]\) M?^"Z7[-OQ5,<9\=/X9NY<8@URPFM-G^]* T(^OF=J_G5H/7_ #Q]*\/$\%Y? M5UC>/H_T/H,-QSF-*RE:2\U^J/ZQ/AS\9_"/Q=TO[9X5\4>'_$EGC=YVF:A% M=H![F-B*Z;=TK^2/P_XDU+PIJ<=]I=_>Z9>PG*3VL[0R1'U!4YS],5]%?!O_ M (+ _M%_!(Q)I_Q,UO5+.,8-MK>S54=1T4F<,ZC_ '6!YKP<1P)77\"HGZGT M6%\0*+TQ%-KT/Z4AS_\ KHW>]?BY\&O^#GKQKHAAA\>?#KP[KT> KW&CWDNG MR_[VV02J3[90?2OKGX*?\'"G[/?Q3\J/6-2U[P->28!36=.9H=W&<26YD&/= M]O3M7S^*X;S&AJZ=UW6I])A.*,MKZ1J6?9Z'W6M**XOX4_M#^!/CCIWVKP;X MP\->)X0H9CIFI0W)C&/X@C$K]" :[0,"*\6=.4':2L>Y3J0FKP:?H%%&: ..?NVZ9E;H?NJ:TIT9U'RTTV_ M(RJUZ=)GKG_2-3OH[6,GT!=@"?8_'C_@X0_9]^$AFM]%U#6O'U]&2NS1 MK(K;AAZS3F-2OO'OK\$_&?CW7?B-KLNJ>(M9U37M3N.9+O4;N2ZN&.3U>0LQ MZ^IK)_R3CK7U.#X%HQUQ$V_38^3QG'V(GIAX**\]S],OCI_PS*P^M?&OQN_X**_&_P#:':9?%GQ*\47U MK<$E[."Z-I9L#G@P0>7'[S?HF*6 M9SRQW*<@L<_4T@Z445ZJC;3\CR=]?S"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH"X4444 %%%% !1110 449HSF@+A11G)H MSS0 44'BCM0 44#D4#F@ HHS10 44=:* "BC-&>: "BC-&* "BBC.: "BC%% M !11T-&,4 %%&:* "BB@#)H **,8HS0 449YHH **** "BBB@ HHHHU"X444 M4 %%%% !1110 4#_ /5Z444>H;EK1M;O/#VH0W6GWEU8W5N=T4UO*T!+J'AR[:/ M'N+: M%[ACF0Z;?20)-_UT0,$<<=&##VK[4^ /_!Q[\:OAHT%OXRT_P_\ $*Q0J'DG MA_L^^<#KB6']V#]8CGUKY?&<$8JGK0DI>6S/K,%Q[A)Z8B+CY[H_>'S.?O"G M+TK\_P#]GS_@XL^!GQ5:"U\51Z[\/=2DP':_MC=V6X]A-#EL>[QH*^U_A;\: M_"'QI\/KJGA'Q/H/B73VY^T:9?1W,8SS@E"=IYZ'!KY?%9;B<,[5H->O]6/K M,)FF%Q*O1J)G5449S2!P>XKC/0%HHSFC- !11FB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BDW4N: "BC-(75>X]: %IK'#4[- M>./#_A^15+I:RW DO)1_L0)F5O\ @*FO@3]H[_@YK\(^''N++X7>"=2\37*Y M5-2UJ3[#:9[.L*YDD'3AC$:_&K5-5NMZ\,Z3-G&G>'%.G1J",8,JYF8$<$.["OEN^OIM2O);BXFDN+B4EWED)D M=V.,G1\CB,=7Q$N:M-R]0/7T_'-%%%=)RA1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 9'X9H MH **!R* <_AUH *.U+M.>AXK=\'?"WQ-\0;E8]!\.ZYK4C'&VPL);EC[8136 M_>!_^"6?[0_Q%$?]G_!_QM'OY4ZA8FP4 M_C<; /K7LG@7_@WH_:2\7E?MVB^&O#>_^+4]:B;;]?L_FG].U<%;-\!2^.JO MO.ZADN.J_!2?W'P[WHQ7ZC>"?^#7GQY?JO\ PD7Q.\*Z7W;^S]/GOL'V#F&O M5_!W_!KKX,M O]O_ !2\3:A_>_L_3(+//TWF7%>=4XKRV&CJ?82?O24 M?G<_F_ +=*>D$DA 6-V+= %ZU_4;X6_8,^"?@M%_LSX2_#FU9/NNOAVU:0?\ M"*%OUKO_ ]\-M \)KC2=#TC31V^RV<<'_H*BN*7'E/[%*_JST*?A[5?\2LO MDC^5KPY\"O&_C#;_ &3X.\4ZIO\ N_9-+GFW?3:IKOO#G_!.7X^>+2IL_@[\ M1F5NCS:!<0H?HTBJ*_I_6V4?PJ/P_P#K4JIY?_ZJXI\=5OL4DO5W.ZGX?45\ M=5OY'\W>A?\ !%?]ISQ&B^1\*=50-T^TZC96V/J))5KL-#_X-_OVF]6"_:/" M.DZ?G_GYUZT;;_W[D?\ 2OZ%B>* ,"N6?&^.E\*BOD=D. L OBE)_,_!;1O^ M#;/]H/5 /.OOAWIO?_2-5F('_?NW>NMT3_@V&^+5SM.I>/?A[:]S]G-U/CZ; MH4_I7[>8Y_\ K4NW-S2]$=$.!\LCJU)^K/QLT[_@UN\22A6O/BYHL M+'[WE:')+CZ9F%;EC_P:R9.ZZ^-A]UC\*?U-W_2OUVV4?=K&7%69/_EY^".F M/!^5K>G^+/RET_\ X-;_ Z@_P!*^+FM3>OE:'''G\Y6K:T[_@U\^'*/BK)_O:I9?TM*L1_P#!M/\ &(_-KGQ M,D^NJVO]+:OT.HJ?]8,Q_P"?TOO*_P!6\L_Y\Q/SW_XAL?V?2O\ R$OB-GU_ MM6W_ /D>HV_X-J/@ XXUCXD+]-5MOZVYK]#**7]OYC_S^E]X_P#5O+/^?,3\ M[9/^#9[X!O\ \S#\4%^FJ6?];4U5NO\ @V1^!*,R7_+W\%_D92X1RM_\ +K\6?C/JG_!KGXNA#?8?BQX>G/I-I$L( M/Y.]ZQT^T37D.?RMWK]PME!'^<5O'B[,E]N_R M1C+@S+']AKT9^">L?\&W7[0FF@^3<^ -0QT%OJ\JY^F^%?Z5Q_B+_@@)^T[H MV?L_@K2]4]K;7K/_ -J2+_*OZ&\X-+C=6\>-,P6KY7\O^"W,OF?S6 MZ[_P1R_:6\-!OM'PE\02;?\ GUEMKG_T6[9_"N)\0?\ !/;X[^& S7WP=^)4 M:+]YT\.W375#CK%+XH1_$Y)>'^$^Q4:^YG\G?B7X-^ M+O!F[^V/"WB+2]G4WFG30X_[Z45SK1,O56';D5_7(]LI'W%]^.M<_P"(_@]X M4\8AAJ_AG0=4#<,+O3XILC_@2FNVGQ[+:=)?)G%4\/>L*WWH_DYHQFOZ@_%7 M_!.KX$>-%;^T/A!\.I&;K)'H-O#+_P!]HH;]:\P\6_\ !#7]F/QAN:3X:PV$ MK='L=5O8-OT43;/_ !VNRGQWAK^_3:^YG#5X Q:^"HG^!_.7G-&*_>;Q;_P; M9_L_^(-S66H?$#1&/W1:ZI#(J_A+ Y_6O*/&O_!K?X>NB[>'?BUK.GC/RKJ& MBQ7>?J4DB_\ 0:[Z?&672W;7JO\ (\^IP5FD/ABGZ,_'"@\?RK],O&O_ ;" M_%/3BQ\/^/O ^JJOW1?1W-DS#Z(DF/SKR'QS_P &_P!^TOX.+&U\+:/X@5>K M:;K=NN1])FC8_EFO0I\09=/:JOZ]3RZO#N94_BI/[KGQ7C-&>?IUKV[QU_P3 M6^/OPXW'5OA#X\6&/(>6VTB2]B7ZO$K #WS7D?B+P=K'@VZ^SZQI>I:7<+P8 M[NW>%A^# &O2IXNA4UA)/YH\ZKA*\/C@U\F9M%#?*<'@^]%="UV.9IK<**", M49H **",44 %%%% !1110 4444 '7U'(P1V/J*VO 7Q&\0?"WQ!%JOAG7-6\ M.ZE 08[O3;N2UF3GLR'_ .M6+14RBI*TE=%0G*+YHNS/N;]G+_@X)^/7P5%O M:^(+[2_B'I<6$\O68-MTJ@]KB+8Q/^U+YAYZ=*^^/V;/^#C7X,_%EX+/QI8: MU\.=2DPK/<*;_3]Q[":-=X[\O$H [U^$- Z_K^/;VKY_'<+9?B-7#D?DSZ/ M\69AADH\_.O-']8GPO\ C'X3^-'AR/5_"'B30O$NER#Y;G3;R.XC^A*$@$>A MY%=*&^?M7\FWPV^*_B?X.^(HM7\)^(=:\-ZI"1MN]-NY+688:I:.*CR/NM4?O,'R?O#\*5#D5\4_LO?\%W?@)^T4;>T MU+6I_A[KTVT/9^( L-N6_P!FZ&8L=@7*$XZ5]F:#K=GXBTN&]T^[M[ZSN%\R M*>"421R*>A5AP0?45\EB,#7PTN6M!Q]3[/"X_#XE:A=);PQ_5G(&?09K\]_VM?^#CSX;?"S M[5IGPQTF[^(>L)N1;^;=9:5"?4,R^;+TZ!5!!&'].[!Y9B<7*U&#?Y?>>=CL MVPN#5Z\TOS^X_22658UW,V%')STKY;_:K_X+$? G]DZ2XM-4\60^(_$%OE3I M'A\+?7"L.JNP81Q$=Q(ZMZ U^)/[5G_!5_XX?M>O<6_B+Q==$T7-A M8[?[KJAWRCVF>0?2OG')/7K[]:^VR_@;[>+G\H_JSX/,N/OL82'S?^7^9^CW M[4O_ N-C$=F)Z? OQ0 M^,7BSXV>)IM9\8>(M8\2ZI,1NNM2O'N'QU !8G &3A1@#/3K7-T5]G@\IPF% MCRT()>?7[SX?&9QC,7+FKS;\N@'DY]?UHHHKT?0\P**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHS1GK_L]?:BX!11GF@#-&X!CBCK71> /A%X MK^*VIBS\+^&?$'B*\S@1:7I\MU)GZ1@G]*^E/A-_P0__ &E/BV8Y5\ 2^';. M;&;C7;R&RV_[T18S#_OV:XZ^/PU%7JU%'YG90R[%5OX5-OY'R2.:#P:_5+X2 M_P#!KUXJU,QR>./B=H>EKP7@T73Y+XGV#RF(+]=I^E?3WPK_ .#O6O$K\7Y=3T4G)^2_4][#<&YG55W% M17F_T/P/VDG&.?2NF^'_ ,%_&/Q9N5@\*^%?$GB28M@1Z7IT]TV?^V8)K^E; MX8_\$V_@1\'A&V@?"GP7;S18V7%QIJ7=PN/^FDP=_P!:]GT_2[?2;-8+6WAM MX8QM2.- J(/0 <"O$K<>17\*E][_ ,CWL/X>R>M:K;T5_P S^<;X8_\ !%'] MI3XI-#)#\-;[1[9^6GUFYM['R_?,!VHP2><_A7BUN-\_#W_@@A^S3X"\M MKCP;J'B2:/I+JVL7,G/J4C=(S_WS7V:>!_C1C->36S[,*OQU7\M/R/;P_#N7 M4?@I+YZ_F>4?#S]AGX-_"I(SX>^%_@72YH>%FAT2W\X?]M"FX_4DUZ?::7#8 M0+'##'#&HP$10J@?0<58/%*.E>;4Q%2;O*3?JSTJ>%HPTA%+T0P+AZ?0!BBL MSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M&"#[ M^U4M8\.V.OVK07UE;7D#C#1SQB16'T.:OTC4U)IZ.Q,J<9?$KGB?Q"_X)R_ MOXI"3^VOA/X&GDD^]-!I45K.W_;2(*_ZUX5\0_\ @WP_9M\;&0V7A_Q%X7DD MY+Z5K4S$'V6X\U1^5?<(&12,N6KKI9EBJ?P5)?>SSZV48*K_ !*47\C\J?B+ M_P &NWA:^5V\(_%37M+YRL>K:5#?9]BT3P_GBO /B3_P;3_&[PP)9/#_ (@\ M#^)K<'Y46[GL[EO^ R1E!_W\K]U0M!!%>OA^+,QI?;OZI'CXC@[*ZFO);T=C M^:GXD_\ !(']I'X5&1M0^$_B*\C4_?T<1ZEN'J!;.[?F,UX+XR^'/B'X=ZD; M/Q!H6L:'=@X,.H6SU73[/4K208>&Z MA6:-OJK @UZ]#CJLM*M-/S3:/%Q'A_1>M"JUY-)G\DHYHSFOZ9/BC_P2C_9Y M^,'F-K'PG\)1RS'=)+IMJ=,D8^I:V*$GW-?-OQ7_ .#:GX*^+5ED\,ZYXV\( MW#?ZN,74=]:I]4D3S#]/-'3ZU[6'XVP4M*D7%]]SP\1P'CXZTI*7SLS\+2<" M@G;UXK]./BO_ ,&Q'Q(\.-))X,^('A3Q)$I)$>HV\VF32#TPGFH3]6 KYD^* M_P#P1Q_:0^#@DDOOACK6J6T?W9]$>/4MX]=D#,X'L5%>]A\^P%;X*BOV>A\_ MBN'\PH/]Y3=NZU/F*BM+Q1X,UCP1JTECK6E:EI-]%_K+>]MGMY4[I?L M[_MK?%3]E/4EN/ /CC7= B5PS6:3^=8S?[]O(#&Q]V7CUZ5Y;16=:C2JJU2* M:\S:C7JT7S4Y-/R/UF_95_X.9[VS-OIOQ@\&QW4?"MK/AP[)!V)>VE(!)ZY2 M0 =EZ9_23]F?]O#X2_MI0WEC=7%G=6S>9%-#(T/X-PE9N5!\C\ MMOZ]#Z[+N.,90M&O[Z\]S^N(."M /%?SW_LH_P#!>KXY?LYO:V.N:G#\1] C MPK6VNDO>*H_N78_>;L#&9?-'L*_3O]DG_@NI\#_VGC:Z?JFK-\//$=QA#I^O MNL=L[GM'=#]TP/0;]C$]%Z5\/F'#&-PMW;FCW6OX;GW^6\58'%I+FY9=G_GL M?:B\]J>#D57L+R+4+6.:":.:&8!D>-@RN#T((ZBIE(%?/ZK1GTB::NF.HH#9 MHS0,**"<"@'- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4449H ** +M'\-6[ ^2EU-FXN2.T4*@R2' MV121Z5^8W[8'_!R[)-;U37M8O6W37E_ M#,+0M+$_O)?=U\=?VFO'W[3/B=M8\>>+-9\37P M;=']LG9X;?/.(H\A(QR>$51ST%<+T_S_ )_F:**^NIT8TTHQ5O):'QE2M.I) MRF[W[ZA1116AF%%%% !1110 4444 %%%% !1110 4444 %%% &30 448XSV/ M2CI^'7VH **W? /PP\2_%77%TSPOX?UKQ%J38(M=.LI;J7![[8P6_I7UK\#/ M^"!_[1?QG$,U]X=TWP3I\P#>?X@OEA?'_7&+S)5;V917'B,RPU!7J32]6=N' MRW%8AVI4W+T1\6DXHQ7[,_ W_@V#\*:,8;CXB?$+6M;D W/9Z):16,8/=3+( M)&8>X5#]*^Q_@=_P2A_9_P#V>Q#)H'PST"XOH<8O=5C;4K@,/XE:X+[#_N!: M^;QG&F!IZ4DY/R5E]Y]/@^!E"[%'/5F KZQ^#'_!NS^T%\2A#-KT'AKP/:GD_VIJ(GN # MCE4MQ(,^S,O3M7[XVFGPZ="D<$,<4<8"JJ#:H [ 581<#_ZW6OG<1QQC)_P8 MJ*\U=GTV%X!P<-:\G+T=D?ES\&/^#8;P+H!AF\=_$+Q)XBD49:VTBWCTV$^J MDN96(Z\C:?I7UE\&O^"1/[.WP,6%M*^%WA_4+F/_ )>-81M4D)_O?Z0753_N M@5]+ 8I",GK7SN*SS'5_XE1V[+1?@?387A_+\/\ PZ2OW>OYE#0O#FG^&-.C MM-.L+6PM8AM2&VA6*.,>@48 J]'P/QH(_P FE7I7EN3;O+<]:,5%6BA:***" M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8X^;\*?36&3_] M:@#!\#/"4*_7RS7R1 M\:/^"!G[1WPA,LEEX;TSQE90DYET'44D8K[12B.0GV5">>]?T-8^E-96)_SB MO>PO%^8TM&U)>:/G\7P7EM;5)Q?DS^3[XD_!3QC\&M4^P^+?"OB'PS=[BJQ: MGITUHSGV\P#/X5S!X-?UL>(_"&F^,-)FT_5M.LM4L+@;9;>[A6:&4>C*P(/X MBOF3XX?\$5?V=/CCYTEQ\/[3P[?2GB[\/2MIK1YZD11XA[]XS]*^BPO'4'_O M$&O-'S.*\/ZL=<-4379G\X6.: V:_7KXX_\ !KU"XFG^&_Q*DB'_ "RL/$5D M&!')PUQ!C_T3ZU\8_'G_ ((L_M%_ 0SR77@6\\4:?"3B\\.R#4E8>OE(?/ ^ ML8%?2X7B++\1;VA\OC.&\PPVM6%_-:GRG15O6_#]_X8U*:RU*RN]/O+ M=MLT%S"89(CZ,K $'Z\U4 R<=_2O:C.,E>+N>'*$HZ35F%% Y&:*9(4 [3G) M'&#R>?P__7]***EV>X]5L>[?LI_\%)?C%^QM=PKX-\87RZ1&PW:+?L;O39!Z M>4Y(CZ=8]C?[0K]2/V/?^#CWX?\ Q1%KI/Q6TJ7P#K4@"'5+4/=:3*W') !E MAR>Q5U Y+@5^(-'4_3WQC\>WY5XN9YEO$F-P6E.=X]GJ?U MH> ?B!H?Q.\+6NM>'-8TW7-(OEWP7MA=)<02CU5U)!_.MD_6OY7?V=?VM_B1 M^R?XG_M;X?>+M5\.S.ZM-#!,6M;L#M+ P\MQQ_$AQ^5?J'^QC_P:U)Z$S6V3(G3.Z,R9_N*!7P&9<'XK#WG1?/'\3]& MROC;"8BT:ZY)>>Q^L#'BE4Y%N:^4E"47RR5F?94ZD9KF@[KNAU% ;-&:DL** M"V#1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T%@#36;)- !G' M?%&>>O;KFO/_ -H?]IWP#^RSX)D\0^/O$^E^'=-0%8S<2?OKEAR4BB7,DK=/ ME12?:OR5_;A_X.._%'CQ[S0?@QIA,47,4(]"Q=\8^ MXP('J9;DN+QLOW,=.[V/%S3/L)@(WK2U[+<_4O\ :L_;D^&/[&/AK^TO'WBB MQTR61"UMIZ-Y^H7G7'E0+EF&01N.%&.2*_)K]M/_ (.,?'OQ9^V:+\)M-_X0 M#07W1C4Y]EQK%POJO6*#/HN]O1P>!^=WC3QQK/Q(\3WFL^(-5U#6]8OG,D][ M>SM-/.QZEI&);T_#CM65^OX8K]&ROA#"X>TZW[R7X+Y'YGFO&6+Q/N8?]W#[ MV_F:/BSQ;JGCOQ#N9+F[NYVN)YV/4L[G)[>_;M6=G-%%?61C M&*M!61\?*3D^9N["BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****/( HHQ@T M8X'OT]Z>P!1G]*]<_9[_ &"_B_\ M3S0GP/X!\0:Q9S' U V_P!GL/QN)=L7 M'LQ//2OO+]G+_@V0\5^(1;WOQ0\ M1C,[P6%TJU-?O_(]C!9'C<7K2INW?8_+''S8[GM7J/P(_8I^*_[34T:^!_ / MB3Q!!(VT7<5F4LU/O/)B%>HZL*_>_P#9T_X(S_L__LW"":Q\#VOB35H0I_M' MQ"?[1E9A_$(W'DHPZY1%//TKZBLM.ATRVCAMH([>&)0J1QJ%50.@ '8>E?)X MSCJ-[8:%_-Z?@C[# >'\]\5.WDM?Q/Q*^ /_ ;/?$[QIY%W\0/%GA_P3:MA MFM;-3JE\OJIV[(E^HD?Z5]N_ '_@W[_9]^#/D7&K:/JWCW4H.1+KMWN@#=\0 M1!(V!]) _7Z5]OQ_\"_&E49%?*XOB7'XG>I9=EH?78/A;+L/JJ=WWEJ<_P" M/A;X;^%.A1Z7X9\/Z+X>TV+[EKIUE':PKP!PL8 [#MVKH(Q@4$8[4J]*\.4G M)WE=L^@A3C!6BDD+11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DSG^'\:?2 M%#?#GBB%5*Q_VCI\5PT.>I1F4LA]U(-?&/[0/_ M ;D_!#XI1SW'A.X\0?#W4)/F5+2X-]8[N?O0S$N1[+(HK]!NE-P=WM79A?BLIP>)7[ZFG\C\&?V@?^#%[LDA5U*PEMQ-UY1F #C@\ MJ2.*_JX[_=_2LWQ9X-TGQSHTVFZUI>GZQI]R-LUK>VR3PS#T9&!!_$5]3@^. M,5'2M%27W,^3QG >%G[V&DX>3U1_)3FC./PZ^U?T+?M%?\$%?V??CKY]QI_A MV\\!ZI+D_:/#MQ]GA)/K;N'B 'HB(3ZBO@W]HS_@VK^*7P^BFO/A_P"(M%\> M6\J9].U?68/B[+Z_P ;Y7YK^D?&X[@W,WK7T=*I"<>:#NN]SYFI1J0ERS5GVMJ%!YX]\_CV_*CH:*TU,SN/@-^TE MX[_9A\7QZ]X#\4:MX;U)2/,:TE*QW !SMEB.8Y%SGAP0.3CFOU*_8K_X.3[7 M5&M-#^-VAK83';&/$>BQ.\/8%I[;)9?7=$6]HP*_'VCK^?KC/X_Y%>3F&28/ M&K][#7NMSV,MS[&8*2]A/3L]C^L/X2_%_P +_&_P7:^(/"'B#2?$6BW@S'=Z M?FBYD@R>Z^8G4DH*_.\TX0Q6&7/0]^/XH_2LIXTPN):IUUR2_!GZ MD$;L4X5C^#/&>D>/_#-GJ^A:I8:SI.H)YUM>6=PD\$Z'NKJ2K#Z&M<-7R+33 MM+1]C[6,E)76PM%&>:,T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 449I"X'<4 *6Q3= MV:;,ZJ"Q/"@Y/H.]?#__ 4!_P""X_PU_8_^W>'O#( MKBZL8I"]GI%L/(TVPS_<@!(W#^^Y=SQES@ >,DY8G]?7_/O7Z+E'!M*G^\QO MO2[+;YGYAG''%6M^[P7NQZM[_P# .L^,OQT\8?M#>-KCQ%XV\1:IXDUJXZSW MLYD\D9)"H,%409.$3"C)P!7)]#_@,445]O3IPA%1@K)=CX6=24VY2=[]]0HH MHJS,**** "BBB@ HHHH **** "BBB@ HHSBB@-4!.*,9JQI.EW6M:C#:V5O/ M=W5TVR*&&,O).>R@+DD^@ YK[(_99_X(/?'C]HW[/>ZEHL/P^T&;:_VSQ"## M<,IYRELH,I.#T<1@_P!_J!R8K'X?#1YJ\U'\_N.S!Y?B<5+EH0#]>\476=L@L;1Y(X?^NCXV(.>KLH'K7[>?LM?\&] M7P5^!8M;_P 6+J'Q,UR##;M4_<:"&E ]*_ M0S]FS_@B]\ /V9?L]U9^#X?%6M0D$ZGXC8:A*6'1A&P$*$=BL8(]>E?5B&6Z3PRCT9&!!_$5\;_M*_P#! OX!_'C[1>:/H]Y\/=9FRWVC M0)=EN6/K;N&C"^T8C)]:^W&7CBD 8FNG#8_$8=WH3:^9PXK+L-B5:O!/\_O/ MP8_::_X-U?C1\'A<7W@NZTOXD:/'DA;1Q8ZB%'K;R'8WT21V)SQ7PU\0?AAX MD^$WB.71_%&@ZQX=U2#[]GJ-G):S)R1]UP#C@\@8K^LHY+8_I7*?%OX%>#OC MQX=DT?QIX7T/Q1IL@/[C4K)+A4R,97-L13]W$Q4O-:,^-Q M_ >'J7EA9.+[/5'\H>>/UH[?K7[@?M2_\&V'PW^(8N-0^&.O:IX"U-\LME=9 MU+36/H-["9/3.]P !A?7\WOVI?\ @CY\>/V4FN+K5O!MQK^A6Y)_M?P_G4+9 M5'5W50)HQ[R(![U]M@>),#BDN65I=GH?#YAPSF&$OS0O'NM3Y@H ^@/K_D&E MD&QL,-O)'/7CK25[?3R/ L[VZGM7[(7_ 4"^*7[$GB5;SP+XDN;73Y) ]WH MUT6N--NQP,-"Q !( &]-K@8Y S7[%_L)?\%[/AC^T^+'0?&GD_#?QE-B)8KR M<'2[V0\ 17!P%).?DDV^@9^M?@51W[8/!R,Y'TZ'\>E>%FG#N$QRYI1M+^9' MOY3Q)B\ U&G+FCU3U_X8_KDM[A)XE:-E96^Z0?E;W%3!\9[5_.K^P/\ \%G? MBE^Q0;/1;JX;QMX#A(1M$U*:#?D0:C:'O\F2)$'&7C++SR0<@?F>:\.XO N\U> M/='ZMD_$V$QZM%\L^J?Z/J?06:*:C*J]AW_QI0P/>O!/HA:*,T YH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M IK'!_"G;J@O;R*RMVFFD2*&-2S.[!54#J23Q@4+71";25V29P?Z^E>4_M5_ MMG_#O]C/P,WB#Q_X@M=+A8,+2R4B2]U%Q_!#"/F<^_09R2!S7Q+_ ,%&_P#@ MX'\-?!DWWA/X.?8?%_BI=T$^NO\ /I.F'H?+QG[1(, _+^['JY!2OQP^,?QN M\6?M!^.[SQ-XTU_4O$6MWQ_>7-[.7.W_ )YJ.B(,\(H"CD# X'U^2\)5L3^] MQ/N1_%_Y'Q&><94<+>EA;3GWZ+_,^P/^"@?_ 72^(W[64M[X?\ !\EW\/? MWY4BC _P#K?SI: M_3<%E^'PM/V="-OZZGY;CLPKXN?M*\FW^'R"BBBNPX0HHHH **** "BBB@ H MHHH **** "BC/Z=?:@#)Q0]-PUZ!_CC\:,=/]KI[U]$_LB?\$L_C-^VA-;W' MA?PO/8^'9B VNZL6LM/*]]CD;IOI&K8[^WZC_LE_\&X_PO\ A(+;4_B1J5Y\ M1]:3:[6I!L]*C8=C&A\R7'3YWVD=4[5X68\1X'!Z2ES2[(]_+.&<;C/>A!Q7 M=_Y'XV_ 3]EOXA?M0>)AI/@'PCK7B:Z! E:TMR8+8>LLK8CC'/5R*_27]DG_ M (-G-0U#[+JGQD\5KI\.56E%17EH+11169L% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %12Q[Y/PZ5+32,F@32>Y\W?M6?\$H M_@E^U[]INO$?@^TT_P 07&6_MS1L6-^7/\3LHV2G_KJC]*_,_P#:M_X-M?B- M\.!<:E\+]H:/.<;?7]P@,>E,>/-L8^92#[U^;_[7/_!M#H7B W6J?!OQ1+H%PX9UT/7'>XL\ M]ECN%S,@]G$A.>2!T^XR_C3#5;1Q,>1^6J/S_,N!<51O+"OGCVV?_!/QKZU? M\+^*M4\$>(;35M%U"^TG5-/E$UM=VD[0SV[CHZ.I!5AG\?P->C_M-_L2?%+] MD#7?L/Q!\'ZIHL?_!Q->:#]A\*?'B.34+/Y88?%EE!FXB'&#=PJ M/W@'>2,%N.4;)8?K;\-OB7H'Q:\(6.O^&-8T[7M#U*/S;6]LIUFAF7V921QT MQU!&*_DT.Y2/S_'L3W_*O:?V-OV_/B9^PWXP&I>!]>ECT^XD#WNCW9:73=1_ MZZ1$X#'&/,7:P&,$#.?C/O+S/X?O9AFX8#+-:R' F7J<8#@ MEE P3]=1L #SWK\WQ.%JX>?LZT>5GZE@\91Q5/VE"7,OZW'T49HS7.=04444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111N% 6VCFFL M^/\ ]=-E8+\WH.OM7P?_ ,%,_P#@MYX/_8XAOO"?@O[#XS^)$8:)X5D+Z?HC M],W#J07<<_ND(;@[BG&>K!X&MBJBI45=_P!;G'CLPH82DZM>5E_6Q]/?M9?M MB?#_ /8T^'$GB3Q]KL.EVV"+6UC(DO-1D'/EP19#.W3GA5R"Q4X\%_#MBR)H]I-BXU%3R&NY1@.#_P \Q^[&1G>1N/S9 M\??VB?&?[3WQ%N_%7CG7]0\0:S=D_O9Y,)"F3^ZB082)!DX5% Y/7-<3^7X" MOU+)>%><68C&OV>']R'XOU#.:***^LTW/C_ ""BBB@ MHHHH **** "BBB@ HHHH *,\_7I1_AFE5=S8Q]XA>>G/K]/ZT.RW"-W\(A.! M2HC2L%4;LD*!C.">,U]A_L4?\$2_C+^UV;/5+K3F\!>$9]K_ -K:U%)'+<1^ ML%MQ(YP<@G8G)^?/ _7;]BK_ ((W_!O]C-+/4+71?^$L\76X!_MW6XTGEA;C M)@CQYY^/_ .QW_P $ M5?C=^UJUGJ+:(?!'A>XPW]K:\CP-(GK% ,2R9'(. AS]\'-?JQ^QY_P0J^"W M[+:6NH:IIK?$3Q/;X;[?KD*O:Q..LZ=9ZMI ME[&8KBTNX%F@G0]5='!5@?0@BOS_ /VO_P#@W7^%OQH%UJGPYNIOAOKT@+BU MB0W&DS-SP83\T?U1MJXX0]*_1)1F@#-=F#S#$867-AYM'GX[*\+BX\N(@G^? MWG\R7[7_ /P3*^,'[%%],_C#PM/-H2OMBUW3(ICK@GK]WEO&T)6AC(V?=; M?-'Y[FG _R9^!VG:E&!"D M$8/''.,?I]_P3E_X.$-8\ QZ?X0^.37.OZ'A8(/%,<9EU"S7H/M*=;A!U+@^ M9UR)">/D+]LK_@EU\8/V'[V:;Q5X=:^\.A\1^(-*W7&G2#G&]]H>$MZ2!23T MR,$_/&0'_P!KKD<$GZ^V>]?4XC#8'-**U4E;=;H^3P^*S#*J_6,NJ>S/ZS_A MW\1-#^*G@W3]?\.:M8:WHVJ1":UO+.<313*>X8'GN/4$$8&,5MJ< U_,U^P= M_P %*OB1^P#XO%QX9OSJ7ANYD#ZCX>OI&:RO!P&91R89<# D3!^5=RNH*G]X M?V$O^"D7PW_;W\&+=>%M0^P:_9QA]2\/WKA+ZP/0G:.)(LD8=?EY&=IRH_,< MZX2S,Q '/7_]?#?M7?M=>!?V-_AC<^+/'.L1 M:?9Q*RVULA#W>HR@<0P19!=SQW 7.6*C)'X$_P#!1O\ X*K^._\ @H!XHDM9 MYI/#_@&SESI_A^WE)C?!XDN6P#+(<=P53L O6'P3X=F;28Y-ESK=]F MWTRU(QG,I!W,N<[(PS_,#CT_8?\ 87_X()_"W]E_[%K?C.)/B5XPA"R>;J$ M_LRSD&/]5;'(<@]'EW'@$!#7@YIQ)A,%[LGS2[+^M#Z'*N&<;CFI1CRQ[L_+ M+]AW_@CY\7OVVYK74K'2_P#A%/!DS!V\0:O&\<,B^L$?WIS@G!0!+[M1K,\+CDF"+_5PC/0@%P.-YKZVM(%M MX5CC18U3A55< < 8]JD P:_-LTXFQF,;C%\L>R_5]3]0RGA3!8).?#7:ZU9[KC3+P MCH%E ^4D#A'". !\N,$^6_#;XF^(/@[XWT_Q'X7UB^T+7-*D$MI>60< M*@&:^_ROC*E67LL=%*_7=/U70_.F/2 MOY5?VAOV8_'W[*OCF3P_X_\ #>I>'=43=Y)N(\PW2@@;H91N25<_Q(Q *C.# MP/NK_@EC_P %V=:^ T^G>!/B_>7NO>",I!8ZV^9K[14/ $O4S0#CG)=0#C<- MJ#CSCA:%2+Q>6M..[C_EY>1V9'Q94IR6$S--2V3_ ,_/S/W#!R/6EK(\$^,] M)^(/A2QUK0]2L]6T?4X5N+2\M)A-#<1L,JRL."#6L&S7P/*T[/<_1XR4ES1U M0M%!:B@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4UF^?KVZ4XMBHY&4'/6@ + =Z^8_ M^"D'_!3WP3_P3[\"%K^:/7/&FH1%M*\/P2@2R=0)ICSY4(((W$$L00H;!V^8 M?\%7O^"R>@_L0Z5<^$?![6?B+XH74>/))\RUT%".)9]O63NL7!(^9L#:'_"# MXG?$_P 0?&;QYJ'B;Q5JUYKFO:K,9[J\NGWN['TQP% P HP% %?8GYTJ*SNNWYFS\H/\ >Z#G\?Y5]_?\$\O^""OCS]J!+'Q)\0OMW@#P M--B1(Y(=NK:G&?\ GG$P_*_CWXYM/#7@WP_JGB+7+X_N[6Q@,DFT=7;H%5>[,R MJO.2 37ZV?L!_P#!N9I/A5;+Q+\N>E?FF<<7U\1^[PON1[]7_ )'ZEDO!=##?O,7[\OP1F^$/!NE^ M ?#MGI.BZ;9:3I=A&(;:TLX$MX($'1510%4#T Q6JM(!S2U\Y!+6]Y#NV/C ='X:-P"<.A##L17Y'_M]?\&Z& MN> EO?$OP1NI_$FEINFD\.WKJ-0MQR3]GDP%FP,X5MLF!@%V-?M(>M,E'.<= M!Z=:]++LXQ.!E>C+3MT9X^9Y'A,=%^VCKWZH_G5_X)^?\%.OB/\ \$S/B-/X M;UBSU*_\'_:C'K/A?40\4UC(<;I8 XS%,!U7[K#A@,*R_O5^S)^T_P""_P!K M?X46/C'P/K$.K:3>#9(OW;BRE !:":/K'(N1D'J"""5(8^<_MK_\$S/A;^W= MH+Q^+-$6S\01QE+3Q!IZK;ZA;=P&8#$R9YV29 ZC:W-?E?XE_9L_:(_X(1?& M-O''A>1O%7P]FD6.]N[:-CI^HP Y$5[",M;N 2%DR0"?E=LLI^BQ$L%G*YZ= MJ=?MTE_P3YO#+'Y(U"M>K0[K>*]#]U@VX_I3U.?SKPG]A3]OKP+^WM\+%U_P MK=F'4K4*FK:+FJM*7-%[,=11G(H!S69L%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.*<6%0R,,[NP') M]![4>@>H2^_/KZ5^:W_!7S_@MA;?L\+J7PS^%%Y;WWCI@UOJFL(5D@\/9R&C MCZA[D=#U6,]0S J.8_X+)?\ !; ?#EM5^%/P?U17\0KNM->\16TF5TL]&M[9 MAR9NH>1?]7C"_/EH_P ;+B=[F=Y)&:221B69CDL>Y)[Y]3UK[SAOA?VEL5C% MITC^K/SGBCBSV;>$P;U^U+MY(GUO6[SQ+K%UJ&H75Q?7U]*T]Q1CE MG9F))8DY)/)/-5:**_2XQ27*EL?EKDY.[^_N%%%%, HHHH **** "BBB@ HS MQ].OM0!D_B!^)Z?R-$?[UEV99F.%P>N>./\ ZW6AV6K'&[=D%>K?LG_L7?$7 M]M#QZNA> ?#]SJ4D;*UW?O\ NK+35/1YIB-J]R!RS8PH.2#]@?\ !-G_ ((( M^*OVB_[/\7?%1=0\&^"I-LT&G!?*U;5TX(X(!MXV_O,"Y'10"''[3?!GX'^% M/V>_ %EX7\&Z#IWAW0M/7$-K9Q;5SQEV)^9W/!+L2S'DDGFOC$.W5GR5_P3R_X(??#O]CA;+Q%XDCM?'?Q B4/]ONH/ M]"TR3O\ 9H6S@@Y_>/E_[OECBON* ;4Q[TB@[/Q]*D7I7YGB\;6Q53VM:5V? MJV!P%#"4U2H127];A1117*=@4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %5=4TZ'5+66WN(8[BWN$,4LL0_#GQ]8LTLNANVW1=8 M4D,\)7GRU?&"G,9XXC(#K]!?L;_MHQ_M&6UYX;\4Z'=>!/BKX;C']O>%[\;9 M8L':+JW).)K5V^[(I.,@$]"?=I!\W ^O^?SKB?BQ\ ] ^+=YINH7D$]AX@T- MS+I.MV!$.H:8^.?+DPT MPNB>\>GKY'=1-N7V-*HQ5+PW;WUIH\,>I2V]Q>1C;)-"AC28C^+8<[<]=N2! MZFKV:\_9GJ+;4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHH)Q0 4USBEW#-1S$%OPH 23!Y^HSZ?_7K\I_\ @M-_ MP6?_ .$+75OA#\(]45M:(>T\0>(+63/V#.0]K;./^6W4/)_ <@?/DIM?\%KO M^"Q@^#5EJ7PC^%VIY\77"-;^(-:MI<_V&A&#;PLO_+R>C-_RS&0/G.8_Q9EE M::1F=BS,26)ZD]S^/\J^^X7X:Y[8O%+3HOU/SCBOBI1O@L(]=I2[>2"20RR, MQ9F+$G+=3_G^>:;117Z4HV1^7ZO<****!!1110 4444 %%%!X&>W2BS */Z4 M'BOJ;_@G7_P2D^('_!0#Q#'>6D,GAWP':S;+WQ#=PDQG!^:.V3@S2]B 0J_Q M,,@'FQ6,I8:FZM9V7];'5A,'6Q-14J*;9XA^S_\ LY^,OVHOB1:>$_ ^AWFN M:S>9S'$N([>,$;I)G)"QQC(RS<-OLGC MCXAQ@2I+)'NT_2'Z_P"CQO\ ?D7H)7&00"JI7TO^R+^Q/X!_8E^&D?AKP)HZ MV2L%>]U&;$E]JDH!_>3RX!8\DA0 B9PJJ.*];A!$>,;<<8K\LSSBJMB_W6'] MV'XL_6LAX1HX2U;$VE/\%Z#DR%]/2G4TGFG U\F?:!1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %-?DTZD)Q]*0$;-@\X^GK7Y]?\%I_P#@K7#^R/X4N/AWX"OX9_B5 MKEOBYN8G#?\ ".6[C'F'MY[ _(I^Z/G(QM#>G?\ !6G_ (*7Z5^P#\'_ "=. MDMK_ .(WB2%X]$T]L.+8<@W/QIXSU;XB^+=1U[7-0N MM5UC5[A[N\O+ER\MS*YW,[$\DDFOM.%^'OK,EB:Z]Q;>;/@^+>)/JT?J>&?O MOXGV10O;Z;4[R6XN9I+BXG.@)^G6OVS_P""4W_!#+2_V>_[ M-^(7Q:MK/7?'B[;BPTA@LUGH#\$,Q^[+<#UY2,CY=Q <>/FV<8?+Z?-5=Y/9 M'LY+DN)S&IRTE:*W9\\?\$JO^"#%_P#%J'3OB!\:K.[T?PS(%N-.\-',-UJ8 M."LEP>&BBZ848=\Y)50-_P"S7@[PCIG@3PW9Z/H^GV6E:7IL2P6MI:0K%#;Q MJ,*B*H XP*O1Q_+TZ=JE6OR+-,XQ&/J^TK/Y+9'[/E&2X;+Z?)1CKU;W8H MHHHKS#V HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "C-%(W(H 0G'H*\=_;D_;)\-?L M.? /5/''B&996A0P:;IZ.%FU6[8$QPIGIG!);D*@9B#BO1OB'X]T?X7^#-6\ M1>(+^#2]%T6UDN[R[F.(X(D!+$]^W0#]%=[3P]I;M@6T&[YI9,''G2[0S$9Q\B9PF3[W#^2RQ]?7X([O]#YO MB3/(9?0M'XY;+]3RC]I+]HWQ1^U;\9-:\<>+[YK[6-9E+,JL5AMHNB0Q*3\D M:K@ =>N23R>$[>OT% Z#VXSZT5^S4Z,:4%3@K);(_#ZM6I4FZE1W@VXU'Q)J$:'6=?F M0"YU!Q_".OEQ*>%C!X')+,23\YGO$%++X\L/>J/IV\V?3\/\-U#H=2NUM?$/Q(U"'&H:VT>5MAK\BQ6*JXFHZM9W;/V?!X.CA:2HT(V2' M4445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 444$XH *BN/O?=W<=/7_/^>E2; MU]:^(_\ @MG_ ,%'H_V*?@+_ ,(_X$J8FLJ-):LY,=C*>%HRKU7I$^)/\ @OO_ ,%-&^+_ (RN/@KX M*O\ S/"_ARY_XJ&[B;Y-4OHSQ;@YR8X&!#9^](._EC/YED\]_P 33IYGN)FD MD+-(YRS,:;7[?EN7T\%0C1IK;=]WW/P+-,RJ8[$2Q%1[[+LNP44 M45Z!YX4444 %%%% !111_7B@-PKV#]BK]BOQK^W+\9+7PGX/M&&PK-J.I2 B MUTF#.#+*P'U"H/F<\#H(H8&'LJ6M1_AYL^LX:X:J8^7M*NE-?CY%3]B?\ 8B\& M?L,?!RS\)^$;,9^674M1F1?M.JW &#-(1Z=%4'" XY.:]GA.4Z$>QI"IV]>] M.48K\CK5IU9NI4=Y/<_9L/0IT8*E25HK86BBBLS8**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHS0 4U^M.W5'*I?L>?LA>+_VV_C7IW@KP=:^;2 _9M,M@0)+B4C^%=PP.K,0J MY) KG_V?_@'XH_:=^+.C^"O!^FR:IKFM2B.*/'[I%'+22MT2-5RS.>@'?-?T M;?\ !/#]@#PS_P $_?@C!X;T<+J.NWP2?7=:=,3:G<@8^JQKN8(F> 2>69C7 MS?$&?0P%/DIZU)+3R\SZCAOAVIF-7GJ:4UOY^1T'[$W[%G@_]AKX*6/@_P ) MVNYEQ+J6I2(/M6K7) WS2$>IZ*.%4 #IS[$@PM-"87NOH/2I!7X[4K3JS=2H M[R>Y^UT*$*--4J:M%;!1114FH4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'K M12'GB@!"?I7S9_P5/_;>:5BTDLC$LS,3R26)))[FJ]#')_B_&BOVM144HQV1 M^%N4G[T]WOZA1110(**** "BBB@ SBM#PKX3U/QWXFL=$T:QN-2U?59TM+.U M@CWRSRN0$10.22Q48'?%9Z@LZA?O]!\V,G\.1]??ZU^VW_!"'_@E8/@7X5M/ MC)X\TW;XOUNV#>']/GCPVC6Y_\$E_^"8>F_L"_"3[=JT=M>?$KQ)"K:S?+AA8J2&%G M">?W:M@L1P[ $Y"KC[ @.4[]<E?BN*Q57$U76K.[9^[8/! MTL+25&BK)"T445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36.*= M3)7VCZSR1^U?SL.6+G=U]?6OK_\ X+:?M@M^UA^VWK4.GWGVCPKX%8Z!I:HV8I#& MY^T3#LV^;< PZHB=J^/UX'OW/K7[)POEJPF#BY?'/5_HC\/XKS;Z[C6H_!#1 M?JPHHHKZ0^7"BBB@ HHHH *,]?S_ *?X4$[17N7_ 3X_8DUW]O/]HW2_!FE M^9:Z7'_I>MZCM^33;)6 D;W=LA$'=B,X7<1CB,13HTW5J.R6IOA\/4KU%1I* M\GL?4/\ P0I_X)>_\--_$"/XI>.-.6;P#X7N@NGVDZ9CUV^0@X*GAH8B 6SP MSX3D"0#]UH$V)W_&N<^$'PIT'X'_ TT7PCX9T^'3-#T&U2TL[>, !$4=3_> M8G+,QY9B22223TPK\3SG-)X[$NI+9:)=D?N^0Y/#+\*J2^)_$^["BBBO)/:" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQS11F@ )Q7S7_P5D_:S/[' MO[$OBKQ'97'V?Q#JD?\ 8NAE#^\6[G#*)$_VHD$DH_ZY8KZ2D/'\Z_#?_@Y$ M_:L/Q/\ VF='^&.GW&[2_A_:B:^4-\LE_M>UP_E_P!; MQL(/X5J_1'@\29C]3P,IKXGHO5GYORS-<2-(QW,Q))R3G\3S^?--HZ_YZ45^ MW?4**** "BBB@ HS10?F*C(!SQGH,]3^%'6P="YX?T*^\4 M:[9Z9IMK/>ZCJ-PEK:V\"%Y;B9SM1$ Y+$G Y)(]*_HX_X)1_\ !/RR_8)_ M9NM=-NH89/&WB/9?>(KM,-F7!V0*W>.($J.Q8NW\0KX+_P"#=O\ X)Y?\)IX MHD^.OBNQ9M+T:22T\+PS+D7-UC;+=X/\,0)5(/%6L3?9])\-Z=/J=V_I%$A=L>IPO [DU_*[\:/BIJ7QQ^+GB7QCK#[ M]3\3:E/J=QSD(TKE]H]EW8'H !VK]Q/^#BW]HL?"?]B*#PE:W CU+XB:G%8L MBMML]GBKXD0QRVOF+\]II8^:$9Q_P MCB4X_A\D?PFO%X@S18'" MNB]3WN'>:5ND:*"S$^P /-%F]$*4K*[/P?_P"# MB_X_-\4/VYX_"=O-OT[X>Z3#9F/=N3[5.!<2M]=CPJ?>,CM7P#C'I^%=I^T9 M\7+KX]_'SQEXTO-WG^)]8NM1*L>8A)*S*GT52%'L!7%U^\Y3A/JV$A1ZI(_G MC-L6\5BZE?NV%%%%=YYX4444 % &3]>!11C=\O7=Q@C@\@?UY_"@#Z(_X)K6IC\3?$X MQZFQD7]Y!8*"+5.G\09I3CC$J#^&OO=/NU^-\49H\7B^6/PPT7ZL_;>$EJ_3HA:**"VT9+J/HJ,W48_Y:+^='VR+_GHOYTNK=?JX%-1D]D'MJ?\R^\M45''>0S+E9$8$9!!ZTX MR*#U%39HN,D]AU%&[FC.:!A1110 4444 %%%% !1110 4444 %%%% !1106" M]30 45&]U'']Z15^IJ$:W9EMOVJWW>GF"J49/9&;JP3LVBU14(OX6'$L9_&G M?;(?^>B_G1ROL'MH=U]Y)14?VR+_ )Z+^='VF/\ OK^=+E8_:0[HDHIGVB/^ M^OYTOG+_ 'E_.BS'SQ[CJ*:)5/\ $*<&S2*N@HHS1F@ HHW49S0 449Q1F@ MHHW4TRJ#]Y?SH%S);CJ*;YZ?WE_.D^T1X^^OYT[,7M(]Q]%1_;(O^>B_G1]L MA_YZ+^=/E9/M8=U]Y)15>75K6 ?/<0I_O.!3HK^&< I-&P;H0V3,(8,@]5$LB,1Q\JGFM*-*56I&G'=NR,,36 MC1I2JRVBKGIUQ\3O#MCXI71)M>T:+6& 9;!KV,7)!Y!\O=NY^E;0D#D8-?R3 M^)_&&J>-O$=]K6L:A>:IJVJ3-OV:/^"J M_P =?V5#;6_AOQUJ-]HUN JZ1K#'4;'8/X%63YHA_P!E43 MEV9\%0\0*+J6JTW%=.I_2_T]*4/D=?SK\D?@=_P=!6C6T=O\1OAG=1R* )+S MP[>JX<^UO,1M[_\ +9J^G_A=_P %Z_V;?B48XY_%U_X7N),8AUK3)XL'T,D: MO$/J7Q7S>(R#,*/Q4V_-:_D?3X;B3+L0O3T9]HYHSFO%?"O_ 43^ WB MP*+'XP?#EV;[J2Z_;0R-]%=U/Z5Z)X9^,OA'Q@%_L?Q1X=U0-T^R:E#/G_OE MC7FRPM:/QQ:^3/5CBZ$OAFG\T=-14:7D4@^616^AIRRJW1E/XUERLV52+V8Z MB@-FC-(H***"<4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 M %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J- MU !11NHW4 %%&ZC=0 449I"P% "TC4AG0?Q+^=4-:\5:7X?@\W4-2LK&,=7G MG6-?S)%5&,F[)&],A3:F/?BI!7B1V/>"BBBJ **** "BC-(7"]2!WH 6BF-<1IU=1]34/] MLV>_;]J@W>F\9JE&3V1#J06[19HJ(7L)_P"6B?G2_:XA_P M%_.CE8O:P[HD MHJ/[5&?XU_.E$Z'^)?SI697M(]Q]%-\Y/[R_G2JZL."*6HR%[:FMY+[RU1 M4<=U', 5D5@>F#UJ0L!4V:W+C)/5!10#FC.:!A1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?-?_!7?XR_\*._X)W_$ M_5(Y?)NM0TEM&MB#\^^[86V5]U65FX_NU]*9P:_,7_@YY^*G]@_LU^ ?"$S?\$^_V7;C]L3]KKP9X%6.1 MM/O[P7&JNO2*QBP]P2>Q* JN>K.!UKQD]?U]B>V?SS^%?LY_P;1_LE?\(Q\, M?$WQAU2U_P!,\32G1M%=UY6TA;,\B^SS )Z@VY]:\?/LP^J8*=1;[+U9[?#V M7/&XZ%'IN_1'ZC:3I5OHNEV]G:P1V]K:QK#%%&NU(D4 !5 Z 8 ]!5H<"H_ MN\8IP; ]*_#]6[L_>XV2LAU4]9U.WT2PN+V\FBM;2SA:>::5@J1(HRS$G@ # M)R> *MEU4>E? G_ <(?MB-^SY^R.G@O2+KR?$?Q,E?3SL;#Q:>@!N6 MXY&_='#[B9\(/!WQ&\=>%?"LEV;?1[#2M;NK&W2UB^2-S&CJ \@'F-D9W.1T QYE#_ M ,%%?CY ?E^-'Q//^]XEO&_G(:\:'0GR/<(/^"EW[04'W?C)\1C_ +VNW#?S:K'_ ]!_:&\ MO;_PN'Q]C_L*R9_]")KP>BK_ +/PW\D?N7^1G_:&)_Y^2^]GN$W_ 4O_:"F M!W?&3XC?\!URX7^3"JD__!13X^72X;XS_$\?[OB6\C_E)7C5%']GX5;4U]R# M^T,3UJ2^]GJTW[=WQONA^]^,7Q2D'??XJOC_ .U*H77[8OQJ-Q\<_&MY_K?%_BF3_ ']5F.?_ !XURM!.!1]7I;:]K4@[[[V1OYM5.7Q1J4W^LU"];/]Z9N?_'JH@9->P_!W_@G]\:OC MW'#-X3^&7B_5+6Y&8KPV#VMI*/:XEVQ?FV*QJ2PM)?O.6/K8TIQQ59VI-6C;5(?!_A&-N M6&HZMYTB#Z6R2 GV)Q7LV@_\&M_B:YA!U3XN:-9R8Y%KHCP_G%57C"7S9^7?A_QMK7A6[CN-+U?4M/GA8.DMM7PWX%T^XC2\<37]_>RF>\U&0#:&D; & .BJ%49) MQDDGY?B+/LMQ&&]E05Y=^6WXGU?#7#^9X?%*KB':/76_X'L:MN_K[4Y#34&$ MZ-4@&*_/S]*"BBB@ HHHH **** "BBB@ HHHH **** "OSB_X.'/VU?B!^R[ M\./ WA_P'JEYX9"^" VTD88,ISR#Q7H977 MHT<5"I75XIZH\W-\/7KX2=+#NTFM&?S#^*/B1X@\;W\ESK.O:SJUQ+R\MY>2 M3N^>>2Q+'J?3Z5C^>^/O-7[">+O^#6[1[JYD?0_C!J=E"S$I%>^'TN64=@66 M>,'C'11]!7/77_!K-J:QGR?C-92-V#^&60?F+DU^H4^)LH:T:2Z)H_)I<*YR MGJFWUU_(_)Y;J5#Q)(OH=YJ1-:O(FVK=72M_LRM_C7Z:^(_^#7WXD6D+'2?B M1X-OI.RW5K<6RGZE5D/Y"O'/BI_P;[_M(?#B!Y++0_#_ (NBC&3_ &-JR94< M]$N/*8GV4$UTT\[RJH[*:_KU.*KD.;T]90E^)\:P>+]5@.Z/4]00^JW#?T:K MD/Q/\2VW^K\0:U&>VR]E&/\ QZKWQ5^!OC/X&:W_ &;XR\*Z_P"%[XD[8M3L M);4R8ZE=X&X>XR/>N5)VCGCJ?RZUZ].G1FKQ2:[Z'D5*E>G+EDW%]G-K4_N_%_BB/_J[;_M*_$:U/[KQ]XRCQ_.FWQ#=_\ QRKUO^W)\:K3_5_%SXG1 MD=-OB>]'_M2O+:*7U2ANX+[D4L97V4Y?>SV&W_X*$_'JT^[\:/BG_P "\57K M?^U*N1?\%)_C_%]WXR_$K_@6OW+?S?M"W'WOC'\0E_P!W5Y5_DU>$T4?V M=A?^?Q/6I+[V>FW'[:GQCO/]=\ M5_B1+GKN\2WAS^#]YXT\62>N[5[@Y_-ZH7'Q6\478_?>(]>ESUWW\K?S M8U@9Q_.@#)QWSC%5]7I+517W(/K5;^=_>S0F\6:KA_!C]C?XJ?M$"-_!?P_P#%?B*UD)5;NUTYS:@].9F41+]2 MPKZ6^'7_ ;V?M)>.%C:^T;PYX55^K:IK4;X'N+?S3^@K@KX[+Z+_>SBON._ M#X',:^M&$G]Y\0I<,<_.WO@YJUI?B"^T>=9+.]O+5UY#0S%&_,'^5?IYX<_X M->?'=U;Q_P!K?$[PK92?Q+:Z?<72K]"YCS^0KM/#?_!K1;QRJVL?&6:50>8[ M3PRJ'_OIKEOT7\^E>=4XDRA/6:^Z_P"AZE/AG.)-6B_F['DO_!"+]OWXJW/[ M87A_X9:OXDUKQ5X1\3072/;:E=27;:8T-K+,DD3N2R+F+:5X4AR<%@N/W'@& MV/IBOF+]A'_@E-\,?^"?TMQJ7AFVU+6/$][ +6XUO591)A1XNNRXN': M9S[9B,'Y5]%PKA_;9E#^[=_?GAV_P _C11THK]E/P_3 M<*,^WXT44P#=@_3\?Z4[S74?>8?\#--HJ91B]RHRDNIIZ3XTUC0&S8ZIJ5GZ M&"Y:/'Y$5U&E_M1_$O0D"V/Q"\;V87IY.N7,?\GKA**S^K4GK9?SU2U_;I^-EC@0_&#XH1;>FSQ3>K^@E-:EK_P %&?C]9_<^,_Q./^_XDNW_ M )O7B]%9O!8>6\(_SWS_AZ5^T1_T6 M'QS_ .#-_P#Z]'_#TK]HC_HL7CG_ ,&3_P"%>!T4?V;A/^?:^Y#_ +0Q7_/R M7WL]\_X>E?M$?]%B\<_^#)_\*/\ AZ5^T1_T6+QS_P"#)_\ "O Z*/[-PG_/ MM?<@_M#%?\_)?>SWS_AZ5^T1_P!%B\<_^#)_\*/^'I7[1'_18O'/_@R?_"O MZ*/[-PG_ #[7W(/[0Q7_ #\E][/?/^'I7[1'_18O'/\ X,G_ ,*/^'I7[1'_ M $6+QS_X,G_PKP.BC^S<)_S[7W(/[0Q7_/R7WL]\_P"'I7[1'_18O'/_ (,G M_P */^'I7[1'_18O'/\ X,G_ ,*\#HH_LW"?\^U]R#^T,5_S\E][/?/^'I7[ M1'_18O'/_@R?_"C_ (>E?M$?]%B\<_\ @R?_ KP.BC^S<)_S[7W(/[0Q7_/ MR7WL]\_X>E?M$?\ 18O'/_@R?_"C_AZ5^T1_T6+QS_X,G_PKP.BC^S<)_P ^ MU]R#^T,5_P _)?>SWS_AZ5^T1_T6+QS_ .#)_P#"C_AZ5^T1_P!%B\<_^#)_ M\*\#HH_LW"?\^U]R#^T,5_S\E][/?/\ AZ5^T1_T6+QS_P"#)_\ "C_AZ5^T M1_T6+QS_ .#)_P#"O Z*/[-PG_/M?<@_M#%?\_)?>SWS_AZ5^T1_T6+QS_X, MG_PH_P"'I7[1'_18O'/_ (,G_P *\#HH_LW"?\^U]R#^T,5_S\E][/?/^'I7 M[1'_ $6+QS_X,G_PH_X>E?M$?]%B\<_^#)_\*\#HH_LW"?\ /M?<@_M#%?\ M/R7WL]\_X>E?M$?]%B\<_P#@R?\ PH_X>E?M$?\ 18O'/_@R?_"O Z*/[-PG M_/M?<@_M#%?\_)?>SWS_ (>E?M$?]%B\<_\ @R?_ H_X>E?M$?]%B\<_P#@ MR?\ PKP.BC^S<)_S[7W(/[0Q7_/R7WL]\_X>E?M$?]%B\<_^#)_\*/\ AZ5^ MT1_T6+QS_P"#)_\ "O Z*/[-PG_/M?<@_M#%?\_)?>SWS_AZ5^T1_P!%B\<_ M^#)_\*/^'I7[1'_18O'/_@R?_"O Z*/[-PG_ #[7W(/[0Q7_ #\E][/?/^'I M7[1'_18O'/\ X,G_ ,*1O^"H_P"T0ZX_X7#XZ^HU)_\ $&O!**/[.PG_ #[7 MW(/[2Q2_Y>2^]GN%S_P4P_:"NC\WQD^(O_ -;G7^3"LS5/V__CIK*%+CXQ_$ MZ2,]5_X2:\"G\/,Q7D5%..7X9.ZIK[D+^T,2U_$E][.TU?\ :0^(?B(-_:'C MOQC>ANOVC6;B;=^!:N2OM5N=3N#+<7$\TC;_$.2V3AN<\_SZT#@8]***M66B,&V]PKZ;_X(W:U)H/\ P4O^$\T3M&TN MIR6S;3]Y9;>6,C\FKYDKZ2_X)!0?:/\ @I/\)%ZXU@O^4,A_I7#FBO@ZO^%G MH92VL;2M_,OS/Z6.@'UIPIIX-.'2OP8_H@**** "BBB@ ZU^6?\ P<._MT_% M#]G7Q'X-\%^!]>OO">E^(-/EOKW4=/;2]5T^18[O3W8 ,%+*RLC;5W(P(. MU3PRJP]+*<10H8J-3$QYH]CR-;J2XUC7]:U M6XE.Z26\O99GD)Y))+9)R2>?6L7SI.3YDGJ>:_7G7O\ @UGM9+AO[+^,MQ;P MY^6.Y\,K*P'NZW"Y_*N>UG_@UL\101;M.^+NCW,@Z"YT&2$?FLSG]*_3H\29 M0]I)?]NV/R>?"^<+[+?_ &]<_*N.]F3!2:9<]-K$5/'XDU"#'EW]XGIME(_D M:^^_B+_P;9_'CPLDDNC:GX&\31]1'!J$MO,W_ 98U7GW?%?+/QV_X)^_&C]F MJ&:?QG\.?$VCV4)P]Z+;[58Q_6>'=%VZ[J]'#YGE]?2G*+?RN>?B,KS+#O\ M>1DE\_T/-[;XC>(++B'7-8A(_N7DJX_\>%7H/C=XTM#^Z\7>)H\?W=3F_P#B MJY?;@8"D;>WI1G(KT?846K\J^Y'F_6*R=N9_>SMK?]I?XC6;?N?'WC2/_$?N17UW$+_ )>2^]GMT/\ P4H_: @^[\9/B/\ 0Z]<'_V:K<7_ 5 M_:&A7CXQ>/OQU:0_^S5X-14?V?AGO"/W+_(?]H8E?\O)?>SW6;_@IU^T) M^,7Q"'^[K$J_R:J=Q_P4<^/UQ][XS?$P?[OB.Z7^3BO%J*%E^%_Y]Q^Y#_M# M$_\ /R7WL];N/V^?CI= ^9\9OBHX/4'Q7?8_+S*H7'[9_P 8+P'SOBK\2)?7 M=XDO#G\Y*\SHK2.#H+10C]R,_KF)O?GE][_S.[N?VH_B9>_ZWXA^.)?7?KMR M?YR&J%Q\>O'-W_K?&7BJ3_>U:<_^S&N3H S5?5:*^PON0OK5:_Q2^]F]<_%# MQ)>?ZWQ#KDGKNOY6_K5"7Q5J=P,R:A?R>[3L?ZU0[X[^E>L?!K]A3XQ?M +! M+X/^&_B[6K2X_P!7>1Z=)%9O_P!O#A8OS;%8U'AJ2O4Y8^MC6G]:K:4N:7I< M\MEU&XF/SW$[?[SD_P S4?G/C.^3'NQK[K^&G_!NO^T7XY,;:I:^$_",;O1X>S>JE)0E\W;\S\Q/"?Q,\1> =0CO=#U_6M%NH3E+BQO9+>1 M/<,K _CGBOVA_P"#>/\ ;4^)/[3?A;QYX>\>:U>>*+?PA]ADL-2O&\VZ03^> M&BDEP&E'[D,&?+";6[\NZF^U7]]>2>;=ZC,%"[Y&P!PH "J HYP M,DD_+<1YYEN(PWLJ&LN_+;\3ZOAG(G*-M?GT;VU/TH6BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ***1FQ0 UF^:OP[_ .#FKXF/XA_:\\'^&8Y-]OX;\-"Y89^Y M/_ M9?\ @A8_LV_L^^$? NF[6MO#&F0V)D"[?M$BJ/,E(]7D+.?=C7X7_P#!O_\ MLY+\V4FMR[ERC7'$5NI[;@[^8/\ K@?>OZ"H_N_C7YCQ MOCN>M'#1^SJ_5_\ /U;@'+_ &=">*EO+1>B'4UUS3J:YXKX4_0M]".=EC!/ MI\U?S??\%A_VM6_:Y_;B\3:A:W'G>'/"[C0-&7.4:*!B'D';$LQDD!_N%!VK M]N_^"JO[4/\ PR1^P]XT\46]Q]GUJZMCI.C%6P_VRY!C1E_VHU+2X](C7\T# MN7=B>6SSSGGO^M?H' ^7W<\7+T7ZGYKQ]F32C@X^K_03/']?7THHHK](\C\Q M"BBB@ HHHH **** #_#-=Q^SE^SSXH_:F^,FB^"/!]BU]KFM2[(^2L=N@Y>6 M1@/EC5O(SS,OJ6$=;KLO5GLY#E?U_%QH/;=^B/?OV$O M^",GPG_8Z\.V-Y?Z38^./'" -/K>K6PF2&0?\^T+%EA4=B,OZMC 'V)!$L:8 M4;0.GTIJ)_>Y/O4D??K7XMB<96Q$_:5Y7?X?(_=,'@J&&A[.A%17X_,G6G4UNM# P?'OPYT#XG^'[C2/$FB:7KVEW0_>VE_:)AZ_H\QANK.X3;(AZ@\$@JRX8,I(((()'-<[7[T?\%[_P!@.Q_: M*_9NO/B-HMBJ^-?A[:M=R21J/,O].7)FC?\ O&-=TBD\@!P,EJ_!?/\ L[<< M8]/\^_-?L.19M',,/[1;K==O^ S\5X@R>678GV?V7L^X4445[)X84444 %%% M% !1110 4449H#3J6] \/WWBO7;/3--M9[[4-0G2WMK>&+S)+B5V"HBJ.69F M( 'O[C_ /!-?_@@YX-^!/A'3O%'Q8TNP\8>.[I!/_9MTJW&F:)GD1>7 MC9/(/XF;*@C"# #-\?\ _!N9^R;:_&?]J;5OB!J]JUQIGPUMDDLU="8XXY6]F\L]0*_=:,;5XW#V]*_..+\\JQJ_4J$K"\@I3I/&X MF/-S;7[%?3]-ATFSBM[6&&WM[=!'''&NU44< #H!V XJU%]VC;2J,5^?7OK M<_2HQ25D+1110,**** "BBB@ HHHH *",BBFOTH ;(WEK[*,U_,7_P %,?BM M_P +J_;W^*GB!9/.@D\07%G;/G(:&V/V:,CV*1*?QK^DCX^?$:/X/_ _QAXL MGV^7X:T6\U1@YP&\F%Y,?CMQ^-?RDZC?2ZIJ$]U-(TTUQ(TKR-]Z1B_X(S0?:/\ @II\)U]-1G?_ +YM9C_2OF&OJS_@B':_:_\ M@J)\*U_NW%])_P!\Z?=-_2O.S?\ W*K_ (6>ED^N-I?XE^9_1]W_ !%*M)3A MTK\(/Z&"BBB@ HHHH **** "BBB@ J"[MUN%V,NY6&"",CFIZ:QYHU6PI)-6 M9\/_ +>O_!#KX6?M9:1?:MX8L++X>^.MK2Q7^G6XCLKV3D[;FW7"D,2"_&6FR:7KFDR;9$)W1RH>5EC;)#1L.01]."" M*_JR=&+K[O_ <*_L66WQK_ &7/^%E:79K_ ,)1\.<2RR(/GN-, M9@)E;U\IBLH)^ZHEQRU?9<,\15:-58?$/FB]->A\+Q5PS0K47B<.N6:[=>]S M\(Z*._I[>GX]_K17ZM8_(E\*"BBB@ HHHH **** "BBB@ Q74?!3X,^(OVA/ MBEHO@[PGITFJ:]KURMM:VZ 8)M+T_Q]X\"B6XU#4H/.L[ M.7KBV@?**%.?WC N3D_)G:/M>TMUMX0B(%51M"J, < 4X# Z-UZ8Z4]:_%< M5CJ^*FZM>3;?W?(_=L'@,/A::I4(I)??\Q11117,=@4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T_>IU-/WZ M &R\#\*_EI_;?\6?\)U^V5\5=8W^8NH>+=3FC.5 M9^2/S?Q"J?NZ,/-E&BBBOTH_+PHHHH *"=O/MG\1T_G13K>W>[NHHHU9Y)'" M(JC+,QX 'XXI2:2NPLWHC]R?^#;/]GP?#_\ 9&U[QW<0[;[Q_JS) ^.MG:%H M5P?^NQN3[X'I7Z/Q#"UYE^QG\%5_9W_94\ >"UC6.;P_H=M;76/X[C8&G;_@ M4I=OQKT]>E?A&:XJ6)QE2L^K/Z&R?!K#8.G171(*9)][\.GK3Z:XR?YUYYZ1 M^,__ TX/2ORM MP!]*]_\ ^"I_CK5/B%_P4.^+UYJ[;KBT\276FQ 9VK;VS_9X0!V_=QH2/4FO M *_I_/\ Q!C'BLPJ5.SM]V@4445ZQXX4444 %%%% !11 M11TU!;@%W,._;\_\FOZBO^"??PM'P8_8F^%_ASR1#-8^'+-KI=N/](DB668X M]Y7<_C7\P7AO2)/$'B/3[&+_ %M[<1P)Q_$[!1_.OZU="LH],T:UMXEVQ6\2 MQHH_A"@ #]*_/N/*S4:5+S;/TCP]HISJU?)(M4445^<'Z@%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-8X-.II&3 M0!4UW2;?7='NK&ZACN+6\A>&:*0925&!#*1W!!(_&OY5?VD/A:WP/_:!\;># M6+,/"^N7FEHQ_C2&=T5OQ4 _C7]6C]1_G%?S=?\ !:7PPOA+_@IO\5+:.,1I M/>VU[P,9,]G!,Q_%G-?<<"UFL1.EW7Y'Y_X@8=/#4ZO5,^6Z***_4#\G"BBB M@ HHHH **** "CKW_"BC^@S1U#;4_>__ (-R_A6O@?\ X)]C7&A"S>,]?O-0 M\S;AGBCVVRC/H&AD(]W-??<8PM?-?_!(3PQ_PB'_ 38^$=KMV^=HHO,8Z^? M+)-_[4-?2J=*_!\WK.ICJLW_ #,_H3):*HX&E272*%HHHKSSU HHHH **** M"BBB@ HHHH *1J6F2G H ^1_^"Y/Q3_X5=_P37\?&*3R[SQ MMHMO@_>\^9! M(/QA$M?SG?3IDX_.OV@_X.@OBC_9?P2^&G@V.3YM:UFXU>10V/EM8!&-WMF[ M)'NE?B_G/_ZJ_6N"Z')E_/\ S-_Y'XSQQB/:9C[/^5)??J%%'7^5 .?\_A7U MWJ?&[[!1G@_[/7VKZ(_9!_X):?&7]M9H;KPGX8>S\.R/M;7=7S::>,'#;7(+ MRX/&(E?!R#BOT6^ W_!L5X/T2WM[CXD>/M MO("'GM7BXWB+ X3W:E1-]DKL]S+^&L?BUS4J=EW;LC\83Q2A2QP 21UXK^D? MX9?\$9?V;?A=M^R_"[1M4D4#=)K$LVH^:?5DG9D_("O:O"'[,OPY\ 0)'H?@ M+P;HL%+X_KY5?U'^4 > M%6E$=9RX[K]*:^]FT?#VAUJO[D?R_P!K_P $W_C]=8V?!GXE+_O^';I/YH*T MK?\ X);_ +0]X1M^#WCH?[^F.G_H6*_INQCUHQ[FLY<=8I_\NX_B:+P_PO\ MS\?W(_FBMO\ @D?^TA=8V?"/Q5_P.-$_FPK1MO\ @C3^TU>M\OPGUH?[]W:K M_P"A2BOZ3<4AXJ/]>,7T@OQ*7A_A%O4E^!_.';_\$0/VH[O&WX67([?/K&G+ M_P"A7%:5I_P0?_:DN/O_ WBA_W_ !#IG])S7]%1HV\5$N.,<_LQ^[_@FL> M\#UE(_GEMO\ @@#^TY?]I.8_-HOAF'_ ']< MBX_+-?T$X(I:Q_UTS#M'[O\ @FBX#R]=9?>?@-:?\&YG[15Q]Z/P5#_OZR?Z M1FM&V_X-K_V@)\"34OAQ%W_>:K<-_*W;]*_>?RC_'WX+:M^SI\9/$7@?7IK*XUCPO>/874EI(TD#NO4H656Q]0 M*X^OH+_@JS_RD7^,'_8QW']*^?:_4L'6E5H0J3W:3T\S\CQE*-*O.G#9-K[F M%%%%=1RA1110 4444 %%%%&Z#7H>E_LC_LK>)/VT/CEIOP_\*W.DVFM:G%// M!+J4TD5NOE1M(V61'8?*IZ+Z5]=W'_!M;^T!']S5/AS(HZ!-6NS/P-F_X-P_VB(!\O\ P@LGLFKN,_G$*HW'_!NS^T? /ET_PE+_ +FM M*,_FHK^@#'^<4HR!7SW^NF8+M]W_ 3Z/_47+?[WWG\^$W_!O=^TM /E\.^' MY/9--\??51^[_@DO@+ =)2^\_F]F_X(H?M/6X^; MX4ZD?]W4K%OY3&J,_P#P1P_:7M1\WPEUYN_R36S?RDK^E T;# MHF;6/A?\0M+51DM=^'KR$ ?5HQ7!:GH=]HEP8;RSNK24<%)HF1A^!%?UO&$% MONCZU1USPMIWB*T:WU"PL]0@<8,=Q"LB,/<,#75#CRIM.DODSEJ>'M/>%5_< M?R2_Q;>_I1G]*_IT^)'_ 3+^ ?Q8W?VS\)O!;22??EM-.2RE8^I>#8Q/OFO ME_XX_P#!MC\&?'ZSS^#M8\5> [Q\F.%9QJ5C$?\ KG+^]/\ W^[5ZF&XVP"->NM)UK3K[2=4L9#%<6E["\,\#_ -UT M7G?^X5O\+/5R/7'TO\2/Z'!POZ4ZCM17X4NY_084444P"BBB@ MHHHH **** "BBB@ K!^)O@FQ^)?@#6_#NIQ"?3=>T^>PNHR,B2*5"CC\F-;U M1RC&3C/%5&3BTT34@IQ<'UT^\_DM\>^$;GP!XXUG0KP8O-%OI["<8Q^\BD:- MOU4_2LFO=_\ @I[X37P5_P %"/C!8H@C1O%%Y=JH'"B>0S#'_?RO"*_?L'5= M6A&H^J7Y'\XXJFJ=:=-=&U]S"BBBN@YPHHHH **** "BBBC2VHUN ..^W'(/ M^?K_ #K^F+_@DW\+%^#_ /P3O^%.E>3Y,MSH<6J3*1AO,N\W3;O<>;CGL!7\ MS\63(N.N:_K$^#'AH>#/A#X7T<+M&DZ3:V8&.GEPHG]*^"X[K-4:4.[;/T+P M]I*5:K4[*WXG34445^:'ZJ%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !2-V^M+2-_6DP.4^.VKGP]\%? M&&H [38Z+>7 /IL@=OZ5_*#(3X5U-\_2TE-?R ML-]XU^C\!1_=U7YH_+?$*7[VDO)_F)1117Z$?G(4444 %>Y?\$T/A#_PO7]O M3X6^&VA^T6\^O07MS&1E7M[;-S,"/0QQ,/QKPVOT2_X-K/A2OB_]MC7/$T\8 MDA\(^'9GA;'W+B>1(D_.(SBO+SK$.A@:M5=G^.AZF2X;ZQCZ5)]9(_=A!\BT MJC%(#\O'K2JNZ MYC']:_JRA&V,5_+C^P#I7]M_MS_!VUV[EE\::0&'JHO82?T!K^I =*_,^.Y7 MK4E_=?YGZIX>QM0JOS7Y!1117P9^B!1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !0310>E)[ ,8\U_/)_P7YL/L?\ MP4Y\:28Q]JLM-EZ=<64*?^RU_0X1S^-?@!_P<36/V3_@H[?2=/M6@Z?+]<*Z M?^R5]?P5_P C%_X7^A\5QTKY1\*44&BOUH_' HHHH **** "BBB@ H(W M#\A^>:*='Q(OUSCUI2=DV-*[L?U&?L#Z-_PC_P"PY\'[/;M:W\&:2KC'\7V. M(M^N:]<0<5Q7[-FG#2OV>/ MJJX6V\/V$0'LMO&/Z5VXK^?L3*]:3\W^9_1^ M#C:A!>2_)!1116)T!1110 4444 %%%% !1110 4V3K]13J9+S\OYT">Q^%O_ M *^EO^"PGQ M*_X6G_P4D^*VH+)YD-CJPTB,9R$^R1);,![;HF/XU\TU^YY'1=' 4J=NE_O/ MY_S[$*MF%6H^]ON#&Y@,_>R!D9QZ_P#U_P *_63_ (([?\$0K7Q?H6D_%;XS M:6UQ9W2QW>@^&KI] #1VPR,%5!#R#G*E%(Q)D?O]:VZP6X51A5 MX48QM'85\IQ5Q!*F_J>&EK]I_H?7<'\-QJKZYBH^[]E=_,CT?2[?1M-@M;2" M.UM;9!%##$@2.) ,!54< < #BK6:0#%"C%?F^K=S]2BDE9"T444#"BBB@ H MHHH **** "BBB@ HHHH **** "FOUIU-?K0!_,O_ ,%6?^4B_P 8/^QCN/Z5 M\^U]!?\ !5G_ )2+_&#_ +&.X_I7S[7[UEO^Z4_\*_(_G7,O][J_XG^84445 MW'"%%%% !1110 4444 ?:'_! /\ Y2=>"_\ KQU/_P!(Y:_H;3[M?SR?\$ _ M^4G7@O\ Z\=3_P#2.6OZ&T^[7Y+QI_OZ_P */V+@/_D7/_$_T%HHHKY$^V"B MBB@ HHHH **** "BBB@ HHHH **** &NNX5XW^U?^P7\+OVT/#;6/CSPO9ZE M=1QF.VU.$>3J-EG.#'.N& !).QLH>ZFO9J:RUI1K5*4N>G*S75&-;#TZT>2J MDUYG\[__ 4F_P""-GCC]@V6?Q%IGZ5_6UXF\-6/C'0KS2=4LK74--U&![:ZMKF(213Q. MI5D93PRD$@@]037\[W_!8+_@G-+^P/\ M +_ &1'))X \8&6\T)V+,;(@YEL MV)ZM&74JVNU^T?\%*M ;_GCI&HO_Y *_\ LU?$!.2>^><^N>:^\/\ @W2M M/M'_ 47MW_Y]_#U^_T_U:_UKWL^_P"1?6_PL^>X?_Y&-'_$C]^C]RE7^E)U M2E']*_##]_ZBT444QA1110 4444 %%%% !1110 4UCAJ=36^]0!_-O\ \%H; M/[#_ ,%-_BLF,;KZVD_[ZLX&_K7R[7UM_P %S[?[-_P5,^**]F?37_/3+0_S M-?)-?NV42YL%2?\ =7Y'\\YQ'EQU5>;_ #"BBBO2/-"BBB@ HHHH **** -3 MP-HW_"1>-M'T_O?7T%N!Z[G"_P!17]:=D-MI'QCY17\J?[+NGC5OVEOA[:L- MRW'B33XB#W#7,8K^JVW&(U^@_E7YMQY+WZ*\I?FC]0\/5^[K/T_(DHHHKX _ M2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH ***#0!YO^V-;&\_9'^*$(Y,GA+5$&.^;.45_*XWWC]?SK M^K7]I.U^W_L\^/+?&?.\/7Z?G;2"OY2Y1B1O8XK](X#?[NJO-?D?EOB%'][2 M?D_S&T445^@'YR%%%%&K6@ #@&OV8_X->_AI]@^$?Q0\7-'_ ,A75[328W*] M/LT+2L ?^WI<_05^,^,G]:_H)_X-Z?!0\+?\$U]"OA'L/B+5M0U \8+XF^SY M/X6X_*OD^,JSAEW(NK1]AP30]IF7,]DF?<*#Y?H:<* 3_P4*MF_P">GA:Q?_R)<#^E?O?_ !?A7X.?\'*D/E_M_P"D M-C_6>#[)O_)F[']*^LX+_P"1C\F?&\<_\BQ_XD?GN**!17ZX?C(4444 %%%% M !1110 4Z'_7)_O"FTZ$XE7ZYJ*GP/T-*/QKU7YG]8WP?M?L/PE\,P]/)TJV M3'TB45TE97@B#[+X,TN/_GG:1+^2 5JU_/U;^(_5G]'X?^%'T7Y!11169J%% M%% !1110 4444 %%%% !5?5+B.RLIKB1ECCA0N[$X"@T^! MGC*2U!:YCT.\>(#^^('Q^N*NG'FFH]VC*O+EIREV3/Y9/BYXTD^)'Q5\3>(I MF9IM>U6ZU"0MU+2RLY_]"JK\/_!&I?$SQSH_AW1K>2[U;7+V&PLX4/S2S2NJ M1@>AW'K62X8R8ZMG''K7Z"?\&Z'[,J?&#]L>\\;W]OYVE?#>P^TQ,PRGVZXW M10\>R"9P>S(IK]SQV+6#PU'VVX1-OVV[?YIYCW^:0L0#R%VKVKUA!@4B#Y>!CF MGBOPRK5G5FZD]WJ_4_?L/1A2IJG3V2L@HHHJ#8**** "BBB@ HHHH **** " MBBB@ HHHH **** "FOUIU-?K0!_,O_P59_Y2+_&#_L8[C^E?/M?07_!5G_E( MO\8/^QCN/Z5\^U^]9;_NE/\ PK\C^=?A2^;_R+;C^M? MY"UM=R1NI5XW*,",$$'%?H-_P;40>;^W[K+?\\_!M MZW_DS:#^M?LF?2OEM62_E/P_A^+6:T4_YC]X/X6^M.'2F[LJ?K3ATK\/1^^! M1115 %%%% !1110 4444 %%%% !36^]^%.H-#V _G5_X+S0^5_P5'^(C?\]( M=+;_ ,IML/Z5\>U]F?\ !?6/9_P4\\<'^]9Z8?\ R1A']*^,Z_<\C_W"C_A1 M_/F>?[_5_P 3"BBBO5/*"BBB@ HHHH **** /3OV*;7[;^V-\)X?^>WC#24Q MZYO(A7]3J?=K^6_]@.'[1^W7\&(_[WCG11^=]"*_J04U^9\=R_?TEY/\S]4\ M/(VP]5_WE^0M%%%?!GZ(%%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 9?B_1X_$/A74M/E_U= M]:R6[@],,I4_SK^2V_MGLKZ:&0;9(9&1ACH02#7]<5PNZ)O<8K^4O]I'PV?! MO[0_CS1RGEG2_$-_9E2,;3'_8IT#_A%?V//A7IFW:=/\):7;L,8Y6TB4_J*^%X\J6H4H>?Z'Z%X>T[XF MK4_NK\STZBBBOS$_5@II^]3J:?OT ?S>_P#!;)=O_!3_ .*O_7U9G_R0MJ^5 MZ^K?^"W:[/\ @J%\5/\ KXL?_3?;5\I5^\93_N=/T7Y'\\YQ_OM7U?YA1117 MH'FA1110 4444 %%%%'1AU/I/_@C_;_:O^"E/PD7TU@O^*PR'^E?TL@Y%?S6 M_P#!&\9_X*8?"7_L*2'_ ,EY:_I2'2ORSCC_ 'R'^$_6_#__ '*?^+] HHHK MXH^]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@!#P:_"C_@YFA\G]O3PRW_/3P/:-_P"3M^/Z5^Z[?TK\,/\ M@YRB_P",Y/"#?WO!%LO_ )/7W^-?5<&_\C)>C_(^0XX_Y%;_ ,43\X^]% .1 M17Z\?BP4444 %%%% !1110 4Z'_6K]<4VI+9=]S$O]Y@/Y5G6^!^C-:'\2/J MC^MSP^GE:':+_=A0?H*N5#IZ[+*(>BBIJ_GV;O)L_H^C_#CZ(****DT"BBB@ M HHHH **** "BBB@ JGK.FPZSI\]I^/'P]^-FJZ-X2\'S>+O#$UXW]DZI;WELD(KDZGKLT#; MHXY-H6.W0]UC08ST+LY'!%?4VSF@+D5[V8<18O%X>.'J6LM^[]3Y_+>&<)@\ M3+$T[MOOT] #=*=0!BBO!/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "FOUIU-?K0!_,O_P %6?\ E(O\8/\ L8[C^E?/M?07_!5G_E(O\8/^ MQCN/Z5\^U^]9;_NE/_"OR/YUS+_>ZO\ B?YA1117<<(4444 %%%% !1110!] MH?\ ! /_ )2=>"_^O'4__2.6OZ&T^[7\\G_! /\ Y2=>"_\ KQU/_P!(Y:_H M;3[M?DO&G^_K_"C]BX#_ .1<_P#$_P!!:***^1/M@HHHH **** "BBB@ HHH MH **** "BBB@ HHHH *CG/R,/45)39!GW]L4 U=6/Y6_VO\ P%)\+/VJ_B1X M=DB\D:/XDO[6-2,?NUN'"$>Q4 CU!S7WA_P;#?#JXU+]I[X@>*O+D^RZ-X:7 M3&?'RA[JYCD7GUVVK?G7UY_P44_X(4^&?VX/B])X\T7Q5<^!?$FHQI'JA_LT M7UMJ!10BRE/,C*2;5"E@Q#!5X!R3[K_P3F_X)[>'?^"=OP:G\,Z-J%QKFI:K M=?;=5U6:W$#7DH4*H6,%MD:J.%+-RS'/.!^@9EQ-AZV5^PBWSR2B_EN?FN5\ M+XJAFWMYI>SBVUZL^@57C\M?NF1_P#(OH_X4?S_ )]_O]7_ !,****]0\<**** "BBB M@ HHHH ]E_X)V1>;^WM\&/;QMH[?E>1'^E?U"H,"OY@?^";<7G_M_?!M?^IP MTP_^3,=?T_K_ %K\OXZ_WFG_ (?U/U;P]_W6KZK\A:***^'/T(**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "FN:=37ZT !&!7\T/_!6_P-_PKS_@I!\7-/">6+C7&U$+C'_'U&ES^OFY M_&OZ73G%?@9_P<:_#MO!_P#P4,;5O+VQ>*_#]E?[\?>:/S+8_B! N?0$5]AP M16Y<$8,;?)T:S3'T@05_)_!Q,I[ Y^M?UH?#:-8?AYH*K]U=/@ ^@C6OS MWCS:DO7]#](\/(^]5?DC:HHHK\Y/U *0]:6D/6@#^P_]-UK7RA7U?_P7!_Y2C?%/_KO8?^FZUKY0K]XRG_/VTO!;_P![P; OY7MW_C7[D'I7X??\ M'/,>/VO_ *_][PBJ_E>7/\ C7U'!_\ R,H^C/D>-O\ D5OU1^:@^Z/I10:* M_8#\5"BBB@ HHHH **** "K&DKOU:U'_ $U7^8JO5K05WZY9C_ING\ZSK? _ M1FM#^)'U1_6Y:?\ 'FG^[4U16G_'G'_NU+7\]O<_H^C\"]$%%%%!H%%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %-?K3J:_6@#^9?_ (*L_P#*1?XP?]C'LM_W2G_A7Y'\ZYE_O=7_$_P PHHHKN.$**** "BBB M@ HHHH ^T/\ @@'_ ,I.O!?_ %XZG_Z1RU_0VGW:_GD_X(!_\I.O!?\ UXZG M_P"DJ>2%%%% !1110 4 M444UN![E_P $S5W?\%!?@W_V-NGG_P CK7]/0Z5_,1_P3'7=_P %!_@Y_P!C M78?^CEK^G<=*_+N.O]ZI_P"%_F?K'A]_NU7_ !+\@HHHKX<_0 HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** FOR0_X.COAAOTGX5>-(8N8);[1KF3'W@ZQS1+GVV3D#W-?K?7Q7 M_P %^/@X?BQ_P3D\2WD49DNO!MY:Z_$ .R.89#G_ &89Y6_"O8X?Q'L'Q)AO;Y=5AY7^X_GG_S]:*#17[AY'X'YA1110]@6Z'1#]XOUQ7]8WP: MO/[1^$7A>X!W";2;60$=\Q*:_DX0X8>QS^5?U2?L>:P/$/[)?PPU -O%]X4T MN<-G.=]I$W]:_/\ CR/NTGYO]#]&\.Y?O*R\D>CT445^;GZD%(>M+2'K0!_. M'_P7!_Y2C?%/_KO8?^FZUKY0KZO_ ."X/_*4;XI_]=[#_P!-UK7RA7[QE/\ MN5+T7Y'\\YQ_OU7U?YA1117H'FA1110 4444 %%%% =3ZB_X(O#=_P %-_A/ M_P!A"X/_ ))SU_22O"U_-O\ \$6O^4G/PI_Z_P"X_P#2.>OZ2$/RU^5\\-./_)F6OIN$?^1E'T?Y'R?&G_(KEZH_,?O1 M1G-%?L1^)] HHHH **** "BBB@ J]X:7=XCT_P#Z^8__ $(51K0\)#=XITT? M]/<7_H:UG6^!^C-:'\2/JC^M>T_X\X_]VI:BM/\ CSC_ -VI:_GM[G]'T?@7 MH@HHHH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ IK]:=37ZT ?S+_\ !5G_ )2+_&#_ +&. MX_I7S[7T%_P59_Y2+_&#_L8[C^E?/M?O66_[I3_PK\C^=*O\ L&Z;_P"DJ5\4'K7[GD?^X4?\*/Y]S[_D85?\3"BB MBO5/)"BBB@ HHHH **** />/^"8(W?\ !0OX._\ 8U67_HT5_3FOW17\QW_! M+M=W_!0SX._]C39G_P B5_3BOW:_+>./]ZI_X?U/UCP__P!VJ>J_(6BBBOB3 M] "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH *Y/XZ?#BV^,GP;\5^$;S;]G\3:1X%=93)$YS^=5"3C)270BI!3@XOJC^2+Q#H=SX8UZ\TV\B:"[T^=[::- MNL;HQ5@??(/':J=?5W_!:SX ?\,__P#!1+QS;P0F'3?%$J^)+'C 9;G)EP/0 M7"SJ,=E%?*(.17[Y@<1[>A"M_,DS^=L?A7AL1.A+[+:"BBBNHXP_S^HK^FK_ M ()4^*?^$O\ ^"=GPANBV[R?#EM9YS_SP!@_3R\?A7\RH&2/Q_'I_C7]"W_! MOYXX_P"$M_X)G^$[1GWR>'[_ %#37.?^GEYU'_?,RC\*^)XXIWPD)]I?H?=\ M U.7&RAWC^I]K44 \4 YK\M/UT*0]:6D/6@#^P_] M-UK7RA7U?_P7!_Y2C?%/_KO8?^FZUKY0K]XRG_OVRK\3_\ @Z$7/[2?PX_[%N3_ -*F MKZ;A+_D91]'^1\KQG_R+)>J/S#/6BBBOV'J?B(4444P"BBB@ HHHH *T?!__ M "-VE_\ 7W%_Z&*SJT?!_P#R-VE_]?<7_H8K*M_#EZ&M#^)'U1_6O9_\>L?^ MZ*DJ.S_X]8_]T5)7\^=3^CZ/P+T04444&@4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U^M.I MK]: /YE_^"K/_*1?XP?]C'.I M_P#I'+7]#:?=K^>3_@@'_P I.O!?_7CJ?_I'+7]#:?=K\EXT_P!_7^%'[%P' M_P BY_XG^@M%%%?(GVP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4UNHIU-;J* /Y[/\ @X'_ M .4F7BK_ +!NF_\ I*E?%!ZU]K_\' __ "DR\5?]@W3?_25*^*#UK]SR/_<* M/^%'\^Y]_P C"K_B84445ZIY(4444 %%%% !1111U ]\_P""6W_*0_X/?]C/ M9_\ HP5_3>O?ZU_,A_P2V_Y2'_![_L9[/_T8*_IO7O\ 6ORWCC_>X?X?U/UG MP_\ ]UJ?XE^0M%%%?$GWX4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.#^5.IKG!H _*/_@YW M_9Z;5O OP_\ BA9V^YM)N9= U.11\WE3#S8"?]E7249/>4#O7XXYR3ZYY'I7 M]1'[?G[.W[U$S[9'>OY>[NUDL; MJ2&:.2*:%BCHXPR,#@@CL%9)/+A\4>'#<1C_ )Z3VLR%1C_KG-,?P-?. M\54?:9;4\K/[F?2<)8CV6:4WWT^\_<8')^M.48IBC"?2I AK0_B1]4?UKV?_ !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C M\"]$%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C M'3_ ((! M_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6W_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ M!+;_ )2'_![_ +&>S_\ 1@K^F]>_UK\MXX_WN'^']3]9\/\ _=:G^)?D+111 M7Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4V04ZD89- $3C.[_ &CBOYS?^"UG[+3_ ++G M[>7BA;6W\G0?&3?\)'IA PF)V8S(.PVSK* O9=A[BOZ-L<&OSW_X.)_V4A\: M?V0[;QUI]JTFM_#2Z-S(R#]X^GS[8[A?^ L(I,]%6-SQDU])PKF2PV/C?X9: M/]#Y3B[+7BLO;C\4-5^I^#IX8T4 Y';GGCH/I17[(?B5K.P5]#?\$HOC"OP. M_P""AGPLUR23R[:;6!I=P2<*L=VC6I+?[(\[=[; :^>:L:7J4VCZC;W=O(\- MQ:RK-%(IPT3J$_\ MD8Q]&?*\9_\ (LEZH_+P44#I17[&?B/0**** "BBB@ HHHH *T?!_P#R-VE_ M]?<7_H8K.K1\'_\ (W:7_P!?<7_H8K*M_#EZ&M#^)'U1_6O9_P#'K'_NBI*C ML_\ CUC_ -T5)7\^=3^CZ/P+T04444&@4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U^M.IK] M: /YE_\ @JS_ ,I%_C!_V,=Q_2OGVOH+_@JS_P I%_C!_P!C'3_@@'_RDZ\%_P#7CJ?_ *1RU_0VGW:_)>-/]_7^ M%'[%P'_R+G_B?Z"T445\B?;!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH _GL_X M.!_^4F7BK_L&Z;_Z2I7Q0>M?:_\ P<#_ /*3+Q5_V#=-_P#25*^*#UK]SR/_ M '"C_A1_/N??\C"K_B84445ZIY(4444 %%%% !1111U ]\_X);?\I#_@]_V, M]G_Z,%?TWKW^M?S(?\$MO^4A_P 'O^QGL_\ T8*_IO7O]:_+>./][A_A_4_6 M?#__ '6I_B7Y"T445\2??A1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61XY\)Z?X^\(ZI MH>K6L5YI>L6DME>02#*S0R(4=3[%216O4UL[L\6_;< M_>;_ (-S?CZOQ1_8;N/"-S,)-0^'^K2V@0MN86LY-Q"Q]M[3J/:.OT$B^[7X M(_\ !NS^T2/A+^V])X3O+CR=-^(FF26**S;5^V0_OH6/;)43(.^9 *_>Z/[M M?B_$^!>&S":Z2U^\_\?=?R'4AZTM(>M?/GTQ_.'_P7!_Y2C?%/ M_KO8?^FZUKY0KZO_ ."X/_*4;XI_]=[#_P!-UK7RA7[QE/\ N5+T7Y'\\YQ_ MOU7U?YA1117H'FA1110 4444 %%%% 'U'_P1;_Y2OZ1TX%? MS3_@@'_RDZ\%_P#7CJ?_ *1RU_0VGW:_)>-/]_7^%'[%P'_R+G_B?Z"T M445\B?;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH _GL_X.!_^4F7BK_L&Z;_Z M2I7Q0>M?:_\ P<#_ /*3+Q5_V#=-_P#25*^*#UK]SR/_ '"C_A1_/N??\C"K M_B84445ZIY(4444 %%%% !1111U ]\_X);?\I#_@]_V,]G_Z,%?TWKW^M?S( M?\$MO^4A_P 'O^QGL_\ T8*_IO7O]:_+>./][A_A_4_6?#__ '6I_B7Y"T44 M5\2??A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !0>1110!SOQ3^'FD_%SX>ZUX7UVS2^T M?7K*6PO+=QE9(I%*,/R.0>H(!'2OY@OVQ/V9M7_9 _:-\4> =861I="NRMM< ML,+>VK?-!,/]^,J2.S;AU!K^IN0?-QZ>G%?FS_P M(O ,/EZJL2G?=Z86)+G'),#,6]HWE/85]5PGFWU3%>RJ?#/3Y]#XWC+)_K>& M]M3^*'Y=3\/>A_2BC&SY>FW@CTH[U^O[R\C\9U:O8Z#X4_$;4OA!\3/#_BO1 MI/)U;PYJ$&I6DF?NRQ2*Z9]5R,$=QFOZI/@I\4]-^-OPC\->,-'D$FF>)M-M M]2M^ZF'CB8[Q?X,^^X M%S!4L5+#2VDOQ1^E5(>M /%!/-?ER/UH_G#_ ."X/_*4;XI_]=[#_P!-UK7R MA7U?_P %P?\ E*-\4_\ KO8?^FZUKY0K]YRG_C]ER[L(I9OB)<6OYU:*\G_ %&PG\\OP_R/8_U^ MQW\D?Q/Z*O\ A_!^RQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU: M*/\ 4;"?SR_#_(/]?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+' M_13)/_"=U3_Y'K^=6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ MPG=4_P#D>C_A_!^RQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z M*O\ A_!^RQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"? MSR_#_(/]?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"= MU3_Y'K^=6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D M>C_A_!^RQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^ MRQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"?SR_#_(/] M?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"=U3_Y'K^= M6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D>C_A_!^R MQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^RQ_T4R3_ M ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"?SR_#_(/]?L=_)'\3 M^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"=U3_Y'K^=6BC_ %&P MG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D>C_A_!^RQ_T4R3_P MG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^RQ_T4R3_ ,)W5/\ MY'I1_P %X?V6!_S4QO\ PG=4_P#D:OYU**/]1L)_/+\/\@_U^QW\D?Q/Z*G_ M ."\/[+.>/B8WK_R+NJ?_(U?E'_P6S_;R\(_MU?M&Z'>>!6O+KPWX7TL6,5[ M<6[6_P!LE:1Y'=$;#A,% -P!R#QTKXQHKT,LX7PV"K>WIMM^9YN:<68O'4?J M]1)+?1=@'US]:***^F/EEH%%%% PHHHH **** "M'P?_ ,C=I?\ U]Q?^ABL MZM'P?_R-VE_]?<7_ *&*RK?PY>AK0_B1]4?UKV?_ !ZQ_P"Z*DJ.S_X]8_\ M=%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?K3J:_6@#^9?_@JS M_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6W_*0_P"#W_8SV?\ Z,%? MTWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^F]>_UK\MXX_WN'^']3]9\/\ M_=:G^)?D+1117Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+7=*MM>TVXL; MRWANK6[B:&:&5-Z2HP*LI!X(()!!Z@D5=IK#.?I1JM4*235F?S3_ /!5#]AR MZ_82_:LU;P[;PS?\(GK1.I>')WRV^T=B/*+=WB;*'O@*Q^^*^;0<_P">M?TE M?\%7_P!@RS_;S_9COM&MX81XQT -J/AVXX[=!^Q\,9LL;AN63] M^.C_ ,S\0XJR=X'%>XO?EYR.WK^=>]BB"BBB@T"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "FOUIU-?K0!_,O\ \%6?^4B_Q@_[&.X_I7S[7T%_P59_Y2+_ !@_[&.X M_I7S[7[UEO\ NE/_ K\C^=_P"QGL__ $8*_IO7O]:_F0_X);?\I#_@]_V,]G_Z,%?TWKW^M?EO M''^]P_P_J?K/A_\ [K4_Q+\A:***^)/OPHHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *:V:=36&30!'.GF$?+NW#!R.W>OQG_ .#A?_@G%)X.\5M\=/"-B_\ 9.L2 M)!XI@@7;]DNFPB7F /NR<(Y_OX/_ "TK]G/SK%^('@+2?BAX,U3P]KEC#J>C MZU:O:7EK.NZ.>)QM8'\#U&".HYP:]'*3G65PQ^%=":UZ/S M/Y+\Y&?Y#C_(Z?AZ45]"_P#!2S]A#5OV!?VD=0\+SK<77AK4B;SP]J#@_P"E MVA. K'&/-C/R.!WPV '6OGK]:_<<+B(8FDJ]+:6Q^"8K#3PU5T:V\=SZN_X( MY_MJM^QC^V)I-SJ5T;?PCXOVZ+KFY\1PH[#RKDCI^YDP2>NQG ZU_1S&5,6X M$88D\=*_D8ZC&2,\5_01_P $*_VZO^&L_P!E&#P[K5YYGC/X=K%IE[YC?O+R MT(/V6XYY)**8V[[H\G[U? \;97>V.I+RE_F?HO >;-7P-7UC_D?E-_P7!_Y2 MC?%3_KO8?^FZUKY0KZN_X+?_ /*4/XI8Z":P ]M.M17RC7V>4O_ &.DO[J/ MAB>:%%%% !1110 4444 !.**]6_8?_9UA_:R_:O\ !/P] MNKZ;3;/Q)J'DW5Q 98X41I7V9XW%8V"D@@$@D$5^U&E_P#!NW^SA:V,<4VE M^*[J2,!6FDUIU:0^IVA1^0KP\TX@PN FJ=:[;UT/>RCAO%YA!SHV27<_ &BO MZ!O^(>']FS_H"^)O_!Y-1_Q#P_LV?] 7Q-_X/)J\O_7; =I?<>Q_J'F/>/WG M\_-%?T#?\0\/[-G_ $!?$W_@\FH_XAX?V;/^@+XF_P#!Y-1_KM@.TON#_4/, M>\?O/Y^:*_H&_P"(>']FS_H"^)O_ >34?\ $/#^S9_T!?$W_@\FH_UVP':7 MW!_J'F/>/WG\_-%?T#?\0\/[-G_0%\3?^#R:C_B'A_9L_P"@+XF_\'DU'^NV M [2^X/\ 4/,>\?O/Y^:*_H&_XAX?V;/^@+XF_P#!Y-1_Q#P_LV?] 7Q-_P"# MR:C_ %VP':7W!_J'F/>/WG\_-%?T#?\ $/#^S9_T!?$W_@\FH_XAX?V;/^@+ MXF_\'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_B'A_9L_P"@+XF_\'DU'_$/#^S9 M_P! 7Q-_X/)J/]=L!VE]P?ZAYCWC]Y_/S17] W_$/#^S9_T!?$W_ (/)J/\ MB'A_9L_Z OB;_P 'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_B'A_9L_Z OB;_P> M34?\0\/[-G_0%\3?^#R:C_7; =I?<'^H>8]X_>?S\T5_0-_Q#P_LV?\ 0%\3 M?^#R:C_B'A_9L_Z OB;_ ,'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_ (AX?V;/ M^@+XF_\ !Y-1_P 0\/[-G_0%\3?^#R:C_7; =I?<'^H>8]X_>?S\T5_0-_Q# MP_LV?] 7Q-_X/)J/^(>']FS_ * OB;_P>34?Z[8#M+[@_P!0\Q[Q^\_GYHK^ M@;_B'A_9L_Z OB;_ ,'DU'_$/#^S9_T!?$W_ (/)J/\ 7; =I?<'^H>8]X_> M?S\T5_0-_P 0\/[-G_0%\3?^#R:C_B'A_9L_Z OB;_P>34?Z[8#M+[A?ZAYC MWC]Y_/S1T_+-?T"-_P &\O[-P(VZ'XG_ !UN; _7\_PK\N/^"QW_ 3YT'_@ MG[^T#H^E^$[_ %&\\-^)M-_M&VBOW5Y[-U=HWB+J!N7A2"0#\V#D@L>_+>)L M)C:OL:5^;S78\[-.%<9@:/MZMN7R=SY"Z44#@?YYHKZ$^;"BBB@ HHHH *** M* "M'P?_ ,C=I?\ U]Q?^ABLZM'P?_R-VE_]?<7_ *&*RK?PY>AK0_B1]4?U MKV?_ !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C\"]$%%%%!H%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/? M/^"6W_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^ MF]>_UK\MXX_WN'^']3]9\/\ _=:G^)?D+1117Q)]^%%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4$X%%(_2@#P#_@HY^PGH/[?7[/M]X5U'R;/7+0-=Z#JC M+EM/NPO'3DQN!M<=PO:#=-:7EO(,% M67N#T92N"K#AE((R""?ZQ2-V>M?GQ_P7$_X)9?\ #5_@'_A9'@?3@WQ$\+VY M%S;0)\^OV:_,8\#EIX^2F,ELLO4J5^PX5S[ZK4^K5G[DMO)_\$^'XOX=^MP^ MM4%[\=_-?\ _![->Z?\ !.K]LW4OV&/VHM#\:6_G3:.Q-AKEFC<7EC(1YBXZ M%EP)$[;XP"0#7ALT3P2M'(&5U8J01@YS_/V]:;T_ETSG(_IP?PK]0Q&'A7HR MHSUC)'Y/AZU7#UHUJ>DHL^G/^"QOB_3O'_\ P47^(&N:1>0ZAI6KIIEY9W41 MW)<0R:9:.CJ?0J017S'4EQ=2WDF^:221PJH"[%B%4!5&3V"@ #L,#M4=&%H* MC2C27V5;_(6*Q'MZLJO=W"BBBN@P"BBB@ HHHH **** /J/_ ((M_P#*3CX4 M_P#7]<_^D<]?TCIP*_FX_P""+?\ RDX^%/\ U_7/_I'/7](Z=*_*^./]\C_A M1^N\ _[E/_$QU%%%?%GW84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %?BS_P="_\E^^&?_8!G_\ 2BOVFK\6 M?^#H7_DOWPS_ .P#/_Z45]+PG_R,8^C/E>,_^19+U1^7(HH%%?L9^(] HHHH M **** "BBB@ K1\'_P#(W:7_ -?<7_H8K.K1\'_\C=I?_7W%_P"ABLJW\.7H M:T/XD?5']:]G_P >L?\ NBI*CL_^/6/_ '14E?SYU/Z/H_ O1!1110:!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !37ZTZFOUH _F7_X*L_\ *1?XP?\ 8QW']*^?:^@O^"K/ M_*1?XP?]C'_P"Q MGL__ $8*_IO7O]:_+>./][A_A_4_6?#_ /W6I_B7Y"T445\2??A1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !44XRWMC'%2TC<]J/0/4_&[_@O/_P2 MB_X1.ZU#XY?#W3=NFW3&;Q;IEJG_ !YR'.;^-0/N-_RU &0S;\89ROY2D$'[ MNW'!&,8_S_G/6OZX-8TNWUK3KBTN[>*ZM;B-HIH94#QRHPVLK*//!%G+-\,=>N/FA5=Q\.W#'_ %#'D^2W.QS_ +C' M.PM^D\*<1AK0_B1]4?UKV?_ M !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6 MW_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^F]>_ MUK\MXX_WN'^']3]9\/\ _=:G^)?D+1117Q)]^%%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !6'\1/A]H_Q5\&ZGX=U_3K75M&UFV>TO+2Y3=% M<1.,%6'XY&,$'D$5N4A^]3C)Q:E%V9,HJ2Y9*Z9_.?\ \%8/^"6NN?\ !/\ M^)SW^FQ76K?#37IV_L?42N]K-SEOL=P>@D7G:_ D"Y !#*OR(PVD\L<';D^M M?UA?&CX/>'?C[\-=6\(^+-)M]:T#6H&M[JUG3BN 6 &2J_JO M#/$<<7%8?$.U1=?YO^"?D'%7#,L)+ZSAU>F]_P"[_P ^7**"PQN^7;G&1PO MX?D:.]?9'Q 4444 %%%% !1110!]1_\ !%O_ )2L?^Z*DJ.S_ ./6/_=%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%-?K3J:_6@#^9?\ X*L_\I%_C!_V,=Q_2OGVOH+_ (*KG_C8M\8/^QDN/YBO MGVOWK+?]TI_X5^1_.N9?[W5_Q/\ ,****[CA"BBB@ HHHH **** /M#_ ((! MG_C9UX+_ .O'4O\ TCEK^AM/NU_/%_P0$_Y2=^"_^O+4O_2.:OZ'5^[7Y+QI M_P C!?X4?L/ 7_(N?^)BT445\B?;A1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH M_GL_X.!_^4F7BK_L&Z;_ .DJ5\4'K7VM_P ' QS_ ,%,_%G_ &#=-_\ 25*^ M*3UK]SR/_<*/^%'\^Y]_R,*O^)A1117JGDA1110 4444 %%%%'4#WS_@EL?^ M-A_P>_[&>S_]&"OZ;U[_ %K^8_\ X)5 =9D9=%UM5Y(//V:<@?),JCV5PI*X^8#Y;7]X&_C[\.M4\)^+M'M=(PJO3?3^7_ (!\@ Y%%#G!;GOC)^O%!&#B MOLM3X:(4444#"BBB@:W/J'_@B[_RDZ^$_P#U_P!Q_P"D=Q7])2?=K^;7_@B^ MOZ2D^[7Y7QQ_OL?\*/UO@#_%_^1DT_P#Z^(__ $(5G6^!^C-:'\2/JC^MFT_X\X_] MVI:BM/\ CSC_ -VI:_GM[G]'T?@7H@HHHH- HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK]? MPIU-?K^% '\RO_!5+_E(I\8/^QEN?_0J^?Z]^_X*GG/_ 42^,'_ &,MU_Z% M7@-?O66_[K3]%^1_.N9?[W5_Q/\ ,****[CA"BBB@ HHHH **** >Q]F?\$" M&V_\%/? _P#M6FI?^D,]?T0"OYV_^"!S[?\ @J!X#_VK74Q_Y(SU_1(*_)>- M/]_7^%'[#P%_R+W_ (F%%%%?(GVX4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=:6D(H _GH M_P"#@(_\;,O%G_8.TW_TECKXK/6OM/\ X. #G_@IIXN_[!^F_P#I)'7Q8>M? MN>1_[A1_PH_G_/?]_K?XF%%%%>J>.%%%% !1110 4444 >]_\$NCC_@H9\'? M^QHL_P#T,5_3C7\QG_!+XX_X*%_!W_L:;+_T8*_ISK\MXX_WJG_A_4_6?#__ M '6I_B7Y!1117Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1106Q0 44@8'N*7.: "L/XB?#_1?BKX.U'P[XBTRSUC1=7@:WO+.ZC$D5 MQ&W56!__ %CJ,$"MS-!&:(R:::)E%27+)71^!/\ P5E_X(Q:U^QCJ5[XX\!0 M7FN?#":0R2+_ *RY\.%C]R7^]!SA9>WW7.=I;X)^Z,#@+QCD;?3@]/IVZ5_7 M#JNEV^M6,]I=017-K=1M#-%(@=)$((*LI!# @XP>,$U^-_\ P5C_ ."#UUX& M;4OB-\$=-DO-%^>XU3PK"K236&>6DLQRS1=S$#E /D!7*K^D\/\ %:FEAL:] M=E+OY,_+>).#W3;Q6!6G6/8_*ZBG/&R.0593G&",$'_/T_+%-!R*^_NGHM3\ M[VT>C"BBBA[!U/I[_@C.^S_@IE\*#_U$I1^=M-7])PK^:S_@CB^S_@IA\)?? M59!_Y+RU_2F.E?EG''^^0_P_J?K?A_\ [E/_ !?H%%%%?%'WH4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? MBG_P="G_ (R,^&O_ &+LW_I2:_:ROQ1_X.@S_P 9(?#?_L79?_2EJ^FX2_Y& M4?1_D?*\9_\ (LEZH_,$=** ,"BOV'J?B(4444P"BBB@ HHHH *N^'#M\0V/ M_7Q'_P"A"J57- .-=LO^NZ?^A"LZWP/T9K0_B1]4?UM6?_'E'_NBIJALO^/- M/]T5-7\]O<_H^C\$?1!1110:!1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37Z_A3J;)W^E'4# M^9'_ (*E'_C8A\8/^QFNA_X]7@=>]_\ !4+5/_3;./]ZI_X?U/U MCP^_W:K_ (E^0M%%%?$GZ %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !49<:(YL;8--:YQ\O=XNAZ@AL@_J3\+OB;H'QB\ Z9XF\,ZM9ZUH> ML0BXM+RVDWQS(?Y$="#@@@@@$8K^=K_@M8?-_P""GGQ7]#>6HZ_].5L1].E2 M?\$T/^"J/C#_ ()\^-A;K]HU_P"'VJ3AM4T%I,>43@&>V)XCF X^[(!M8 A M67]$QW"\,5@J>(PJM/E5UWT_,_,8Y%R,JW/(/(()[T,*_ M/9TY0ER3T:/TNG4C4BIP=TQ:BF 9L>W?D5+NIIY/X5)9^<'_ 55_P""&>D? MM+-J'C[X5P6'A_QXX:XOM*VK%8Z\PR2W]V&=CDE@-LC'_$6EWVC:WI5R2I&2#]ED M?%53#6H8EWAWZH^#XBX0AB;XC!JT^JZ,_FV!R**]:_; _8G^('[$'Q(D\.^. MM(DM&D+M9:A#F2QU6,'F2&7&&Z@LI^=2?F )KR7&#COZ5^H8?$4ZT(U*3NF? ME.(HU*-5PJJS73M_F?2G_!'U_+_X*4_"5O\ J,,/_($M?TKKTK^:3_@D0VW_ M (*2?",_]1G_ -I25_2VIXK\SXX_WN'^']3]5\/_ /OVPK\3?^#H(Y_:8^'?\ V+,O M_I3)7TW"7_(RCZ/\CY7C/_D62]4?F+GFBC_&BOV'J?B(4444P"BBB@ HHHH M*M:*<:Q:G_ILG\ZJU8TIMNIVY_Z:+_,5G6^!^C-:'\2/JC^M^T_X]$_W:EJ* MTYM(_P#=J6OY[>Y_1]'X%Z(****#0**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)_2GTV3H? MI0!_,?\ \%1#G_@H;\8O^QIO/_1AKP6O>/\ @J <_P#!0SXQ?]C5>_\ HTUX M/7[YE_\ NM/_ K\D?SKF7^]U?\ $_S"BBBNPX0HHHH **** "BBB@:/K[_@ M@^^W_@J3\-_]I-4'_E,NJ_HN'2OYS?\ @A(V/^"IWPQ]QJG_ *:KROZ,A7Y/ MQM_O\?\ "OU/U_@/_<9?XF%%%%?'GW 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$44AH8'\ M\7_!?@Y_X*=>-/\ KRTW_P!(H:^,:^S/^"^QS_P4\\;?]>>F_P#I##7QG7[G MD?\ N%'_ H_GS//]_J_XF%%%%>J>4%%%% !1110 4444UN![G_P3+./^"@_ MP;_[&RP_]'+7]/(K^87_ ()G?\I!?@W_ -C=IW_H]:_IZ!S7Y=QU_O-/_"_S M/UCP^_W6K_B7Y!1117PY^@!1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4UCAA3J:WW@: /YLO^"R\_VC_@IE\6&]-1A7\K6 ?TKYB!P??J". M"#VKZ2_X*]S_ &C_ (*2_%MO36=OY11C^E?-M?O.5_[G2]%^1_.^;?[[5]7^ M9[A^PS^WWXZ_8(^**:]X3O/M&FW15-5T2X=OL6I1 ]&'\$@R=LB_,I)ZJS*? MZ"/V'/V^O 7[>?PN37O"-Z(M0M0JZKHUP5%YI'^)ZN7OVSJ01D\]17X8_P#!2W_@B9XT_8MN M+[Q/X3CO/&GPTW-+]KCC#7VCH>=MU&HP5' \]5*G&65,XK^@FJ][:K=1M&Z+ M)'(-K*PW*P/4$>F*]G)\\Q& G^[=X]4]F>#G7#V&SȄ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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
9 Months Ended
Sep. 30, 2023
Nov. 06, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-39153  
Entity Registrant Name Healthcare Trust, Inc.  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 38-3888962  
Entity Address, Address Line One 222 Bellevue Ave.  
Entity Address, City or Town Newport  
Entity Address, State or Province RI  
Entity Address, Postal Zip Code 02840  
City Area Code 212  
Local Phone Number 415-6500  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   111,545,038
Entity Central Index Key 0001561032  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Former Address    
Document Information [Line Items]    
Entity Address, Address Line One 650 Fifth Ave.  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Address Line Two 30th Floor  
Series A Preferred Stock    
Document Information [Line Items]    
Title of 12(b) Security 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share  
Trading Symbol HTIA  
Security Exchange Name NASDAQ  
Series B Preferred Stock    
Document Information [Line Items]    
Title of 12(b) Security 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share  
Trading Symbol HTIBP  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Real estate investments, at cost:    
Land $ 208,594 $ 206,454
Buildings, fixtures and improvements 2,119,797 2,089,133
Acquired intangible assets 293,295 292,034
Total real estate investments, at cost 2,621,686 2,587,621
Less: accumulated depreciation and amortization (663,534) (609,324)
Total real estate investments, net 1,958,152 1,978,297
Cash and cash equivalents 51,041 53,654
Restricted cash 40,245 22,884
Derivative assets, at fair value 37,547 40,647
Straight-line rent receivable, net 26,214 25,276
Operating lease right-of-use assets 7,739 7,814
Prepaid expenses and other assets 36,019 34,554
Deferred costs, net 15,300 17,223
Total assets 2,172,257 2,180,349
LIABILITIES AND EQUITY    
Mortgage notes payable, net 808,752 578,700
Credit facilities, net 347,720 530,297
Market lease intangible liabilities, net 8,519 9,407
Accounts payable and accrued expenses (including $665 and $47, respectively, due to related parties as of September 30, 2023 and December 31, 2022) 48,234 45,247
Operating lease liabilities 8,051 8,087
Deferred rent 6,904 5,925
Distributions payable 3,496 3,496
Total liabilities 1,231,676 1,181,159
Stockholders’ Equity    
Common stock, $0.01 par value, 300,000,000 shares authorized, 109,877,212 shares and 105,080,531 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 1,098 1,051
Additional paid-in capital 2,485,745 2,417,059
Accumulated other comprehensive income 35,340 36,910
Distributions in excess of accumulated earnings (1,588,261) (1,462,457)
Total stockholders’ equity 933,998 992,639
Non-controlling interests 6,583 6,551
Total equity 940,581 999,190
Total liabilities and equity 2,172,257 2,180,349
Series A Preferred Stock    
Stockholders’ Equity    
Preferred stock 40 40
Series B Preferred Stock    
Stockholders’ Equity    
Preferred stock $ 36 $ 36
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accounts payable and accrued expenses $ 48,234 $ 45,247
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 109,877,212 105,080,531
Common stock, shares outstanding (in shares) 109,877,212 105,080,531
Series A Preferred Stock    
Preferred stock, dividend rate, percentage 7.375%  
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 4,740,000 4,740,000
Preferred stock, shares issued (in shares) 3,977,144 3,977,144
Preferred stock, shares outstanding (in shares) 3,977,144 3,977,144
Series B Preferred Stock    
Preferred stock, dividend rate, percentage 7.125%  
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 3,680,000 3,680,000
Preferred stock, shares issued (in shares) 3,630,000 3,630,000
Preferred stock, shares outstanding (in shares) 3,630,000 3,630,000
Related Party    
Accounts payable and accrued expenses $ 665 $ 47
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenue from tenants $ 85,686 $ 83,460 $ 259,145 $ 250,936
Operating expenses:        
Property operating and maintenance 54,326 51,198 161,778 156,880
Impairment charges 0 8,949 0 25,786
Operating fees to related parties 6,397 6,333 19,153 19,003
Acquisition and transaction related 173 199 384 1,153
General and administrative 4,753 4,471 14,105 13,369
Depreciation and amortization 20,776 20,854 61,520 61,525
Total expenses 86,425 92,004 256,940 277,716
Operating (loss) income before loss (gain) on sale of real estate investments (739) (8,544) 2,205 (26,780)
(Loss) gain on sale of real estate investments (173) 194 (364) (109)
Operating (loss) income (912) (8,350) 1,841 (26,889)
Other income (expense):        
Interest expense (15,720) (13,284) (50,208) (37,098)
Interest and other income 258 10 576 24
Gain on non-designated derivatives 406 1,826 510 3,212
Total other expenses (15,056) (11,448) (49,122) (33,862)
Loss before income taxes (15,968) (19,798) (47,281) (60,751)
Income tax expense (157) (77) (244) (159)
Net loss (16,125) (19,875) (47,525) (60,910)
Net loss attributable to non-controlling interests 14 22 45 100
Allocation for preferred stock (3,450) (3,450) (10,349) (10,349)
Net loss attributable to common stockholders (19,561) (23,303) (57,829) (71,159)
Other comprehensive income (loss):        
Unrealized gain (loss) on designated derivatives 395 16,948 (1,570) 53,384
Comprehensive loss attributable to common stockholders $ (19,166) $ (6,355) $ (59,399) $ (17,775)
Weighted-average shares outstanding - Basic (in shares) [1] 111,426,241 111,365,461 111,404,655 111,333,801
Weighted-average shares outstanding - Diluted (in shares) [1] 111,426,241 111,365,461 111,404,655 111,333,801
Net loss per common share attributable to common stockholders - Basic (in usd per share) [1] $ (0.18) $ (0.21) $ (0.52) $ (0.64)
Net loss per common share attributable to common stockholders - Diluted (in usd per share) [1] $ (0.18) $ (0.21) $ (0.52) $ (0.64)
[1] Retroactively adjusted for the effects of the stock dividends (see Note 1).
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Total
Series A Preferred Stock
Series B Preferred Stock
Total Stockholders Equity
Total Stockholders Equity
Series A Preferred Stock
Total Stockholders Equity
Series B Preferred Stock
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Distributions in excess of accumulated earnings
Distributions in excess of accumulated earnings
Series A Preferred Stock
Distributions in excess of accumulated earnings
Series B Preferred Stock
Non-controlling Interests
Preferred stock, shares outstanding beginning balance (in shares) at Dec. 31, 2021             3,977,144 3,630,000              
Beginning balance at Dec. 31, 2021 $ 1,040,400     $ 1,033,696     $ 40 $ 36 $ 993 $ 2,329,839 $ (14,341) $ (1,282,871)     $ 6,704
Common stock, shares outstanding beginning balance (in shares) at Dec. 31, 2021                 99,281,754            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of Preferred Stock, net (39)     (39)           (39)          
Share-based compensation, net 955     955           955          
Distributions declared in common stock (in shares)                 4,330,590            
Distributions declared in common stock 0     0         $ 43 64,237   (64,280)      
Distributions declared on preferred stock (10,349) $ (5,500) $ (4,850)   $ (5,500) $ (4,850)             $ (5,500) $ (4,850)  
Distributions to non-controlling interest holders (138)                           (138)
Net loss (60,910)     (60,810)               (60,810)     (100)
Unrealized gain (loss) on designated derivatives 53,384     53,384             53,384        
Rebalancing of ownership percentage 0     (202)           (202)         202
Preferred stock, shares outstanding Ending balance (in shares) at Sep. 30, 2022             3,977,144 3,630,000              
Ending balance at Sep. 30, 2022 1,023,302     1,016,634     $ 40 $ 36 $ 1,036 2,394,790 39,043 (1,418,311)     6,668
Common stock, shares outstanding ending balance (in shares) at Sep. 30, 2022                 103,612,344            
Preferred stock, shares outstanding beginning balance (in shares) at Jun. 30, 2022             3,977,144 3,630,000              
Beginning balance at Jun. 30, 2022 1,029,463     1,022,786     $ 40 $ 36 $ 1,022 2,372,889 22,095 (1,373,296)     6,677
Common stock, shares outstanding beginning balance (in shares) at Jun. 30, 2022                 102,164,671            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of Preferred Stock, net (28)     (28)           (28)          
Share-based compensation, net 291     291           291          
Distributions declared in common stock (in shares)                 1,447,673            
Distributions declared in common stock 0     0         $ 14 21,697   (21,711)      
Distributions declared on preferred stock (3,450) $ (1,834) $ (1,617)   (1,834) (1,617)             (1,834) (1,617)  
Distributions to non-controlling interest holders (46)                           (46)
Net loss (19,875)     (19,853)               (19,853)     (22)
Unrealized gain (loss) on designated derivatives 16,948     16,948             16,948        
Rebalancing of ownership percentage 0     (59)           (59)         59
Preferred stock, shares outstanding Ending balance (in shares) at Sep. 30, 2022             3,977,144 3,630,000              
Ending balance at Sep. 30, 2022 1,023,302     1,016,634     $ 40 $ 36 $ 1,036 2,394,790 39,043 (1,418,311)     6,668
Common stock, shares outstanding ending balance (in shares) at Sep. 30, 2022                 103,612,344            
Preferred stock, shares outstanding beginning balance (in shares) at Dec. 31, 2022   3,977,144 3,630,000       3,977,144 3,630,000              
Beginning balance at Dec. 31, 2022 $ 999,190     992,639     $ 40 $ 36 $ 1,051 2,417,059 36,910 (1,462,457)     6,551
Common stock, shares outstanding beginning balance (in shares) at Dec. 31, 2022 105,080,531               105,080,531            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Share-based compensation, net $ 689     689           689          
Distributions declared in common stock (in shares)                 4,796,681            
Distributions declared in common stock 0     0         $ 47 67,928   (67,975)      
Distributions declared on preferred stock (10,349) $ (5,500) $ (4,849)   (5,500) (4,849)             (5,500) (4,849)  
Distributions to non-controlling interest holders (138)                           (138)
Net loss (47,525)     (47,480)               (47,480)     (45)
Unrealized gain (loss) on designated derivatives (1,570)     (1,570)             (1,570)        
Contributions from minority interests 284                           284
Rebalancing of ownership percentage 0     69           69 0       (69)
Preferred stock, shares outstanding Ending balance (in shares) at Sep. 30, 2023   3,977,144 3,630,000       3,977,144 3,630,000              
Ending balance at Sep. 30, 2023 $ 940,581     933,998     $ 40 $ 36 $ 1,098 2,485,745 35,340 (1,588,261)     6,583
Common stock, shares outstanding ending balance (in shares) at Sep. 30, 2023 109,877,212               109,877,212            
Preferred stock, shares outstanding beginning balance (in shares) at Jun. 30, 2023             3,977,144 3,630,000              
Beginning balance at Jun. 30, 2023 $ 959,578     952,918     $ 40 $ 36 $ 1,082 2,462,523 34,945 (1,545,708)     6,660
Common stock, shares outstanding beginning balance (in shares) at Jun. 30, 2023                 108,284,434            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Share-based compensation, net 229     229           229          
Distributions declared in common stock (in shares)                 1,592,778            
Distributions declared in common stock 0     0         $ 16 22,976   (22,992)      
Distributions declared on preferred stock (3,450) $ (1,834) $ (1,616)   $ (1,834) $ (1,616)             $ (1,834) $ (1,616)  
Distributions to non-controlling interest holders (46)                           (46)
Net loss (16,125)     (16,111)               (16,111)     (14)
Unrealized gain (loss) on designated derivatives 395     395             395        
Rebalancing of ownership percentage 0     17           17         (17)
Preferred stock, shares outstanding Ending balance (in shares) at Sep. 30, 2023   3,977,144 3,630,000       3,977,144 3,630,000              
Ending balance at Sep. 30, 2023 $ 940,581     $ 933,998     $ 40 $ 36 $ 1,098 $ 2,485,745 $ 35,340 $ (1,588,261)     $ 6,583
Common stock, shares outstanding ending balance (in shares) at Sep. 30, 2023 109,877,212               109,877,212            
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Distributions declared in common stock (in usd per share) $ 0.21 $ 0.21 $ 0.42 $ 0.42
Series A Preferred Stock        
Distributions declared on preferred stock (in usd per share) 0.46 0.46 0.92 0.92
Series B Preferred Stock        
Distributions declared on preferred stock (in usd per share) $ 0.45 $ 0.45 $ 0.90 $ 0.90
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (47,525) $ (60,910)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 61,520 61,525
Amortization of deferred financing costs 5,954 3,542
(Accretion) amortization of terminated swap (2,660) 423
Amortization of mortgage premiums and discounts, net 69 28
Accretion of market lease and other intangibles, net (675) (421)
Bad debt expense 909 2,559
Equity-based compensation 689 955
Loss on sale of real estate investments, net 364 109
Cash received from non-designated derivative instruments 3,866 0
Gain on non-designated derivative instruments (510) (3,212)
Impairment charges 0 25,786
Changes in assets and liabilities:    
Straight-line rent receivable (938) (1,236)
Prepaid expenses and other assets (4,180) (986)
Accounts payable, accrued expenses and other liabilities (1,504) (4,855)
Deferred rent 979 (2,212)
Net cash provided by operating activities 16,358 21,095
Cash flows from investing activities:    
Property acquisitions (35,261) (17,799)
Capital expenditures (13,998) (16,707)
Investments in non-designated interest rate caps (4,580) 0
Proceeds from sales of real estate investments 4,803 11,759
Net cash used in investing activities (49,036) (22,747)
Cash flows from financing activities:    
Payments on credit facilities (199,160) 0
Proceeds from credit facilities 20,000 0
Proceeds from mortgage notes payable 240,000 0
Payments on mortgage notes payable (850) (8,329)
Proceeds from termination of derivative instruments 5,413 0
Payments of deferred financing costs (7,774) (858)
Payments for derivative instruments 0 (39)
Preferred stock issuance costs 0 (39)
Contributions from non-controlling interests 284 0
Distributions to non-controlling interest holders (138) (138)
Net cash provided by (used in) financing activities 47,426 (19,752)
Net change in cash, cash equivalents and restricted cash 14,748 (21,404)
Cash, cash equivalents and restricted cash, beginning of period 76,538 85,382
Cash, cash equivalents and restricted cash, end of period 91,286 63,978
Cash and cash equivalents, end of period 51,041 40,120
Restricted cash, end of period 40,245 23,858
Cash, cash equivalents and restricted cash, end of period 91,286 63,978
Supplemental disclosures of cash flow information:    
Cash paid for interest 46,905 32,448
Cash paid for income and franchise taxes 416 566
Non-cash investing and financing activities:    
Common stock issued through stock dividends 67,975 64,280
Proceeds from real estate sales used to repay mortgage notes payable 2,663 0
Mortgage notes payable repaid with proceeds from real estate sales (2,663) 0
Proceeds from real estate sales used to repay amounts outstanding under the Prior Credit Facility 5,167 0
Amounts outstanding under the Prior Credit Facility repaid with proceeds from real estate sales (5,167) 0
Series A Preferred Stock    
Cash flows from financing activities:    
Dividends paid on preferred stock (5,500) (5,500)
Series B Preferred Stock    
Cash flows from financing activities:    
Dividends paid on preferred stock $ (4,849) $ (4,849)
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Organization
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Healthcare Trust, Inc. (including, as required by context, Healthcare Trust Operating Partnership, L.P. (the “OP”) and its subsidiaries, the “Company”), is an externally managed entity that for U.S. federal income tax purposes has qualified as a real estate investment trust (“REIT”). The Company acquires, owns and manages a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”) and senior housing operating properties (“SHOPs”).
As of September 30, 2023, the Company owned 204 properties located in 33 states and comprised of 9.0 million rentable square feet.
Substantially all of the Company’s business is conducted through the OP and its wholly-owned subsidiaries including taxable REIT subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages its day-to-day business with the assistance of its property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to the Company. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP. As of September 30, 2023, the Company owned 46 seniors housing properties using the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure in its SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor.
The Company operates in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. All of the Company’s properties across both business segments are located throughout the United States. In its MOB operating segment, the Company owns, manages, and leases single- and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. The Property Manager or third-party managers manage the Company’s MOBs. In its SHOP segment, the Company invests in seniors housing properties through the RIDEA structure. As of September 30, 2023, the Company had four eligible independent contractors operating 46 SHOPs, although effective on September 30, 2023, the Company terminated its contract with one independent contractor which managed 20 SHOPs. The Company is in the process of transferring the management of these 20 SHOPs to a new independent contractor, which the Company expects to be completed before December 31, 2023. The Company incurred $0.3 million of costs directly related to the termination in the three and nine months ended September 30, 2023.
The Company has declared quarterly dividends entirely in shares of its common stock since October 2020. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. Since October 2020, the Company has issued an aggregate of approximately 17.3 million shares as stock dividends. No other additional shares of common stock have been issued since October 2020. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding resulting from the stock dividends since October 2020 and through October 2023, and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. Please see Note 8 — Stockholder’s Equity for additional information on the stock dividends.
On March 31, 2023, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2022. The Estimated Per-Share NAV published on March 31, 2023 has not been adjusted since publication and will not be adjusted until the Company’s board of directors (the “Board”) determines a new Estimated Per-Share NAV. Issuing dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a stock dividend; however, because each stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
The accompanying unaudited consolidated financial statements of the Company included herein were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to this Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished includes all adjustments and accruals of a normal recurring nature, which, in the opinion of management, are necessary for a fair statement of results for the interim periods. The results of operations for the nine months ended September 30, 2023 and 2022 are not necessarily indicative of the results for the entire year or any subsequent interim periods.
These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2023. Except for those required by new accounting pronouncements discussed below, there have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2023.
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Continuing Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic commenced. The pandemic and its aftermath has had, and could continue to have, adverse impacts on economic and market conditions. The Company’s tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted, and may continue to impact, the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants which may further impact the ability of the Company’s tenants to pay their rent obligations to the Company when due.
The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy as could the rates charged to residents at its SHOPs. Moreover, the demand for leasing space at the Company’s MOB properties could decline, negatively impacting occupancy percentage, revenue and earnings. Additionally, downturns or stagnation in the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs.
Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates have had, and may continue to have, adverse impacts on the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing wars in Ukraine, Israel and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants to pay rent and hence the Company’s results of operations and liquidity.
Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:
COVID-19 Impact — MOB Segment
The financial stability and overall health of the Company’s tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its tenants in this segment, and all amounts previously deferred under prior rent deferral agreements have been collected.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases were modified, the Financial Accounting Standards Board (“FASB”) and SEC provided relief that allowed companies to elect whether they treated COVID-19 related lease amendments as provisions included in the pre-concession arrangements, and therefore, not lease modifications, or to treat lease amendments as modifications. In order to be considered COVID-19 related, cash flows had to be substantially the same or less than those prior to the concessions. For COVID-19 relief qualified changes, there were two methods to potentially account for such rent deferrals or abatements under the relief: (i) as if the changes were originally contemplated in the lease contract or (ii) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company was required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualified for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there was no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact was recognized ratably over the remaining life of the leases. For leases not qualifying for this relief, the Company applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
COVID-19 Impact — SHOP Segment
In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and then stabilized until June 2022. Since then, SHOP occupancy has trended downward. The Company also experienced lower inquiry volumes and reduced in-person tours during the COVID-19 pandemic compared to pre-pandemic periods. In addition, beginning in March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See “CARES Act Grants” below for additional information on the CARES Act.
During the year ended December 31, 2022, the Company relied more on the use of temporary contract labor and agencies than it had historically. The Company has since reduced its reliance on this labor source in the nine months ended September 30, 2023. However, the wage expenses (including overtime, training and bonus wages) incurred by the Company from employees of its third party operators has increased due to, among other things, inflation raising the cost of labor generally, a lack of qualified personnel that the Company’s third party operators are able to employ on a permanent basis and training hours and other onboarding costs for permanent staff which replaced previously utilized contract and agency labor.
The persistence of high inflation, labor shortages and supply chain disruptions have caused adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have a material adverse effect on its operations in future periods.
The adverse financial impacts of the COVID-19 pandemic on the Company were partially offset by funds received by the Company under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million under the CARES Act during the years ended December 31, 2022, 2021, and 2020, respectively. The Company did not receive any such funds during the three and nine months ended September 30, 2023 and it received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the Company treated these funds as grant contributions from the government. The full amounts received were recognized as reductions of property operating and maintenance expenses in the Company’s consolidated statements of operations and comprehensive loss
for the periods in which the funds were received, to partially offset the incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of September 30, 2023, these leases had a weighted average remaining lease term of 4.8 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with any increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short term in nature.
As of September 30, 2023:
(In thousands)Future 
Base Rent Payments
2023 (remainder)$27,566 
2024108,291 
202598,378 
202690,299 
202771,439 
Thereafter240,452 
Total$636,425 
The Company continually reviews receivables related to rent and unbilled rent and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments
at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive loss in the period the related costs are incurred, as applicable.
The Company recorded reductions in revenue of $0.2 million and $0.9 million, respectively, for uncollectable amounts during the three and nine months ended September 30, 2023, and $1.7 million and $2.6 million, respectively, during the three and nine months ended September 30, 2022.
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the three months ended September 30, 2023 and 2022. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of September 30, 2023 or December 31, 2022.
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the nine months ended September 30, 2023 were asset acquisitions. The Company acquired seven properties during the nine months ended September 30, 2023.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationships, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the nine months ended September 30, 2023 or 2022.
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of September 30, 2023 and December 31, 2022, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (i) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Lessee Accounting
The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheets as of September 30, 2023 and December 31, 2022, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023 and 2022.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a
right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see Note 16Commitments and Contingencies.
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statements of operations and comprehensive income to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held for use. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see Note 15 — Segment Reporting.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress is not depreciated until the project has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of September 30, 2023, the Company owned 46 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of September 30, 2023 and December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the COVID-19 pandemic. During the three months ended September 30, 2023, the Company modified 26 intercompany leases with the TRS which reduced intercompany rent.
Because of the TRS's recent operating history of losses and the impact of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $7.6 million as of September 30, 2023. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive loss. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance.
CARES Act Grants
On March 27, 2020, the CARES Act was signed into law and provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designed to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company did not receive any funding from the CARES Act during the three and nine months ended September 30, 2023 and the Company received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. Any funding that the Company would receive is recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2022:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.
Not yet Fully Adopted as of September 30, 2023:
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform
activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net
9 Months Ended
Sep. 30, 2023
Real Estate Investments, Net [Abstract]  
Real Estate Investments, Net Real Estate Investments, Net
Property Acquisitions
The Company invests in healthcare-related facilities, primarily MOBs and seniors housing properties which expand and diversify its portfolio and revenue base. The Company owned 204 properties as of September 30, 2023. During the nine months ended September 30, 2023 and 2022, the Company acquired seven and three properties, respectively. All acquisitions in the nine months ended September 30, 2023 and 2022 were considered asset acquisitions for accounting purposes.
The following table presents the allocation of real estate assets acquired and liabilities assumed during the nine months ended September 30, 2023 and 2022:
Nine Months Ended September 30,
(In thousands)20232022
Real estate investments, at cost:
Land$3,373 $4,199 
Buildings, fixtures and improvements27,069 10,662 
Total tangible assets30,442 14,861 
Acquired intangibles:
In-place leases and other intangible assets5,057 2,670 
Market lease and other intangible assets33 268 
Market lease liabilities(271)— 
Total intangible assets and liabilities4,819 2,938 
Cash paid for real estate investments, including acquisitions$35,261 $17,799 
Number of properties purchased

Significant Tenants
As of September 30, 2023 and 2022, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income for the portfolio on a straight-line basis. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of September 30, 2023 and 2022:
September 30,
State20232022
Florida19.8%19.0%
Pennsylvania10.6%*
_________
* The annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the date specified.
Intangible Assets and Liabilities
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above- and below-market lease assets and liabilities, net and the amortization and accretion of above- and below-market ground leases, net, for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Amortization of in-place leases and other intangible assets (1)
$3,455 $3,815 $10,414 $11,502 
Accretion of above -and below-market leases, net (2)
$(244)$(219)$(795)$(549)
Amortization of above -and below-market ground leases, net (3)
$40 $40 $120 $120 
________
(1)Reflected within depreciation and amortization expense.
(2)Reflected within rental income.
(3)Reflected within property operating and maintenance expense.
The following table provides the projected amortization expense and adjustments to revenues for the next five years:
(In thousands)2023 (remainder)2024202520262027
In-place lease assets$3,157 $11,812 $10,224 $8,979 $5,468 
Other intangible assets10 10 10 10 10 
Total to be added to amortization expense$3,167 $11,822 $10,234 $8,989 $5,478 
Above-market lease assets$(101)$(419)$(366)$(331)$(243)
Below-market lease liabilities309 1,297 1,127 972 654 
Total to be added to revenue from tenants
$208 $878 $761 $641 $411 
Dispositions
Three and Nine Months Ended September 30, 2023
During the three months ended September 30, 2023, the Company did not dispose of any properties. During the nine months ended September 30, 2023, the Company disposed of four SHOPs and one MOB for an aggregate contract sales price of $13.8 million. Two of the four disposed SHOPs were impaired by $15.1 million in the year ended December 31, 2022 (see below). As a result, the Company recorded an aggregate loss on sale of $0.4 million, which is presented in the Company’s consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2023.
Three and Nine Months Ended September 30, 2022
On July 1, 2020, the Company transitioned four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) from the former triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties were leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. During the third quarter of 2021, the Company began to actively market the LaSalle Properties for sale, and a non-binding letter of intent was signed in the fourth quarter of 2021 for an aggregate contract sales price of $12.4 million. The Company had previously recorded $34.0 million of impairment charges on the LaSalle Properties in the year ended December 31, 2021. The Company completed the sale of the LaSalle Properties in the first quarter of 2022 and recorded a loss on sale of $0.3 million in the first quarter of 2022, which is presented in the Company’s consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2022.The Company recorded a gain on sale of $0.2 million in the three months ended September 30, 2022 related to the settlement of a lien on formerly disposed properties.
Assets Held for Sale
When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.
There were no assets held for sale as of September 30, 2023 and December 31, 2022.
Assets Held for Use
When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single-tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.
Impairment Charges
There were no impairment charges recorded in the three and nine months ended September 30, 2023. The following table presents impairment charges by segment recorded during the nine months ended September 30, 2022:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20222022
MOB Segment:
Illinois skilled nursing facilities (1)
$— $10,644 
Total MOB impairment charges— 10,644 
SHOP Segment:
Various held for use SHOPs (2)
8,949 15,142 
Total SHOP impairment charges8,949 15,142 
Total impairment charges$8,949 $25,786 
(1)These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of September 30, 2023, these properties were not disposed of, nor were any under contract for disposal.
(2)Consists of eight total properties that were impaired as a result of the Company reassessing the holding period for the properties. Two of these properties were sold in the nine months ended September 30, 2023.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Mortgage Notes Payable, Net
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Mortgage Notes Payable, Net Mortgage Notes Payable, Net
The following table reflects the Company’s mortgage notes payable as of September 30, 2023 and December 31, 2022:
Outstanding Loan Amount as of
Effective Interest Rate (1) as of
PortfolioEncumbered PropertiesSeptember 30,
2023
December 31, 2022September 30,
2023
December 31, 2022Interest RateMaturity
(In thousands)(In thousands)
Fox Ridge Bryant - Bryant, AR1$6,689 $6,817 3.98 %3.98 %FixedMay 2047
Fox Ridge Chenal - Little Rock, AR115,344 15,639 2.95 %2.95 %FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR19,520 9,704 2.95 %2.95 %FixedMay 2049
Capital One MOB Loan (2)
41378,500 378,500 3.71 %3.73 %Fixed(2)Dec. 2026
Multi-Property CMBS Loan20116,037 118,700 4.60 %4.60 %FixedMay 2028
Shiloh - Illinois
112,828 13,071 4.34 %4.34 %FixedJan. 2025
BMO CMBS Loan942,750 42,750 2.89 %2.89 %FixedDec. 2031
Barclays MOB Loan62240,000 — 6.45 %— %FixedJune 2033
Gross mortgage notes payable136821,668 585,181 4.58 %3.83 %
Deferred financing costs, net of accumulated amortization (3)
(11,620)(5,117)
Mortgage premiums and discounts, net(1,296)(1,364)
Mortgage notes payable, net$808,752 $578,700 
_____________
(1)Calculated on a weighted average basis for all mortgages outstanding as of September 30, 2023 and December 31, 2022. For the SOFR (defined in Note 5 — Credit Facilities)/LIBOR based loans, the Company used the applicable SOFR/LIBOR rate index in effect at the balance sheet date. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(2)Variable rate loan, based on daily SOFR as of September 30, 2023 and December 31, 2022, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of September 30, 2023 and December 31, 2022.
(3)Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close or result in a definitive agreement.

As of September 30, 2023, the Company had pledged $1.3 billion in total real estate investments, at cost, as collateral for its $0.8 billion of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.
Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants, including debt service coverage ratios. As of September 30, 2023, the Company was in compliance with these financial covenants.
See Note 5 — Credit Facilities - Future Principal Payment and LIBOR Transition for a schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and discussion of the cessation of LIBOR publication.
Barclays MOB Loan
On May 24, 2023, the Company, through certain subsidiaries of the OP), entered into a non-recourse loan agreement (the “Barclays MOB Loan Agreement”), with (i) Barclays Capital Real Estate Inc., (ii) Société Générale Financial Corporation and (iii) KeyBank National Association (each individually, a “Lender,” and collectively, the “Lenders”), in the aggregate amount of $240.0 million (the “Barclay’s MOB Loan”). In connection with the Barclay’s MOB Loan Agreement, the OP entered into a Guaranty Agreement (the “Guaranty”) and an Environmental Indemnity Agreement (the “Environmental Indemnity”) for the benefit of the Lenders.
The Barclays MOB Loan is secured by, among other things, first priority mortgages on the Company’s interests in 62 MOBs with an aggregate gross asset value of $416.8 million. The Barclays MOB Loan has a 10-year term and is interest-only at a fixed rate of 6.453% per year. Under the Barclays MOB Loan Agreement, the Company is required to make interest-only
payments on a monthly basis with the principal balance due on the maturity date of June 6, 2033. The Barclays MOB Loan Agreement requires the OP to comply with certain covenants, including, maintaining combined cash and cash equivalents totaling at least $12.5 million at all times.
Subject to certain conditions, the Company may prepay the Barclays MOB Loan in whole or in part at any time after one year from closing with a pre-payment premium equal to the Yield Maintenance Program (as defined in the Barclays MOB Loan Agreement) by providing the lenders thereunder with prior written notice of prepayment no less than thirty days before prepayment, subject to a pre-payment premium equal to the Yield Maintenance Premium (as defined in the Barclay’s MOB Loan Agreement). Following the earlier of May 24, 2026 and the date that is two years after the securitization of the Barclay’s MOB Loan, the Company may prepay the Barclays MOB Loan through defeasance, Notwithstanding the foregoing, the Barclays MOB Loan may be prepaid at par during the final six months of the term. The Company paid $7.8 million in deferred financing costs related to the Barclay’s MOB Loan, which is amortized into interest expense over the term of the loan.
At the closing of the Barclays MOB Loan, the Company applied $194.8 million of the Barclays MOB Loan proceeds to repay and terminate the Company’s then-existing credit facility (the “Prior Credit Facility”). The Company also terminated its interest rate swap contracts that formerly hedged interest rate changes under the Prior Credit Facility (see Note 7 — Derivatives and Hedging Activities for additional information). The remaining proceeds of approximately $39.0 million (after the payment of Barclays MOB Loan closing costs and reimbursement of deposits) are available for general corporate purposes, subject to the terms of the Barclays MOB Loan Agreement. Additionally, by terminating the Prior Credit Facility, the Company is no longer subject to certain restrictive covenants previously imposed by the Prior Credit Facility (see Note 5 — Credit Facilities for additional information).
Under the Guaranty, the OP has (i) guaranteed the full repayment of the Barclays MOB Loan in the case of certain major defaults by the Company or the OP, including bankruptcy, and (ii) indemnified the Lenders against losses, costs or liabilities related to certain other “bad boy” acts of the Company or the OP, including fraud, willful misconduct, bad faith, and gross negligence. Pursuant to the Environmental Indemnity, the OP and the Company have indemnified the Lenders against losses, costs or liabilities related to certain environmental matters.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facilities
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Credit Facilities Credit Facilities
    The Company had the following credit facilities outstanding as of September 30, 2023 and December 31, 2022:
Outstanding Facility
Amount as of
Effective Interest Rate (8)
Credit Facilities
Encumbered Properties (1)
September 30,
2023
December 31, 2022September 30,
2023
December 31, 2022Interest RateMaturity
(In thousands)(In thousands)
Prior Credit Facility:
   Revolving Credit Facility$— $30,000 — %7.26 %VariableMar. 2024(7)
   Term Loan
— 150,000 — %5.11 %Fixed(5)Mar. 2024
   Deferred financing costs— (1,750)
   Term Loan, net
— 148,250 
Total Prior Credit Facility$— $178,250 
Fannie Mae Master Credit Facilities:
Capital One Facility
11(2)$207,829 $210,483 7.84 %5.90 %Variable(6)Nov. 2026
KeyBank Facility
10(3)139,891 141,564 7.89 %6.60 %Variable(6)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$347,720 $352,047 
Total Credit Facilities21$347,720 $530,297 7.86 %(4)5.94 %(4)
________
(1)Encumbered properties are as of September 30, 2023.
(2)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $350.5 million.
(3)Secured by first-priority mortgages on ten of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $261.9 million.
(4)Calculated on a weighted average basis for all credit facilities outstanding as of September 30, 2023 and December 31, 2022, respectively.
(5)Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see Note 7 — Derivatives and Hedging Activities for additional details).
(6)The effective rates above only include the impact of designated hedging instruments. The Company has seven non-designated interest rate cap agreements with an aggregate notional amount of $351.6 million which limited 30-day LIBOR (until June 30, 2023, and SOFR thereafter) to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see Note 7 — Derivatives and Hedging Activities for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility and KeyBank Fannie Mae Facility was 5.89% and 5.93%, respectively, as of September 30, 2023, and 5.26%, and 5.96%, respectively, as of December 31, 2022.
(7)During the year ended December 31 2022, the Company exercised its option to extend the maturity one year to March 2024 subject to certain conditions.
(8)Effective interest rate below for variable rate debt gives effect to any outstanding “pay-fixed” swaps entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of September 30, 2023 and December 31, 2022. The Company allocated $150.0 million of its SOFR-based interest rate swaps to the Term Loan $50.0 million of its LIBOR-based interest rate swaps to the Capital One Facility as of December 31, 2022. The interest rate swaps allocated to the Prior Credit Facility were all terminated in the nine months ended September 30, 2023. Upon termination, the fair values of terminated swaps are recorded within AOCI, and are amortized into interest expense over the original term of the then-existing swap. These amortized amounts from terminated swaps are not included in the calculation of effective interest. The Company continues to have $378.5 million of SOFR-based “pay-fixed” interest rate swaps allocated to a variable-rate mortgage note payable as of September 30, 2023. See Note 7 — Derivatives and Hedging Activities for additional details.
As of September 30, 2023, the carrying value of the Company’s real estate investments, at cost was $2.6 billion, with $1.3 billion of this asset value pledged as collateral for mortgage notes payable and $0.6 billion of this asset value pledged to secure advances under the Fannie Mae Master Credit Facilities. All of the real estate assets pledged to secure debt or to secure the Fannie Mae Master Credit Facilities are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the pledged collateral.
Unencumbered real estate investments, at cost as of September 30, 2023 were $0.7 billion, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for future mortgage loans, future advances under the Fannie Mae Master Credit Facilities, or other future financings.
Prior Credit Facility
The Prior Credit Facility consisted of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”). The Revolving Credit Facility and Term Loan were interest-only and would have matured on March 13, 2024. The Prior Credit Facility was fully repaid in May 2023 with net proceeds provided by the Barclays MOB Loan (see Note 4 — Mortgage Notes Payable, Net for details) and the Prior Credit Facility was terminated.
Amounts outstanding under the Prior Credit Facility bore interest at the Company’s option of either (i) Secured Overnight Financing Rate (“SOFR”), plus an applicable margin that ranges, depending on the Company’s leverage, from 2.10% to 2.85% or (ii) the Base Rate (as defined in the Prior Credit Facility), plus an applicable margin that ranged, depending on the Company’s leverage, from 0.85% to 1.60%. For the period from January 1, 2023 through the termination of the Prior Credit Facility in May 2023, the Company elected to use the SOFR option for all of its borrowings under the Prior Credit Facility. At termination, the Company wrote off the remaining deferred financing costs associated with the Prior Credit Facility of $2.6 million which is included in interest expense in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023.
The Prior Credit Facility contained various restrictions which no longer apply, that limited the Company’s ability to incur additional debt, maintain certain cash balances or pay dividends, among other things.
Fannie Mae Master Credit Facilities
On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually as a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements were assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.
In connection with the Fannie Mae Master Credit Facilities, the Company was required to enter into interest rate cap agreements which the Company periodically renews upon their expiration. During the three months ended September 30, 2023, the Company paid premiums of $4.6 million to renew three caps which matured in the three months ended September 30, 2023.
As of September 30, 2023 the Company had six non-designated interest rate cap agreements with an aggregate current effective notional amount of $351.6 million which caps SOFR at 3.50% and various maturities through April 2024. The existing caps were transitioned to SOFR-based contracts effective July 1, 2023. The Company does not apply hedge accounting to these non-designated interest cap agreements and changes in value are reflected in earnings (see Note 7Derivatives and Hedging Activities for additional information regarding the Company’s derivatives).
As of September 30, 2023, $347.7 million was outstanding under the Fannie Mae Master Credit Facilities. The Company may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. Borrowings under the Fannie Mae Master Credit Facilities bore annual interest at a rate that varied on a monthly basis and was equal to the sum of the current LIBOR for one month U.S. dollar-denominated deposits and a spread (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively). Effective July 1, 2023, the Fannie Mae Master Credit Facilities automatically transitioned to SOFR-based borrowings with monthly interest equal to the sum of the current SOFR for one-month denominated deposits and a spread of (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively). The Fannie Mae Master Credit Facilities mature on November 1, 2026.
As of December 31, 2022, the Company had $150.0 million of SOFR-based interest swap agreements, which were allocated to the Term Loan, and $50.0 million of LIBOR-based interest swap agreements which were allocated to the Capital One Facility. These swaps were all terminated in the six months ended June 30, 2023. The Term Loan was fully repaid in the three months ended June 30, 2023, but the Capital One Facility remained outstanding.
In the three months ended September 30, 2023, the Company provided a $5.1 million cash deposit to Fannie Mae because the debt service coverage ratios of the underlying properties of each facility were below the minimum required amount per the debt agreements. This amount will be recorded as restricted cash and is pledged as additional collateral for the Fannie Mae Master Credit Facilities. This deposit will be refunded the earlier of the Company’s achievement of a debt service coverage ratio above the minimum required amount of 1.40 or the maturity of the Fannie Mae Master Credit Facilities. Subsequent to September 30, 2023, the Company provided an additional deposit of $6.7 million, which brought the total deposit to $11.8 million (see Note 17 — Subsequent Events for additional information).
Future Principal Payments
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to September 30, 2023 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2023 (remainder)$289 $1,442 $1,731 
20241,178 5,769 6,947 
202513,270 5,769 19,039 
2026379,393 334,740 714,133 
2027922 — 922 
Thereafter426,616 — 426,616 
Total$821,668 $347,720 $1,169,388 
LIBOR Transition
In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the SOFR as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings were published through June 30, 2023.
The Company had no LIBOR-based borrowings or derivative instruments as of September 30, 2023. As of September 30, 2023, the Company had $347.7 million of variable-rate, SOFR-based borrowings under the Fannie Mae Master Credit Facilities, which automatically transitioned from variable-rate, LIBOR-based borrowings on July 1, 2023. As of September 30, 2023, the Company had SOFR-based interest rate caps with notional amounts of $351.6 million which are not designated as hedging instruments which also transitioned from LIBOR-based contracts effective July 1, 2023.
During the year ended December 31, 2022, the Company converted $150.0 million of its “pay-fixed” swaps on its Prior Credit Facility from LIBOR to SOFR, as well as its $378.5 million Capital One MOB Loan and the related “pay-fixed” swap from LIBOR to SOFR. During the nine months ended September 30, 2023, the Company terminated its remaining $50.0 million of LIBOR-based “pay-fixed” swaps. The “pay-fixed” swaps were terminated in an asset position and the Company received $5.4 million in cash following the termination. This amount was included in accumulated other comprehensive income (“AOCI”), and will amortize into earnings as a reduction to interest expense through March 2024 (the original term of the swap and variable hedged debt). See Note 7 — Derivatives and Hedging Activities for additional details.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring assets and liabilities at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below:
Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.
Level 3 — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.
The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.
Financial Instruments Measured at Fair Value on a Recurring Basis
Derivative Instruments
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of September 30, 2023, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.
The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.
The following table presents information about the Company’s assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
September 30, 2023
Derivative assets, at fair value (non-designated)$— $4,946 $— $4,946 
Derivative assets, at fair value (designated)— 32,601 — 32,601 
Total $— $37,547 $— $37,547 
December 31, 2022
Derivative assets, at fair value (non-designated)$— $3,737 $— $3,737 
Derivative assets, at fair value (designated)— 36,910 — 36,910 
Total $— $40,647 $— $40,647 
A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2023.
Real Estate Investments Measured at Fair Value on a Non-Recurring Basis
Real Estate Investments - Held for Use
The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheets as of September 30, 2023 and December 31, 2022.
As of September 30, 2023, the Company owned 16 held for use properties (10 MOBs and six SHOPs) for which the Company had reconsidered their expected holding periods, of which six properties (three MOB and three SHOPs) are being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying values of the respective properties, and has previously recorded impairment charges on 10 properties (eight MOBs and two SHOPs) to reduce the carrying values to their estimated fair values during the year ended December 31, 2022.
See Note 3 — Real Estate Investments, Net - “Assets Held for Use and Related Impairments” for additional details.
Real Estate Investments - Held for Sale
Real estate investments held for sale are carried at net realizable value on a non-recurring basis and are generally classified in Level 3 of the fair value hierarchy. The Company did not have any real estate investments classified as held for sale as of September 30, 2023 and December 31, 2022.
Financial Instruments Not Measured at Fair Value
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
September 30, 2023December 31, 2022
(In thousands)LevelCarrying Amount Fair Value Carrying AmountFair Value 
Gross mortgage notes payable and mortgage premium and discounts, net
3$820,372 $766,584 $583,817 $550,626 
Prior Credit Facility3$— $— $180,000 $179,496 
Fannie Mae Master Credit Facilities
3$347,720 $348,120 $352,047 $353,034 

The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities
9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities Derivatives and Hedging Activities
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings.
The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of September 30, 2023 and December 31, 2022:
(In thousands)Balance Sheet LocationSeptember 30,
2023
December 31, 2022
Derivatives designated as hedging instruments:
    Interest rate “pay-fixed” swapsDerivative assets, at fair value$32,601 $36,910 
Derivatives not designated as hedging instruments:
    Interest rate capsDerivative assets, at fair value$4,946 $3,737 
Cash Flow Hedges of Interest Rate Risk
As of September 30, 2023 and December 31, 2022, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
September 30, 2023December 31, 2022
Interest Rate DerivativesNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
SOFR-based interest rate “pay-fixed” swaps$378,500 $528,500 
LIBOR-based interest rate “pay-fixed” swaps— — 50,000 
Total interest rate “pay-fixed” swaps$378,500 $578,500 
The table below details the location in the financial statements of the gain (loss) recognized on interest rate derivatives designated as cash flow hedges for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives$5,418 $17,513 $12,078 $49,522 
Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense$5,023 $565 $13,648 $(3,862)
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$(15,720)$(13,284)$(50,208)$(37,098)
As of September 30, 2023, the Company had one SOFR-based “pay-fixed” interest rate swap that is designated as a cash flow hedge. The Company uses its interest rate swap as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for fixed-rate payments by the Company over the life of the agreement without exchange of the underlying notional amount. During the nine months ended September 30, 2023 and the year ended December 31, 2022, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. The remaining interest rate “pay-fixed” swap has a base interest rate of 1.61% and matures December 2026.
The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in AOCI and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.
MOB Loan Swap Termination
In connection with the refinancing of the $250.0 million loan made by Capital One, National Association and certain other lenders to certain subsidiaries of the OP on June 30, 2017 (the “MOB Loan”), during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and was reclassified as an increase to interest expense over the original term of the two terminated swaps and the MOB Loan prior to its refinancing. For the nine months ended September 30, 2022, the Company reclassified $0.4 million from AOCI as an increase to interest expense. No amounts remained in AOCI related to this swap termination designated to the MOB Loan as of December 31, 2022.
Prior Credit Facility Swap Terminations
During the nine months ended September 30, 2023, the Company terminated two LIBOR-based interest rate swap agreements with an aggregate notional amount of $50.0 million and six SOFR-based interest rate swap agreements with an aggregate notional amount of $150.0 million. The swaps were terminated in asset positions, and the Company received $1.9 million in cash from the LIBOR-based swap terminations, and $3.5 million in cash from the SOFR-based swap terminations. These amounts were included in AOCI and will be amortized into earnings as a reduction to interest expense from the termination dates of the swaps through March 2024 (the original term of the swap and the Prior Credit Facility). For the three and nine months ended September 30, 2023, the Company reclassified $1.5 million and $2.7 million, respectively, from AOCI as decreases to interest expense, and $2.7 million remained in AOCI as of September 30, 2023.
Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from October 1, 2023 through September 30, 2024, the Company estimates that $16.5 million will be reclassified from AOCI as a decrease to interest expense or other comprehensive income relating to the “pay-fixed” swaps designated as derivatives.
Non-Designated Derivatives
The Company had the following outstanding interest rate derivatives with current effective notional amounts that were not designated as hedges in qualified hedging relationships as of September 30, 2023 and December 31, 2022:
September 30, 2023December 31, 2022
Interest Rate DerivativesNumber of Instruments
Notional Amount (1)
Number of Instruments
Notional Amount (1)
(In thousands)(In thousands)
Interest rate caps (2)
$351,572 $354,624 
(1)Notional amount represents the currently active interest rate cap contracts.
(2)All of the Company’s interest rate cap agreements limited 30-day LIBOR through June 30, 2023 (and SOFR, thereafter) to 3.50% with terms through July 2025. The actual 30-day LIBOR rates during the six months ended June 30, 2023, and the SOFR rates during the three months ended September 30, 2023, exceeded the strike price rate of 3.50% and the Company received payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.
These derivatives are used to limit the Company’s exposure to interest rate movements for economic purposes, however, the Company has not elected to apply hedge accounting. As of September 30, 2023 and December 31, 2022, the Company had entered into six SOFR-based and seven LIBOR-based interest rate caps, respectively, with notional amounts of $351.6 million and $354.6 million, respectively, which limited 30-day SOFR/LIBOR borrowings to 3.50% and have varying maturities through July 2025.
The Company paid premiums of $4.6 million to renew three caps with an aggregate notional amount of $138.5 million which matured in the nine months ended September 30, 2023. Subsequent to September 30, 2023, the Company paid premiums of $5.0 million to renew two maturing interest rate caps with an aggregate notional amount of $150.9 million (see Note 17 — Subsequent Events for additional information). One interest rate cap with a notional amount of $60.0 million matures in April 2024, which represents the next interest rate cap maturity excluding those renewed subsequent to September 30, 2023. All of the Company’s LIBOR-based interest rate caps were transitioned to SOFR-based contracts effective July 1, 2023.
Beginning in the year ended December 31, 2022, LIBOR exceeded 3.50% and the Company began receiving payments under these interest rate caps. While the Company does not apply hedge accounting for these interest rate caps, they are economically hedging the Capital One Facility and KeyBank Facility. Changes in the fair value of, and any cash received from, derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net loss and are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive loss.
The gains on non-designated derivatives were $0.4 million and $0.5 million, respectively, for the three and nine months ended September 30, 2023, and were $1.8 million and $3.2 million, respectively, for the three and nine months ended September 30, 2022. During the nine months ended September 30, 2023, the Company received aggregate payments of $3.9 million related to its effective interest rate caps as LIBOR/SOFR exceeded the effective rates of the capped debt. No such amounts were received during the nine months ended September 30, 2022.
Offsetting Derivatives
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives (both designated and non-designated) as of September 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
September 30, 2023$37,547 $— $— $37,547 $— $— $37,547 
December 31, 2022$40,647 $— $— $40,647 $— $— $40,647 


Credit-risk-related Contingent Features
The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.
As of September 30, 2023, there were no derivatives in a net liability position. The Company is not required to post any collateral related to these agreements and was not in breach of any agreement provisions.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Common Stock
As of September 30, 2023 and December 31, 2022, the Company had 109,877,212 and 105,080,531 shares of common stock outstanding, respectively, including unvested restricted shares, shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases, and shares issued as stock dividends since October 2020. Since October 2020, the Company has issued an aggregate of approximately 17.3 million shares in respect to the stock dividends. Except for shares issued as dividends, no additional shares of common stock were issued during the nine months ended September 30, 2023 or the year ended December 31, 2022. References made to weighted-average shares and per-share amounts in the consolidated statements of operations and comprehensive loss have been retroactively adjusted to reflect the cumulative increase in shares outstanding due to the stock dividends (including the October 2023 stock dividend) and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. See Note 1 — Organization for additional information.
On March 31, 2023, the Company published a new Estimated Per-Share NAV as of December 31, 2022, which was approved by the Board on March 31, 2023. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.
Share Repurchase Program
Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.
Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
The Board suspended the SRP in August 2020 and rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated.
When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.
The table below reflects the number of shares repurchased and the average price per share, under the SRP and does not include any repurchases under tender offers, cumulatively through September 30, 2023.
Number of Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 20224,896,620 $20.60 
Nine months ended September 30, 2023— — 
Cumulative repurchases as of September 30, 20234,896,620 20.60 
Distribution Reinvestment Plan
Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheets in the period distributions are declared. During the nine months ended September 30, 2023 and the year ended December 31, 2022, the Company did not issue any shares of common stock pursuant to the DRIP. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.
Stockholder Rights Plan
In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its Board in its discretion.
Preferred Stock and Preferred Units
The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019, the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC, (the “Preferred Stock Equity Line”) and in May 2021, the Board authorized the classification of 2,530,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the offering in May 2021. Also, in connection with an underwritten offering in October 2021, the Company classified and designated 3,680,000 shares of its authorized preferred stock on October 4, 2021 as authorized shares of its Series B Preferred Stock.
The Company had 3,977,144 shares of Series A Preferred Stock issued and outstanding as of September 30, 2023 and December 31, 2022.
The Company had 3,630,000 shares of Series B Preferred Stock issued and outstanding as of September 30, 2023 and December 31, 2022.
The Company also had 100,000 Series A Preferred Units outstanding as of September 30, 2023 and December 31, 2022, which were accounted for as a component of non-controlling interests. See Note 13 — Non-controlling Interests for additional information.
Distributions and Dividends
Common Stock
From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock.
On August 13, 2020, the Board changed the Company’s common stock distribution policy to preserve the Company’s liquidity and maintain additional financial flexibility. Under the policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s Estimated Per Share NAV of common stock in effect on the applicable date:
Stock Dividend Declaration DateStock Dividend Issue DateQuarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 20200.013492
January 4, 2021January 15, 20210.013492
April 2, 2021April 15, 20210.014655
July 1, 2021July 15, 20210.014655
October 1, 2021October 15, 20210.014655
January 3, 2022January 15, 20220.014655
April 1, 2022April 18, 20220.014167
July 1, 2022July 15, 20220.014167
October 3, 2022October 17, 20220.014167
January 3, 2023January 18, 20230.014167
April 3, 2023April 17, 20230.015179
July 3, 2023July 17, 20230.015179
October 2, 2023October 16, 20230.015179
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Arrangements
9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions and Arrangements Related Party Transactions and Arrangements
As of September 30, 2023 and December 31, 2022, the Special Limited Partner owned 10,550 and 10,094 shares (assuming conversion of its partnership interests), respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of September 30, 2023 and December 31, 2022, the Advisor held 90 partnership units in the OP designated as “Common OP Units”.
The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP.  In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.
Fees Incurred in Connection with the Operations of the Company
The Second Amended and Restated Advisory Agreement by and among the Company, the OP and the Advisor (as amended the “Second A&R Advisory Agreement”) took effect on February 17, 2017 and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days’ prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&R Advisory Agreement or (b) any material breach of the Second A&R Advisory Agreement of any nature whatsoever by the Company.
On July 25, 2019, the Company entered into Amendment No. 1 to the Second A&R Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “—Professional Fees and Other Reimbursements.”
Acquisition Expense Reimbursements
The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for
third-party acquisition expenses. Under the Second A&R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through September 30, 2023.
Asset Management Fees and Variable Management/Incentive Fees
Under the LPA and the advisory agreement that was superseded by the original amended and restated advisory agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the “Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).
Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.
Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of September 30, 2023, the Company determined that achieving the Performance Condition was not yet considered probable for accounting purposes. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any, on the Company’s common stock. These cash distributions on Class B Units are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss until the Performance Condition is considered probable to occur. stock dividends do not cause the OP to issue additional Class B Units, rather, the redemption ratio to common stock is adjusted. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that the Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units.
On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.
Effective February 17, 2017, the Second A&R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. There are no variable management fees earned from the issuance of common stock dividends. The base management fee is payable to the Advisor or its assignees in cash, Common OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any Common OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.
In addition, the Second A&R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted shares of common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt
reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No incentive fee was incurred for the three and nine months ended September 30, 2023 or 2022.
Property Management Fees
Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by the Company’s Board (including a majority of the independent directors).
If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.
On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&R Property Management Agreement”) with the OP and the Property Manager. The A&R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&R Property Management Agreement at least 90 days prior to the end of the term. Neither party has provided notice of intent to terminate. The current term of the A&R Property Management Agreement expires February 17, 2024. The Property Manager may assign the A&R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.
On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&R Property Management Agreement. See the Mortgage Notes Payable table included in Note 4 — Mortgage Notes Payable, Net for additional information on the Multi-Property CMBS Loan.
Professional Fees and Other Reimbursements
The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the three and nine months ended September 30, 2023, the Company incurred $2.5 million and $6.4 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. During the three and nine months ended September 30, 2022, the Company incurred $2.4 million and $6.7 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive loss.
On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Advisory Agreement Amendment, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.
The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.
Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), is limited to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”).
Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the Advisory Agreement Amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2020; (a) the Fixed Component was equal to $6.8 million (currently $7.7 million) and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.
If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the Advisory Agreement Amendment requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the Advisory Agreement Amendment requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.
Summary of fees, expenses and related payables
The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,Payable (Prepayments) as of
 2023202220232022
(In thousands)IncurredIncurred
Incurred
IncurredSeptember 30,
2023
December 31, 2022
Non-recurring fees and reimbursements:
Acquisition cost reimbursements$10 $— $31 $18 $10 $
Ongoing fees and reimbursements:
Asset management fees 5,458 5,458 16,374 16,374 — — 
Property management and fees (2)
1,155 1,101 3,132 3,058 161 
Professional fees and other reimbursements (1)
2,824 2,398 7,584 6,748 

494 39 
Total related party operation fees and reimbursements$9,447 $8,957 $27,121 $26,198 $665 $47 
___________
(1)Included in general and administrative expenses in the consolidated statements of operations. Includes $2.0 million and $5.2 million, respectively, for the three and nine months ended September 30, 2023, and $1.7 million and $4.6 million, respectively, for the three and nine months ended September 30, 2022, subject to the Capped Reimbursement.
(2)The three and nine months ended September 30, 2023 includes $0.2 million and $0.4 million of leasing commissions, respectively, which are capitalized and included in prepaid expenses and other assets as of September 30, 2023.
Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets
Fees Incurred in Connection with a Listing
If the common stock of the Company is listed on a national securities exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the nine months ended September 30, 2023 or 2022. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.
Subordinated Participation in Net Sales Proceeds
Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the nine months ended September 30, 2023 or 2022. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.
Termination Fees
Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.
Under the Advisory Agreement Amendment, upon the termination or non-renewal of the agreement, the Advisor will be entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination or non-renewal of the Advisory Agreement Amendment.
Upon a termination by either party in connection with a change of control (as defined in the Advisory Agreement Amendment), the Company would be required to pay the Advisor a change of control fee equal to the product of four and the “Subject Fees” described below.
Upon a termination by the Company in connection with a transition to self-management, the Company would be required to pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.
The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Economic Dependency
9 Months Ended
Sep. 30, 2023
Economic Dependency [Abstract]  
Economic Dependency Economic Dependency
Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.
As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Equity-Based Compensation
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Equity-Based Compensation Equity-Based Compensation
Restricted Share Plan
The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.6 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).
Restricted shares vest on a straight-line basis over periods of three to five years and may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.
The following table reflects the amount of restricted shares outstanding as of September 30, 2023 and activity for the period presented:
Number of Shares of Common StockWeighted Average Issue Price
Unvested, December 31, 202297,343 $18.89 
Stock dividend4,399 14.32 
Vested(50,871)20.40 
Unvested, September 30, 202350,871 $16.98 
As of September 30, 2023, the Company had $0.8 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. This cost will be recognized over a weighted-average period of 0.9 years. Compensation expense related to restricted shares was $0.2 million and $0.7 million, respectively, for the three and nine months ended September 30, 2023, and $0.3 million and $1.0 million, respectively, for the three and nine months ended September 30, 2022.
Other Share-Based Compensation
The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the nine months ended September 30, 2023 or 2022.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income
    The following table illustrates the changes in accumulated other comprehensive income as of and for the period presented:
(In thousands)Unrealized Gain (loss) on Designated Derivative
Balance, December 31, 2022$36,910 
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives12,078 
Amount of gain reclassified from accumulated other comprehensive income(13,648)
Rebalancing of ownership percentage — 
Balance, September 30, 2023$35,340 
Accumulated other comprehensive income predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in Note 7 — Derivatives and Hedging Activities, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests
9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Non-controlling Interests Non-controlling Interests
Non-controlling interests on the Company’s consolidated balance sheets is comprised of the following:
Balance as of
(In thousands)September 30, 2023December 31, 2022
Series A Preferred Units held by third parties$2,578 $2,578 
Common OP Units held by third parties3,316 3,584 
 Total Non-controlling Interests in the OP5,894 6,162 
Non-controlling Interests in property owning subsidiaries689 389 
Total Non-controlling interests$6,583 $6,551 
Non-Controlling Interests in the OP
For preferred and common shares issued by the Company, the Company typically issues mirror securities with substantially equivalent economic rights between the Company and the OP. The securities held by the Company are eliminated in consolidation.
Series A Preferred Units
The Company is the sole general partner and holds substantially all of the Series A Preferred Units (except as discussed below). All common and preferred units in the OP held by the Company are eliminated in consolidation.
In September 2021, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 100,000 Series A Preferred Units to the unaffiliated third party, with a face value of $25.00 per unit, which were recorded at issuance at a then fair value of $2.6 million, or $25.78 per unit, to the unaffiliated third party.
A holder of Series A Preferred Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s Series A Preferred Stock, which earn dividends at a rate equal to 7.375% of its face value. After holding the Series A Preferred Units for a period of one year, a holder of Series A Preferred Units has the right to redeem Series A Preferred Units for, at the option of the OP, the corresponding number of shares of the Company’s Series A Preferred Stock, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During both the three months ended September 30, 2023 and 2022, Series A Preferred Unit holders were paid $0.1 million.
Common OP Units
The Company is the sole general partner and holds substantially all of the Common OP Units. As of September 30, 2023 and December 31, 2022, the Advisor held 90 Common OP Units, which represents a nominal percentage of the aggregate ownership in the OP.
In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 Common OP Units, with a value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.
A holder of Common OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the stock dividends, other stock dividends and other similar events. After holding the Common OP Units for a period of one year, a holder of Common OP Units has the right to redeem Common OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock, as retroactively adjusted for the stock dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the nine months ended September 30, 2023 and 2022, Common OP Unit non-controlling interest holders were not paid any cash distributions.
Stock dividends do not cause the OP to issue additional Common OP Units, rather, the redemption ratio to common stock is adjusted. The 405,998 Common OP Units outstanding as of September 30, 2023 would be redeemable for 489,233 shares of common stock, giving effect to adjustments for the impact of the stock dividends through October 2023.
Non-Controlling Interests in Property Owning Subsidiaries
The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.
The following table summarizes the activity related to investment arrangements with the unaffiliated third parties:
Distributions
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementThree Months Ended September 30,
Property Name
(Dollar amounts in thousands)
Investment DateSeptember 30, 2023September 30, 2023September 30, 2023As of December 31, 202220232022
Plaza Del Rio Medical Office Campus Portfolio (1)
May 2015
$689 4.4 %$12,426 $12,455 — — 
_______
(1)One property within the Plaza Del Rio Medical Office Campus Portfolio was pledged to secure the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable, net for additional information. In the nine months ended September 30, 2023, the unaffiliated third party contributed $0.3 million to increase its ownership from 2.6% to 4.4%.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The following is a summary of the basic and diluted net loss per share computation for the periods presented and has been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss attributable to common stockholders (in thousands)
$(19,561)$(23,303)$(57,829)$(71,159)
Basic and diluted weighted-average shares outstanding (1)
111,426,241 111,365,461 111,404,655 111,333,801 
Basic and diluted net loss per share (1)
$(0.18)$(0.21)$(0.52)$(0.64)
(1)Retroactively adjusted for the effects of the stock dividends (see Note 1 — Organization and Note 8 — Stockholders’ Equity for additional information).
Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, Common OP Units and Class B Units to be common share equivalents. Series A Preferred Units are non-participating. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Unvested restricted shares (1)
70,730 131,279 92,316 162,938 
Common OP Units (2)
489,233 489,233 489,233 489,233 
Class B Units (3)
432,901 432,901 432,901 432,901 
Total weighted average antidilutive common stock equivalents
992,864 1,053,413 1,014,450 1,085,072 
________
(1)Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 50,871 and 95,983 unvested restricted shares outstanding, respectively, as of September 30, 2023 and 2022.
(2)Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see Note 1 — Organization for additional details). There were 405,998 Common OP Units outstanding as of September 30, 2023 and 2022. The securities held by the Company are eliminated in consolidation.
(3)Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see Note 1 — Organization for additional details). There were 359,250 Class B Units outstanding as of September 30, 2023 and 2022. These Class B Units were unvested as of September 30, 2023 and 2022 (see Note 9 — Related Party Transactions for additional information).
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting
9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The disclosures below for the three and nine months ended September 30, 2023 and 2022 are presented for the Company’s two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs.
The Company evaluates performance and makes resource allocations based on its two business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses as well as seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.
Net Operating Income
The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net loss. The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net loss.
NOI excludes certain components from net loss in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net loss as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net loss as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.
The following tables reconcile the segment activity to consolidated net loss for the periods presented:
Three Months Ended September 30,Three Months Ended September 30,
20232022
(In thousands)Medical Office BuildingsSeniors Housing — Operating Properties ConsolidatedMedical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants
$33,657 $52,029 $85,686 $33,185 $50,275 $83,460 
Property operating and maintenance
9,379 44,947 54,326 9,377 41,821 51,198 
NOI
$24,278 $7,082 31,360 $23,808 $8,454 32,262 
Impairment charges
— (8,949)
Operating fees to related parties
(6,397)(6,333)
Acquisition and transaction related
(173)(199)
General and administrative
(4,753)(4,471)
Depreciation and amortization
(20,776)(20,854)
Interest expense
(15,720)(13,284)
Interest and other income
258 10 
(Loss) gain on sale of real estate investments(173)194 
Gain on non-designated derivatives406 1,826 
Income tax expense(157)(77)
Net loss attributable to non-controlling interests14 22 
Allocation for preferred stock (3,450)(3,450)
Net loss attributable to common stockholders$(19,561)$(23,303)


Nine Months Ended September 30,Nine Months Ended September 30,
20232022
(In thousands)Medical Office BuildingsSeniors Housing — Operating Properties ConsolidatedMedical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants
$101,187 $157,958 $259,145 $98,026 $152,910 $250,936 
Property operating and maintenance
27,772 134,006 161,778 26,417 130,463 156,880 
NOI
$73,415 $23,952 97,367 $71,609 $22,447 94,056 
Impairment charges
— (25,786)
Operating fees to related parties
(19,153)(19,003)
Acquisition and transaction related
(384)(1,153)
General and administrative
(14,105)(13,369)
Depreciation and amortization
(61,520)(61,525)
Interest expense
(50,208)(37,098)
Interest and other income
576 24 
Loss on sale of real estate investments(364)(109)
Gain on non-designated derivatives510 3,212 
Income tax expense(244)(159)
Net loss attributable to non-controlling interests45 100 
Allocation for preferred stock (10,349)(10,349)
Net loss attributable to common stockholders$(57,829)$(71,159)
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
(In thousands)September 30, 2023December 31, 2022
ASSETS
Investments in real estate, net:
MOB Segment$1,126,677 $1,121,857 
SHOP Segment831,475 856,440 
Total investments in real estate, net
1,958,152 1,978,297 
Cash and cash equivalents51,041 53,654 
Restricted cash40,245 22,884 
Derivative assets, at fair value37,547 40,647 
Straight-line rent receivable, net26,214 25,276 
Operating lease right-of-use assets7,739 7,814 
Prepaid expenses and other assets36,019 34,554 
Deferred costs, net15,300 17,223 
Total assets$2,172,257 $2,180,349 
The following table reconciles capital expenditures by reportable business segment, excluding corporate non-real estate expenditures, for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
MOB Segment$1,686 $2,309 $4,650 $5,981 
SHOP Segment3,172 5,323 9,348 10,726 
Total capital expenditures$4,858 $7,632 $13,998 $16,707 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Commitments and Contingencies Commitments and Contingencies
As of September 30, 2023, the Company had seven operating and six direct financing lease agreements. The seven operating leases have durations, including assumed renewals, ranging from 19.1 years to 84.0 years, excluding an adjacent parking lot lease with a term of 1.0 year. The Company did not enter into any additional ground leases during the nine months ended September 30, 2023.
As of September 30, 2023, the Company’s balance sheet included ROU assets and liabilities of $7.7 million and $8.1 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the lease guidance issued in 2019, as well as for new operating leases in the current period, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Because the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment.
The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 33.6 years and a weighted-average discount rate of 7.37% as of September 30, 2023. For each of the three months ended September 30, 2023 and 2022, the Company paid cash of $0.2 million for amounts included in the measurement of lease liabilities and recorded expense of $0.2 million on a straight-line basis in accordance with the current accounting guidance. For the nine months ended September 30, 2023, the Company paid cash of $0.6 million for amounts included in the measurement of lease liabilities and recorded expense of $0.6 million. For the nine months ended September 30, 2022, the Company paid cash of $0.7 million for amounts included in the measurement of lease liabilities and recorded expense of $0.7 million. The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss.
The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023 (remainder)$162 $22 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,943 7,215 
Total minimum lease payments24,541 7,612 
Less: amounts representing interest(16,490)(2,778)
Total present value of minimum lease payments$8,051 $4,834 
_______
(1)The direct finance lease liability is included in accounts payable and accrued expenses on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Litigation and Regulatory Matters
In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.
Environmental Matters
In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of September 30, 2023, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except for the following:
Dividend Declaration
On October 2, 2023, the Company announced the declaration of a stock dividend of 0.015179 shares of the Company’s common stock, on each share of the Company’s outstanding common stock. The stock dividend was issued on October 16, 2023 to holders of record of the Company’s common stock at the close of business on October 12, 2023.
Other Subsequent Events
Subsequent to September 30, 2023, the Company renewed two interest rate caps, which matured on November 1, 2023, with an aggregate notional amount of $150.9 million and a strike price of 3.50% for $5.0 million. Additionally, the Company provided a $6.7 million cash deposit to Fannie Mae. This deposit was provided because the debt service coverage ratio of the underlying properties of each facility were below the minimum required amount per the debt agreements. This deposit will be refunded at the earlier of the Company’s achievement of a debt service coverage ratio above the minimum required amount of 1.40 or the maturity of the Fannie Mae Master Credit Facilities.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying unaudited consolidated financial statements of the Company included herein were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to this Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished includes all adjustments and accruals of a normal recurring nature, which, in the opinion of management, are necessary for a fair statement of results for the interim periods. The results of operations for the nine months ended September 30, 2023 and 2022 are not necessarily indicative of the results for the entire year or any subsequent interim periods.
These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2023. Except for those required by new accounting pronouncements discussed below, there have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2023.
Continuing Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic commenced. The pandemic and its aftermath has had, and could continue to have, adverse impacts on economic and market conditions. The Company’s tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted, and may continue to impact, the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants which may further impact the ability of the Company’s tenants to pay their rent obligations to the Company when due.
The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy as could the rates charged to residents at its SHOPs. Moreover, the demand for leasing space at the Company’s MOB properties could decline, negatively impacting occupancy percentage, revenue and earnings. Additionally, downturns or stagnation in the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs.
Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates have had, and may continue to have, adverse impacts on the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing wars in Ukraine, Israel and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants to pay rent and hence the Company’s results of operations and liquidity.
Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:
COVID-19 Impact — MOB Segment
The financial stability and overall health of the Company’s tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its tenants in this segment, and all amounts previously deferred under prior rent deferral agreements have been collected.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases were modified, the Financial Accounting Standards Board (“FASB”) and SEC provided relief that allowed companies to elect whether they treated COVID-19 related lease amendments as provisions included in the pre-concession arrangements, and therefore, not lease modifications, or to treat lease amendments as modifications. In order to be considered COVID-19 related, cash flows had to be substantially the same or less than those prior to the concessions. For COVID-19 relief qualified changes, there were two methods to potentially account for such rent deferrals or abatements under the relief: (i) as if the changes were originally contemplated in the lease contract or (ii) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company was required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualified for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there was no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact was recognized ratably over the remaining life of the leases. For leases not qualifying for this relief, the Company applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
COVID-19 Impact — SHOP Segment
In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and then stabilized until June 2022. Since then, SHOP occupancy has trended downward. The Company also experienced lower inquiry volumes and reduced in-person tours during the COVID-19 pandemic compared to pre-pandemic periods. In addition, beginning in March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See “CARES Act Grants” below for additional information on the CARES Act.
During the year ended December 31, 2022, the Company relied more on the use of temporary contract labor and agencies than it had historically. The Company has since reduced its reliance on this labor source in the nine months ended September 30, 2023. However, the wage expenses (including overtime, training and bonus wages) incurred by the Company from employees of its third party operators has increased due to, among other things, inflation raising the cost of labor generally, a lack of qualified personnel that the Company’s third party operators are able to employ on a permanent basis and training hours and other onboarding costs for permanent staff which replaced previously utilized contract and agency labor.
The persistence of high inflation, labor shortages and supply chain disruptions have caused adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have a material adverse effect on its operations in future periods.
The adverse financial impacts of the COVID-19 pandemic on the Company were partially offset by funds received by the Company under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million under the CARES Act during the years ended December 31, 2022, 2021, and 2020, respectively. The Company did not receive any such funds during the three and nine months ended September 30, 2023 and it received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the Company treated these funds as grant contributions from the government. The full amounts received were recognized as reductions of property operating and maintenance expenses in the Company’s consolidated statements of operations and comprehensive loss
for the periods in which the funds were received, to partially offset the incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Principles of Consolidation and Basis of Presentation
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Revenue Recognition
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of September 30, 2023, these leases had a weighted average remaining lease term of 4.8 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with any increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.
The Company continually reviews receivables related to rent and unbilled rent and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive loss in the period the related costs are incurred, as applicable.
Investments in Real Estate
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the three months ended September 30, 2023 and 2022. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of September 30, 2023 or December 31, 2022.
Purchase Price Allocation
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the nine months ended September 30, 2023 were asset acquisitions. The Company acquired seven properties during the nine months ended September 30, 2023.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationships, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the nine months ended September 30, 2023 or 2022.
Accounting for Leases, Lessor Accounting
Accounting for Leases
Lessor Accounting
In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of September 30, 2023 and December 31, 2022, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (i) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.
Accounting for Leases, Lessee Accounting
Lessee Accounting
The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheets as of September 30, 2023 and December 31, 2022, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023 and 2022.
For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a
right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see Note 16Commitments and Contingencies.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statements of operations and comprehensive income to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held for use. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
Reportable Segments
The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see Note 15 — Segment Reporting.
Depreciation and Amortization
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress is not depreciated until the project has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Income Taxes
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of September 30, 2023, the Company owned 46 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of September 30, 2023 and December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the COVID-19 pandemic. During the three months ended September 30, 2023, the Company modified 26 intercompany leases with the TRS which reduced intercompany rent.
Because of the TRS's recent operating history of losses and the impact of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $7.6 million as of September 30, 2023. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive loss. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance.
CARES Act Grants
CARES Act Grants
On March 27, 2020, the CARES Act was signed into law and provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designed to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company did not receive any funding from the CARES Act during the three and nine months ended September 30, 2023 and the Company received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. Any funding that the Company would receive is recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2022:
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.
Not yet Fully Adopted as of September 30, 2023:
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform
activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Future Base Rent Payments
The following table presents future base rent payments on a cash basis due to the Company over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short term in nature.
As of September 30, 2023:
(In thousands)Future 
Base Rent Payments
2023 (remainder)$27,566 
2024108,291 
202598,378 
202690,299 
202771,439 
Thereafter240,452 
Total$636,425 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net (Tables)
9 Months Ended
Sep. 30, 2023
Real Estate Investments, Net [Abstract]  
Schedule of Business Acquisition
The following table presents the allocation of real estate assets acquired and liabilities assumed during the nine months ended September 30, 2023 and 2022:
Nine Months Ended September 30,
(In thousands)20232022
Real estate investments, at cost:
Land$3,373 $4,199 
Buildings, fixtures and improvements27,069 10,662 
Total tangible assets30,442 14,861 
Acquired intangibles:
In-place leases and other intangible assets5,057 2,670 
Market lease and other intangible assets33 268 
Market lease liabilities(271)— 
Total intangible assets and liabilities4,819 2,938 
Cash paid for real estate investments, including acquisitions$35,261 $17,799 
Number of properties purchased
Schedule of Revenue The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of September 30, 2023 and 2022:
September 30,
State20232022
Florida19.8%19.0%
Pennsylvania10.6%*
_________
* The annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the date specified.
Schedule of Finite-Lived Intangible Assets
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above- and below-market lease assets and liabilities, net and the amortization and accretion of above- and below-market ground leases, net, for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Amortization of in-place leases and other intangible assets (1)
$3,455 $3,815 $10,414 $11,502 
Accretion of above -and below-market leases, net (2)
$(244)$(219)$(795)$(549)
Amortization of above -and below-market ground leases, net (3)
$40 $40 $120 $120 
________
(1)Reflected within depreciation and amortization expense.
(2)Reflected within rental income.
(3)Reflected within property operating and maintenance expense
Schedule of Projected Amortization Expense
The following table provides the projected amortization expense and adjustments to revenues for the next five years:
(In thousands)2023 (remainder)2024202520262027
In-place lease assets$3,157 $11,812 $10,224 $8,979 $5,468 
Other intangible assets10 10 10 10 10 
Total to be added to amortization expense$3,167 $11,822 $10,234 $8,989 $5,478 
Above-market lease assets$(101)$(419)$(366)$(331)$(243)
Below-market lease liabilities309 1,297 1,127 972 654 
Total to be added to revenue from tenants
$208 $878 $761 $641 $411 
Schedule of Impairments Recorded The following table presents impairment charges by segment recorded during the nine months ended September 30, 2022:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20222022
MOB Segment:
Illinois skilled nursing facilities (1)
$— $10,644 
Total MOB impairment charges— 10,644 
SHOP Segment:
Various held for use SHOPs (2)
8,949 15,142 
Total SHOP impairment charges8,949 15,142 
Total impairment charges$8,949 $25,786 
(1)These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of September 30, 2023, these properties were not disposed of, nor were any under contract for disposal.
(2)Consists of eight total properties that were impaired as a result of the Company reassessing the holding period for the properties. Two of these properties were sold in the nine months ended September 30, 2023.
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Mortgage Notes Payable, Net (Tables)
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
The following table reflects the Company’s mortgage notes payable as of September 30, 2023 and December 31, 2022:
Outstanding Loan Amount as of
Effective Interest Rate (1) as of
PortfolioEncumbered PropertiesSeptember 30,
2023
December 31, 2022September 30,
2023
December 31, 2022Interest RateMaturity
(In thousands)(In thousands)
Fox Ridge Bryant - Bryant, AR1$6,689 $6,817 3.98 %3.98 %FixedMay 2047
Fox Ridge Chenal - Little Rock, AR115,344 15,639 2.95 %2.95 %FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR19,520 9,704 2.95 %2.95 %FixedMay 2049
Capital One MOB Loan (2)
41378,500 378,500 3.71 %3.73 %Fixed(2)Dec. 2026
Multi-Property CMBS Loan20116,037 118,700 4.60 %4.60 %FixedMay 2028
Shiloh - Illinois
112,828 13,071 4.34 %4.34 %FixedJan. 2025
BMO CMBS Loan942,750 42,750 2.89 %2.89 %FixedDec. 2031
Barclays MOB Loan62240,000 — 6.45 %— %FixedJune 2033
Gross mortgage notes payable136821,668 585,181 4.58 %3.83 %
Deferred financing costs, net of accumulated amortization (3)
(11,620)(5,117)
Mortgage premiums and discounts, net(1,296)(1,364)
Mortgage notes payable, net$808,752 $578,700 
_____________
(1)Calculated on a weighted average basis for all mortgages outstanding as of September 30, 2023 and December 31, 2022. For the SOFR (defined in Note 5 — Credit Facilities)/LIBOR based loans, the Company used the applicable SOFR/LIBOR rate index in effect at the balance sheet date. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(2)Variable rate loan, based on daily SOFR as of September 30, 2023 and December 31, 2022, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of September 30, 2023 and December 31, 2022.
(3)Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close or result in a definitive agreement.
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facilities (Tables)
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Credit Facilities The Company had the following credit facilities outstanding as of September 30, 2023 and December 31, 2022:
Outstanding Facility
Amount as of
Effective Interest Rate (8)
Credit Facilities
Encumbered Properties (1)
September 30,
2023
December 31, 2022September 30,
2023
December 31, 2022Interest RateMaturity
(In thousands)(In thousands)
Prior Credit Facility:
   Revolving Credit Facility$— $30,000 — %7.26 %VariableMar. 2024(7)
   Term Loan
— 150,000 — %5.11 %Fixed(5)Mar. 2024
   Deferred financing costs— (1,750)
   Term Loan, net
— 148,250 
Total Prior Credit Facility$— $178,250 
Fannie Mae Master Credit Facilities:
Capital One Facility
11(2)$207,829 $210,483 7.84 %5.90 %Variable(6)Nov. 2026
KeyBank Facility
10(3)139,891 141,564 7.89 %6.60 %Variable(6)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$347,720 $352,047 
Total Credit Facilities21$347,720 $530,297 7.86 %(4)5.94 %(4)
________
(1)Encumbered properties are as of September 30, 2023.
(2)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $350.5 million.
(3)Secured by first-priority mortgages on ten of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $261.9 million.
(4)Calculated on a weighted average basis for all credit facilities outstanding as of September 30, 2023 and December 31, 2022, respectively.
(5)Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see Note 7 — Derivatives and Hedging Activities for additional details).
(6)The effective rates above only include the impact of designated hedging instruments. The Company has seven non-designated interest rate cap agreements with an aggregate notional amount of $351.6 million which limited 30-day LIBOR (until June 30, 2023, and SOFR thereafter) to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (see Note 7 — Derivatives and Hedging Activities for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility and KeyBank Fannie Mae Facility was 5.89% and 5.93%, respectively, as of September 30, 2023, and 5.26%, and 5.96%, respectively, as of December 31, 2022.
(7)During the year ended December 31 2022, the Company exercised its option to extend the maturity one year to March 2024 subject to certain conditions.
(8)Effective interest rate below for variable rate debt gives effect to any outstanding “pay-fixed” swaps entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of September 30, 2023 and December 31, 2022. The Company allocated $150.0 million of its SOFR-based interest rate swaps to the Term Loan $50.0 million of its LIBOR-based interest rate swaps to the Capital One Facility as of December 31, 2022. The interest rate swaps allocated to the Prior Credit Facility were all terminated in the nine months ended September 30, 2023. Upon termination, the fair values of terminated swaps are recorded within AOCI, and are amortized into interest expense over the original term of the then-existing swap. These amortized amounts from terminated swaps are not included in the calculation of effective interest. The Company continues to have $378.5 million of SOFR-based “pay-fixed” interest rate swaps allocated to a variable-rate mortgage note payable as of September 30, 2023. See Note 7 — Derivatives and Hedging Activities for additional details.
Schedule of Maturities of Long-term Debt
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to September 30, 2023 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2023 (remainder)$289 $1,442 $1,731 
20241,178 5,769 6,947 
202513,270 5,769 19,039 
2026379,393 334,740 714,133 
2027922 — 922 
Thereafter426,616 — 426,616 
Total$821,668 $347,720 $1,169,388 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Summary of Recurring Fair Value Measurements
The following table presents information about the Company’s assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
September 30, 2023
Derivative assets, at fair value (non-designated)$— $4,946 $— $4,946 
Derivative assets, at fair value (designated)— 32,601 — 32,601 
Total $— $37,547 $— $37,547 
December 31, 2022
Derivative assets, at fair value (non-designated)$— $3,737 $— $3,737 
Derivative assets, at fair value (designated)— 36,910 — 36,910 
Total $— $40,647 $— $40,647 
Summary of Fair Value by Balance Sheet
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
September 30, 2023December 31, 2022
(In thousands)LevelCarrying Amount Fair Value Carrying AmountFair Value 
Gross mortgage notes payable and mortgage premium and discounts, net
3$820,372 $766,584 $583,817 $550,626 
Prior Credit Facility3$— $— $180,000 $179,496 
Fannie Mae Master Credit Facilities
3$347,720 $348,120 $352,047 $353,034 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities (Tables)
9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Balance Sheet Location
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of September 30, 2023 and December 31, 2022:
(In thousands)Balance Sheet LocationSeptember 30,
2023
December 31, 2022
Derivatives designated as hedging instruments:
    Interest rate “pay-fixed” swapsDerivative assets, at fair value$32,601 $36,910 
Derivatives not designated as hedging instruments:
    Interest rate capsDerivative assets, at fair value$4,946 $3,737 
Summary of Derivative Instruments
As of September 30, 2023 and December 31, 2022, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
September 30, 2023December 31, 2022
Interest Rate DerivativesNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
SOFR-based interest rate “pay-fixed” swaps$378,500 $528,500 
LIBOR-based interest rate “pay-fixed” swaps— — 50,000 
Total interest rate “pay-fixed” swaps$378,500 $578,500 
The Company had the following outstanding interest rate derivatives with current effective notional amounts that were not designated as hedges in qualified hedging relationships as of September 30, 2023 and December 31, 2022:
September 30, 2023December 31, 2022
Interest Rate DerivativesNumber of Instruments
Notional Amount (1)
Number of Instruments
Notional Amount (1)
(In thousands)(In thousands)
Interest rate caps (2)
$351,572 $354,624 
(1)Notional amount represents the currently active interest rate cap contracts.
(2)All of the Company’s interest rate cap agreements limited 30-day LIBOR through June 30, 2023 (and SOFR, thereafter) to 3.50% with terms through July 2025. The actual 30-day LIBOR rates during the six months ended June 30, 2023, and the SOFR rates during the three months ended September 30, 2023, exceeded the strike price rate of 3.50% and the Company received payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.
Schedule of Derivatives Included in AOCI
The table below details the location in the financial statements of the gain (loss) recognized on interest rate derivatives designated as cash flow hedges for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives$5,418 $17,513 $12,078 $49,522 
Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense$5,023 $565 $13,648 $(3,862)
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$(15,720)$(13,284)$(50,208)$(37,098)
Schedule of Offsetting Assets The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives (both designated and non-designated) as of September 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
September 30, 2023$37,547 $— $— $37,547 $— $— $37,547 
December 31, 2022$40,647 $— $— $40,647 $— $— $40,647 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Cumulative Share Repurchases
The table below reflects the number of shares repurchased and the average price per share, under the SRP and does not include any repurchases under tender offers, cumulatively through September 30, 2023.
Number of Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 20224,896,620 $20.60 
Nine months ended September 30, 2023— — 
Cumulative repurchases as of September 30, 20234,896,620 20.60 
Schedule of Stock Dividends
Stock Dividend Declaration DateStock Dividend Issue DateQuarterly Stock Dividend Rate (per share)
October 1, 2020October 15, 20200.013492
January 4, 2021January 15, 20210.013492
April 2, 2021April 15, 20210.014655
July 1, 2021July 15, 20210.014655
October 1, 2021October 15, 20210.014655
January 3, 2022January 15, 20220.014655
April 1, 2022April 18, 20220.014167
July 1, 2022July 15, 20220.014167
October 3, 2022October 17, 20220.014167
January 3, 2023January 18, 20230.014167
April 3, 2023April 17, 20230.015179
July 3, 2023July 17, 20230.015179
October 2, 2023October 16, 20230.015179
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Arrangements (Tables)
9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services
The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,Payable (Prepayments) as of
 2023202220232022
(In thousands)IncurredIncurred
Incurred
IncurredSeptember 30,
2023
December 31, 2022
Non-recurring fees and reimbursements:
Acquisition cost reimbursements$10 $— $31 $18 $10 $
Ongoing fees and reimbursements:
Asset management fees 5,458 5,458 16,374 16,374 — — 
Property management and fees (2)
1,155 1,101 3,132 3,058 161 
Professional fees and other reimbursements (1)
2,824 2,398 7,584 6,748 

494 39 
Total related party operation fees and reimbursements$9,447 $8,957 $27,121 $26,198 $665 $47 
___________
(1)Included in general and administrative expenses in the consolidated statements of operations. Includes $2.0 million and $5.2 million, respectively, for the three and nine months ended September 30, 2023, and $1.7 million and $4.6 million, respectively, for the three and nine months ended September 30, 2022, subject to the Capped Reimbursement.
(2)The three and nine months ended September 30, 2023 includes $0.2 million and $0.4 million of leasing commissions, respectively, which are capitalized and included in prepaid expenses and other assets as of September 30, 2023.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Equity-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Share Award Activity
The following table reflects the amount of restricted shares outstanding as of September 30, 2023 and activity for the period presented:
Number of Shares of Common StockWeighted Average Issue Price
Unvested, December 31, 202297,343 $18.89 
Stock dividend4,399 14.32 
Vested(50,871)20.40 
Unvested, September 30, 202350,871 $16.98 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income The following table illustrates the changes in accumulated other comprehensive income as of and for the period presented:
(In thousands)Unrealized Gain (loss) on Designated Derivative
Balance, December 31, 2022$36,910 
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives12,078 
Amount of gain reclassified from accumulated other comprehensive income(13,648)
Rebalancing of ownership percentage — 
Balance, September 30, 2023$35,340 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests (Tables)
9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Schedule of Noncontrolling Interest on Balance Sheet
Non-controlling interests on the Company’s consolidated balance sheets is comprised of the following:
Balance as of
(In thousands)September 30, 2023December 31, 2022
Series A Preferred Units held by third parties$2,578 $2,578 
Common OP Units held by third parties3,316 3,584 
 Total Non-controlling Interests in the OP5,894 6,162 
Non-controlling Interests in property owning subsidiaries689 389 
Total Non-controlling interests$6,583 $6,551 
Summary of Non-controlling Interest
The following table summarizes the activity related to investment arrangements with the unaffiliated third parties:
Distributions
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementThree Months Ended September 30,
Property Name
(Dollar amounts in thousands)
Investment DateSeptember 30, 2023September 30, 2023September 30, 2023As of December 31, 202220232022
Plaza Del Rio Medical Office Campus Portfolio (1)
May 2015
$689 4.4 %$12,426 $12,455 — — 
_______
(1)One property within the Plaza Del Rio Medical Office Campus Portfolio was pledged to secure the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable, net for additional information. In the nine months ended September 30, 2023, the unaffiliated third party contributed $0.3 million to increase its ownership from 2.6% to 4.4%.
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Loss Per Share Computation
The following is a summary of the basic and diluted net loss per share computation for the periods presented and has been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss attributable to common stockholders (in thousands)
$(19,561)$(23,303)$(57,829)$(71,159)
Basic and diluted weighted-average shares outstanding (1)
111,426,241 111,365,461 111,404,655 111,333,801 
Basic and diluted net loss per share (1)
$(0.18)$(0.21)$(0.52)$(0.64)
(1)Retroactively adjusted for the effects of the stock dividends (see Note 1 — Organization and Note 8 — Stockholders’ Equity for additional information).
Summary of Antidilutive Securities Excluded from Computation of Loss Per Share The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see Note 1 — Organization for additional details):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Unvested restricted shares (1)
70,730 131,279 92,316 162,938 
Common OP Units (2)
489,233 489,233 489,233 489,233 
Class B Units (3)
432,901 432,901 432,901 432,901 
Total weighted average antidilutive common stock equivalents
992,864 1,053,413 1,014,450 1,085,072 
________
(1)Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 50,871 and 95,983 unvested restricted shares outstanding, respectively, as of September 30, 2023 and 2022.
(2)Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see Note 1 — Organization for additional details). There were 405,998 Common OP Units outstanding as of September 30, 2023 and 2022. The securities held by the Company are eliminated in consolidation.
(3)Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see Note 1 — Organization for additional details). There were 359,250 Class B Units outstanding as of September 30, 2023 and 2022. These Class B Units were unvested as of September 30, 2023 and 2022 (see Note 9 — Related Party Transactions for additional information).
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables reconcile the segment activity to consolidated net loss for the periods presented:
Three Months Ended September 30,Three Months Ended September 30,
20232022
(In thousands)Medical Office BuildingsSeniors Housing — Operating Properties ConsolidatedMedical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants
$33,657 $52,029 $85,686 $33,185 $50,275 $83,460 
Property operating and maintenance
9,379 44,947 54,326 9,377 41,821 51,198 
NOI
$24,278 $7,082 31,360 $23,808 $8,454 32,262 
Impairment charges
— (8,949)
Operating fees to related parties
(6,397)(6,333)
Acquisition and transaction related
(173)(199)
General and administrative
(4,753)(4,471)
Depreciation and amortization
(20,776)(20,854)
Interest expense
(15,720)(13,284)
Interest and other income
258 10 
(Loss) gain on sale of real estate investments(173)194 
Gain on non-designated derivatives406 1,826 
Income tax expense(157)(77)
Net loss attributable to non-controlling interests14 22 
Allocation for preferred stock (3,450)(3,450)
Net loss attributable to common stockholders$(19,561)$(23,303)


Nine Months Ended September 30,Nine Months Ended September 30,
20232022
(In thousands)Medical Office BuildingsSeniors Housing — Operating Properties ConsolidatedMedical Office BuildingsSeniors Housing — Operating PropertiesConsolidated
Revenue from tenants
$101,187 $157,958 $259,145 $98,026 $152,910 $250,936 
Property operating and maintenance
27,772 134,006 161,778 26,417 130,463 156,880 
NOI
$73,415 $23,952 97,367 $71,609 $22,447 94,056 
Impairment charges
— (25,786)
Operating fees to related parties
(19,153)(19,003)
Acquisition and transaction related
(384)(1,153)
General and administrative
(14,105)(13,369)
Depreciation and amortization
(61,520)(61,525)
Interest expense
(50,208)(37,098)
Interest and other income
576 24 
Loss on sale of real estate investments(364)(109)
Gain on non-designated derivatives510 3,212 
Income tax expense(244)(159)
Net loss attributable to non-controlling interests45 100 
Allocation for preferred stock (10,349)(10,349)
Net loss attributable to common stockholders$(57,829)$(71,159)
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
(In thousands)September 30, 2023December 31, 2022
ASSETS
Investments in real estate, net:
MOB Segment$1,126,677 $1,121,857 
SHOP Segment831,475 856,440 
Total investments in real estate, net
1,958,152 1,978,297 
Cash and cash equivalents51,041 53,654 
Restricted cash40,245 22,884 
Derivative assets, at fair value37,547 40,647 
Straight-line rent receivable, net26,214 25,276 
Operating lease right-of-use assets7,739 7,814 
Prepaid expenses and other assets36,019 34,554 
Deferred costs, net15,300 17,223 
Total assets$2,172,257 $2,180,349 
The following table reconciles capital expenditures by reportable business segment, excluding corporate non-real estate expenditures, for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
MOB Segment$1,686 $2,309 $4,650 $5,981 
SHOP Segment3,172 5,323 9,348 10,726 
Total capital expenditures$4,858 $7,632 $13,998 $16,707 
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Summary of Operating Lease Maturities The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023 (remainder)$162 $22 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,943 7,215 
Total minimum lease payments24,541 7,612 
Less: amounts representing interest(16,490)(2,778)
Total present value of minimum lease payments$8,051 $4,834 
_______
(1)The direct finance lease liability is included in accounts payable and accrued expenses on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Summary of Finance Lease Maturities The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2023 (remainder)$162 $22 
2024632 90 
2025588 93 
2026599 95 
2027617 97 
Thereafter21,943 7,215 
Total minimum lease payments24,541 7,612 
Less: amounts representing interest(16,490)(2,778)
Total present value of minimum lease payments$8,051 $4,834 
_______
(1)The direct finance lease liability is included in accounts payable and accrued expenses on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Organization (Details)
ft² in Millions, $ in Millions
3 Months Ended 9 Months Ended 12 Months Ended 36 Months Ended
Sep. 30, 2023
USD ($)
property
segment
Sep. 30, 2022
segment
Sep. 30, 2023
USD ($)
property
segment
contractor
shares
Sep. 30, 2022
segment
Dec. 31, 2022
shares
Sep. 30, 2023
property
shares
Sep. 30, 2023
state
Sep. 30, 2023
ft²
Sep. 30, 2023
contractor
Sep. 30, 2023
encumberedProperty
Organization, Consolidation and Presentation of Financial Statements [Abstract]                    
Number of properties owned 204   204     204       21
Number of states properties are located in | state             33      
Rentable square feet | ft²               9.0    
Number of senior housing communities | property 46   46     46        
Number of reportable segments | segment 2 2 2 2            
Number of independent contractors | contractor     4              
Number of contractors terminated | contractor                 1  
Number of senior housing communities managed by terminated contractor | property 20   20     20        
Termination costs incurred | $ $ 0.3   $ 0.3              
Share increase from stock dividends (in shares) | shares           17,300,000        
Stock issued during period, shares, new issues (in shares) | shares     0   0 0        
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
property
segment
lease
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2023
USD ($)
property
segment
Sep. 30, 2022
USD ($)
segment
property
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
lease
Lessee, Lease, Description [Line Items]              
Additional CARES Act funding $ 0 $ 4,300,000 $ 0 $ 4,500,000 $ 4,500,000 $ 5,100,000 $ 3,600,000
Remaining lease term     4 years 9 months 18 days        
Bad debt expense 200,000 $ 1,700,000 $ 909,000 $ 2,559,000      
Assets held for sale $ 0   $ 0   0    
Number of reportable segments | segment 2 2 2 2      
Number of senior housing communities | property 46   46        
Number of intercompany leases modified | lease 26           25
Valuation allowance, percentage     100.00%        
Deferred tax asset $ 7,600,000   $ 7,600,000   $ 6,900,000    
Building              
Lessee, Lease, Description [Line Items]              
Property, plant and equipment, useful life 40 years   40 years        
Land Improvements              
Lessee, Lease, Description [Line Items]              
Property, plant and equipment, useful life 15 years   15 years        
Minimum              
Lessee, Lease, Description [Line Items]              
Lease intangibles, lease-up period     6 months        
Minimum | Furniture and Fixtures              
Lessee, Lease, Description [Line Items]              
Property, plant and equipment, useful life 7 years   7 years        
Maximum              
Lessee, Lease, Description [Line Items]              
Lease intangibles, lease-up period     24 months        
Maximum | Furniture and Fixtures              
Lessee, Lease, Description [Line Items]              
Property, plant and equipment, useful life 10 years   10 years        
Individual business acquisitions              
Lessee, Lease, Description [Line Items]              
Number of properties purchased | property     7 3      
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Lessor Maturity Schedule (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Future  Base Rent Payments  
2023 (remainder) $ 27,566
2024 108,291
2025 98,378
2026 90,299
2027 71,439
Thereafter 240,452
Total $ 636,425
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
property
Sep. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
property
Sep. 30, 2022
USD ($)
property
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
Sep. 30, 2023
property
Sep. 30, 2023
encumberedProperty
Jul. 01, 2020
property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Number of properties owned               204 21  
Impairment charges $ 0 $ 8,949,000   $ 0 $ 25,786,000          
Gain (loss) on sale of real estate investments (173,000) 194,000   (364,000) (109,000)          
Assets held for sale $ 0     $ 0   $ 0        
Texas                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Impairment charges             $ 34,000,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | LaSalle Properties                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Aggregate contract sale price             $ 12,400,000      
Gain (loss) on sale of real estate investments   (200,000) $ (300,000)              
Disposal Group, Disposed of by Sale, Not Discontinued Operations | SHOP Segment:                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Number of properties disposed | property 0     4            
Aggregate contract sale price $ 13,800,000     $ 13,800,000            
Number of properties impaired | property           2        
Impairment charges           $ 15,100,000        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | MOB Segment                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Number of properties disposed | property       1            
Disposal Group, Held-for-sale, Not Discontinued Operations                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Assets held for sale 0     $ 0   $ 0        
Disposal Group, Held-for-sale, Not Discontinued Operations | Texas | Triple-Net Leased Properties                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Number of properties held for sale | property                   4
Disposal Group, Held-for-sale, Not Discontinued Operations | SHOP Segment:                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Disposal group, gain (loss) on disposal       (400,000)            
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Impairment charges $ 0 8,949,000   $ 0 25,786,000          
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | SHOP Segment:                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Impairment charges   8,949,000     15,142,000          
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | MOB Segment                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Impairment charges   $ 0     $ 10,644,000          
Individual business acquisitions                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Number of properties purchased | property       7 3          
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net - Acquired Assets (Details) - Individual business acquisitions
$ in Thousands
9 Months Ended
Sep. 30, 2023
USD ($)
property
Sep. 30, 2022
USD ($)
property
Real estate investments, at cost:    
Land $ 3,373 $ 4,199
Buildings, fixtures and improvements 27,069 10,662
Total tangible assets 30,442 14,861
Acquired intangibles:    
Market lease liabilities (271) 0
Total intangible assets and liabilities 4,819 2,938
Cash paid for real estate investments, including acquisitions $ 35,261 $ 17,799
Number of properties purchased | property 7 3
In-place lease assets    
Acquired intangibles:    
In-place leases, market leases, and other intangible assets $ 5,057 $ 2,670
Above-market lease assets    
Acquired intangibles:    
In-place leases, market leases, and other intangible assets $ 33 $ 268
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net - Geographic Concentrations (Details) - Revenue Benchmark - Geographic Concentration Risk
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Florida    
Concentration Risk [Line Items]    
Concentration risk, percentage 19.80% 19.00%
Pennsylvania    
Concentration Risk [Line Items]    
Concentration risk, percentage 10.60%  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net - Summary of Amortization and Accretion Recognized (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Finite-Lived Intangible Assets [Line Items]        
Accretion of above-and below-market leases, net     $ (675) $ (421)
Depreciation and Amortization Expense | In-place Leases and Other Intangible Assets        
Finite-Lived Intangible Assets [Line Items]        
Amortization of market least intangibles $ 3,455 $ 3,815 10,414 11,502
Rental Income | Above and Below Market Leases        
Finite-Lived Intangible Assets [Line Items]        
Accretion of above-and below-market leases, net (244) (219) (795) (549)
Property Operating and Maintenance Expense | Above and Below Market Leases        
Finite-Lived Intangible Assets [Line Items]        
Amortization of market least intangibles $ 40 $ 40 $ 120 $ 120
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net - Summary of Intangible Assets and Liabilities Future Amortization Expense (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
2023 (remainder) $ 3,167
2024 11,822
2025 10,234
2026 8,989
2027 5,478
Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Below market leases, amortization income, remainder 2023 (reminder) 208
Below market leases, amortization income, 2024 878
Below market leases, amortization income, 2025 761
Below market leases, amortization income, 2026 641
Below market leases, amortization income, 2027 411
In-place lease assets | Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
2023 (remainder) 3,157
2024 11,812
2025 10,224
2026 8,979
2027 5,468
Other intangible assets | Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
2023 (remainder) 10
2024 10
2025 10
2026 10
2027 10
Above-market lease assets | Rental Income  
Finite-Lived Intangible Assets [Line Items]  
2023 (remainder) (101)
2024 (419)
2025 (366)
2026 (331)
2027 (243)
Below-market lease liabilities | Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Below market leases, amortization income, remainder 2023 (reminder) 309
Below market leases, amortization income, 2024 1,297
Below market leases, amortization income, 2025 1,127
Below market leases, amortization income, 2026 972
Below market leases, amortization income, 2027 $ 654
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Real Estate Investments, Net - Impairments (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
property
Sep. 30, 2023
USD ($)
property
Sep. 30, 2022
USD ($)
property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 0 $ 8,949,000 $ 0 $ 25,786,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges $ 0 8,949,000 $ 0 25,786,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | MOB Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges   0   10,644,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | SHOP Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges   $ 8,949,000   $ 15,142,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Illinois skilled nursing facilities        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of real estate properties impaired | property   7   7
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Illinois skilled nursing facilities | MOB Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges   $ 0   $ 10,644,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Various held for use SHOPs        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of real estate properties impaired | property   8   8
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Various held for use SHOPs | SHOP Segment:        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Impairment charges   $ 8,949,000   $ 15,142,000
Number of properties disposed | property     2  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Mortgage Notes Payable, Net - Mortgage Notes (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
property
Dec. 31, 2022
USD ($)
Jun. 30, 2017
USD ($)
Debt Instrument [Line Items]      
Outstanding loan amount $ 1,169,388    
Effective interest rate 7.86% 5.94%  
MOB Loan | LIBOR      
Debt Instrument [Line Items]      
Notional amount $ 378,500 $ 378,500  
Mortgages      
Debt Instrument [Line Items]      
Encumbered Properties | property 136    
Outstanding loan amount $ 821,668 $ 585,181  
Effective interest rate 4.58% 3.83%  
Deferred financing costs, net of accumulated amortization $ (11,620) $ (5,117)  
Mortgage premiums and discounts, net (1,296) (1,364)  
Mortgage notes payable, net $ 808,752 578,700  
Mortgages | MOB Loan      
Debt Instrument [Line Items]      
Encumbered Properties | property 41    
Outstanding loan amount $ 378,500 $ 378,500 $ 250,000
Effective interest rate 3.71% 3.73%  
Mortgages | Multi-Property CMBS Loan      
Debt Instrument [Line Items]      
Encumbered Properties | property 20    
Outstanding loan amount $ 116,037 $ 118,700  
Effective interest rate 4.60% 4.60%  
Mortgages | Shiloh - Illinois      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 12,828 $ 13,071  
Effective interest rate 4.34% 4.34%  
Mortgages | BMO CMBS Loan      
Debt Instrument [Line Items]      
Encumbered Properties | property 9    
Outstanding loan amount $ 42,750 $ 42,750  
Effective interest rate 2.89% 2.89%  
Mortgages | Barclays MOB Loan      
Debt Instrument [Line Items]      
Encumbered Properties | property 62    
Outstanding loan amount $ 240,000 $ 0  
Effective interest rate 6.45% 0.00%  
Mortgages | Fox Ridge Bryant - Bryant, AR      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 6,689 $ 6,817  
Effective interest rate 3.98% 3.98%  
Mortgages | Fox Ridge Chenal - Little Rock, AR      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 15,344 $ 15,639  
Effective interest rate 2.95% 2.95%  
Mortgages | Fox Ridge North Little Rock - North Little Rock, AR      
Debt Instrument [Line Items]      
Encumbered Properties | property 1    
Outstanding loan amount $ 9,520 $ 9,704  
Effective interest rate 2.95% 2.95%  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Mortgage Notes Payable, Net - Narrative (Details)
9 Months Ended
May 24, 2023
USD ($)
property
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
property
Sep. 30, 2023
encumberedProperty
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]            
Real estate investment, at cost relating to notes payable   $ 1,300,000,000        
Outstanding loan amount   1,169,388,000        
Number of properties owned       204 21  
Payments on credit facilities   199,160,000 $ 0      
Revolving Credit Facility            
Debt Instrument [Line Items]            
Payments on credit facilities $ 194,800,000          
Mortgages            
Debt Instrument [Line Items]            
Outstanding loan amount   821,668,000       $ 585,181,000
Mortgages | Barclays MOB Loan            
Debt Instrument [Line Items]            
Outstanding loan amount   $ 240,000,000       $ 0
Debt instrument, face amount $ 240,000,000          
Number of properties owned | property 62          
Debt instrument, collateral amount $ 416,800,000          
Term 10 years          
Debt instrument, interest rate, stated percentage 6.453%          
Long-term debt, covenant requirements, amount $ 12,500,000          
Period after closing required before prepayment 1 year          
Debt prepayment, written notice requirement 30 days          
Payments of deferred financing costs $ 7,800,000          
Proceeds from loans $ 39,000,000          
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facilities - Summary of Credit Facilities (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
property
Sep. 30, 2023
Sep. 30, 2023
encumberedProperty
Sep. 30, 2023
instrument
Sep. 30, 2023
derivative
Line of Credit Facility [Line Items]              
Encumbered properties     204   21    
Outstanding balance $ 530,297 $ 347,720          
Effective interest rate 5.94%     7.86%      
Prior Credit Facility              
Line of Credit Facility [Line Items]              
Outstanding balance $ 178,250 0          
Fannie Mae Master Credit Facilities | Interest rate caps              
Line of Credit Facility [Line Items]              
Number of Instruments           7 6
Notional amount   351,600          
Interest rate cap 3.50%     3.50%      
Fannie Mae Master Credit Facilities | Capital One Facility              
Line of Credit Facility [Line Items]              
Debt instrument, collateral amount   350,500          
Fannie Mae Master Credit Facilities | Capital One Facility | Interest rate caps              
Line of Credit Facility [Line Items]              
Interest rate 5.26%     5.89%      
Fannie Mae Master Credit Facilities | KeyBank Facility              
Line of Credit Facility [Line Items]              
Debt instrument, collateral amount   261,900          
Fannie Mae Master Credit Facilities | KeyBank Facility | Interest rate caps              
Line of Credit Facility [Line Items]              
Interest rate 5.96%     5.93%      
Credit Facilities | Prior Credit Facility              
Line of Credit Facility [Line Items]              
Encumbered properties | encumberedProperty         0    
Credit Facilities | Fannie Mae Master Credit Facilities              
Line of Credit Facility [Line Items]              
Encumbered properties | encumberedProperty         21    
Outstanding balance $ 352,047 347,720          
Credit Facilities | Fannie Mae Master Credit Facilities | Capital One Facility              
Line of Credit Facility [Line Items]              
Encumbered properties | encumberedProperty         11    
Outstanding balance $ 210,483 207,829          
Effective interest rate 5.90%     7.84%      
Credit Facilities | Fannie Mae Master Credit Facilities | Capital One Facility | LIBOR              
Line of Credit Facility [Line Items]              
Notional amount $ 50,000            
Credit Facilities | Fannie Mae Master Credit Facilities | KeyBank Facility              
Line of Credit Facility [Line Items]              
Encumbered properties | encumberedProperty         10    
Outstanding balance $ 141,564 139,891          
Effective interest rate 6.60%     7.89%      
Credit Facilities | Revolving Credit Facility | Prior Credit Facility              
Line of Credit Facility [Line Items]              
Outstanding balance $ 30,000 0          
Effective interest rate 7.26%     0.00%      
Maturity extension 1 year            
Credit Facilities | Secured Debt | SOFR              
Line of Credit Facility [Line Items]              
Notional amount $ 150,000            
Credit Facilities | Secured Debt | LIBOR              
Line of Credit Facility [Line Items]              
Notional amount 150,000            
Credit Facilities | Secured Debt | Prior Credit Facility              
Line of Credit Facility [Line Items]              
Outstanding balance 150,000 0          
Deferred financing costs (1,750) 0          
Term Loan, net $ 148,250 0          
Effective interest rate 5.11%     0.00%      
Mortgage Note Payable | SOFR              
Line of Credit Facility [Line Items]              
Notional amount   $ 378,500          
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facilities - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 13, 2023
USD ($)
Jul. 31, 2023
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Nov. 10, 2023
USD ($)
derivative
Sep. 30, 2023
instrument
Sep. 30, 2023
Sep. 30, 2023
derivative
Dec. 31, 2022
USD ($)
instrument
Jun. 30, 2017
USD ($)
Line of Credit Facility [Line Items]                    
Total real estate investments, at cost     $ 2,621,686 $ 2,621,686         $ 2,587,621  
Real estate investment, at cost relating to notes payable     1,300,000 1,300,000            
Outstanding balance     347,720 347,720         $ 530,297  
Outstanding loan amount     1,169,388 1,169,388            
LIBOR | Derivatives designated as hedging instruments:                    
Line of Credit Facility [Line Items]                    
Number of Instruments | instrument           0     2  
Notional Amount     0 0         $ 50,000  
Derivatives terminated in period       50,000            
Cash from termination       5,400            
Interest rate caps | Derivatives not designated as hedging instruments:                    
Line of Credit Facility [Line Items]                    
Number of Instruments | instrument           6     7  
Notional Amount     351,572 351,572         $ 354,624  
SOFR | Derivatives designated as hedging instruments:                    
Line of Credit Facility [Line Items]                    
Number of Instruments | instrument           1     7  
Notional Amount     378,500 378,500         $ 528,500  
Derivatives terminated in period       150,000            
Credit Facilities                    
Line of Credit Facility [Line Items]                    
Outstanding loan amount     347,720 347,720            
Mortgages                    
Line of Credit Facility [Line Items]                    
Outstanding loan amount     821,668 821,668         585,181  
Unencumbered Properties                    
Line of Credit Facility [Line Items]                    
Total real estate investments, at cost     700,000 700,000            
Secured Debt | Credit Facilities | LIBOR                    
Line of Credit Facility [Line Items]                    
Notional Amount                 150,000  
Secured Debt | Credit Facilities | SOFR                    
Line of Credit Facility [Line Items]                    
Notional Amount                 $ 150,000  
Fannie Mae Master Credit Facilities                    
Line of Credit Facility [Line Items]                    
Total real estate investments, at cost     600,000 600,000            
Fannie Mae Master Credit Facilities | Interest rate caps                    
Line of Credit Facility [Line Items]                    
Derivative, premium paid     (4,600) (4,600)            
Number of instruments held, renew | derivative               3    
Number of Instruments           7   6    
Notional Amount     351,600 351,600            
Interest rate cap             3.50%   3.50%  
Fannie Mae Master Credit Facilities | SOFR | Derivatives designated as hedging instruments:                    
Line of Credit Facility [Line Items]                    
Notional Amount     347,700 $ 347,700            
Fannie Mae Master Credit Facilities | LIBOR One Month | Capital One Facility                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       2.41%            
Fannie Mae Master Credit Facilities | LIBOR One Month | KeyBank Facility                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       2.46%            
Fannie Mae Master Credit Facilities | Secured Overnight Financing Rate One Month | Capital One Facility                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       2.41%            
Fannie Mae Master Credit Facilities | Secured Overnight Financing Rate One Month | KeyBank Facility                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       2.46%            
Fannie Mae Master Credit Facilities | Credit Facilities                    
Line of Credit Facility [Line Items]                    
Outstanding balance     347,720 $ 347,720         $ 352,047  
Payments for escrow deposit     5,100              
Debt service coverage ratio   1.40                
Fannie Mae Master Credit Facilities | Credit Facilities | Subsequent Event                    
Line of Credit Facility [Line Items]                    
Payments for escrow deposit $ 6,700                  
Debt service coverage ratio 1.40                  
Escrow deposit $ 11,800                  
Fannie Mae Master Credit Facilities | Credit Facilities | Interest rate caps | Subsequent Event                    
Line of Credit Facility [Line Items]                    
Derivative, premium paid         $ (5,000)          
Number of instruments held, renew | derivative         2          
Notional Amount         $ 150,900          
Fannie Mae Master Credit Facilities | Credit Facilities | Capital One Facility                    
Line of Credit Facility [Line Items]                    
Outstanding balance     207,829 207,829         210,483  
Fannie Mae Master Credit Facilities | Credit Facilities | Capital One Facility | LIBOR                    
Line of Credit Facility [Line Items]                    
Notional Amount                 50,000  
Fannie Mae Master Credit Facilities | Credit Facilities | KeyBank Facility                    
Line of Credit Facility [Line Items]                    
Outstanding balance     139,891 139,891         141,564  
Prior Credit Facility                    
Line of Credit Facility [Line Items]                    
Outstanding balance     0 0         178,250  
Prior Credit Facility | Credit Facilities                    
Line of Credit Facility [Line Items]                    
Debt financing wrote off     2,600 $ 2,600            
Prior Credit Facility | Minimum | Credit Facilities | Secured Overnight Financing Rate (SOFR)                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       2.10%            
Prior Credit Facility | Minimum | Credit Facilities | Base Rate                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       0.85%            
Prior Credit Facility | Maximum | Credit Facilities | Secured Overnight Financing Rate (SOFR)                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       2.85%            
Prior Credit Facility | Maximum | Credit Facilities | Base Rate                    
Line of Credit Facility [Line Items]                    
Basis spread on variable rate       1.60%            
Prior Credit Facility | Secured Debt | Credit Facilities                    
Line of Credit Facility [Line Items]                    
Outstanding balance     0 $ 0         150,000  
MOB Loan | LIBOR                    
Line of Credit Facility [Line Items]                    
Notional Amount     378,500 378,500         378,500  
MOB Loan | Mortgages                    
Line of Credit Facility [Line Items]                    
Outstanding loan amount     $ 378,500 $ 378,500         $ 378,500 $ 250,000
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facilities - Future Principal Payments of Outstanding Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
2023 (remainder) $ 1,731  
2024 6,947  
2025 19,039  
2026 714,133  
2027 922  
Thereafter 426,616  
Total 1,169,388  
Mortgage Notes Payable    
Debt Instrument [Line Items]    
2023 (remainder) 289  
2024 1,178  
2025 13,270  
2026 379,393  
2027 922  
Thereafter 426,616  
Total 821,668 $ 585,181
Credit Facilities    
Debt Instrument [Line Items]    
2023 (remainder) 1,442  
2024 5,769  
2025 5,769  
2026 334,740  
2027 0  
Thereafter 0  
Total $ 347,720  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments - Assets Measured at Fair Value (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total $ 37,547 $ 40,647
Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 4,946 3,737
Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 32,601 36,910
Quoted Prices in Active Markets Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 0 0
Quoted Prices in Active Markets Level 1 | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 0 0
Quoted Prices in Active Markets Level 1 | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 0 0
Significant Other Observable Inputs Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 37,547 40,647
Significant Other Observable Inputs Level 2 | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 4,946 3,737
Significant Other Observable Inputs Level 2 | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 32,601 36,910
Significant Unobservable Inputs Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 0 0
Significant Unobservable Inputs Level 3 | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 0 0
Significant Unobservable Inputs Level 3 | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value $ 0 $ 0
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments - Narrative (Details) - Disposal Group, Held-for-use, Not Discontinued Operations
Sep. 30, 2023
property
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Number of properties held for use 16
Number of properties marketed for sale 6
Number of properties impaired 10
MOB Segment  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Number of properties held for use 10
Number of properties marketed for sale 3
Number of properties impaired 8
SHOP Segment:  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Number of properties held for use 6
Number of properties marketed for sale 3
Number of properties impaired 2
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments - Carrying Amounts and Fair Values of Debt (Details) - Significant Unobservable Inputs Level 3 - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Gross mortgage notes payable and mortgage premium and discounts, net | Carrying Amount    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, fair value disclosure $ 820,372 $ 583,817
Gross mortgage notes payable and mortgage premium and discounts, net | Fair Value     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, fair value disclosure 766,584 550,626
Credit Facilities | Carrying Amount    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, fair value disclosure 0 180,000
Credit Facilities | Carrying Amount | Fannie Mae Master Credit Facilities    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, fair value disclosure 347,720 352,047
Credit Facilities | Fair Value     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, fair value disclosure 0 179,496
Credit Facilities | Fair Value  | Fannie Mae Master Credit Facilities    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, fair value disclosure $ 348,120 $ 353,034
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities - Balance Sheet Classification (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Derivative [Line Items]    
Derivative assets, at fair value $ 37,547 $ 40,647
Derivative assets, at fair value | Derivatives designated as hedging instruments: | Interest rate “pay-fixed” swaps    
Derivative [Line Items]    
Derivative assets, at fair value 32,601 36,910
Derivative assets, at fair value | Derivatives not designated as hedging instruments: | Interest rate caps    
Derivative [Line Items]    
Derivative assets, at fair value $ 4,946 $ 3,737
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities - Summary of Derivative Instruments (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Sep. 30, 2023
instrument
Sep. 30, 2023
derivative
Sep. 30, 2023
Dec. 31, 2022
USD ($)
instrument
Interest rate caps | Fannie Mae Master Credit Facilities          
Derivative [Line Items]          
Number of Instruments   7 6    
Notional Amount $ 351,600        
Interest rate cap       3.50% 3.50%
Derivatives designated as hedging instruments: | Interest rate “pay-fixed” swaps          
Derivative [Line Items]          
Number of Instruments | instrument   1     9
Notional Amount 378,500       $ 578,500
Derivatives designated as hedging instruments: | SOFR          
Derivative [Line Items]          
Number of Instruments | instrument   1     7
Notional Amount 378,500       $ 528,500
Derivatives designated as hedging instruments: | SOFR | Fannie Mae Master Credit Facilities          
Derivative [Line Items]          
Notional Amount 347,700        
Derivatives designated as hedging instruments: | LIBOR          
Derivative [Line Items]          
Number of Instruments | instrument   0     2
Notional Amount 0       $ 50,000
Derivatives not designated as hedging instruments: | Interest rate caps          
Derivative [Line Items]          
Number of Instruments | instrument   6     7
Notional Amount $ 351,572       $ 354,624
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities - Derivatives Included in AOCI (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative [Line Items]        
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss $ (15,720) $ (13,284) $ (50,208) $ (37,098)
Interest rate “pay-fixed” swaps        
Derivative [Line Items]        
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives 5,418 17,513 12,078 49,522
Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense $ 5,023 $ 565 $ 13,648 $ (3,862)
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2019
USD ($)
instrument
Sep. 30, 2023
USD ($)
instrument
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
instrument
Sep. 30, 2023
instrument
Sep. 30, 2023
derivative
Sep. 30, 2023
Jun. 30, 2017
USD ($)
Derivative [Line Items]                    
Outstanding loan amount $ 1,169,388,000     $ 1,169,388,000            
Gain on non-designated derivatives 406,000 $ 1,826,000   510,000 $ 3,212,000          
Cash received from non-designated derivative instruments       3,866,000 0          
Mortgages                    
Derivative [Line Items]                    
Outstanding loan amount 821,668,000     821,668,000   $ 585,181,000        
MOB Loan | Mortgages                    
Derivative [Line Items]                    
Outstanding loan amount 378,500,000     $ 378,500,000   $ 378,500,000       $ 250,000,000
SOFR | Derivatives designated as hedging instruments:                    
Derivative [Line Items]                    
Number of instruments | instrument           7 1      
Number of instruments terminated | instrument       6            
Derivatives terminated in period       $ 150,000,000            
Proceeds from sale of interest rate cash flow hedge       3,500,000            
Notional amount 378,500,000     378,500,000   $ 528,500,000        
SOFR | Derivatives designated as hedging instruments: | Fannie Mae Master Credit Facilities                    
Derivative [Line Items]                    
Notional amount 347,700,000     347,700,000            
Interest rate “pay-fixed” swaps | Derivatives designated as hedging instruments:                    
Derivative [Line Items]                    
Number of instruments | instrument           9 1      
Average variable interest rate                 1.61%  
Number of instruments terminated | instrument     2              
Payment for termination of swap     $ 2,200,000              
Notional amount 378,500,000     378,500,000   $ 578,500,000        
Interest rate “pay-fixed” swaps | Derivatives designated as hedging instruments: | MOB Loan                    
Derivative [Line Items]                    
Derivatives terminated in period     250,000,000              
Interest Rate Contract | Derivatives designated as hedging instruments:                    
Derivative [Line Items]                    
Cash flow hedge reclassification current       2,700,000   0        
Interest Rate Contract | Derivatives designated as hedging instruments: | Interest Expense                    
Derivative [Line Items]                    
Cash flow hedge reclassification current (1,500,000)     (2,700,000)            
Cash flow hedge reclassification in next twelve months 16,500,000     16,500,000            
Interest Rate Contract | Derivatives designated as hedging instruments: | MOB Loan | Interest Expense                    
Derivative [Line Items]                    
Cash flow hedge reclassification current     $ 2,200,000   $ 400,000          
LIBOR | MOB Loan                    
Derivative [Line Items]                    
Notional amount 378,500,000     $ 378,500,000   $ 378,500,000        
LIBOR | Derivatives designated as hedging instruments:                    
Derivative [Line Items]                    
Number of instruments | instrument           2 0      
Number of instruments terminated | instrument       2            
Derivatives terminated in period       $ 50,000,000            
Proceeds from sale of interest rate cash flow hedge       1,900,000            
Notional amount 0     0   $ 50,000,000        
Interest rate caps | Fannie Mae Master Credit Facilities                    
Derivative [Line Items]                    
Number of instruments             7 6    
Notional amount 351,600,000     351,600,000            
Interest rate cap           3.50%     3.50%  
Derivative, premium paid 4,600,000     4,600,000            
Number of instruments held, renew | derivative               3    
Notional amount renewed       138,500,000            
Interest rate caps | Derivatives not designated as hedging instruments:                    
Derivative [Line Items]                    
Number of instruments | instrument           7 6      
Notional amount 351,572,000     351,572,000   $ 354,624,000        
Interest Rate Cap Maturing April 2024                    
Derivative [Line Items]                    
Number of instruments | derivative               1    
Notional amount $ 60,000,000     $ 60,000,000            
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Derivatives and Hedging Activities - Offsetting Derivatives (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross Amounts of Recognized Assets $ 37,547 $ 40,647
Gross Amounts of Recognized (Liabilities) 0 0
Gross Amounts Offset in the Consolidated Balance Sheet 0 0
Net Amounts of Assets presented in the Consolidated Balance Sheet 37,547 40,647
Gross Amounts Not Offset in the Consolidated Balance Sheet, Financial Instruments 0 0
Gross Amounts Not Offset in the Consolidated Balance Sheet, Cash Collateral Received 0 0
Net Amount $ 37,547 $ 40,647
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Narrative (Details) - $ / shares
9 Months Ended 12 Months Ended 36 Months Ended
Mar. 01, 2018
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2023
Oct. 04, 2021
May 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Class of Stock [Line Items]                  
Common stock, shares outstanding (in shares)   109,877,212 105,080,531 109,877,212          
Distributions declared in common stock (in shares)       17,300,000          
Stock issued during period, shares, new issues (in shares)   0 0 0          
Repurchase price per share, percentage of estimated per-share NAV   100.00%              
DRIP period of notice to alter agreement   10 days              
Common stock issued through distribution reinvestment plan (in shares)   0 0            
Number or rights per share (in shares)             1    
Preferred stock, additional shares authorized (in shares)               600,000  
Distribution declared on common stock (in usd per share) $ 0.85                
Non-controlling Interests                  
Class of Stock [Line Items]                  
Preferred units outstanding (in shares)   100,000 100,000 100,000          
Series B Preferred Stock                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized (in shares)   3,680,000 3,680,000 3,680,000          
Preferred stock, shares issued (in shares)   3,630,000 3,630,000 3,630,000          
Preferred stock, shares outstanding (in shares)   3,630,000 3,630,000 3,630,000          
Series A Preferred Stock                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized (in shares)   4,740,000 4,740,000 4,740,000          
Preferred stock, shares issued (in shares)   3,977,144 3,977,144 3,977,144          
Preferred stock, shares outstanding (in shares)   3,977,144 3,977,144 3,977,144          
Public Stock Offering                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized (in shares)           2,530,000     1,610,000
Public Stock Offering | Series B Preferred Stock                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized (in shares)         3,680,000        
Maximum                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized (in shares)                 50,000,000
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Cumulative Share Repurchases (Details) - $ / shares
9 Months Ended 123 Months Ended 132 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2023
Equity [Abstract]      
Number of Shares Repurchased (in shares) 0 4,896,620 4,896,620
Average Price per Share (in usd per share) $ 0 $ 20.60 $ 20.60
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Stock Dividends (Details) - shares
Oct. 02, 2023
Jul. 03, 2023
Apr. 03, 2023
Jan. 03, 2023
Oct. 03, 2022
Jul. 01, 2022
Apr. 01, 2022
Jan. 03, 2022
Oct. 01, 2021
Jul. 01, 2021
Apr. 02, 2021
Jan. 04, 2021
Oct. 01, 2020
Dividends Payable [Line Items]                          
Stock dividends (in shares)   0.015179 0.015179 0.014167 0.014167 0.014167 0.014167 0.014655 0.014655 0.014655 0.014655 0.013492 0.013492
Subsequent Event                          
Dividends Payable [Line Items]                          
Stock dividends (in shares) 0.015179                        
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Arrangements - Narrative (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Common stock, shares outstanding (in shares) 109,877,212 105,080,531
Limited partner units (in shares) 90 90
Affiliated Entity | Tax Depreciation Deduction | Advisor    
Related Party Transaction [Line Items]    
Excess depreciation deductions maximum $ 10,000,000  
American Realty Capital Healthcare II Special Limited Partnership, LLC | Affiliated Entity | Special Limited Partner    
Related Party Transaction [Line Items]    
Common stock, shares outstanding (in shares) 10,550 10,094
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Jul. 25, 2019
USD ($)
Feb. 17, 2017
USD ($)
Sep. 30, 2023
USD ($)
$ / shares
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
Related Party Transaction [Line Items]            
Renewal period   10 years        
Percent of board approval required for early termination   67.00%        
Period to terminate early with board approval   45 days        
Related Party            
Related Party Transaction [Line Items]            
Equity instruments, net of selling commissions (in usd per share) | $ / shares     $ 22.50   $ 22.50  
Capped Reimbursement Amount | Related Party            
Related Party Transaction [Line Items]            
Fixed component     $ 2,000 $ 1,700 $ 5,200 $ 4,600
American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Period to terminate early with board approval   60 days        
Advisor | Related Party            
Related Party Transaction [Line Items]            
Shares approved for issuance (in shares) | shares         359,250  
Advisor | American Realty Capital Healthcare Advisors, LLC | Related Party            
Related Party Transaction [Line Items]            
Assets under management threshold         $ 100,000  
Advisor | American Realty Capital Healthcare Advisors, LLC | Advance on Loan or Other Investment | Related Party            
Related Party Transaction [Line Items]            
Reimbursed fees to related party, percentage of benchmark     0.50%   0.50%  
Financing advance fees as a percentage of benchmark, expected company portfolio cost     4.50%   4.50%  
Advisor | American Realty Capital Healthcare Advisors, LLC | Contract Purchase Price | Related Party            
Related Party Transaction [Line Items]            
Quarterly asset management earned by related party, percentage of benchmark     0.1875%   0.1875%  
Advisor | American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Stand-alone Single-tenant Net Leased Properties | Related Party            
Related Party Transaction [Line Items]            
Property management fees     1.50%   1.50%  
Advisor | American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties | Related Party            
Related Party Transaction [Line Items]            
Property management fees     2.50%   2.50%  
Advisor | American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Managed Properties | Related Party | Maximum            
Related Party Transaction [Line Items]            
Oversight fees earned by related party     1.00%   1.00%  
Second Amended and Restated Advisory Agreement            
Related Party Transaction [Line Items]            
Period of notice of termination   365 days        
Monthly Base Management Fee | American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Base management fee of net proceeds, variable portion factor, percent   8.33%        
Monthly Base Management Fee | American Realty Capital Healthcare Advisors, LLC | Related Party            
Related Party Transaction [Line Items]            
Transaction amount   $ 1,625        
Base management fee of net proceeds   1.25%        
Quarterly Variable Management Fee, Benchmark One | American Realty Capital Healthcare Advisors, LLC | Related Party            
Related Party Transaction [Line Items]            
Basis of core earnings, percent         15.00%  
Basis of core earnings, share basis (in usd per share) | $ / shares         $ 0.375  
Quarterly Variable Management Fee, Benchmark Two | American Realty Capital Healthcare Advisors, LLC | Related Party            
Related Party Transaction [Line Items]            
Basis of core earnings, percent         10.00%  
Basis of core earnings, share basis (in usd per share) | $ / shares         $ 0.47  
Amended and Restated Property Management and Leasing Agreement | Related Party            
Related Party Transaction [Line Items]            
Renewal period   1 year        
Period of notice of termination   90 days        
Reimbursements of Administrative Services | American Realty Capital Healthcare Advisors, LLC | Related Party            
Related Party Transaction [Line Items]            
Transaction amount     $ 2,500 $ 2,400 $ 6,400 $ 6,700
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Cost Of Living | Related Party            
Related Party Transaction [Line Items]            
Cost of living percent multiplier 0.030          
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Capped Reimbursement Amount | Related Party            
Related Party Transaction [Line Items]            
Fixed component $ 6,800       $ 7,700  
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Real Estate Cost | Related Party            
Related Party Transaction [Line Items]            
Fee multiplier 4          
Real estate cost percent multiplier 0.0029          
Reduction of real estate cost percent 0.250          
Third Amended And Restated Advisory Agreement | Advisor | Related Party            
Related Party Transaction [Line Items]            
Contingent good faith negotiations of fixed component, term 12 months          
Third Amended And Restated Advisory Agreement | Advisor And Company | Related Party            
Related Party Transaction [Line Items]            
Contingent good faith negotiations of fixed component, term 90 days          
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]          
Expenses incurred $ 86,425 $ 92,004 $ 256,940 $ 277,716  
Related Party | Capped Reimbursement Amount          
Related Party Transaction [Line Items]          
Fixed component 2,000 1,700 5,200 4,600  
Related Party | Total related party operation fees and reimbursements          
Related Party Transaction [Line Items]          
Expenses incurred 9,447 8,957 27,121 26,198  
Payable (Prepayment) 665   665   $ 47
Related Party | Acquisition cost reimbursements          
Related Party Transaction [Line Items]          
Expenses incurred 10 0 31 18  
Payable (Prepayment) 10   10   5
Related Party | Asset management fees          
Related Party Transaction [Line Items]          
Expenses incurred 5,458 5,458 16,374 16,374  
Payable (Prepayment) 0   0   0
Related Party | Property management and fees          
Related Party Transaction [Line Items]          
Expenses incurred 1,155 1,101 3,132 3,058  
Payable (Prepayment) 161   161   3
Leasing commissions 200   400    
Related Party | Professional fees and other reimbursements          
Related Party Transaction [Line Items]          
Expenses incurred 2,824 $ 2,398 7,584 $ 6,748  
Payable (Prepayment) $ 494   $ 494   $ 39
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Arrangements - Fees and Participations Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets (Details) - Related Party
$ in Millions
9 Months Ended
Sep. 30, 2023
USD ($)
Second Amended and Restated Advisory Agreement | Advisor  
Related Party Transaction [Line Items]  
Fee payment period 30 days
Asset management fees  
Related Party Transaction [Line Items]  
Fee multiplier 4
Transition Fee  
Related Party Transaction [Line Items]  
Transaction amount $ 15.0
Subject Fees (Transition Fee Not in Excess of the Product)  
Related Party Transaction [Line Items]  
Fee multiplier 4
Subject Fees (Transition Fee Not in Excess of the Product) | Maximum  
Related Party Transaction [Line Items]  
Fee multiplier 4.5
Change in Control Fee  
Related Party Transaction [Line Items]  
Fee multiplier 4
Variable Management - Incentive Fee  
Related Party Transaction [Line Items]  
Fee multiplier 4
Healthcare Trust Special Limited Partnership, LLC | Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital | Special Limited Partner  
Related Party Transaction [Line Items]  
Subordinated incentive listing distribution 15.00%
Distribution upon nonrenewal of advisory agreement 15.00%
Healthcare Trust Special Limited Partnership, LLC | Pre-tax Non-compounded Return on Capital Contribution | Annual Targeted Investor Return | Special Limited Partner  
Related Party Transaction [Line Items]  
Cumulative capital investment return to investors as a percentage of benchmark 6.00%
Healthcare Trust Special Limited Partnership, LLC | Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return | Special Limited Partner  
Related Party Transaction [Line Items]  
Subordinated performance fee as a percentage of benchmark 15.00%
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.23.3
Equity-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Director        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock issued during period, issued for services (in shares)     0 0
Restricted Share Plan | Unvested Restricted Stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Maximum authorized amount as a percentage of shares authorized     5.00%  
Number of shares authorized (in shares) 3,600,000   3,600,000  
Unrecognized compensation cost $ 0.8   $ 0.8  
Weighted-average period     10 months 24 days  
Share-based payment arrangement, expense $ 0.2 $ 0.3 $ 0.7 $ 1.0
Restricted Share Plan | Unvested Restricted Stock | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Restricted share vesting period     3 years  
Restricted Share Plan | Unvested Restricted Stock | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Restricted share vesting period     5 years  
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.23.3
Equity-Based Compensation - Summary of Activity (Details) - Restricted Share Plan - Unvested Restricted Stock
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Number of Shares of Common Stock  
Beginning balance (in shares) | shares 97,343
Stock dividend (in shares) | shares 4,399
Vested (in shares) | shares (50,871)
Ending balance (in shares) | shares 50,871
Weighted Average Issue Price  
Beginning balance (in usd per share) | $ / shares $ 18.89
Stock dividend (in usd per share) | $ / shares 14.32
Vested (in usd per share) | $ / shares 20.40
Ending balance (in usd per share) | $ / shares $ 16.98
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income - Summary of Changes in AOCI (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance $ 959,578 $ 1,029,463 $ 999,190 $ 1,040,400
Rebalancing of ownership percentage 0 0 0 0
Ending balance 940,581 1,023,302 940,581 1,023,302
Unrealized Gain (loss) on Designated Derivative        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance 34,945 22,095 36,910 (14,341)
Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives     12,078  
Amount of gain reclassified from accumulated other comprehensive income     (13,648)  
Rebalancing of ownership percentage     0  
Ending balance $ 35,340 $ 39,043 $ 35,340 $ 39,043
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests - Balance Sheet Breakdown (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Noncontrolling Interest [Line Items]    
Total Non-controlling Interests in the OP $ 5,894 $ 6,162
Non-controlling Interests in property owning subsidiaries 689 389
Total Non-controlling interests 6,583 6,551
Series A Preferred Unit    
Noncontrolling Interest [Line Items]    
Total Non-controlling Interests in the OP 2,578 2,578
Common OP Unit    
Noncontrolling Interest [Line Items]    
Total Non-controlling Interests in the OP $ 3,316 $ 3,584
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Sep. 30, 2021
Nov. 30, 2014
Noncontrolling Interest [Line Items]              
Distributions to non-controlling interest holders $ 100,000 $ 100,000 $ 138,000 $ 138,000      
Limited partner units (in shares) 90   90   90    
Payments to noncontrolling interests     $ 0 $ 0      
Series A Preferred Stock              
Noncontrolling Interest [Line Items]              
Preferred stock, dividend rate, percentage     7.375%        
OP Units              
Noncontrolling Interest [Line Items]              
Redeemable amount of shares (in shares)     489,233        
Non-controlling Interests              
Noncontrolling Interest [Line Items]              
Number of preferred OP units issued (in shares)           100,000  
Preferred unit, face value (in usd per share)           $ 25.00  
Value of preferred OP Units           $ 2,600,000  
Preferred units issued (in usd per share)           $ 25.78  
Preferred units, redemption period     1 year        
Limited partner units (in shares) 405,998   405,998       405,908
Units issued             $ 10,100,000
Units issued (in usd per share)             $ 25.00
Limited partner units, redemption period     1 year        
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests - Summary of Non-controlling Interests (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Noncontrolling Interest [Line Items]          
Third Party Net Investment Amount $ 6,583   $ 6,583   $ 6,551
Net Real Estate Assets Subject to Investment Arrangement 1,958,152   1,958,152   1,978,297
Distributions 46 $ 46 138 $ 138  
Contributions from non-controlling interests     284 0  
Non-controlling Interests          
Noncontrolling Interest [Line Items]          
Distributions 46 46 138 $ 138  
Plaza Del Rio Medical Office Campus Portfolio - Peoria, AZ | Non-controlling Interests          
Noncontrolling Interest [Line Items]          
Third Party Net Investment Amount 689   689    
Net Real Estate Assets Subject to Investment Arrangement 12,426   12,426   $ 12,455
Distributions $ 0 $ 0      
Contributions from non-controlling interests     $ 300    
Plaza Del Rio Medical Office Campus Portfolio - Peoria, AZ | Non-controlling Interests | Healthcare Trust Operating Partnership, L.P.          
Noncontrolling Interest [Line Items]          
Non-Controlling Ownership Percentage 4.40%   4.40%   2.60%
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Computation (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share [Abstract]        
Net loss attributable to common stockholders $ (19,561) $ (23,303) $ (57,829) $ (71,159)
Basic weighted-average shares outstanding (in shares) [1] 111,426,241 111,365,461 111,404,655 111,333,801
Diluted weighted-average shares outstanding (in shares) [1] 111,426,241 111,365,461 111,404,655 111,333,801
Basic net loss per share (in usd per share) [1] $ (0.18) $ (0.21) $ (0.52) $ (0.64)
Diluted net loss per share (in usd per share) [1] $ (0.18) $ (0.21) $ (0.52) $ (0.64)
[1] Retroactively adjusted for the effects of the stock dividends (see Note 1).
XML 87 R77.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]          
Antidilutive securities excluded from computation of earnings per share (in shares) 992,864 1,053,413 1,014,450 1,085,072  
Limited partner units (in shares) 90   90   90
Class B units (in shares) 359,250 359,250 359,250 359,250  
Advisor | American Realty Capital Healthcare III Advisors, LLC          
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]          
Limited partner units (in shares) 405,998 405,998 405,998 405,998  
Unvested Restricted Stock | Restricted Share Plan          
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]          
Unvested restricted stock (in shares) 50,871 95,983 50,871 95,983 97,343
Unvested Restricted Stock          
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]          
Antidilutive securities excluded from computation of earnings per share (in shares) 70,730 131,279 92,316 162,938  
Common OP Units          
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]          
Antidilutive securities excluded from computation of earnings per share (in shares) 489,233 489,233 489,233 489,233  
Class B Units          
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]          
Antidilutive securities excluded from computation of earnings per share (in shares) 432,901 432,901 432,901 432,901  
XML 88 R78.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Narrative (Details) - segment
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting [Abstract]        
Number of reportable segments 2 2 2 2
XML 89 R79.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Reconciliation of Segment Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Revenue from tenants $ 85,686 $ 83,460 $ 259,145 $ 250,936
Property operating and maintenance 54,326 51,198 161,778 156,880
NOI 31,360 32,262 97,367 94,056
Impairment charges 0 (8,949) 0 (25,786)
Operating fees to related parties (6,397) (6,333) (19,153) (19,003)
Acquisition and transaction related (173) (199) (384) (1,153)
General and administrative (4,753) (4,471) (14,105) (13,369)
Depreciation and amortization (20,776) (20,854) (61,520) (61,525)
Interest expense (15,720) (13,284) (50,208) (37,098)
Interest and other income 258 10 576 24
(Loss) gain on sale of real estate investments (173) 194 (364) (109)
Gain on non-designated derivatives 406 1,826 510 3,212
Income tax expense (157) (77) (244) (159)
Net loss attributable to non-controlling interests 14 22 45 100
Allocation for preferred stock (3,450) (3,450) (10,349) (10,349)
Net loss attributable to common stockholders (19,561) (23,303) (57,829) (71,159)
MOB Segment        
Segment Reporting Information [Line Items]        
Revenue from tenants 33,657 33,185 101,187 98,026
Property operating and maintenance 9,379 9,377 27,772 26,417
NOI 24,278 23,808 73,415 71,609
SHOP Segment        
Segment Reporting Information [Line Items]        
Revenue from tenants 52,029 50,275 157,958 152,910
Property operating and maintenance 44,947 41,821 134,006 130,463
NOI $ 7,082 $ 8,454 $ 23,952 $ 22,447
XML 90 R80.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Reconciliation of Segment Activity to Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Investments in real estate, net:      
Total investments in real estate, net $ 1,958,152 $ 1,978,297  
Cash and cash equivalents 51,041 53,654 $ 40,120
Restricted cash 40,245 22,884 $ 23,858
Derivative assets, at fair value 37,547 40,647  
Straight-line rent receivable, net 26,214 25,276  
Operating lease right-of-use assets 7,739 7,814  
Prepaid expenses and other assets 36,019 34,554  
Deferred costs, net 15,300 17,223  
Total assets 2,172,257 2,180,349  
MOB Segment      
Investments in real estate, net:      
Total investments in real estate, net 1,126,677 1,121,857  
SHOP Segment      
Investments in real estate, net:      
Total investments in real estate, net $ 831,475 $ 856,440  
XML 91 R81.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Reconciliation of Capital Expenditures by Segment (Details) - Operating Segments - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Total capital expenditures $ 4,858 $ 7,632 $ 13,998 $ 16,707
MOB Segment        
Segment Reporting Information [Line Items]        
Total capital expenditures 1,686 2,309 4,650 5,981
SHOP Segment        
Segment Reporting Information [Line Items]        
Total capital expenditures $ 3,172 $ 5,323 $ 9,348 $ 10,726
XML 92 R82.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
lease
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Lessee, Lease, Description [Line Items]          
Number of operating lease contracts | lease     7    
Number of finance lease contracts | lease     6    
Renewal term of lease excluded     1 year    
Operating lease right-of-use assets $ 7,739   $ 7,739   $ 7,814
Operating lease liabilities $ 8,051   $ 8,051   $ 8,087
Remaining lease term 33 years 7 months 6 days   33 years 7 months 6 days    
Weighted average discount rate, percent 7.37%   7.37%    
Operating lease payments $ 200 $ 200 $ 600 $ 700  
Operating lease liability $ 200 $ 200 $ 600 $ 700  
Minimum          
Lessee, Lease, Description [Line Items]          
Renewal term     19 years 1 month 6 days    
Maximum          
Lessee, Lease, Description [Line Items]          
Renewal term     84 years    
XML 93 R83.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Operating Leases    
2023 (remainder) $ 162  
2024 632  
2025 588  
2026 599  
2027 617  
Thereafter 21,943  
Total minimum lease payments 24,541  
Less: amounts representing interest (16,490)  
Total present value of minimum lease payments 8,051 $ 8,087
Direct Financing Leases    
2023 (remainder) 22  
2024 90  
2025 93  
2026 95  
2027 97  
Thereafter 7,215  
Total minimum lease payments 7,612  
Less: amounts representing interest (2,778)  
Total present value of minimum lease payments $ 4,834  
Finance Lease, Liability, Statement of Financial Position [Extensible List] Accounts payable and accrued expenses (including $665 and $47, respectively, due to related parties as of September 30, 2023 and December 31, 2022)  
XML 94 R84.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Details)
$ in Millions
1 Months Ended 3 Months Ended
Oct. 02, 2023
shares
Jul. 03, 2023
shares
Apr. 03, 2023
shares
Jan. 03, 2023
shares
Oct. 03, 2022
shares
Jul. 01, 2022
shares
Apr. 01, 2022
shares
Jan. 03, 2022
shares
Oct. 01, 2021
shares
Jul. 01, 2021
shares
Apr. 02, 2021
shares
Jan. 04, 2021
shares
Oct. 01, 2020
shares
Nov. 13, 2023
USD ($)
Jul. 31, 2023
Sep. 30, 2023
USD ($)
derivative
Nov. 10, 2023
USD ($)
derivative
Subsequent Event [Line Items]                                  
Stock dividends (in shares) | shares   0.015179 0.015179 0.014167 0.014167 0.014167 0.014167 0.014655 0.014655 0.014655 0.014655 0.013492 0.013492        
Fannie Mae Master Credit Facilities | Credit Facilities                                  
Subsequent Event [Line Items]                                  
Payments for escrow deposit                               $ 5.1  
Debt service coverage ratio                             1.40    
Interest rate caps | Fannie Mae Master Credit Facilities                                  
Subsequent Event [Line Items]                                  
Number of instruments held, renew | derivative                               3  
Notional Amount                               $ 351.6  
Derivative, premium paid                               $ 4.6  
Subsequent Event                                  
Subsequent Event [Line Items]                                  
Stock dividends (in shares) | shares 0.015179                                
Subsequent Event | Fannie Mae Master Credit Facilities | Credit Facilities                                  
Subsequent Event [Line Items]                                  
Payments for escrow deposit                           $ 6.7      
Debt service coverage ratio                           1.40      
Subsequent Event | Interest rate caps | Fannie Mae Master Credit Facilities | Credit Facilities                                  
Subsequent Event [Line Items]                                  
Number of instruments held, renew | derivative                                 2
Notional Amount                                 $ 150.9
Strike price percentage                           3.50%      
Derivative, premium paid                                 $ 5.0
XML 95 hct-20230930_htm.xml IDEA: XBRL DOCUMENT 0001561032 2023-01-01 2023-09-30 0001561032 dei:FormerAddressMember 2023-01-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2023-01-01 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2023-01-01 2023-09-30 0001561032 2023-11-06 0001561032 2023-09-30 0001561032 2022-12-31 0001561032 us-gaap:RelatedPartyMember 2023-09-30 0001561032 us-gaap:RelatedPartyMember 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2022-12-31 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2022-12-31 0001561032 2023-07-01 2023-09-30 0001561032 2022-07-01 2022-09-30 0001561032 2022-01-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001561032 us-gaap:CommonStockMember 2022-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001561032 us-gaap:RetainedEarningsMember 2022-12-31 0001561032 us-gaap:ParentMember 2022-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2022-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001561032 us-gaap:ParentMember 2023-01-01 2023-09-30 0001561032 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001561032 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2023-01-01 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2023-01-01 2023-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001561032 us-gaap:CommonStockMember 2023-09-30 0001561032 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001561032 us-gaap:RetainedEarningsMember 2023-09-30 0001561032 us-gaap:ParentMember 2023-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001561032 us-gaap:CommonStockMember 2023-06-30 0001561032 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001561032 us-gaap:RetainedEarningsMember 2023-06-30 0001561032 us-gaap:ParentMember 2023-06-30 0001561032 us-gaap:NoncontrollingInterestMember 2023-06-30 0001561032 2023-06-30 0001561032 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001561032 us-gaap:ParentMember 2023-07-01 2023-09-30 0001561032 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001561032 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2023-07-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2023-07-01 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2023-07-01 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2023-07-01 2023-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001561032 us-gaap:CommonStockMember 2021-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001561032 us-gaap:RetainedEarningsMember 2021-12-31 0001561032 us-gaap:ParentMember 2021-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2021-12-31 0001561032 2021-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001561032 us-gaap:ParentMember 2022-01-01 2022-09-30 0001561032 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001561032 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2022-01-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2022-01-01 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2022-01-01 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2022-01-01 2022-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001561032 us-gaap:CommonStockMember 2022-09-30 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001561032 us-gaap:RetainedEarningsMember 2022-09-30 0001561032 us-gaap:ParentMember 2022-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2022-09-30 0001561032 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001561032 us-gaap:CommonStockMember 2022-06-30 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001561032 us-gaap:RetainedEarningsMember 2022-06-30 0001561032 us-gaap:ParentMember 2022-06-30 0001561032 us-gaap:NoncontrollingInterestMember 2022-06-30 0001561032 2022-06-30 0001561032 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001561032 us-gaap:ParentMember 2022-07-01 2022-09-30 0001561032 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001561032 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2022-07-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2022-07-01 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2022-07-01 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember us-gaap:ParentMember 2022-07-01 2022-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001561032 2020-10-01 2023-09-30 0001561032 2022-01-01 2022-12-31 0001561032 2021-01-01 2021-12-31 0001561032 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-01-01 2023-09-30 0001561032 srt:MinimumMember 2023-01-01 2023-09-30 0001561032 srt:MaximumMember 2023-01-01 2023-09-30 0001561032 us-gaap:BuildingMember 2023-09-30 0001561032 us-gaap:LandImprovementsMember 2023-09-30 0001561032 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-09-30 0001561032 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-09-30 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-09-30 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2023-01-01 2023-09-30 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2022-01-01 2022-09-30 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2023-01-01 2023-09-30 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2022-01-01 2022-09-30 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0001561032 stpr:PA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2023-07-01 2023-09-30 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2022-07-01 2022-09-30 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2023-01-01 2023-09-30 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2022-01-01 2022-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2023-07-01 2023-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2022-07-01 2022-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2023-01-01 2023-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2022-01-01 2022-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:PropertyOperatingandMaintenanceExpenseMember 2023-07-01 2023-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:PropertyOperatingandMaintenanceExpenseMember 2022-07-01 2022-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:PropertyOperatingandMaintenanceExpenseMember 2023-01-01 2023-09-30 0001561032 hct:AboveandBelowMarketLeasesMember hct:PropertyOperatingandMaintenanceExpenseMember 2022-01-01 2022-09-30 0001561032 us-gaap:LeasesAcquiredInPlaceMember hct:AmortizationExpenseMember 2023-09-30 0001561032 us-gaap:OtherIntangibleAssetsMember hct:AmortizationExpenseMember 2023-09-30 0001561032 hct:AmortizationExpenseMember 2023-09-30 0001561032 us-gaap:AboveMarketLeasesMember hct:RentalIncomeMember 2023-09-30 0001561032 hct:BelowMarketLeaseMember hct:RentalIncomeMember 2023-09-30 0001561032 hct:RentalIncomeMember 2023-09-30 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2023-07-01 2023-09-30 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2023-01-01 2023-09-30 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2023-01-01 2023-09-30 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2023-09-30 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-12-31 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2023-01-01 2023-09-30 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember stpr:TX us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-07-01 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2021-12-31 0001561032 stpr:TX 2021-01-01 2021-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2022-01-01 2022-03-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:LaSallePropertiesMember 2022-07-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2022-12-31 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2023-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2023-07-01 2023-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2023-01-01 2023-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember hct:MedicalOfficeBuildingsMember 2022-07-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2022-07-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember hct:SeniorsHousingCommunitiesMember 2022-07-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-07-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2022-07-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2022-01-01 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:MOBPropertyIllinoisSkilledNursingFacilitiesMember 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember 2022-09-30 0001561032 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember hct:VariousSeniorsHousingCommunitiesMember hct:SeniorsHousingCommunitiesMember 2023-01-01 2023-09-30 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:ShilohIllinoisMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:ShilohIllinoisMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:BMOMOBLoanMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:BMOMOBLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 hct:BarclaysMOBLoanMember us-gaap:MortgagesMember 2023-09-30 0001561032 hct:BarclaysMOBLoanMember us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:MortgagesMember 2023-09-30 0001561032 us-gaap:MortgagesMember 2022-12-31 0001561032 hct:MOBLoanMember hct:LIBORBasedInterestRateSwapMember 2022-12-31 0001561032 hct:MOBLoanMember hct:LIBORBasedInterestRateSwapMember 2023-09-30 0001561032 hct:BarclaysMOBLoanMember us-gaap:MortgagesMember 2023-05-24 0001561032 hct:BarclaysMOBLoanMember us-gaap:MortgagesMember 2023-05-24 2023-05-24 0001561032 us-gaap:RevolvingCreditFacilityMember 2023-05-24 2023-05-24 0001561032 us-gaap:RevolvingCreditFacilityMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 us-gaap:RevolvingCreditFacilityMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:SecuredDebtMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 us-gaap:SecuredDebtMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:PriorCreditFacilityMember 2023-09-30 0001561032 hct:PriorCreditFacilityMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember hct:KeyBankFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:KeyBankFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:KeyBankFacilityMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember hct:CapitalOneFacilityMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember hct:KeyBankFacilityMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember hct:CapitalOneFacilityMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember hct:KeyBankFacilityMember 2022-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2022-01-01 2022-12-31 0001561032 us-gaap:SecuredDebtMember hct:SOFRBasedInterestRateSwapMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember hct:LIBORBasedInterestRateSwapMember hct:CapitalOneFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:SOFRBasedInterestRateSwapMember hct:MortgageNotePayableMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember 2023-09-30 0001561032 hct:UnencumberedPropertiesMember 2023-09-30 0001561032 srt:MinimumMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember hct:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001561032 srt:MaximumMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember hct:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001561032 srt:MinimumMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001561032 srt:MaximumMember hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2023-01-01 2023-09-30 0001561032 hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2023-07-01 2023-09-30 0001561032 hct:PriorCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember hct:LondonInterbankOfferedRateOneMonthMember 2023-01-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:KeyBankFacilityMember hct:LondonInterbankOfferedRateOneMonthMember 2023-01-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember hct:SecuredOvernightFinancingRateOneMonthMember 2023-01-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:KeyBankFacilityMember hct:SecuredOvernightFinancingRateOneMonthMember 2023-01-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:LineOfCreditMember 2023-07-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:LineOfCreditMember 2023-07-01 2023-07-31 0001561032 hct:MasterCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-10-01 2023-11-13 0001561032 hct:MasterCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-13 0001561032 us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:MasterCreditFacilityMember hct:SOFRBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2023-09-30 0001561032 us-gaap:SecuredDebtMember hct:LIBORBasedInterestRateSwapMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-09-30 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001561032 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2023-09-30 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember hct:MedicalOfficeBuildingsMember 2023-09-30 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember hct:SeniorsHousingCommunitiesMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgagesMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgagesMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgagesMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2023-09-30 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2023-09-30 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2022-12-31 0001561032 hct:SOFRBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 hct:SOFRBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 hct:LIBORBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001561032 us-gaap:InterestRateSwapMember 2023-07-01 2023-09-30 0001561032 us-gaap:InterestRateSwapMember 2022-07-01 2022-09-30 0001561032 us-gaap:InterestRateSwapMember 2023-01-01 2023-09-30 0001561032 us-gaap:InterestRateSwapMember 2022-01-01 2022-09-30 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2017-06-30 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-01 2019-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-01 2019-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-10-01 2019-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0001561032 hct:SOFRBasedInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-09-30 0001561032 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2022-12-31 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember 2023-01-01 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-10 0001561032 hct:InterestRateCapMaturingApril2024Member 2023-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember 2022-12-31 0001561032 2012-10-15 2022-12-31 0001561032 2012-10-15 2023-09-30 0001561032 2020-12-31 0001561032 srt:MaximumMember 2019-12-31 0001561032 hct:PublicStockOfferingMember 2019-12-31 0001561032 2020-09-30 0001561032 hct:PublicStockOfferingMember 2021-05-31 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember hct:PublicStockOfferingMember 2021-10-04 0001561032 2018-03-01 2018-03-01 0001561032 2020-10-01 2020-10-01 0001561032 2021-01-04 2021-01-04 0001561032 2021-04-02 2021-04-02 0001561032 2021-07-01 2021-07-01 0001561032 2021-10-01 2021-10-01 0001561032 2022-01-03 2022-01-03 0001561032 2022-04-01 2022-04-01 0001561032 2022-07-01 2022-07-01 0001561032 2022-10-03 2022-10-03 0001561032 2023-01-03 2023-01-03 0001561032 2023-04-03 2023-04-03 0001561032 2023-07-03 2023-07-03 0001561032 us-gaap:SubsequentEventMember 2023-10-02 2023-10-02 0001561032 hct:SpecialLimitedPartnerMember srt:AffiliatedEntityMember hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember 2023-09-30 0001561032 hct:SpecialLimitedPartnerMember srt:AffiliatedEntityMember hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember 2022-12-31 0001561032 hct:AdvisorMember hct:TaxDepreciationDeductionMember srt:AffiliatedEntityMember 2023-09-30 0001561032 2017-02-17 2017-02-17 0001561032 hct:SecondAmendedandRestatedAdvisoryAgreementMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2017-02-17 2017-02-17 0001561032 hct:AdvisorMember us-gaap:RelatedPartyMember hct:AdvanceOnLoanOrOtherInvestmentMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2023-09-30 0001561032 hct:SpecialLimitedPartnerMember hct:AnnualTargetedInvestorReturnMember us-gaap:RelatedPartyMember hct:PreTaxNonCompoundedReturnOnCapitalContributionMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2023-09-30 0001561032 hct:AdvisorMember us-gaap:RelatedPartyMember hct:ContractPurchasePriceMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2023-09-30 0001561032 hct:AdvisorMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:MonthlyBaseManagementFeeMember us-gaap:RelatedPartyMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:QuarterlyVariableManagementFeeBenchmarkOneMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:QuarterlyVariableManagementFeeBenchmarkTwoMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AdvisorMember us-gaap:RelatedPartyMember hct:GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2023-09-30 0001561032 hct:AdvisorMember us-gaap:RelatedPartyMember hct:GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2023-09-30 0001561032 hct:AdvisorMember srt:MaximumMember us-gaap:RelatedPartyMember hct:GrossRevenueManagedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2023-09-30 0001561032 hct:AmendedandRestatedPropertyManagementandLeasingAgreementMember us-gaap:RelatedPartyMember 2017-02-17 2017-02-17 0001561032 hct:AdvisorMember us-gaap:RelatedPartyMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2023-01-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember hct:ConsumerPriceIndexMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember hct:CappedReimbursementAmountMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember hct:CappedReimbursementAmountMember 2023-01-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember hct:RealEstateCostMember 2019-07-25 2019-07-25 0001561032 hct:AdvisorMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember 2019-07-25 2019-07-25 0001561032 hct:AdvisorAndCompanyMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember 2019-07-25 2019-07-25 0001561032 hct:AcquisitionCostsReimbursementsMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001561032 hct:AcquisitionCostsReimbursementsMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001561032 hct:AcquisitionCostsReimbursementsMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AcquisitionCostsReimbursementsMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001561032 hct:AcquisitionCostsReimbursementsMember us-gaap:RelatedPartyMember 2023-09-30 0001561032 hct:AcquisitionCostsReimbursementsMember us-gaap:RelatedPartyMember 2022-12-31 0001561032 hct:AssetManagementFeesMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001561032 hct:AssetManagementFeesMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001561032 hct:AssetManagementFeesMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AssetManagementFeesMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001561032 hct:AssetManagementFeesMember us-gaap:RelatedPartyMember 2023-09-30 0001561032 hct:AssetManagementFeesMember us-gaap:RelatedPartyMember 2022-12-31 0001561032 hct:PropertyManagementFeesMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001561032 hct:PropertyManagementFeesMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001561032 hct:PropertyManagementFeesMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:PropertyManagementFeesMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001561032 hct:PropertyManagementFeesMember us-gaap:RelatedPartyMember 2023-09-30 0001561032 hct:PropertyManagementFeesMember us-gaap:RelatedPartyMember 2022-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001561032 hct:TransferAgentandOtherProfessionalFeesMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001561032 hct:TransferAgentandOtherProfessionalFeesMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:TransferAgentandOtherProfessionalFeesMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001561032 hct:TransferAgentandOtherProfessionalFeesMember us-gaap:RelatedPartyMember 2023-09-30 0001561032 hct:TransferAgentandOtherProfessionalFeesMember us-gaap:RelatedPartyMember 2022-12-31 0001561032 hct:OperationFeesAndReimbursementsMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001561032 hct:OperationFeesAndReimbursementsMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001561032 hct:OperationFeesAndReimbursementsMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:OperationFeesAndReimbursementsMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001561032 hct:OperationFeesAndReimbursementsMember us-gaap:RelatedPartyMember 2023-09-30 0001561032 hct:OperationFeesAndReimbursementsMember us-gaap:RelatedPartyMember 2022-12-31 0001561032 us-gaap:RelatedPartyMember hct:CappedReimbursementAmountMember 2023-07-01 2023-09-30 0001561032 us-gaap:RelatedPartyMember hct:CappedReimbursementAmountMember 2023-01-01 2023-09-30 0001561032 us-gaap:RelatedPartyMember hct:CappedReimbursementAmountMember 2022-07-01 2022-09-30 0001561032 us-gaap:RelatedPartyMember hct:CappedReimbursementAmountMember 2022-01-01 2022-09-30 0001561032 hct:SpecialLimitedPartnerMember us-gaap:RelatedPartyMember hct:ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2023-09-30 0001561032 hct:SpecialLimitedPartnerMember us-gaap:RelatedPartyMember hct:NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2023-09-30 0001561032 hct:AdvisorMember hct:SecondAmendedandRestatedAdvisoryAgreementMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:TransitionFeeMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:SubjectFeesTransitionFeeNotinExcessoftheProductMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 srt:MaximumMember hct:SubjectFeesTransitionFeeNotinExcessoftheProductMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:ChangeinControlFeeMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:VariableManagementIncentiveFeeMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:MonthlyBaseManagementFeeMember 2017-02-17 2017-02-17 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2023-01-01 2023-09-30 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2023-09-30 0001561032 srt:MinimumMember us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2023-01-01 2023-09-30 0001561032 srt:MaximumMember us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2023-01-01 2023-09-30 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2023-07-01 2023-09-30 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-07-01 2022-09-30 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-01-01 2022-09-30 0001561032 srt:DirectorMember 2023-01-01 2023-09-30 0001561032 srt:DirectorMember 2022-01-01 2022-09-30 0001561032 hct:SeriesAPreferredUnitMember 2023-09-30 0001561032 hct:SeriesAPreferredUnitMember 2022-12-31 0001561032 hct:CommonOperatingPartnershipUnitMember 2023-09-30 0001561032 hct:CommonOperatingPartnershipUnitMember 2022-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2021-09-30 0001561032 us-gaap:NoncontrollingInterestMember 2014-11-30 0001561032 hct:OpUnitsMember 2023-01-01 2023-09-30 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2023-09-30 0001561032 hct:HealthcareTrustOperatingPartnershipL.P.Member hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2023-09-30 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001561032 hct:HealthcareTrustOperatingPartnershipL.P.Member hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001561032 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0001561032 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0001561032 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001561032 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001561032 hct:OpUnitsMember 2023-07-01 2023-09-30 0001561032 hct:OpUnitsMember 2022-07-01 2022-09-30 0001561032 hct:OpUnitsMember 2022-01-01 2022-09-30 0001561032 hct:ClassBUnitsMember 2023-07-01 2023-09-30 0001561032 hct:ClassBUnitsMember 2022-07-01 2022-09-30 0001561032 hct:ClassBUnitsMember 2023-01-01 2023-09-30 0001561032 hct:ClassBUnitsMember 2022-01-01 2022-09-30 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2022-09-30 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2023-09-30 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2022-09-30 0001561032 hct:MedicalOfficeBuildingsMember 2023-07-01 2023-09-30 0001561032 hct:SeniorsHousingCommunitiesMember 2023-07-01 2023-09-30 0001561032 hct:MedicalOfficeBuildingsMember 2022-07-01 2022-09-30 0001561032 hct:SeniorsHousingCommunitiesMember 2022-07-01 2022-09-30 0001561032 hct:MedicalOfficeBuildingsMember 2023-01-01 2023-09-30 0001561032 hct:SeniorsHousingCommunitiesMember 2023-01-01 2023-09-30 0001561032 hct:MedicalOfficeBuildingsMember 2022-01-01 2022-09-30 0001561032 hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-09-30 0001561032 hct:MedicalOfficeBuildingsMember 2023-09-30 0001561032 hct:MedicalOfficeBuildingsMember 2022-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2023-09-30 0001561032 hct:SeniorsHousingCommunitiesMember 2022-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2023-07-01 2023-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2022-07-01 2022-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2023-01-01 2023-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2022-01-01 2022-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2023-07-01 2023-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2022-07-01 2022-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2023-01-01 2023-09-30 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2022-01-01 2022-09-30 0001561032 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0001561032 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0001561032 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0001561032 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0001561032 hct:MasterCreditFacilityMember us-gaap:InterestRateCapMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-10-01 2023-11-13 shares iso4217:USD pure iso4217:USD shares hct:property hct:state utr:sqft hct:segment hct:contractor hct:lease hct:encumberedProperty hct:instrument hct:derivative 0001561032 --12-31 2023 Q3 false P6M 0.0833 P3Y http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent 10-Q true 2023-09-30 false 001-39153 Healthcare Trust, Inc. MD 38-3888962 222 Bellevue Ave. Newport RI 02840 212 415-6500 650 Fifth Ave. 30th Floor New York NY 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIA NASDAQ 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIBP NASDAQ Yes Yes Non-accelerated Filer false false false 111545038 208594000 206454000 2119797000 2089133000 293295000 292034000 2621686000 2587621000 663534000 609324000 1958152000 1978297000 51041000 53654000 40245000 22884000 37547000 40647000 26214000 25276000 7739000 7814000 36019000 34554000 15300000 17223000 2172257000 2180349000 808752000 578700000 347720000 530297000 8519000 9407000 665000 47000 48234000 45247000 8051000 8087000 6904000 5925000 3496000 3496000 1231676000 1181159000 0.07375 0.01 0.01 4740000 4740000 3977144 3977144 3977144 3977144 40000 40000 0.07125 0.01 0.01 3680000 3680000 3630000 3630000 3630000 3630000 36000 36000 0.01 0.01 300000000 300000000 109877212 109877212 105080531 105080531 1098000 1051000 2485745000 2417059000 35340000 36910000 1588261000 1462457000 933998000 992639000 6583000 6551000 940581000 999190000 2172257000 2180349000 85686000 83460000 259145000 250936000 54326000 51198000 161778000 156880000 0 8949000 0 25786000 6397000 6333000 19153000 19003000 173000 199000 384000 1153000 4753000 4471000 14105000 13369000 20776000 20854000 61520000 61525000 86425000 92004000 256940000 277716000 -739000 -8544000 2205000 -26780000 -173000 194000 -364000 -109000 -912000 -8350000 1841000 -26889000 15720000 13284000 50208000 37098000 258000 10000 576000 24000 406000 1826000 510000 3212000 -15056000 -11448000 -49122000 -33862000 -15968000 -19798000 -47281000 -60751000 157000 77000 244000 159000 -16125000 -19875000 -47525000 -60910000 -14000 -22000 -45000 -100000 3450000 3450000 10349000 10349000 -19561000 -23303000 -57829000 -71159000 395000 16948000 -1570000 53384000 -19166000 -6355000 -59399000 -17775000 111426241 111426241 111365461 111365461 111404655 111404655 111333801 111333801 -0.18 -0.18 -0.21 -0.21 -0.52 -0.52 -0.64 -0.64 3977144 40000 3630000 36000 105080531 1051000 2417059000 36910000 -1462457000 992639000 6551000 999190000 689000 689000 689000 0.42 4796681 47000 67928000 -67975000 0 0 0.92 5500000 5500000 5500000 0.90 4849000 4849000 4849000 138000 138000 -47480000 -47480000 -45000 -47525000 -1570000 -1570000 -1570000 284000 284000 69000 69000 -69000 0 3977144 40000 3630000 36000 109877212 1098000 2485745000 35340000 -1588261000 933998000 6583000 940581000 3977144 40000 3630000 36000 108284434 1082000 2462523000 34945000 -1545708000 952918000 6660000 959578000 229000 229000 229000 0.21 1592778 16000 22976000 -22992000 0 0 0.46 1834000 1834000 1834000 0.45 1616000 1616000 1616000 46000 46000 -16111000 -16111000 -14000 -16125000 395000 395000 395000 17000 17000 -17000 0 3977144 40000 3630000 36000 109877212 1098000 2485745000 35340000 -1588261000 933998000 6583000 940581000 3977144 40000 3630000 36000 99281754 993000 2329839000 -14341000 -1282871000 1033696000 6704000 1040400000 -39000 -39000 -39000 955000 955000 955000 0.42 4330590 43000 64237000 -64280000 0 0 0.92 5500000 5500000 5500000 0.90 4850000 4850000 4850000 138000 138000 -60810000 -60810000 -100000 -60910000 53384000 53384000 53384000 -202000 -202000 202000 0 3977144 40000 3630000 36000 103612344 1036000 2394790000 39043000 -1418311000 1016634000 6668000 1023302000 3977144 40000 3630000 36000 102164671 1022000 2372889000 22095000 -1373296000 1022786000 6677000 1029463000 -28000 -28000 -28000 291000 291000 291000 0.21 1447673 14000 21697000 -21711000 0 0 0.46 1834000 1834000 1834000 0.45 1617000 1617000 1617000 46000 46000 -19853000 -19853000 -22000 -19875000 16948000 16948000 16948000 -59000 -59000 59000 0 3977144 40000 3630000 36000 103612344 1036000 2394790000 39043000 -1418311000 1016634000 6668000 1023302000 -47525000 -60910000 61520000 61525000 5954000 3542000 -2660000 423000 69000 28000 -675000 -421000 909000 2559000 689000 955000 -364000 -109000 3866000 0 510000 3212000 0 25786000 938000 1236000 4180000 986000 -1504000 -4855000 979000 -2212000 16358000 21095000 35261000 17799000 13998000 16707000 4580000 0 4803000 11759000 -49036000 -22747000 199160000 0 20000000 0 240000000 0 850000 8329000 5413000 0 7774000 858000 0 39000 0 39000 284000 0 5500000 5500000 4849000 4849000 138000 138000 47426000 -19752000 14748000 -21404000 76538000 85382000 91286000 63978000 51041000 40120000 40245000 23858000 91286000 63978000 46905000 32448000 416000 566000 67975000 64280000 2663000 0 -2663000 0 5167000 0 -5167000 0 Organization <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare Trust, Inc. (including, as required by context, Healthcare Trust Operating Partnership, L.P. (the “OP”) and its subsidiaries, the “Company”), is an externally managed entity that for U.S. federal income tax purposes has qualified as a real estate investment trust (“REIT”). The Company acquires, owns and manages a diversified portfolio of healthcare-related real estate, focused on medical office and other healthcare-related buildings (“MOBs”) and senior housing operating properties (“SHOPs”).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company owned 204 properties located in 33 states and comprised of 9.0 million rentable square feet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through the OP and its wholly-owned subsidiaries including taxable REIT subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages its day-to-day business with the assistance of its property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to the Company. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP. As of September 30, 2023, the Company owned 46 seniors housing properties using the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) structure in its SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs. All of the Company’s properties across both business segments are located throughout the United States. In its MOB operating segment, the Company owns, manages, and leases single- and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. The Property Manager or third-party managers manage the Company’s MOBs. In its SHOP segment, the Company invests in seniors housing properties through the RIDEA structure. As of September 30, 2023, the Company had four eligible independent contractors operating 46 SHOPs, although effective on September 30, 2023, the Company terminated its contract with one independent contractor which managed 20 SHOPs. The Company is in the process of transferring the management of these 20 SHOPs to a new independent contractor, which the Company expects to be completed before December 31, 2023. The Company incurred $0.3 million of costs directly related to the termination in the three and nine months ended September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has declared quarterly dividends entirely in shares of its common stock since October 2020. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. Since October 2020, the Company has issued an aggregate of approximately 17.3 million shares as stock dividends. No other additional shares of common stock have been issued since October 2020. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the cumulative increase in shares outstanding resulting from the stock dividends since October 2020 and through October 2023, and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. Please see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Stockholder’s Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the stock dividends.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2022. The Estimated Per-Share NAV published on March 31, 2023 has not been adjusted since publication and will not be adjusted until the Company’s board of directors (the “Board”) determines a new Estimated Per-Share NAV. Issuing dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a stock dividend; however, because each stockholder will receive the same number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.</span></div> 204 33 9000000 46 2 4 46 1 20 20 300000 300000 17300000 0 Summary of Significant Accounting Policies <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements of the Company included herein were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to this Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished includes all adjustments and accruals of a normal recurring nature, which, in the opinion of management, are necessary for a fair statement of results for the interim periods. The results of operations for the nine months ended September 30, 2023 and 2022 are not necessarily indicative of the results for the entire year or any subsequent interim periods.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2023. Except for those required by new accounting pronouncements discussed below, there have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continuing Impacts of the COVID-19 Pandemic</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, the global COVID-19 pandemic commenced. The pandemic and its aftermath has had, and could continue to have, adverse impacts on economic and market conditions. The Company’s tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted, and may continue to impact, the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants which may further impact the ability of the Company’s tenants to pay their rent obligations to the Company when due.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy as could the rates charged to residents at its SHOPs. Moreover, the demand for leasing space at the Company’s MOB properties could decline, negatively impacting occupancy percentage, revenue and earnings. Additionally, downturns or stagnation in the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates have had, and may continue to have, adverse impacts on the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing wars in Ukraine, Israel and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants to pay rent and hence the Company’s results of operations and liquidity.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — MOB Segment</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial stability and overall health of the Company’s tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its tenants in this segment, and all amounts previously deferred under prior rent deferral agreements have been collected.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases were modified, the Financial Accounting Standards Board (“FASB”) and SEC provided relief that allowed companies to elect whether they treated COVID-19 related lease amendments as provisions included in the pre-concession arrangements, and therefore, not lease modifications, or to treat lease amendments as modifications. In order to be considered COVID-19 related, cash flows had to be substantially the same or less than those prior to the concessions. For COVID-19 relief qualified changes, there were two methods to potentially account for such rent deferrals or abatements under the relief: (i) as if the changes were originally contemplated in the lease contract or (ii) as if the deferred payments are variable lease payments contained in the lease contract.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all other lease changes that did not qualify for FASB relief, the Company was required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualified for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there was no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact was recognized ratably over the remaining life of the leases. For leases not qualifying for this relief, the Company applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — SHOP Segment</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and then stabilized until June 2022. Since then, SHOP occupancy has trended downward. The Company also experienced lower inquiry volumes and reduced in-person tours during the COVID-19 pandemic compared to pre-pandemic periods. In addition, beginning in March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CARES Act Grants”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for additional information on the CARES Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company relied more on the use of temporary contract labor and agencies than it had historically. The Company has since reduced its reliance on this labor source in the nine months ended September 30, 2023. However, the wage expenses (including overtime, training and bonus wages) incurred by the Company from employees of its third party operators has increased due to, among other things, inflation raising the cost of labor generally, a lack of qualified personnel that the Company’s third party operators are able to employ on a permanent basis and training hours and other onboarding costs for permanent staff which replaced previously utilized contract and agency labor.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The persistence of high inflation, labor shortages and supply chain disruptions have caused adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have a material adverse effect on its operations in future periods.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adverse financial impacts of the COVID-19 pandemic on the Company were partially offset by funds received by the Company under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million under the CARES Act during the years ended December 31, 2022, 2021, and 2020, respectively. The Company did not receive any such funds during the three and nine months ended September 30, 2023 and it received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the Company treated these funds as grant contributions from the government. The full amounts received were recognized as reductions of property operating and maintenance expenses in the Company’s consolidated statements of operations and comprehensive loss </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the periods in which the funds were received, to partially offset the incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of September 30, 2023, these leases had a weighted average remaining lease term of 4.8 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with any increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future base rent payments on a cash basis due to the Company over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short term in nature.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">As of September 30, 2023:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,425 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews receivables related to rent and unbilled rent and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive loss in the period the related costs are incurred, as applicable.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded reductions in revenue of $0.2 million and $0.9 million, respectively, for uncollectable amounts during the three and nine months ended September 30, 2023, and $1.7 million and $2.6 million, respectively, during the three and nine months ended September 30, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Real Estate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section in this Note for a discussion of the initial accounting for investments in real estate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the three months ended September 30, 2023 and 2022. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of September 30, 2023 or December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the nine months ended September 30, 2023 were asset acquisitions. The Company acquired seven properties during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from <span style="-sec-ix-hidden:f-606">six</span> to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate value of intangible assets related to customer relationships, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the nine months ended September 30, 2023 or 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Leases</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Accounting</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of September 30, 2023 and December 31, 2022, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (i) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheets as of September 30, 2023 and December 31, 2022, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023 and 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statements of operations and comprehensive income to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held for use. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 15</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress is not depreciated until the project has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company owned 46 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of September 30, 2023 and December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the COVID-19 pandemic. During the three months ended September 30, 2023, the Company modified 26 intercompany leases with the TRS which reduced intercompany rent.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the TRS's recent operating history of losses and the impact of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $7.6 million as of September 30, 2023. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive loss. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into law and provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designed to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company did not receive any funding from the CARES Act during the three and nine months ended September 30, 2023 and the Company received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. Any funding that the Company would receive is recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2022:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not yet Fully Adopted as of September 30, 2023:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform </span></div>activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur. <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements of the Company included herein were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to this Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished includes all adjustments and accruals of a normal recurring nature, which, in the opinion of management, are necessary for a fair statement of results for the interim periods. The results of operations for the nine months ended September 30, 2023 and 2022 are not necessarily indicative of the results for the entire year or any subsequent interim periods.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2023. Except for those required by new accounting pronouncements discussed below, there have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continuing Impacts of the COVID-19 Pandemic</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, the global COVID-19 pandemic commenced. The pandemic and its aftermath has had, and could continue to have, adverse impacts on economic and market conditions. The Company’s tenants and SHOP properties operate businesses that require in-person interactions with their patients and residents, and concern regarding the transmission of COVID-19 impacted, and may continue to impact, the willingness of persons to, among other things, live in or use facilities at the Company’s properties, and impact the revenues generated by the Company’s tenants which may further impact the ability of the Company’s tenants to pay their rent obligations to the Company when due.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to lease space and negotiate and maintain favorable rents and the results of operations at its SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy as could the rates charged to residents at its SHOPs. Moreover, the demand for leasing space at the Company’s MOB properties could decline, negatively impacting occupancy percentage, revenue and earnings. Additionally, downturns or stagnation in the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at the Company’s SHOPs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, recent and continuing increases in inflation brought about by labor shortages, supply chain disruptions and increases in interest rates have had, and may continue to have, adverse impacts on the Company’s results of operations. Moreover, these increases in the rate of inflation, the ongoing wars in Ukraine, Israel and related sanctions, supply chain disruptions and increases in interest rates may also impact the ability of the Company’s tenants to pay rent and hence the Company’s results of operations and liquidity.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways that vary by operating segment:</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — MOB Segment</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial stability and overall health of the Company’s tenants is critical to its business. The Company took a proactive approach to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent. Since the year ended December 31, 2020, the Company has not entered into any rent deferral agreements with any of its tenants in this segment, and all amounts previously deferred under prior rent deferral agreements have been collected.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases were modified, the Financial Accounting Standards Board (“FASB”) and SEC provided relief that allowed companies to elect whether they treated COVID-19 related lease amendments as provisions included in the pre-concession arrangements, and therefore, not lease modifications, or to treat lease amendments as modifications. In order to be considered COVID-19 related, cash flows had to be substantially the same or less than those prior to the concessions. For COVID-19 relief qualified changes, there were two methods to potentially account for such rent deferrals or abatements under the relief: (i) as if the changes were originally contemplated in the lease contract or (ii) as if the deferred payments are variable lease payments contained in the lease contract.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all other lease changes that did not qualify for FASB relief, the Company was required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualified for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there was no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact was recognized ratably over the remaining life of the leases. For leases not qualifying for this relief, the Company applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact — SHOP Segment</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company’s SHOP segment, occupancy trended downward from March 2020 until June 2021 and then stabilized until June 2022. Since then, SHOP occupancy has trended downward. The Company also experienced lower inquiry volumes and reduced in-person tours during the COVID-19 pandemic compared to pre-pandemic periods. In addition, beginning in March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOPs, the Company generally bears these cost increases, which were partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), and to a lesser extent, cost recoveries for personal protective equipment from residents. See “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CARES Act Grants”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for additional information on the CARES Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company relied more on the use of temporary contract labor and agencies than it had historically. The Company has since reduced its reliance on this labor source in the nine months ended September 30, 2023. However, the wage expenses (including overtime, training and bonus wages) incurred by the Company from employees of its third party operators has increased due to, among other things, inflation raising the cost of labor generally, a lack of qualified personnel that the Company’s third party operators are able to employ on a permanent basis and training hours and other onboarding costs for permanent staff which replaced previously utilized contract and agency labor.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The persistence of high inflation, labor shortages and supply chain disruptions have caused adverse impacts to the Company’s occupancy and cost levels, and these trends may continue to impact the Company and have a material adverse effect on its operations in future periods.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adverse financial impacts of the COVID-19 pandemic on the Company were partially offset by funds received by the Company under the CARES Act. The Company received $4.5 million, $5.1 million and $3.6 million under the CARES Act during the years ended December 31, 2022, 2021, and 2020, respectively. The Company did not receive any such funds during the three and nine months ended September 30, 2023 and it received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the Company treated these funds as grant contributions from the government. The full amounts received were recognized as reductions of property operating and maintenance expenses in the Company’s consolidated statements of operations and comprehensive loss </span></div>for the periods in which the funds were received, to partially offset the incurred COVID-19 expenses. The Company does not anticipate that any further funds under the CARES Act will be received, and there can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs. <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.</span></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.</span></div> 4500000 5100000 3600000 0 0 4300000 4500000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in its MOB segment. As of September 30, 2023, these leases had a weighted average remaining lease term of 4.8 years. Rent from tenants in the Company’s MOB operating segment (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Tenant revenue also includes operating expense reimbursements which generally increase with any increase in property operating and maintenance expenses in our MOB segment. In addition to base rent, dependent on the specific lease, tenants are generally required to pay either (i) their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors or (ii) their share of increases in property operating and maintenance expenses to the extent they exceed the properties’ expenses for the base year of the respective leases. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOP segment, held using a structure permitted under RIDEA. Rental income from residents in the Company’s SHOP segment is recognized as earned when services are provided. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the leases are short term in nature, primarily month-to-month.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating and maintenance expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating and maintenance costs of the respective properties.</span></div>The Company continually reviews receivables related to rent and unbilled rent and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards, the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive loss in the period the related costs are incurred, as applicable. P4Y9M18D <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future base rent payments on a cash basis due to the Company over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short term in nature.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">As of September 30, 2023:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,425 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 27566000 108291000 98378000 90299000 71439000 240452000 636425000 200000 900000 1700000 2600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Real Estate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section in this Note for a discussion of the initial accounting for investments in real estate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the three months ended September 30, 2023 and 2022. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were no real estate investments held for sale as of September 30, 2023 or December 31, 2022.</span></div> 0 0 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In allocating the fair value to any assumed or issued non-controlling interests, amounts are recorded at their fair value at the close of business on the acquisition date. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the nine months ended September 30, 2023 were asset acquisitions. The Company acquired seven properties during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates the fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from <span style="-sec-ix-hidden:f-606">six</span> to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate value of intangible assets related to customer relationships, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the nine months ended September 30, 2023 or 2022.</span></div> 7 P24M <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Leases</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Accounting</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the lease accounting standard, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than a major part of the remaining economic useful life of the asset (e.g., equal to or greater than 75%), the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or the asset is so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. As of September 30, 2023 and December 31, 2022, the Company had no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor of real estate, the Company has elected, by class of underlying assets, to account for lease and non-lease components (such as tenant reimbursements of property operating and maintenance expenses) as a single lease component as an operating lease because (i) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under the accounting guidance. Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed.</span></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also the lessee under certain land leases which will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheets as of September 30, 2023 and December 31, 2022, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023 and 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lessees, the accounting standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction. For additional information and disclosures related to the Company’s operating leases, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statements of operations and comprehensive income to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held for use. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.</span></div> <div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has two reportable segments, with activities related to investing in MOBs and SHOPs. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level. For additional information see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 15</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 2 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress is not depreciated until the project has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.</span></div> P40Y P15Y P7Y P10Y <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and local income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2022, 2021 and 2020. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company owned 46 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of September 30, 2023 and December 31, 2022 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the COVID-19 pandemic. During the three months ended September 30, 2023, the Company modified 26 intercompany leases with the TRS which reduced intercompany rent.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the TRS's recent operating history of losses and the impact of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $7.6 million as of September 30, 2023. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive loss. As of December 31, 2022, the Company had a deferred tax asset of $6.9 million with a full valuation allowance.</span></div> 46 25 26 1 7600000 6900000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into law and provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designed to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company did not receive any funding from the CARES Act during the three and nine months ended September 30, 2023 and the Company received $4.3 million and $4.5 million, respectively, in funding from the CARES Act during the three and nine months ended September 30, 2022. For accounting purposes, the CARES Act funds are treated as a grant contribution from the government. Any funding that the Company would receive is recognized as a reduction of property operating and maintenance expenses in the Company’s consolidated statements of operations to offset the negative impacts of COVID-19. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.</span></div> 0 0 4300000 4500000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2022:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition methods. The Company adopted the new guidance on January 1, 2022 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not yet Fully Adopted as of September 30, 2023:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period from March 12, 2020 through June 30, 2023 as reference rate reform </span></div>activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that the Company’s hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of the Company’s derivatives, which will be consistent with the Company’s past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur. Real Estate Investments, Net <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property Acquisitions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in healthcare-related facilities, primarily MOBs and seniors housing properties which expand and diversify its portfolio and revenue base. The Company owned 204 properties as of September 30, 2023. During the nine months ended September 30, 2023 and 2022, the Company acquired seven and three properties, respectively. All acquisitions in the nine months ended September 30, 2023 and 2022 were considered asset acquisitions for accounting purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the allocation of real estate assets acquired and liabilities assumed during the nine months ended September 30, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,861 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases and other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease and other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for real estate investments, including acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,261 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,799 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of properties purchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Tenants</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and 2022, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income for the portfolio on a straight-line basis. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of September 30, 2023 and 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the date specified.</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Intangible Assets and Liabilities</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above- and below-market lease assets and liabilities, net and the amortization and accretion of above- and below-market ground leases, net, for the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of in-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of above -and below-market leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of above -and below-market ground leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within depreciation and amortization expense.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within rental income.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within property operating and maintenance expense.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the projected amortization expense and adjustments to revenues for the next five years: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Above-market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below-market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to revenue from tenants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dispositions</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three and Nine Months Ended September 30, 2023</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, the Company did not dispose of any properties. During the nine months ended September 30, 2023, the Company disposed of four SHOPs and one MOB for an aggregate contract sales price of $13.8 million. Two of the four disposed SHOPs were impaired by $15.1 million in the year ended December 31, 2022 (see below). As a result, the Company recorded an aggregate loss on sale of $0.4 million, which is presented in the Company’s consolidated statement of operations and comprehensive loss</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three and Nine Months Ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2020, the Company transitioned four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) from the former triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties were leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. During the third quarter of 2021, the Company began to actively market the LaSalle Properties for sale, and a non-binding letter of intent was signed in the fourth quarter of 2021 for an aggregate contract sales price of $12.4 million. The Company had previously recorded $34.0 million of impairment charges on the LaSalle Properties in the year ended December 31, 2021. The Company completed the sale of the LaSalle Properties in the first quarter of 2022 and recorded a loss on sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million in the first quarter of 2022, wh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ich is presented in the Company’s consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2022.The Company recorded a gain on sale of $0.2 million in the three months ended September 30, 2022 related to the settlement of a lien on formerly disposed properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no assets held for sale as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Use</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single-tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Charges</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment charges recorded in the three and nine months ended September 30, 2023. The following table presents impairment charges by segment recorded during the nine months ended September 30, 2022:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MOB Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois skilled nursing facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total MOB impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHOP Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various held for use SHOPs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total SHOP impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of September 30, 2023, these properties were not disposed of, nor were any under contract for disposal.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Consists of eight total properties that were impaired as a result of the Company reassessing the holding period for the properties. Two of these properties were sold in the nine months ended September 30, 2023.</span></div> 204 7 3 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the allocation of real estate assets acquired and liabilities assumed during the nine months ended September 30, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,861 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases and other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease and other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for real estate investments, including acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,261 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,799 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of properties purchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3373000 4199000 27069000 10662000 30442000 14861000 5057000 2670000 33000 268000 271000 0 4819000 2938000 35261000 17799000 7 3 The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of September 30, 2023 and 2022:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the date specified.</span></div> 0.198 0.190 0.106 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above- and below-market lease assets and liabilities, net and the amortization and accretion of above- and below-market ground leases, net, for the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of in-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of above -and below-market leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of above -and below-market ground leases, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within depreciation and amortization expense.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflected within rental income.</span></div>(3)Reflected within property operating and maintenance expense 3455000 3815000 10414000 11502000 -244000 -219000 -795000 -549000 40000 40000 120000 120000 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the projected amortization expense and adjustments to revenues for the next five years: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Above-market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below-market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to revenue from tenants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3157000 11812000 10224000 8979000 5468000 10000 10000 10000 10000 10000 3167000 11822000 10234000 8989000 5478000 -101000 -419000 -366000 -331000 -243000 309000 1297000 1127000 972000 654000 208000 878000 761000 641000 411000 0 4 1 13800000 2 4 15100000 -400000 4 12400000 34000000 -300000 -200000 0 0 0 0 The following table presents impairment charges by segment recorded during the nine months ended September 30, 2022:<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MOB Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois skilled nursing facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total MOB impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHOP Segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various held for use SHOPs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total SHOP impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">These seven properties were impaired after the Company received an offer by the tenant to purchase all seven properties, which caused the Company to reassess its expected holding period for these properties. As of September 30, 2023, these properties were not disposed of, nor were any under contract for disposal.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Consists of eight total properties that were impaired as a result of the Company reassessing the holding period for the properties. Two of these properties were sold in the nine months ended September 30, 2023.</span></div> 0 10644000 0 10644000 8949000 15142000 8949000 15142000 8949000 25786000 7 7 8 2 Mortgage Notes Payable, Net<div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s mortgage notes payable as of September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Loan Amount as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One MOB Loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multi-Property CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shiloh - Illinois</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan. 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BMO CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Barclays MOB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross mortgage notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs, net of accumulated amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage premiums and discounts, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808,752 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all mortgages outstanding as of September 30, 2023 and December 31, 2022. For the SOFR (defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)/LIBOR based loans, the Company used the applicable SOFR/LIBOR rate index in effect at the balance sheet date. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on daily SOFR as of September 30, 2023 and December 31, 2022, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close or result in a definitive agreement.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company had pledged $1.3 billion in total real estate investments, at cost, as collateral for its $0.8 billion of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants, including debt service coverage ratios. As of September 30, 2023, the Company was in compliance with these financial covenants.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities - Future Principal Payment and LIBOR Transition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and discussion of the cessation of LIBOR publication.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Barclays MOB Loan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2023, the Company, through certain subsidiaries of the OP), entered into a non-recourse loan agreement (the “Barclays MOB Loan Agreement”), with (i) Barclays Capital Real Estate Inc., (ii) Société Générale Financial Corporation and (iii) KeyBank National Association (each individually, a “Lender,” and collectively, the “Lenders”), in the aggregate amount of $240.0 million (the “Barclay’s MOB Loan”). In connection with the Barclay’s MOB Loan Agreement, the OP entered into a Guaranty Agreement (the “Guaranty”) and an Environmental Indemnity Agreement (the “Environmental Indemnity”) for the benefit of the Lenders.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Barclays MOB Loan is secured by, among other things, first priority mortgages on the Company’s interests in 62 MOBs with an aggregate gross asset value of $416.8 million. The Barclays MOB Loan has a 10-year term and is interest-only at a fixed rate of 6.453% per year. Under the Barclays MOB Loan Agreement, the Company is required to make interest-only </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments on a monthly basis with the principal balance due on the maturity date of June 6, 2033. The Barclays MOB Loan Agreement requires the OP to comply with certain covenants, including, maintaining combined cash and cash equivalents totaling at least $12.5 million at all times.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain conditions, the Company may prepay the Barclays MOB Loan in whole or in part at any time after one year from closing with a pre-payment premium equal to the Yield Maintenance Program (as defined in the Barclays MOB Loan Agreement) by providing the lenders thereunder with prior written notice of prepayment no less than thirty days before prepayment, subject to a pre-payment premium equal to the Yield Maintenance Premium (as defined in the Barclay’s MOB Loan Agreement). Following the earlier of May 24, 2026 and the date that is two years after the securitization of the Barclay’s MOB Loan, the Company may prepay the Barclays MOB Loan through defeasance, Notwithstanding the foregoing, the Barclays MOB Loan may be prepaid at par during the final six months of the term. The Company paid $7.8 million in deferred financing costs related to the Barclay’s MOB Loan, which is amortized into interest expense over the term of the loan.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Barclays MOB Loan, the Company applied $194.8 million of the Barclays MOB Loan proceeds to repay and terminate the Company’s then-existing credit facility (the “Prior Credit Facility”). The Company also terminated its interest rate swap contracts that formerly hedged interest rate changes under the Prior Credit Facility (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information). The remaining proceeds of approximately $39.0 million (after the payment of Barclays MOB Loan closing costs and reimbursement of deposits) are available for general corporate purposes, subject to the terms of the Barclays MOB Loan Agreement. Additionally, by terminating the Prior Credit Facility, the Company is no longer subject to certain restrictive covenants previously imposed by the Prior Credit Facility (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Guaranty, the OP has (i) guaranteed the full repayment of the Barclays MOB Loan in the case of certain major defaults by the Company or the OP, including bankruptcy, and (ii) indemnified the Lenders against losses, costs or liabilities related to certain other “bad boy” acts of the Company or the OP, including fraud, willful misconduct, bad faith, and gross negligence. Pursuant to the Environmental Indemnity, the OP and the Company have indemnified the Lenders against losses, costs or liabilities related to certain environmental matters.</span></div> <div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s mortgage notes payable as of September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Loan Amount as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One MOB Loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multi-Property CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shiloh - Illinois</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan. 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BMO CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Barclays MOB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross mortgage notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs, net of accumulated amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage premiums and discounts, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808,752 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all mortgages outstanding as of September 30, 2023 and December 31, 2022. For the SOFR (defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)/LIBOR based loans, the Company used the applicable SOFR/LIBOR rate index in effect at the balance sheet date. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on daily SOFR as of September 30, 2023 and December 31, 2022, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. The Company allocated $378.5 million of its “pay-fixed” interest rate swaps to this mortgage consistently as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close or result in a definitive agreement.</span></div> 1 6689000 6817000 0.0398 0.0398 1 15344000 15639000 0.0295 0.0295 1 9520000 9704000 0.0295 0.0295 41 378500000 378500000 0.0371 0.0373 20 116037000 118700000 0.0460 0.0460 1 12828000 13071000 0.0434 0.0434 9 42750000 42750000 0.0289 0.0289 62 240000000 0 0.0645 0 136 821668000 585181000 0.0458 0.0383 11620000 5117000 1296000 1364000 808752000 578700000 378500000 378500000 1300000000 800000000 240000000 62 416800000 P10Y 0.06453 12500000 P1Y P30D 7800000 194800000 39000000 Credit Facilities <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company had the following credit facilities outstanding as of September 30, 2023 and December 31, 2022:</span></div><div style="margin-bottom:1pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Facility <br/>Amount as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior Credit Facility:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Term Loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Term Loan, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Prior Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fannie Mae Master Credit Facilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KeyBank Facility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530,297 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.86 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.94 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Encumbered properties are as of September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on 11 of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $350.5 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on ten of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $261.9 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all credit facilities outstanding as of September 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details).</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The effective rates above only include the impact of designated hedging instruments. The Company has seven non-designated interest rate cap agreements with an aggregate notional amount of $351.6 million which limited 30-day LIBOR (until June 30, 2023, and SOFR thereafter) to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility and KeyBank Fannie Mae Facility was 5.89% and 5.93%, respectively, as of September 30, 2023, and 5.26%, and 5.96%, respectively, as of December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended December 31 2022, the Company exercised its option to extend the maturity one year to March 2024 subject to certain conditions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Effective interest rate below for variable rate debt gives effect to any outstanding “pay-fixed” swaps entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of September 30, 2023 and December 31, 2022. The Company allocated $150.0 million of its SOFR-based interest rate swaps to the Term Loan $50.0 million of its LIBOR-based interest rate swaps to the Capital One Facility as of December 31, 2022. The interest rate swaps allocated to the Prior Credit Facility were all terminated in the nine months ended September 30, 2023. Upon termination, the fair values of terminated swaps are recorded within AOCI, and are amortized into interest expense over the original term of the then-existing swap. These amortized amounts from terminated swaps are not included in the calculation of effective interest. The Company continues to have $378.5 million of SOFR-based “pay-fixed” interest rate swaps allocated to a variable-rate mortgage note payable as of September 30, 2023. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the carrying value of the Company’s real estate investments, at cost was $2.6 billion, with $1.3 billion of this asset value pledged as collateral for mortgage notes payable and $0.6 billion of this asset value pledged to secure advances under the Fannie Mae Master Credit Facilities. All of the real estate assets pledged to secure debt or to secure the Fannie Mae Master Credit Facilities are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the pledged collateral.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unencumbered real estate investments, at cost as of September 30, 2023 were $0.7 billion, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for future mortgage loans, future advances under the Fannie Mae Master Credit Facilities, or other future financings.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Credit Facility</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior Credit Facility consisted of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”). The Revolving Credit Facility and Term Loan were interest-only and would have matured on March 13, 2024. The Prior Credit Facility was fully repaid in May 2023 with net proceeds provided by the Barclays MOB Loan (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for details) and the Prior Credit Facility was terminated.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Prior Credit Facility bore interest at the Company’s option of either (i) Secured Overnight Financing Rate (“SOFR”), plus an applicable margin that ranges, depending on the Company’s leverage, from 2.10% to 2.85% or (ii) the Base Rate (as defined in the Prior Credit Facility), plus an applicable margin that ranged, depending on the Company’s leverage, from 0.85% to 1.60%. For the period from January 1, 2023 through the termination of the Prior Credit Facility in May 2023, the Company elected to use the SOFR option for all of its borrowings under the Prior Credit Facility. At termination, the Company wrote off the remaining deferred financing costs associated with the Prior Credit Facility of $2.6 million which is included in interest expense in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior Credit Facility contained various restrictions which no longer apply, that limited the Company’s ability to incur additional debt, maintain certain cash balances or pay dividends, among other things.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fannie Mae Master Credit Facilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually as a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements were assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Fannie Mae Master Credit Facilities, the Company was required to enter into interest rate cap agreements which the Company periodically renews upon their expiration. During the three months ended September 30, 2023, the Company paid premiums of $4.6 million to renew three caps which matured in the three months ended September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 the Company had six non-designated interest rate cap agreements with an aggregate current effective notional amount of $351.6 million which caps SOFR at 3.50% and various maturities through April 2024. The existing caps were transitioned to SOFR-based contracts effective July 1, 2023. The Company does not apply hedge accounting to these non-designated interest cap agreements and changes in value are reflected in earnings (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding the Company’s derivatives).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, $347.7 million was outstanding under the Fannie Mae Master Credit Facilities. The Company may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. Borrowings under the Fannie Mae Master Credit Facilities bore annual interest at a rate that varied on a monthly basis and was equal to the sum of the current LIBOR for one month U.S. dollar-denominated deposits and a spread (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively). Effective July 1, 2023, the Fannie Mae Master Credit Facilities automatically transitioned to SOFR-based borrowings with monthly interest equal to the sum of the current SOFR for one-month denominated deposits and a spread of (2.41% and 2.46% for the Capital One Facility and the KeyBank Facility, respectively). The Fannie Mae Master Credit Facilities mature on November 1, 2026.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had $150.0 million of SOFR-based interest swap agreements, which were allocated to the Term Loan, and $50.0 million of LIBOR-based interest swap agreements which were allocated to the Capital One Facility. These swaps were all terminated in the six months ended June 30, 2023. The Term Loan was fully repaid in the three months ended June 30, 2023, but the Capital One Facility remained outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2023, the Company provided a $5.1 million cash deposit to Fannie Mae because the debt service coverage ratios of the underlying properties of each facility were below the minimum required amount per the debt agreements. This amount will be recorded as restricted cash and is pledged as additional collateral for the Fannie Mae Master Credit Facilities. This deposit will be refunded the earlier of the Company’s achievement of a debt service coverage ratio above the minimum required amount of 1.40 or the maturity of the Fannie Mae Master Credit Facilities. Subsequent to September 30, 2023, the Company provided an additional deposit of $6.7 million, which brought the total deposit to $11.8 million (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Principal Payments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled aggregate principal payments for the five years subsequent to September 30, 2023 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:65.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Principal<br/>Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mortgage Notes Payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821,668 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169,388 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIBOR Transition</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the SOFR as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings were published through June 30, 2023. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no LIBOR-based borrowings or derivative instruments as of September 30, 2023. As of September 30, 2023, the Company had $347.7 million of variable-rate, SOFR-based borrowings under the Fannie Mae Master Credit Facilities, which automatically transitioned from variable-rate, LIBOR-based borrowings on July 1, 2023. As of September 30, 2023, the Company had SOFR-based interest rate caps with notional amounts of $351.6 million which are not designated as hedging instruments which also transitioned from LIBOR-based contracts effective July 1, 2023. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company converted $150.0 million of its “pay-fixed” swaps on its Prior Credit Facility from LIBOR to SOFR, as well as its $378.5 million Capital One MOB Loan and the related “pay-fixed” swap from LIBOR to SOFR. During the nine months ended September 30, 2023, the Company terminated its remaining $50.0 million of LIBOR-based “pay-fixed” swaps. The “pay-fixed” swaps were terminated in an asset position and the Company received $5.4 million in cash following the termination. This amount was included in accumulated other comprehensive income (“AOCI”), and will amortize into earnings as a reduction to interest expense through March 2024 (the original term of the swap and variable hedged debt). See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details.</span></div> The Company had the following credit facilities outstanding as of September 30, 2023 and December 31, 2022:<div style="margin-bottom:1pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Facility <br/>Amount as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior Credit Facility:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Term Loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Term Loan, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Prior Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fannie Mae Master Credit Facilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KeyBank Facility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530,297 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.86 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.94 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Encumbered properties are as of September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on 11 of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $350.5 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on ten of the Company’s seniors housing properties as of September 30, 2023 with an aggregate carrying value, at cost of $261.9 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all credit facilities outstanding as of September 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on SOFR, all of which was economically fixed as a result of entering into “pay-fixed” interest rate swap agreements (the Company designates its SOFR “pay-fixed” interest rate swaps against all 30-day SOFR debt, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details).</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The effective rates above only include the impact of designated hedging instruments. The Company has seven non-designated interest rate cap agreements with an aggregate notional amount of $351.6 million which limited 30-day LIBOR (until June 30, 2023, and SOFR thereafter) to 3.50%. The Company did not designate these derivatives as hedges and accordingly, the changes in value and any cash received from these derivatives are presented within gain (loss) on derivative instruments on the consolidated statements of operations and comprehensive income (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details). Inclusive of the impact of these interest rate caps on these non-designated derivatives, the economic interest rate on the Capital One Fannie Mae Facility and KeyBank Fannie Mae Facility was 5.89% and 5.93%, respectively, as of September 30, 2023, and 5.26%, and 5.96%, respectively, as of December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended December 31 2022, the Company exercised its option to extend the maturity one year to March 2024 subject to certain conditions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Effective interest rate below for variable rate debt gives effect to any outstanding “pay-fixed” swaps entered into by the Company allocated to the loan for presentation purposes. If no “pay-fixed” swaps are allocated, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of September 30, 2023 and December 31, 2022. The Company allocated $150.0 million of its SOFR-based interest rate swaps to the Term Loan $50.0 million of its LIBOR-based interest rate swaps to the Capital One Facility as of December 31, 2022. The interest rate swaps allocated to the Prior Credit Facility were all terminated in the nine months ended September 30, 2023. Upon termination, the fair values of terminated swaps are recorded within AOCI, and are amortized into interest expense over the original term of the then-existing swap. These amortized amounts from terminated swaps are not included in the calculation of effective interest. The Company continues to have $378.5 million of SOFR-based “pay-fixed” interest rate swaps allocated to a variable-rate mortgage note payable as of September 30, 2023. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details.</span></div> 0 30000000 0 0.0726 0 150000000 0 0.0511 0 1750000 0 148250000 0 0 178250000 11 207829000 210483000 0.0784 0.0590 10 139891000 141564000 0.0789 0.0660 21 347720000 352047000 21 347720000 530297000 0.0786 0.0594 11 350500000 10 261900000 7 351600000 0.0350 0.0589 0.0593 0.0526 0.0596 P1Y 150000000 50000000 378500000 2600000000 1300000000 600000000 700000000 0.0210 0.0285 0.0085 0.0160 2600000 2600000 4600000 3 6 351600000 0.0350 347700000 0.0241 0.0246 0.0241 0.0246 150000000 50000000 5100000 1.40 6700000 11800000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled aggregate principal payments for the five years subsequent to September 30, 2023 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:65.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Principal<br/>Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mortgage Notes Payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821,668 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169,388 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 289000 1442000 1731000 1178000 5769000 6947000 13270000 5769000 19039000 379393000 334740000 714133000 922000 0 922000 426616000 0 426616000 821668000 347720000 1169388000 347700000 351600000 150000000 378500000 50000000 -5400000 Fair Value of Financial Instruments <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring assets and liabilities at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of September 30, 2023, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022, aggregated by the level in the fair value hierarchy within which those instruments fall.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets<br/>Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Investments Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments - Held for Use</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheets as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company owned 16 held for use properties (10 MOBs and six SHOPs) for which the Company had reconsidered their expected holding periods, of which six properties (three MOB and three SHOPs) are being marketed for sale. As a result, the Company evaluated the impact on its ability to recover the carrying values of the respective properties, and has previously recorded impairment charges on 10 properties (eight MOBs and two SHOPs) to reduce the carrying values to their estimated fair values during the year ended December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate Investments, Net - “Assets Held for Use and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments - Held for Sale</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate investments held for sale are carried at net realizable value on a non-recurring basis and are generally classified in Level 3 of the fair value hierarchy. The Company did not have any real estate investments classified as held for sale as of September 30, 2023 and December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross mortgage notes payable and mortgage premium and discounts, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,496 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,034 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022, aggregated by the level in the fair value hierarchy within which those instruments fall.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets<br/>Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (non-designated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets, at fair value (designated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 4946000 0 4946000 0 32601000 0 32601000 0 37547000 0 37547000 0 3737000 0 3737000 0 36910000 0 36910000 0 40647000 0 40647000 16 10 6 6 3 3 10 8 2 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross mortgage notes payable and mortgage premium and discounts, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,496 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,120 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,047 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,034 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 820372000 766584000 583817000 550626000 0 0 180000000 179496000 347720000 348120000 352047000 353034000 Derivatives and Hedging Activities <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management Objective of Using Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of September 30, 2023 and December 31, 2022: </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,946 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges of Interest Rate Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below details the location in the financial statements of the gain (loss) recognized on interest rate derivatives designated as cash flow hedges for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,648 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,862)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount of interest expense presented in the</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">consolidated statements of operations and comprehensive loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,720)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,284)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,208)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,098)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company had one SOFR-based “pay-fixed” interest rate swap that is designated as a cash flow hedge. The Company uses its interest rate swap as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for fixed-rate payments by the Company over the life of the agreement without exchange of the underlying notional amount. During the nine months ended September 30, 2023 and the year ended December 31, 2022, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. The remaining interest rate “pay-fixed” swap has a base interest rate of 1.61% and matures December 2026.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in AOCI and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MOB Loan Swap Termination</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the refinancing of the $250.0 million loan made by Capital One, National Association and certain other lenders to certain subsidiaries of the OP on June 30, 2017 (the “MOB Loan”), during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and was reclassified as an increase to interest expense over the original term of the two terminated swaps and the MOB Loan prior to its refinancing. For the nine months ended September 30, 2022, the Company reclassified $0.4 million from AOCI as an increase to interest expense. No amounts remained in AOCI related to this swap termination designated to the MOB Loan as of December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior Credit Facility Swap Terminations</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company terminated two LIBOR-based interest rate swap agreements with an aggregate notional amount of $50.0 million and six SOFR-based interest rate swap agreements with an aggregate notional amount of $150.0 million. The swaps were terminated in asset positions, and the Company received $1.9 million in cash from the LIBOR-based swap terminations, and $3.5 million in cash from the SOFR-based swap terminations. These amounts were included in AOCI and will be amortized into earnings as a reduction to interest expense from the termination dates of the swaps through March 2024 (the original term of the swap and the Prior Credit Facility). For the three and nine months ended September 30, 2023, the Company reclassified $1.5 million and $2.7 million, respectively, from AOCI as decreases to interest expense, and $2.7 million remained in AOCI as of September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from October 1, 2023 through September 30, 2024, the Company estimates that $16.5 million will be reclassified from AOCI as a decrease to interest expense or other comprehensive income relating to the “pay-fixed” swaps designated as derivatives.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Designated Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following outstanding interest rate derivatives with current effective notional amounts that were not designated as hedges in qualified hedging relationships as of September 30, 2023 and December 31, 2022:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,624 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Notional amount represents the currently active interest rate cap contracts.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">All of the Company’s interest rate cap agreements limited 30-day LIBOR through June 30, 2023 (and SOFR, thereafter) to 3.50% with terms through July 2025. The actual 30-day LIBOR rates during the six months ended June 30, 2023, and the SOFR rates during the three months ended September 30, 2023, exceeded the strike price rate of 3.50% and the Company received payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These derivatives are used to limit the Company’s exposure to interest rate movements for economic purposes, however, the Company has not elected to apply hedge accounting. As of September 30, 2023 and December 31, 2022, the Company had entered into six SOFR-based and seven LIBOR-based interest rate caps, respectively, with notional amounts of $351.6 million and $354.6 million, respectively, which limited 30-day SOFR/LIBOR borrowings to 3.50% and have varying maturities through July 2025.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid premiums of $4.6 million to renew three caps with an aggregate notional amount of $138.5 million which matured in the nine months ended September 30, 2023. Subsequent to September 30, 2023, the Company paid premiums of $5.0 million to renew two maturing interest rate caps with an aggregate notional amount of $150.9 million (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information). One interest rate cap with a notional amount of $60.0 million matures in April 2024, which represents the next interest rate cap maturity excluding those renewed subsequent to September 30, 2023. All of the Company’s LIBOR-based interest rate caps were transitioned to SOFR-based contracts effective July 1, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the year ended December 31, 2022, LIBOR exceeded 3.50% and the Company began receiving payments under these interest rate caps. While the Company does not apply hedge accounting for these interest rate caps, they are economically hedging the Capital One Facility and KeyBank Facility. Changes in the fair value of, and any cash received from, derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net loss and are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains on non-designated derivatives were $0.4 million and $0.5 million, respectively, for the three and nine months ended September 30, 2023, and were $1.8 million and $3.2 million, respectively, for the three and nine months ended September 30, 2022. During the nine months ended September 30, 2023, the Company received aggregate payments of $3.9 million related to its effective interest rate caps as LIBOR/SOFR exceeded the effective rates of the capped debt. No such amounts were received during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offsetting Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives (both designated and non-designated) as of September 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amounts of Assets presented in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit-risk-related Contingent Features</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there were no derivatives in a net liability position. The Company is not required to post any collateral related to these agreements and was not in breach of any agreement provisions.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of September 30, 2023 and December 31, 2022: </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,946 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 32601000 36910000 4946000 3737000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR-based interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following outstanding interest rate derivatives with current effective notional amounts that were not designated as hedges in qualified hedging relationships as of September 30, 2023 and December 31, 2022:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,624 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Notional amount represents the currently active interest rate cap contracts.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">All of the Company’s interest rate cap agreements limited 30-day LIBOR through June 30, 2023 (and SOFR, thereafter) to 3.50% with terms through July 2025. The actual 30-day LIBOR rates during the six months ended June 30, 2023, and the SOFR rates during the three months ended September 30, 2023, exceeded the strike price rate of 3.50% and the Company received payments under these agreements. Changes in the fair market value of these non-designated derivatives, as well as any cash received, are presented within gain (loss) on non-designated derivatives in the Company’s consolidated statements of operations and comprehensive income.</span></div> 1 378500000 7 528500000 0 0 2 50000000 1 378500000 9 578500000 <div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below details the location in the financial statements of the gain (loss) recognized on interest rate derivatives designated as cash flow hedges for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,648 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,862)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount of interest expense presented in the</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">consolidated statements of operations and comprehensive loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,720)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,284)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,208)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,098)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5418000 17513000 12078000 49522000 5023000 565000 13648000 -3862000 15720000 13284000 50208000 37098000 1 0.0161 250000000 2 250000000 2200000 -2200000 2 -400000 0 2 50000000 6 150000000 1900000 3500000 1500000 2700000 -2700000 16500000 6 351572000 7 354624000 0.0350 0.0350 6 7 351600000 354600000 0.0350 4600000 3 138500000 5000000 2 150900000 1 60000000 0.0350 400000 500000 1800000 3200000 3900000 The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives (both designated and non-designated) as of September 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amounts of Assets presented in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 37547000 0 0 37547000 0 0 37547000 40647000 0 0 40647000 0 0 40647000 Stockholders’ Equity <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company had 109,877,212 and 105,080,531 shares of common stock outstanding, respectively, including unvested restricted shares, shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases, and shares issued as stock dividends since October 2020. Since October 2020, the Company has issued an aggregate of approximately 17.3 million shares in respect to the stock dividends. Except for shares issued as dividends, no additional shares of common stock were issued during the nine months ended September 30, 2023 or the year ended December 31, 2022. References made to weighted-average shares and per-share amounts in the consolidated statements of operations and comprehensive loss have been retroactively adjusted to reflect the cumulative increase in shares outstanding due to the stock dividends (including the October 2023 stock dividend) and are noted as such throughout the accompanying financial statements and notes. Any future issuances of stock dividends will also result in retroactive adjustments. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the Company published a new Estimated Per-Share NAV as of December 31, 2022, which was approved by the Board on March 31, 2023. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually unless the Company lists its common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board suspended the SRP in August 2020 and rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the number of shares repurchased and the average price per share, under the SRP and does not include any repurchases under tender offers, cumulatively through September 30, 2023. </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares Repurchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price per Share</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine months ended September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative repurchases as of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Reinvestment Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheets in the period distributions are declared. During the nine months ended September 30, 2023 and the year ended December 31, 2022, the Company did not issue any shares of common stock pursuant to the DRIP. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Rights Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its Board in its discretion.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock and Preferred Units</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019, the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC, (the “Preferred Stock Equity Line”) and in May 2021, the Board authorized the classification of 2,530,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the offering in May 2021. Also, in connection with an underwritten offering in October 2021, the Company classified and designated 3,680,000 shares of its authorized preferred stock on October 4, 2021 as authorized shares of its Series B Preferred Stock. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had 3,977,144 shares of Series A Preferred Stock issued and outstanding as of September 30, 2023 and December 31, 2022. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had 3,630,000 shares of Series B Preferred Stock issued and outstanding as of September 30, 2023 and December 31, 2022. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had 100,000 Series A Preferred Units outstanding as of September 30, 2023 and December 31, 2022, which were accounted for as a component of non-controlling interests. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Non-controlling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Distributions and Dividends</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2020, the Board changed the Company’s common stock distribution policy to preserve the Company’s liquidity and maintain additional financial flexibility. Under the policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s Estimated Per Share NAV of common stock in effect on the applicable date:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Issue Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Stock Dividend Rate (per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 18, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 17, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.015179</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.015179</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 16, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.015179</span></td></tr></table></div> 109877212 105080531 17300000 0 0 1 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the number of shares repurchased and the average price per share, under the SRP and does not include any repurchases under tender offers, cumulatively through September 30, 2023. </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares Repurchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price per Share</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine months ended September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative repurchases as of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4896620 20.60 0 0 4896620 20.60 P10D 0 0 1 50000000 1610000 600000 2530000 3680000 3977144 3977144 3977144 3977144 3630000 3630000 3630000 3630000 100000 100000 0.85 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Dividend Issue Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Stock Dividend Rate (per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.013492</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 18, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.014167</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 17, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.015179</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.015179</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 16, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.015179</span></td></tr></table> 0.013492 0.013492 0.014655 0.014655 0.014655 0.014655 0.014167 0.014167 0.014167 0.014167 0.015179 0.015179 0.015179 Related Party Transactions and Arrangements<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Special Limited Partner owned 10,550 and 10,094 shares (assuming conversion of its partnership interests), respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of September 30, 2023 and December 31, 2022, the Advisor held 90 partnership units in the OP designated as “Common OP Units”.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP.  In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees Incurred in Connection with the Operations of the Company</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Second Amended and Restated Advisory Agreement by and among the Company, the OP and the Advisor (as amended the “Second A&amp;R Advisory Agreement”) took effect on February 17, 2017 and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&amp;R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&amp;R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days’ prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&amp;R Advisory Agreement or (b) any material breach of the Second A&amp;R Advisory Agreement of any nature whatsoever by the Company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2019, the Company entered into Amendment No. 1 to the Second A&amp;R Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “—Professional Fees and Other Reimbursements.”</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition Expense Reimbursements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for </span></div>third-party acquisition expenses. Under the Second A&amp;R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through September 30, 2023.<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Asset Management Fees and Variable Management/Incentive Fees</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LPA and the advisory agreement that was superseded by the original amended and restated advisory agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the “Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of September 30, 2023, the Company determined that achieving the Performance Condition was not yet considered probable for accounting purposes. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any, on the Company’s common stock. These cash distributions on Class B Units are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss until the Performance Condition is considered probable to occur. stock dividends do not cause the OP to issue additional Class B Units, rather, the redemption ratio to common stock is adjusted. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that the Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 17, 2017, the Second A&amp;R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. There are no variable management fees earned from the issuance of common stock dividends. The base management fee is payable to the Advisor or its assignees in cash, Common OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any Common OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Second A&amp;R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted shares of common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No incentive fee was incurred for the three and nine months ended September 30, 2023 or 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property Management Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by the Company’s Board (including a majority of the independent directors).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&amp;R Property Management Agreement”) with the OP and the Property Manager. The A&amp;R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&amp;R Property Management Agreement at least 90 days prior to the end of the term. Neither party has provided notice of intent to terminate. The current term of the A&amp;R Property Management Agreement expires February 17, 2024. The Property Manager may assign the A&amp;R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&amp;R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&amp;R Property Management Agreement. See the Mortgage Notes Payable table included in <span id="i15782567d42a42e983081c5387387dd2_23215"></span></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i15782567d42a42e983081c5387387dd2_23215" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the Multi-Property CMBS Loan.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Professional Fees and Other Reimbursements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the three and nine months ended September 30, 2023, the Company incurred $2.5 million and $6.4 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. During the three and nine months ended September 30, 2022, the Company incurred $2.4 million and $6.7 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Advisory Agreement Amendment, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), is limited to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the Advisory Agreement Amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2020; (a) the Fixed Component was equal to $6.8 million (currently $7.7 million) and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the Advisory Agreement Amendment requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the Advisory Agreement Amendment requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of fees, expenses and related payables</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.850%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payable (Prepayments) as of</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-recurring fees and reimbursements:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition cost reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing fees and reimbursements:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset management fees </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property management and fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional fees and other reimbursements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total related party operation fees and reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,121 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Included in general and administrative expenses in the consolidated statements of operations. Includes $2.0 million and $5.2 million, respectively, for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2023, and $1.7 million and $4.6 million, respectively, for the three and nine months ended September 30, 2022, subject to the Capped Reimbursement.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The three and nine months ended September 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">es $0.2 million and $0.4 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of leasing commissions, respectively, which are capitalized and included in prepaid expenses and other assets as of September 30, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fees Incurred in Connection with a Listing</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the common stock of the Company is listed on a national securities exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the nine months ended September 30, 2023 or 2022. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Participation in Net Sales Proceeds</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the nine months ended September 30, 2023 or 2022. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advisory Agreement Amendment, upon the termination or non-renewal of the agreement, the Advisor will be entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination or non-renewal of the Advisory Agreement Amendment.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a termination by either party in connection with a change of control (as defined in the Advisory Agreement Amendment), the Company would be required to pay the Advisor a change of control fee equal to the product of four and the “Subject Fees” described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a termination by the Company in connection with a transition to self-management, the Company would be required to pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.</span></div> 10550 10094 90 90 10000000 P10Y P10Y P365D 0.67 P45D P60D 0.005 0.005 0.045 0.045 0.060 0.001875 22.50 359250 1625000 0.0125 0.150 0.375 0.100 0.47 0.015 0.025 0.010 P1Y P90D 100000000 2500000 6400000 2400000 6700000 0.030 6800000 7700000 4 0.0029 0.250 P12M P90D <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.850%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payable (Prepayments) as of</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-recurring fees and reimbursements:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition cost reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing fees and reimbursements:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset management fees </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property management and fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional fees and other reimbursements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total related party operation fees and reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,121 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Included in general and administrative expenses in the consolidated statements of operations. Includes $2.0 million and $5.2 million, respectively, for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2023, and $1.7 million and $4.6 million, respectively, for the three and nine months ended September 30, 2022, subject to the Capped Reimbursement.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The three and nine months ended September 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">es $0.2 million and $0.4 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of leasing commissions, respectively, which are capitalized and included in prepaid expenses and other assets as of September 30, 2023.</span></div> 10000 0 31000 18000 10000 5000 5458000 5458000 16374000 16374000 0 0 1155000 1101000 3132000 3058000 161000 3000 2824000 2398000 7584000 6748000 494000 39000 9447000 8957000 27121000 26198000 665000 47000 2000000 5200000 1700000 4600000 200000 400000 0.150 0.060 0.150 0.060 0.150 0.060 P30D 4 15000000 4 4.5 4 4 Economic Dependency<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.</span></div> Equity-Based Compensation<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.6 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted shares vest on a straight-line basis over periods of <span style="-sec-ix-hidden:f-1193">three</span> to five years and may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amount of restricted shares outstanding as of September 30, 2023 and activity for the period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Issue Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested, September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,871 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.98 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company had $0.8 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. This cost will be recognized over a weighted-average period of 0.9 years. Compensation expense related to restricted shares was $0.2 million and $0.7 million, respectively, for the three and nine months ended September 30, 2023, and $0.3 million and $1.0 million, respectively, for the three and nine months ended September 30, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Share-Based Compensation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the nine months ended September 30, 2023 or 2022.</span></div> 0.050 3600000 P5Y <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amount of restricted shares outstanding as of September 30, 2023 and activity for the period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Issue Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested, September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,871 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.98 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 97343 18.89 4399 14.32 50871 20.40 50871 16.98 800000 P0Y10M24D 200000 700000 300000 1000000 0 0 Accumulated Other Comprehensive Income<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the changes in accumulated other comprehensive income as of and for the period presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gain (loss) on Designated Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebalancing of ownership percentage </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item.</span></div> The following table illustrates the changes in accumulated other comprehensive income as of and for the period presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gain (loss) on Designated Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebalancing of ownership percentage </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 36910000 12078000 13648000 0 35340000 Non-controlling Interests<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interests on the Company’s consolidated balance sheets is comprised of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Units held by third parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units held by third parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Total Non-controlling Interests in the OP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling Interests in property owning subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests in the OP</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For preferred and common shares issued by the Company, the Company typically issues mirror securities with substantially equivalent economic rights between the Company and the OP. The securities held by the Company are eliminated in consolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series A Preferred Units</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the sole general partner and holds substantially all of the Series A Preferred Units (except as discussed below). All common and preferred units in the OP held by the Company are eliminated in consolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 100,000 Series A Preferred Units to the unaffiliated third party, with a face value of $25.00 per unit, which were recorded at issuance at a then fair value of $2.6 million, or $25.78 per unit, to the unaffiliated third party.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of Series A Preferred Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s Series A Preferred Stock, which earn dividends at a rate equal to 7.375% of its face value. After holding the Series A Preferred Units for a period of one year, a holder of Series A Preferred Units has the right to redeem Series A Preferred Units for, at the option of the OP, the corresponding number of shares of the Company’s Series A Preferred Stock, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During both the three months ended September 30, 2023 and 2022, Series A Preferred Unit holders were paid $0.1 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Common OP Units</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the sole general partner and holds substantially all of the Common OP Units. As of September 30, 2023 and December 31, 2022, the Advisor held 90 Common OP Units, which represents a nominal percentage of the aggregate ownership in the OP.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 Common OP Units, with a value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of Common OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the stock dividends, other stock dividends and other similar events. After holding the Common OP Units for a period of one year, a holder of Common OP Units has the right to redeem Common OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock, as retroactively adjusted for the stock dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. Dur</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ing the nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, Common OP Unit non-controlling interest holders were not paid any cash distribu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock dividends do not cause the OP to issue additional Common OP Units, rather, the redemption ratio to common stock is adjusted. The 405,998 Common OP Units outstanding as of September 30, 2023 would be redeemable for 489,233 shares of common stock, giving effect to adjustments for the impact of the stock dividends through October 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests in Property Owning Subsidiaries</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to investment arrangements with the unaffiliated third parties:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Distributions </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Third Party Net Investment Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Ownership Percentage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Real Estate Assets Subject to Investment Arrangement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property Name </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollar amounts in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaza Del Rio Medical Office Campus Portfolio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2015</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.2pt">One property within the Plaza Del Rio Medical Office Campus Portfolio was pledged to secure the Multi-Property CMBS Loan. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Mortgage Notes Payable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information. In the nine months ended September 30, 2023, the unaffiliated third party contributed $0.3 million to increase its ownership from 2.6% to 4.4%.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interests on the Company’s consolidated balance sheets is comprised of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Units held by third parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units held by third parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Total Non-controlling Interests in the OP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling Interests in property owning subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2578000 2578000 3316000 3584000 5894000 6162000 689000 389000 6583000 6551000 100000 25.00 2600000 25.78 0.07375 P1Y 100000 100000 90 90 405908 10100000 25.00 P1Y 0 0 405998 489233 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to investment arrangements with the unaffiliated third parties:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Distributions </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Third Party Net Investment Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Ownership Percentage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Real Estate Assets Subject to Investment Arrangement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property Name </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollar amounts in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaza Del Rio Medical Office Campus Portfolio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2015</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.2pt">One property within the Plaza Del Rio Medical Office Campus Portfolio was pledged to secure the Multi-Property CMBS Loan. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Mortgage Notes Payable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information. In the nine months ended September 30, 2023, the unaffiliated third party contributed $0.3 million to increase its ownership from 2.6% to 4.4%.</span></div> 689000 0.044 12426000 12455000 0 0 300000 0.026 0.044 Net Loss Per Share<div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the basic and diluted net loss per share computation for the periods presented and has been retroactively adjusted to reflect the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,561)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,829)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,159)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,426,241 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,365,461 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,404,655 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,333,801 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Retroactively adjusted for the effects of the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Stockholders’ Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, Common OP Units and Class B Units to be common share equivalents. Series A Preferred Units are non-participating. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,730 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total weighted average antidilutive common stock equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014,450 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085,072 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. Th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ere were 50,871 and 95,983 unvested restricted shares outstanding, respectively, as of September 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional details). There were 405,998 Common OP Units outstanding as of September 30, 2023 and 2022. The securities held by the Company are eliminated in consolidation.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional details). There were 359,250 Class B Units outstanding as of September 30, 2023 and 2022. These Class B Units were unvested as of September 30, 2023 and 2022 (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Related Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information).</span></div> <div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the basic and diluted net loss per share computation for the periods presented and has been retroactively adjusted to reflect the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,561)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,829)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,159)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,426,241 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,365,461 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,404,655 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,333,801 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Retroactively adjusted for the effects of the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Stockholders’ Equity</span> for additional information). -19561000 -23303000 -57829000 -71159000 111426241 111426241 111365461 111365461 111404655 111404655 111333801 111333801 -0.18 -0.18 -0.21 -0.21 -0.52 -0.52 -0.64 -0.64 The amounts in the table below have been retroactively adjusted to reflect the stock dividends (see <span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,730 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total weighted average antidilutive common stock equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014,450 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085,072 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.94pt">Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. Th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ere were 50,871 and 95,983 unvested restricted shares outstanding, respectively, as of September 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Weighted average number of antidilutive Common OP Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional details). There were 405,998 Common OP Units outstanding as of September 30, 2023 and 2022. The securities held by the Company are eliminated in consolidation.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current redemption rate reflecting adjustments for the effect of the stock dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional details). There were 359,250 Class B Units outstanding as of September 30, 2023 and 2022. These Class B Units were unvested as of September 30, 2023 and 2022 (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iadd7b4fb4511404a8c2c8b445e8f0f23_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Related Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information).</span></div> 70730 131279 92316 162938 489233 489233 489233 489233 432901 432901 432901 432901 992864 1053413 1014450 1085072 50871 95983 405998 405998 359250 359250 Segment Reporting <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosures below for the three and nine months ended September 30, 2023 and 2022 are presented for the Company’s two reportable business segments for management and internal financial reporting purposes: MOBs and SHOPs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance and makes resource allocations based on its two business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses as well as seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Income</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net loss. The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net loss.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOI excludes certain components from net loss in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net loss as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net loss as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the segment activity to consolidated net loss for the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue from tenants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33,657 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52,029 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">85,686 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33,185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">50,275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">83,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating and maintenance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">54,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">51,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NOI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24,278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,082 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31,360 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23,808 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">32,262 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating fees to related parties</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(20,776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(20,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(15,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(13,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on non-designated derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation for preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(23,303)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue from tenants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">101,187 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">157,958 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">259,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">98,026 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">152,910 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">250,936 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating and maintenance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">27,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">134,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">161,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">26,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">130,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">156,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NOI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">73,415 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23,952 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">97,367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">71,609 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">22,447 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">94,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(25,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating fees to related parties</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(14,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(13,369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(61,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(61,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(50,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(37,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of real estate investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on non-designated derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation for preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(57,829)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(71,159)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the segment activity to consolidated total assets as of the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in real estate, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOB Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHOP Segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in real estate, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978,297 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,172,257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180,349 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table reconciles capital expenditures by reportable business segment, excluding corporate non-real estate expenditures, for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOB Segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHOP Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 2 2 2 2 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the segment activity to consolidated net loss for the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue from tenants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33,657 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52,029 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">85,686 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33,185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">50,275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">83,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating and maintenance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">54,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">51,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NOI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24,278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,082 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31,360 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23,808 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">32,262 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating fees to related parties</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(20,776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(20,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(15,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(13,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on non-designated derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation for preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(23,303)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue from tenants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">101,187 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">157,958 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">259,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">98,026 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">152,910 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">250,936 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating and maintenance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">27,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">134,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">161,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">26,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">130,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">156,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NOI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">73,415 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23,952 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">97,367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">71,609 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">22,447 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">94,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(25,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating fees to related parties</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(14,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(13,369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(61,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(61,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(50,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(37,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of real estate investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on non-designated derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation for preferred stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(57,829)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(71,159)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the segment activity to consolidated total assets as of the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in real estate, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOB Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHOP Segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in real estate, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978,297 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,172,257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180,349 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table reconciles capital expenditures by reportable business segment, excluding corporate non-real estate expenditures, for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOB Segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHOP Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33657000 52029000 85686000 33185000 50275000 83460000 9379000 44947000 54326000 9377000 41821000 51198000 24278000 7082000 31360000 23808000 8454000 32262000 0 8949000 6397000 6333000 173000 199000 4753000 4471000 20776000 20854000 15720000 13284000 258000 10000 -173000 194000 406000 1826000 157000 77000 -14000 -22000 3450000 3450000 -19561000 -23303000 101187000 157958000 259145000 98026000 152910000 250936000 27772000 134006000 161778000 26417000 130463000 156880000 73415000 23952000 97367000 71609000 22447000 94056000 0 25786000 19153000 19003000 384000 1153000 14105000 13369000 61520000 61525000 50208000 37098000 576000 24000 -364000 -109000 510000 3212000 244000 159000 -45000 -100000 10349000 10349000 -57829000 -71159000 1126677000 1121857000 831475000 856440000 1958152000 1978297000 51041000 53654000 40245000 22884000 37547000 40647000 26214000 25276000 7739000 7814000 36019000 34554000 15300000 17223000 2172257000 2180349000 1686000 2309000 4650000 5981000 3172000 5323000 9348000 10726000 4858000 7632000 13998000 16707000 Commitments and Contingencies <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company had seven operating and six direct financing lease agreements. The seven operating leases have durations, including assumed renewals, ranging from 19.1 years to 84.0 years, excluding an adjacent parking lot lease with a term of 1.0 year. The Company did not enter into any additional ground leases during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company’s balance sheet included ROU assets and liabilities of $7.7 million and $8.1 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the lease guidance issued in 2019, as well as for new operating leases in the current period, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Because the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 33.6 years and a weighted-average discount rate of 7.37% as of September 30, 2023. For each of the three months ended September 30, 2023 and 2022, the Company paid cash of $0.2 million for amounts included in the measurement of lease liabilities and recorded expense of $0.2 million on a straight-line basis in accordance with the current accounting guidance. For the nine months ended September 30, 2023, the Company paid cash of $0.6 million for amounts included in the measurement of lease liabilities and recorded expense of $0.6 million. For the nine months ended September 30, 2022, the Company paid cash of $0.7 million for amounts included in the measurement of lease liabilities and recorded expense of $0.7 million. The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The direct finance lease liability is included in <span style="-sec-ix-hidden:f-1472">accounts payable and accrued expenses</span> on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of September 30, 2023, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.</span></div> 7 6 7 P19Y1M6D P84Y P1Y 7700000 8100000 P33Y7M6D 0.0737 200000 200000 200000 200000 600000 600000 700000 700000 The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The direct finance lease liability is included in <span style="-sec-ix-hidden:f-1472">accounts payable and accrued expenses</span> on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.</span></div> The following table reflects the base cash rental payments due from the Company for the next five years as of September 30, 2023:<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The direct finance lease liability is included in <span style="-sec-ix-hidden:f-1472">accounts payable and accrued expenses</span> on the balance sheet as of September 30, 2023. The direct financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.</span></div> 162000 22000 632000 90000 588000 93000 599000 95000 617000 97000 21943000 7215000 24541000 7612000 16490000 2778000 8051000 4834000 Subsequent Events<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except for the following:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Declaration</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2023, the Company announced the declaration of a stock dividend of 0.015179 shares of the Company’s common stock, on each share of the Company’s outstanding common stock. The stock dividend was issued on October 16, 2023 to holders of record of the Company’s common stock at the close of business on October 12, 2023.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Subsequent Events</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2023, the Company renewed two interest rate caps, which matured on November 1, 2023, with an aggregate notional amount of $150.9 million and a strike price of 3.50% for $5.0 million. Additionally, the Company provided a $6.7 million cash deposit to Fannie Mae. This deposit was provided because the debt service coverage ratio of the underlying properties of each facility were below the minimum required amount per the debt agreements. This deposit will be refunded at the earlier of the Company’s achievement of a debt service coverage ratio above the minimum required amount of 1.40 or the maturity of the Fannie Mae Master Credit Facilities.</span></div> 0.015179 2 150900000 0.0350 5000000 6700000 1.40 false false false false Retroactively adjusted for the effects of the stock dividends (see Note 1). EXCEL 96 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
SAH;6!#UAQNI\;1/>^+@!L*RQ4KR[&4IK96 M:V*=O;8Y=H.%(>6T#E-:NWN!,O'0F(HR?;,$?$_[R&JU+A0=@U8TW/2;O0^9 M6T6?'(ESOR?:0V4*]'#:W=<%GVUV5JUWQY/Y7O"[#1>W('C(T>O&6I'0$:#@^IC$!V7(=!KYW,@T=:;*!(M=7H]-A,AP.Z>KD M57+XZAA;JDK3<$'_')W';=*B%D/4)HGR2A<'8V3(2/6R=$D&4X. MM\*AB88=QM"NTWJ^:[9/-L]0+[-[[8QMHXQ2!$6; H*/M9PN-9V*$[#ET)S2 M%PB>+^$_PKZQ+:F'[@C?RMX]0NG[+'C0^9);*K1G^EX=CZ["1]WV:?M)_#)\ M"5XO#]_3,=S-D1 8*6?8.MP_.1I@6N9OU.'&FP5_%YX:[TW)E[F2D) 6X/W, MP+;QAABT_U'@XO]02P,$% @ %3IM5QE)&* 3#P =C( !D !X;"]W M;W)K&ULS1O;2=/NPLP\0"4EH2((!2,OJU^\Y!R )D)1LISL[^Y"8$H%SOP-ZN57ZJ]D( M4;#[-,G,JZ--4>3/S\Y,M!$I-T.5BPS>K)1.>0$?]?K,Y%KPF#:ER=ED-%J< MI5QF1Z]?TGN7JBP2F8F/FIDR3;G>78M$;5\=C8^J+S[)]:; +\Y>O\SY M6GP6Q6_Y1PV?SFHHL4Q%9J3*F!:K5T=7X^?7,UQ/"_XIQ=9XSPPY62KU%3^\ MBU\=C9 @D8BH0 @<_MR)&Y$D" C(^.9@'M4H<:/_7$%_2[P#+TMNQ(U*?I=Q ML7EU=''$8K'B95)\4MM?A.-GCO BE1CZGVWMV@4LCDI3J-1M!@I2F=F__-[) MP=MP,=JS8>(V3(ANBXBH?,,+_OJE5ENF<35 PP=BE78#<3)#I7PN-+R5L*]X M_49H><=1,H;Q+&:_B'@MLS6[0FG)0@KS\JP /+CZ+'(PKRW,R1Z8E^R]RHJ- M83]GL8C#_6= 7TWDI"+R>G(0X&>1#]ET-&"3T61Z -ZT9GI*\*8/,LW>9:;0 M)5A9L8]_]D::*%&FU(+]ZVH)R\&2_MTG%8MTUH\4O>NYR7DD7AV!^QBA[\31 MZY]^&"]&+PZP-*M9FAV"_IUZ_*LPV2=IOK+W/ /_11FRV^4?@OR,J17[S>!J M'\J7C6 W*LUYM@,CWK'2"'"A6ADKF?$LDCQALE'+ #Y$21DC+)D5 F17,,T+ MPM< Q:9%:!ATB -X.DRE7\*0HE(B(\S("A2!DVUA;)H!/O3#Q>3\?D+ M X(00".*#470R!8E&Q5HSMRP+<1#_%OS;7(1R96,8%,AD6+$ =+)#*-Q#*3PI4QDL<,OZOWB'E(.6 :2C;(@ M\R*IPAOKB/YR0I>J.RO 86!DL0*KRU1!JRVXL@",?P8$,DANQ'B96(/(2PV( MX 5\WSR3$14;GO4905H[@:4 31L4_)!U@_5JC9X4"5U #K7*]FV^L@#$7-"G M2)6(/^>:?!!X@F]-8\8EH ALBH/$4 A\F9#HP# PG;,2XK,FD'RM12T_-+]" MKI&U8@/VB-A#':HLV3&!1!B4A7J83;+2%N'TW0;2)HNT )-BUERMR]++E/\! M&@@ARJ(D.[0KMAL9!>8_H-UH+'RU DT#%R!.##8\,6#D'!V/--F U0+U#C W M,M]G0(T[6$60&%:$J,,6N-2*RX2,%PLK0"%***NJT??M!>?NN3=BC!&(&.C:WT2QSII09E6ORB$. MX77 !.DB%D:N,Z(-B-FX]..Q^1SRM^^)*)_)Z$7.=Z2]B^CQ^83.%!QKC MI\!P#XKTA/V,32>#Q6B,#XO!Y7@44(-6\&2*HDOCY]NWGTZQK(]; M?!PV)3*1\XO!?#1BY_ \G]CG7]]=WWX//'+LR8OZ[X3-1X,1 /RB"O+L[R/M M$DESS^V($PO(-XD-.$GEG=*&!;]8 (Q6L"X4K3%+'4-!#-+3(E+K#+)IS%0[ M*\9[';EC1)A^$33D):EB4P5#$3\'JB$Q!?U$R[8^0-%ZZ'U+WV2*9'W-DS,4 MX(]X\YB2V#9&98IU@:C*R @\2(L--J9W6 _"9W&8?5#"8#:^@+_C\\%\/,6' MR6!TCM_,+@?S+@V-?%W8!NPKK=+'DD-)V3USTRVMD"+D'_XNYDC.=+"8(3G' MT\'%8G+B[([75'4@U#JJ;"9():'9N$H4DS9&II!BY!01C^>#\\GHA!ZG@\G% MC![!#2:C"WJ2;*RVT!T5JG+75@/WKDZ,I&KNF:I:TJJU%19 M-&#="JH_DQTFGZR*VI:R(7M3ZJKZS=#%4^OBHL?%ZY2'BW>":[>J)P-2O^6[ M)N6X$JVC[H 02B6M1KS=GBN4:"R6KO+7 H=AW8[H4-@&+ M\8_$8,JQ;S,-9\#5PF*UDC5U! ]*R'VQF&0&EOX-6@:YVO7:$S8/&!)U;'W] MZO;F'>W$%Z9<&O&M!"5#0Q!$*XI H(N,*GI'E0WP32=#*&*T,@%X6YTF%O#0 M*9L:RI"]O[V&2A(:L,\HLR]"0Y]L$Q=$>0A F9OUU3VQ%BZ5@3:%1).\403QB_7JMGXFZ"Q:6K#JAA1')YTK"RJ>%&;5 ZFJ0EZ87R[0:[T8^-0J\@.^'@V&LX: ML6+@M3P_R-X0:MHZ8MOHXLF,FE<;OZA;M_G+VHH.'9MGB=.#ED'TD8 M-[8M?\LC.Z1I>YUY:I0^:+'[:V>;0>L1Q2/M.#!C5+>1]_OK_>_#,?:1V$#L M7 WSBL<@5I+8^K%<&>G\H3)!SUH$A&BPE/'PLJ8<=MJ8C!:#RWTYM97MH#Z; M#N?[ 7@RZ.PG'DQ3(! ?=AC5]E,<R'?$IH8$"E#L->\\UI&\PI)D-G;W>;A7I1-MKQR>-2Q?47N#JIYMOZ-QC M3^*D@LGPO/IB &MQO(@)&$>F@?/'PGJ^Z1/1H .K&P#VS6F&KJG F(%#[/Z8 M$11#3J4!9[V36:^"K6M"K =IJ(7-EH>[A=#ZMY M3QL8];/3-\WK?0)+4,_<[AD::AGKS\6!^/J%)T70^ M&RPP@"'J5D8!/_7'P$XW4&79L^N6+@%%&C5/S'N[O6272)3B1J= MCDYCOK,9IO8UKV8%)1RCOC"#D,.!CZP [@G:.N2#%7!]$XH*+)G4A)=[<-ZP]&<^A'A<"7A+'0\BL=U$6B;KTL M3WL3=1W[ZI,4$YZEW/1T92G77Z$0\.?[!GTK._5\*S@^\X;YB)ZR>47#@.)N M,XU!^0,V?XH$(6\_](JTMKU\[SC'!L&JC/ 1<:_3)H/KQ?N((S[J2:!UR%0J MH_I\;L V:BN@$6C/@>SDGNZ!6.30P8!!NF/>B&8?5.?_U7$Z'8A5=5"KV*3Z M$ZC+#I2Y]B [+!7(G3HA&4M/""K#15AR0&QIONI HI.REJ[ZX$DG,9HUFFLDPMP1YMB %"F]@Z3XT>WYV.IQ=^ M*B>F[%BDGD0^II0;LL_UZ *I>:C8Z[(S][J+AIVMK=VZPO>UAJ>DE8^,U3-7;"\A'B M8^(*+BO\5M*B,JZ+RAG.#F-N?; -;FOEAB'F 74,#R6WPS[EFC&<+)%T;!3P MG+/.HEX91&8]KG!?"RAIW$SO$6-&ZU%U>NG/(DLP@,S%<83>&3G.XK.54S%BQUU&4=XFKE8,PU ?OXA=M<\^UI_V9_Q MJE1GTW8GA5'M/0ARQ=Y*T\J&5Q-+)+"OW@RGEK&$1ZRC0.T9I%XZ?=5Y;<0TN.?VWX: -[-$D?X)\' MWJ'M'"D?@/"VOJ'@=^UT;^8&;X*"!\.[3Y6+-0C[S XO3 SF,VS/J_K*?WK, MR^YLXAF;C0:+O?L>\]+.+4_Q>/BTBE8@$_11K)/>"E>7?6GU.UYG#Y+,$PYB MHUI/< A"[@@ZN/\:7BA$(\::"!,AMY9N;+5-T^ @"C A:13F;L*3'TITOYPB M$2!;"GN[* )_LKIU:QEED?H:G$XP:@PP.:\)A07WX M9:^KLJ6NM$6W9NO#]%H=9MAW;_S,^RU *O2:?O'@[BC:GP74W]8_JKBROR5H MEMM?9+SG>HUU2")6L'4T/)\?,6U_Y6 _%"JG7Q9 S"]42H\;P4%^N #>KQ1T M+>X#(JA_:O+Z/U!+ P04 " 5.FU7(*#*V5H, !C) &0 'AL+W=O M6G?':WJ>OWZ^-BF*U5(.ZK6JL23164*6>/2+(_MVBB9\4M%?CP= MC\^."ZG+HZNW?._.7+VMFCK7I;HSPC9%(E#U+^L[@ZOCP"73A2JMKDIAU.+=T?7D])Y'X4AZ,?[<7U?;?ZNO#ZGQ"^M+$M+%U5?B7<5WHTOV5 M3]X.T0L7XP,O3/T+4Y;;'<12WLI:7KTUU488H@8W^L"J\ML03I?DE(?:X*G& M>_750UVE?ZRJ/%/&_DU\^-+H>OOVN 9G>GZ<>BXWCLOT )=+\7-5UBLK/I29 MROKO'T.B(-:T%>MF^BS#![4>B=DX$=/Q=/8,OUE0<\;\9@?X.<7$OZ[GMC:( MA'_OT]&Q.-G/@K+CM5W+5+T[0OA;91[5T=7W?YFY?[8>O MY_+]7RZFD_,WGI=X7Q4%LH IQ+45U4+ R+4JYLH$2PM99N)6I?[NA.].$U&O M%#%8RW(K5C(3D_%EIT6%,TN20B"F041DL?@@V[L(?-U $_B1==#M#C*%YF ]J7+#$U4S7+%LGS;J9YQHU#]HC9S?B@ZTY33)QAY!XX)#X M=/TKV09:[,&SS4J#^0;/.\>9\RT?<5-)DHAJ>/Q+_C,[79N//E0$W>F6AI9B%^0G68OI@YQD>3E M5UX0M4?4A_L(4,G A4OWA:D* 5U<"N!O(KY :+W@"+51X>+@EO.<*=&_Y22, M#OC5!WP*P5P7FBR?:H-DI'1+*:K)8Y"&7%!H!@>J 96Q^_G.)6)]P%PN:F>+ MK8.%E=0< )(+=)=V++!#H5'D AN* MCVT#8^B"V(<4QHQ27QHNFHDSG(LQX-_!0!M%/H:!>E*GRM1HY2.)$ZB'T(K< M[D_T(+VH:<85%22G MH5CFPUNQ@9\!QJB=&;8F;&+ZT,LHQ8+< M5;EJEU,(9G+;OKB UPGJ@?,("P2EK[U6/[WB,NU!B>HPN>?'!OK/QD060:7+ M'P>'MD&343I@6QH.:J,HA@B3D5D'HR7J&[P4[*\?)1#,H,M) M'$-4<\WYZ76%FTM"-J^B$\A&@0VA1B@W*&,&EV:O $T<]1!G&^#4XR:IT9W, M>EJ\SM6-/,$G2%1(XTHDG]^(3L:YT(F)"%/%VLVL M;-=PJ0_4JWYUY ,1XX@+BPQT=:1"F5KZPDL&5VXJ@,@2<-2FYYRST,>5576= M<[,@'F7>J-;4'2M?16QD[6Q@989-U_'(NF$'RJ9>54;_24J@6VE*WU*Z_'5Q M5S/^SVEGT#9;KJR5#<=G!Y3QT60N;GY\KSC(LF0@&Y%G%7B@#?)#"-72&.M" MT"C^4R$8#1"QZ_GR;8"1W:X7\1+$]9:ZC\2]]F+>!3%=EK_O.LI8D@/=C#A) M+B[/DC-DS7>X,3H;BT]?TY&W35G[]]E3][S?'>L.O8TGKOMXXKJCB>MN@(HT M>27]8D 9J7)?B-J9K3?)6;&6.B/T88SV.1"U9=6!V84S%[4IAP:%+&%U(Q:* MZ RW H1)1(]0#(#/1VTT\#(:LCS[?>%.&KGHW2$:E@0BC5(#/9(P-.?8T-S7 M@ L"4S_1, D$+W$6-57(\#8;&>XZK>.!HV^!#L_)T)FB!H5&3:[!H>Z376$4 MQ[9O>X"8>N(L\:C=GZOWZ-AOFVG6Y3I(JC+T4&_8&83J%/5J7BI_ESV _*,2 M%Y8:R%C*&6K I<%'C0-XZ.C-N'W?"->]II7)W-SD,=";N#I'"C%T'9O?]WKE1J6RL M.O02:!UC8Y4! N[:Q]/M6YS=N>Z(HP1&'$SKI>;,UM(\"A#QI.N]F M@P 1W;A-4:N&,X$?: @R FJM);IG9*P%!TT8T6(]0OVMM0?+CM M(D5)=^^7DNA[XW./.QSIHK=9T^?3<3(>\[\H*M>!F\>RC[NA!I>PXS=&UP07 M'+.DC.Z9( VNKH?F8F4Z M,.@<[NP=6XJV35[<5+9CW9FWUM[]W;XQ:H_0AV0[E-)#%B':Y-(HUS*ZUG5) M2>9$;0MDX3\1//[U/>KN%H71^M?T3L+7= M.?"Y.J3FY)M,.4U.9_]_8\:!VHJ-F3*W5;+OE>?B/-H;3KXVS&?)V<4WAGG5 MG73"56GR-9%_LQOY_>Z 9+D\/T\F)R<1A\/F;-?FV1"[ON&[C7TRG,V&]CBD MP?]"!MZONB]9G!A[#. P];\_,6Q ::-/C0^F7K_7($?R6APEQ=5K7HF@]MOHTCHL';N?77U S6>;CG+RDPN_,CN MUQC)GI+)/08W7_EV4/>II>_M'H%]U ;U%^<%.\TT\FM!8AP7A+TK;)23=L MT<:#%H<&$9/S-D)S9R81]-+8^&N5K]@0\M(B:Q>B0]+>>DUTZ[5A#[RS;D,' M!PMQ#TKCP6L?EVVX4K)!+U=3;BF0!L\_4T;-):8 Z;M5-_(U!>KPW29NIONZL>UF\=.<1U>GD_-()%)BQ=#LTH63[!T&ZLP'EOA\9'$<_ M_"B46?+/6R@- (GN-R#A;O@%S;7[X4A'[GY^ TA=8O81N5K@U?'H_/3(M6SM M15VM^6+ZH4 C\!1T0?E=T]1]02P,$% @ %3IM M5VB17$T:' &ULU5WI M;]O&MO]7!K[IA0W0LB3OV0#'3>_-0],:6>[[\/#P,))&TK04J7)(.^I?_\XR M*TG)9R#B\.%E)71R\?DG/[JK7+\NFSG6A M[BIAFM5*5ILW*B\?7AV,#MR##WJQK/'!R>N7:[E0'U7]>7U7P:<3W\M,KU1A M=%F(2LU?'=R,GK\YP_;4X#]:/9CH;X$KF93EK_CAW>S5P1 GI'(UK;$'";_N MU:W*<^P(IO&;[?/ #XDOQG^[WG^@M<-:)M*HVS+_;SVKEZ\.K@[$3,UED]<^QO6N:&?HH';GMV=B"FC:G+E7T99K#2!?^67RP=HA>NAEM>&-L7 MQC1O'HAF^;VLY>N75?D@*FP-O>$?M%1Z&R:G"]R4CW4%WVIXKW[]0>6R5C-Q M)ZMZ(SY5LC"2Z&6$+&;BIH(G"P6[4)N7)S4,B*^=3&WG;[CS\9;.K\7[LJB7 M1KPM9FJ6OG\"$_6S';O9OAGO[/"C6@_$Z3 3X^'X=$=_IW[UI]3?Z=-7_S\W M$U-7\.E_^];-W9[U=XN"]-RLY52].@!),:JZ5P>O__F/T<7PQ8Y)G_E)G^WJ M_8]NV3?K7-P84U@O:U.-SU M:@7=@LQ-?QV(3]#Z9G:O35G1A' H.9_K7 .!#,C@!D:;-OSE&CY-2U,SE>8* M&D!/$[64^;PU]."KZ.9FLE3Y3%P/DT4W![&SO"D9 Y:'XCP(!0"V,Y !]/);)6)DR9PR9Q$_E%K)MJ71IE:-?4 MEZDR!A8%H@0ODBZ'"326*Z%%L\8Y/!L-!T-0D7F.+7!2@6R9D.U%AF4-Q+L" MV:JPAN)!UTOX2IO>J2:;@?1 .LUP/.2[LE(P%%@%/=4UF(M<%E.%6X,[-)5K M76-WTVG9 &'MCJE[2V6&:U5)3]^(>8E=/BJ@%N@" MRPDXO0^P=F(X2YJ-N/'\,]E0$PGLMXC[RN+UQ62-V2SB*3?L/^5J_>)#STB> MXVH 4+-Y[ L%,,?U*0",FW$Z!)%:G3)\@R#-&!>89U3V. -[%^A'N0D5\2' MLBAA;.!'51QOE,0_JA6P&O2GY'09GLNBT*B1<("FR)'<=42DK;/%"6"?FB7U M4!\Q_6%<#3R#_ !#.?0"3YG'8(Y"UB)7TM3B].)5ZG<.: M<"4P2^@RFF(& \%(NB NK&;$GS2N%-,EZG8<&:9>5X!%<">0F0MFE;W6=82L M*$6-ID/75A8!ALV/5[*0;#MH%C -8(V+R^\Z)"4RE[RV!+X9)$R;=0Z5K()9[ M 286<^2_0Q MI_>!-7&Q#TM _B7HJ1$NCYVO<;+,XV59.U=4UBYGL[%0\2R2\+O2H; RL%Z0+M"XM* M2>$112\7@]&?S4@:8#-TP(SBJ618TVM:R!8Y7E M#TLCFLKXQ5U5SH'O>$Q2^[CXGTFK?5!Z-6DJPTAN8"DG;J9@?ZS4OOT"JS"J MU32!18B!)@J4DFW!\HEX%V3(."O%3Q^6&AA0UPR:<$7W8#.PS^/*8D[%(Z+9 MQR6:LJFFT6/>*]A;M)VM,;NM:7*H-1$_P//AX-PK&E)O(*\(-$#IP2)!";#. M)3&12 ;D6U@!2"-;U[@#.PDYNT?]R5, ZUV"QH:_V'"$!<:;GV]2"?'K,!V% M_@?"4*-ZCU\>0(F'7Z!FN=FG[W" "CFN5XZ-@M:J@;9)AXW M#2P5Z!DXNZST0B/SR,C25\[2]_2%WP-== X3 \):"#L"U4![A.B8UA0,@6>6 ME"H:U*)*00&0MOMR,P$39@THXCI 76N6*U@"V@EM]0"@#% WU*TXA-=^06C MNE:7,SVU4HV:2X.OQS183(H!UAMT7R8']/F8X.WT5XOD=L"""3 M;TE6 43X'G4Z>00K^0N((4/ZO:V-QT8$E5X00QS^?I2P,KHW(*FYU=*X5C\U MK\%;@"4FYQVC%,*/X$*P?@M,_)EV$C:FQ ; R2E]'Z$BF9T+U%"XN.]AKB3]X8(,0<'49\O<6=Y.]-% #2 ME0+[\3'(;Z^BLMJS1VE819JJ,1#1"I:)%(?E@2,H4>* SQM9U*XQTL'K-S B MK)B*AH(3\#@=S0Z$_<&>V '(KI!"@$Z?DXM##B][]-#'X0T_@26A0T^/-D?6 M1AN&H:QR0 /4&MP:WA5DYN%@='6))AEAZ>$;EF'6,!@3VI"!1$^RH"8&P[,8 MF;%.C9F"WL'>,"Y]Q, %=2'X@K!KTA/I!>P>HQ@<5^N6@D2E03$J=IM" F' MML3+T54#EP,_]XZ1672$Y-) 3DW^J".<>#8>#\Z'+'T,5*POUN4Y>A>V$ER' M*0PW!_.&2JPU->#OAO4R^&6Y"WUIPHIL2&8*IEA96UM10,M:)K]RN^/]\CU3 M+$86-%A0-H-UJF3JT%"M>"H O#0HT#CDU*MC@OV;X!9O#Z=EK8'\C CR\' . M'_2/A/N!$'(#L /DTP ;6%0X"7$"#N9@1RYLE<8.0?05J X,_YAERV*Z8$(/ M+7'[]3TRBI?(3@? YAID7Y.SECE?HLT5G;"FZ>F*YI+NI2308?T.X+B% NB# M5AR=U1F0$E]GM>A!MV5,)%:98R0+7B6\R,X#"DP(+6%':,(KM<0L#_23E\98 M!+E]5[3IW0STR-%8#RR3L]@6 $!F)>TBZ]PV&I3!+TN6GPF8YA)E$]^ D=1J M3]WR'2G<85#?LMMQ>GZ=C4'&TQUH MJ6V])4PI0U ^'COB>!T%P0"07[$(]-N=&=L=#FJ OLW$LGP@W[^($!)!'0/- M8=>([!6V9'8A+.&PTC;[F% /TW."[37L@U'0'VP*\!.8"@I*>0U9-OF,1_43 M9%^%S#]B#ARS4N3 Q;HDH2R1J2+KBTC2\2]M%X6BT+\S ;ND[W3Z MUH&F9A$I^1$K:QQPB&S+&2#BC!*DZ >6"H)T@+RCBPQ28%O<(\ M)@O77']!M5-6,:KO&0<'""9\-+@8G_OLQ!IM*W9)D\F5Q136JW]BWR"5Q_6# MRN/M; ]Y^,/$N'!:"G@AS M Z(RF4N0L2M'Y/VEF2U8NY'-!-@+(((R=QTG+X@8 M(VAY,_,&D?Q,YQ3AL,GL-N/%.>B6GS,^HI@,Z,UA"#Z&] [G+NRLO&F]1:?R M+; ]VH DAV.='90AWG181O#&G@T'IY?GT;<4A$&'#%.K7SO^]L'.+L.7@]9; M.DQ:FLPGC^.QR=9DI-=@E\H5I7D006:$*HGB/7FN?]WNS!NB'?#0F&"C%RV-DHRX#:C M"JKX=YN8!F;,":LL0%'SNT@,KD0@7T_F*GC4&2F#IFB]9DFH3 AD>P+I>U M1$65=0FZM-^U4Y5:2 29S #@"E+WI#*XZ[;'P>.G+D)[JQD7AXED; \QHFDQ M:AS88#1)VAGY(+%M?IW0J%H@Q34H"UV1%@FD1(()#H+[W0JQ_ECE43 *%@;V M'$U8Z(U5I4>Y6;*3^!VPOJ+\?& ,JB[IMJQ5(:F4 #0..UG=-NBF8?3C&(M] M1.4B]62"C2F1I5 WR!F;=%NQU-/12E:_*LX]4SP::(E(P.%,*LJ9.T; ;(C) M(G(@?2M<=,6,#KO3J(3'$8@PWIKB"(P?T;PU-C0Q40!T5-%KY/H#;K30*&/7 M#=SUON>#'8]9A*-U3-/10%_(YO_4RE2FG.8S%:P M.'U3+S%]3JD/Y/(5%QYRQJ2GU K>PN*J@;AS*;YVHNUSJ.5PJ,'E#8VKF W MJ^+,4RNMM\:B# IAI-WC?OND8@MSCHD+9LL(3X>RV M>TV XECF%)^$/,=8V'6QVJWS9JQ3+>7C)$# MJXOC"8V%0W8BC5&A"@O/0I6+2J[!01.NY,JQLR.;39 Y'R(W93N)VJ$Y\HBG M>@[KR>.(E64DR_KMEWFX3I>8768[@04@"E@ [0%NHV-(;X9<5!85[W&S)M/% MQ*!/<]B1AYR8"Q0UX,9T8RBB[C)GM@K(IK1)1RAERX1!5>5N3@Q\JI5GAUP5 M"XQ9Q/6Z:J1=E:#//\ TENRVY(A+^Z3 MSHS(Q\*0&.4R:1(MQ=8_(9N-\Q6R/H;?;HCV;8<69&326EQOK(GR_4W$?!N_ M=YU!;1S,!,:.(=JR-+8NE>*)EN?[+,--B+IMW=X>E>^T.J[%JW0@\HK3?S0' M+,.@P%0W2D<]EZF]X30F\%JKIM"6JU,=ATMD^60SDW&_.;KJS^MA3_&G0O3%'("= WQ2 MFEB=)\<)"1L4CB9&DTIFQ&1S<6>J?G7 X;2QG2PPLU.6"W5!Z.:WQSSBW_&PTC"O+=>%R MTEQT%_07B5/1M#O9@OWH!E/"H@80PXPQN:E9W=OI67YP9D-:R^ZS").RJL".5W%EZK8E M10Y!$ND-I5/4;?E0.&BD>DUZ!(JDK9I@B\R5LF4R&1D?5(DC !T=NZW_R$1: M"=IJ]Q*]3)8+G=0M@+)3:+'7C@W B>$UOP>?? '?@U^$YU#NG/=)/^/H"7XO MSH2M!MWR7@;ZP98J[RQ0W;:YY$#M66:: /?^PL#XI&X<$%%I1C;83IX;0/83U@1:8D'&X2( MGJ7F^C2?OU5BZOR^9^#N>N6.?3V[&)RY!SVGR%("A?USGGA<3U1>LJ73IU>4./7S1PI*GG1((5IR;S'^(*JLWM4N M%JL$G^U^*9Z7+P&T&2SK-%O*MC>G/_\?J1PC<[:[Y%Q*"G!/8 /FV@6MG4[" M$"'X,_O+;H^BQ<2Y?_\OT+J/'*&8XMKG3E=E'8=2?5'3AABOA%5-5=5>=+L^ M?8]-Z:HX%QKZVEWI0RW=F6>Q;^NJ9#O-O/]($33I2MLSL6(U@^:($V*HE*GB M\^:#^%=>3F2>]3J<7D/_P-@TB^#8XUPO%PO,#]4JJA+WBH/R+*0F2T^QC,E% M1'(4BZ6.#&IW6TG7^"#F$^Q3[*3>RO5:S5)X PO">3O7-$/:NC.G+KH)&U\3 M+9^[XV143$)U[$7;$_Z!OKMUWX7335C-C0>\0GJBOP-_3*33QT"\*2W2;XWB M78[NRTC;BM"YK8OFDGM7J)OK>[8,6 7'>M]%.M*U4T;[%&-5M!);[WM[]RX3 MW>.&.Z7:R1,K6/+)V5I&AZA-C1$M6U,;$LG]C)Z9C2L5][2 M'EI'&:S,L\M@<,-N;:%ITJ,KD#:-][7YX$3LO$:Y1CK!0?2745[6YV?X\#'? M[3%S!U-Z:I(IXS;79@J#N,KMF(\^X.AO>?1;&,USHMTCHF54)3TO&U_2;(59 M$\HON( ZK7$8#L;7WW6BKEB8;+:MVRL+8C@?'0\5454461N[VHGV,L@WIY+& MB@R*FS;KD7#[%P8,]BLNHV WU+0_-D:U(HC-J[A0$O/XNFG_/N=I= MC'Z4,?70:D'ST=AAPW!.I3N-[''Y24ICVNG"J%2F4(NRUKP)<2:0#[VKND]6 M7K1J#_5\7])A43,I>DQ1+LM\%EEC'Q@A#&"/YR]= Q'.V0D_)>69U'UW(X4=V@,3 P:^@L9=OR1#MBY)T3\ ME-17^#Q2XHN9Y\D97[(=:0/Q3(R&\,.%C9[! /CLRGUQ#N[4HMP]1/N@)K4\ MS\[.K^S/T45V>GGF?KFQW.^[GMR0OU<%:^)&V>C\''\.1^(T&YV.X>>0NH7/ M:43*3Y(!7VNQ6+(WSJ[&9_#S]/I*7&;G5V?B(KL\NQ)GUV?B]%I\LA;8,3O% M^!S_;:,!T.DZ.SN[A-]7V?4Y_AY?9J,QDG)\D8VND9P7%^?P$QK]7_A',WKW M)YZZ&+C>#88*AFFHX'PPWA8J^+HZ"TX&/QL%1,0/S@87WW2@<1:?<265T0/1 M!\0\GYZ\"NM5"*39,)"(ES*,XBT(@[MU#NT56F14*7<,ENKOJ!HZVO@U*A(] M2W4N,['-/\@M!Y\&(0Q[%Q^*WGWOBQ0_NA,;]N!X]S*:MAZ.(=4-3^K1^V7" M.._<:?RX%C:U\^1#$8+:XX@(OKCM?BEW, U3;W7>+D TXF;A9:;KE.@8R!8 M#![2=A49SN2MY/AY*%%R!U\26.+C:9C*\44]25DO@UA Q %HVIJ 4+D%B["U M],0-4>'PEMIB*L1)#WK%Y[*#U]UW(IL/87?Q]?9SV8\RX?(VX.1_RW M\'5G%ND5";9L%LN"383+JUVSCP]6)X1O':BE(\NA@[OVP)AT^D@#W[F!/Z]) MQ),KL*I0M(PA&TX@ L?;$[+TL%\SN2+G.+E1ETC-4W>3B)U=J^%W:XU*X:V;5,-N.P]]<^VLE;N^"Q=(%7Q#@61E$96J MAH[IO/S7:0P7_G_DNHB@#?9A\8F:8CG;S%8?.]_CJ]7%C3]XSM5\G0&=1_M5 M2B7)'K0W)X],=GS7A*NVQAO-O(STW'?@/:QP45YOA%%Z8D],.GO?OBK MT4I"UVW4?$SA;(,I4;RRS: )@GD$C$3=?&M<\MA],=\2F'S:L;&8;['ESG2U M'_Y!ASWVPI@)YW=8E,_-VUJ5Z/SU8\ YG/3IW&1#E]_\N7AH&R_^?3#1/KIM M_[0Q;^M2[:-]TF+4<#![N_)HGQ<@".5BF1@74Q:;GADA7LAM=]TAW MK% E2/N6%;(N#PJ'M-="X=%V&X;#F'+5\7BBR422R'=>M205#'%NXSW^&I)& MN=#JJ0VM,C"B]+,_B#Z+LIB/D_V1\@"&L7$WH8*,HT<]0EM\FJ3>GJ&A"V?TZ?"KN_"G380TAT6J*J)#W\4+K9'!7R=]Y2\H[+%G9UB9 MM',@:VVB)Q17ZF04'Y^^G-;X3M^I]Z=2PG:UQW%9E]Y ]LL1%AF:,>5,8;S, M8W,7%&QE*>/+PQ*^W=8!OEE# MS8-5L^##Y].U/U'7H3WH.:0O1MN=ZM[O3H=*:DR#'>YY04,15\/\'2@]Z+M) M_R3ZCQ#(R[^E-#*EROC_1/!/_?\H<&PO=V]R:W-H965T75Q>BGQ2^&=S'T1HD MDHWW=R)\*I;95 BA14V"H/BWPVNT5H"8QJ\>,QM M1@:OI_\PF/4&L\2[^0ZUR@T_>+G!A8CG/=@UQU(+-_@+R!S]Y1%>$](Q3']CD3&EC-#JRN M9BQY-.N8R- MTKC,N!4BAAUFJ^?/SE].WYY@>S&PO3B%_M2:_#<(?.5_@)T*QK<1U#8@WEI+8N=B;Z< :&&*,LC36*D)>N8#4R M9%AHDR?MZYH[CYE02#>;JC$$D(N=+Z5\M@W:3A7<+$QO?RP7JY(^]+9N!WRF B,997XCQ-8\Y%@ M\VCJ@X[X<%Z9YJ^2F\BDNVM"T#*CHS(E+T?%GL"G3@5W8I%J==HBE;)U:F-Q M7/8QB>%Z2%(P3>M1'8\U.:4;4>0B!"X3(Y9&:F,)@^M2V[L(\2$#![3)8TV: MCX9HC6&;GHH(*>G=/!UVA]=HW0WA!_7N*?NLPM:XR#>K9-/IY-6+#$+W/'0" M^2:-Y(TG'O!I6?&+BD$4^+STG@Z".!C>Z-4?4$L#!!0 ( !4Z;5&PO=V]R:W-H965TE.M!%(8G@URHHC>[X+4;.[LPE=>JD#<67)7GPJZOI#:KR]ZPUR[< MJF7F:6$PNRC%4MY)_Z6\L?@VZ% 2EEE;SX\NQJ3/ M\57+EMIZ! M+%D8\X->/B:7O9 (22UC3P@"?^[EM=2:@)#&SP:SUZFDC=O/+?JO;#O:LA!. M7AO]324^N^Q->I#(5%3:WYK5;[*QYYCP8J,=_P^K6G8\ZD%<.6_R9C,RR%51 M_XJ'Q@];&R;A"QNB9D/$O&M%S/*]\&)V88MY\M=SQM?8X^>QJ7;.7"EB>=G#XG#2WLO>[-V;X4EXOH?Y MN&,^WH?^NBC]1RBXE6B]BCVNLZ?@1HL"_L@DBXEB#9EP(!)3D@A^DGFIS5I* M?$X@418+S5A018S.Q%+#FNT '0.6!'A (.AOS!%(K=Y:Z/F*F*I77LD=8]#@Y4 MND-8WDO+SNQ$T,"-N*FEY\F],1%<*^&E>R1,[O:*G2)\ZR*@'$0R M[A'M_H;O8T7T[]5H:*['WH^^+!QV0O3Z8QDV8+]!I!HWO4IUP*GIC1<:BBI? M2&;_0G 9,!=K6"!>M?B.#B"X)C\X63#>%2:E91V8>BQ>& _R(9;X\3@(?VD] M]C@%<-HY-#U1Q?(E!C2!(*VT7F, =$7J<)HH] *F*3J)JX ]4T"3(YC *Z7U M-HE1<()30&NJUT81U9.KL#8:)S16II5%INCLY#M.$:HU]'%-Q958)9A$]5NB MR,M%@@M(>*$*[@9U"CN%RH2MR;C#8+M'-.KO<:4VCGHGS< C:CF-<88RO916 MF:1)-XO]@@*7&HT' G*8%PM-S2*E25U7MLA-A=8_7[=;OA8,BG/"2[:]'19, MG@<^M0.RG%!K'L#]F>)]!I^[O+GKHG9=1^V.G?.-ISHJGZ,A>$B!C\Y5V!F1 MDH0O!1DODSZ\EW%#8,@$(IB>]D?C$;R%X2283!NTUM4P[H^F4QB.@U$$7QD# M#H[#_N1T>(C;@W&XA?V,=;4H@9\$TPG,7_!"?Z<*,Y' VS"8=/F#>ZH"6X%9 M%NIO9!!O#X/88%BMU(*X8:54#9^G37U?#5&-8A8P&*?R@@+=:>3L$+!JG'PD M&B:''464Q9@0NG[4*?-I62#X8: M>UF;*'66DG1!J9S7QYIZ9#WGY@9WM*MH&(3_JZ(H@-^YI+?/,3M>V9[5U 84 M)^M.&\+NHI6LN#T)EY'C2I1,:92@GPMJ2^O]8XXZ%@EL3.J^=<+MJ9N;-"4) M_A6;&'&#V;0PYID\X;:3D([.%:07HU[6AS?W9$>=#F34MD'<^=HA@KE%5QF9 M!/#9U(VS31'/@QPRO:M*2 M 'Y/C?'M"RGH+G^S?P!02P,$% @ %3IM5V6&?G9X P !@@ !D !X M;"]W;W)K&ULK551;]LV$/XK!W4H4L"(9,E)G-0V M8"?=FH=N0;)N#\,>:.DL$:5(E:2L9K]^=Y0M.T 2!-A>;/)T]]UWWY''66?L M-UOA1*^WF4>5]U MD#I:S(+MSBYFIO5*:KRSX-JZ%O9QA+S>H_\<:J=:UL+AM5%_RL)7\V@:08$;T2I_;[K/ MN*OGC/%RHUSXA:[WS2XCR%OG3;T+)@:UU/V_^+'3X2A@FKP0D.X"TL"[3Q18 MW@@O%C-K.K#L36B\"*6&:"(G-3?EP5OZ*BG.+Y9YWM:M$AX+^,U7:.':U-3> MBG7?(MSJW-0XBSWEXH@XW^&N>MST!=Q+^&*TKQQ\T@463^-CXC@03?=$5^FK M@ _8G$*6C"!-TNP5O&PH/ MXV0MXG[ZWTC_"7\NU\Y;.QM_/U=A#3)Z'X/MR MY1J1XSPBQ1S:+4:+]^_&Y\G'5PA.!H*3U]#_0V?^#USXO4+8&$675NH2O%@K M!*E4RVIY=$"1D%="E[26?+L.J":@YD]098\J')@-"%T0M@T8#5II"@@":HJ^ M@I-;35],Z\C-?8"OFH:-DO\0\"\T9.!$&4=FNM$WZ&2I0\H;0MD*ON"P$DKH M'$=DR[%>$Y-L'$Y-"C]!=CZZ'">PK$VK/5,I&=)B;DH=4KR]%"(@B3#Q]L"2 MT"S82H#?6U&_-=3+.1N>3Z0>XQW4HCWM"J*;3:%TE M&Y8Q)_UHCL+[=]-TG'X\"$%7Q^^4V-T?5N)LE$U(B;<1($MA:/R0GWJD.E1_ M!DQH87OH$)?I^A9AWZ3BT*0C@490F0ZW:$=\) A]*ZGA!%U(1U//]9WXU9"L M%T-!-T<"\Q'ZC$7)0BQYLDLOR4QP3] .R2MR1N@H&_6LKZ0(*%S!WL3O1&Z< M)WR+L$9&%[6Q/A1GB._@SO+S.N 26U+X]+E;'Q_-YAIM&5X@1UGH8/1C>K . MC]RRG^T']_Z%_")LR?(JW%!H'HWPK*BAQHM.]#W MC2%!=QM.,#S]BW\!4$L#!!0 ( !4Z;5?U_AS?.@D $,< 9 >&PO M=V]R:W-H965TE";] MT6!PTD^ESCJ7Y_QL9B_/3>$3G:F9%:Y(4VDWURHQZXO.L%,]^*B7*T\/^I?G MN5RJ!^4_YS.+7_U:2ZQ3E3EM,F'5XJ)S-7QW/2%Y%OB;5FO7NA?DR=R8+_3C M?7S1&9!!*E&1)PT2ET=UHY*$%,&,WTJ=G7I)FMB^K[3_PK[#E[ETZL8D?]>Q M7UUT3CLB5@M9)/ZC6?]%E?Y,25]D$L=_Q3K(CJ<=$17.F[2<# M2G86K_%K& MH37A='!DPJB<,&*[PT)LY:WT\O+665\^Z\[Z&>A/I1J>HZJ!H=474F[J!HY<3/6:SB[?E] MF%7;-JILNQX]J?!!Y3TQ'G3%:# :/Z%O7/LZ9GWCX[X>#K][3 J9P,HO=:X%\>Y7.E:V3+FY55#X9\I,1A*Q6 M3ER)&D)KPZ1 D:)QV3\\FXJ0[/!D]+9];D*KU&V'6&0VZ8NYT MK"5[=G)Z)L;X?WC=)CDOL-+T=!RNTR%+WOR!A2 R+%[%#5&G9%$\W$I"%MES MA2KC4>>]V_XA_";7D4R231!V("5KH=:IJ+":H[?6?L4^>9EYS;+JMT(_RD1E M7BBX8U(-S!)A.C%7?JW4%M+8LF!R3WS"M:6\25A+W"JA$@UZ9$C"WP:BH/[> M<=!\:FD!=$DIYBFQ5)FR"#\! G=LT,HDL=OQ"W\JE!]=XY7Z&@'9A/E8.W Z ME<:I))ZQ4 M:$@0.+? F^E*%2DF;0>6CCA78 M-\3'PCE:'EYRA22;GSJ\LT/M90#_ :[+3<;&9P47!V1*#BREGQ]. M.%BGJ,E<("ZKJ#&F=4JV*[53T1*.2GYI%SH5=3G<1836ZE&11R"'V(C, -)9 ME!2Q8GDY!R)1@!R8/*$4T>-=^B(3C9 Y-I['(.%@9+=5ZY8Z;/!(%I&Q=<1J M]R58"]V_N 4/0V!N4),DXE=6*9&&QD\QB1S8QLEZVKV[Q_)60L&% LZECL6+ M06]8%69O;]_^+Q+WCFJ@VP5('G1CKR,)H+J*'[5#%)FFSP:[2JNB0Y*H2\S@ M@12T#69DJ[(1'N$,5)DDETNKEE2,Z! 0EI7.&X0PK7] (DM6'T[^?%:?#*;= ML\%>.U63=4.OPU8::W[=8NYOXM>]_NW/IM6J8:+:IYP@@#(U!71:A=XKG#() M8/&O.+V1*V33@DZA :4\L>9=K(.G=OW9@\CW*? M$4EFV@/:_R<$VPYLEYJE(_%'D M,-,X,=)6F0FNLU[8/5N)*J-$C*/V^$;&L:9YB,T>Y:!I65&H&;S ;!I ::D' M)@W;%>MJ)(5,,Y.=[1\,3>%INV (RV,;PMH4U)6KLE;D/%&,S\GI67E-W]N/?T(7!6 M'3OOP['SH7WL;&^H,G&&^4!GCRJ8!7A;F2U5,)%9/E35$=KF@C*=<9A,8:GX M#%=MR&\@D)U<$)^H:A.%)45CQ6ZVL(I)'ADW 380PAI;<*J.^TXO,[W0$1_8 MRF-'"X*:7@,G?+2MUFZ-ENMO'1W;;1%Y&2O$&$T70Y5.AUZ4*0 32CH4$6PV M):L?,1.$:VR@*!8GV+%= 6V')EJU_=*, J$/]Q&OJ*%-;:SU<:"U,P(F BOIEG?!,9^%MO?Y=A>Z ]V,*4G''[^0%X?M^HO@I=UB[#W=>>S9HVFJ9^5(CASQQ$=/0,XH>F^MJ* M&YNQ/AUGVN^Q=VB_YM /,E7BU2VL0$L1.L"R&ZC?9[;6N"4K#FP@SWL4#B3[ M[T)YD.]FB?Q=0B(1'['IW:F8WM&)>T0=E70CT[QP8@;>0'8Q_FKX6MS)#9T= MIO3^\/1,3'H3\1+WPU%W,CHI;Z93P0@:_51?_Q7^L8K[K*&4-J2_S9@UZC(' M4R\#F/A57ZBNNR+Q^DT=\9N[ZP?Q5R/Y?1YR;!#2B7B#;%F_Y*SC"33+#0&W MRWS(K7#3.^@L?,:J7HX]MQOJ/GE""1Q"&%9\;!U7YYU0')%5U*IQ4U&#E?EY MU#MY23((_LO>H<\%_=:'G539)7^^HE89: O?>.JG]1>RJ_!AJ!$/G]?NI%UJ M5%BB%I@ZZ+V==D)O6_WP)N?/1#C:>Y/R[4I);'\D@/&%07C+'[1 _=WP\M]0 M2P,$% @ %3IM5P5NL.R'!0 3Q !D !X;"]W;W)K&ULW5A;;]LV%/XKA#H4":#:NMIR+@:2M,,&K*F1-.O#, RT1-M< M*5(EJ;C9K]\YE.3(B>TE>VP>["->/I[+]QV9.5LK_=6L&+/D>RFD.?=6UE8G MPZ')5ZRD9J J)F%FH71)+3SJY=!4FM'";2K%, J"T;"D7'K3,SP$ZQ 3++2)0^+IG5TP(! (W MOK68WN9(W-BW._2?7>P0RYP:=J7$%U[8U;F7>:1@"UH+>Z/6O[ VGA3Q"2OC55ENQD\*+ELONGW-@^]#=F^#5&[(7)^-PT&Y[C$HMQ:#;,<]MGI-=3]-V4,F3%-;E=4L[.A!5R<'>8MQF6# M$>W!F)"/2MJ5(1]DP8KM_4/P9^-4U#EU&1T$O&75@,2!3Z(@B@_@Q9L@8X<7 M[\'[0+7D<33;.)H?07UB1UV*0SRM&%DJ ""$3A!M".R$2M2 69H'S(,$:NE64D)&_?9%$8G9)/>DDE_^?Q M=%H4'!^H "5:RH4Y/H%(-6SM4Y( H2PKYQ %LNH:LG5H'EF''U'/NNY20:W5 M? XIF N&,4!"2O#&N;]2HF :?.<28E*U@3R88_(3.0HG?CH*G1G%?AS$SDS' M?A9-G#D._3 %\_)9$=:NL;#B';UG&OID4PA#H,,:"PNQG$< '8:AGT0C/TI" M9\>CU$]&C9T$B3]*TV8\COTL"'>[U TY3(;:*31B<=$\%,-X /E"!RMX8D;4C%.SL"K;8VN^3 M6@IF3"\Y3I;2V*P%AD* ,0@^;@[@69@3Z9U@#>0L%*J>2[BFK+ MH2SW67^K6J!3:M>]9TK>=UH*6JFUH[/QK8.?ZLZ6W[(9K= MW5Y^.:&/ W\(G:8!6EOK! M.")_M7\NYB]/3WJ4]]:9^Z6YU;#WOCJ1:@2)[]B?!GXV#IV&)ZD_R>(7XOLX M7;&6ACZ2'1S=47A$QI(/7)E>&N33$O=>_.95T8)GC2#R&OH,-$UH-JRL'.4U M!3FTHD&01DNE*^#V.^5_OU+VJ,K)O2M!$D#B)\]IW8_O!>G%!F(8A F'0796 M#)K-_,&YW?5.UX@%AQ_Y%%,);08[OA*\<-X.G"Y>7*(M1?W(!8I3Z"$@W.V( M7U\>\S1I#GVCM_\$Z44SV41SPX0KY@Q>F0_DLZ;24'<=-0=_H>RZ1@Q[E[R2 MZ:6[RAK@"+R4FOO>9G1S6[YH+HF/RYNK]D>JEQQ<$&P!6X/!./6(;JZOS8-5 ME;LRSI6%"Z@S5W#C9QH7P/Q"09CM QZP^1_"]%]02P,$% @ %3IM5]R^ MMFSP"@ >QP !D !X;"]W;W)K&ULW5E;;]RX M%?XKQ.QB80.TK?LE<0S$R>[&0!,;<=H^%'W@2)P1:TF<%35VW%_?[Y"21G;L ML=NB+WV9H7@Y]_.=0^GT3G('H_=^L1L.BE*>ZBI3P+/2TX:H=K%V:F=N^K.3O6VKU4KKSIFMDTCNOMS M6>N[=PM_,4Y\5>NJIXF3L].-6,MKV?]Y<]7AZ62B4JI&MD;IEG5R]6[QWG]S M'M%^N^$O2MZ9V9B1)DNM;^CAHGRW\$@@6@3$[U"U\;^LCNW M-\@7K-B:7C?#84C0J-;]B^^#'68',N^9 \%P(+!R.T96RH^B%V>GG;YC'>T& M-1I85>UI"*=:I"EQ9-B(''N2 3/ MD,C99]WVE6&_MJ4L'YX_@3B33,$HTWFPE^"UW!RST.,L\()P#[UPTC&T],+7 MZLC^]GYI^@X1\?>GU'74HJ>I49:\,1M1R'<+I(&1W:UTD\+>"/-OA6258J4]3:;+&-+2E!&=*<]5CIJTY*)MJ2M2#/&N=A M21YF\$\OFZ7L)B?9C1@$3'226:YMCYTCM0^ZV8CV_I>?LL!/WQK6WVED-$DB MEK5DRZT!$V.8<5(:>[ 1+6#!2DWD%2AVK:C92K6B+11&W:3,9MMMM)'F#?M\ M>6[L_NM/EU?FV*HYL&?R5M1;T4/9C>PLH+6%4[(1-YB%W'K;T51=ZT(0;!B; M\R4#@*C>"?Z#M(Y)(TM50"B]6JF"=%)U2:(-NV 5!=A3]3TK0%894-,K)VXM M+8]>LTJ*NJ\*6/&HD[4@&_82ZF+S%K;O6*W;]1$,T;A#AK.[2A45%+B'^']L M%>QOMI@8CX'H!FL"_&%S0 0S%3D)O#$#._3W$ROY'5@/HDP8=@>@I']X4NG. ML$J3VNOQD"+6E38;U8L:0]5N8"_2LY.56*H:\Q9V5Z*@!R6=5\R-JFNP:K>= M)3=;?DY!-^_4'+4B#=:RE1T\18J;#=F48@GZEC!"T6.>%']62><&#$%3.+%$S),A4M@PH?6 M"CUXV-&7WXMZ6U+T(9XUE.F0R+*Q/AXV#O!BY<0?;:=GJ_D.; P"6DZ!@$PO MMK7C3PH#11^!S982B21 1"(,2';B4]"R!R@%<5V!!OA7]:'((M]K:_!8/6#?(.50#'"H$]E ( MRG:4&1XJ.FTL>BI=PB-$#5T4M5@N=A0V(FM(JE&^T8L=@M2:3A?%%I(5]P1' M%.98L5YW3SN_[N"H)=8 -Z-VK9RB&,"X!4"0#3L4BY*B4-E<'#,0U,Q&VMZ/ MM1H)W1!0@Q7R5&Q(+<2NE7#GQ@=Q Z/W0CDCZ-95I_EVJU)'$$50:_E*0B2T MA8/-R=U(;Z01]DN+5P.T:X?+-A"FXCB>A5]W1CQF:$(AE&@VM>2N& *8IA"& M3TF[5@(XC$,A] 4WCLDL7IQ%YODMP!#6ES:^;:3VQP ))LK26ILC!E'1D0/. M]N2+ALKN/X5;'F*%:%4 .]W9,EAH2">*0F_;*4F'J*O52A(_P*7U.-6NTI[L MGQ%3]/,0'W+&^6G7;"SOY[V&I4HF6CB@1MJA4Z&&S&86])Y+@%74)54\ *C'4CR(0VNZ0IB*K="&.B(3&CU#H%: MA-+B0,=M-+JZ.XN?% J4:(2IBJ*BDE,=F\"%!)H; M:E)P[&H'&-S9^PWX4-L\OP\]ZI9?W&#;:=M*'UR0]]!H(&[,(?L\])>7KK\\ M'_I+@_.N)_DT]"36/L';6RK]#D/TYQ%$<^CE,41#X/$SJ4L\CE$ M9K'/_3RST?PS"R(PR#!(N9<%+/1Y"#:8#WGFT7S&HSAB8<"#)& 7"#;5N;X0 M'?,:FHYF.,C ,#^S!WZ*G0=^#@Z_NQ[7H6Z)]*>P=BEW$/$TIHT1CU+_D'WL0YYD,VW$+FA=W)M4A!GS/?8P9^0#X=L3?413(RH M;;+."\J\@7::^7G$?A].M+H]0I%5Z]:J#GA1MU8]PR(O8>3$9.Q8>_%]+BM9 M-<7/EPEW>I?Q(\X3;21PWR'O72?JM#',CQCRZ_UTR;,9#>L!Z@G>4(F*&W: M*(S)&L/_LWP@7$/*TZE*UP3UB"7XC\<)_((A BSTH/D7*BM[ 3 2NQCPW+?Y"J3(P^0U !&DB/J ^6'$/8JG MQ,=SQH*$1WZ*:0]($X)TPK/,&V BA^.[H/K3P(^Y[L4ON,,E?Q M8 M*K9@8 ?Q4WA!@.UEE"$ U#S;AQ=QF@!^&<'%JX B3*Q:'D'@RU 1(RP 67[P M)%0$D:45Y_\15B (?<][$2Q\CX=4$J;!OPL7"/TLR"U%G\L75Y!"E/(,]'7"[R;F'%3!A81FH$,F1E%'OMFU5#[^8 8T .V M"VB49CS(4_:!>DI[\:8!O2&[1? 1!?0&7H06@5J3".!$#6-!-K,[(P0W?(]4 MS[((JH_1-MB2TYUDA;QG].Y$,J1 #$C J01_UT@[^AQP1.]F[?V6'"=!8ED/ MLL(" =6A&#U),L,'^]:+=?:T7AW1Q6KP'J LS/&;X=@5+C!"E0^OR"[CAMUA MPCT_9P"^.";YAW"E:YD9K!6C*GG,3WD YWZ;!PH@COLI^B#;LV&9[Y#X,Z))MB(00E=*D1M5#HN)+!]D]:CPAFL6M: MDS @AJA*.4WX"4^]E#WUT>%D]D&HD2A)]-F+[GVXC+MO0]/L]&7MO?N@M-ON M/LM]1D53+;VC7N&H=YS&"Q>=XT.O-_;STE+WO6[LL)("L$8;L+[2NA\?B,'T MO?'L7U!+ P04 " 5.FU7:( ?\CL' !T$@ &0 'AL+W=O==0C51;_O\[4LA>_92AJL+*TK1<"M6_5]Y:0HHE"I^]E@,.F70IG.]65\ M]L%=7]HZ:&7D!T>^+DOAMC=2V\U59]C9/;A5JW7@!_WKRTJLY$<9?JL^.-SU M6Y1"E=)X90TYN;SJO!Y>W(QY?]SP;R4W_N":^"0+:[_PS;OBJC-@@Z26>6 $ M@9\[^49JS4 PX\\&L].J9,'#ZQWZVWAVG&4AO'QC]7]4$=97G5F'"KD4M0ZW M=O,OV9SGG/%RJWW\3YNT=S3H4%[[8,M&&!:4RJ1?<=_P<" P>TX@:P2R:'=2 M%*W\201Q?>GLAASO!AI?Q*-&:1BG##OE8W!859 +UV]L6:H EH,G80IZ8TU0 M9B5-KJ2_[ >HX(W]O(&[27#9,W!S>@^ M:>?32&+8_D^3&OMRW;VW60O GZ4 M58]&@RYE@VST MZH/>\HXHV>P?M%PH6>_OMZX8-#2/S^U!D3Q/AI"$Z3"U^) M7%YUD =>NCO9N?[AN^%D\.,+!HY; \Y2 M6$OL+2MAMK06!7EY)PVA%CC!\A'+JWLJE$-^T5(9 4@L:":8Q,I)&;7VZ!.@ M'HKKY(:UN)-4U/S0&M\E97)=%Q'?HTS( GEOY$9HK#EA5KRR=+:DX;PWI*T4 MSE.P-!OW!NFN2_*^A4#.%Y_A)Q.H$NY+U&M#8^%&A34)"M*5S,&P04CF[DY> MJ((,1 !=I2!+GXLBD*QQ4+3RMD:5#3GP5%8"Y-GX @J4S)(3H8G:.Y]FP-^ M^&Z6#:<_>I0?#9;!9BS7B2P W_[Z&_,E&Q=K)19*PT 9P4^FO2DJA]:Q"&+] M9 ;NF@>@5?I*QM*HMUW:K%4.6IS[,+L]J=O5>\\-]!Y8<*^K1 M.X/:R>0KP_OWD@\/\Q"(T(B>)$?>*Q^.L1JOU!5.SB*BL%7L!:"%[Q/XJE9% MI%4AYM*!L\%PWH49M$&[X%]6BD!\C*T2QS('@5H3)@Z1 2C8N"VO4U:^5E:@=%]EQ'%8"U2P7/H*=#'I96Q4X?$3)AOFC MO&?I$N>O4URRW.-\9&7H =:QD+S'M.CE(PW1^]QQ8^7@)M5$KN+!C(5C!L:B M?)A/O%;'CM6F:2+E6TOLRQ1,_G$*6@U_R>RO>&[ZCYL]W9O]J2V4NRV/6.3VAK#^/]*?W:4M ,FC^E^>AM.Q\USU\-3U.N MODJEII#NE$YH.,GP/\MX;4R344;S 5^?T_EL1O,17T_H?#ZG^3E?3VDRG-)\ MRASAG6S)8THV[,['(YIVL^$Y?;+,!W?9LBX;/[;L9./N^7B(G9-A!L.\OVB# MR>[J?3A[^@6QOA)A-_S< MRE6-YF/=EMZ+@&-Y>I=B%/$,O7@.5)<285%[Y*H_;DYX^]K2 O%?HC_6B\]L M,7J=;O5T*=="E;O\:O6525\O^2KV5V/Y*68&D*CE"O\1F@[1T/V8HLH&#A^!CL]VLANUC+F76]],=X4H MT18YVI+]/!T=V=9R]NUO*CRO+R3>-G"!X8 'C&V.H BRO M&FO.N/C 3L1>]R#L8+&%$I?MSSB<@E1M(3S3AK\=S?!5O&[PL*&8,MX MN98"A8PW8'UI$0'-#2MH/S1=_Q]02P,$% @ %3IM5T;DPNU&ULE59;4^,V&/TKWWCI/E'' M20BW33+#97>V#W19Z.6ATP?9_A*KV):1Y!C^?8^DV, 6,G0&8LO2.3K?59IW M2M^9@MG20U769A$5UC:GHY')"JZ$B57#-6962E?"8JC7(]-H%KD'5>5HDB2' MHTK(.EK._;=KO9RKUI:RYFM-IJTJH1_/N53=(AI'_8<;N2ZL^S!:SANQYENV MOS?7&J/1P)++BFLC54V:5XOH;'QZ?N#6^P5_2.[,LW=REJ1*W;G!+_DB2IP@ M+CFSCD'@L>$++DM'!!GW6\YHV-(!G[_W[%^\[; E%88O5/FGS&VQB(XCRGDE MVM+>J.XK;^V9.;Y,E<;_4A?63DXBREIC5;4%0T$EZ_ 4#UL_/ ,<)V\ )EO MQ.L.&WF5E\**Y5RKCK1;#3;WXDWU:(B3M0O*K=68E<#9Y6V;&KYON;;T>8-? M,Q]9T+K)4;:E. \4DSK[I>VVDO\Y28S4RXN_7S UL!Z^SN2HY-8W(>!&A# SK#4?+ MCQ_&A\FG'5H/!JT'N]C?%X__24&_%4P7JFI$_4B%,,0;4;;"(;_C*K4M8T"6FX[W&]$T5=J[;.O%Z&U4](^$I@8Y7=0>B6 M&=^2.!G/QD?# RI*I!X_+YS+XNL")BW(&BTL+/. M7:">PV,?]1^4= B^-*:%:U@R)+$47DCJ@08.MLV1O/ MDO@$O;8.G\2SYR:?7WBQ.^L4QG>6Y#(SEXTOYC58N M*(YL[S ^&O@S80ID5*.,]&[X@ER33%>"7411A?VQ0*6U9M MU1=FWCL)^*>-!5P9BNY'O3 09.XD=]OG?=*PT*4$PQMY!D$2[<(QAN+:99Y( M,=ZI%13C^""A;2/PZ>%,W>[^Y&W\&R0570 ,]5^"3^"F^+4N/WIV E>LU_Z> MX8H$>X;#>/@Z7&7.P@G^M#S<@ZZ$7LO:4,DK0)/X:!:1#G>+,+"J\>=YJBQN M!_ZUP'6,M5N ^952MA^X#88+WO)?4$L#!!0 ( !4Z;5=(-45^0P( (H& M 9 >&PO=V]R:W-H965T^KK(0*JY&H@9LGN9 5UF8J"U_5$C!Q217SPR"8^16F MW$MCM[:1:2P:S2B'C42JJ2HL7U? Q#'QQMYI84N+4ML%/XUK7, .](]Z(\W, M[RF$5L 5%1Q)R!-O.5ZLYC;>!?RD<%1G8V0KV0OQ;"=KDGB!%0(&F;8$;&X' M> #&+,AH_.Z87K^E33P?G^A?7>VFECU6\"#8+TITF7@?/$0@QPW36W'\!ET] M4\O+!%/NBHYM;/310UFCM*BZ9&-04=[>\4MW#F<)AG,Y(>P20N?=;N0L/V.- MTUB*(Y(VVM#LP)7JLHT>-);A8/ '=0C% 5W* S" M:( 7]>5&CA==X5TJ\P[M7]&:$WJ@I,'L4M4M='(9:K^;A:IQ!HEG/@P%\@!> M^O[=>!9\&E">],J3(7JZ;1B@<;"?WH_/M=&2B%K_?\BM[C PQTS!@-BT%YL. M[Z=2>0)JO"%]Q&V:^Y3;OW>8W']RPWS#WJI]_UA\J MD(7K@@IEHN&Z;17]:M]HEVU_^1O>=NE'+ O*%6*0F]1@-#>O4[:=KYUH4;MN MLQ?:]"XW+,W/ J0-,,]S(?1I8C?H?S_I'U!+ P04 " 5.FU7.!S.'E L M ,E@ &0 'AL+W=OZ"1C=) M.TG5^\%6LQNXR[EGW^X/-VWWM;]R;LB^;>JF__'1U3!L7S]YTA=7;I/W)^W6 M-?3+JNTV^4!_=NLG_;9S>HGYZ>G+YYL\JIY].8'_NY3]^:'=ASJJG&? MNJP?-YN\NWWKZO;FQT=GC^R+S]7Z:L 73][\L,W7[M(-OVP_=?37$S]*66U< MTU=MDW5N]>.CB[/7;\]>X@5^XF^5N^FCSQFVLFS;K_CC0_GCHU.LR-6N&#!$ M3O]NKC$2K>/O.N@C/R=>C#_;Z#_SYFDSR[QW[]KZWZMRN/KQT:M'6>E6 M^5@/G]N;/SO=T'.,5[1US__/;N39Y\\>9<78#^U&7Z85;*I&_LV_*2"B%UZ= M[GGA7%\XYW7+1+S*G_(A?_-#U]YD'9ZFT?"!M\IOT^*J!J=R.73T:T7O#6\N MY32R=I5=5NNF6E5%W@S915&T8S-4S3K[U-954;D^>VR?CGYX,M#4&.!)H=.\ ME6G.]TSS7?;7MAFN^NQ]4[HR??\)+=FO^]S6_?;\X("7;GN2/3U=9.>GYT\/ MC/?4P^$IC_=TSWAS&_Z/BV4_=(0W_SFW81GOV?QX(*;7_38OW(^/B%IZUUV[ M1V_^Z1_.7IQ^?V"US_QJGQT:_J1#CR[T9=5PQ-U)8WC".^'*_Y;CV';T=O5MJ:#6+O& M=7E=W^)WMQWD74ST2\,+N\0*>/:+C>L(A;/'__0/K\[/3[__T\7%)_YX]OU1 M1DR,7ASHB4VT_*H1YL9,HBEE(1B\:NCX1^8>?3:T]!T!_=_&O*,1:"V?W;;M MAHS> G_(SDZ/_XW?O^B&JJ@=?8$%?7;KL9;!+X__WPE35E?2!NO;!6:YS3?F-4,WIY72ZS7-7XQ=AV-J\F'LW"*[N:J* MJX6=2[NM&LQ![VSRAM@[QEMD=.Q9XPK7]^ Y6'.>K?*J"^O$&X2*Q%-[_EW M($>VI?^WI>[$'J+G241UN9R2O=(0IF<;83D.+">[!-YLEJ[S7(-W1Q_.95ET M!+:TJ@;JEH1'$!EV&M-ET6KI"+);EW<9=D+XWH_+GDX&^YA;=.\>1$S]53O6 M=,28.F>4IW=^'1N19QY-[S\@-BSX,X @":5S.5;&+=D5;T= ]A.!0R!VQA [ MUU-F>'G2UA-7D@>MG;W\OL\NFH:P9H9(_H765KN(S%(:O@1F50/X+Y;U_EMQ ME3=K'G]3]:P,/,9;2M^7[]]Y\J:?_IIWM+ZSEW+")WB=SETWU_8N(9R&=(:$ MX;0-?2X46&75D_SM\2ATEX7 ++O*"2.6SC4$R:R/1*:L4QG%+CSB1^-)3=B4 M(Y/3?9'WA"; ""->^D!3%1'W_?BW#S\=GWV7?2((NDU59#^%P5=5UP_9WX6+ MX0T:[90WEZWK=DE'YE_?VNO$6 @FA2N%]/SW.* *>+6BL8BK7!%T>OJO7/!/ M!:-O(>MT R 1[^5UZZCLZALV4WFZ*G6AB2%Y"OIH_05(3;(6J:=0G1PA.** MU9=__O@)!TC4QJ@C+($.:NP)F'2*0/E\L.,GI#VF)WJ:F>DT5R9O.$D<:4NT M[XF&2+\J\9=MC(#102M=Y\S+&7RD*C2]X2@!UL-1]ND4*IO\-H&)_"HG<%/5 M)*/76#%&D"4"I>A50HAUU@()(8B:-:VE!GJ[RH:B6=818) X1D M+3*W.;AX=;$9ZJ7:DIV>LV0C/<^MVJ( /<@!TYO0?P>NZ M[?)E[7AF.>EAKV@AD +7@6F]HC9)Q38YRR7$VYJE!D2(GCL F0/V-1VA S9! MS%2,?,(!3RY/E 1NP9)E=%X*\T1B+1U>I!D\)B;K.2'UNG,MD97@$9&G\73 M ABJT)C'B[]^?!M3C\Q?N@(*XV)W2QBO+8J1QBAN@:4%=- U/:I8Q* D0=( M3TGG*860H<(M2-^Y:4AG()"V+/C7C>@C,3!(\O&JE1403'(]%I%7@6'8:'8D MPEN@*JY6+D7&!2;DU=)FRNC;549*=-5VC''T'BEHA@@,[&SE5!Q!1ZZ*_02F MI_&S$,2"CQH,O_%\$+LBV=D!17OLF50RU0^773N2#4D+(_,92%/3IPYJ0 ?H M$LWVXW9+6R-\H!=)0'7C5I&S*:>C$EMSQ.D%@UAJ><8\94%[V?+<%F>I8X* MO4M78ZB,E_Q^!56))%K Y";O^-%?OG8Y8]V'OLM=K>RW9H;4YZ+[_!Y(8.], MM[^9675VHE>0B?>'$;]35R2 B!IN3[*W;ETUC>"#*BY!%N\*83XXVA5IV[(4 MIC5A N*1(?:S)M(0'#;<#Z88M/>1E0A:UDU^JR+Q&JHX(9LN%*S"K:$"O0Z+ M$ 6#=:ZS\^^975S*0\R*$V5388GE A]@4ERYO";!>@=XR;@JH/D5- [D(GUE MXCOA^/1C^U48JOATLGS+GZ]XZ\5518#)-N,PBLFX[IQC+D_:\1C)>4P0ZQ $ MH;[=N*P YBQBA>R 3FS'I4MSWTA]!:J*",H)1*6HD[3"ZXIU!7#ETJU<1[ 1 M_9MNFA1^5Z%INV9/V;62W] M7#HHK5"U*\'+F<>"!380@>%<61+U<&" G>DI WE6.(E%^GJT1;]"PM6Z@OG# MVI-\;5IIV!!+>MT UE;4]$<8N(U7_%A,,$H.:#*"G)W ]I2X M 7@6E"+9(FUOL$F\ Q4@9:;+@^;%5Y))K*6R^@RJ==^VKE2MN2:;"3BR53&2 ME^W6UJY':N9DV;J^478PV!RM;2;8U/2U@->51R?9GVE\EC>$,S5\KSOFCV>= M\#RILDJPU7'9%V7C"5W][/E8Y XDN[0I2,]2S]?7+[UIB?;(._? M*96SCD>GO!(.:["0PZV$?3-8H=*J1N]N/8[Y#9C 9VV[BD0_SP(US&VV'5^Y,;R.C(KZJWDS@,!EQ7XCA:4X[H#^ MNM=4* DOB=@PT_,^OAAXEW [?#K JLY)4)*,7I!F,/"2(F_I5*^80>L(&\S? M%>V#L7@J?L*11B2W8-\P5"[,#1I158$F5"!%['A*+1.5081BH#;\F*Y:3CX2 MP7N.5'1E(J]!+5J8']4U(P4MOM^Z0NVXQY!7YH@E9OJ+HF\>.Z<6#*1T*?P( M(W%$"8WZLD%5K)*8<@UVKSH@%L2.XV @KM1KZLG(:QOJJRG'@@$C+]+OPBID M5\:T=2I!NZ)=-]5_@?_FI(G21C&]GB'L?CZ5:N42":J<0T\K0G33UE@UFL-U M$^;[L!N[]'I&*=N*N \!RNA,SQ%>=6QT5]Y#6],5QGX%S5X]I>9 M"O]AWM#C9[Q"&.Q]PE)63F%YWT BKKIV$QDP&39?9_\\DFI%?Y^9R&G,.O@O MUAWC9\XC_9?L0IXY3 @U=SII:A&P00?MHZO83YE!X"+6 S9TFUV3XK]QYLH3 MK H>P*$=N\3_.NL E9"5V%W'_@?OW0?G4"_' G;8O&47;*RB[6'?F,'656!5 M.4(&XB0)?)'EC[H=%NH2P$9D]4091-F#$'8&MKO=F'TJ_)PM9?'X];/G+(L2 M[P<,*QA3)&/971:"7SI+[(""4X.@LJ[@-SC)+H1UL0LD)9,0OULZF/G"* &" M8*J;,B@A0M(_10JWJU7OV!FR(CG0>]J/!.Z[MB,X7%?=V&<7%7&%STJI'#\P M/Y'&%6Y)M1N\#O?NXO/[2WQCBISJ1RU;#220R!#[-C#^\VK!8*Z!9*)C'SX" M)@L/+L)PYZ,6F9\X^U,'2M7Y)=0@C-'[S)*@G3EE[/V3V+=_.'83GP@S,_ M M:",R)#S(X(JDC;0=? )> 0DX1QI_P]$*5L>J@?4W8HZ$/3 ZMN4+$&X/=.U MI[I!&"G+UU:-3G5S$1D6SACA_6(@W@9@YSGL$3"!!DPRLHIP9$,%K6'H5 9@ M,\NV(8S!6_T1\'#LNAVGMQPB%+3VUDF$F?GK5=65C*6W$?E@NX;/)1S5>QWW MP>='"^KM^!C%: :!AR>:!9"1S"W\%/07P;W&U5ZJ[#I69E<)59$U A@AO#$< M1(X!R3P"XBXYNX )P>!UQ3PR,)6V6;8:^A!.IN2@(Q"C7ZV4H#M'VBW./M)? MQD'%@,LDVH+\!EB%;EG]7XE3CQV<(,/?>PT1)QB M1(@]#7_;>U$:PYX@H)=5J3_WWHQV0A 1WPT\Z$O"6O3%/SP[>9YM$-'"6?WA M^6C"Y2@_:$I;+I M:,KAJG,:/;IO+D$U))M_FFXW@4:\PH6<<2/2'OQF+QP>M*CS WZV^$3-[2#H M+( @3K;N.*H- JV6ZC?UJUN#IS8;]ERR!WB,?(4>"(QBD5+.*GII&37L.N*8 M4^Q\]A$ZJ+!%Q-#WY!DD60]I)M+$]0XEKG-7R"BDDZ_;OL\.I&(]]ZE8SP^F M8GT*:4J(^?K5V+G?.U7K?V$:X11Q+M?=.2*6AC3HJ^-N6I>@#ZGH%O^'[Z8J MJQR*$>F!=2U!%W-F^F%4I#2]Z9601:0-D'5D_H\BWAFKU68_L1IZD=FGLAZ,?O[;T=X:@"=AIB/:RKV*C]F4$H1D8Y.QLYZAAR&ORWJX> M(7@6LLQ3D%QS0T*\OZJV?BG$I\:!)):&JC?Y5YC2A;KR+% (F8CT&9%HZAF[ M5GY->""TTL'MZ4]')#.>P)QP&VV8'S UWS@0:)] 4':"N$L>G$<>9/JKJK-WPP,. M(7B8!@O#29R*-J+^D^?CHYP!=>>+[PXB#!_B+J]/N>-$\$'N=(_F$C MB$;42>Q!O0+WH6<\! ,"I\D> DX85+3O8SPV?'1^2E;+^G[<;"/W3Q1=[#B] M"ZQ]XZED'YCA"ZGZ@A@OR$\6#S1F(\MMW]I\E@LG*)AH MB22LO,3"DM4M)&PR)5I(5W,C*H)!9_(07FD/LQ.R^#U$ 'D0CS_K[CZ'W.*_$R!F'."D$'@+@ZADC!&',VM4) M+1-"O78PE7/BP^#90$KX1=>)7Y+7 [Z(\9Z=O!*U]X3V;-Z$)%P[G\:S$\;/ M'N<[R8Q'6=4K"LWG8;.R22OAK3F$UF5U;"DB*1Z[.,8AJ;7H_:P5#@<1?-V' M][(BX8'-+XG")0Y8BYNQ9%%/<4CB("X ;5GL7I9/A,C( 9E91Z3M>@Z7*+N> M=/+8.T[S+HP6& >8F 3E$LCO \""3!AB6S6'_CSZ8.Q^QT#G-#_VFGL[1 ,[ M,HMR#?.:ATA."*M<<:J02/%OVZI+PL('CN#?X89-;-)"@91[97RA>@_]T NA M,?^M^CBJ)YYX8A4TQO,E]N?3 M%J/3WL.!R/;/U2,R<.(D7$VER)XO @ ?9N%,)TOO#[Q!11\]5VV68]=;>@CS MS."N-1H,>2/^&UK' ZVW=NQ2QAGYS!FP>2^\=T%PVL*H;09S6BC]%P*C1EAN''9&IY2K6=1&)%4#1BCDRE/57>><>:($NHHQ7"5C_RFI0ZZ'IOA&@ M@R*_JMM6%'&.W\H2_,Q)DMI#0*G.*G%,9YPY0!,[5:5#&J>*A?"BA3P9T%*V MX"L;U!OA V*_Q$'7W:RC*&@I&A,H9\GZ? A%-FUS;$)VLVT;TU)R.(77"%2# M?:I]\7F&VYZ86QPTZ[=!6@T4,"(/9(2HTBYO+-21M&Q#XA OY=6SF=2ISJUL M&U=N(ZR]<>K_G$\R#OIC1%@A3S2DA^+XG3/5*F@>$;EK/D$7:'RBD0C5A8#+ M'JF?QNG8DI'D61948V'.0S( !A\X^?SAI_<7HEJ(K,4RTXC%?>8S/2(X>)#U MR^E-B/=Y<'#9EZ3&8%*; 43*3JQ:<]985'*,)?:^>D8WDF03WST=41&%Q8*S MGUW+DN%.BFZM3F'L#CG%[JMS6U&.Y%4Y9J_J1"H)ULRN99&C! PK=0JGR6L_ M'MIC_O _SNN3TH.[./\G8N-CKDX,X@#P?Q_,C A)>BD_C;FHEP]I4 3Y9#K% M0SA7M'_P!D8DM?P>Q]KHG.9U),F!D;P@X&&V2&S<(+2>6S*.!\(0TEJ2/7NV M(?OV+ 7L$")?%4-Q*>S=G<0_=CEI8,2'C*A7WHAZ==#^^9 :>I]AZ+UG0V_. MEOJM8V4?]MJ3BAIZ2$RE/63X!G0=&9,:[@EI246^K8C','^X4?7S5J17:8'' MU5AK6@87D6!$$V;L+N;(#:EO49(VXPVJH'JS[&'M]CO'PRY&04#F3Q;H\_%J M1 914< #LAM*5.)RDJ8#XSG7VCD:93L"AVB!A907<6QL'/!ULD0_W&S.:>0- M%0^893RK/%6]OHO'$A690,^%$+&>;M'!7M)4Y\9:*)HJ(4;3"QZGI]QSJ85J M-Y:B\CL<[G^K31_,-G#OXR=NK"?:M@NG3\?[!FR1R MCQ\L>O_)7#.?V#5SX5TSIJ_TFC)K:=7_VJI9E)LE/F.N1::K%"KO(\63[*>* M.%1OZ>.!1N-W-(=J*_$ M5H'MX;_+:&=ZT,YM?YC4S M,N[QX%VBFIT"+VK>=2P(QVBAFI!I M0$H$+YILT98849^G=_S&H> )8)-MC_SC*,1>R1"2 'D\ ME= 3]SGB$L;6(XX!6SIOUJSJL?L/JC:=EX7"_&^BI<)U%(4G/%(.6K_JE;] M@; P)J/ @6"F(]%VN>#_F^*CVNERK.I2LH56U;>!J[X8><7!$S_,EBO =+<23 T[")M@?<2PD8O8/@+ZD.8[%XH+?^%CK,:-'1+M.X'8' ML-23W 73(3">JQR6+_$>XEC%-*V2#QG!*,E<&]:<]!-Y<3%F?IO;8<;/0Z#2 M1R=>B3A:; %/3AG;@X%'.]JOG'A@K,F!8]6*W%9U'SBR5":EFUCX&%4R#VN, MRP$,>%.-&P8I2S1^-,8^X]'A.-E%Y)<72B[,BQ6Y9#5//ZIW4,<9'S\F30X_ M+:B\QVX?=@Q[8.%A'@VN<@8A1=ZS/SJK.9KXL&6M!_1B">MQNMG2#3=.G>73 M4)S*D&@EH)^8!!H78IK&=N 5%KC&"O:Z;4N)!W2JM>?=F@UKFQ1_R/3/2\ZN'$ M8YU2'>_M,M2^%$B!G?;#B; >RK"8)LC!W>>CN8TDF3(Y8A?Y3(U!R/1)DK)M M15*YS_'2,'3:NV#.'X>2@H17P:M'\%HS1=,V]31F^*N.F&++802)?I[!E5UU MY?](5?DRARU(2VK'8,'LN%SB8T@<+.* B:;Q!\* F]@>'MLGX!5'.I!!G)$! M)1=:%"*5Y; X%EXVQP*75IG7MY90K3@F%8?$5,),4-QJII H3C'I+Q"'5MTFZ%Z'/DD60Q.>%2HS->QA!0%D"D$0]5 C'LRPL8TR]IKDAO(/KUI2\D,>T M-_TD(OU=._+ &-MZ['U&DO3_N4V1@L2.*^7$",[N!I[1;>@(.&.[:A7%>HTL MO"'A,E/N%D6MI"$K:_"2RH+4WFG.W )*L =9@G-3P:\^K\@9O,\4]GE8(E2G MH3P%X$X!BR^^#VR-9=>S-<^>KE7KNG7-.)G?D?47XBNGAN5X;SQA*# MG*0YG"NY'%_[7;3=$RX=.$I$ *,$S;<>*P4.>Y#SB+URIH/%K%?L[!#EG!T^ MP3[E614DTM,&*NPQ266O)"E#BC1/%7TD_'B72V"M,@5A2UYKIRNB@ MRD#4]#$?*"<3A<65.I%\AHQ8Z]5@*3_<$2*O:2F---1%$K"BLZ+@XZ0MC;9% M DNUQ&!..Y$Z2.]8#.\?1007SC7JP\=V4D2JOAV3$7)IM3\0?&E;'O\L@0?Y MO: 4R6M;HBHW+6AJREU6$CP0R;/*"F0'^]/(>GV&>=RE!E&K @<5/N[FS: ML),SU3E==2/I@I(IY5N+BLVJWKG8K1RJ>B.Q;<(+INSL0#-N/5!NJ[T8.# B M1VY^U8I- FDOOG21!5L>5(JB.Q+.?JM2Y-Q=2M'AH7?&2-2,2A--?<3?37+; MV&MC/$WZ9R"6,.E)>]@O;<<$+!3_H[5\PT^<0##;@\U:FD?YDB&C5@V>:?+" M WE<, Q1.65Y2'TZSQT%*;&<__T93+^MP[Q5'> $^\64(DR132M6U* TXS G MA8=(3TD^;0]D_2\7]L.D^Y2&G<+!>S[O3V_B&M%B8RG&%%F(DHUVB$"*>!9G M!TE+J=R&+(/Z%8DX1P3/A.//$9#*[)CM.9_/[A M![1=A5"G>&P/3(N(5M\N[(RSS:CM8GA\1 !X"^WJ&")#M41+??_X2])(T/1Y M\\[?^BQ4HW2NQO"+2/2\LW/#2JDOK+67N 1^4L2)%"1C*(F&HN;%$)3 U)\S M6"+-L5D2B? 9)@F.+&*#:IZFKLG&O8JV8'G2$*>>=/5D@=K?;NA$N.=,3$BJ M$R+)2=?D9C,M;[1O:A[U4YFH.;.*7#ZORFEP<+YA3UKVFMC_LQZ;G: A]L#Y M@V@T+O/ B]\\-9PKY\%$?U%S+4CO_"*>H7K*[- MRKK?-:(4IQ555XP;L,2"G4I\"X=6FIFSVQM+H6A-T670_G#L^&)?7*R,H@&- MN[%2E\:A]"X([T$S=Q0>=*8>-4D/3@< MAS@,N1NS-_F(!$.K?SWK._%CTJ-2V^YZ]IS,R7+^=^H*5E,]J=6RC)5TI5*^ MU4]R=G:CO G.IEEL2Q<2!<=>RQRC1R9IFPS'R8Y]F$2@HYX$=F'9C4"8:7]R M*3=(0A"6D3-UB1B62I?/J#5T;M9$:!G9<)(1P\]L+%F;V$XS"Y>4XZJ17S>N MY.YU=F_!9 ,8WM]-<(A5AKO#S@Y>]O5&+KEA(M&>BO/L\<&C'.Z;(4X6[HYX M8W5X$H[6UQ=VJ19!08+\D?21'%-K4OCQK6"Q72<16ABDA0^!9= 'EG*A'FE' MF.U/89?4?+UTP2Y[B.]OD:,DQGHMC,:C/C?@.BAQ@\!\'OI=:KG:9]_>X>#) MAWO8S@Y?Q/:39?X:/[N0"H.]&;*_9[PL^94+DS=;[C8_^AYRJ;(\55L#K7K7 MY;4$=L-ZVU)8VY9PL &D.7*V.MJEZV9 Z,.BT[BU,-?+(&D)QU<(%]XS292=_\=>RJGO2>T"-I MIF[%RW(-QB+]D;OBD%T1JF%85X_!E3A1N*%*8PD6<9CGO26-.\5L:-#\MG6!UE_Z/MV=K@CVP?14+X@H6:6T]__]32T&$KK MEY*OH[=.?'[_X8OZZB[-/_?J^8O,FH&\>G%JN_[0<+ %U^]))>V[MF2D.?ON MU0M)5]B(TRJ^2P\/A4:XV@J#2VM\1"__QCBXO]'LV5/&Q5C9-F8YZ*]U9%?8$/$47R&2N$.$ )Z M"/A=-Z6%3,#;Y0(/]@!(!,.WZ*UUK=-+:!ABYF:;GL8*S5:BVTACD.XDKQAN ME',X2VJ=X,<^>O$Y9(I#]^C5:G[QT\EUN$T;#H_'32B]U6MBTW.)+!K6K^:6 M:'<#=-$E*3L0F[TS]SW*!JI[\+.4A>VVB(FQ-<8QV82V_34&TY21WP)_)7"( MGB)E 8WCDT'8&^5/5!XF)=@"1M6FLE0GSI+F^R!7;+Y\MHVY8ZD_36;FCXJ[Q>&0G0*[L7/2=V/*Q5 M$#*/+I8\W.TM >L8T(Z:489N(>'Z23.A\#9'V.,+P-+&I'$K&5+_5BN"BK;[ MW=T[H[3!FCV< 8J*7K+3.[K>A?PFWLNS%X=L_="H3\&>0-NT&\S-M3^/*V:Y(Z,&@ M(BM#A*7U(W!)LWZ.+M]ZG[GU$(XC7XKY1^J*YALV _N.VP/HS29BC"4*D?G1 M>N]'"SE'R] @7\^ W_4''BF:O@ BC@>@8.=;$>)NC"ZAYH\302?-17 S2HW+ MV*47KR4%\\UAFNE7L8A="9Y)YIBUTX_BF-.UG9 ,WEFV,Y^I==B9.I43 M%'&O3'1%=\C+L=3\&2+>+:)[2-*"D&#/N0FK,+Z_-/3N%=_O0H])/S-+RLC. MG]]).,9QEVK 1$]+3[(0:]FY12!9WKU:9^Q;YXO[KC/ZQV:*NEI-ZG$TZ*RL!3?7:<*\,"#DQ?Q4/9_!YN_I\3%M@7J5^WZKT$!8OY]C.33H'UY&=S3LHP.- MVH76%[M"[\#N//N5+4HT;\]F9NPYD5.AE<%T$]Z?9%S$0*:=? _$]^;:%XG6 M8AJ'@=?GC"S^(-^JM"'_.QP&_'I54.SOJJ'#9%]]-=: MO4R8D7_N)I>NUZ:3UOF-F362$6SW7=!O?W6(\8<.@7(/M+]-TK<&CN0'V_F' M;NQ"9@N"U1[/0RHBN__SC=[_R':UES8J5ZW#^L(N6=;V$[B N>2D$VT1QP/8 MY/*$WHVGFT]:Z(7]82ZY%+F0M#FQ89.Z.RVULWZ3@YATQCULTKNO-_E?N%GD MZ;3@*/0O_/_AWA,_@]YUTDT\*[LWG\Q??'(107>WQ[.E&$A_YVF;S#SR:S\L M57F? ^-^F0JP[^2F'U%,U1*(+@]*,(O[]\&\Y13^WHI&_6X],:EOS6?HZM6. M*\DOV[T:1M-8I1:6Y$'(N4/>@EW#:G(N0-UF/.S$#ZWIS^YJ*U_(_!^D*TF4 MA_NI:QOZK*T,9[GFP;&S;YOZ-?><_O$1UVUTU^[1_2?,+E XI!F[J^R?\V:$ MAJX"YS5,FXMQC2S#P'_Y+E/MKW)Q^0O_?;R]$AUW*ZZ9CP1SO1G5ZZQ8$:]L^\Y^ZS3;ES9>[XV MQ&/EQQOZZN\CWR0BP[XZ>ZY11R3[1;FOT/)$4PGN\(B(27-TM;#.@E<_5-*> M:PEAC@AOB /'#Q#L51"S6U.O-M]P+A-3M!53F0 HH^WV!=$.6W.2_JBSA^TB M*XQW_$>^[(6O_QOTPA._-\[AUBF%K-&>?$#(C#7P.(SMRVE5)&BBBM3D<^_H MD$"/27#.<2:NVEH]I)2X8H-[6HIDO/9R]MRNSHK[;Z .=.-CG=JR3>ZXB(<] MR=[G'<((OHPN[T.78;N@%^LG8:VYJ0]:UNEO7-8$\GS-=-33R!L@ -/(&N00 MKL:-L^!]EX98PN9*E;_TO](@ MM\3$?QX1RDE9Q:ZX9FX1WT.ZGUD\P_695JW^&7ZQSRC)VGCJ??8*U&N?[2;B M?OX6>+G.P8;3^FP>SO [RDT22T @ :I>^+!Z.6% DEKAZ5!.R)\$X458'W+% MMU$PS7S!5CY@X6.+R8>K;,\D6''J/9!\66W0@/H].YN32T^X_N&G?,C?_+!Q M1/;O7%WS73(-B0[4H?AO,0SDUNN+\T=/Z,WP^)L?MOG:T>+6@'?M5O3JZ(!^1TF_\&4$L#!!0 M ( !4Z;5=3KI!V@0, %(' 9 >&PO=V]R:W-H965TPM(L.W5O0]71R.!K[W96('DZ5TFX9E=[73W'LLA(KX?JF1DV6 MPMA*>-K:0^QJBR(/3I6*TR29Q)60.EHMPMG6KA:F\4IJW%IP354)^[Y!98[+ M:!!=#E[DH?1\$*\6M3C@#OUO]=;2+NY0?,V74<*$4&'F&4'0WQL^HU(,1#3^/F-&74AVO%Y?T#\'[:1E M+QP^&_6'S'VYC&81Y%B(1OD7<_R"9SUCQLN,G9( ^\V4&#YL_!BM;#F")9O$QHO@M3@3>2DYJ+LO"6K M)#^_VK7% %/ 3AZT+&0FM(=UEIE&>ZD/L#5*9A(=/+R*O4+WN(@]!6;W.#L' MV;1!T@^"S.&;T;YT\(O.,?^O?TR$.];IA?4FO0NXP[H/PZ0':9(.[^ -NRP, M ][P [Q;G*UR' 94:LXM&\8K7[\83!)?KK# M=M2Q'=U#7^VH,_-&(1?M<^,;B["AAPDO2)7;BG?J&>]ND;X+>YOT:XE0&$6] MR\GQ_ (@6"D$%&UP[@IJ4 I>GX,#]QMDPI5LE [R!L$;\(3V;*I::'IQ;VC# M@<:3AX)Z$]Y16 ="YWQ.(Z;P:/M % A?5%PA!WC*5),3&FI^J!9EM6^LPS8N M^V8F5!*#]8I4#P1=J&NJ+\OH41#AJ9?>88_DI'A08 Z%-15D:#U-M',4%R3F MK*JVYDWR1'($K@0[D"XGJ#$(CQ)3&I6W/*3.2(,C P$)K1NA6D(=&&E!S#FQ MEWA(Y$TE,W+)\83,N3)D-YP0D!XK]_^$".5,EY7=EU^WH-JHQU)F)0@J$)&R MGK38BJEHP57KP]J%KL>:4/>$?NFG)WCX2LI+TSB2X1XO;XQM\&"11WV.]A$^ M03KMC2<3MHQ@D,QZZ7S FS',9[WA=,;K"@K306\TG+."X@]&X[\KK3[H.Q;N?DO]?;K\TW M80^2BJBP(->D/QU'8-L)WFZ\J4+9"^,\9<-!^@^HZM_ M %!+ P04 " 5.FU7%V=-X9 ' ",%0 &0 'AL+W=O&SRM:BX.5$;4>/+4NF*6_S4J['9:,$+-Z@JQW$8IN.*RWIT<>;> M7>N+,]784M;B6C/35!77#U>B5-OS433J7MS(U=K2B_'%V8:OQ*VP_]A<:_P: M]UH*68G:2%4S+9;GH\OH]&I&\D[@=RFV9N>9420+I;[2CP_%^2@DAT0I5/: M&[7]5;3Q3$E?KDKCKFSK99/)B.6-L:IJ!\.#2M;^SN];''8&S,)O#(C; ;'S MVQMR7OZ=6WYQIM66:9*&-GIPH;K1<$[6-"FW5N.KQ#A[<2-XR=X9RZU@'^H[ M82P0MR9@GT"(HR]\40KSYFQL88H&C/-6[957&W]#[9Q]5+5=&_:N+D2Q/WX, M%WL_X\[/J_B@PENQ.6&3,&!Q&$\.Z)OT<4^"[.1\@2(_2=&%W\_%.4AK\<<#OIW4X.:;^X15(632F86K*KQN"K M,>PR_[.11A++A_P]J''8WR]KP9:J1,;*>L4LL8"YKX"(67SD^)9SEU?P1!.8 MPH/)C1$0XN23%@7C=<%*R1>RA(/"T/>FPONBT4XWE-5PB56>+X+XPC#;5E0+ MH?LI=WKP$)^R3R2^2Z\GXDKC59WPNE@<1:$Z9Q%89"F,?NB M+$Q97J\D0==B N>2)&91$LS2R,\:(23K3M"<@HO'FQ*SP4J!6N,-*8"D=\0Z M?=,@G&8L#M(L9!^Y_@KFNE$'!TT 1CK;E]^=GZ,XB]ZPGW^:Q5'\2QO(AOUH_1!>UPTOY5\(6D/434RN M*KB,U8U1Q:(EZ)BY\_I@ZNY_O'6D>,S/]Z72<(A%\Y/9:[K"XVM1U^:AO..UQ(?P)'W-_L;^ MT_WAF2#_?O>W<+96EJU 3PMW[)K7'J$ELX[S_P,D2EN00*KGX-"D$^+,;$0N MEU(4)P>HF_;435],W?>REE8<_X96IT QZ?/VTN7M$*,/ZQYB="%-7BI7G2K5 M4/73(E>KVH&UE78M:Q?I'L4<^7VMA)N$2\MT8@> !5'7U.O=(6.4(96E&V<5 M60&(?_7+C7QYC0SV!Y,DSW,M.E5\@0I^[-XOJ$$]KO;JZ&"Q"U@-"7KI5L(? MTK_2 *YH W * \HB":0@+SY!AQ\/(MQ@?Q:3V*$X2?X_F[I[-I^X^3?#[J=O? MTOL<<78T(35)V%VBN+OV]84"NQ%+VD,\&M[J+SS'@TE_T'=W],;JCM9"+_,;7HOAG#Q@!5_ M-&TC0 FN_7IK^A2HQ;U%LX6)?!!QY&L?$TUDPS^:X3X,$+=+G;Y ]"O?^VUY/@6Z(JQ@H65WD MSG3:F8X[TY/6]*PUG^%_&6K6BT#\:&%I#WRBT\*!A?5\- ME_Z$[5'&PO M=V]R:W-H965T&[*;LA1F-Y.%WI[UXM[^Q8-:KAR_Z)^?KL52/DKW MV_K>8-9O47)5RLHJ79&1B[/>1?QI-N#U?L'O2FYMYYE8D[G6WWARDY_U(B8D M"YDY1A 8GN2E+ H& HV_&LQ>NR4+=I_WZ-=>=^@R%U9>ZN*?*G>KL]ZD1[E< MB$WA'O3V5]GH,V2\3!?6_].V7IM.>Y1MK--E(PP&I:KJ43PW=N@(3*(W!))& M(/&\ZXT\RROAQ/FIT5LRO!IH_.!5]=(@IRIVRJ,S^*H@Y\YOM7%+6)^^:"/2,-\ M4TC2"_JLJ^5')TU)GO]-!Q?YM\ MHKN-LP[?>-?/6E1T4>I-Y1J1O!/[G]Y?[W@JW,5 MPS@SLQ/0YF/S$-#% \7T@4;!:#+UXR0>4QI.)_3C?KA6S]#A5NS 8##N@%VN M9"4*@'U6SL'6#SK[UB#&PR =#'@8I5-*PND00,WP F_:P?L"VZVZ8(#^V[MF M@VDP3"+\CZ/!^_"78JT<6-Y5,-?=K';J47),@YC2\2081M%A#,>QUWNH/)$AS6[O.KM/:9 $XV&T M'Y(0WOQQ/]2RC1)I3#-ALD+L[,$>HX22011$8.T3*CFA43A@:^ZG+8,-[ B4 ME'XQVKZ9=G$Z(@@&H]&$AI-A$$]8H6$=51.V[I5<2,/)L5"5J#+.MTQ;9P.J M4-N122)#_FP*A'E.@K=1_Q:^4QZE"/ 8V$F$!V#'XV-J&P5J7*DVI?4)GJ.$ MNT'FD3PXS#!TW!<>_3/[L\G_:4HLH8C]W#: M^C;+C)^D862T9/@6IQ,21=%:"Z6B4V>^KT:%R!CC2^#CW?4#':''HW;FI"K? M)&G8^NP2YE6.KD6F"N6KSW'_\\WL[L$?%'(JX'I8IE--:5_R M-HV3OIJR$)YR7FHH ?)=6'M1PK#TQ?2\)Z8]E65(^=:["$-P"? M%9M<=M;XF*CCP+<$)EG7YK50(*V)6P^"R=52"(0GA1+(;OVX\,%KMP)]^E'6 MQPD:MY:ZDD8]":91Q\VO,E_R)A=,K3:==V$.>R($H4DNG5"%#7U]^%T857K??5]C@YHNU+9BCA^/'V("S1!BQK$.)); ;-4%91G59+H MI%76S^,3_E@W#,^-+4!B::3T?3FDKQWG(T)UYF/Y RIB.,2!#L4)*F SA;;[ M_V]AO3M6JE,?,HV3LG78%=;XWHCGE'^K8, B_ER#0,AT62K'FM%"2H1V(9?P M%3][9(VX,(V4L%9GRFN[56@Q>@Z'5HS:XGOK6+D7,'(??]*'6ZNV?,8=!.LT MBUY G6+)N0OS _. "I-P^G ^YT$*7$FT\#^FWZK!U_I8AF.%25B@\ M!6SJK2?-8'N*2&S?![[ M0M34EH.F6X1D!]:3]@FAN/SZ6JB\"5L+AZ^=NTO.'/M<%WRCRO<3Z7A M!?B^T"A&S80W:&^\Y_\!4$L#!!0 ( !4Z;5=%+=O9Y0@ $8 9 M>&PO=V]R:W-H965TBX+:O2Z%@9:%-P1U\FN7 ED;PC(B* M?!"'X610<*DZ%V,O]AG0'7>;F798)A:\RMV]7O\J:GU(P%3GEOYG:[]W!">FE76ZJ(GANY#*__+GV@XM M@FEXA""N"6*2VQ]$4EYSQR_.C%XS@[N!&PY(5:(&X:1"ISPX ZL2Z-S%E1&9 M=.R&IS*73@K+NH]\G@O;.QLXX(^[!FG-Z]+SBH_PFK'/6KF59;^H3&3[] .0 MJQ$NW@IW&;_)\$&4?38, Q:'\? -?L-&V2'Q&Q[A=RWFCEU+F^;:5D:P?WZ< M6V<@,/YU2%G/:W28%R;+J2UY*LX[D U6F"?1N?CYIV@2?GA#TE$CZ>@M[A^X$ZTY[K_6#^$DKY"HR=F< ?XP/S*CW0HQ7IW]S??_TS]Q5!L7KWBJPB:XL MR&U[+S_OC-3FA9B;4W8OGG3^A&J^6&+OV,\_3>,H_@ CD",,PV;B/4OZ\01^ M_N!&8J*!$*:/PHU8-^FQ1V$*]DESU5!$XY<5=;9QOJ;A0DX[!U3L 40']SV&@:Q..0/6K'\\.*MW3;C:+$T]UP MI23JA'\6;/W:NZ?LBI<2V7]18L<55.K&/6 5ATDPC6VJ.R*YVF5 V&&TG&VIJ8 OOB3 M," T-A#2 O0:QO/\AP)O "V2+3W(YIL^X4(3W09UR2G;L84AZ1Z^W-P') :< MLE[)=,76<*1(M=*%3&$!;8\0 [,WU"2BPG(JFHAF2G,\UC+4"JTF5YE4F*"PEJ)B2V1HM,[:JST.I3446 MZ;/]&HT!_ 31K;0Z:5'NJY_N&_5U^"I=R\\+7:EMMD7]R39L:\?GLI#(OK;> MI]O++_>L"Q0R9W^K *:WL1>0O9( M8P5\M\QOR1JU(WB::H/!GV\",E^ZX@H7I?(9Z'@M)&K/"Z0JS@&ZK*CXZ^6PPM.J&&O5U\>?5?!QE++4M[8V]1_ MP:0VQ7[5;BIC4V]1E5T1?KV.X#*&XON>=D*9&[[?QZS@*.(%-4D\>;\=SB9' MJ%\!8Y_ZJNN*( L5V0AN ,3@BM+>7(-H&Y?$LS"I1+A$6-(E72,AU,4SU!W? M1!?;#E*KFC&L0SL&.47]F*WF_P$)<3:%ZH.A!T;VCH6.8_#I 9,0W*.)QA+;5AI 5*<4'["&"U@V2(PZ MDRCF65F94EL!.MPN(+"^<2"U*5O&=;"]J;81]6F6-N];H O"@!7IYE9!1"YR M#3-RP7B)51ZV.M&C.$%:F,RAG"%UP0UD&H));;F_5F+WT6UGJ'?0HO?#!E*! MX[:,G?AJ>ZAHU=;=]?OO#C$A)/XVEX,=]=%\0"T.UM&7KC_<_Z^%]R9T7Z:0 MV[I$! KNG="AT2. S[!#;>GO);5NGAB4]0&QX-)XD">Y6\QW,02 #_5AA^4? MOUS=>D2@",/>4/YW&]B-BN*Y!%@&((,FC(Z"3A+B@'L-MD@*?^I$/$OK,('P M3+*4;?/U9=36]>:0A%COZOK?6"6MN\+:KZ\C?S^P,+2E0C. $BOH'*%F)]-= MATPANPNNO]0IM3W,F[0ZH2W;SAIU@+K)-Y0SQV\7#S^PM/7?>#,9-V\FX^]^ M,ZEO]M+'TB>MEB?D:WP!.O1\\B;GPV\]CWMO*(Z,Y9\V(50\;-E:HJS5D@$\ MP;V\!-7!PKZ90)-0!F!,8!&Q6#>L^+."9?34$8#:=6 !73=\*W_H,M0N#50_ MNGO.MCMO8R?S\E;2.V4WE<,'L[M&^!=/))^W['XC=G/C0G9*)X$DVC2+&^_ MO<3O&,P&D\ET[_X.LDW@M.F4'8K?0>M9MA!F28_/%O(;,,2_T#:SS?OV1_^L MN]ON'\<_4^6R+!<+( W["02L\0_._L/IDAYYY]HY7=!P)3C8%C? ^D*#8^H/ M/*!Y];_X'U!+ P04 " 5.FU7B@!M_$($ "W"@ &0 'AL+W=O!#JOH*;Z3#8@<*>4JJ8&IVH=Z$8!+9Q1S8,H#,=!39GPEG.W]J"6 M<]D:S@0\**+;NJ9J>P5<;A;>R'M=>&3KRMB%8#EOZ!I68#XW#PIG08]2L!J$ M9E(0!>7"NQR=7Z7VO#OPA<%&[XV)99))^6PG=\7""ZU#P"$W%H'BSPM< ^<6 M"-WX>X?I]5=:P_WQ*_JMXXY<,JKA6O(_6&&JA3?U2 $E;;EYE)M?8^,T8.:B>Z7?MW%8<]@&G['(-H91,[O[B+GY0TU=#E7 MAG5G>4J;(%\I;(+(DMTQ0D3/*R9W01K48 M?:/)R1/-..C3>6#P1FL7Y#OTJPX]^@[ZC-Q+82I-?A$%%-_:!^AI[V[TZNY5 M=!1P!_JQPXM_3/^&Z9Q+W2K0Y,_+#.ECQOPUQ+F#3(8A MK8K.=4-S6'@H$PWJ!;SEQP^C<7AQQ.&D=S@YAKY<=>*QC_4(>:L4$VNRQ^(> MJ*7@'F[(]Z/HP[X_54!*R5&^]BYCO9=U0L?WX M81J-)A>:4*T!#U-1$,YHQC@S#,-<=\X6A!I26@XOC@/5EAX^M8$Z ]6_M[._ M@7RW.G*KD4_H>JU@30T"95MW/X<7X.B;F^PA5PP457FU1969"O\>#8CE8YN32E11R3]6SI;=B:\%*EE-A MOAE_%C*SL721NQ--BV>?I$&5#7"\ <5>J,/MHN8?1.=$2/%S 1HOL)1/R4_$ MQ3FZP%'BSY+QP,J/4?<17ZWCR!^'H\-IY_K^'?'$3Y/)T-*[U_J?_&)_$D\& M5OXCO[$_&X6'T_?\DM ?'_#;+1U1=-HK.OVWBM[3,2;R%>58C(&L;'$?TO)1 MW"-:[J/B=#:D5RP@^#VWLV[DMA1NG?U;;KV-1M/0#\/0CB8S M/YF-T40(9DN._=,&#K%L6;5H<3+Q)U'H1E-_U(W2R ]='L=I[(=Q,IB^P5XS M48-:NY9)$T>WZROZU;XKN^R:D;?C74N'A7&-:8/EN$33\&R"&:NZ-JF;&-FX MUB23!AL=-ZRPLP1E#^!^*?$Y=A-[0=^K+O\!4$L#!!0 ( !4Z;5?^5@=U M% < %(6 9 >&PO=V]R:W-H965T232AC3Y"5+G'4Z*DQ81E5;+%@.*[&0&=7P*N<= MM9",1H8H2SN![P\[&>5Y8W)AYK[)R84H=,IS]DT25609E:]7+!7+RT:WL9JX MY_-$XT1G.A67B&\FQ4(I'0':^X?S*V@RTS MJMBU2/_BD4XN&^,&B5A,BU3?B^5G5MHS0'ZA2)7Y3Y9V[Q VAX72(BN)08., MY_9)7TH_. 1C_P!!4!($1F\KR&CYD6HZN9!B223N!FXX,*8::E".YW@H#UK" M*@R3P@UX-OUYE?<_P MZ[UI/;G)E98%P$T?=,1'KL)4J$(R\O=T!ML!4O_L\XH5VM\O%,/L3"UHR"X; M$$>*R6?6F'SXJ3OTSVM,ZENX3QX@;*,B943$Y(JF- \9>3#A_46$%"-A MG\:U//=K_)@PHA$99(:A3D_#0DRY),\T+8P>.',ML@7-7S_\- ZZHW,% MD5.Y/N8YJ,EI2KA["(HL(5CQ"?3 +DRI4CSFU@H"?\@W%+D2*8^H9A'$IS78 MQ(-A =(!-)IE,R8KY)@#_LC"_>H=IW],^D%WM#OXF#HG7;]#6URH=^O47BDX+YWVA^B7&_4&Y$:) \J) _J MD6SK!![A_CC=!^1ZEM-W <)S@4L2&EEHBQ3@CDZ+'-?J!/RQ!+=M.3BD*B$Q MQ@>ZFAGY?,._DJNGLWTZ[2*K.IA[)'1/]K8P.X&YF\=N!0(6XFJ:B2+71^[: MBH*MUX>[3_C+3OJD6L0.1I[ ]\G(Q@/ CO^-*)JP.&:F"<% MM"ZGQN4N?/;'*+#B.?E>T!02($ROXE:RU"0EE?#%^_/=_P*Z9K?UCIWUX-N3 MF9I!BYBT,^AZ@U%@P-4;]+UAT+>B-UT-'MLH5.79I*]E?[AUEB "*XPI]:IM MA$VA)AVH:;NT="X9L]:F/.-XHCW_)**O%OC 18IBGI#?BYRM#Z&)YX6!9C(0 M]-HQ\&T1+4BO/?!_L:B"J4PY#, $(!ZT#6Y!7<#*IBQ4"BI2(1$XJ+[B+R2S M#1K#!FU3"\^@!O>A)KO4()FQ3?I=/'F$O82,X:*1J"5_8M J<"BKQDG@26O3 M2M@JXB0 $0>P@J-U;RQ:H;\',NO6MA&7"V:31]:C,=F"?LPP&JT_.&?52GV?/&0TBJMFK32JL=#NO@ MXWOZ_G?$#EJ*@KL#;Q3X+3/L><&X;X;01 3^V Q[(\\_';=J@FQ4!=GHZ""[ MBV-HG[6Y69I&>E]DU;)[YVV,DKE$D\L)XQ?;V-IVQ'JLTLIF?4IRR)XNR=O7 M."C%,X#(1O !J\VLV'IGCV*K&2JSZI2 .-J^C! (Z)33&4_M13VD.;C!1!:D ME12+C[ UB\X S))$ZYL\\%M?8ZRXMW:!8\0SC]A6,C,]W*YN:)>KW&8I>?L6 MVR:_F0.W]OT,>V<767<$?' M+.[VS)!G?;K^V M?J42+A#0E;(82/WV""[.TG[!M"]:+,Q70XAI+3(S3!@%>.,&6(^%T*L7%%!] M1I[\!U!+ P04 " 5.FU7ER]ZMYT# !G"0 &0 'AL+W=O\SY?NZ%7M.QRG:ITAW^8E:Q':Y1_5$M!;7\UB7)"BQEQDL0 MN)U[=^'M_4CKC>#/#/>R\PQZ)AO.GW3C4S+W @V$.<9*.S"Z/>,#YKDV(HSO MSM-K4^K [G/C_HN9.\UEPR0^\/RO+%'IW)MZD."6U;E:\?VOZ.9C &.>2W.% MO=4.*6-<2\4+%TSM(BOMG?UPZ] )F :O!$0N(#+<-I&A?&2*+6:"[T%H-;GI M!S-5$TUP6:E?REH)<H3BW6BL=/*<\3%/)G^/B]SM0!WGUCFQSE^YFO*(46 M^K&SN[=VT2MV-_"%ERJ5\+%,,#F-]PFMY8L:OOOHJN$:JSX,@AY$032XXC=H MYSLP?H-7_-P,_[[;2"6H)/ZY-$=K,;QLH;?)K:Q8C'./]H%$\8S>XNV;L-(4#10UL4&A2:1.KVDT29_ JQ,C(@]HZ#M"Y7(8KJ2WHA[ M4%,)""-9KY9&GG#R*+F"K(SS.J'8\M#QE$T(FAO?;JDH>[0+FE7(#V0G>+U+ M@>I"H:%KBJ,/7UO M. K@)^KHCP/X2LL,A:UZ#9Y<8(.W;Z91&'UH[U>S7H@_IK5)KQ3:J"VTT?\N M-/,5@,?L.4MH"A=KZS_,3@STNN5,,//=I<\2GB6 3U+6:$=^KYE0*.C5GFE6 M>O1=6T_OX;=8<;TH]E4$Q_;(=03](!P,;R+XS$IR/="JZ8&P;3ME>%3>4=7F M$+ENVSI1#<>C$7RN"2]LS$SCA>:4+CRGZ[HYFH$KJ3.ZZ*AT/*[;M:9=53B> M=.FB$[J.IJ%I:AB9R M RW=^$QYJ>S]SN%7H-B9(UY"S.M2V7.P[6W_(N[LX7F4VU^0+TSLLE)"CEL* M#?H3*GIACW7;4+PR1^F&*SJ8S6-*?T(HM(#&MYRKIJ$3M/]6BW\!4$L#!!0 M ( !4Z;5>7OXK6A 0 (\* 9 >&PO=V]R:W-H965T*5$DJ MCO?K=PXEV4Z6&BLP/?"F<_G.C3R3G39?[1; L:="*CL-MLZ55]VNS;90<-O1 M)2C\L]:FX ZW9M.UI0&>>Z9"=I,H&G0++E0PF_BSA9E-=.6D4+ PS%9%P38,X: _NQ6;KZ* [FY1\ P_@?BT7!G?=@Y1<%*"LT(H96$^#>7QUDQ*] M)_A-P,Z>K!E9LM+Z*VWN\FD0$2"0D#F2P'%ZA%N0D@0AC&^-S."@DAA/UZWT M#]YVM&7%+=QJ^47D;CL-1@'+8[U[A=H[.F3O$Q+ZT>V:VBC@&65=;IH MF!%!(50]\Z?&#_^%(6D8$H^[5N11ON>.SR9&[Y@A:I1&"V^JYT9P0E%0'IS! MOP+YW.P>)'>0LP4W;L^6ABO+O;\LXRIG7F]'W?#[_.5=09W?[QF=RTV?5TL5=25+7D&TP!+QH)YA&#V[DT\B*[/ M@$X/H--STF1[3XX(LR/"'2%T*/56%R57^W=O1DD\O+9,MZCM3Z:!;1O8 MJ-%F1JSPB*_T(WK DH-("6KTTI!9Z-PR'Q.%S%=LN34 S[(4_5 Z*%9@?*)] M0EO/_5\T!EPL#* QOF(N&]V4I#0D)ZN+.X58=&41&!+>-6XYMWBN\#UDS28. M:Y&?M$)O$#&Y?PU0U[ !4:PJ8^LJOF+S[%LEK/ .SK1U+PC86Q9'.'A?)]>X MZL5T-FI_]-EGM='G55B+[TG!%:_OCIJR'Z;]43/&@[ W3-NIU=7."T,!QDH\ M$>$#2&(NDDL6AW&_3V,4LUX8]Q(<(R\6]\2^!DOO!I='D!I#;UX:>Q%?LB0< M)2F.O?&(#SY /XW#-!WB/ K' M?9J381@GY,ID$,9CFB M$#X)[4L+=UN1;1DW&#%>"LPN\3?=5BIO]-2!+^DB$?DQRL&UL M?95M;]HP$,>_RBF;IE9B)"1I"PPB0=MI?=$)E3Z\F/;")!<2-;%3VX'R[7=V M0LHDRAOBA[N?_V??'9.MD*\J0]3P7A9<39U,ZVKLNBK.L&2J+RKDM),*63)- M4[EV5261)=:I+%S?\R[=DN7B M>,D3G4V=H0,)IJPN](/8_L(VG@O#BT6A["]L&]LP=""NE19EZTP*RIPW7_;> MWL.!P]#[Q,%O'7RKNSG(JKQAFD43*;8@C371S,"&:KU)7,[-HRRUI-V<_'1T M^U;G>O=]3H$E<"U*>FS%['V=/;)5@>I\XFHZQUB[<_YP0E>T 4=6%[P&2]C$MN8%VQ'.:9A M)B7C:[3C/[.5TI(2YN^QX!MV>)QMBFBL*A;CU*$J42@WZ$3?O@PNO1\GE(>= M\O 4/5I2429U@2!2>$ 2F<>:@K !P6S+9 (SD^?TIL>DGX0?E_Z8(:2BH.+- M^1JTR0E3C*:J%&C:9*6HZ^(768]. &XU; P KP8735"\( OL)@V!^.6EI">A(D:6$O&(U@ M$/8#'YXM \XNO-[P:G!.[OW0.V ?B:XQ-?#+_F@(QW+ /2C?$N7:-BD%L;G7 MII*[U:X/SIKR_S!OFN@]D^N<*R@P)5>O?W7A@&P:4S/1HK+-8"4TM18[S*B7 MHS0&M)\*H?<3U< MH1 >B&0\+C&C-:4/?+M>H7\+N5,N* M9^E6P%ML]B%+>I F:;8%+UM7( MXV0=X%X\M=R_P9SJWSM C^;LIQPYBL!G" M-\Z);5B.XXA*9]$\8339^=(_3$ZW"!RL!0ZVH4]NJ1&+5B#H$CYW79LRV,JQ M.8.[&J'4@OJ6JPJ*3G1KR2/X/P+^3G,&=H6VM$U-?8Z6 M5RI0GA/*$_,]#C,FF,JQ1WLYRCDIR?KAO:3P%;+#WG$_@:G4K7)>2N4A#>:Z M4H'B\ZF0 $Z"2;<#7Q(:!RL-%OII+SD:;N 1S%I>TO-W0JAZH=#8FC>^C#G5CT8I['P9IOWT]+40U#1N68EEY_A*'/2R00*; MGFC\9J)(-%68FY:442[=<%GOKD?SM)M(K^[=7+]BIN+*@L"20I/]HX,(3#&PO=V]R:W-H965T%)20!)"!7%:DD*.3:#U55F=T!W//:6]L;COOU'7LW&^Y* M5FVD8*\]\\R,_*AR*[C$I0:3IRG3ARD*M1\%G>!U MX8EO=]8MM,;#C&UQA?9SMM3TU:I0$IZB-%Q)T+@9!9/.[31R\E[@5XY[/Y*_I//G:*9 =C)8S_A7TA&W4#B'-C55HJDP[,.2]O&>6C8=:[4$[:4)S$Q^JUR;GN'27LK*:=CGI MV?&#DE>QDE8K05M;F$N+&HTUX, M?)())M_KM\B_RLGPU"+C![IS%=\MR:C,4X"B@[#.H7#,8?/W3Z[;L:CWN5Q[TZ]/&*DC') M!8+:P'O>$\>G3# 9(ZP<'T[%4&OE= P_,H17#"&#=HQ2+T]\0L-H3]&WE/S-N\V+N#*C<,)F8 M2R 66$S7J"LJP#W&Y4K'KX0DI#D:F,"2LANU)C.?)2?+.Q3DS8$ N4X@8]HZ MN3,(&]'UH!HIEI3">ES6:G4;W4Z??J-!#YZ590+>3R->'!(A1HW!30_ZC4X_ MK)?/--5<;0^@]M)MFGQM>,*9CZP_N($N_9^V^W8Y9V0I&G2+,>I #0FCBH11 M/0F+PEUR\*3_ISA7#_I\S "PKN:4+P3_1N&ZL_.5F]-Y:!2>5%91H"]DCEX' M"TQK)K?HYH:JI]UYI5RRS88+7B@<7]\MW'-*<[[.W;M@X-EO+ID[\0=Z!N=O MT)-4Y32X:&='T3[N)6JSXQDL4<)3 M\-\)YC?];"G8-T82 IZX@@4F/*;H'^G4*8-G+,UR TNE+=TN[5]T+F'!#J3: MB1PIB<*]9@_.:=X)&[VP7TZB"'PE">^J\<_BST,\2GS+#W?997[]/V?V5& R M@: R*G*\DN.6)JT R"*V&J(NM&JQ3"9O_&PO=V]R:W-H965TC[XU%%F1A,S]S8C9J>R=IP)N!&$5U7%56/,^!RP8RYQJN)3\ M,RM,>3Y(!Z2 !:VYN96;7Z"-QQ',)=?NEVR:M9-L0/):&UFUSLB@8J)YTJ]M M'GH.J;_'(6P=0L>[V28\(6YB@.*Y M_PB)=>S"+;M9>!#P#E9#$OD>"?TP.H 7==%&#B_:@W=%E6!BV8_VCXNY-@J; MX\]=\39P\6XX*Y@3O:(YG ]0$1K4&@;3MV^"L7]Z@&SBY2"0 [<<5LA!.P[Y$P>$4\X19YDL<)5-D;".%J2DFLP!K+*-DHTX^2.A MQ=_8]+C&2*MY*UX'@D+('W#G-2M (-B1!B#7T@ )R-LW:1B$I^2C6E+!_GG: MG18%LR^4HU -95P?GY#[4J%KOU$)MIF!:HY1V%Z[QM0]:'_"GG6]304U M1K$YI@ E9&/ A%3(QM$O)2] (7*G^D:%!ZC32$TP0-8&UQHRWF$T$$0>'$X]L(X M<'8T3KQXW-BQ'WOC)&G&H\A+_6#'3CO*?=1P]H=!VAKA=B0)6V,<'[MUM[OK MO.T26"RPUGK;;=]=;\O4S:?=_%TOZ6YLV?Q9*5GUY6J?GXMTEV,/[6\'22M8"<^;Z"=O--=W< M?FA17FOX@?3U2:S!T<;61H'EUFP;W?;6Q/#'&X1AF*XC;,TXS;PPBO8^+SG%^LRV'BC(.$(T%,:^Y[TTF(>M',E6 MCK3?'/W3@ "VXIIRL!7,D'(ZCDG@^4GDQ4%DK2#VXL2W5IIX_B0D?[5_+N;/ M+W<2M4LA]M:S/>O]J>N?$7M/ZR%6E "*?6-_$M]+)X%36Y9X61J]$M^STRMH MV] CU"E]1^$MLBWYT)7IM4&^+''O6Z._*UIDU@@"5:QP!&D74*U(/KIL"J!%V3^Z&C; MHXH*/"QP-^ ,_^VD-I5XS.12:,E9X=@.G2Y>7:)GBOJ1"Q0E>(:@<)]'_/WE MT2^3YM [O?TG2"^:K(OF%K@KY@U5YI'<*RHT=1] M:T<%:NDN5QI[!#]*S0VD&^WN;Q?-M>5I>7/Y^T#5DB$%#@MT]8<3_/BIYD+5 MO!BY8N31X)7)FB7=04'8!SB\DAMF^V VZ6^WT7U!+ P04 " 5.FU7 M>TDOY.@& "I$0 &0 'AL+W=OG ;9-T&1W'Q;[H$AT+%06/2*=M/OK]UQ* M=MR.ZV1FL2_[8E$D[R?O.;SRR:/M/[F%,9X^+]O.G4X6WJ^.9S-7+A93M3493.EF733;B8_-_<+SQ.SL9%7>FQOC_[:Z[O$VVVJIFZ7I7&,[ZLW\ M='(NCR\T[P\;_MZ81[#EV]*79R>] M?:2>=T,;#T*H01K.-1T?RHWOL=I SI_=F'NDV--'L[*];[I[FMZ6=ZUQ1RH[N@IZ;SN_MX;LG'[O]V4WX!&%+>CNRV;'OB .FMD?Q.W" MT-RV "S;\J$>@,#*=E4#CSR6W>A20%7COY"WA'5GVZ8NO:FI Z&TUCDHZH/$ MRO2-K1T%,QVV'-/MHC?FJZ)!("MOEG>F#^?^[ 8N#/Y1-+WL8,:N7=G5[HC> MF[JIRI:NYO.F,G2Q;MH:P3C(=XWM';W#5H[NIQ]R)=7/= 7_RI#;ZQZ4AS0C MYC>[$?T/5'XT#Z9;(]F]79(W7=EY1S]2'(LTR3!(E(A4@4&>B#1/AR69)[P4 M"97Q((^%3J.-B2]DMU:1"6)>#HKA<2'BK""M1:$S2K2(51KF,M)2P&5*I)!% M3A^N+J%7:1C(,SX5.-,5*J%31Y7)5-GTHB6I1]O>( M=).&:0Z#Q=%..N8&RRB8WK0A#:MRR,TT%7&1'85G'!_1>?7;NG'-0-\(!DCM M7#G0^49V*C/LG,H"%GXU'4RT86]9@RT;!C?3/DVUR!+>J(7.Y!&]-:C#JBFW MNLLE0^O?P\1412++TJ,PR!-]!,!Y@\+U9#[C/G10*!.1J8A-QT+ENUM8G47) M]]1TE5T:4DE.,J+I7X&'([K'D1",N') -^[2EB"'<"#P@!>8V1R4+3KZ-$ M9[M7M7'-?1="KX&HAQ">(QVEQ(>8PHU@TY>?=WWEK&;X^;"!9>E]W]RM [CY M+%@W .Q[X)[/J!FC<20U 5_GH(-JR XC&MF;F[Z'%[BBJD\T114FG(WQ^5T[ M<&[)P;/4PK:(@2L>YR>2%.>"(0HLCA#Y!U#5(>P_M_[_R0TR DAS)@<P11%G+Z$(%2&JEO+^6*F'$ZE8/H(;:06L@H&< =I\6S?(%,)8$,PB#9QQ=,V%'. M" &A%ODAODBR%/1+3!JQX8 "I!Q0?:T!O$&FT"-R::) 3L-)4G+.P4Z.XIYKA+ZIMC&7 N=* M<^">H Z&' MUN"+C/H@;>>OUFYC$5U+%A?XS2%VW1N03KTI#N'%WG(I(%@3B2Q+V?RS7 MRCIV/F0KP:T4D[A8**$[(#'U0Z-DPSD-5/U>15;EJ6$OPJF[\&M7% MO7P?NORP^XXO#0-8C)4KL+EJUWRUP+<>^Y@+&(Z[W+"K4/Q7_?=S5^PW*'BZ M<9]&WQ;ST,8J))/O!HUJXDLJ$44NOR[JF'.*A1B:T*5J;J'0<:5C[O=FCQ7F MR="TIK%B@[B5"IZ0J6$#VW]GSOX#4$L#!!0 ( !4Z;5>SN-+<= , +H) 9 >&PO=V]R M:W-H965TI/JJ]X@& MGNI*Z)6W-Z99^+[.]U@S?2$;%#132E4S0UVU\W6CD!7.J:[\* BF?LVX\-9+ M-W:KUDO9FHH+O%6@V[IFZKC!2AY67NB=!N[X;F_L@+]>-FR']V@^-+>*>OZ M4O :A>92@,)RY5V&BTUJ[9W!1XX'_:P-=B=;*;_:SOMBY066$%:8&XO Z/.( M5UA5%HAH_-MC>L.2UO%Y^X1^[?9.>]DRC5>R^H<79K_RYAX46+*V,G?R\"?V M^W$$O.$2]0^1X=PLYEN^8 M8>NED@=0UIK0;,-MU7D3.2YL4NZ-HEE.?F9])>N:&XJRTWR>. ]'H1'03G06\ MQ^8"XF "41#%9_#B8>.QPXM?P?L+*9<:/EUNM5&DC<\O[;%Z&L/6RT W+ M<>5106A4C^BM?_\MG 9OSQ!,!H+).?3U?5 ZY;8(VSL.G<$#+>G!4;O M!6')5I,2]?C';6MXQQ71A&LN&.GSV_@H'#ML&"FT!U&!:@QO()Q&]!]%=BZ! M:1Q!%MAV"NE\#EELVU-(LPRRU+9G, UGD,V 8D0'7&F(=A1.LB2&V20*4WB0 M-AY4A;QN:ZA<+H;H1,DD34*RG(81$=-Z :R6K9U2Z/3A*@NX(%S4AEA/)TD6 MC&$436:S^;B'[TWAD544;XKA*^N]@?DD2$/Z)I-YG,"7[N>"89-<=,$J7;"P M]ZXXV_**FR-P34SRJJ7JI :=CGG'E?"=)NQA0(.JI7E\HCM _ZBV[U2=#JI. M?U;5USVSG]'T>=!?FOZEZ?]3T_ZS^[1&M7.O!@T.K;M:A]'A87+9W2D-WO6ONZ7&%RAK0?"FE.77L L-S M;?T?4$L#!!0 ( !4Z;5?BZ>/+#P8 /DN 9 >&PO=V]R:W-H965T MU,VE4__-I 2"! @O;,0P:,S^_8YOQ]P1X?*?O"=Q@+]"T,(O[< MV@FQ?VJWN;?#HGQNZ:U3PF>RW0F5T)Z,]^X6K[#X8__*Y%T[ MH_@DQ!$G-$(,;YY;'_4G1^\J@SC'GP0?^<4U4E594_I%W2S\YY:F2H0#[ F% M<.6_-_R"@T"19#F^IM!6YE,97EZ?Z%9<>5F9M&+>3CC7L( MQ&=ZM'%:H9[B>33@\2\ZIGFU%O(.7- P-98E"$F4_'>_I0UQ8= 951@8J8%1 M,#","H-.:M I&/0&%0;=U*![KX=>:M K&N@5!OW4H%^L=%4K#5*#0=%#E<$P M-1@6#/1AA<$H-1@5/?2J7IQV>G-:L1:=*I/L92=!ET1)'&*F*]S)F-$C8BJ_ MY*F+.$YC>QE9)%*26@DFGQ)I)R:_L:T;D7_=.+[?FUBX). ?T$;\_),^&/Z" M2(0^D2"03_D#>G=Y.VX+Z5]1VE[J:YKX,BI\== G&HD=1[/(QWZ)O5EO/[IE M;]7;Z\8MP/Q&!?HU@+9L^:SYC5/S3XU:X@KO'U%'>T"&9G30'RL3O7_W >V9 M[#*9^(XXWLKN2Y24].5^KE&#,2&*ASS9*$QVCE3VU3N7X;+8F,$4V*K'F-B3 M&/V$J2K,O$FUS]6MPME-<%RX I= %DT@)WV6<)9-..G:QWZL0N.G?T3@_H1?8Z-"!^TEFYD8]>Y?N0<9(DT VR2.1&'G$# MM%*MK&*(H[\_KGEEP 0E;0L*< MDJ;0LY;(16XOB]S>G9$;C\'\,H#ER(X"ZLED7TUR?U0.T]-:'TT'#$B8"0F; M0<(L2-@<$F;WKJ*LT\GK;0'I;PD)C MOO_\J)N83FN!394#"3,A83-(F 4)FT/";$C8HG\EPU%>A4M(=PX0+"><02:< MP;VC$(Z(7#+OZ(&3:"O78F%XB$@\'/W(5IUE0AILG3H2#[SJ'"O_N(S'5Y/ M! O!?C.'>3/'[&8.J[:"3:,2$F9#PA:0L"4DS &"Y>)WE,7OZ,[X)9&/]UC^ MY#Y\JABN_9@VK>4WG?U PLS1=0]9$ >D.PL2-H>$V9"P!21L"0ES@& Y'>G: M><-)NU-)E^H1F(4DBI??MX14SV^J)%":"4J;@=(L4-H;=Z4!GP"5M+/WISUVBB%?Z[9QR-_C M'N=]=KUVRW"R4D<;E"08=CE&&T9#Q 7UOB"?O!&YUO$Y>D^B] C$![5@KSH, M,:UWU7A^!KJG#DJ;@=(L4-H\I>5F+8..IOZ*8Q#HICDH;0E*9&=-\[U M^IWS52PHPOE!CCK^@:D9FIQO$>H_I')Z0!$^)CD:Z URV_4%E&;JU[NX5U,X MT-WXVP[GM[/8H&5:@-*6H#0'BI9(HGUQ$#7$;!N?E>9RPG6(1'+")$O-SF-_ MC$\A%]*G^M.+7I)NZD^SLG1;G>N.#\2>W2:'PC^Y;$LBC@*\D470'@?RO;/D MG'5R(^@^/AZ[ID+0,+[<8=?'3&60SS>4BM.-4 &0 'AL+W=OS(>)+?,\I,27VSDBKY^2].]LPWE.GJ,PSFYZFSS?7O7[V7+# M(Y9]2K8\%K^LDC1BN?B:KOO9-N7,+XVBL&\.!N-^Q(*X-[LNK]VEL^NDR,,@ MYG^!:L-[F\T)]=;]F:W_/\]^U=*K[U=Q0_B'B< M!4E,4KZZZ=T:5]2RI$&9XH^ /V5[GXF\E8S?] :R1#SDRUPBF/CS MR!<\#"5)E..?&MK;Y2D-]S^_TMWRYL7-/+",+Y+PS\#/-S>]RQ[Q^8H58?XM M>:*\OJ&1Y"V3,"O_)T]5VO&H1Y9%EB=1;2Q*$ 5Q]9<]UP]BSV!XRL"L#:),^WGX@UN"#FP+3([_6_VW_\8X\'_5()$PFPDS$'"7"3,0\(H"-82X7 GPJ&. M/KOU_4!*CH5DR+P4"EO(HV+FERIO0X&USW'_?E=)QB: WD MOW8Z^RS)49!&"I+[QG3><;J1H4A'C]-9XW:ZUJ,>[1[U2/NHOW$YNY2#;-F# MD)RGD>H1:RE=&S<29NOO;TA>.$LS,B51->(:E\1G+YFJ92.+Y2)A'A)&0;"6 MW,8[N8VUU3%GOIC6/^2$/XNECW(N,J\(HSVEFXH&L1@?-0ACHFK2Q^FF@^E1 M,NIULJO7B;['%K.&/",;'OI$K&9)QD)EW4[. M]M3:?+KV#6>SPCYZU0[(]\UD_CYY7'[/M# V13VV13.V12N]@:[MF0DC()@K8J=[BIV^L:* MS7@*-T@EC,(X5@MBQ^J2:6F9A_^<$JX+X0SRDWQ+S.H-5J M#Z6C+T17[4!I#I3F0FD>E$95-352+T6,/4>@H170'RPL6.5/#L/DB<5+?D%$ M-[,4(PE;JQ6C)79=F$!I=DTSC/TYZD''!,W1A=(\*(VB:&UMF8VV3*VV;+[B M:2JZGYP]$R:GJTHYF4E412M+;7&U6OH?;U? MI+8^1]LT>>2E6TBI**0+= &EV5": Z6Y4)H'I5$4K:V[QA5M3#YLP$7Z9Q=0 MF@VE.5":"Z5Y4!I%T=IJ;/SDAMY1_H,#KAYNC#0#+M(E;;^_( ZT("Z4YD%I M%$5K2ZWQW!MZU_W7( ZB0AF^UUMV[MB@[GLHS8'27"C-@](HBM9^X;#Q]IN# MCQIF3:0K>@&EV5": Z6Y4)H'I5$4K:W&)G1@ZD,'I0IEW(G%Z^ AY-E%%67Z MM=C*"$*0J%[3G>NAG84(C1Z%Q_4*34G70H *4YD%I%$5KJZX)*ICZH$(] MXI+OQ"W2.,B+E)<3/#=XEI^5*UX]LK/FH'$(*,V!TEPHS8/2*(K6EF$3T3 _ M[*5M$QKP@-)L*,V!TEPHS8/2*(K65F,3\#"U+NP?7/&>@4].+WCUEIW%]]YR M.-!RN%":!Z51%*TMM":68>J]_%_9\ZGUKMZR<[<&C5U :0Z4YD)I'I1&4;2V MVIIPACG^L$$6&N2 TFPHS8'27"C-@](HBM968Q/D,/4OW+]SO0N-;T!I]ID; M-H>Z!2\TF@&E>5 :1=':LFNB&:;>SU\/N=T6O$@?^P)*LZ$T!TISH30/2J,H M6EN&3:3#G'[86 R-A$!I-I3F0&DNE.9!:11%:^^8;R(AEG[?PX\M>,_ #.OWIDUQX/2K.A- =*X=6:/?T-'L.ZQWI\=0A;Q=%T>2)>1\APQFU=VA=[?E M46\'U^?&U<)07+>-*T=UW36N:'7479-M=?+>5Y:N@S@C(5^)(@P^341-I=5A M=M67/-F61Z,])'F>1.7'#6<^3V4"\?LJ2?+7+S*#W9&"LW\!4$L#!!0 ( M !4Z;5?::7,XG0( .T& 9 >&PO=V]R:W-H965T,62%CXU^OZ0Q(F[@??Z@_M+6;6EZ)@CO! M_M)Y+W_ M#GL)&!])P'T";GUWH-;E/=$DG4FQ1=+.-FHV:$MMLXTYRNVBK+0TH]3DZ735 M+082!5K1-:<%S0C7Z#;+1,,UY6NT%(QF%!3ZCGZ#4D*B1Z(;2?4.K$/>RCE]4] MNKRX^BSCFA*'.O%0)VYU_2.Z#XWQ#%^_3"+O!UJ89>S")^"ZBY9D9_XU/6JY MDP[&I>VVN5$UR6#NF'VA0&[ 23O1$\;]P;A_2CUMO\.E!+O!% "\_1PC%:>$!+IGX\ M'8=% RPZ!XO&8-$AS,-),@Z+!UA\#A:/P>(#6#P)_".PZ0";GH0]EV".YD*# M'$-.#Y X\((0CS.3@9F<9@I-V!@N.?@M(S\*[#I_PKE[IY>]"!Z)7%.N$(/" M)'K7L3$LN\.U:VA1MP?:J]#F>&S#TMQ'(.T$,UX(H3\:]HP<;KCT/U!+ P04 M " 5.FU7O['C%1@+ #;F &0 'AL+W=O=DD4A/>Z4O4[-F]6.T%L2<.JFU\ M ">M=#[\@D.,QR9CT_Y[D9LVQLQO!GL>9H#'R%R[?MT,LO.._=Y M/C_M=K/AO9A&V?MD+F;%.W=).HWRXF4Z[F;S5$2C9:'II&OT>H/N-(IGG8NS MY;+K].(L6>23>":N4RU;3*=1^N-23)+'\X[>>5[P-1[?Y^6"[L79/!J+&Y'_ M,;].BU?=E3**IV*6Q>>#?AKV^V6!Y1K_CL5CMO:W5F[*;9)\*U_X MH_-.KVR1F(AA7A)1\=^#N!*322D5[?BS0CNK.LN"ZW\_Z\YRXXN-N8TR<95, M_A./\OOSSG%'&XF[:#')OR:/GJ@VZ+#TALDD6_ZK/5;K]CK:<)'ER;0J7+1@ M&L^>_H^^5Q_$6@%3?Z& 414P-@H8Q@L%S*J N6^!?E6@OV^3#JL"A_L6&%0% M!OL6.*H*'.V[#<=5@>/- N8+!4ZJ B>;37JI@-Y[_N9Z^]:AK[[LIT[WU$N6 M7M;1GG7SHMZR='=8U7'Y5(?Q M0AVF]BF9Y?>99L]&8M10WE:7/]E5WE67UPT%T"T^L-6G9CQ_:I>&4KP1\_>: MV7NG&3W#U/ZXL;0W?W^KS=-B3Y?F/QI:>+6_9SQ[#8RE9CY%:<'H.QD;WCKG M)[9.Y;EJSQ+#[=[^GJ[XV/PV'YNB.4$;1\R&B^FM2,7H^F4Q5(O!8O)> MZSUM8.^%EDEQ8*[V'N82-E^ _=DPF0KMIMQ]E/N-=]IE-(EFPV+1 M+<1(^U(T-RJ)3/OOQZ(%FE_4EOVO:4?TU-Q^O]LBED2LTC,)C&'Q%P2\TC,)[& Q$((DR*XOXK@ODJ_^+SO U7 MVVLKV-]2QE:]KVV9W-*:]*296V5LMF6G%C$J4._2T/+033X=V<7UHU]2G!UN!>: ?F5L] MXVI[/?VDO]VQEWFT=N?EHO0&JA90FA\_:55Q=&3[R(/:N M&M2*42NY*\>XF^*8Z9WV.UT2U:B\5S:1FH9J-:@ZJN:CFH9J/:@&J MA90F1W.=^Z K+\Q>?!B/4S$NSZZ7L9=&P_SIU/L\C8>-9RC57NMH0],34,U& M-0?57%3S*FU]]JH;_<;9*YJ @&HAI<_]2Y?M?5O3Z?'(S M-T5=>^MH0K-3&IJ_D=GIH!6ZJ.:AFH]J :J%E":'2)W0HJLS6MJ?$#G>/G@V MCQN.GZ[4-;<.#S219>^M<-!Z753S4,U'M0#50DJ3HZ1.5M&55]*;!Y)X>?E[ M]T""9I:@FH5J-JHYJ.96FO0[AHW\2;1"']4"5 LI3?X=;ITW8A!Y(VJD;=R@ MFH5J-JHYJ.8:VYD>^J'>,%!Z:+T^J@6H%E*:'#YUWHCQV_-&/GVY?#Z'V!AZ M:,((JEFH9J.:@VHNJGFHYJ-:@&HAI,&*\L8<1 $T90S4(U&]4<5'-1 MS4,U']4"5 LI38[F.F'$4">,_,HI1#7=.O#0W!%4LRM-^I'IQGD4M$(7U3Q4 M\U$M0+60TN1HJI-&#'72R.;4U1.3T<%=DAYDNR:MC?&%)I"@FH5J-JHYJ.:B MFH=J/JH%J!92FAR*=2J*:CFHUJ :B&ER=%< MYZT8ZMN)['O#!6/[CAN;E^W4-;6.'#1'I-)4-UU *W1W5^BA%?JH%J!:2&ER M'Z^S.0QU-L?/3QZ+X[3EG1O*_]-X/A$'Y9U2/XJH/(93_W9.W:;6HQ*:,8)J M-JHYJ.:BFH=J/JH%J!92FARQ=7*)M\*)H)@VH6JMFHYJ":BVH>JOFH%J!::&QG$-49 MM?*=N.M,&%.="?-+4]J=OP125]XVWE#-0C4;U1Q4'U5O-\8=FCZ#:A:JV94F_82^Z;8(#EJMBVH>JOFH%J!:2&ER2*T]1D:= M&:.O; Z))N2@FH5J-JHY MJ.:BFH=J/JH%J!92FAS-=4*.J;[;RYYS2#1+IM+VF&ZB"3"HYC1LA'ZH]XV& MF2F:W()J/JH%J!92FAP9=7*+J4YN^1TSTQV_LE>WJ'68H>DPJ&:CFH-J+JIY MJ.:C6H!J(:7)3\"N,V?ZO=;5R5;UC%W)QB MHBDEJ.:C6H!J(:4]Q4@W*\G'XQ.=VOYI7YJZ0W+;?W4:5KNZJ=>TW)?/PV6R[MUS,\[Q03\-LGS9+K\\UY$(Y&6*Q3OWR5)_ORB MK. Q2;\M-__B_U!+ P04 " 5.FU7FV1H)RT$ "!$ &0 'AL+W=O M+ MU%91TO8^K\W:K *[='>Q4^E^_,T"QF P322^Q+S,/#S/SNS,3F8'(9]51*E& M+TG,U=R*M$YO;%MM(IH0=2U2RN'-5LB$:+B5.UNEDI(P=TIBVW4TB;1[8BUE*=O2)ZN_I@X0[ MNT()64*Y8H(C2;=S:XEO;G%@''*+'XP>5.T:&2EK(9[-S7TXMQS#B,9THPT$ M@9\]O:5Q;)" Q\\2U*J^:1SKUT?TOW/Q(&9-%+T5\;\LU-'D,#!+&BU_R4BY$S<'#%QS'?/0[9G808 ZTP! MKE(0%;!7S$1(H7>(\Q&YCNNA[T]WZ/V[#RB5L"FD_M5!\/;U>.YO M\!J$O2HZ7OX!KR\ZM(@.JT>':+012M]T+6H!.>J&-&7A1J5D0^<6['M%Y9Y: MBS__P+[S5]<"# 364#^JU(_ZT!>?(6VZ!!9>?NYERM1^X7F!-[/W=>)MHQ&> M3BNC!J%Q16C<2VB5L3AD? YK'IHMP@3JN<7$#QY^> M,6Y;8\YHY)YQ;%OAT<3' MW1R#BF/0F^55D6'\2%1U9G8P9&8/!-90/*D43WJC\H7(9ZBO,84&A&)&UBR& MFDD[ S-I+?F5&^"SN+2-G.Z83"N&TU?DS2D@9>;DZ?X;PM,6E]$$GR=[V\B= M>I-NSM@Y-3.GE_4M41%*"0L1''#@E'&A>C*^B3.SD1O]JK-!.>U:,W;]\^7O M,,-!<*GF DN.TDQN(DB<$/W7U[M6)79]C8-SWFT3 M[P)G]\39[>5\SZ_2 .F=V7*TX_SENW\U!H3=6G1HW[._6K:Q@>M#T/A=94 M?6K0N+]#-V,-.RNI%39S3(%J(70$*=RJ))UKTV[:8V?<2MJVE>L'%^H=/O5V MW-_['>',6!T)K*3T<$[ ^4N[UGC3>K'@BMJ?ITZ,"]'7[P MW TZ3J7GF=NV&,^4/W78?$_4$L#!!0 ( !4Z;5=-!6LFQ ( (\) 9 >&PO=V]R M:W-H965TN*EQN27OJ_C%#*J.S('@3-+J3)JL*M6OLX5T,2),NZ'03#P,\J$%XW=V%Q% M8[DVG F8*Z+764;5RQ2XW$Z\KK<;6+!5:NR 'XUSNH(',-_RN<*>7[DD+ .A MF11$P7+B774O9R,;[P*^,]CJO3:Q)(]2/MG.73+Q IL0<(B-=:#XMX$9<&Z- M,(W?I:=7/=(*]]L[]UO'CBR/5,-,\A\L,>G$&WDD@25=<[.0V\]0\IQ;OUAR M[7[)MHP-/!*OM9%9*<8,,B:*?_I 'WJ!6$I"(\%_1."7BGH.= B,X=U M30V-QDINB;+1Z&8;;FV<&FF8L+OX8!3.,M29: &4DQMMJ %R)S:@#6Z1T6?D M*U;0!_()Y$K1/&4QF4D1XY2B=ODU>7<-AC*NWV/4 C8@UD"F(.(4B^&I04D6 M3#^-?8.YVPS\N,QS6N09GLCS@MQ+85)-;D0"R:'>1^8*/-R!3\-&PP?(.Z07 MG)$P"'LU^^\$X[]U0'Y^P1AR9R#3O^K8^VVRMV1VP'Y> ML9\W[N\ANT+V,Y*#LF/XL:Q#+_RZ10':C_$F"CK=B]'8W^Q#E6'=H[ JZB#; M097MH#';.0BA7_B&"E9;DHWJUVY+2V8'H,,*=-AV20[;9&_)[(!]5+&/6B[) M46U)!H.CDFQ\[&NA_+VS+0.U^)K%<"U-\[:O1ZE9QY0[3H_$IWC:*R\%? MF^*J@*[D!^W=SF M.+(KE#C)@(F$,Y+#?[CU NJ*?P(IX*_4OVI:UCD6@K),]*9YQ!EK#B2A]*(FH.B-/LX)4.WJF# M_X1#MW3H/C>"7SKXSXW0*QWTTNUB[9JX@$HZ&>5\3W)EC6CJ1K.OO9&OA*F- M_()-VF'W!7[A_ EF68\E\EW6N27 MQ60:13GHT1PBOF+)=XC)VP D35+Q#IV_W@7D[9MWY U)&/FRYEN!;F)D2YRW MBFY'Y1POBSEZ3\RQ2VXXDVM!0A9#W. ?M/L/6_QMY*LBS7LD[=)K!;R#S1GI M.N^)YWC=AOG,GN_N-2WGYZ*'_SOZ$1G=:@=U-5[W";P/"4LD=*ZQWF/<0I*R M5;)(@4R% "G(G]=H3ZXD9.*OIM07X'XSN)+)"[&A$8PMU$$!^0ZLR:^_N'WG MMR;>38(%)L%"0V!'&?*K#/EMZ)-#H6(9TP7?04?5[T*])3I8WO=8ZBF@VF+9 M,Y!-66H-\-(LF00+"K"^!E-OQ=VDTQ_T1O:NSGZ#D>^YE=$1J[V*U5XKJP'@ M]**DIH=U@0P?\%4N@/R#)='9I+@<9-@@4FP MT!#842;[52;[KZE@?9,9,@D6F 0+#8$=96A096C0KF#UTD(1JXF6Q,/%8\8: M"VCP0^UW_=Z)0,P:C,[=$Z.@,.K5C%S'=_T3K6FPU*Q;Q3(G*5*FXEA)]UBX!W//U&!6:.5.SQ1E":KP?#T M]-)DU?.'S8KBUK[\W%8N;G.^@5Q^(Y_Q@M+*5EI0;B@**C#*\,AR.,6\6'#: M@[]T/QM%"XRBA:;0CM/H'=+HO:;LE.BF\F02+3"*%II".\[3X3/9;?W&^ZDS M3 E=/Y_XSJGB_+=-T&#C>LZIW+0;%HR@V^!04 M -@: 9 >&PO=V]R:W-H965TJ2GX3TC2)9':VUNM4K=5[>[V8MH+)W$:JX S["3=M \_0RBF%]O<9LV; M%@(^SV/C\_/!C'5*GX(I^,U?60/3'U9W^7Z+*RC+'C*,LE%!G*VG 07\/R2X*)!><=O MG.UDXQ@479D)\52.7 MZ-=EYW5G9E2R3R+YG2_4:A(, [!@2[I)U+W8_'.1R/(OV%7W1@&8 M;Z02:=58.TAYMO]/GZN!:#1 R-$ 50U0Z7LO5+J\HHI.Q[G8@;RX6TR(_@ ^ 9^'4E-E*WE^-0Z5X47L)YY?AR[Q@Y'#^P]1G T2E $<+@R\,5 M./GP\7684 ]"/1*H'@E4QB6.N#;;-G?>*$42G<1D=.SQ>\XPKUKO5$WEA>2!_W.K[P8UBJ?S39AT?P3JIK1/O\)9/ MZR1G!2D6+/]H\[>/$)<1"IQLIQC&@W&XM>CV:]U^ERZQ:>U;]1M:$ X1LHO% MM5C<)=:WB<5M,3TA-?3C^B;KK1.=:WM/@.XS^%]K!6-UY0U_:"X;_L/!44GD M75X.=6]6%-BYI'06!+"]OF#8=U0$T"PPT+_".&DQLA4%T%$4(+-D("_4G65! MU>RKN@ YZ@)D((_\D'=E-VI3>C@:.$H#U"B<_9AV)2UJP[=/8@=]D:$O\M/W M%[72BQ(W\_W->>L7.'#F(X-I1(Z9M\B["!SJWL <=1;4G7F++-5UY'CNAM:H ML[BV9BVR5=<.,<-6U%EU*5-PN>GL$.I8?;'"*.W<6K*F*V[5L#\>Q0\[P#W?RSYJL MN,V\'L:NP334PYW4LZ8K;E.OAPAVR!GN83_WRE+]=<(FC2V^;\G:8Y25V+ 4 M#X^:M5Y2'^K>P!G[X7RDUW/<9CN.'(E'#-R)'^[___6<6 I@-'+4]\20F[S7 M)H>+':1=*4.(7,8,E,D[;FA8*4/:R!X-'"\HQ!";O..&AA5'E4!S[S;N?_TB M$S:^4Q3??'ZB^2//I%90^F/6]#]02P,$% @ %3IM5]\BO;R&!0 H2T !D !X M;"]W;W)K&ULU9IM3^,X$,>_BI4[G?8D((G[!%RI M1(GWJ'0LB&KW7ISNA6E<&FT2]VR'+M)^^+.3D#0E->UIEE/?T,3Q_,;V?S*M M!P]77'R5"\84^I;$J;QP%DHMSUU7SA8LH?*$+UFJG\RY2*C2M^+1E4O!:)@; M);&+/:_O)C1*G=$P;[L3HR'/5!RE[$X@F24)%<]C%O/5A>,[+PWWT>-"F09W M-%S21S9EZO/R3N@[MZ*$4<)2&?$4"3:_<"[] M_QF%:G'AG#HH9'.:Q>J>KZY9.:&>X8>[YP 55T-!1\ MA83IK6GF(E_]W%JO5Y2:0)DJH9]&VDZ-[AF-$9&**H8FZ1.32D>!DD?HDP[2 M8S1)EC02>1/Z$#!%HUC^.G25]FSLW5GI95QXP5N\=- -3]5"(I*&+&RQ#^SV M9Q9[5\^XFC9^F?886X%3MCQ!'>\(80]WT.=I@#[\W#:OJ]TQ^ 6#ED*_QT(] MM\WS/PS+QB-PXVNL8Z<*GT[NH+/%P22=\82AJ8D?$R5':$QCFLYT4Y[F:!JB MRS",3%+0@19$A6 M#Y<:A$1__:%'@";:F_R[+0Z+X7;;AVNR[KE1U#]P;G/;748V9]JJ9]JPS;<;G$;IF<7BLOYR/=1M#7)0! MK".4STT\3W6SSIQ<;0O?MH6R#F'?B(6$!9 P @1KZ-BO=.P?5I;J0VH."0L@ M800(UM!\4&D^ ,A2@S>S5-&C]V:6>I-$7I/L6>JTFNGI^V8I]!W=W([1E#V: MY3MO6S?KB/8-8$A8 DC0+"&K&>5K&>'E;3.(#6'A 60, ($:VCN>_5VS -( M6W;(OEJ4M-[VW!6 .B0M#GVOW^UN387^VG;6?_=D.+V^O;-F0_N8]I8#DA: MT@@4K:DNKM7%AY43R_%"*0])"T!I!(K65+ZN,_C6+>VN>1%T^U_2WMZA@KHE M+6[]GM_%V[-CO7/W[5OW'Y$=)['VPB.)Y-@50BKP^;2UL4% MWUY=^)\2Z0X[<_O ]Q8+DA: T@@4K1D"==7%/SVPO I:E &E!: T D5K*E\7 M9GQK#6#7WZ*@]9*29JDO!J .28M#^QX=US4.;*]Q_(CD^86*B&<2+30+:1;* M),LW[JW:V >XKS:@M "41J!H3:GK<@SV#RM)8M!2#2@M *41*%I3^;I4@ZT% M ; ?GW8W>PN&7_\[9R.-@CHD5H?-I:UK(=A>"WG?_+E+ =0^X+U% CUW 4HC M4+2F]'4!!WI:HX/EBU5N>)+_-3M!OM8__\RF]I#_QS4IP6KO'%X>4;'?V13DTQ MFVM7WLE SUH4YX&+&\67^8'7!ZX43_++!:,A$Z:#?C[G7+W<& ?5J>S1OU!+ M P04 " 5.FU7%ZWV/+,' !00 &0 'AL+W=O./PY?GO!:/'M%RSU_BY%NZY%R@[ZLP2B\& M2R'6'X?#=+;D*S\]B]<\DN\LXF3E"_DT>1JFZX3[\WS0*AQBRQH-5WX0#2;G M^6MWR>0\WH@PB/A=@M+-:N4GKU,>QB\7 WNP>^$^>%J*[(7AY'SM/_$'+KZN M[Q+Y;+A7F0O"SFT4_Y91S^%X"P.T_Q?]+*-=:T!FFU2$:^*P3*#51!M__K? M"R-* XA]8 N!N#: (P/#"#% -)V "T&T-R9;2FY#\P7_N0\B5]0DD5+M>Q! M;F8^6I8?1-GG_B 2^6X@QXG)39R()_D!HR^QX"FZ\U_]QY"?H"_RD#M%M7?? M,R[\($P_H'-7H79KU&)])/3O7PSL]C0PSR_R^B79IV:Y>9B@-WKN, M]R[C7)<<3.]1H*LH%A*\%7ZC\Z\K1K5JV6MX&.Z]F?\8B#7 M>LJ39SZ8_/R3/;)^T3D'*<: Q"HNDKV+Q*0^N=V(5,CC+8B>4!C[LFFLXDTD M= 9NA4:Y4-;ZGB>V/1H3SSL?/I>],4[8U1L@L8HW=.\--7KSZV+!\Q8J%Z;@ M4E^@Q!=93O[LAUCV3>W4W2='0H_ MT/75]/9>5Z]1H>MB@A1C0&(5YT9[YT:@+6D$Z2*D& ,2J[CH[EUTC<>?/"]* M>O%#0RMR&ZV(N)YC6;75UBZ,&=/I6:RW+]8S+[:"!K3G>^/0KL<'I!@#$JM8 M-MY;-@9=96-(%R'%&)!8Q47;4I1JF4]OT6RS>I3GM3FZVT)B('GTAXD8IX6D M4X8 4C_)F>?M:A*46M6E$LO;4(!4*)7[C8?MT:@.2)HXQW-LSZ[U)7-F?2M7 M?&T;P;,+_A1*=:ZA3J-T?2#Q2+WV8T"QK:C8-F,QXPN>9"MC$41^-,L^_%F< MBO0$1?(B+E[(:VNY>#:A]&.>'1%R[?SG9Z9#.LG6Q=4CK FVTCE,;CQO-0Q=&1G5 M-B?9UP2%R/8;C+PS([2_Q#M3O-SF!YKH/KQ3N-XAW7+W=6"MFQ0P 558U!J50L5X]HN*,380)!:6 FIQJ#4JE8J@K;- M"-V+8[S&0J-V?3&"$C.46M4DQ?GB1668C.65EKP)A3!:7'LOZ++F^G#P99L MENV\#0JIQJ#4JI:6]I.!-Y1A=Y1AMY2/@<]8X3,VXW.?EEQ(EEMR@Y#-TW8V MZ1@@C15(8S-(=VC)A5)M[UUVI;H_NC@-/YHSZUNYHF=LINA#(L#[1:@6:]SDP%%:"BUJI<*H3$L0F-0 MA 958U!J52L50F-XA,9-A&[ %"A!0ZE5/5($C<$(&C>)U\8>KF^&Z<*(54=2 M9LZK[_?#BK()&&43/3Q30NM?$;<,9.;<^M:N*)NTI^SIS:T9K.ILFK'V5W1V\?G*!/VML.S=I=&PVH&H-2J_JJ M$)O"(C8%16Q0-0:E5K52(3:%1VS:1.SZ;HAYULX>'>7.Z-*MT6"(39OL/!HU M.%,7Y37N?3%GU;=J!=@4#+"IGIO)N+X+U#:0F7/K6[L";-H>L%7COESR[%;= M4W0="!%R=!_/OAWLWJ#$#:K&H-2JYBKBIK#$34&)&U2-0:E5K53$3>&)F[Z] MEVV>M;-'QP!NJH";@@$WU6Q2.X36=W2U82-2WR0PY]7WARV*N1TPYG;TS(W' M=>9N&\C,N?6M78&WTP>\O\A7E^7F+5MYX[5##=T\8^>? 8'B.)1:U6V%XPXL MCCN@. ZJQJ#4JE8J''?@<=QY&\?-LW;VZ!@X[B@<=\!PW&F"]MAIW&FCBW*M M^M=SYJSZ5EWZH2(8CCL'MK&;[;QE(#/GUK7V8>GGYME_#G#C)T]!E**0+Z2\ M=>;*V9+M[^VW3T2\SG^!_A@+$:_RATONSWF2!#R?]0 M2P,$% @ %3IM5^UP%#C2!@ /#@ !D !X;"]W;W)K&ULK9M=C]HX%(;_BL6N5JU$AWQ @%D&J0-)ME)GBCK;W8O57G@2 MPT1-8NH8*-+^^+633(+!N(UT>M$)(>>QPWES[+R)9P?*OA8OA'#T/4OSXJ[W MPOGV=C HHA>2X>*&;DDNOEE3EF$N/K+-H-@R@N,R*$L'CF5Y@PPG>6\^*_>M MV'Q&=SQ-Y+2PUW/[KWN^)QL7KC<,9C/MGA#G@C_LETQ\6G0 M4.(D(WF1T!PQLK[KO;=O0\>3 >41?R7D4)QL(WDJSY1^E1\^Q'<]2_:(I"3B M$H'%GSU9D#25)-&/;S6TU[0I T^W7^E!>?+B9)YQ018T_3N)^1%-"W*_]&A.G8D#HYV!:=9'2QZD"5Y]1=_KW^(DP#7NA+@ MU '.68#C7 EPZP#W9P.&=<#P/,"]$C"J T;GYW MP*L#O)_MTK@.&)?)JG[= M,C5+S/%\QN@!,7FTH,F-,K]EM,A(DDLI/G$FODU$')\_4,8W0G/HD7)2H!4^ MXN>4]-&CN K>H4?,&)9:06^6A.,D+=[.!EPT*X,'4=W$HFK"N=+$%#W0G+\4 MR,]C$JOQ ]'=IL_.:Y_O'2/P 1^1,^PCQW)<].5IB=[\^A9MF;@\&3_J^F?& M/9'M#7(ME:?!+'\>XQ@P?I?>&,XJZ,(A>;3+G@DC\>HZ,303ER021-MT@DHZ MW4:";LEUKW*?.?J0%YSM1(WCZ)^/X@#T@9.L^%?3R_N*-M339.F^+;8X(G<] M49L+PO:D-__M%]NS?M=) Q*VA(3YD+ $A8"P12Q#!NQ#$WT^6>"4T0*CCE! M2;X76U(S?80YBFC!Q>B8BH*5;Q"G*"]+VK8J:3HE&9OJJJ0*YI4P.0'8SVW7 MJO_-!OM3G4"VZT/" DA8" 13=#)J=#(RZN33C@N1Y+&40DJQF/-D=)=SG0J, MH*XJJ&"C4Q78WM2=3"Y5 -FN#PD+(&$A$$Q1@=>HP#.JX+$<]!!=OPZDB2@( M])"?3T,J(1A9784 "5M"PGSO0J*.-52U&6B.L=5#0J ^*7D=-WD=&_,JIJFR M[(MHLJN;M=X;45US"PE;0L)\2%@ "0N!8(I2 MIHU2IJ W#U-(L4#"EI P'Q(60,)"()@B%MMJW0X+=N"H>4 2O-!:0$H+82BJ9(X,'3!]^HVQ7>L%*&T)2O-!:0$H+82BJ0IQ M6H4XH&-,C8,2#21M"4KS06D!*"V$HJFB:4U-VVB#=3$@S*3.>G$O;D\FCNUY M&@<"M&$?E!: TL*:=CJ,CR8C>V*?_BAJIEM'TC9;DLT @OY#]YA%*3X6Z.'3 M/?HHTJ[--ZCO"$I;@M)\4%H 2@NA:*IJ6G_2'L$.*J V)2AM"4KS06D!*"V$ MHJFB:>U,V^QG=AE40-W,FG9:/YVA_N$&:,,^*"T I86:'^7:8-(:F[;9V2S+ M0M*4A;Z\/26F-%]:C%<2LS"WW/F:AZ3YH+0 E!9"T51%M%:H;?9"KS_#$/,- MP_L!]S7W="+H.>>: /4[06D^*"T I850-%43K>EI&VVRRRH1T33%G#"9_$&9;Z$@PTSE@ M"W-H5R6 TGQ06@!*"Z%HJA):5],QNYH7%2+)17D@\@T942?ZJ'R#)D9B\(C$ MU^+N52N;JHW)Z03GQO*&(_>L7)@[TUDDH,8F*"T I850-%4DK;'I&#VP^4>: M;]X)660H%G*1H\B>Y#B7;U%]VR6,E(]*^H81I>8K3T>DLT) 74Q0 M6@!*"Z%HJD):%],QNY@KPA(:([P6*D%12@MYYUFK(T;/9$T9$9-0LJV>JVDU M8F[!+H<>[<@#^FXF*,T'I06@M!"*IDJFM4,=LQU:CCRM)/KHP!+.22Y?QTS$ MO>Q);='*Q4QW+13CHWZF FJ$@M)\4%H 2@NA:*I>6B/4,;^IV3Z27\LU)(3) MRK).Q#@4R6(CW^K5/IJML:=CSUA[+V-NO[,N0+U.4%H 2@NA:*HN6J_3,7N= M*T8C0N("K1G-2K=3+X-+$\Z=:OTO&PO=V]R:W-H965TP[31H9G8O%GNA MV'0BU)8\DIPTP/[XE1S%-"69,=O7%S.-;?$Y4OR&/#JO2%X\9?G7XD&(TOJV M7J7%Y>"A+#NXK%[F]\-BDXMXL6NT7@U=VPZ' MZSA)!].+W7LW^?0BVY:K)!4WN55LU^LX?[X2J^SI\HB68NT2++4RL7R[BZ\N MYBXNQ"Q;_3M9E ^7@_' 6HAEO%V57[(G+IH+"FK>/%L5N_];3\VQ]L":;XLR M6S>-JS-8)^G+O_&WYA=QT,!UCS1PFP;NJ0V\IH'7;N =:> W#?Q6 \<_TB!H M&@2M!MZQ"&'3(&R?4G"DP:AI,#JUP;AI,-Y]NR]?Q^Z[C.(RGE[DV9.5UT=7 MM/J'G2!VK:NO,$EK[=Z6>?5I4K4KI[-<+)+2HO$\625E(@KK5^OV1<=6MK2Z M'_\BKE]#ND=".:WW*TO*A ML$BZ$ L5,*RN8W\Q[NO%7+E:8B3F[RW/>6>YMNM:?]Y&UL\__=)S8C,]YE9L M*HR]PW@:3&2"V>15?Y.7SST<8L#I:4Y-3D.D\^WZ3E1?Z\WQ$V(FQ"0MRGQ; M=6=E#XF;D!8B3Q[CNB_3:,';"]O;H;TCZ(_5ZZZ"GZW_[#ZX+L6Z^&^?9E^H M?C^U'DD^%)MX+BX'U5!1B/Q1#*9__YL3VO_HTQD2%B%A! FC2!A#PC@(IBC0 MWRO0U]&G9/^G]OK'7_6??9+38DPEAX1%+[!@!ZNSH,>I:_L7P\=#)2$#TIZ MCAJ/(>-Q$$S11[#71Z#5Q^=M6935T)FD]U7ZM8K3N>A3QPLD//B5!)[M3D;J MKV76/H;R '/= O9[.YBT_F!GVH"F/0021OJO8#0.U2N@R* ,">,@F"*5 MT5XJ(ZU4;O(DR]OY3I]0M!C3\08)BY P@H11)(PA81P$4R0WWDMN?)8D>XQ4 M(!(6(6$$":-(&$/". BF*'"R5^ $D41-.MF1,QJ[02L[FDTZZ6<[?]*>C:D^ MD#"*A#$DC(-@BCX<6Q:X;*U":)RFB; ^Q?5_195#]12U_F=='V97UCS>]!>T MM*%,.RXH+8+2")1&H30&I7$4397G0?W5.NJL5XO:_I]G>#6HZQ]I"T"$HC4!J%TEA#.\Q66D4AWG.( MO)=652+KZHZV:#K]/:M-QWAEQ>MLVUOTO](3C/7A=2[""ZJ#VZD9-"J!TBB4 MQJ TCJ*I>I)5:15>@9E!9!:01*HU :@](XBJ9*4;H!CMX.B,1=>?!PQCMKGJU6U1"; MZU,WJ#G0T-34S0ZZJ1NT\ ^E42B-06D<15,E)JO_CK:T^P/#\>D5-ZA5 *5% M4!J!TBB4QJ TCJ*IJI6.@3,YSQB-+(K/H+0(2B-0&H72&)3&433U<57I3;AZ M;^+ZK63818PGK3M?:%@&I7$4356*M E<;>WW MQ*'VG^+Y*DZ_:N]Z]8%,NS$H+8+2")1&H30&I7$4316G- Y<]RPCJ@OU$:"T M"$HC4!J%TAB4QE$T58K2G7#U[L3WW?7JH<9"[!H6;NA,.G>]T*@$2J-0&H/2 M.(JF2DP:%J[>L/B^H?CD.UY]=&,M0@T1*(U :11*8U :1]%4Q4K;Q W.,SY# M#1(H+8+2")1&H30&I7$4396B-$A<_7R&M^]XCTUCZ-SQ0DT.*(T&> M9ZZ#"W4PH+0(2B-0&H72&)3&4315BM+!A >U/Z"T"$HC4!J%TAB4QE$T58K2_O#T\R9^;#C6PXT% M"35!H#0"I5&O.[>ALU8(-")'T529'2QHI+Q_;'73NJZ M$RY<>S1V)^VD#NI!0&D42F-0&D?15+5(#\+33[@P6 VN(74MR+9BH(8"E$:. M7,-HW%K2CD+#,BB-HVBJ9*17X.F] NQ]0/7VQ^NKSU]Z%0?U%:"T"$HC4!J% MTAB4QE$T=0%=:4'X]EGN!WRHWP"E15 :@=(HE,:@-(ZBJ5*4?H.OGX!QPK(G M#4%9JM>VVX_]SO2!C.4$]0R@- JE,2B-HVBJG*1GX.L]@^\?ED^9XZ,/;MS_ M03T%*(U :11*8U :1]%4P4KWP3_/?@H^=&H%E!9!:01*HU :@](XBJ9*\6!? M!;VU\6.E.3W<6)!0VP)*(U :;6A*::[]_!,T(D?15)E),\*'[,_@=W=><'PG M"-O+[C?'*;\_;S*>M,J;D?ZLC#4 ]0N@- :E<11-58OT"WS81@U^_^R L#W# M01_1N&^!EOV/7,.H,ZEH^) M'_SNG@]>7S7N[3T?].=CK!.H>0"E,2B-HVCJ[FK2/ CT\Q<,,K*@ M?X6B46>9)7U(TPX(2B.O%^$-W3I&QHK!UKUA](HE,:@-(ZBJ1J35?_ O.I_*^;;NI2U M6[FF>OF9]KKK>K)I(@6E15 :@=(HE,:@-(ZBJ6J4)?W@/"7] %K2A](B*(U M:11*8U :1]%4*;:%"*#3"*"T M"$HC4!J%TAB4QE$T58K2= CTIL,I(VUW$D'_2 LU!J T J51*(U!:1Q%4_4D MC8% /R7AA)'V9-]*'\JXNX.:!5 :@=(HE,:@-(ZBJ?*49D%PGLT> NAD!B@M M@M((E$:A- :E<11-D6(H_8A0[T>:*T-I$91&H#0* MI3$HC:-HJ@1E_3X\ST) (;1V#Z5%4!J!TBB4QJ TCJ*I4I2U^U#_8/\)!5,] MP5AU82=?\T;C[J:YT*@$2J-0&H/2.(KVHJ=A\2!$&<5E/+U8B_Q>S,1J550W M;)56+@=U&K]_U\K%LMZ>],-O[F#8>7_F?.!._?Y08J87FVH<_A3G]TE:6"NQ MK)#V^U'U!Y$G]P_[%V6VJ;*=@767E66VWOWX(.*%R.L#JL^76360-R_J $]9 M_G5WVM/_ U!+ P04 " 5.FU7+!VJCDP6 !>>P$ &0 'AL+W=O;0L M/OU\]DO\TL5Q?[O';I/_GA9?5@>_CK;?R\?%XH_M;\SUSV>][2$5L^)JO37R MS?\^%Z^+V6Q+;0[DWWOU[&G0[8Z'OW[4Y>Z[WWPW'_-5\7HQ^Y_I]?KVY[/Q M671=?,H?9NOWBR^ZV']'PZUWM9BM=O^-ONRW[9U%5P^K]>)NO_/F".ZF\Z__ MS__+_#N.T(D_T.D[;?0]Q[_)OKM7V_[*\GW=>S M9'>*9?DZOWBU7'R)EMOM-][V%[OS=+?_YLR:SK>9^K!>;OYTNMEO??%Z65Q/ MUY',KZ:SZ7I:K**?HM_RY3+?GNG1#UFQSJ>SU3^C?T33>?2OV\7#*I]?KUZ= MKS=C;X7SJ_TXEU_'29X9)X[>+.;KVU4DYM?%=*=Y_^MG0W[G] M9]Q?-[^/%I\B_V?$7]'_[O[ K(N[U?\U_23XJ@Z:U>TDX>7J/K\J?C[;S )6 MQ?)S<7;QG_\1I[W_:HH/B64D)DA,DI@B,4UBAL0LB3D(\X(V> K:(*1?_&NQ MSF>;&>KF/\5JG:^+S8^#SYM?;7\7C]Q]9!@WKG_O#I MW!\&S_WWC6?]TTF_2<5L\T0[OXG6BVB^6&\FJ/?Y7_G'6=,S[V5PJ*YQ(+'L M*S8\^*N(^[WM/Y4XM-Q.D@>G2$R3F"$Q2V(.PKS,I$^928.9>?NPW@1F?KV- MQ<=\EL^O&M,01+JF@<2RM':6]P>C45(-0[O-)'EHBL0TB1D2LVGMJ6'8[R63 M4>69 1K3.\M'3V?YJ/59/EOD\RB_6SPTOCZZ#$)=SW02RT;UG^=Q.NF/QY53 MO>5VDCPX16*:Q R)61)S$.8E8OR4B'$P$;^:R[?OH[^C[.GRPRJZ+E;3F_EF M]G0=Y:OHMKB^V>:EO)RP>MD4F. X70-#8AF)"1*3)*9(3).8(3%+8@["O.A- MGJ(W.Z5[TCU@L]ROSWVUPWELY=6:1@E*=X$CS%#U_=K(OEW?3KJYOI/+K?_,FBZ\^(SJ*<'?3L>U32J&52SJ.8HS4]/^:9\''Y7WLPWJ2FV M;T%NWYN\RN]7E4MO\\7Z&R^_A4?NG#?TC7M4$Z@F44VAFD8U@VH6U1RE^;DL M"P/Q\"27XF*T'8!J&:H)5).HIE!-HYI!-8MJCM+\T)6-@SA<.?C&BW)H!0'5 M,E03J"913<7U'D5:O2B'-A50S38 M/N@/X^$HJ5Z9:[>=1(].H9I&-8-J=J^EWN,[2)-!]6P_10YJ0ECHG 2TFI#4>P?]T7A8^X1.R^TD>G0*U32J M&52S24-)(:D_OHX:U3_;RY9"PK<4PF3GTQ]M*:":2.HMA;BIIH".JE!-HYI! M-8MJCM+\*)4UA>1(3:&Z!DEC=M"* JIEJ"903:*:0C6-:@;5+*HY2O,35E89 MDL%)+A8D:$\!U3)4$Z@F44VAFD8U@VH6U1RE^:$K>PI)>&6##I]?#4N=FA! =4R5!.H)E%-H9I&-8-J M%M44"W;:X=3N'$2IVEUL9*6VTGTZ!2J:50SJ&8; M'M_A>!B/J^NV4:/Z9WU904B"[[9>_#XOYE>[=T2+Z^C=H>V#E M M0S6!:A+5%*II5#.H9E'-49J_"F_9.NCW3C*EZZ.] U3+4$V@FD0UA6H:U0RJ M651SE.:'KFPS],-MAF]?DS<,=XX=6G+HU\L+HZ9E2%MN)]&C4ZBF4H8&]10-[CP;V)@WL71K8VS2P]VE@;]3 MWJGA%%V*?MFEZ ??-FY3FH4?WD ME(6(?K@0T6*>N/UL86.BT(($JF6H)E!-HII"-8UJ!M4LJCE*\W-7EBWZZ6FF MB6@/ ]4R5!.H)E%-H9I&-8-J%M4]>$R(L=,X76KE -8%J$M44 MJFE4,ZAF^_7U)9JGB:*C6E"BQ6H MEJ&:0#6):@K5-*H95+.HYBC-SUQ9Y>B?9C6)/MKK0+4,U02J2513J*91S:": M135':?Y-7\M>QR"\FL1WW/85;7:@6C:H+U20-KW%W'([B1Z=0C6-:@;5+*HY M2O.C4K8Q!N$V1HLY8?1W5%^QN3$\:#\#U3)4$Z@F44VAFD8U@VH6U1RE^4$L MNQZ#Y"03Q0':\T"U#-4$JDE44ZBF4QR"\0$:YULR/T6: MN^G#772?3QO7F E3G8.&=CL&]9MO_#1(ZS/#5IM)]-@4JFE4,ZAF4%J1[V"UV>BVF%W_N'EE-2^^;*:%UT_Q:0P,6M9 M0S5!*I)5%.H MIE'-#.KUBK[_L\BB SI*\S-5]C0&X9Y&XRJ7C=%!6QFHEJ&:0#6):FI07WBC MLC*D1@L,@7&^H76IK3 5:<$"U#-4$JDE44ZBF]]KV MSI9//R9Z+WK]H?]3PJ"CVI:C.FI4/Q5E=6'PW=6%?1B? MJUX(2P9Q=6J)MB-03:.:036+:H[2_""5[8AAN!WQK5-+5_QUF<__"$\KT=X$ MJF6H)E!-HII"-8UJ!M4LJCE*\X-95BR&P]-,*]'&!:IEJ"903:*:0C6-:@;5 M+*HY2O-#5_8XAN$>1_=I)=KJ0+4,U<1>JT\KT^JT$BU_H)I&-8-J%M4RU%AX(JFE4,ZAF4DM.R.I.'N MR EFG6VN9<:9H9P75 M,E03J"913:&:1C6#:A;5'*7YH2L[*VGX?BR=9YQAKW/:T+(*JHF]=OPZ)SJL M0C6-:@;5+*HY2O.#5/90TG /I=V,L]7JI.&1.D<,;:B@FD UB6H*U32J&52S MJ.8HS<]A66-)!Z>91:(5%53+4$V@FD0UA6H:U0RJ651SE.:'KJRHI.%50 [O M:?XQG^7SJ^:Y(]I(0;4LK2]4L?T83E+]N,Y^N^K'=:K;2?3H%*II5#.H9IL> MWV'2&U26*7'4J/X97_9#TG _Y%W^U]?EHSXMEE&QNMH"U\7]8C5M_*!:6.M\ MYJ/MD+2^EL=BF=_L+CQ,%XT90NL<>VUR<-;'+P;^29^A0PI4DZBF4$VCFD$UBVJ.TOP( ME2V-E%A$I/&]KX>/J^+?#YOGL$A\+IH_7AT>O'/BT"X'J@E4DZBF4$VCFD$U MBVJ.TOQHEEV.]#1KAJ1HI0/5,E03J"913:&:1C6#:A;5'*5YH1N5O8]1N/?1 M\679J+[V1EI;>>-U>,RN&4(U@6H2U12J:50SJ&91S5&:GZ&RAS$*KS'2\679 M7@N^D'H='K)SA-!6!:I)5%.HIE'-H)I%-4=I?H3*5L4HW*H0QY]YDMHS3QR/ MZT\]:#\"U02J2513J*91S:":135':7YNRA+%Z"0EBL;;>;6\QA$^HJXOMU M M0S6!:A+5%*II5#.H9E'-49J?U[)L,3I-V6*$EBU0+4,U@6H2U12J:50SJ&91 MS5&:'[JR;#$*ERVZW.$K3'4.&MJX0#6!:G)4;R'\-*S=;U:A@VI4,ZAF4I/YLA'8X4,V@FD4U1VE^!ZH)5).HIE!-HYI!-8MJCM+\>)8]CM%I>APCM,>! M:AFJ"523J*903:.:036+:H[2O-"-RQ['.-SC:/F!DK#2-6.HEHWK]W])>J-Q M,JD4ZUMN)]&C4ZBF48%RY+;.C1O7/^+)U,2;N[-)V%OBX4G=C M:-#U,E M0S6!:A+5%*II5#.H9E'-49H?T[+9,3[-/5[&Z+(9J):AFD UB6H* MU32J&52SJ.8HS0]=60L9AVLA+:XMAH7.^4)K'*@F4$VBFD(UC6H&U>Q>\SXT MVZN]0>BH0?W@E/V,.?,H2T.5!.H)E%-H9I&-8-J%M4< MI?G1+%LWT$\3 ?5&> I:AGCLI8Q M#M/PS5+:3N;0'@:J97OMTBWBFZ$).R"S$YLJ9%TQ2N[5K28;OKV8]J M&:H)5).HIE!-HYI!-8MJCM+\Y)6=C,EI[D@R01L6J):AFD UB6H*U32J&52S MJ.8HS0]=V;"8A-?.V"T_\^GI/EQ?EHOU-H2?&H.&MBI0+=MK7N\LK2VK.ZFO M U+?2J)'IE!-HYI!-8MJCM+\8)0MB$FX!?'[A[;IW/8_>X^^'# M6_G^GXWI0CL5J):AFD UB6H*U32J&52SJ.8HS4]K6;V8#$XS=T1+%:B6H9I M-8EJ"M4TJAE4LZCF*,T/75FJF(27QNA\-[NPUSEM:)L"U<1>J]W-KOI^,#JJ M0C6-:@;5+*HY2O-S5/8D)D?N;O)-4\U-^HK=G+(Q:6BG M4R5!.H)E%-H9I& M-8-J%M4ZTZF>R-=Y^!>/JG-K=$:QNHIE'-H)I%-4=I?JS*VL8D M7-MX=FZ9_WFBRYAH 035,E03J"913:&:1C6#:A;5'*5Y:8U[9?MD^^M3S#T? M72AW+)>QG& YR7**Y33+&9:S+.XCS#=\X8V61ZY MT,>X'[=)G]]&LH>E6$ZSG&$YV_1W$#>MR(B-6SGGQP?G?+A7\N;M9?3K(I^' MUN@^8G0_X=$R"6R1^YP9M$?;9N.U2E> MRPTE>X"*Y33+&9:S;1]DAXU;.?,/>AMQN+=Q,,][LUBN;_*;9Z[FA9WNIS]; MUT YP7*2Y13+:98S+&=9SF%<)7 'G8[X-/=F>72Q ++%#903+"=93K&<9CG# MW1;'.\G5^\>JN6-X4KXO9;!5=;<_6[?/+P5>C M9?%I>^J__"4Y.Z]]_3)^^3IN^+J*7YK=U\]+_N+5_68*^"9?WDSGJVA6?-H, MU7LQVLQDE]L/M#S^9KVXWZ3N+/JX6*\7=[M?WA;Y=;'<;K#Y\T^+Q?KQ-]L! MOBR6?^R^G8O_!U!+ P04 " 5.FU7C7D7F5,$ #P%P &0 'AL+W=O MV! @MR32FM.I M)ZUKU&NW%]->.(F3H +.;.?2_O>S"06"'7-#Y$W"#W\?/X\3_#&>'"G[RG>$ M"/ M2W,^=79"[.]=EZ]V),/\CNY)+N]L*,NPD*=LZ_(](WA=%&6IBSPO=#.< MY,YL4EQ;L-F$'D2:Y&3! #]D&6;?WY&4'J<.='Y<^)1L=T)=<&>3/=Z29R*^ M[!=,GKF5RCK)2,X3F@-&-E/G-W@_1Y$J*%K\F9 C;QP#%65)Z5=U\K2>.IYR M1%*R$DH"RZ\7,B=IJI2DCW]+4:?J4Q4VCW^H/Q;A99@EYF1.T[^2M=A-G=@! M:[+!AU1\HL?WI PT4GHKFO+B$QS+MIX#5@<=/7#9DD]<(9VJ_MQ5Z>K=R16Z MX.J9[.^ [_T"D(=\0_G<7OY 5K(<%N7HO-R5XU,-$JH&"15Z_D4]F?,IYX(= MU#B OW^7#<"3(!G_QQ3NI!:8U=2#><_W>$6FCGSR.&$OQ)G]_!,,O5]-40<2 M.PON5\%]F_I,#3^X843-!VO";DUA3PIAH: FC9<9C'PX<5^:(:S=] P15"&" MKA"!R?BI:M0P'HZ#J&7<*MW3^*@R/NHR/C(9'VG&X=CSQRWG5NV>SL/*>=CE M/#0Y#S7G$0R@[[>L6\5[6H\JZU&7]AU,YC-Y8/<% TEG)#A1]( M[3Q\O2R 5OB^"H^E1//OB^+V7&WOIV^.FO*P$_-&0I9EYX]>U'[N[.)]S==T MAYUX-U(2ZGR'/HJ\MOMK$![6B(>=C#>2$NJ0]Z.Q/VZCTB[?UW[->=@)>B,M MH4YZ'9=V[;[>:]!#.^GMQ(0Z\(W(M'?2-T1-?=B!_4O4A#KR8P3#4'MZ8VW] M/HI',*Y7\.?.:IQ#.\^U-TNCRX&@76:YQA( U4L Y W[FCCH0F HM?/P]4( M65G[*A:6$F=3)]S=@.*HI MCNP4MY,0Z2S7_%^#Y*@F.>H@^24(EG5-N,D_3H0T_X-"W&ULQZJ]\ ^8;9.< M@Y1LI+QW%\FA9*?MY=.)H/MBAW9)A:!9<;@C6,ZBJH&\OZ'RG;(\49N^U2;_ M[#]02P,$% @ %3IM5[R&ULS5K1;N(X%/T5*SM:S4C=)G$@E"X@M4755&IGNNUT]F$T M#P8,6$UBUC8P*^W'KQW2.&Z#(8Q'XJ5-PKV'X^-[T].;]-:4/?,YQ@+\2)., M][VY$(MSW^?C.4X1/Z4+G,E/II2E2,A3-O/Y@F$TR9/2Q(=!$/LI(IDWZ.77 M[MF@1Y+CR0V5RH"_Z@MT S_(C%T^*>R3._ M1)F0%&>?Q3@'KE=ZK$ZO$+^G6^>+F8$>+XBB9_DXF8][TS#TSP%"T3 M\4#7'W&QH+;"&].$YS_!NH@-/#!>XX!S+@SN,^)+A"4 "5!+?#[% ).$? M9*2^?/(2GH.<@ <\7C)&LIF,>GH<@O?O/H!W@&3@RYPN.R_0P3X=FNB]U+,6$I9@PQXMVBGGR M(IE<%[@E:$02(@BN2"A+6"NBHC[1C)47+A$G''R[E5\ ;@1.^?$=*R5FW^ UBNUK"W5;\JL[?!D6=:$N9=TJRG1UDFY>X%;'I3CD",Q9_ M5B[^[*A*_,RE<([ #.&ZI7!=YR7>?5N], ["5S5>$Q5WPZ"^R,- VYS 2OBO M)54E?L_(6&ZJ=!T7N7\$=X@]JVV_Q2N<@+#6@EB1F^Z:*S13AXK="X^JX@LZ MKL1SA&:*I^U=:#5!VVU*D5>MVN!575M#3#[:-85VV[1G48/_P*%FQDZ@\?8Y M0C/ETH8N;!U7[3NU@J[03/&T&0RMENF@.WX!:6T+6XA)5=NOT.Z_]F^+@UK" M^N6-=]41FBF5-G]AY[A:PJEU=(5FBJ?-8VBU6(>UQ-GNEK"%F%2U70OM?NU1 MECF9DC'*!/@LYIB!SR,E"!HE>-LCFIHPRZP&5B9O=FO6H,!_P@[9233>RE\Q M,]: VBK![7'7OU%FZ0C,?8FEG&=F'C-L?8P4[ M7;\UQ.2CS5ID-VM[%O5/&"([@:;;YPK-E$M[R.BX'M]&3MVD*S13O,H37/LL M\I![?@%I;0M;B$E5>[?([MWV;XN#6L+IU,\5FBF5=HW1<3T#CIQZ2%=HIGC: M0T;NGP,7D+&M)6PA&ZI^Y84@]3;6'6*R!_4$L#!!0 ( !4Z;5=<":HR M'P, 8, 9 >&PO=V]R:W-H965TS'MA4D.L)K8F>U ^^UW#B&P$=A:%:EO M('9\Y]_?OLM==R'5HYX!&/*4Q$+WG)DQ:<=U=3B#A.ECF8+ -Q.I$F9PJ*:N M3A6P*#=*8M?WO*:;,"Z^Q#+1<^ASFKBGD]G MQDZX03=E4QB!^98.%8[WT:<,:Y"L>."STQC.Q4L92 M/MK!==1S/$L$,83&NF#X-X=SB&/K"3E^%4Z=61F/:?MD @F+(O-O5Q<02$H!PQEK/-?LBC6>@X),VUD4A@C0<+%\I\]%0>Q M8>#7=QCXA8&?K,/N=3<&N&XL+2(#)A2S!X?^70!AO%8?\;9"ZY3J7'Q M5R6SM$:N((Z.,%".,@TU,I#&K@BE,%QD$)&[%*P3*737-8AN =RPP.PO,?T= MF"-(CTG=JQ'?\^LD51B5RCS_Z<=%Z:5^O]3OYX[K_]1?(V=: \IE(B(WG(UY MS T'36Z!Z4RA RB>P@SI;B8YJL&4JARHL\TU^3'#6Y K@TD^F>5S"7-236- M3<&.3ED(/0=S3(.:@Q-\_$";WI<]6NNEUOH^[\$@2\:@[#T7!VC5S?#2"%X: MP4NK EZZ;.0N;8K/ ]KLNO,*C),2X^3E&/A)> 0#2Q2,J4J6DRV6'2B-$J7Q MI!@4$%41-+9/PZM&:)8(S;T(MW=],H*IS;2J#?<:OS)>6B5:ZUWE1NL M6MNEUO;;YT;[OZ/AM,0X/5!NG&ZQU*M1J+:- MWE@:;!OSQQDVZJ#L GP_D=*L!K9W+%O_X#=02P,$% @ %3IM5TS.<3HL M! &Q8 !D !X;"]W;W)K&ULQ5AAC]HX$/TK M5JXZM1*WB1,28 ^0NJ#MK=1*J])M/YSN@PD&K"9VSG:@*]V/O[%) UE"NEM2 ML1)+[,R\S#S//T7B*5IRF1CS9F1%9U0_9/<21FZ)LF IY8H)CB1=CIRW^'J"!\;!6GQF=*L. MKI%)92[$5S.X6XPZ(]B^Q 7#OYS'8+"(;")[B*S:4V))N.A%%LDC36@F0O+C?6& M;!@WRSC3$NXR\-/C6\(D^DR2G"*Q1+>,$QXSDJ [KK3,8;VT0G^@"9'RD?$5 M>IN*W$P1OD![5V5\IW2NT>LIU80EZ@TXS=B*LR6+"=?H@8NYHG)#Y@D%["P' MC/=T0Q,4@.7#;(I>OWJ#7B'&T:>UR!7@JZ&K(4$3IAL7R=SLDO%/)#.CV14* MO [R/3^H<9\TNT]I#.[8NOM5=Q=H+;GU2VY]B]<]@?=."J50*J1>@2(0%QJ8 MRLBC)<$P6-X"!:8L3^WD@JG8DMQ!'&3\WU/RZVAIC,/L!--H"]=MI; M*OD/ROP'ERWP09M,M01680I[^T[.^T4E7@ ?%J_WI+QK3'#?@[_Z^L8'_2<^ MM\+MULXYH^@#,1^EJ41'?K6)-3[[IE'G1[/?]($C5VH>]U3W1(>-_9X<;6KIZ:.IT\N^'YF0O._6<'.[ M]NQJ/^/=T!C!BU>Y);0J7_LV$?1NX$6F3W,FPNM M16HOUY0LJ#0&<'\IX,=S,3#G@^5Y\/A_4$L#!!0 ( !4Z;5?^X!=3^0( M !L+ 9 >&PO=V]R:W-H965TVVX"T'S_;"5$*H1M;OK1^W'-R MS_6Q=65K6Q0<<&Q M>69[CA/8.2;4"F=F[8:',[:1&:%PPY'8Y#GF3Y>0L7)NN=;SPBU9IU(OV.&L MP&M8@;PK;KB:V0U+3'*@@C"*."1SZ\*=+B8ZW@1\)5"*UAAI)?>,/>C)=3RW M')T09!!)S8#5WQ86D&6:2*7QL^:TFD]J8'O\S/[1:%=:[K& !VPZ:VP[[L/^Q3W-Y[ZCV1[91QW)1QW)?3QWUJ[HEL1_.D MT3SIW>F3UT_X9!"\,/KK('_DOWSF[5;KHMO&SY@K'PJ40:)@SME(711>M6+5 M1++"=#/W3*K>R Q3U;T"UP%J/V%,/D]T@]3TP^%O4$L#!!0 ( !4Z;5>\ M-'W AP4 )4O 9 >&PO=V]R:W-H965T4CQY4UOSFB;I#_$BG.)GJ,P%F-C)>7ZRC3%?,4C)BZ2-8_5 MG4621DRJRW1IBG7*F9\'1:&)+:MO1BR(C&;;Q\\1 L5S+[PIR,UFS)9UQ^7]^GZLHL*7X0\5@$28Q2OA@;-_85 MQ6X6D)?X(^!;4?N,LD=Y3)(?V<6=/S:LK$4\Y'.9(9CZ\\2G/ PSDFK'/P74 M*.O, NN?7^@T?WCU,(],\&D2_AGXX1P*<(L!Y;4"O".CM M!=B](P%N$>#N!3C.D8!^$=#/^W[767E/>TRRR2A-MBC-2BM:]B&7*X]6'1S$ MVM"\LOG;R&1#J26<*H/]_A+&Y-T;NV]=MXD-"?,@ M80021H%@#>V=4GLGISLG5P+TUQ=U#]U)'HF_VZ1U(*6%A'F0, ()HT"PAK2] M4MJ>=EK_MHD>U;15RW=MS6X35HOI*NP.YN:P[(#S-!F,S*>Z6H+-808E *,= * M43^=^EP$RU@)XB,FT*HXIU;''W&ESBI-Y=Z]&6)L7:_9ST^+X)G[^;5]C<16 MG6S:--6VIJNFD# /$D8@810(UA@?PW)\#*'.+$-(:2%A'B2,0,(H$*PA[64I M[67W,XN:X=I7N5LMLZO*EP?'$WOO -9'8&$T<.V7[8OQ;95.076KQYA"D*] M6F::I1\VULV*UQ]HT^M&JFK:?KG &E M>: T DJC4+2F_I538V.HK<\&M6) :1XHC8#2*!2MJ7#EQ]A:3^#,'5 /[2RV MRDNQ3Y@IK]@&#XV-]FT0TM[P0&D$E$8+6F,;Q)IM ML+)5;+VO+ZIK6]-Y]D%ZN6 T@@HC4+1FJ.D\G/L/MAF">KK@-(\4!H! MI5$H6E/ARBBR]4[1:U;EP>&JW!L,#E=E4.,&E$9 :12*UM2L,F]LK8'0?>W^ M^Q)L609U=D!I'BB-@-(H%*V93E!Y M1OB$9W36.XP>VCEWX-"4VEOR/= *"2B-MC0?MY^:<64>8;UY](K=LB!H>FVJ MKZ1S5@:HUP-*HP6M\?IB67G MW4:?;U/? >-$GO,_KOF1?V7I:^X\AV 3 M<& S<&!3KHPD_,L).K@U0\<=X/U]$=36 :414!IM[9%>'_?V MU#!K".6)49S0, /X- 9 M>&PO=V]R:W-H965TV+>,40D%SJRXR*G"KEC;LA1 $Z.49[;G. ,[ MIZRPIF,S]B"F8UZIC!7P((BL\IR*;_>0\>W$V3I4>L*?CDJ[A$=27 M\D%@SVY1$I9#(1DOB(#5Q)JYMXN1EC<"OS/8RKTVT2MYXORK[BR3B>5HAR"# M6&D$BK\-S"'+-!"Z\7>#:;4FM>)^>X?^JUD[KN6)2ICS[ ^6J'1BC2R2P(I6 MF?K$M^^A64^H\6*>2?,EVT;6L4A<2<7S1AD]R%E1_^ESP\.> N)T*WB-@G>L M$/Q P6\4_-=:"!J%X+46PD;!+-VNUVZ(BZBBT['@6R*T-*+IAF'?:"-?K-#[ MY%$)G&6HIZ81"+:A.EB2T"(A[R%9LV)-9CJ 3#$TG>ZMG/*:\D8LJQK=!3;<^.&Z_N:Z^\'WCEDP^\ M4*DDBP)-=>A'Y_5OSNC;R%!+D[>CZ=X["_@(Y37QG5^(YWA^AS_SUZM[7@([B$;01B,XAS[]S!7-",UY52C"5WCR%* 5 M1> 9+Q,)Q-C$07-D50KOWHP\W[N+>2%YQA*J9Z3"'Z9_)34$WD*"ZCQ>YX28 MYXB1ZLL!0YYQV7FB:R\'QDM].VVF5VXX])RQO=D/8I>8[XV"0[&H0RQT/&=T M*+;H$/.'SLV+V &E84MI>);2Y8Y"9 &(YLMS[DKZ[6K%GB$Q??>.R"TM.YDX M"_ZSF[Y/L*A/L$5/8 <1&K01&O25@@9]1J-/L*A/L$5/8 ?1&+;1&)X]+[,V M^:RQ,L7R,>;K@OU39QP:QU5>92;-<$P_XBB?L +[0+!H9 ?'+GDI.KK"6GL4 M[IW\,'"/TL/\5,@=AJY_E&LZI#QG>)QJ3J6"FU#?IUV99M0R-_H9YBYTF\N0JZ.)Q=))!0U-D'/#8(30(CU@\E7']07#, MXJG4E3\:'+-H[Q6T.8BU>4E(7#.25=$ !D !X;"]W;W)K M&ULM=U;;]M&&L;QKT*XBZ(+-+%(B;3L.@9B\S0S M31,DZ.[%8B\8B;:%ZK0D':= /_R2,BUJ1'HLVO]>M(EES>\E%;[BZ2%Y?K_* M_LAOT[2POB_FR_S=T6U1K,^.C_/);;I(\K>K=;HL?W.]RA9)4?Z8W1SGZRQ- MIIM!B_FQ,QAXQXMDMCRZ.-^\]BF[.%_=%?/9,OV46?G=8I%D?UZF\]7]NR/[ MZ/&%S[.;VZ)ZX?CB?)W+=)G/5DLK2Z_?';VWSY0W MK@9LWO&O67J?[_S=JF;EZVKU1_6#F+X[&E13E,[325$12?G'M_0JG<\KJ9R. M_]7HT;9F-7#W[X]ZN)GYS8M;M\=C8^L:7J=W,V+SZO[.*UG MR*V\R6J>;_YOW=?O'1Q9D[N\6"WJP>44+&;+AS^3[_4'L3/ <9X8X-0#G$,' M#.L!P[T!P^$3 T;U@-&A ]QZ@'OH)'GU ._0"B?U@)/]"NX3 \;U@/&A T[K M :=[ ^S14_]P@\=_N<&ALVUO_[$?%KJ'I62SB/E)D5R<9ZM[*ZO>7WK57S;+ MZ69\N63-EE5+?2FR\K>S'Q=E]"Y32= M=HP/S.-/GQL?F',XZ!\XL M7:.!UVX/M[T0CIWV^WSC)/9=\MO3YMJ#]E+?GK:A8SNM]T7DM,4D)DA,DIB" M,&V!]K8+M&=MGU M -5"5(M0+48U@6H2U12EZ4VVD3L;NH'T8]\II\UD0';G!GX[6[Q-UXQ,G^)F'[+;;^%H%.DT0U16EZ/O[163!"-5B5!.H)E%-49K>4DU(P3:G%'9WJW8::;:T MUN5O5EU7+%R:R=Y=A,874"VH-2UEU]JOK;L)C2>@6HQJ M4DJBE*T[NI"2G8 MQO.T%Y^RU21-I_E#-BY/YNG#RJKLK#0OK*SL+6M2A>BNYR5=';CHNL+BTERE M=X.A&094"VI-.QK9?1 /32B@6HQJ M4DJBE*T]NKR2G8YJ#";ZOJ@M9D;CJ\ MW3Z[_^3A;32B@&K!X;,1HH4CNR.FX#QQ>!O-*:":1#5%:?KUFDU4P3%'%5YT M!+P<$";+Y2RU/B35?WFY#K*NLG0Z*\I?3&;SS66R72UDGIJ^:Q]4\U$M0+40 MU2)4BU%-H)I$-45I>J\VB0<'2SPX:.(!U7Q4"U M1+4(U6)4$Z@F44U1FMYG M3>+!,2<>#M@4=#J2#J.3DZY-07.QWLV#)AT.GXT0+1RA6HQJ M4DJBE*TSNC MR4LXYKR$T(XV_/C#V'$&OZR3/]]_=6&BTHM9VOV0=_>,/T((A MJD6H%J.:0#6):HK2])9J(A7.,Y&*Y,^J6:SK5;9MI.JNQF6/5<QO M&Z):A&HQJ@E4DZBF*$UOI28^X;PZ/N$<'I\P%^O=%VA\ MXO#9"-'"D=,1GWCBZD"TL$ UB6J*TO0;_S;QB:$Y/O%W'A"O[AY1WTBBJYW, M4]9W381J/JH%J!:B6H1J,:H)5).HIBA-[]LF2C'$HA1#-$J!:CZJ!:@6HEJ$ M:C&J"523J*8H3>^S)DHQ-$33O/F3@P?O&YVMJ\6BV++)D42-+"7+EWT[&/IF"?3<$^G()] M.@7[> KV^13L RK8)U3\'4F+89.T&&))BR&:M$ U']4"5 M1+4*U&-4$JDE4 M4Y2F]UF3M!B:DQ97^N6-U>,"YDF>SZYGDX<#]Y.[+'OB[)>9[MUX:-X"U8)A M.[#@=$9ZT;)11]G]PY)H08%J$M44I>F-TJ0NAN;4!;2A6 [82L'W=;K,.Q,; MYHGIW5IH8@/5 E0+42U"M1C5!*I)5%.4IK=J$^L8GF#;CFB ]5\5 M0+42U M"-5B5!.H)E%-49K>9TW68VC.>KQJV[%])XDW=N>):_-$]&XJ]'X877/QQ(8A MFNA M1C5!*I)5%.4IC=,D^@8FA,=SS;,;&DMT^^%5=RG\W+MM=@\2KJS?=J) M"=OK;A\T]X%JP<%S$:)U(U2+44V@FD0U16GZ8VN;9,CHP&3(JW?!=IXF MF'FZ^FXEHIJ/:@&JA:@6H5J,:@+5)*HI2M.[MLF%C+!OXO+CYV?BP&:B=U>@ 0Y4"U M1+4(U6)4 M$Z@F44U1FMY@38!CA 4X1FB ]5\5 M0+42U"-5B5!.H)E%-49K>9TV 8_3, MK3*>OTILU(X1/'65F+E8[^9!0QBU=L@SY-#"T>&%8[2P0#6):HK2],6^B6., MS'&,Q^VWU\=TS85ZKWW0J 6J!:@6HEJ$:C&J"523J*8H36_#)FHQPJ(6(S1J M@6H^J@6H%J):A&HQJ@E4DZBF*$WOLR9J,3)'+5YV0S0SVKOET" &J@6H%J): M-&J'1)S]S<;V6_:V+ 4Z31+5%*7IS='$*D;/W"CCM;=Q,ON]^P1-7*!:,&HG M+IS]?2C\TB0?7 MG'@X9#?':P=]W'(".H(^YF*]%W,TIW#X;(1HX0C58E03J"9135&:WAE-",$U M/\:CM6O4V1MH_ #5?%0+4"U$M:C6]I\,,W3W#RN@P0)4DP?.@Z*JZEW11 9< M^LN:;ENHLVG0U "J^:@6H%J(:A&JQ:@F MW([GFNSOHJ"I 4K3>LIK4@.>.36PMXORT$=IYQK'+/5M'E3S42VH->UDYK#[ ML@6T<(1J,:H)5).HIBA-;Z(F+>"9TP*=)WIV\SC+5?'"2QW,E7LW'9H@0+4 MU4)4BU M1C6!:A+5%*7I?=G$##R'.N_CH;=30#4?U0)4"U$M0K48U02J2513 ME*;W61-T\,Q!AY==ZF!&>[<<&FE M0#50E2+:LUPVB;N>,O>:1N!3I-$-45I M>G,TX0//>-+UD)- M;!W]L0]<=I'\\S%>B_F:*+@\-D(T<)1K6E7>[LCSQFU MPV]H88%J$M44I>F+?9,%\,Q9@+T[/R9KZT-2W&75/L_[=3:;6\[ &74V YH- M0#4?U0)4"U$M0K48U02J2513E*9W79,X\#QLCP>]B0*J^:@6H%J(:A&JQ:@F M4$VBFJ(TO<^:_()GSB\\M<=C/OUD1GNW'!IH0+4 U4)4BU M1C51:]J9A[W3 M3VA!16EZ'S6)!^^9FR0YT7MER9:_5N"#3I.T?' MK=7I>3,'A[4G[G M9+.;V^T/Q6K][L@^LKZNBF*UV/SU-DW*%5SUAO+WUZM5\?A#5>!^E?VQF&ULM59=;]HP%/TK5E9-K=0U(7QW$(F"NE;:NJJLV\.T!Y-< MB%7'SFP'NOWZ72\CIM0)IQ@D/?=JF @,\.9@%M% M=)8D5/VZ "Y70Z?A/'7 M0\),&YFLR:@@8:+XIX_K/%0(C=8S!']-\ \E-->$9FZT4);;FE!#@X&2*Z(L M&J/9CSPW.1O=,&%7<6H4CC+DF6 "BBVI3:4F5$3D"J(%$PLRLNEEAF'W._)Y M/M=@C.VOXH\G8"CC^@0A]],).3XZ(4>$"?(EEIG&:'K@&M1H9W+#M9Z+0H__ MC)XII&>DZ9T2W_.;-?3Q;OH$0J0WOFET MO/=U&?E'P3;RTRSST]P5/?B@I-9DE,C,ID7.R1V$IX+:$-PJ!;=>+?CX(Z,SQO.U/*G3781N5Q1Y M?VG>A=C0VR[UME^@M]B(=HN9&,A8"BTYBZA!\1>44Q$"F=JCH$Y\>Z_X78@- M\9U2?&>G^!O46DEU41 D+T-A-;_*1V=+95WQ;*-V%$^W]--]P6+<2'/P@IR2 M2R:PR2BO'B1U_KI[UVD78L-7K_35^V^^QE3'". %Q&==9Z>ZWM M0FQ8ZY?6^@>68)V@_D$'T3:JKI;,OGGS&^PT!9 ([/I31/#7O5ER^[X ]02P,$% @ %3IM5Y,: M=5+=" S&8 !D !X;"]W;W)K&ULM9U9;]M& M%(7_RD MN@")Q45K:@N(S6V()C42M'TH^D"+8XD(%W4XLI.B/[Y#BA)%BQJ1 MS6D>8DF^][L<^EQJAD/&4\"(9_RU3#?&"ZN-\&*?63BU\T]E\^&!TH8)2S-HRPEG#W> M#-[J;WQS5"24$;]%[#D_>DR*H3QDV:?B"0UO!EJQ12QF2U$@ OGCB=VQ."Y( M#>0AR=I?%OT>A6-\,9@,2LL=@&XL/V;/'J@&- M"]XRB_/R?_*\BYW*BLMM+K*D2I;/DRC=_0P^5SOB*$$?G4DPJ@3C9<+X3()9 M)9@O$R9G$D95PJAKPKA*&'<=PZ1*F+Q,,,\D3*N$:=<*LRIAUC5A7B7,NR;H MVOXOIY4*VOW)2[U8@0@6USQ[)KR(E[SB02FZ,E_*)$J+_O@HN/QM)//$XJ/( MEI_661PRGG]/[+^VD?A"7I/W >=!H5SR@\5$$,7YC_+5;\F0Y.N L_QZ*&3Q M C%<5H7N=H6,,X7FY%V6BG5.[#1D84N^I<[7C4L 6PTP)PK 4.ZVP[XS]OON MUE 2WP7\BFCZ*V)H^JQMCZC3/[+-%3&U(MTPVW:(.MUB2YE>5C>,MMWQ==4= M=?HO2R''/BK3]99T]]*N^[+?]K9LK_O0M99TVGWH;>E^Y^KZ7"$C\]""9LDS MS_#NXB#/2?9(REXD?_PL?T^H8$G^9\O&W>Y@HW98\7;Z)M\$2W8SD.^7.>-/ M;+#X[AM]HOW4IE DS$+";"3,0<)<),Q#PB@2YH-@C988'5IBI*(O[K(DD9.G MO&B(5]5;#I&SNUP$:1BE*_)#E%8O_]C6(TIZWQ[9P<8EK)AN/BUT;3Z;3@U= M'G:?CAN@+7*LS;2QJ3/2P M+6;_N9RI+V.ITI!(O2Z/1'U)P,H:?06,A%E(F#T^;8.IJ17_7G0!LJJ+A'E( M&$7"?!"LT0630Q=,E%VPF\I$>;Z5V@^WO#AF;QB/LG!_.']%4KEX+B/R2]V@ MK-6W&R8GFGLA-NMBA'TQPD%NLHN$>4@81<)\$*PAV.E!L%.E8#^PS98OUT'. MR(9'2U:H=2?)5\7#)4M%L&+%+)WE(DH"(74M7W]=AI#W;W]KTZVR9%_=[F"Z M?GRP?"%<9#T;"7.0,!<)\Y PBH3Y(%BC'6:'=IBI9S$?Z'UUP"XTGV:BZ F1 MD2 6LC&"%6;9=K4EX--LGG$7IDWQ[*!J#;.(@O32O4=;MVRGS MB_.:BQ$V\L)7R>A)T M2BC:$WU'SEANE+]]YP],EZ< MK*G..P9A&!4']B#>GX(,MF*=\>AO&7.I(92U>C<$DF9!:3:4YD!I+I3F06FT MHAVWUZ3EU)>/JMKL"J/N"J/S^S<7/ M=^H-ZBUV),V&TAPHS872/"B-0FD^BM9LB=JOU97>U^)]EKY>9JG@61P7)S9I M*M?$6U (NC^^M0H6Z MM5":!:794)H#I;E0F@>E42C-1]&:K5'[QOH4.N&!>L)0F@6EV5": Z6Y4)H' MI5$HS4?1FMU1V\BZVJ ].:?:_T0JU$ZN:,?S%',R:YOX= RTNP8ZT(&X4)H' MI5$HS4?1F@JNS5]=[?Z>4W!E!%]2+]3BU4\=7'-BMJFW8Z#=-="!#L2%TCPH MC4)I/HK6_()2[>@::D?WG'I[+#S5%?I*V#@U%=LEW#70[AKH0 ?B0FD>E$:A M-!]%:TJXMF4-M2U;K3W?=EE[JE&]M0IU7:$T&TISH#072O.@- JE^2A:LS5J M;]8PD&M/ VG"W4%I%I1F0VD.E.9":1Z41J$T'T5K=D=MTQIJF_;KUY[J KT; MQCR9J(RFH[:I3\= NVN@ QV("Z5Y4!J%TGP4K:G@VDPUE';45ZX]U?#>ZAV= M3K/GTZD^&KU4;\= NVN@ QV("Z5Y4!J%TGP4K:G>VNPTNIJ=_WWM"34]C5.3 M\HR$.P;:70,=Z$!<*,V#TBB4YJ-H30G7OJ>A]CWOMP]QM*RFU[\\2CE+T;8* M%6IZ0FD6E&9#:0Z4YD)I'I1&H30?16OV16UZ&E#3TX":GE":!:794)H#I;E0 MF@>E42C-1]&:W5&;GL;_;7JJ"_1N&"3-@M)L*,V!TESCU-HUQBW.@@ZHG5ZSYQ=P M>\^;U 5Z-PS4_X72;"C-,4^_B]KZ(3876M:#TBB4YJ-HS5ZHK5U3_;7;=\'G M*-DFK2*'VKA0F@6EV5": Z6Y4)H'I5$HS4?1FIUP='5D[.61L=='QEX@&7N% M9.PEDK'72,9>)!E[E63L99+_#XO8K"UB\[]9Q#WF3%";&$JSH#0;2G.@-!=* M\Z T"J7YYJGM/]8TK>6,U/#HMA8)XZOR-BHY66;;5.SN<'%X]7"KEK?E#4J& M=?CN/B_O KZ*TIS$[%&F:E=369[O;IVR>R*R37F3C(=,B"PI'ZY9$#)>!,C? M/V:9V#\I"AQN8+/X%U!+ P04 " 5.FU7;!,<_+8" #H!P &0 'AL M+W=O.IP\$%!*I%;!Z;&$. ME&HA=8R'6M-IMM3$]GBO?F.\*R\K+&#.Z ^2RFSJG#LHA36NJ+QCN\]0^S$' M3!@5YA?M+/9L[*"D$I+E-5F=(">%?>+'.H<687B(X-<$_R7A[ AJ G!OQ)& M-6%DDK%63 XQEC@*.=LAKM%*30],F(:M[)-"?_:EY.HM43P9+25+[C-&4^#B M/;I^J(A\0A_1O,HKBO4G0;2JF]1[7]F]_0-[7Z!;5LA,H.LBA;2#/^_G#_W@F$)\1"'P>Q1>JGQY H^M#0_2Y#_[W[,S=!\_<(C%YP0*_^0_R< MK83DZH[^ZOK*5F+4+:'KUJ4H<0)31Q4F 7P+3O3NS7#B?>J*YS7%XE<2>Q;= MJ(ENU*<>?:WR%7#$UO8&B=852M$)*>IK<]J5J%4>&V5=N+>1%[K;=DQ_(T;G M%Y.)_P(7'\<],S=NS(U[S> M19RU$+XWF+SP=@1DC;FMVI@#WY@>(U#"JD+:,MFL-FUL9JJW^P=N>^ MYAM2 M"$1AK:C>0'<-;ON*G4A6FDJ[8E+5;3/,5"L&K@'J_9HQN9_H#9KF'OT&4$L# M!!0 ( !4Z;5>%/G,8K , -<; 9 >&PO=V]R:W-H965TDGB5'2MK92[6]L6ZRU- MB+AB.YJJ(QO&$R)5DS_:8LZ["]C*.4WG,D M]DE"^.LW&K-CU\+6:ZY:=FD)HX2F(F(IXG33 MM;[BVV6@X[. 'Q$]BK-MI#-9,?:D&Y.P:SGZA&A,UU(;B/HZT#L:QUJD3N.Y M<%IEEQH\WS[9AUGN*I<5$?2.Q3^C4&Z[UK6%0KHA^UA^9\ZZO@]5Y(EA2P.H,D2O-O\E+\#F< ]FH MP!<4Z!5 "U3P"L SQ3P"\ W M!8(""$R!=@&T38'K K@V!6X*X,84P,YIY!QCI!QLX]'&I^'&QN.-3P..C4<< MGX8<9V-NY],WF_M](DFOP]D1<1VO?'HC6T 9KZ9\E.JE_B"Y.AHI3O8>)%L_ M;5D<4B[>H\'S/I*OZ#/*=J-^=(A"FH8"?>A32:)8?%3'Q)9P*CJV5-UKB;TN MNOJ6=^76=/7O6EXAQ_V$7,=M5>!WS?AT'RN\58OWF_&O.]Z(#_ZG=Y(VXD.3 MW'/]XXK\)EY[E7XW"1WMQ9?F.3NU>)+ M\]R=2]Q6*[54#2!E0TC9"%(VAI1-(&532-D, M4C:'E"T@94L@V44E:965I-5DSR_\*/Q[A8_2XLK^L:J,-,K>6D9R&8KN5X(^[VDJT>"@/JOF9:/AK?,24M:' ME T@94-(V0A2-H:432!E4TC9#%(VAY0M(&5+(-E%[?#+VN$#WRC[D)4$4M:' ME T@94-(V0A2-H:432!E4TC9#%(VAY0M(&5+(-E%)0G*2A) WB@'IG>L=XW= MOK5&0,H&D+(AI&P$*1M#RB:0LBFD; 8IFT/*%I"R)9 LKQ'VV1-U_ M[P]02P,$% @ %3IM5]).^ZA) P \PL !D !X;"]W;W)K&ULM59K;],P%/TK5D!H2&-Y]#W:2*,%;=) U_?$2KF5\LX.KN*)X]F,@$-D+ 7%RP:FP+EEPCR^EZ1. MM:8%[M_OV-_EXE',+=4PE?P+BTTR<88.B6%)U]S@Z)UMI(48(Q \'2XDKO2R/V '[W 4!0 H)_!71*0"<76F26RYI10\.QDENB M;#2RV9O_D9 :&,JY?XNRGQ8RZR;11R*K6="I+.BTL8=3*03JQ;*+ M[DZ)3B@N0;#[M<%J8.F*G+"TG&[<[X*]E[/;-\@F]+W1<# (?-R@S;[*ILB> M-_1Z';^*K$GH5A*ZK1*NF6!V%S/7?_R&;D'23<&E++M%=E MVFO-]&*Y9)SE)?VG9HZ)\'8$UFM6;YV'HY$EG-T%%EZ.B) M6F9T3 N.1%:SP/=^GV.\)_URE?0''Z3>8>,TAGFC[L&7P-T[D=GC\'NJ5@Q[ ME\,2<=[9 E4<<(L!D9F^2'M5AH\\N6W"9[*0=D ?+Z4TNP&]MQ7G?/#7U!+ M P04 " 5.FU7O@WHTNH. 3L@ &0 'AL+W=O]OVS8>QO\5PC<<-B"++=F2DEYJ(#%_;(?VFFNZ[<7A7B@V M'0N5)4^2DP;8'W^4K)BF+3-6^NB 88T5\D/*?,(O^8@BKY[2[&N^D+(@WY9Q MDK_O+8IB]:[?SZ<+N0SS\W0E$_6;>9HMPT)]S![Z^2J3X:S*M(S[[F#@]Y=A ME/3&5]6UVVQ\E:Z+.$KD;4;R]7(99L\W,DZ?WO>3\?>_:>2>"RS)#E>+W2#[E.S^3\E;NT_1K M^>'7V?O>H*R1C.6T*!&A^N=13F018_,Y#Q9$NZ\RJ M!LLHV?P;?JN_B)T,KGLD@UMG<$_-,*PS#/AM&Q MF_;K#/ZI)01UAJ!JK,VW6S4-#8MP?)6E3R0K4RM:^4/5OE5NU2)14DKQKLC4 M;R.5KQA_EG%8R!FY#;/BF7S)PB0/*Y'D)$QFY#I35QZDTEZ1DY\)ES)72:,9 MB1(R29.D%M0?4;$@Q4*23RN9A9OLZ;RZ,DF7JS!Y)C]26811G/]$?B!]DB_" M3*$4Y;7].G*#"!!8,M6/NY.J<# ZEHKQ[ZO8\?J)[ZZ? MT:[#[1_,L.(.V_[!D/]\4$G)KX5R2>13&!/5/T9I4_]T M8\W?5A[VRC@#\BS#K+&;15:#(6$<"1,@F*$%;ZL%S_KUW\ILJ@)J&2'OTS"; MD7"URM)'I8Y,_KF.,M6[J#$F42T4/Y-"9BKL5S&U2376DMJJ9@-S-F.%K[.\\H/(]3)=JW_^(J_&(#N];7-#:11*8U :A]($BF9J:,=H=#J*1348 M)1\DC4)I#$KC4)I T4SYN%H^KK4+XM$W)1X5=E9IHGJ?1IU8":UU@J31FN;O M]O*#P6 OKC2D?NIQ(-J4;^3BJS';3]Z5AMLO'U4LU-IV&B>OTP M5G_(*C1$11B37\J/BZD*^.1Z]ACE::8\^3!H;"FJ%0FD42F-0&H?2!(IF M"DD;HLZHJW@ M4JA- JE,2B-0VD"13/EHSU4YU43]?LL,CN_M8KLM?4'1TTR M:#T8E,:A-(&BF8K1GJIC-RKKL'32A 7JGT)I%$IC4!J'T@2*9NI%.ZM.T%6 M@IJN4!J%TAB4QJ$T@:*9\M'6JV.UZ,9WF_4+FQ!4/]*+\GP=)E-9668;=ZST MRH[[9/8R6BL):L1":0Q*XS7-VYG\#+U+USN8)'5ALSK:9W7L1JL.26VG52=% M,:C+"J51*(U!:1Q*$RB:N0I-6[?NH*,HYD)=6RB-0FD,2N-0FD#13/EHU]:U MVGKCZSR714[6R4QF9!DFX68Q*"D6JK1%&C/LY6D[/RQ88B)5FMJ%6IJ+-R14.Y4E,%O6JQIDRFBV68?6U4%-24AM)H M37/6 M*E"EF@+1OK%[JF_\AN'.)$V*3 4E1)0QRH"0VE42B-06D< M2A,HFBD^;4*[79G0+M2$AM(HE,:@- ZE"13-E(\VH5V["?WOM=*-+)^*AN5$ M?G<&+\,L4<*Z?_Z>00_4GH;2:$US1GO##^S*OQY"_6LHC4)I#$KC4)I MT4SY:/]Z:/>OZQ[G>3?RE?.[1L% ;6LHC=:T_;F2LQ_*H*7R$TL5J%+-1M:& M]+!#0WHOCK%OTW@]*^V #B*:_3Y:*PSJ6D-I#$KC4)I T4RU[FP@T=D.$M@M M)+![2& WD<#N(H'=1J(+UWJH7>NAW;5N%=&@IC241H?-]K![$-&@IO2)I0I4 MJ68C:U-Z:#>ED1'M8Z436ZA2GS^&WZ+E>MDH(JAQ#:51*(U!:1Q*$RB:*4AM M@@_]KH(6U,:&TBB4QJ T#J4)%,V4C[:QA_9M*CX]RBPO=P75&U=1VOGLGU0R:K 4QCPT.]92B-0FD,2N-0FD#13!EIAWIXV578@9K'4!J% MTAB4QJ$T@:*9>^YI\WADW[>B?DDPG9,D+S$MKIYI7Y#__CF M6="*,"B-0VD"13-%HBWBD=TBKC9^C9_)3;DZXZ.>5',IWS#_:M04U%B&TBB4 MQJ T#J4)%,V4F3:I1VY'H6P$=8VA- JE,2B-0VD"13/EHUWCD7W?C:IW,BV_ M*J[)@JRR="KE3/4_CV$6A?>QK)8CEM*:*XFEV79-1Z.ZH*9R3=OWURZ&P[U= M1*'%,BB-0VD"13.%L[/QL-TOQH:W4YYRV2O46E%0UQE*8U :A]($BF;*3CO8 M(Z^K< ?UFZ$T"J4Q*(U#:0)%,^6C_>:1?='UKF#":J/!1JE O>6:9KQ^Y^\_ M&:+0,AF4QJ$T@:*9$M">\UBR33TEG@QRH/0VE42B-06D<2A,HFJE%;4^/ MNK*G1U![&DJC4!J#TCB4)E T\Q@0;4][=OM71;BH.BAKFF;5[G5)E#SDUMFZ MG=A6-U :A=(8E,9KVMY3TX.%K*A"34%H*]JS6]''!%%M$%4>N1>]:;=U>ZFM M10/UGZ$T!J7QFN9XAFB&!Z_QH$HU5:.=9<^^_+G5B.C+4]K1B,A>R]8J@]K4 M4!J#TCB4)E T4XO:IO:Z6MSL07UH*(U":0Q*XU":0-%,^6BSVK.;U6\9$4'= M9BB-0FD,2N,U;7]$M!_:NG"1O9V3\NSKH+L:$&&/S8-:S% :@])X30L,R8R" M? M':J8$$N5%ID3R*,F=*E)I)^_(X[%7KZW@H#0* MI3$HC4-I D4S1:A=:K^KD_Q\J!$-I5$HC4%I'$H3*)HI'VU7^W:[^K2E/79( M:ZE W62_X3 _[^ POZ94HX/#_!I2^0>I1%.JX-AA?KYV:WW[HN(OBRC3+^E= MVU_2>^L&F'E!/LW)A^BQG&>?$F.@1C"41J$T!J5Q*$V@:*8RM1'LC[J*,5 _ M&$JC4!J#TCB4)E T4S[:-_;MOG'5ZZC1<;SI=>K'!V2YCHMH%4>R::9[4S.= MW5YV<#[8>W-A8B^ZM22@=B^4QJ$T@:*9DM"VL/_*BN+_0ZS[OF/2[3?0NN>" MVLI0&H/2.)0F4#13IMI6]KNRE7VHK0RE42B-06D<2A,HFBD?;2O[=A_WA&/2 M:X(QE[C8GW%,[.6T;G^HB0RE\8;O(S@X=%V@RC3;59O#OMU\_3]$KS(E815T M,VL[)61!#6@HC4)I#$KC4)I T0QM!MJ4#KK:HCF VLE0&H72&)3&H32!HIGR MT79R8%_T7+Z(;)^8U8#=9;BCO7!E+Z-UVT.]8"B-0VD"13/;7GO!@=T+KF+. M)I!5!R>=.%.OJ8ZY$&DP<"_W90'U?:$T!J5Q*$V@:*8LM"\=V'WISW*VWD20 M=$ZR(QII%,:PR<+9?UES8B^^M2R@IC"4QJ$T@:*9LM"F<&!U#=L/@K>[Z+XZ MD+67W'HD G6-H30&I7$H3:!HIKZT:QQTM6=% %U0#*51*(U!:1Q*$RB:*1_M M, =VA[D\ZR]*'LJ^YR%-9V0>1L6")/(A+:)J"5>U8&=N.C1GU1JO1DW92W-< MLBRW]FE:D#6QYVVM(*CY"Z5Q*$V@:*:"M/D;V+>\>&N *U-.ZI-(3PEV4*<8 M2J-0&H/2.)0F4#13:]HI#BZZ"G;0ADT<'N MK6N/)_:^NW5[_X#IUWC&GX3IWWHGJ>E_CQU>K\$%^#+.'2,DMEG-5U."\ M' 5FY5D#+Q^*=/6^Y_3(?5H4Z;+Z<2'#FXML-N5[&4+YQ$VVV,K\QG$UW=,-NF?RZ6V3J M:EA15E'"4A'Q%&5L?3FXPA<*A<1?$7L01Y]1/I0[SK_G%Q]7EP,K_T4L M9DN9(ZCZ<\_F+(YSDOH=_Y;0064S5SS^_$P/B\&KP=Q1P>8\_A:MY/9R,!Z@ M%5O3?2QO^,,?K!R0F_.6/!;%O^BAE+4&:+D7DB>ELOH%290>_M+'TA%'"HJC M5R"E FDK."\HV*6"W=>"4RHX?2VXI8+;5\$K%;S"]P=G%9[VJ:2S:<8?4)9+ M*UK^H0A7H:T<'*7YS+J5F?HV4GIR=L-B*MD*+6@FG]"7C*:"%C$7B*8K=)6I M.QNFII(4Z#<4,B:4:+1"48KF/$W+^?$MDELDMPS]N6,9/:CS=7%GSI,=39_> MHX_IJ2FQ4=,I+2PLZ!.]BQEZZS-)HUB\4V:^WOKH[9MWZ$UNYLN6 M[X62%-.A5 /.?_9P60[N^C X\L+@;/29IW(K4)"NV$JC[YOU)P;]H7)TY6WR M[.UK8@3>LMT'9%OO$;&(K?D]\_[J1#>_)SUT*SNLZ52QSKUAB_M:N;: M!<\^=>:BOS\I4?11LD3\HYLT!ZZCY^:I_$+LZ))=#E2N%BR[9X/9K[]@S_I= M%S%(F \)"R!A(1"L$6FGBK1CHL^"1U5'A M%<*CMI#?%7))6RCH"CE>6R@T#NJ5+AM7+AN?E N_<$ECM3LZW-T5=_GS^A6M M\Z5NOD#-CG.E=A%J-'OJLP,)\R%A 20L!((U)L*DF@B3,V7)"62D(6$^)"R MA(5 L$:DL55O;ZV?7SN6C./<-7&<42M5:J3&$[W6N]=]0>^UMMG7JA.]C,@ U&9:T MXP7_T21INIC4+B8G5:6KY;_[2$1%.EIR(7O4'[.%4],2*,T'I06@M!"*UHQ\ MW;_ YVI@8- .!BC-!Z4%H+00BM8,>-W&P !]C)+16)&W%^T:F?:272-B=VJ0 MQE2G )VC>X'K]@4V]R]Z%R"WA]= &Q ]+ :@%D.-1?>%ZE/W"[!QD]JM/D(P MB1*:TD/3O]@&:1T.VC I?F@M "4%D+1FO&NNP9X=*Z: [1U+P,.2?-!:0$H M+82B-0->]SRPN>G1K^:,NYG%<.>W4V$LL-(_NM=ZK&P78 MN#OM7WXF/RK(<[.EDV?\#PT&H 9#H\'FN]!Z;T[,>_-V\5ED>?M-?3RJ/WD' M[J4:9,:?FI) :3XH+0"EA5"T9MCKI@+!9ZI!!'([/P>E^:"T )060M&: :]; M',3VVM]5S<)B'%/ MVKL"E9AF/<5M[X'N]/N8#$!-AAJ3]@M5J-Z5$_.N_!.C(DHW^;NT)!+YB3E] ML>ENECOOP.9F4R<[N&O2Z;QV S490M&:L:BW^^2TXPIJ1;!F14QH7+^1XW++ MLAY]4;.QD\L%:/L E!: TD(H6G,2U#T)2.GLSXXQ_Z>U/M[ M8M[?]UX?C+OOKB8=[X$>/NAC,@ U&6I,VI/6 F%X=%@Z8=FF.-8N5/G?I_)P M^K2Z6QV=ORH.C+?N7^.+.=;<]_%%<#@87^,/Y_0_TVP3I0+%;*U,61]&:@9F MAZ/OAPO)=\51[3LN)4^*CUM&5RS+!=3W:\[E\T5NH/H/"+/_ 5!+ P04 M" 5.FU722)PX9$% ,&@ &0 'AL+W=OB>.]W?,CC<"W5-[T$,.0Q2X6^["V-R=_U^SI>0L;T MLY5!DS^*H6?9TK8(DCRM(^#8)!/V-<]$9#-S95HZ$L3,H%3!71198Q M]70%J5Q?]L+>9N">+Y;&#O1'PYPMX ',EWRJ\*U?X'5"%*(C67!\-\*)I"FEA/J\;UBVJME M6L+MYPWW#\YX-&;&-$QD^C=/S/*R=]XC"I>"G);7S+#14,DU478V0,@,)F3)EGLAGQ81FSE^:,)&0L<*1!6 8C"9' MY - .6ZG\YCGK)PZ93PA7)")%*)R]YJ;)3%+(+?\>\$3-Y%(A:_:<+$@5U5>EU72'U1?D3@JSU.2]2"!Y3M]'#]9NI!LW7E$OPP?(CTD4O"4TH!'Y M\G!-7K]ZX^$;U>&)'-^3G7QC:<. 4!%G>OOP?D(!Y,5UU(]D?%"@0L1^;$9 M;'.)5Y*M_GKV/Z4YR]N1-@>Z[*Q6\JRC0)]UH/5YK?7Y3P.=X3K.\Y1#:_&4]*>. MWB+=:G0R[*]:1%[4(B^\(IUKN/,,2F\3Z:4_T"%AT.!"T%$@*\:_6/$M0 M_ M[MA*59;)0IA6)4LF@ZV AJ?M$0UI(YKZ5^MB]A_"7PF3KY]'F'R2QH+6^\<8 MM-[ WU3)I(C-FU85O<(.]6.#/&'450)T@31A S6A%Q/V*.:*P1[5'#90$?K7 M^<-CCZA]QQYY5F2MNGK%'NK,!G/"05=9T 4,A0T.A5[ V"<+2@;A^78:'.]: M!!HH"?U8,EG:'7.U&S8*=_0[UG<_GT,=U.!/>-%59+M )MH@$_4"R!Z1K1CL M4=^T@17JAY6O3'$V2P%KM=Z '9$;$>,#GBMW!=G/]5!?-8A$:4=!IEV@#VW0 MA_H//GL$.=H[R UT4#]T?,0SJ%G&3 'Z"@_?Y"&'F..Y])9G?.-' 4HO>?Z6 MW-Y.<.UN%O5Q\A_2X*P[IK[A5OTK2PNP'UJ.MM.TT.0:S\**SXKR$/W7"A2> MY? PM[ 3W>IA/R+#&['"4Q^>GBUY6>5AV,9"MZK=J7W,-P*T.#XUV[3-H@&_4CVW;6D"+' M'R&% @%K3 ?,-K;I"[!-7Z!5N[,7:=? '_7#WR$E-%5P9-@C;I/$42RS'#?M MMMMQ#Z90@J"!F[2O:\*:_H.,A2AP]#-3"WA6)A7ERZJD"SBF#1S3KN"8=@'' M40/'D1^.)P6NT\Q51ER%B;LX.(A4922,K :ETH3AG^VGV()"*+4Y.P,1+S-< M-EL;5T%;J@:#]E2-&DB/_)!^2*I^PG7]@:5N]QX#)/HM87,#=PVA26R[$V6OOAZMKSK&98._F5[>D^#>8L$QGU*8(VEP?(88J&ULQ5E; M3^,X%/XK5G:T @G(I1<*VU:")J,=:1DA$#L/JWUP$[>U2.*.[;1TM3]^;2?D MTG$-G;4$#S1QSOF._7WVL8\\WA+ZS%8(NR^(5RB"[(&N4 MBR\+0C/(Q2M=NFQ-$4R44Y:Z@><-W0SBW)F.5=L]G8Y)P5.\'+%98,[':_A$CTB_K2^I^+-K5$2G*&<89(#BA83Y\:_COR1 M=% 6?V*T9:UG((X12%',) <7/!LU0FDHDT8_O%:A3QY2. M[>=7],]J\&(P<\C0C*3?<,)7$V?D@ 0M8)'R![+]'54#&DB\F*1,_0?;TO;R MR@%QP3C)*F?1@PSGY2]\J8AH.0@=D9!N7 6^+0,'!P+WP!W)^8J!*$]0HO$/S?Y7!G]7D% S$;PR<1L8 1_1 M^@+TO#,0>$%/TY_9^]T#W7#^7_3HIZ-WR.C5TZ*G\/H'\$),Q4HF5*>KT5,F MMFNVAC&:.")S,40WR)G^^HL_]'[3D6H3++0)%ED"Z]#?K^GO*_3>(3E7D*+S M^8^+\D:LR'R)1*;F8+X#;;M[N%/--UM($_#7'P(2?.$H8W_K1.S;%-$F6&@3 M++($UA%Q4(LX,*ZA1T[B9X 9*X0Z24%QO@1K1#%)SEY;Q48/9%@<(P9.1#YE M4E!VJE/,&.Q8Q6R"A2780(')@\EFZHW=35L&DT6'VV'-[=#([0-BG.*8"P[5 M&@#W*U3I60G;4N*K5N#*J\;7(YHAJJ7YK M"[GZ(0WWAI[\ZPYO9NS L8R^,VAD*6B'4]]KRB#/R.I3+@Z\9)DK&N-VIHH) MX]KRI@24/ZVI,MJCTASV6"[?%3.R%;-+9:NB](U4?E/%.4K.X091F17*0X^6 M0R/2L8G *EKXQBA]#V1E 1KT00)WNA(XLM6CKA)!HT1@/H&V=M5UM:O"9N,] M ^A%SG.DE2;03;5@?WIKK7I=JU!O=;D_;4NK8D8G"K>51M]9WFS?J1F^O_=:_GOF: M]E#>A:KKM@:^O$B]@W2)7;G'!.,O6X0C!! M5!J([PM"^.N+#%#?$$__ U!+ P04 " 5.FU7J@\3%1D# "O"0 &0 M 'AL+W=OY M E#D-4N9'%LKI?(+VY;1"C(J.SP'AC,++C*JL"N6MLP%T-@89:GM.4[?SFC" MK'!DQJ8B'/%"I0F#J2"RR#(JWB:0\LW8CG"YA!NHAGPKL MV;67.,F R80S(F QMB[=BXGK:0.SXC&!C6RTB4YESOFS[MS&8\O11)!"I+0+ MBG]KN((TU9Z0XZ5R:M4QM6&SO?7^PR2/R/B6Q6HVMP"(Q+&B1JGN^ M^0E50CWM+^*I-+]D4ZUU+!(54O&L,D:"+&'E/WVMA&@8^-X1 Z\R,$+892!# M>4T5#4>";XC0J]&;;IA4C37")4SORDP)G$W03H4W+T6BWLXGF%A,KGB&NRVI MT>N1S4%HT6:E9VRAL!E*>E2$TF/W ML$=],"]D3B,86WCR)(@U6.&73V[?^=["VZUYNVW>PPDL$\82ML3JQOV+@)PE MK)+C*_E]4)B2NO3;,W[UZ5^'PX'?]4?V^@!.K\;IM>(8C4B,U18#B]_-TMMC MZ?K#X6&4?HW2;T5Y+*OXO0C]/83SGA,,W,,0@QIBT J!A?^1O1GLP;2P!#5+ MT%K:3^8;AY)#N M"W H@3+$H*&B&W2"(V7E.KMOKG-JC9\(5@48-LFZ'=\[0M:X#=SWEORI1.X> MD>=TND> O!V0=VKYGPKF[6]BOS,,_B&S&W=H!F)I7@J21+Q@JKQ.Z]'Z-7)9 MWL&[Y>53YHX*K#U)4EB@J=,9X#$4Y>N@["B>FQMYSA7>[Z:YPA<5"+T YQ>< MJVU'!ZC?:.$?4$L#!!0 ( !4Z;5<"W@>18P0 .03 9 >&PO=V]R M:W-H965TTY3M_.*./6 M>)B/W0BNW(N;Q1RB5\9;-7>,S&N/ GQU;S68V8$*<3: M0%#\V< 4TM0@X3S^+$&MRJ91W']^0?\Q=QZ=>:(*IB+]C"C%ED@CC6CF(8]^KHWQ8MPD MRH.6^)6AGAY/XGB=K5.J84X^ZP0DF8H,4RXQN; !V5>/ODDN$X4F?$YS!OTHW;]L$7?QAA5@?)> G7CM0(^P.J2^,X'XCF> MWS"?Z>GJ7I,[WV9]]J^MUX+A5UGCYWC^:UEC:)]H+=G36M.G%(@6Y(Y*X/H# M^07+&V;)%_I,?K\7:4IP16^IG/_1E 6%G:#9CJF2UVI%8QA9F),*Y :L\??? MN7WGAR8*N@2+N@2;=016(RNHR K:T,&/3]NES4 !>&;NC4Q69-< '^[>1J'OX/<_I'),'!Z _? NV,Q)-?W'>_ Q]/@9F_#U=R]JMR]:G7WD6-#E+*_ M<H2+.H2;-816(VLL"(K_/8=(CQ:SGX0!KV#&G(LY7E.>" 5 M-6#U0_>P4AY+?70#/W";ZX?K[%I>I]7=22;6/,_ I2D@$F*QY'E!8>;DLFN( M1=X0Q[6&F!4-,98;QC4@%YI(%,;#R4O%:>YV6Z=T;AIWBA:5:+5*[3F'>_^L M*Z-UUO8.*NZ9K*54*;9@2-1"BNQ$YAK):;5\-CE=HD4E6GT5^/W@B)V.K-;9 M\7;L>/]%R]6.>G;DNT2+2K2V7JXK@_6@[TYA;NNYX83.KP38[[#]GA\<]K5- M8J$3'';UIZ'-WD0KW+7W;BTRD,O\NDCAHL5E7AQ%J]'J2FJ27\0&ULM59=;YLP%/TK%JNF3EK+5TA( MER UJ:95VM:H:;>':0\.W 2K8#/;2=I_/YL0!@EAZY2\)!CN.9QSN)@[6#/^ M)&( B9[3A(JA$4N979FF"&-(L;AD&5!U9O@M0H[ZF!U>,M^\?Y@M9(O)?M"YJ+0.%2R%96H"5@I30S3]^+H*H .S. 8!3 )Q_!;@% MP,V-;I3EMFZPQ,& LS7BNEJQZ8,\FQRMW!"J'^-4(K2DZOP&)22+>J9K'Z0TZ/WN'SA"A MZ"%F2X%I) :F5-KT'CJ4I%?3CLRI$MQ)2\;/)Y(:UT\RJ7\DKD>$0AH9ZYP3P M%1C!VS=VU_K09/E(9+4 W#( MXT]>& 2)^AP=ZBG+6- =Y.F%#;4W9Q:[R.K MP//[G8&YJKK;+^K:7:>R?9&GK'#.!(9+4 _#( M_W1;@[_7A8[7\W=:]2]%-=7]4G6_5?68I:D:&^XF!SNT%?_:!W0DLII5V_KS M4;=.TJ,%[9$R.!9;/83*9&.?KD\+[NKGR77M[DZC-E5Y?F>G4\W*>*9GXR^8 M+P@5*(&Y@EF7/=7I?#-N;A:29?G$-F-2S7_Y8:Q&=."Z0%V?,R:W"ST$ED-_ M\!M02P,$% @ %3IM5R>4-]&ULM9MK;]LV%(;_"N$-0P>DL27?,\= 8]T*M%G0(-V'81\4 MB[:%2J)'TD[[[T==+%F.3-OKFWR()9GG.:+YBD*V MM9)R?=-NB_F*QKZX9FN:J&\6C,>^5+M\V19K3OT@,XJCMMGI#-JQ'R:MZ20[ M]L"G$[:149C0!T[$)HY]_N..1NSEMF6T=@>^A,N53 ^TIY.UOZ2/5#ZM'[C: M:Y>4((QI(D*6$$X7MZT/QHUG=E.#K,77D+Z(O6V2=N69L6_ISL?@MM5)SXA& M="Y3A*\^MG1&HR@EJ?/XMX"V2I^IX?[VCNYDG5>=>?8%G;'HKS"0J]O6J$4" MNO WD?S"7CQ:=*B?\N8L$ME_\I*W[:O&\XV0+"Z,U1G$89)_^M^+'V+/0'&: M#^H5!_UR#06$P.-=@6!@,SS48%0:C;'3S MXDWN?F'D?A='7UZM,B[7W^?M*5RGT+:\\+57>[* M/.*J2SXK1RM!["2@08.]I;';VY1>?*W#AJ[I[OW6@P]_3F]VR[,S=ZFI'LEBKN9KSN M<14WB9C\_4DU)!\EC<4_38+-J;UF:AHV;L3:G]/;EHH+@O(M;4U_^\48=/YH M4@L29B%A-A+F(&$N$N:!8#4%]DH%]G3TJ14*R6B28ZYBT'F(KWIV$Z-3OHW:6_WA79>,ZNA67?TJIE]7C-'V_U+AQT)\T"P MVK#WRV'O:X?]4QB'D@9D[7.94$XV2:A"Y[LP(6+E*W>-83)']O=^\?'A$&N] M7CJ7G/9G(_TYI_VY2'\>"%83P* 4P$ K@ ?_A[J3E[M+ONF*;[S4M=1+(P\2 M9@U>S0>'8CG9PD&>D(N$>2!832O#4BM#K58>*0^I(!_(@WH^HYRK>>-1LOFW M)GUH29?J PFSD# ;"7.0,!<)\T"PFNI&I>I&;W)O/$(J$ FSD# ;"7.0,!<) M\T"PF@+'I0+'^AA93GZN2!!NPX F >&^I%=D3?E-T9=H?]@WB)=.H@82X2YH%@-8D9G2J/U=&*[,\'\I3>?#?FI;2F MEVH(2K.@-!M*%!I3&_G-$B1^S32()6Q3IAU.9"#WY8C4B:59!VT\C]$9CL]L] MB*Y0KPZ4YD)I'HI6UUF58S>T"=3CI:)&94%3ZU":!:794)H#I;E0FH>BU?57 M9=B-WMN$7&2V>0:E65":#:4Y4)H+I7DH6EV*5=;?T*?][S?Q,^5IG%V7S[;J M 23/_H=";-3^J="+3('/H#0+2K.A- =*PM"A%&58DP MM&GF@VFL%BG/F,*@!0DHS8+2;"C-@=+<@C:L36'7P]&AT-ZBWF!4!0?CW(I# M)K0KHC9IO,[>EE4J"UG3ZX=W>NC%"H/6&DYTV" _J,\;Q02M/D!I+I3FH6CU M=TFK H2I+T#\KU>!"F8MR=7IC\<'U]-,[_M2,9WIU89Z=: T%TKSCOPBG>H7 MJ:NBJA.8VN3O]&DOT#4* %H/@-(L*,V&TAPHS872O()6?T'SX+&R+J).O:JO+[ICZ_WQC SKQUTJ,O M%ADTW7^BV\=OG:"GX4!I+I3FH6BY\MI[RY%BRI?9TC1!YFEM,E_341XME[]] MR!9]'1R_,VYF1L-QR[BQ\\5M%3Y?:_?9Y\LP$22B"^6J&ULM5IM;^(X M$/XK%KT6E>Z==*?[X 8#N4UBUC9E]W0__IP7 @G! M"^WT"^3%\SSV/,8S'CS8,/Y5+"F5Z'L4QF+86$JYNFJUA+^D$1%-MJ*Q>C-G M/")2W?)%2ZPX);/4* I;IF'8K8@$<6,T2)]-^&C UC(,8CKA2*RCB/ ?-S1D MFV$#-[8/'H+%4B8/6J/!BBSHE,HOJPE7=ZT"919$-!8!BQ&G\V'C&E]YN)\8 MI"U^#^A&[%VC9"A/C'U-;FYGPX:1](B&U)<)!%%?SW1,PS!!4OWXEH,V"L[$ M#>2*"CEGX1S"3RV&CUT S.B?K4#ZPS4>:#\A*\'P6BO03;?*V M1@/Y:R%9E!NK'D1!G'V3[[DC]@P43KV!F1N858/.$8-V;M ^E:&3&W1.9;!R M ^M4 SLWL%/?9\Y*/>T0248#SC:()ZT56G*1RI5:*P<'<3*SII*KMX&RDZ// M++[T62PY"]6K!;J-)>542($NT32;;8C-T?%F[QTJ21"*#\K@R]1![]]]0.]0 M$*/')5L+$L_$H"551Q.ZEI]WZB;KE'FD4VUTI[B6 KGQC,YJ[!V]?5]CWU(. M*KQD;KUT8VH!IW351&WC IF&V:[IS_AT<[-N.*]C=U_'[NG-'>HK,RX#,T(5S^0)]5B+R-GY7, M*BA)=!VQ=2SK1,X@[10R"8K/(]OJJ3G_O"^>EO=<\4YA="$9O3I&"Q>,)6=; MA;,MK;,3!S]0$B)72"(INA:"JL5YNG[Z1X5P)%G)_9R3>$&3ZSH-,B9KKW^X M;_6P959DT/;H7!E.)'4A2;TZTF[/['?KQ; +,6RM&$X@) ^>UDGJ5!O][ /> MCEUQKGTP2:I-G$,4W.Y5W'4(<]#&TP[FA8M$MW!55^NJ<1()MJY"<\XB%%=2 MC6";:M1Y4HM^;E" !'.Z!^J8O4Y%G<,V1D4;H"Z5M.D5VO3T:\JQG*].""W4 MN4) @CF08"XDF <$5A*W7XC;?Y,LK ^I,R28 PGF0H)Y0& EG;&QV^ 9KXM& MN;TV')W0QJEI4$YDT2Z)<3+E8!JL+]*DY:=9.$]"R"RB: XKF@J)Y4&CE^;2K MY^#>VZ2MH,4=4#0'%,T%1?.@T,IR[RH\6%M82.MWXSV][S?Y#ULM%-Q761!9 MT%JY,UAL[L?@IM'I5$,U:/GF1%87E-4[PKJ7@&7.;^W]PQY1ODC/0@CD)]E_ M]M=G\;0X;W&=GC*H/+_!5V-<\]S!5VYVFF('GQWNN"-\$:AH'M*YHC*:795B M\.R\1'8CV2K]?_^)2&PO=V]R:W-H965TLIW,T@(>.1&[/*?\VP-D M[#"R7.L8>$HWB50!>SSB>K*DK$75?@]'EF.:A%DL)+*@N+?'B:094Q!>$/B5P&\*@@N"H!($U]805H+PVAJB M2A!I]B4L37I*)1T/.3L0KK+133WHSZ75"#@MU,A:2(YO4]3)\2<$%C&9IME.0DP,B@G+MSM)]5"YF8*D:29NT>=Y M,24W[V[).V(3H3(%20OR7*12O,<@/O^9L)U =S&T)?9&M52V?E"WW+K3< M)Q]9(1-!9D4,L4$_:]?W6_0V4JQ1>D>4$Z_5< ';#O&=]\1S/-_0GNGU5%6FQ.1\F7^Z60')>2OTT?N[0+S'9J?1V( M+5W!R,(%5 #?@S7^]1QIPFKV;,': MK;%VKQBKQ7'R;G%!U>0TPYV(7R-&E.WF%U"6HN[IK',Z;J^!T9CE-1$:LT*O M@<^8%05F=+T:7>^J$?G3\-KM+\#K707/F/4=/&/6=_",69?@]:U&P'5>#XO. MCSI,GD!R5EX(LF^$QO_@(141XR6'R 0(K-=X:1#J[*B*>D\A<;I/8\!C'KD1 M .03DT!<]2ND.4"7T?KJ\V#/M WXA-W,'4-\9FZ M"AGB]_W!K&^*N\Y@5MZ=[-<&E3>OCY1OTD*0#-;8.*?3Q?G/R\M,69!LJP_? M2R;Q**\?$[P E<)^'[-D$554!745\KQ?U!+ P04 " 5.FU7HPA<-XD% M "N)P &0 'AL+W=O61YLDSJ6$@.Z2+DVBGOMBZHO-K".48!U=]?QG70?OKM P&!"2&X4 MY4T,ZYG?++/#'S/9^9[Q>[&A5**O:9*)L]%&RNWI>"S"#4V)^,BV-%/?K!E/ MB52G_&XLMIR2*'=*D[%I&)-Q2N)LM)CG8]=\,6<[F<09O>9([-*4\&\7-&'[ MLQ$>/0[W%PC/2EW#)VKT\NH[.1H6=$$QI*C2#JXX$N:9)HDIK'?R5T5,74CH?' MC_0@OWAU,;=$T"5+_HXCN3D;S48HHFNR2^0-VW^BY04YFA>R1.1_T;ZT-48H MW G)TM)9S2"-L^*3?"T3<>"@.-T.9NE@MAWL)QRLTL$:&L$N'>RA$9S2P1GJ M,"D=)GGNBV3EF?:()(LY9WO$M;6BZ8-\N7)OE> XTY6UDEQ]&RL_N?A=%>\5 M$P)=4XY6&\(I^A6MBC)#;(W.,QE'<;+3ZX]6--SQ6,94(/]KF.PB&J$U9RE: MLG2[DR2O%>7D$Y[%V=TA]!>/2A(GXH/""STBYF.IYJ]G,0[+N5X4_['*6Y4\\S%Y%V8O<$6W'Y%EG"#3,*V.^2R'NYM= ME_-CT?T?BQ[TNWLT5.ZXR[V12ZLJ1"OG64_PCFOF!%T0$8>(9!'R= G2Z 3= M?M/%EJHZ6R9$B!-TF>E"5)[HSSTK!M%G*C?CA\,% M/S;#AF/9V&K:>5UVV+8=HVGG=]G-'&-J-NV"WAR]<@6<:@61R2#-U0 MDDCU "';6)($?=*GFU!+PN7E)2H=U#/EZFK9E>G>>"]]7D#"/$B8#PD+@&"- M"IA5%3![;S\I9I E @GS(&$^)"P @C5*Q*U*Q(5_H+E'XF<;CNO.6HH[S,P; M9N8/,PMZ+_>5R<1&_3)I]*;S2_9 A<[GC?I0FJL/5Y*%]TJ%#X?RGV'7": T'Y060-&::W_02,#O36W+&4%5"B3- Z7YH+0 BM:L%+.N M%'.82O!:$D2N$L\(;\D]%$''F$UQ2W@[S%S'G;5?S(;1_&&TH,ML:ME6]YL MKMLBN/>5^FE)[4P0:$L#E.:!TGQ06@!%:ZYQW=? ]KN33J V0EDID#0/E.:# MT@(H6K-2ZOX+[F_ O%$+#!_W-*;&U&KW%#K,L(7-J=M6VHX6B6GA25MI.W 3 MT[7:OW'[<_3:-:B;,_B9[DQQ#_YQC;[HMX7._ $U/LHT0](\4)H/2@N@:,V5 MK3M&>/KN=!BTJ01*\T!I/B@M@*(U*Z7N+.'>KL2;Z?#L^*U_IJ33:@OQ,#MO MH)T_T"[HS])K5Z%NWN#^[LUCG_QI'09JAY19AJ1YH#0?E!9 T9K_5:_;2*;Q MWG38!&TZ@=(\4)H/2@N@:,U*J9M.9F^KXJUTN)Q%0P\MTS7:G8>!=MY .W^@ M7="?I9>NPOA@.U%*^5V^\4NH+.XR66SHJ$:KS67G^9:JUO@%/EWBCG$/G_K% MUK$:7^QD^TSX79P)E-"U"F5\G*I+Y\7FL.)$LFV^F>F62&PO M=V]R:W-H965T\YV&KHIZRK82V)?[OO.WYUS-]Y)=:LK $/N M:B[T)*B,:49AJ/,*:JK/9 ,"OZREJJG!K2I#W2B@A0/5/(RCZ#RL*1-!-G:V M:Y6-Y<9P)N!:$;VI:ZI^3X'+W208!'O##2LK8PUA-FYH"4LP7YMKA;NP8RE8 M#4(S*8B"]22X&(P6J?5W#M\8[/3!FE@E*REO[>9+,0DB>R#@D!O+0/&UA1EP M;HGP&+]:SJ +:8&'ZSW[)Z<=M:RHAIGDWUEAJDGP/B %K.F&FQNY^PRMGJ'E MRR77[DEVWG<8!23?:"/K%HPGJ)GP;WK7YN$ @#S]@+@%Q \!Z2. I 4DIT9( M6T!Z:H1A"W#20Z_=)6Y.#D/B*$YZSC,['1[WR?F_ MZ(M_CGXO&4EW 1+'EYQ\ 7Y2]!A[=K6I5Z"(7&,CMD6A*P[[WT_W MU<33#1V='0S;#&_&]C#13WK,G_18'//P.L.#/E2#*MT T"27&V'\C>RLW8RY M<*WU@7TZ&,T&/?8YSB0_0O[2^X%V257)A"8Z985S%91UP.]K*>. M?.XHWG.TSA]%]:E>7J;#RNTR4ODOJU6/%2_6KBB>SQJC(QQ1C;UPD63F:G#?W;JO)N5C+/"OY;87J=5$DU9K9,'ON?RXNJW4M_'>RRPK>%EGHD05GU^,+LE93$-MT"#^ MS/AC?7"--)4'(3[I+]>SBQ'6,^(Y3Z5VD:B/#9_R/->>U#P^[YR.]F-JP\/K M9^^_-^05F8>DYE.1_Y7-Y/)B%(S0C,^3=2[OQ.-;OB/D:G^IR.OF+WK<8?$( MI>M:BF)GK&909.7V,WG:!>+ 0/F!#>C.@)H&3H\!VQFP4T=P=@;.J2.X.X.& M^GC+O0EI*-,LSY(FEV*.GE&7.JV9_()>1EPF65[_HN ?[R/T\L4OZ 7* M2O3'4JSKI)S5YV.IIJ<'&:>[J5QMIT)[IL+0>U'*98WBKCF:5Z) DI=)*<&'<.O%:[SH,K*9 M!*X7>.?CS6&, 11S/'R,BKHHZH;$<8]A,03#(6O'/"+L[@F[5L*WE2J7E=J, M]$?2+$FU\2!='1OZ*8?H;WVZ!W-Q'49-^@"*D# PZ'=1Q".^;\!B *8B'F"8 MOK>G[UGI?[BYAOAYG<$886;BI@"*4H\:_+JHT&>>;] #4 YV>Y+K[]GY5G;7 MQ2K)JF;'29=)M>#@6O8[0YM$NXA70>B$!M&O^HD!/]3U@QZ6P9YE8&5YLU^Y M<\YK)(727GDB^0RM$K7)PJ2#[E0\%AI9F8(HQ@SB (J$Q#5@,0C#F,'LPSW[ MT,K^,OV\SNIL*QC5DRNKI*R3K8#N8 M$0!P'G&I^=CWX=R>"- V M2^OZD:I32 1/Q)]7PUG'0*A-_US4E.01RCYDJ. M()R+57A,T@".^?B@_!V3;B4DL0J@EK1.N9!+7JF6(14%S)YU9D'=P*3>!1%3 MI 8UUPX,32:T\.W563$+LE>OA.U:I$62I$@M=#K).>ZFU(-?8Y4&-0&I_AO MU)6N^E6K$KM7>[$)0BO+5C-?9HFRJ MW(Q7V:;9]&#V7>7DX,XC#\BKP!1T$8!RS942 R!&">TAWPHU8E=JU\T:1S)Y MLC[M71VEGW:3+8#R?9,L *).)]7@@'VI;H4;L2NW#URB7*U[E$A990]KF3RH M9:^DC 4]\57,0Q8]'%4%/" IA.>P*-A7O4.6FE';%K MN\L\%^FVPJD^&:F"-^=5I19]+47Z">0,R"SFN)WM_B18!,$(9J;VC;^..PY MJ^Z(7=[U+@3U-!1Z.]1Q6(I<;0+P$@ UG.L1,QX CC*&3:T+X92$IYV #B? M]#X9M)5\U"[YWM]3M.4RN1J5TBGWJ@1;MR5?4HG>@"X M,,"TYT" MAJ9VC7R]YUJT:Y\#9D?FB$ 4:9Z %#4]WUJ!@" >0[Q>P+0BF9J M%\T]YUJT*TRI0\VSMBD$8X'9XD0 S&<.,94!!%/KNZ\2M'*8VN7P_=N;6VLI ML)I_\QXSI+=H4&_Q4-Z.$]%*<^K]R%)@U?W?G*8AO46#>HN'\G: MXN12T%7R+L6FPIM",$S]3BD ^@+7#\U#B!C$T9#TM!"T;2&HO87XSEK0%?2. M$SJ=>@C 5.-LGA4",,(<;+;A,8C#CM=S4$K;-H)^I8WHJ0=AYTM:EW/[>NK^[?]7BLGG! MP+A_1^2D>U?55B^T6*5?,N MP(.04A3-Y9(GJ@/3 /7_N1#R^8L>8/_"RN0_4$L#!!0 ( !4Z;5?>KY.. M600 . 4 9 >&PO=V]R:W-H965TV@>F_KQU"@"1X9U%>P$GN M/=QS[.L>C@_H?U?D%9E7(F#& MLG_I0JXG5FRA!2S))I//;/<9:D*!QDM9)JI/M*MC'0NE&R%97B>K"G):[+_) M6RW$20+V+R2X=8+[W@2O3O#>F^#7"7ZES)Y*I4-"))F..=LAKJ,5FAY48E;9 MBCXM]+R_2*Z>4I4GIR^P4K,HT3.4C$M:K-"M&J>L2&E&234U;(D.40]ZEJC\ MA21##T* %.AC I+03'Q2B=]?$O3QPR?T =$"?5NSC2#%0HQMJ0K5/V>G=5&/ M^Z+DU2GHF].DW)I5VU*QGGYQ[V+""U3OA=HI'08P#-;W; M4Z7ZXJ+8'47G<8FQS"M%\!L1?*,(,R+62/452O4 ?F[HEF1:C#[B>ZC@A%" M'1^W:/=$>6'@MTC['7%\![M.$W7&)FC8!$8VSVKF.$TE[/GT<0@ZU?F.ZP@P\'UXB#NYQ V'$(CAP2XF@/]_D*DVA1O$)%H22A':FHVT$S;I3OA.VHQ%C=E:LQ:KA'1NYJ3/2K]58_4+VH7A(<4E!ZO&:7 M^S'J3E;HXM9DS7JB C<*6^R-]5W)/F[8QT;V3R5P4KTU,U#F _%*"K:\W8C# M6NBC'W>(19$W:K'O"8K;$B7&\JXD/VK(CXSDYQQ*0A<(WI0)%2"J38G)-7 # M]5%WW8<.;G/OB?*#SH9D+.]*\M@Y&B?G/[I^"9SK?8L)W?(7EGJ-@-CQ_-';<+&@JXE M?+1NV.AGIE^?'@_FMY?OH#YM4+1D*+1SY8Y6#7N#NUX\D*^JY1P2+1D*[5S. MH^G#9M=WM?7%77.'L1N&4:P-QW.[=Q%SIM4H<#2,V.\:7ST]S8T\:T__W M(AH2+1D*[5RZHT_%X? ].9"[K.4<$BT9"NUWU/1IV_(;&'_:C] MGZ8O+@A]WVEWY* >V#XY3=)G?U\)7]%"*(N[5/#.7:06,=\?I^TO)"NK Z97 M)B7+J^$:R *X#E#/EXS)PX4^LVH.-:>_ 5!+ P04 " 5.FU7E+R#E'P# M !+$ &0 'AL+W=O;Y'%>17M$9$WME25D$AAVQG M\YHA6&A15=J>XT1V!3&QDH6>NV?)@AY$B0FZ9X ?J@JR+RM4TN/2 M[86:L)-%#7=H@\3'^I[)D=U1"EPAPC$E@*'MTGKK7F>NHP3:XA-&1WYV#90K MCY1^5H.;8FDY:D>H1+E0""B_GM :E:4BR7W\VT*M;DTE/+\^T=]IYZ4SCY"C M-2W_PH78+ZVY!0JTA8=2/-#C>]0Z%"I>3DNN/\&QM74LD!^XH%4KECNH,&F^ MX7,;B#.!Y(P+O%;@#07!-P1^*_!?ND+0"H*7KA"V NVZW?BN Y=" 9,%HT? ME+6DJ0L=?:V6\<)$'92-8/(NECJ1;-!.IEV !U13)C#9@=_E=4Y)CDL,=2[I M%JQAC04L0?8L#VB!Q8$A#AZ_@)/Z=8H$Q"5_(]5W-6)0D]J[7$Y^W*3@]:LW MX!7 !'S8TP.'I. +6T@7U$;LO-WNJMFN]XWM^N"6$K'G(",%*D;TZ;0^GM#; M,G1=_+Q3_%;>)'"#ZBO@.[\!S_'\D?VL7R[WQMSY?ZMG/[QZ+QA^=YA\S?-? M?)AN2%/+U#GZ^T]I#FX$JO@_8YEOV,$X6Q7,:U[#'"TM61$Y8D_(2G[]Q8V< M/\;";A*6FH1EAF"]! 5=@H(I>O*!JJ3+M_>K4Z%:,S'2?'W M'CJ3L-0D+#,$ZV4@ZC(0_<2J$)E,D$E8:A*6&8+U$C3K$C0S6!4:5MA[2N?1 MH"I<&GF^$P^JPJ51$(7.H"A<&H7QW!VO"?/.X?FDPYOW=_=316%2_;UGSB0L M-0G+#,%Z*8B[%,0_L2C$)A-D$I::A&6&8+T$N<[7SL Q6!9:V/FOM^_.!B\" MZQ&KT%>OKKW",&(5^\'P=6'$RG5F7C2H#?99X/YE7N]=D?F4]4IZV;L*[YILV\AVV'"08FVRVT=,&Z;CO9 M!@4 !8A 9 >&PO=V]R:W-H965T5;26X[$JB@(?Y[0G*U' M#G9>'MQE\X74#]SQ<$GF])[*;\M;KN[KA'-:2(U@JBO1SJE>:Y)JA[_;J!.XU,;[EZ_ MT..J\:HQ#T30*@@>:]#;&/2JV-?!JB(=$DG&0\[6B.O2BJ8O*KDJ:Q7@K-0]ZUYR]6NF[.1X MRHHBDZJK2(%(F:(I*V56SFF99%2@<_25<$ZT^.AC2"7)U>UOPF"_Q*$B6\% MWM/E!0J\,^1[?H"^W8?HXX=/AGI-C\?X%DSXCMJ@G*KQ8X!%,'6*[9B0)@J# M;9A6Y(.F^P45-SC O:9"4'J&KG7KSE!(1<*S995S_KY69=$720OQCZF/U>". M&:P3\I58DH2.')5Q!>6/U!G_^@ON>;^9A(6$A9"P"!(6 \%:4G<:J3LV^OCK MJGB@'+$94J]%G5/*>=VI4:)&,U>O&('^.]C-)U;XJ7)#PL(:UJU@^D7^..X/ MW<==#2'=Q4"PEH;=1L/ND1K.LI*4"3U%02OZ5 4A86'WE8*]/04AW<5 L):" MO4;!GE7!.UK2-/[5Z/E6I M8SQ&D!YC@\6^$>-.$>G!3N/",/69Y)-5,VA7GPJ@H#KXOWPFSU>&J8 MC_$807J,31X'?7.8+YLP7[Z1HO2*>!MFG:I,\;53@J :_P+U45&O%GHH)<\F MI:96TJDB@%4K@JQ6# 1K*8J][2K3LS;[>[7"IRDBCVH,S2E*,Y&P52F1&E%J MXJ]&5J+6H,:U9$W&_DXG\RZ\?K WRYK:JW"JC,>ZC4#=QE"TMDX[NP'XI!2W M),_5WH!1&/QJ\/N>MR_*$85"0Z'>?J'(4*B_7RBV-^^]X?.WX?/?]89X-L;/ M/R9^1Q0*#84,\7M=R! _:_O>&[_M;@"VKD#'-RKO%RMCMK=;GCH/!:6%H+0( ME!9#T=J*;A?]N/.S-G@PZ)(?E!:"TB)06@Q%:RN^W2+ ]CV"W16F45;0?0!0 M6OA&T_#E9O*&Z\F;9>X&6J\8BM:6=+MG@.U+Z1OR=# M@VX/@-)"4%H$2HNA M:&U%MQL'N/_3TC+D.GT*2@M!:1$H+8:BM17?[EU@^^;%FVD9&PO=V]R:W-H965T<_EQ MF#O;,_Y=[ D>DSB5,R=G939U6 @PATD1%RR#%+U9R&)A_J)]V==U4)@+R9(R6#%(:%K\DLH7.SSZ@,T13]'7'R>P(['#2NS0 MAK[0*4?G'/1A$ '_T"6V0 @,@CXQ'A8X4(E^.-1@':6G!K_2X+^FP>_B742- M#G@'PR9O*W)/WJ.*]^@UWJ,NWJ,6[]%DTN!M1>[).ZAX!Z_Q#KIX!VW>TVF# MMQ6Y)^]QQ7O\&N]Q%^]Q>YW@<8.W%;DG[TG%>V+E_74'RKRW$G@7^TF+O8>G M_K#!WSI"3_[3BO_4SI]I"TE*1XGUH8JRTE"Z%$W;BOR1CQN*K&/V5(3=VE%= MJZ8;$.(*D83EVA4YF$&,JRHS5#,%0G8:H=O2]A$'_M1MB+./WE?=P7T!OV'& M2DWH@<2YN1N\?0I+_$.=$W?4G,*R5W#4:U)OO6/VM7]CNX&O*%?W1W1-4Z)N M.%8?Q^]JY.^%=JR[MG+\XUY>0AQMKJ8GVH?I*Z-V<]S/SG';S]O[YA1^CFM# MQ_T<';W0?:G7GH[[F3INN_ITU*1^"E?'M:WC?KZ.V\8^;?JZ';HO M]=K9\8]8.VY[^]C#K>R?PMMQ;>[X?=T=M^U]'.#6&70*>_=J>_=.8N]>A[U[ MXW'S\FX?O*^XVMV]$[N[U_9M?S+TFRJM+/JJ//@OWNJVB\+^H3#_"W1#R8;& M5#Y=H+4D$K0X4^\H;@FZQL$$-56GOW]]E+J&M8E5-!7RG\X&PO=V]R M:W-H965TV9JJZA 1![56J6LGS M([%F]\76OHAPU%0#89*H,U7SX3>! ,:&&&;_^Z)MP'/_$A)S<0S<\?HM2;]G MST+DTN^+^3*[Z3SG^>IKMYM-G\4BRLZ2E5@6WWE,TD64%W?3IVZV2D4T6Q@Z>MF"=O-QVYLWT@C)^> M\_*![NAZ%3V)>Y'_N@K2XEYWI\SBA5AF<;*44O%XT_DF?PV585FP'O'/6+QE M[VY+Y5-Y2)+OY1US=M/IE6LDYF*:ET14_/OQ6H9W=,LO"][>W MNK9^\L63>8@R<9?,_Q7/\N>;SF5'FHG'Z&6>A\F;(:HG-"B]:3+/UE^EMVIL MKR--7[(\653%Q1HLXN7F_^CW:D.\*U#D(P5*5:"T+>A7!?VV!>=5P7G;@D%5 M,&A;,*P*AFT++JJ"B[8%EU7!9=N"JZK@JFV!W-ONN5[KDMW.;KVWY>WNEEOO M;WF[P^76>US>[G+YAWVN'"O9[G3YXUXOL<,EV]TN?]SO_?ZQDNV.ES_N^>,E MVUTOK_=]=W,HKH_C<91'H^LT>9/2%GFUGV>%M^-B[I\ M=/_RD(G?7L0RE]37XFLF_3P6>13/LU^DGZ1X*;GQ?%X$3';=S8O%E47=:47[ M&UHY0LN2FRSSYTQ2ES,Q.U _::[O-]1WBZ>Y>Z[*]KG>*HV@/\W/I)[R15)Z M2E_*GJ-4''I:=\V*]3(OE/YGRKA9^;9*VRCJ)^L2+=LH6IOMLE&4XXK>9KO( MGRE&F^WRJ6*VWRX-BM5FNVS613ZNV.VW2X/BM-DNRF>*VV:[G'^F>.VW2^^X MXC_F9E^H="IKG\7JR*\EY]+8J)3QJ_ M1N6,ZH 8MGE>;<5:D/5WH=U?+Z+?,K2E?SO%",G,Q2+[SX$UOMUPYX>Y:^F4A?16?T][_)P]X_#L4CB8U)3"4QC<1T$C-(S"0QB\1L$G-( MS"4QC\1\$@M(;$)B(835PO=\%[[G3?KH/D^FWZ59_!K/Q')6S)>+2?+F-? 7 MZ<_CKX:WC>JI&;S!Y,T+1'ENXG74.^O) _GBZKK[^CY@6X]4CXP\EX<7]9%: MZY%ZZY%&ZY'FL9'#P: ^TFH]TFX]TFD]TCTRLG]^I=1'>JU'^N0/44!B$Q(+ M(:QV? ]VQ_>@\?C6HN4R%I(;E?^R7*3272IF<2YIT32>QWDLLN(X_^&Q0X=\ MXX)./>1);$QB*HEI)*:3F$%B)HE9)&:3F$-B+HEY).:36$!B$Q(+(:P6R\-= M+ _9WWF'9/B2V)C$5!+32$PG,8/$3!*S2,PF,8?$7!+S2,PGL8#$)B060E@M M?"]VX7O1."<.HC\6ZS>''I-4$MFT+)^)59+%^:'H;<1.C5X2&Y.82F(:B>DD M9I"826(6B=DDYI"82V(>B?DD%I#89(.5GV+8G5(9G,GULRDAM,1:I%[N(O6R M,5+'XB&72C2>"FF:O(HT>A)2&N5Q[1+UJ3%1SF8M"S23F MDUA 8A,2"R&LELMR;Q?,Y3R;/'=;>5#^HMH8U514TU!-1S4#U4Q4LU#-1C4' MU5Q4\U#-1[4 U2:H%E):/8_??>9?;IPI>R^+AV(FG#Q*\3++TY?-N=UG,9]] MD5*Q%&_%Q+GQ(["WS0LX.:!);8QJ*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C M6H!JDTH;O#O7T?]PNI=:8#UUE7WJ*LVIFY2=FM%<^K9(7I8'WSAK%DZ.55(; MHYJ*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H-JDTFIOI/4'\MGP8[9"2ZUG MZ[XA2F[\R/]HO)NM?I&*!2SBEX6TBN)#7:>WS=3)(8NV0Z&:BFH:JNFH9J": MB6H6JMFHYJ":BVH>JOFH%J#:I-)J(7O^8\3^/[J>Y'W;4WEE@X:(_7@2]V"T M-A(G1RNIC5%-134-U714,U#-1#4+U6Q4-^9 M)@_@]]'0#C14&Z.:BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J#:!-5"2JOG M\;XE36YLNOC+EP*HV!9-^7?-:W!RYJ*M9ZBFH9J.:@:JF:AFH9J-:@ZJN:CF MH9J/:@&J35 MI+1ZYNX[T>3F5K0?YL"M/N/;]HH-S0L_><*,]JZAFHIJ&JKI MJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@V@350DJKA_>^YTV^A$]@H'UOJ#9&-175 M-%334]7 MC6A>P,D!C7;>H9J*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H-H$U<)*>W\- MBOT?<*JG[K[MKKC9F+J?7S6B63@Y5DEMC&HJJFFHIJ.:@6HFJEFH9J.:@VHN MJGFHYJ-:@&H35 LKK?8&I#SHG5T=R=9]/YW2_*?>BMOQ=R&MTO*-N95(I\6, M-GHZ/'5%.^E0;8QJ*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.97FJR\2Y[>6:\_ M^/B^'-HCAVHAI=4S=M\CIS3WR)UR99YFZN2015OG4$U%-0W5=%0S4,U$-0O5 M;%1S4,U%-0_5?%0+4&V":F&E#=^]F@P^S&&[V;,0^3C*H]'U0J1/XD[,YYDT M+7_W+V*W\^Y1*16/Y4=\OWY3.MT?'O?EKX%DAR?-DL;[Y+**92,L!Q?K/?HO4$L#!!0 ( !4Z;5&PO9EC.MBO MGR\.>:$^1/MA)0LJL>_R//?X?':P.LGECM/[-:72VL8\R:?V6LKLD^/DRS6- M27Z59C11GB@5,9&J*U9.G@E*PAQ ,7<&_;[OQ(0E]FR2;.+;6.;6,MTD''1?[R\.;3W"L>E[1A) MAR>07O5Q7N7#J/TV]?[Q_GM%UJM[&'QTDK(CPC#BL4%7K0G5$YB'TQH-!A[U MD5STB]3VFGV,PL4HVOG$-0Q.F^JCP!= I ME]EL$J5)O=H\6QL4,XFI]43XU)X3SA:" 2HB,>,[;1Z 89GR5%A2+7,5R@5+ M_D>[7=V#':#DB5F2BB*VCJ"_%^7C!XY]#P0RSBN!L!N 83;)B)14)+>J4SQ< M&)^YK++]L,N4PI4@.W"4 M,HU5(V1DE2:DT+!'E U%NZ2PIE5\V:CA)T8<2IW>"1FQ;]+=1)0!C=W%VDF5\]YFS51)3/?B3 M \XF9(^SUJE@?U0T*)6E,E!A6T]42+9L6GX+DCW0K=R7TS;"-0\ZJ/G?YGE% M$RH(;XI6M7_.67ZU8F_T5I*+7>50L%%C^9/GW$4.NR#2/W^17G#^&LN?I>PO$>EV0>2@"R*]+HCLPEMQ=)YO1:<\0C3.*:U32F6UX#0X MM7_ N9+70:W%AG')DK*W9F%(DV>'%44OR8+3-K]Z/J01V7#Y4#FG=MW^3D.V MB8/JJ3M(1/E4W?X&PW/]ZBBJ8K$DI%L:SLNN6"V*IJ4:*FIY >#0>;%!XMCQ@3J,H\T M"#S/][&,SN=&!7,L;[X/?V8V3!L@L#@0Z66YQF<;KY#C=8#-Z;$*P4:*5R(V M4CS7X#'G#1!!8)YM+ X@L%G :@?BF^- 39DQG@>SBFG#5C#N"0+, [5HKE'? M1[+CP\<\/]@J\;P@,'O 9U;@>9@'5B/NP12 !LSC><5[\.!]Y.S?4T[];Y/9 M7U!+ P04 " 5.FU7EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W MO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B MM/XU@LD/['X 4$L#!!0 ( !4Z;5=0BU[(!@8 *(W / >&PO=V]R M:V)O;VLN>&ULQ9M=;^(X%(;_BL7-=J5E*?ED1M.1.D"WE3I0-=7.T]-7>G'(%.) ^V/@\Q\?NIQ_&?K\WYKOXMRKKYFRT<^[A MXV32Y#M5R>9/\Z!JNK(QMI*.7MKMI'FP2A;-3BE7E9/@]#295%+7H\^?GN]U M8R?^"^-4[K2IJ;%K^*;5C^;7]>ZE>-2-OM>E=D]GH_YYJ4:BTK6N]$]5G(U. M1Z+9F1^7QNJ?IG:RS')KRO)L--U?^*:LT_FKYJR#O)/W3=_BY/VM))"S47)* M-]QHV[C^'?W])3$^*GKS_E7KS(4NG;(+Z=1?UK0/NMYVMZ%O,?&^1M\/SX_[ M3OQH_T\WFLU&YVIA\K92M=OWHU5E!U@W._W0C$0M*W4VFIM'9<6-W*KN2]%? MN2KV7] 1F===]J.F"_:JZ!D9>=:K;'U]M3B_6R[$E_/K\]5\*;++Y?(N\P # M !@<#5"#G%^>KSS(&$#& M1X3\._ @$P"9' _R/+OT(%, F?)"KNU6UOIG?\$CF@&B&2]1UE:5M$_";$2F MM[6FC\G:B?,\-VWMM ?Y 4!^X(6\5;(4R_ZOBZOZ436N^T#SAU@IYX?L4Q2S M3WD9OQKKMJ00L2(;-V23)TD KQ"A5KB]8E6AG;B0>9<(:-7X8$@G4V:?7$AM MQ3=9MJK['5[H6M:YIB&_JAMGV\K'1$*9,AMEH:Q^E%T2TPA9%^)2%5O*66BR M4)L>##-2RI39*9DS^?>=*0MEF]_$\I^6DCZ?#9EDRJR2VZY1%30]K'L2=U;6 MC>Q3UWV/^IC()5-FF2QS4YM*YV*AZ"Z%JO-!#R*#3)D5LA_/\1?94#?.346W M:E[Z9(J$,F4V"JFCK=K],*_=CC+KCM*J'8'2U/$QD5*FS$Y9F7I,H^RZY4PW MB:]J6HJ06?R@&""A!,Q"(7&(:].02J@+LYVT?M<%R",!LTW>(6[5 TF/ M.L\'@\L2[G6)J2J]SPWZ<#*G\24\FKY#V07((@&S1;+VOE'_M%T'+A\[5!\, M>2-@]@;95I,SNJA<]%JS%)ZWJGK)B/P1,/L#IJN#I4B _!$P^P-CACXFI=<='"$TO_L%$:24D%DI,,\> MS)X0^25D]@O,LX>8R#8ALVT.Y=D'AQP6P9AM Q/N85\B]X3,[GDSJ]UWJ(^) M]!,RZP?FML/>1/H)F?7S9F[[NC>1?D)F_;S.< ].'Z2>D+L\]C+5/4B(K!-R M6P?EO.+$+W,C]43,ZO$KG^)DH9S4Y: 3(V2"6R_,SH&8@V >(>=$["4SA.FO)2+DG(C9.1AS,(60U+))_X>'LSA#G89446BM][?X;@ MO)#O8R(+Q=Q5M@.8*VEMOV(;9!PQLE#,O?]_ /.B=2UEF3=6^^7R&%DH9K80 M7I/[X3V&1P"8+80Q_? >(PO%S!;"F'YXCY&%8F8+X0K'8-"1A6)F"V',P: C M"\7,%L*8_J GR$()LX4PIN_T!%DH.6KU+?4QD8628U3??HG(QT062KAW>PYC MSO=E)/]\38(LE!SAS$"7?73-8C' 1!9*CGE\8! W$W@4C7TMA##]N)D@"R7L M:R&$.8B;R$()^UH(80[B)K)0PFRAMTO8?53R#R B"Z7,%D*8V>"L58HLE#); M"%?:_9F>(@NES!9ZN](^%E^D7VE/D8529@LAS!>_362AE-E""//%;Q-9*&6V MT(%]"W^A[F,B"Z7:N^^$S2FY_1K[3,;S]@ ( ),Q M : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VDUNHT 0AN&K6!P@ M[:[JJNZ,XJQFD^TH%T!.^T>QC06,)KG]6,["_M L9A/QK5"#*-X%>H2 IU_U MT([[[C3L]N=A\7$\G(95LQO'\X\0AO6N'MOAH3O7T^7(INN/[7A9]MMP;M?O M[;8&62X]]/G^YF+U\]S_9^)W6:S7]>?W?KWL9[&?PP.?[K^?=C5.C:+ MU[;?UG'5A(_#;?<0KIOX<)G<+%[>5DW_\A:;,'>00)#,'Z00I/,')0A*\P<9 M!-G\00Y!/G]0AJ \?U"!H#)_T",$/$.Q+('9'N2&!W1+PC@=Z">@N!WH)Z"X'>,GG8 M)M!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M1;R706U%O M)=!;46\ET%LG+TL(]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]$ZH M=R+0.Z'>B4#OA'HG KT3ZIT(]$Z3E]T$>B?4.Q'HG5#O1*!W0KT3@=X)]4X$ M>B?4.Q'H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&V3CY4$>AOJ;01Z&^IM M!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z^^1G M$P*]'?5V KT=]78"O1WU=@*],^J="?3.J'\4YW%<,SW\!4$L# M!!0 ( !4Z;5?W,"8&)P( #(P 3 6T-O;G1E;G1?5'EP97-=+GAM M;,W;36[;,! %X*L8V@86S7^UB+-INVVSZ 58:1P+ED2"9%+G]J7D)$"+U$C@ M GT;"S;)>2,.\.U\_?TQ4%H=QV%*VVJ?<_C(6&KW-+I4^T!36=GY.+IY[E&=7/]F7;N?LBK+\?R<^K]M*TB#:E:?3IMG+.V ME0MAZ%N7RSI[F+H_4M9/"74YN>Q)^SZDJ[*A8J\FS"M_#W@Z]^V!8NP[6MVZ MF+^ZL>QBQX&E_#A0JL^7>*5'O]OU+76^O1_+D3J%2*Y+>Z(\#O6IZ-7YY%QN MF$Z?_.+\I23SZ74HA2CF_OPKOB26TA>_'\W3[JA[ M8W:YWI\^'I9Y)+8\+K_CWV?\4O^=?0B0/B1('PJD#PW2AP'IPX+TT8#T\0&D M#[Y!:01%5(Y"*D5>T K @ $0 @ &O 9&]C4')O<',O8V]R92YX M;6Q02P$"% ,4 " 5.FU7F5R<(Q & "<)P $P @ '+ M 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( !4Z;5>V7T/L 0< M )XK 8 " @0P( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5T6T M_B1 ! (Q, !@ ("!&1< 'AL+W=O%W&PO=V]R:W-H965T M&UL4$L! A0#% @ %3IM5W %V^,/ P I L !@ M ("!@3D 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ %3IM5T)C'](_*0 >(8 !@ ("!1U$ 'AL M+W=O&UL4$L! A0#% @ %3IM5S;X)47.# \"$ !D ("! M8(@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %3IM5QE)&* 3#P =C( !D ("!5[, 'AL+W=O&UL4$L! A0#% @ %3IM5TD<1 U$ M P KP< !D ("!@^L 'AL+W=O&PO=V]R:W-H965T , 8( 9 " @;[T !X;"]W;W)K&UL4$L! A0#% @ %3IM5_7^'-\Z"0 0QP !D M ("!;?@ 'AL+W=O 0$ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ %3IM5VB '_([!P =!( !D ("!PQ(! M 'AL+W=O&PO=V]R:W-H965T 0!X;"]W;W)K&UL4$L! A0#% @ M%3IM5S@&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5_?0)JJG!@ M_0X !D ("!2%D! 'AL+W=O4( !& &0 @($F M8 $ >&PO=V]R:W-H965T* M &W\0@0 +<* 9 " @4)I 0!X;"]W;W)K&UL4$L! A0#% @ %3IM5_Y6!W44!P 4A8 !D M ("!NVT! 'AL+W=O&PO=V]R:W-H M965T7OXK6A 0 (\* 9 M " @=IX 0!X;"]W;W)K&UL4$L! M A0#% @ %3IM5V_!.L;@ @ *08 !D ("!E7T! 'AL M+W=O&PO=V]R:W-H965T2# 0!X;"]W;W)K&UL4$L! A0#% @ %3IM M5]*MT'\6!0 X0X !D ("!G8@! 'AL+W=OTDOY.@& "I$0 &0 M @('JC0$ >&PO=V]R:W-H965TSN-+<= , +H) 9 " @0F5 0!X;"]W;W)K M&UL4$L! A0#% @ %3IM5^+IX\L/!@ ^2X M !D ("!M)@! 'AL+W=O4 &0 @('ZG@$ M>&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5[^QXQ48"P VY@ !D M ("!0*H! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ %3IM5SUA40X_! H14 !D ("![KP! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5Q>M M]CRS!P 4$ !D ("!7&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5RP=JHY,%@ 7GL! !D M ("!I>&PO M=V]R:W-H965T\G)WG* 4 M '(F 9 " @;(" @!X;"]W;W)K&UL4$L! A0#% @ %3IM5UP)JC(? P !@P !D ("! M$0@" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %3IM5[PT?<"'!0 E2\ !D ("!^A(" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5X4^&PO=V]R M:W-H965T^#>C2Z@X !.R M 9 " @==" @!X;"]W;W)K&UL M4$L! A0#% @ %3IM5QY",T5N!@ C# !D ("!^%$" M 'AL+W=O&PO=V]R:W-H965T 9 M " @65> @!X;"]W;W)K&UL4$L! A0#% @ M%3IM5ZH/$Q49 P KPD !D ("!;F," 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5R>4-]&PO=V]R:W-H965T&UL4$L! A0#% @ %3IM5Z,(7#>)!0 KB< !D M ("!MGX" 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ %3IM5]ZODXY9! X!0 !D ("!78X" 'AL M+W=O&PO=V]R:W-H965TZ;CO9!@4 !8A 9 " M@:"6 @!X;"]W;W)K&UL4$L! A0#% @ %3IM M5PTM89E_! "14 !D ("!W9L" 'AL+W=O&PO=V]R:W-H965T3,;S]@ ( ),Q : " 3"U @!X;"]?BW @!;0V]N=&5N=%]4>7!E&UL4$L%!@ !< - %P .QD $"Z @ $! end XML 97 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 98 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 99 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 473 420 1 true 133 0 false 13 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.thehealthcarereit2.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - Organization Sheet http://www.thehealthcarereit2.com/role/Organization Organization Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Real Estate Investments, Net Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet Real Estate Investments, Net Notes 10 false false R11.htm 0000011 - Disclosure - Mortgage Notes Payable, Net Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet Mortgage Notes Payable, Net Notes 11 false false R12.htm 0000012 - Disclosure - Credit Facilities Sheet http://www.thehealthcarereit2.com/role/CreditFacilities Credit Facilities Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value of Financial Instruments Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Derivatives and Hedging Activities Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities Derivatives and Hedging Activities Notes 14 false false R15.htm 0000015 - Disclosure - Stockholders' Equity Sheet http://www.thehealthcarereit2.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 0000016 - Disclosure - Related Party Transactions and Arrangements Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements Related Party Transactions and Arrangements Notes 16 false false R17.htm 0000017 - Disclosure - Economic Dependency Sheet http://www.thehealthcarereit2.com/role/EconomicDependency Economic Dependency Notes 17 false false R18.htm 0000018 - Disclosure - Equity-Based Compensation Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensation Equity-Based Compensation Notes 18 false false R19.htm 0000019 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 19 false false R20.htm 0000020 - Disclosure - Non-controlling Interests Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterests Non-controlling Interests Notes 20 false false R21.htm 0000021 - Disclosure - Net Loss Per Share Sheet http://www.thehealthcarereit2.com/role/NetLossPerShare Net Loss Per Share Notes 21 false false R22.htm 0000022 - Disclosure - Segment Reporting Sheet http://www.thehealthcarereit2.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 0000023 - Disclosure - Commitments and Contingencies Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 0000024 - Disclosure - Subsequent Events Sheet http://www.thehealthcarereit2.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 9954473 - Disclosure - Real Estate Investments, Net (Tables) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables Real Estate Investments, Net (Tables) Tables http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet 28 false false R29.htm 9954474 - Disclosure - Mortgage Notes Payable, Net (Tables) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables Mortgage Notes Payable, Net (Tables) Tables http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet 29 false false R30.htm 9954475 - Disclosure - Credit Facilities (Tables) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesTables Credit Facilities (Tables) Tables http://www.thehealthcarereit2.com/role/CreditFacilities 30 false false R31.htm 9954476 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments 31 false false R32.htm 9954477 - Disclosure - Derivatives and Hedging Activities (Tables) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables Derivatives and Hedging Activities (Tables) Tables http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities 32 false false R33.htm 9954478 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.thehealthcarereit2.com/role/StockholdersEquity 33 false false R34.htm 9954479 - Disclosure - Related Party Transactions and Arrangements (Tables) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables Related Party Transactions and Arrangements (Tables) Tables http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements 34 false false R35.htm 9954480 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.thehealthcarereit2.com/role/EquityBasedCompensation 35 false false R36.htm 9954481 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncome 36 false false R37.htm 9954482 - Disclosure - Non-controlling Interests (Tables) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsTables Non-controlling Interests (Tables) Tables http://www.thehealthcarereit2.com/role/NoncontrollingInterests 37 false false R38.htm 9954483 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.thehealthcarereit2.com/role/NetLossPerShare 38 false false R39.htm 9954484 - Disclosure - Segment Reporting (Tables) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.thehealthcarereit2.com/role/SegmentReporting 39 false false R40.htm 9954485 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.thehealthcarereit2.com/role/CommitmentsandContingencies 40 false false R41.htm 9954486 - Disclosure - Organization (Details) Sheet http://www.thehealthcarereit2.com/role/OrganizationDetails Organization (Details) Details http://www.thehealthcarereit2.com/role/Organization 41 false false R42.htm 9954487 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 42 false false R43.htm 9954488 - Disclosure - Summary of Significant Accounting Policies - Lessor Maturity Schedule (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails Summary of Significant Accounting Policies - Lessor Maturity Schedule (Details) Details 43 false false R44.htm 9954489 - Disclosure - Real Estate Investments, Net - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails Real Estate Investments, Net - Narrative (Details) Details 44 false false R45.htm 9954490 - Disclosure - Real Estate Investments, Net - Acquired Assets (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails Real Estate Investments, Net - Acquired Assets (Details) Details 45 false false R46.htm 9954491 - Disclosure - Real Estate Investments, Net - Geographic Concentrations (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails Real Estate Investments, Net - Geographic Concentrations (Details) Details 46 false false R47.htm 9954492 - Disclosure - Real Estate Investments, Net - Summary of Amortization and Accretion Recognized (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails Real Estate Investments, Net - Summary of Amortization and Accretion Recognized (Details) Details 47 false false R48.htm 9954493 - Disclosure - Real Estate Investments, Net - Summary of Intangible Assets and Liabilities Future Amortization Expense (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails Real Estate Investments, Net - Summary of Intangible Assets and Liabilities Future Amortization Expense (Details) Details 48 false false R49.htm 9954494 - Disclosure - Real Estate Investments, Net - Impairments (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails Real Estate Investments, Net - Impairments (Details) Details 49 false false R50.htm 9954495 - Disclosure - Mortgage Notes Payable, Net - Mortgage Notes (Details) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails Mortgage Notes Payable, Net - Mortgage Notes (Details) Details 50 false false R51.htm 9954496 - Disclosure - Mortgage Notes Payable, Net - Narrative (Details) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails Mortgage Notes Payable, Net - Narrative (Details) Details 51 false false R52.htm 9954497 - Disclosure - Credit Facilities - Summary of Credit Facilities (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails Credit Facilities - Summary of Credit Facilities (Details) Details 52 false false R53.htm 9954498 - Disclosure - Credit Facilities - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails Credit Facilities - Narrative (Details) Details 53 false false R54.htm 9954499 - Disclosure - Credit Facilities - Future Principal Payments of Outstanding Debt (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails Credit Facilities - Future Principal Payments of Outstanding Debt (Details) Details 54 false false R55.htm 9954500 - Disclosure - Fair Value of Financial Instruments - Assets Measured at Fair Value (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails Fair Value of Financial Instruments - Assets Measured at Fair Value (Details) Details 55 false false R56.htm 9954501 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 56 false false R57.htm 9954502 - Disclosure - Fair Value of Financial Instruments - Carrying Amounts and Fair Values of Debt (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails Fair Value of Financial Instruments - Carrying Amounts and Fair Values of Debt (Details) Details 57 false false R58.htm 9954503 - Disclosure - Derivatives and Hedging Activities - Balance Sheet Classification (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails Derivatives and Hedging Activities - Balance Sheet Classification (Details) Details 58 false false R59.htm 9954504 - Disclosure - Derivatives and Hedging Activities - Summary of Derivative Instruments (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails Derivatives and Hedging Activities - Summary of Derivative Instruments (Details) Details 59 false false R60.htm 9954505 - Disclosure - Derivatives and Hedging Activities - Derivatives Included in AOCI (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails Derivatives and Hedging Activities - Derivatives Included in AOCI (Details) Details 60 false false R61.htm 9954506 - Disclosure - Derivatives and Hedging Activities - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails Derivatives and Hedging Activities - Narrative (Details) Details 61 false false R62.htm 9954507 - Disclosure - Derivatives and Hedging Activities - Offsetting Derivatives (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails Derivatives and Hedging Activities - Offsetting Derivatives (Details) Details 62 false false R63.htm 9954508 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 63 false false R64.htm 9954509 - Disclosure - Stockholders' Equity - Cumulative Share Repurchases (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityCumulativeShareRepurchasesDetails Stockholders' Equity - Cumulative Share Repurchases (Details) Details 64 false false R65.htm 9954510 - Disclosure - Stockholders' Equity - Stock Dividends (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails Stockholders' Equity - Stock Dividends (Details) Details 65 false false R66.htm 9954511 - Disclosure - Related Party Transactions and Arrangements - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails Related Party Transactions and Arrangements - Narrative (Details) Details 66 false false R67.htm 9954512 - Disclosure - Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company (Details) Details 67 false false R68.htm 9954513 - Disclosure - Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable (Details) Details 68 false false R69.htm 9954514 - Disclosure - Related Party Transactions and Arrangements - Fees and Participations Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails Related Party Transactions and Arrangements - Fees and Participations Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets (Details) Details 69 false false R70.htm 9954515 - Disclosure - Equity-Based Compensation - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails Equity-Based Compensation - Narrative (Details) Details 70 false false R71.htm 9954516 - Disclosure - Equity-Based Compensation - Summary of Activity (Details) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails Equity-Based Compensation - Summary of Activity (Details) Details 71 false false R72.htm 9954517 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in AOCI (Details) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails Accumulated Other Comprehensive Income - Summary of Changes in AOCI (Details) Details 72 false false R73.htm 9954518 - Disclosure - Non-controlling Interests - Balance Sheet Breakdown (Details) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails Non-controlling Interests - Balance Sheet Breakdown (Details) Details 73 false false R74.htm 9954519 - Disclosure - Non-controlling Interests - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails Non-controlling Interests - Narrative (Details) Details 74 false false R75.htm 9954520 - Disclosure - Non-controlling Interests - Summary of Non-controlling Interests (Details) Sheet http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails Non-controlling Interests - Summary of Non-controlling Interests (Details) Details 75 false false R76.htm 9954521 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Computation (Details) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Computation (Details) Details 76 false false R77.htm 9954522 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 77 false false R78.htm 9954523 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 78 false false R79.htm 9954524 - Disclosure - Segment Reporting - Reconciliation of Segment Activity (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails Segment Reporting - Reconciliation of Segment Activity (Details) Details 79 false false R80.htm 9954525 - Disclosure - Segment Reporting - Reconciliation of Segment Activity to Assets (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails Segment Reporting - Reconciliation of Segment Activity to Assets (Details) Details 80 false false R81.htm 9954526 - Disclosure - Segment Reporting - Reconciliation of Capital Expenditures by Segment (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails Segment Reporting - Reconciliation of Capital Expenditures by Segment (Details) Details 81 false false R82.htm 9954527 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 82 false false R83.htm 9954528 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) Details 83 false false R84.htm 9954529 - Disclosure - Subsequent Events (Details) Sheet http://www.thehealthcarereit2.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.thehealthcarereit2.com/role/SubsequentEvents 84 false false All Reports Book All Reports hct-20230930.htm hct-20230930.xsd hct-20230930_cal.xml hct-20230930_def.xml hct-20230930_lab.xml hct-20230930_pre.xml hct-20230930_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 102 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hct-20230930.htm": { "nsprefix": "hct", "nsuri": "http://www.thehealthcarereit2.com/20230930", "dts": { "inline": { "local": [ "hct-20230930.htm" ] }, "schema": { "local": [ "hct-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "hct-20230930_cal.xml" ] }, "definitionLink": { "local": [ "hct-20230930_def.xml" ] }, "labelLink": { "local": [ "hct-20230930_lab.xml" ] }, "presentationLink": { "local": [ "hct-20230930_pre.xml" ] } }, "keyStandard": 313, "keyCustom": 107, "axisStandard": 40, "axisCustom": 1, "memberStandard": 49, "memberCustom": 81, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://www.thehealthcarereit2.com/20230930": 2, "http://fasb.org/us-gaap/2023": 2 }, "contextCount": 473, "entityCount": 1, "segmentCount": 133, "elementCount": 804, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1195, "http://xbrl.sec.gov/dei/2023": 36, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.thehealthcarereit2.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R4": { "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CostsAndExpensesRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R5": { "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-64", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "hct:CommonStockStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "hct:CommonStockStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R8": { "role": "http://www.thehealthcarereit2.com/role/Organization", "longName": "0000008 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet", "longName": "0000010 - Disclosure - Real Estate Investments, Net", "shortName": "Real Estate Investments, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet", "longName": "0000011 - Disclosure - Mortgage Notes Payable, Net", "shortName": "Mortgage Notes Payable, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.thehealthcarereit2.com/role/CreditFacilities", "longName": "0000012 - Disclosure - Credit Facilities", "shortName": "Credit Facilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments", "longName": "0000013 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities", "longName": "0000014 - Disclosure - Derivatives and Hedging Activities", "shortName": "Derivatives and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.thehealthcarereit2.com/role/StockholdersEquity", "longName": "0000015 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements", "longName": "0000016 - Disclosure - Related Party Transactions and Arrangements", "shortName": "Related Party Transactions and Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.thehealthcarereit2.com/role/EconomicDependency", "longName": "0000017 - Disclosure - Economic Dependency", "shortName": "Economic Dependency", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "hct:EconomicDependencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hct:EconomicDependencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensation", "longName": "0000018 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncome", "longName": "0000019 - Disclosure - Accumulated Other Comprehensive Income", "shortName": "Accumulated Other Comprehensive Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterests", "longName": "0000020 - Disclosure - Non-controlling Interests", "shortName": "Non-controlling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.thehealthcarereit2.com/role/NetLossPerShare", "longName": "0000021 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.thehealthcarereit2.com/role/SegmentReporting", "longName": "0000022 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingencies", "longName": "0000023 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.thehealthcarereit2.com/role/SubsequentEvents", "longName": "0000024 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables", "longName": "9954473 - Disclosure - Real Estate Investments, Net (Tables)", "shortName": "Real Estate Investments, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables", "longName": "9954474 - Disclosure - Mortgage Notes Payable, Net (Tables)", "shortName": "Mortgage Notes Payable, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesTables", "longName": "9954475 - Disclosure - Credit Facilities (Tables)", "shortName": "Credit Facilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954476 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables", "longName": "9954477 - Disclosure - Derivatives and Hedging Activities (Tables)", "shortName": "Derivatives and Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityTables", "longName": "9954478 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables", "longName": "9954479 - Disclosure - Related Party Transactions and Arrangements (Tables)", "shortName": "Related Party Transactions and Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables", "longName": "9954480 - Disclosure - Equity-Based Compensation (Tables)", "shortName": "Equity-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeTables", "longName": "9954481 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "shortName": "Accumulated Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsTables", "longName": "9954482 - Disclosure - Non-controlling Interests (Tables)", "shortName": "Non-controlling Interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "hct:NoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hct:NoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareTables", "longName": "9954483 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.thehealthcarereit2.com/role/SegmentReportingTables", "longName": "9954484 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables", "longName": "9954485 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.thehealthcarereit2.com/role/OrganizationDetails", "longName": "9954486 - Disclosure - Organization (Details)", "shortName": "Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "unitRef": "state", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R42": { "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-14", "name": "hct:ProceedsFromGovernmentAssistanceCARESAct", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "hct:ProceedsFromGovernmentAssistanceCARESAct", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "hct:ProceedsFromGovernmentAssistanceCARESAct", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "hct:ProceedsFromGovernmentAssistanceCARESAct", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails", "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Lessor Maturity Schedule (Details)", "shortName": "Summary of Significant Accounting Policies - Lessor Maturity Schedule (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "longName": "9954489 - Disclosure - Real Estate Investments, Net - Narrative (Details)", "shortName": "Real Estate Investments, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R45": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "longName": "9954490 - Disclosure - Real Estate Investments, Net - Acquired Assets (Details)", "shortName": "Real Estate Investments, Net - Acquired Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-119", "name": "hct:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "hct:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "longName": "9954491 - Disclosure - Real Estate Investments, Net - Geographic Concentrations (Details)", "shortName": "Real Estate Investments, Net - Geographic Concentrations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-131", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-131", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "longName": "9954492 - Disclosure - Real Estate Investments, Net - Summary of Amortization and Accretion Recognized (Details)", "shortName": "Real Estate Investments, Net - Summary of Amortization and Accretion Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "hct:AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R48": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "longName": "9954493 - Disclosure - Real Estate Investments, Net - Summary of Intangible Assets and Liabilities Future Amortization Expense (Details)", "shortName": "Real Estate Investments, Net - Summary of Intangible Assets and Liabilities Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-148", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-148", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "longName": "9954494 - Disclosure - Real Estate Investments, Net - Impairments (Details)", "shortName": "Real Estate Investments, Net - Impairments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-168", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R50": { "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "longName": "9954495 - Disclosure - Mortgage Notes Payable, Net - Mortgage Notes (Details)", "shortName": "Mortgage Notes Payable, Net - Mortgage Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-197", "name": "hct:NumberOfRealEstatePropertiesEncumbered", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R51": { "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "longName": "9954496 - Disclosure - Mortgage Notes Payable, Net - Narrative (Details)", "shortName": "Mortgage Notes Payable, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "hct:RealEstateInvestmentAtCostRelatingtoNotesPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-203", "name": "us-gaap:RepaymentsOfLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R52": { "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "longName": "9954497 - Disclosure - Credit Facilities - Summary of Credit Facilities (Details)", "shortName": "Credit Facilities - Summary of Credit Facilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-217", "name": "us-gaap:DebtInstrumentCollateralAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R53": { "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "longName": "9954498 - Disclosure - Credit Facilities - Narrative (Details)", "shortName": "Credit Facilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-248", "name": "us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R54": { "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "longName": "9954499 - Disclosure - Credit Facilities - Future Principal Payments of Outstanding Debt (Details)", "shortName": "Credit Facilities - Future Principal Payments of Outstanding Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "longName": "9954500 - Disclosure - Fair Value of Financial Instruments - Assets Measured at Fair Value (Details)", "shortName": "Fair Value of Financial Instruments - Assets Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-260", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "longName": "9954501 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-273", "name": "hct:DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-273", "name": "hct:DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "longName": "9954502 - Disclosure - Fair Value of Financial Instruments - Carrying Amounts and Fair Values of Debt (Details)", "shortName": "Fair Value of Financial Instruments - Carrying Amounts and Fair Values of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-276", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-276", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "longName": "9954503 - Disclosure - Derivatives and Hedging Activities - Balance Sheet Classification (Details)", "shortName": "Derivatives and Hedging Activities - Balance Sheet Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-288", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R59": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "longName": "9954504 - Disclosure - Derivatives and Hedging Activities - Summary of Derivative Instruments (Details)", "shortName": "Derivatives and Hedging Activities - Summary of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-219", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "unitRef": "instrument", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "longName": "9954505 - Disclosure - Derivatives and Hedging Activities - Derivatives Included in AOCI (Details)", "shortName": "Derivatives and Hedging Activities - Derivatives Included in AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-298", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R61": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "longName": "9954506 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)", "shortName": "Derivatives and Hedging Activities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-308", "name": "hct:DerivativeNumberOfInstrumentsTerminated", "unitRef": "instrument", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R62": { "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails", "longName": "9954507 - Disclosure - Derivatives and Hedging Activities - Offsetting Derivatives (Details)", "shortName": "Derivatives and Hedging Activities - Offsetting Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R63": { "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "longName": "9954508 - Disclosure - Stockholders' Equity - Narrative (Details)", "shortName": "Stockholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hct:StockRepurchaseProgramSharePricePercentageOfEstimatedPerShareNAV", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R64": { "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityCumulativeShareRepurchasesDetails", "longName": "9954509 - Disclosure - Stockholders' Equity - Cumulative Share Repurchases (Details)", "shortName": "Stockholders' Equity - Cumulative Share Repurchases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "longName": "9954510 - Disclosure - Stockholders' Equity - Stock Dividends (Details)", "shortName": "Stockholders' Equity - Stock Dividends (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-338", "name": "us-gaap:StockDividendsShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails", "longName": "9954511 - Disclosure - Related Party Transactions and Arrangements - Narrative (Details)", "shortName": "Related Party Transactions and Arrangements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-342", "name": "hct:RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R67": { "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "longName": "9954512 - Disclosure - Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company (Details)", "shortName": "Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-343", "name": "hct:RelatedPartyAgreementTermofAgreementRenewalPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-343", "name": "hct:RelatedPartyAgreementTermofAgreementRenewalPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "longName": "9954513 - Disclosure - Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable (Details)", "shortName": "Related Party Transactions and Arrangements - Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-392", "name": "us-gaap:OperatingExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R69": { "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "longName": "9954514 - Disclosure - Related Party Transactions and Arrangements - Fees and Participations Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets (Details)", "shortName": "Related Party Transactions and Arrangements - Fees and Participations Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-404", "name": "hct:RelatedPartyTransactionFeePaymentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-404", "name": "hct:RelatedPartyTransactionFeePaymentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "longName": "9954515 - Disclosure - Equity-Based Compensation - Narrative (Details)", "shortName": "Equity-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-419", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-419", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "longName": "9954516 - Disclosure - Equity-Based Compensation - Summary of Activity (Details)", "shortName": "Equity-Based Compensation - Summary of Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-415", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-411", "name": "hct:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R72": { "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails", "longName": "9954517 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in AOCI (Details)", "shortName": "Accumulated Other Comprehensive Income - Summary of Changes in AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-51", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-34", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R73": { "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "longName": "9954518 - Disclosure - Non-controlling Interests - Balance Sheet Breakdown (Details)", "shortName": "Non-controlling Interests - Balance Sheet Breakdown (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:MinorityInterestInOperatingPartnerships", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "hct:NoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:MinorityInterestInOperatingPartnerships", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "hct:NoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "longName": "9954519 - Disclosure - Non-controlling Interests - Narrative (Details)", "shortName": "Non-controlling Interests - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PaymentsOfDividendsMinorityInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:PaymentsOfDividendsMinorityInterest", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToMinorityShareholders", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PaymentsToMinorityShareholders", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R75": { "role": "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "longName": "9954520 - Disclosure - Non-controlling Interests - Summary of Non-controlling Interests (Details)", "shortName": "Non-controlling Interests - Summary of Non-controlling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:MinorityInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-430", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R76": { "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails", "longName": "9954521 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Computation (Details)", "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": null }, "R77": { "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9954522 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "longName": "9954523 - Disclosure - Segment Reporting - Narrative (Details)", "shortName": "Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "longName": "9954524 - Disclosure - Segment Reporting - Reconciliation of Segment Activity (Details)", "shortName": "Segment Reporting - Reconciliation of Segment Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R80": { "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "longName": "9954525 - Disclosure - Segment Reporting - Reconciliation of Segment Activity to Assets (Details)", "shortName": "Segment Reporting - Reconciliation of Segment Activity to Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-457", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } }, "R81": { "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "longName": "9954526 - Disclosure - Segment Reporting - Reconciliation of Capital Expenditures by Segment (Details)", "shortName": "Segment Reporting - Reconciliation of Capital Expenditures by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-469", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-469", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954527 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "hct:LesseeOperatingLeaseNumberOfContracts", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hct:LesseeOperatingLeaseNumberOfContracts", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails", "longName": "9954528 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails", "longName": "9954529 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-338", "name": "us-gaap:StockDividendsShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-473", "name": "hct:DerivativeStrikePricePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hct-20230930.htm", "unique": true } } }, "tag": { "us-gaap_StockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockDividendsShares", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock dividends (in shares)", "label": "Stock Dividends, Shares", "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r17" ] }, "hct_AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of market lease and other intangibles, net", "verboseLabel": "Accretion of above-and below-market leases, net", "label": "Accretion of Below-Market Lease Liabilities and Amortization of Above-Market Lease Assets, Net", "documentation": "Adjustment for noncash decrease (increase) in rental revenue related to assets (liabilities) associated with the acquisition of an off-market lease when the terms of the lease are favorable (unfavorable) to the market terms for the lease at the date of acquisition." } } }, "auth_ref": [] }, "hct_PropertyManagementFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PropertyManagementFeesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property management and fees", "label": "Property Management Fees [Member]", "documentation": "Property Management Fees [Member]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r828" ] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDistributionsInExcessOfNetIncome", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions in excess of accumulated earnings", "label": "Accumulated Distributions in Excess of Net Income", "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings)." } } }, "auth_ref": [ "r999" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_RealEstateDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investments, Net", "label": "Real Estate Disclosure [Text Block]", "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures." } } }, "auth_ref": [ "r213", "r214", "r215", "r216", "r217" ] }, "hct_AccountsPayablePrepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AccountsPayablePrepayments", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payable (Prepayment)", "label": "Accounts Payable (Prepayments)", "documentation": "Accounts Payable (Prepayments)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r828" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r410", "r452", "r453", "r454", "r455", "r456", "r457", "r532", "r577", "r578", "r579", "r794", "r795", "r800", "r801", "r802" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r139", "r140", "r701", "r702", "r705" ] }, "hct_NoncashOrPartNoncashProceedsFromRealEstateSalesUsedToRepayAmountsOutstandingUnderPriorCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NoncashOrPartNoncashProceedsFromRealEstateSalesUsedToRepayAmountsOutstandingUnderPriorCreditFacility", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from real estate sales used to repay amounts outstanding under the Prior Credit Facility", "label": "Noncash, Or Part Noncash, Proceeds From Real Estate Sales Used To Repay Amounts Outstanding Under Prior Credit Facility", "documentation": "Noncash, Or Part Noncash, Proceeds From Real Estate Sales Used To Repay Amounts Outstanding Under Prior Credit Facility" } } }, "auth_ref": [] }, "us-gaap_AffiliateCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AffiliateCosts", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating fees to related parties", "label": "Affiliate Costs", "documentation": "Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership." } } }, "auth_ref": [ "r175" ] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfBusinessesAcquired", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties purchased", "label": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions and Arrangements", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r566", "r567", "r568", "r570", "r573", "r643", "r644", "r645", "r703", "r704", "r705", "r725", "r727" ] }, "hct_FoxRidgeSeniorLivingatBryantBryantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "FoxRidgeSeniorLivingatBryantBryantMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fox Ridge Bryant - Bryant, AR", "label": "Fox Ridge Senior Living at Bryant - Bryant [Member]", "documentation": "Fox Ridge Senior Living at Bryant - Bryant [Member]" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "hct_LesseeFinanceLeaseNumberOfContracts": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LesseeFinanceLeaseNumberOfContracts", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of finance lease contracts", "label": "Lessee, Finance Lease, Number Of Contracts", "documentation": "Lessee, Finance Lease, Number Of Contracts" } } }, "auth_ref": [] }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesImpaired": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesImpaired", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties impaired", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Impaired", "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Impaired" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsPerShareDeclared", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions declared on preferred stock (in usd per share)", "label": "Preferred Stock, Dividends Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding." } } }, "auth_ref": [] }, "hct_ThirdAmendedAndRestatedAdvisoryAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ThirdAmendedAndRestatedAdvisoryAgreementMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Amended And Restated Advisory Agreement", "label": "Third Amended And Restated Advisory Agreement [Member]", "documentation": "Third Amended And Restated Advisory Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investments, Net [Abstract]", "label": "Real Estate Investments, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r701", "r702", "r705" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r12" ] }, "hct_EconomicDependencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "EconomicDependencyAbstract", "lang": { "en-us": { "role": { "terseLabel": "Economic Dependency [Abstract]", "label": "Economic Dependency [Abstract]", "documentation": "Economic Dependency [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r531", "r532", "r533", "r534", "r536" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r285", "r414" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r285", "r414" ] }, "hct_AdvisorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AdvisorMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisor", "label": "Advisor [Member]", "documentation": "Advisor [Member]" } } }, "auth_ref": [] }, "hct_LeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LeaseRemainingLeaseTerm", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Lease, Remaining Lease Term", "documentation": "Lease, Remaining Lease Term" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r98", "r442", "r926", "r927", "r928", "r1006" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Basic and Diluted Net Loss Per Share Computation", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r930" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r285", "r414" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r285", "r414" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r828" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r899" ] }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForSale": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForSale", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties held for sale", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale", "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale" } } }, "auth_ref": [] }, "hct_PurchasePriceAllocationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PurchasePriceAllocationPolicyPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Price Allocation", "label": "Purchase Price Allocation Policy [Policy Text Block]", "documentation": "Purchase Price Allocation Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_DividendsPayableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableTable", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable [Table]", "label": "Dividends Payable [Table]", "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid." } } }, "auth_ref": [ "r55" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r98", "r99", "r102", "r234", "r235", "r260", "r286", "r287", "r288", "r290", "r296", "r358", "r359", "r442", "r495", "r496", "r497", "r506", "r507", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r540", "r542", "r546", "r565", "r630", "r631", "r646", "r679", "r695", "r722", "r723", "r757", "r825", "r924", "r933", "r973", "r1006" ] }, "us-gaap_RealEstatePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Real Estate", "label": "Real Estate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise." } } }, "auth_ref": [ "r0", "r133" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r96", "r97" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r354", "r355", "r662", "r665", "r667", "r731", "r734", "r738", "r751", "r759", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r777", "r799", "r815", "r941", "r998" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "hct_NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return", "label": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member]", "documentation": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r38", "r79" ] }, "hct_AdvisorAndCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AdvisorAndCompanyMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisor And Company", "label": "Advisor And Company [Member]", "documentation": "Advisor And Company [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r18" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable [Line Items]", "label": "Dividends Payable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "hct_CappedReimbursementAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CappedReimbursementAmountMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capped Reimbursement Amount", "label": "Capped Reimbursement Amount [Member]", "documentation": "Capped Reimbursement Amount [Member]" } } }, "auth_ref": [] }, "hct_SeriesACumulativeRedeemablePerpetualPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SeriesACumulativeRedeemablePerpetualPreferredStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock", "label": "Series A Cumulative Redeemable Perpetual Preferred Stock [Member]", "documentation": "Series A Cumulative Redeemable Perpetual Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total real estate investments, at cost", "terseLabel": "Total real estate investments, at cost", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r602" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r38", "r83", "r86", "r134", "r135", "r138", "r143", "r194", "r195", "r794", "r796", "r925" ] }, "us-gaap_RealEstateInvestmentPropertyAtCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAtCostAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Real estate investments, at cost:", "terseLabel": "Investments in real estate, net:", "label": "Real Estate Investment Property, at Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total real estate investments, net", "verboseLabel": "Net Real Estate Assets Subject to Investment Arrangement", "terseLabel": "Total investments in real estate, net", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r994" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and Fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "hct_TransitionFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "TransitionFeeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition Fee", "label": "Transition Fee [Member]", "documentation": "Transition Fee [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r827" ] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from loans", "label": "Proceeds from Loans", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": [ "r51" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Mortgage notes payable, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r33", "r207", "r409", "r424", "r794", "r795", "r996" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r969" ] }, "hct_MOBLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MOBLoanMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MOB Loan", "label": "MOB Loan [Member]", "documentation": "MOB Loan [Member]" } } }, "auth_ref": [] }, "hct_PreferredUnitsRedemptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PreferredUnitsRedemptionPeriod", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred units, redemption period", "label": "Preferred Units, Redemption Period", "documentation": "Preferred Units, Redemption Period" } } }, "auth_ref": [] }, "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Impairments Recorded", "label": "Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]", "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported." } } }, "auth_ref": [ "r78", "r191" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r241", "r242", "r243", "r315", "r427", "r428", "r429", "r431", "r434", "r439", "r441", "r639", "r640", "r641", "r642", "r798", "r905", "r922" ] }, "hct_RelatedPartyFeesBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyFeesBenchmarkDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Fees, Benchmark [Domain]", "label": "Related Party Fees, Benchmark [Domain]", "documentation": "Related Party Fees, Benchmark [Domain]" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r354", "r355", "r662", "r665", "r667", "r731", "r734", "r738", "r751", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r777", "r799", "r815", "r941", "r998" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedCompanysPortfolioCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedCompanysPortfolioCosts", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing advance fees as a percentage of benchmark, expected company portfolio cost", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs", "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs" } } }, "auth_ref": [] }, "hct_ProceedsFromSaleofInterestRateCashFlowHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ProceedsFromSaleofInterestRateCashFlowHedge", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of interest rate cash flow hedge", "label": "Proceeds From Sale of Interest Rate Cash Flow Hedge", "documentation": "Proceeds From Sale of Interest Rate Cash Flow Hedge" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r250", "r251" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r829" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "hct_MedicalOfficeBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MedicalOfficeBuildingsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MOB Segment", "verboseLabel": "MOB Segment:", "label": "Medical Office Buildings [Member]", "documentation": "Medical Office Buildings [Member]" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r356", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r377", "r378", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r792", "r909", "r998" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r35", "r923" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r892" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r894" ] }, "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovementsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land Improvements", "label": "Land Improvements [Member]", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails": { "parentTag": "hct_LongtermLineofCreditIncludingFinancingCosts", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Credit facilities, net", "terseLabel": "Outstanding balance", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r33", "r207", "r996" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r890" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r867" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facilities", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share attributable to common stockholders - Diluted (in usd per share)", "verboseLabel": "Diluted net loss per share (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r266", "r291", "r292", "r293", "r294", "r295", "r303", "r307", "r308", "r309", "r313", "r528", "r529", "r599", "r615", "r787" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Credit Facilities", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r35" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r560", "r810" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested Restricted Stock", "verboseLabel": "Unvested restricted shares", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r58" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r891" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r283", "r284", "r400", "r429", "r572", "r779", "r782" ] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from non-controlling interests", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": [ "r45" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Share Award Activity", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r13", "r93" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Projected Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r74" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r772", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r772", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "negatedLabel": "Total amount of interest expense presented in the\u2028consolidated statements of operations and comprehensive loss", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r136", "r212", "r262", "r325", "r548", "r706", "r824", "r1004" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r891" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r531", "r532", "r535" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation and Basis of Presentation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r100", "r784" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, end of period", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r53", "r239", "r778" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r893" ] }, "hct_PaymentForSaleOfInterestRateCashFlowHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PaymentForSaleOfInterestRateCashFlowHedge", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for termination of swap", "label": "Payment For Sale Of Interest Rate Cash Flow Hedge", "documentation": "Payment For Sale Of Interest Rate Cash Flow Hedge" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r76" ] }, "us-gaap_CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating fees to related parties", "label": "Costs and Expenses, Related Party", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": [ "r175" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from credit facilities", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r46", "r923" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r895" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r900" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r896" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r187" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r187" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r187" ] }, "hct_ChangeinControlFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ChangeinControlFeeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Control Fee", "label": "Change in Control Fee [Member]", "documentation": "Change in Control Fee [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r832", "r903" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r902" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution declared on common stock (in usd per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r196" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r61", "r760" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "NOI", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r173", "r280", "r321", "r341", "r347", "r350", "r357", "r383", "r384", "r386", "r387", "r388", "r390", "r392", "r394", "r395", "r539", "r789", "r937" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash, end of period", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r912", "r921", "r992", "r997" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum authorized amount as a percentage of shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r181" ] }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditures", "label": "Payments to Acquire Other Property, Plant, and Equipment", "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [ "r180" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r53", "r181", "r276" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of mortgage premiums and discounts, net", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r9", "r134", "r178", "r418" ] }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r601" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r160" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to noncontrolling interests", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r60", "r62", "r131", "r132", "r356", "r760" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r27", "r127", "r410", "r794", "r795" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r60", "r62", "r131", "r132", "r356", "r634", "r760" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r42", "r43", "r168", "r244", "r606", "r632", "r633" ] }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease liability." } } }, "auth_ref": [ "r554" ] }, "hct_SeniorsHousingCommunitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SeniorsHousingCommunitiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SHOP Segment:", "verboseLabel": "SHOP Segment", "label": "Seniors Housing Communities [Member]", "documentation": "Seniors Housing Communities [Member]" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Depreciation, Depletion, and Amortization [Policy Text Block]", "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized." } } }, "auth_ref": [ "r785" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r898" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r555", "r559" ] }, "hct_NumberOfRealEstatePropertiesEncumbered": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberOfRealEstatePropertiesEncumbered", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Encumbered Properties", "label": "Number of Real Estate Properties, Encumbered", "documentation": "Number of Real Estate Properties, Encumbered" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r38", "r83", "r86", "r134", "r135", "r138", "r143", "r194", "r195", "r285", "r397", "r398", "r399", "r400", "r401", "r403", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r550", "r793", "r794", "r795", "r796", "r797", "r923" ] }, "hct_RelatedPartyTransactionBasisofCoreEarningsPerShareBasis": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionBasisofCoreEarningsPerShareBasis", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of core earnings, share basis (in usd per share)", "label": "Related Party Transaction, Basis of Core Earnings, Per Share Basis", "documentation": "Related Party Transaction, Basis of Core Earnings, Per Share Basis" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of deferred financing costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r50" ] }, "hct_DisposalGroupHeldforuseNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DisposalGroupHeldforuseNotDiscontinuedOperationsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-use, Not Discontinued Operations", "label": "Disposal Group, Held-for-use, Not Discontinued Operations [Member]", "documentation": "Disposal Group, Held-for-use, Not Discontinued Operations [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding loan amount", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r33", "r207", "r423" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r356", "r906" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Direct Financing Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r558", "r810" ] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Individual business acquisitions", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r97" ] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Instruments", "verboseLabel": "Number of instruments", "label": "Derivative, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r106", "r107", "r669", "r739", "r740", "r742", "r815" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r547", "r575" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notional amount", "terseLabel": "Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r970", "r971" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate \u201cpay-fixed\u201d swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r776", "r820", "r821" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r547", "r575" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r547", "r575" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r135", "r138", "r397", "r550", "r794", "r795" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, fair value disclosure", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r410", "r538", "r794", "r795" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Straight-line rent receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r547", "r575" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r35", "r923" ] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDeposit", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Escrow deposit", "label": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r141", "r761" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0, "order": 3.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets, at fair value", "totalLabel": "Net Amounts of Assets presented in the Consolidated Balance Sheet", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r246", "r249", "r538", "r660", "r661", "r662", "r663", "r664", "r666", "r667", "r668", "r669", "r670", "r683", "r684", "r739", "r743", "r744", "r745", "r747", "r748", "r782", "r815", "r1001" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r35", "r923" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r286", "r287", "r288", "r314", "r582", "r637", "r659", "r671", "r672", "r673", "r674", "r675", "r676", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r694", "r696", "r699", "r700", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r721", "r816" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r923" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r806" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "terseLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r268", "r291", "r292", "r293", "r294", "r300", "r301", "r306", "r309", "r321", "r341", "r347", "r350", "r789" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r58" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r493" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Ownership Percentage", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r286", "r287", "r288", "r314", "r582", "r637", "r659", "r671", "r672", "r673", "r674", "r675", "r676", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r694", "r696", "r699", "r700", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r721", "r816" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r832", "r903" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate contract sale price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r157", "r158", "r206", "r823", "r995" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r233", "r241", "r242", "r243", "r280", "r303", "r304", "r307", "r309", "r315", "r316", "r357", "r383", "r386", "r387", "r388", "r394", "r395", "r427", "r428", "r431", "r434", "r441", "r539", "r639", "r640", "r641", "r642", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r678", "r698", "r721", "r752", "r753", "r754", "r755", "r756", "r905", "r922", "r929" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "totalLabel": "Total Non-controlling interests", "verboseLabel": "Third Party Net Investment Amount", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r41", "r208", "r280", "r357", "r383", "r386", "r387", "r388", "r394", "r395", "r539", "r607", "r679" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r2", "r169", "r210", "r321", "r341", "r347", "r350", "r600", "r609", "r789" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments:", "verboseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r180" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to non-controlling interest holders", "terseLabel": "Distributions", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r196" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r198" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r41", "r99", "r101", "r174" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireRealEstate", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Property acquisitions", "label": "Payments to Acquire Real Estate", "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner." } } }, "auth_ref": [ "r180" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r9", "r77" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r4", "r146", "r152", "r189", "r237", "r238" ] }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred costs, net", "label": "Deferred Costs", "documentation": "The carrying amount of deferred costs." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r668", "r670", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r709", "r710", "r711", "r712", "r715", "r716", "r717", "r718", "r739", "r741", "r744", "r747", "r813", "r815" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r187" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r460", "r463", "r491", "r492", "r494", "r806" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated as hedging instruments:", "verboseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r18" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r900" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r43", "r974", "r975" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r879" ] }, "hct_LondonInterbankOfferedRateOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LondonInterbankOfferedRateOneMonthMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIBOR One Month", "label": "London Interbank Offered Rate One Month [Member]", "documentation": "London Interbank Offered Rate One Month" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r866" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r879" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r834", "r845", "r856", "r881" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r879" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r843", "r851", "r862", "r879", "r887", "r891", "r899" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r843", "r851", "r862", "r879", "r887", "r891", "r899" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r160", "r162", "r163", "r185", "r679", "r695", "r722", "r723", "r811", "r826", "r924", "r933", "r973", "r1006" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r833", "r844", "r855", "r880" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during period, issued for services (in shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r127", "r129", "r130" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r410", "r794", "r795" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r835", "r846", "r857", "r882" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r129", "r130" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r833", "r844", "r855", "r880" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, net", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r94", "r159", "r160", "r196" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2023 (remainder)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r925" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r531", "r532", "r535" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r537" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair\u00a0Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r410", "r538", "r794", "r795" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding - Diluted (in shares)", "verboseLabel": "Diluted weighted-average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r302", "r309" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Preferred Stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r17", "r159", "r160", "r196", "r648", "r721", "r753", "r825" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r836", "r847", "r858", "r883" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r836", "r847", "r858", "r883" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding - Basic (in shares)", "verboseLabel": "Basic weighted-average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r300", "r309" ] }, "us-gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Offsetting Assets", "label": "Offsetting Assets [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r165", "r248" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r828" ] }, "hct_AdvanceOnLoanOrOtherInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AdvanceOnLoanOrOtherInvestmentMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance on Loan or Other Investment", "label": "Advance on Loan or Other Investment [Member]", "documentation": "Advance on Loan or Other Investment [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r867" ] }, "hct_NumberofSeniorHousingCommunities": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberofSeniorHousingCommunities", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of senior housing communities", "label": "Number of Senior Housing Communities", "documentation": "Number of Senior Housing Communities" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "terseLabel": "Expenses incurred", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r867" ] }, "hct_DRIPPeriodofNoticetoAlterAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DRIPPeriodofNoticetoAlterAgreement", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DRIP period of notice to alter agreement", "label": "DRIP, Period of Notice to Alter Agreement", "documentation": "DRIP, Period of Notice to Alter Agreement" } } }, "auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties owned", "verboseLabel": "Encumbered properties", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "hct_SecuredOvernightFinancingRateOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SecuredOvernightFinancingRateOneMonthMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate One Month", "label": "Secured Overnight Financing Rate One Month [Member]", "documentation": "Secured Overnight Financing Rate One Month" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r871" ] }, "hct_LongTermDebtMaturityafterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LongTermDebtMaturityafterYearFour", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Four", "documentation": "Long-Term Debt, Maturity, after Year Four" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r870" ] }, "us-gaap_DeferredRentCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRentCredit", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent", "label": "Deferred Rent Credit", "documentation": "Amount of excess of rental payment required by lease over rental income recognized." } } }, "auth_ref": [ "r218", "r978" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r828" ] }, "hct_AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Realty Capital Healthcare III Advisors, LLC", "label": "American Realty Capital Healthcare III Advisors, LLC [Member]", "documentation": "American Realty Capital Healthcare III Advisors, LLC [Member]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r869" ] }, "hct_DerivativeStrikePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DerivativeStrikePricePercentage", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strike price percentage", "label": "Derivative, Strike Price, Percentage", "documentation": "Derivative, Strike Price, Percentage" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r1", "r191" ] }, "hct_RelatedPartyTransactionOversightFeesEarnedByRelatedPartyPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionOversightFeesEarnedByRelatedPartyPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oversight fees earned by related party", "label": "Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark", "documentation": "Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark" } } }, "auth_ref": [] }, "hct_VariousSeniorsHousingCommunitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "VariousSeniorsHousingCommunitiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Various held for use SHOPs", "label": "Various Seniors Housing Communities [Member]", "documentation": "Various Seniors Housing Communities [Member]" } } }, "auth_ref": [] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r868" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charges", "negatedLabel": "Impairment charges", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": [ "r920", "r935" ] }, "hct_SOFRBasedInterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SOFRBasedInterestRateSwapMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "SOFR Based Interest Rate Swap [Member]", "documentation": "SOFR Based Interest Rate Swap" } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued through stock dividends", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedThirdPartyAcquisitionCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedThirdPartyAcquisitionCosts", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursed fees to related party, percentage of benchmark", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs", "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r58" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r868" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r159", "r427" ] }, "hct_TransferAgentandOtherProfessionalFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "TransferAgentandOtherProfessionalFeesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees and other reimbursements", "label": "Transfer Agent and Other Professional Fees [Member]", "documentation": "Transfer Agent and other professional fees [Member]" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r869" ] }, "hct_RelatedPartyAgreementTermofAgreementRenewalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyAgreementTermofAgreementRenewalPeriod", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal period", "label": "Related Party Agreement, Term of Agreement, Renewal Period", "documentation": "Related Party Agreement, Term of Agreement, Renewal Period" } } }, "auth_ref": [] }, "hct_BelowMarketLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BelowMarketLeaseMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below-market lease liabilities", "label": "Below Market Lease [Member]", "documentation": "Below Market Lease [Member]" } } }, "auth_ref": [] }, "hct_KeyBankFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "KeyBankFacilityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "KeyBank Facility", "label": "KeyBank Facility [Member]", "documentation": "KeyBank Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r310" ] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period" } } }, "auth_ref": [] }, "hct_LongTermLineOfCreditMaturityExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LongTermLineOfCreditMaturityExtensionTerm", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity extension", "label": "Long Term Line Of Credit, Maturity, Extension Term", "documentation": "Long Term Line Of Credit, Maturity, Extension Term" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsShares", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions declared in common stock (in shares)", "verboseLabel": "Share increase from stock dividends (in shares)", "label": "Common Stock Dividends, Shares", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r159", "r678" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r870" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "periodStartLabel": "Preferred stock, shares outstanding beginning balance (in shares)", "periodEndLabel": "Preferred stock, shares outstanding Ending balance (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r159", "r678", "r695", "r1006", "r1007" ] }, "hct_NoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NoncontrollingInterestTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Noncontrolling Interest on Balance Sheet", "label": "Noncontrolling Interest [Table Text Block]", "documentation": "Noncontrolling Interest" } } }, "auth_ref": [] }, "hct_BarclaysMOBLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BarclaysMOBLoanMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Barclays MOB Loan", "label": "Barclay\u2019s MOB Loan [Member]", "documentation": "Barclay\u2019s MOB Loan" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r60", "r62", "r131", "r132", "r356", "r760" ] }, "us-gaap_PreferredUnitsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredUnitsIssued", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of preferred OP units issued (in shares)", "label": "Preferred Units, Issued", "documentation": "The number of preferred units issued." } } }, "auth_ref": [ "r197" ] }, "hct_LesseeLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LesseeLeaseRenewalTerm", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term", "label": "Lessee, Lease, Renewal Term", "documentation": "Lessee, Lease, Renewal Term" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r111", "r114", "r116", "r119", "r668", "r670", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r709", "r710", "r711", "r712", "r715", "r716", "r717", "r718", "r739", "r741", "r744", "r747", "r782", "r813", "r815" ] }, "hct_NoncashOrPartNoncashAmountsOutstandingUnderPriorCreditFacilityRepaidWithProceedsFromRealEstateSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NoncashOrPartNoncashAmountsOutstandingUnderPriorCreditFacilityRepaidWithProceedsFromRealEstateSales", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts outstanding under the Prior Credit Facility repaid with proceeds from real estate sales", "label": "Noncash, Or Part Noncash, Amounts Outstanding Under Prior Credit Facility Repaid With Proceeds From Real Estate Sales", "documentation": "Noncash, Or Part Noncash, Amounts Outstanding Under Prior Credit Facility Repaid With Proceeds From Real Estate Sales" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r870" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r870" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r159", "r427" ] }, "hct_TaxDepreciationDeductionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "TaxDepreciationDeductionMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Depreciation Deduction", "label": "Tax Depreciation Deduction [Member]", "documentation": "Tax Depreciation Deduction [Member]" } } }, "auth_ref": [] }, "hct_BuildingsFixturesandImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BuildingsFixturesandImprovements", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings, fixtures and improvements", "label": "Buildings, Fixtures and Improvements", "documentation": "Buildings, Fixtures and Improvements" } } }, "auth_ref": [] }, "hct_AcquisitionCostsReimbursementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AcquisitionCostsReimbursementsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition cost reimbursements", "label": "Acquisition Costs Reimbursements [Member]", "documentation": "Acquisition Costs Reimbursements [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r58" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r871" ] }, "hct_RelatedPartyTransactionContingentGoodFaithNegotiationsOfFixedComponentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionContingentGoodFaithNegotiationsOfFixedComponentTerm", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent good faith negotiations of fixed component, term", "label": "Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term", "documentation": "Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term" } } }, "auth_ref": [] }, "us-gaap_InterestRateCapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCapMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate caps", "label": "Interest Rate Cap [Member]", "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount." } } }, "auth_ref": [ "r776" ] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "hct_ClassBUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ClassBUnitsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Units", "label": "Class B Units [Member]", "documentation": "Class B Units [Member]" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "hct_BMOMOBLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BMOMOBLoanMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BMO CMBS Loan", "label": "BMO MOB Loan [Member]", "documentation": "BMO MOB Loan" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, gain (loss) on disposal", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r373", "r920", "r934" ] }, "hct_ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services", "label": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block]", "documentation": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r871" ] }, "us-gaap_PreferredUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredUnitsOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred units outstanding (in shares)", "label": "Preferred Units, Outstanding", "documentation": "The number of preferred units outstanding." } } }, "auth_ref": [ "r197" ] }, "hct_RelatedPartyTransactionFeePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionFeePaymentPeriod", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fee payment period", "label": "Related Party Transaction, Fee Payment Period", "documentation": "Related Party Transaction, Fee Payment Period" } } }, "auth_ref": [] }, "hct_DebtInstrumentInterestRateEconomicPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DebtInstrumentInterestRateEconomicPercentage", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Economic Percentage", "documentation": "Debt Instrument, Interest Rate, Economic Percentage" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting for Leases, Lessee Accounting", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r556" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStock", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allocation for preferred stock", "negatedLabel": "Distributions declared on preferred stock", "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r7", "r196" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r160" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value by Balance Sheet", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r127", "r129" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r530" ] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Dividends", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilities" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facilities", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r192", "r278", "r396", "r402", "r403", "r404", "r405", "r406", "r407", "r412", "r419", "r420", "r422" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r557" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "negatedTerseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r176", "r700" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r830" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value, 300,000,000 shares authorized, 109,877,212 shares and 105,080,531 shares issued and outstanding as of September\u00a030, 2023 and December\u00a031, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r160", "r605", "r811" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash flow hedge reclassification current", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings." } } }, "auth_ref": [ "r117" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r159", "r604", "r811" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r160", "r678" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge reclassification in next twelve months", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r126" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Common stock, shares outstanding beginning balance (in shares)", "periodEndLabel": "Common stock, shares outstanding ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r160", "r678", "r695", "r1006", "r1007" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r865" ] }, "us-gaap_DeferredRentReceivablesNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRentReceivablesNetNoncurrent", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Straight-line rent receivable, net", "label": "Deferred Rent Receivables, Net, Noncurrent", "documentation": "Amount of excess of rental income recognized over rental payment required by lease, classified as noncurrent." } } }, "auth_ref": [ "r219", "r978" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r557" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r898" ] }, "hct_RelatedPartyTransactionAssetThresholdQualifyingManagement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionAssetThresholdQualifyingManagement", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under management threshold", "label": "Related Party Transaction, Asset Threshold Qualifying Management", "documentation": "Related Party Transaction, Asset Threshold Qualifying Management" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r932", "r982" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofBasicandDilutedNetLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share attributable to common stockholders - Basic (in usd per share)", "verboseLabel": "Basic net loss per share (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r266", "r291", "r292", "r293", "r294", "r295", "r300", "r303", "r307", "r308", "r309", "r313", "r528", "r529", "r599", "r615", "r787" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r904" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r285", "r323", "r340", "r341", "r342", "r343", "r344", "r346", "r350", "r383", "r384", "r385", "r386", "r388", "r389", "r391", "r393", "r394", "r937", "r938" ] }, "us-gaap_PaymentsForDerivativeInstrumentInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForDerivativeInstrumentInvestingActivities", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments in non-designated interest rate caps", "label": "Payments for Derivative Instrument, Investing Activities", "documentation": "The cash outflow for derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [ "r919" ] }, "us-gaap_CommonUnitIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssuanceValue", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units issued", "label": "Common Unit, Issuance Value", "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r285", "r323", "r340", "r341", "r342", "r343", "r344", "r346", "r350", "r383", "r384", "r385", "r386", "r388", "r389", "r391", "r393", "r394", "r937", "r938" ] }, "us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedPartnersCapitalAccountUnitsOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited partner units (in shares)", "label": "Limited Partners' Capital Account, Units Outstanding", "documentation": "The number of limited partner units outstanding." } } }, "auth_ref": [ "r197" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": [ "r759", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770" ] }, "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForDerivativeInstrumentFinancingActivities", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for derivative instruments", "label": "Payments for Derivative Instrument, Financing Activities", "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [ "r270", "r783" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]" } } }, "auth_ref": [ "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rentable square feet", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r898" ] }, "hct_SharePriceEquityInstrumentsNetofSellingCommissionsandDealerFees": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SharePriceEquityInstrumentsNetofSellingCommissionsandDealerFees", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity instruments, net of selling commissions (in usd per share)", "label": "Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees", "documentation": "Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r410", "r452", "r453", "r454", "r455", "r456", "r457", "r577", "r578", "r579", "r794", "r795", "r800", "r801", "r802" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r273" ] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredIntangiblesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredIntangiblesAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intangibles:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired Intangibles [Abstract]", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired Intangibles [Abstract]" } } }, "auth_ref": [] }, "hct_LesseeOperatingLeaseRenewalTermExcluded": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LesseeOperatingLeaseRenewalTermExcluded", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term of lease excluded", "label": "Lessee, Operating Lease, Renewal Term, Excluded", "documentation": "Lessee, Operating Lease, Renewal Term, Excluded" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "hct_PublicStockOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PublicStockOfferingMember", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Stock Offering", "label": "Public Stock Offering [Member]", "documentation": "Public Stock Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r37", "r135", "r425", "r550" ] }, "stpr_PA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "PA", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pennsylvania", "label": "PENNSYLVANIA" } } }, "auth_ref": [] }, "hct_ReimbursementsofAdministrativeServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ReimbursementsofAdministrativeServicesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursements of Administrative Services", "label": "Reimbursements of Administrative Services [Member]", "documentation": "Reimbursements of Administrative Services [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, stated percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r37", "r398" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Recurring Fair Value Measurements", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r21", "r127", "r128", "r202" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r273" ] }, "hct_NumberOfIntercompanyLeasesModified": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberOfIntercompanyLeasesModified", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of intercompany leases modified", "label": "Number Of Intercompany Leases Modified", "documentation": "Number Of Intercompany Leases Modified" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, dividend rate, percentage", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r428", "r730", "r733", "r735", "r750" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r181", "r182", "r183" ] }, "hct_AssetManagementFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AssetManagementFeesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset management fees", "label": "Asset Management Fees [Member]", "documentation": "Asset Management Fees [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r36", "r280", "r357", "r383", "r384", "r386", "r387", "r388", "r390", "r392", "r394", "r395", "r512", "r515", "r516", "r539", "r677", "r788", "r826", "r937", "r984", "r985" ] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "TX", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Texas", "label": "TEXAS" } } }, "auth_ref": [] }, "hct_AmendedandRestatedPropertyManagementandLeasingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AmendedandRestatedPropertyManagementandLeasingAgreementMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended and Restated Property Management and Leasing Agreement", "label": "Amended and Restated Property Management and Leasing Agreement [Member]", "documentation": "Amended and Restated Property Management and Leasing Agreement [Member]" } } }, "auth_ref": [] }, "hct_AmortizationAccretionOfTerminatedSwapPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AmortizationAccretionOfTerminatedSwapPayment", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Accretion) amortization of terminated swap", "label": "Amortization (Accretion) Of Terminated Swap Payment", "documentation": "Amortization (Accretion) Of Terminated Swap Payment" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r490", "r498" ] }, "hct_DerivativeNumberOfInstrumentsRenewed": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DerivativeNumberOfInstrumentsRenewed", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments held, renew", "label": "Derivative, Number Of Instruments Renewed", "documentation": "Derivative, Number Of Instruments Renewed" } } }, "auth_ref": [] }, "hct_CommonUnitIssuanceValueSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CommonUnitIssuanceValueSharePrice", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units issued (in usd per share)", "label": "Common Unit, Issuance Value Share Price", "documentation": "Common Unit, Issuance Value Share Price" } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r832", "r903" ] }, "hct_DebtInstrumentCovenantsDebtServiceCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DebtInstrumentCovenantsDebtServiceCoverageRatio", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt service coverage ratio", "label": "Debt Instrument, Covenants, Debt Service Coverage Ratio", "documentation": "Debt Instrument, Covenants, Debt Service Coverage Ratio" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionBasisofRealEstateCostPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionBasisofRealEstateCostPercent", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate cost percent multiplier", "label": "Related Party Transaction Basis of Real Estate Cost Percent", "documentation": "Related Party Transaction Basis of Real Estate Cost Percent" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r458", "r569", "r570", "r672", "r673", "r674", "r675", "r676", "r694", "r696", "r728" ] }, "hct_ScheduleOfEarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodTable": { "xbrltype": "stringItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodTable", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "documentation": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]" } } }, "auth_ref": [] }, "hct_OpUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "OpUnitsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OP Units", "verboseLabel": "Common OP Units", "label": "OP Units [Member]", "documentation": "OP Units [Member]" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r899" ] }, "hct_NumberOfContractorsTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberOfContractorsTerminated", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of contractors terminated", "label": "Number Of Contractors Terminated", "documentation": "Number Of Contractors Terminated" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "hct_RelatedPartyFeesByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyFeesByBenchmarkAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Fees, by Benchmark [Axis]", "label": "Related Party Fees, by Benchmark [Axis]", "documentation": "Related Party Fees, by Benchmark [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r38", "r285", "r397", "r398", "r399", "r400", "r401", "r403", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r418", "r550", "r793", "r794", "r795", "r796", "r797", "r923" ] }, "hct_CapitalOneFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CapitalOneFacilityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital One Facility", "label": "Capital One Facility [Member]", "documentation": "Capital One Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r164", "r209", "r608", "r811", "r924", "r933", "r973" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r283", "r284", "r400", "r429", "r572", "r781", "r782" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "hct_ProceedsFromGovernmentAssistanceCARESAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ProceedsFromGovernmentAssistanceCARESAct", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional CARES Act funding", "label": "Proceeds From Government Assistance, CARES Act", "documentation": "Proceeds From Government Assistance, CARES Act" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionQuarterlyAssetManagementFeeEarnedByRelatedPartyPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionQuarterlyAssetManagementFeeEarnedByRelatedPartyPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly asset management earned by related party, percentage of benchmark", "label": "Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark", "documentation": "Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark" } } }, "auth_ref": [] }, "hct_DeferredTaxAssetValuationAllowancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DeferredTaxAssetValuationAllowancePercentage", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance, percentage", "label": "Deferred Tax Asset, Valuation Allowance, Percentage", "documentation": "Deferred Tax Asset, Valuation Allowance, Percentage" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionPeriodofNoticetoAlterAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionPeriodofNoticetoAlterAgreement", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period to terminate early with board approval", "label": "Related Party Transaction, Period of Notice to Alter Agreement", "documentation": "Related Party Transaction, Period of Notice to Alter Agreement" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionFeeMultiplier": { "xbrltype": "pureItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionFeeMultiplier", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fee multiplier", "label": "Related Party Transaction, Fee Multiplier", "documentation": "Related Party Transaction, Fee Multiplier" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionVotingPercentageRequiredtoAlterAgreement": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionVotingPercentageRequiredtoAlterAgreement", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of board approval required for early termination", "label": "Related Party Transaction, Voting Percentage Required to Alter Agreement", "documentation": "Related Party Transaction, Voting Percentage Required to Alter Agreement" } } }, "auth_ref": [] }, "hct_PreTaxNonCompoundedReturnOnCapitalContributionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PreTaxNonCompoundedReturnOnCapitalContributionMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax Non-compounded Return on Capital Contribution", "label": "Pre-tax Non-compounded Return on Capital Contribution [Member]", "documentation": "Pre-tax Non-compounded Return on Capital Contribution [Member]" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionSubordinatedPerformanceFeeEarnedByRelatedPartyPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionSubordinatedPerformanceFeeEarnedByRelatedPartyPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subordinated performance fee as a percentage of benchmark", "label": "Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark", "documentation": "Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark" } } }, "auth_ref": [] }, "hct_LesseeOperatingLeaseNumberOfContracts": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LesseeOperatingLeaseNumberOfContracts", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating lease contracts", "label": "Lessee, Operating Lease, Number Of Contracts", "documentation": "Lessee, Operating Lease, Number Of Contracts" } } }, "auth_ref": [] }, "hct_SeriesBCumulativeRedeemablePerpetualPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SeriesBCumulativeRedeemablePerpetualPreferredStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Preferred Stock", "label": "Series B Cumulative Redeemable Perpetual Preferred Stock [Member]", "documentation": "Series B Cumulative Redeemable Perpetual Preferred Stock" } } }, "auth_ref": [] }, "hct_RealEstateInvestmentAtCostRelatingtoNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RealEstateInvestmentAtCostRelatingtoNotesPayable", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate investment, at cost relating to notes payable", "label": "Real Estate Investment, At Cost Relating to Notes Payable", "documentation": "Real Estate Investment, At Cost Relating to Notes Payable" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expenses", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r177" ] }, "hct_PriorCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PriorCreditFacilityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Credit Facility", "label": "Prior Credit Facility [Member]", "documentation": "Prior Credit Facility" } } }, "auth_ref": [] }, "hct_ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital", "label": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member]", "documentation": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r285", "r397", "r398", "r399", "r400", "r401", "r403", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r550", "r793", "r794", "r795", "r796", "r797", "r923" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction amount", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r140", "r569" ] }, "hct_RelatedPartyTransactionBaseManagementFeeofNetProceedsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionBaseManagementFeeofNetProceedsPercent", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base management fee of net proceeds", "label": "Related Party Transaction, Base Management Fee of Net Proceeds, Percent", "documentation": "Related Party Transaction, Base Management Fee of Net Proceeds, Percent" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r33", "r156", "r157", "r205", "r207", "r285", "r397", "r398", "r399", "r400", "r401", "r403", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r418", "r550", "r793", "r794", "r795", "r796", "r797", "r923" ] }, "hct_AmericanRealtyCapitalHealthcareAdvisorsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AmericanRealtyCapitalHealthcareAdvisorsLLCMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Realty Capital Healthcare Advisors, LLC", "label": "American Realty Capital Healthcare Advisors, LLC [Member]", "documentation": "American Realty Capital Healthcare Advisors, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r530", "r536" ] }, "hct_ShilohIllinoisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ShilohIllinoisMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shiloh - Illinois", "label": "Shiloh - Illinois [Member]", "documentation": "Shiloh - Illinois [Member]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r837", "r848", "r859", "r884" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r236", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r356", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r375", "r377", "r378", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r792", "r909", "r998" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r839", "r850", "r861", "r886" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r841", "r852", "r863", "r888" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on credit facilities", "terseLabel": "Payments on credit facilities", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r49", "r923" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r47" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r838", "r849", "r860", "r885" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r583" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r551" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r840", "r851", "r862", "r887" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r840", "r851", "r862", "r879", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r583", "r584" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other assets", "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, collateral amount", "label": "Debt Instrument, Collateral Amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r144" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r73", "r74" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r840", "r851", "r862", "r887" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting for Leases, Lessor Accounting", "label": "Lessor, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r228", "r229", "r230", "r563" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r840", "r851", "r862", "r887" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r271", "r274", "r275" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r841", "r852", "r863", "r888" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r840", "r851", "r862", "r887" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r840", "r851", "r862", "r887" ] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to non-controlling interest holders", "terseLabel": "Distributions to non-controlling interest holders", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": [ "r48" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on mortgage notes payable", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r49" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "hct_GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties", "label": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member]", "documentation": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r842", "r853", "r864", "r889" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r170", "r183", "r211", "r238", "r253", "r256", "r261", "r280", "r289", "r291", "r292", "r293", "r294", "r297", "r298", "r305", "r321", "r341", "r347", "r350", "r357", "r383", "r384", "r386", "r387", "r388", "r390", "r392", "r394", "r395", "r529", "r539", "r612", "r697", "r719", "r720", "r789", "r824", "r937" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r64", "r65", "r66", "r224", "r225", "r226", "r227" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intangible assets", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r186", "r583" ] }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends paid on preferred stock", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." } } }, "auth_ref": [ "r48" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r334", "r335", "r336", "r337", "r338", "r339", "r354", "r790" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r188" ] }, "hct_MortgageNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MortgageNotePayableMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage Note Payable", "label": "Mortgage Note Payable [Member]", "documentation": "Mortgage Note Payable" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r552" ] }, "hct_AnnualTargetedInvestorReturnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AnnualTargetedInvestorReturnMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual Targeted Investor Return", "label": "Annual Targeted Investor Return [Member]", "documentation": "Annual Targeted Investor Return [Member]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r913" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on designated derivatives", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r30", "r254", "r257", "r264", "r540", "r541", "r546", "r597", "r613", "r914", "r915" ] }, "hct_LessorOperatingLeasePaymenttobeReceivedafterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LessorOperatingLeasePaymenttobeReceivedafterYearFour", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Four", "documentation": "Lessor, Operating Lease, Payment to be Received, after Year Four" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r29", "r122" ] }, "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash paid for real estate investments, including acquisitions", "label": "Business Acquisition Cost Of Acquired Entity Cash Paid In Period", "documentation": "Business Acquisition Cost Of Acquired Entity Cash Paid In Period" } } }, "auth_ref": [] }, "hct_PropertyOperatingandMaintenanceExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PropertyOperatingandMaintenanceExpenseMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Operating and Maintenance Expense", "label": "Property Operating and Maintenance Expense [Member]", "documentation": "Property Operating and Maintenance Expense [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r451", "r459", "r486", "r487", "r488", "r580", "r581", "r628", "r669", "r670", "r729", "r732", "r736", "r737", "r749", "r773", "r774", "r791", "r798", "r805", "r812", "r815", "r936", "r939", "r987", "r988", "r989", "r990", "r991" ] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets, at fair value", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral", "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r28", "r32", "r124" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r237" ] }, "hct_FannieCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "FannieCreditFacilityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fannie Mae Master Credit Facilities", "label": "Fannie Credit Facility [Member]", "documentation": "Fannie Credit Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "CARES Act Grants", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r699", "r775", "r786" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r562" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "hct_PaymentsForEscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PaymentsForEscrowDeposit", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for escrow deposit", "label": "Payments For Escrow Deposit", "documentation": "Payments For Escrow Deposit" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives and Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r201", "r518", "r525" ] }, "hct_RelatedPartyTransactionCumulativeCapitalInvestmentReturnAsPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionCumulativeCapitalInvestmentReturnAsPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative capital investment return to investors as a percentage of benchmark", "label": "Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark", "documentation": "Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r459", "r581", "r628", "r669", "r670", "r729", "r732", "r736", "r737", "r749", "r773", "r774", "r791", "r798", "r805", "r812", "r939", "r986", "r987", "r988", "r989", "r990", "r991" ] }, "us-gaap_DerivativeCapInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCapInterestRate", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap", "label": "Derivative, Cap Interest Rate", "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r451", "r459", "r486", "r487", "r488", "r580", "r581", "r628", "r669", "r670", "r729", "r732", "r736", "r737", "r749", "r773", "r774", "r791", "r798", "r805", "r812", "r815", "r936", "r939", "r987", "r988", "r989", "r990", "r991" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "terseLabel": "Total present value of minimum lease payments", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r553" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 10.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on non-designated derivatives", "negatedTerseLabel": "Gain on non-designated derivative instruments", "verboseLabel": "Gain on non-designated derivatives", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r118", "r908" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "hct_NumberOfIndependentContractors": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberOfIndependentContractors", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of independent contractors", "label": "Number Of Independent Contractors", "documentation": "Number Of Independent Contractors" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r459", "r581", "r628", "r669", "r670", "r729", "r732", "r736", "r737", "r749", "r773", "r774", "r791", "r798", "r805", "r812", "r939", "r986", "r987", "r988", "r989", "r990", "r991" ] }, "us-gaap_DerivativeAverageVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAverageVariableInterestRate", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average variable interest rate", "label": "Derivative, Average Variable Interest Rate", "documentation": "Average variable interest rate related to the group of interest rate derivatives." } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionBaseManagementFeeOfNetProceedsVariablePortionFactorPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionBaseManagementFeeOfNetProceedsVariablePortionFactorPercent", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base management fee of net proceeds, variable portion factor, percent", "label": "Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent", "documentation": "Related Party Transaction, Base Management Fee Of Net Proceeds, Variable Portion Factor, Percent" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ] }, "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating (loss) income before loss (gain) on sale of real estate investments", "label": "Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments", "documentation": "Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r6", "r10", "r22" ] }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 9.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Loss) gain on sale of real estate investments", "negatedTerseLabel": "Loss on sale of real estate investments, net", "verboseLabel": "Gain (loss) on sale of real estate investments", "label": "Gains (Losses) on Sales of Investment Real Estate", "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes." } } }, "auth_ref": [ "r221", "r222", "r223", "r917", "r918", "r920", "r993", "r1005" ] }, "hct_CommonShareEquivalentsSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CommonShareEquivalentsSharesOutstanding", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B units (in shares)", "label": "Common Share Equivalents, Shares Outstanding", "documentation": "Common Share Equivalents, Shares Outstanding" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r96", "r97", "r509", "r803", "r804" ] }, "hct_RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess depreciation deductions maximum", "label": "Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum", "documentation": "Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum" } } }, "auth_ref": [] }, "hct_DepreciationandAmortizationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DepreciationandAmortizationExpenseMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization Expense", "label": "Depreciation and Amortization Expense [Member]", "documentation": "Depreciation and Amortization Expense [Member]" } } }, "auth_ref": [] }, "hct_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsCashReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsCashReceived", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from non-designated derivative instruments", "label": "Derivative Instruments Not Designated As Hedging Instruments, Cash Received", "documentation": "Derivative Instruments Not Designated As Hedging Instruments, Cash Received" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets, at fair value", "verboseLabel": "Gross Amounts of Recognized Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r26", "r113", "r166", "r245", "r782" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r509", "r803", "r804" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r525" ] }, "hct_DerivativeNumberOfInstrumentsTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DerivativeNumberOfInstrumentsTerminated", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments terminated", "label": "Derivative, Number of Instruments Terminated", "documentation": "Derivative, Number of Instruments Terminated" } } }, "auth_ref": [] }, "stpr_FL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "FL", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Florida", "label": "FLORIDA" } } }, "auth_ref": [] }, "hct_MasterCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MasterCreditFacilityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fannie Mae Master Credit Facilities", "label": "Master Credit Facility [Member]", "documentation": "Master Credit Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r18", "r104", "r105", "r107", "r108", "r112", "r116", "r120", "r121", "r125", "r525" ] }, "us-gaap_BelowMarketLeaseAmortizationIncomeNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market leases, amortization income, 2024", "label": "Below Market Lease, Amortization Income, Year One", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "hct_DebtInstrumentPeriodRequiredAfterClosingBeforePrepayment": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DebtInstrumentPeriodRequiredAfterClosingBeforePrepayment", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period after closing required before prepayment", "label": "Debt Instrument, Period Required After Closing Before Prepayment", "documentation": "Debt Instrument, Period Required After Closing Before Prepayment" } } }, "auth_ref": [] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBuildingFixturesandImprovementsCapitalLeasesAcquiredinPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBuildingFixturesandImprovementsCapitalLeasesAcquiredinPeriod", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings, fixtures and improvements", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future\u00a0 Base\u00a0Rent\u00a0Payments", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "hct_StockRepurchaseProgramSharePricePercentageOfEstimatedPerShareNAV": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "StockRepurchaseProgramSharePricePercentageOfEstimatedPerShareNAV", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase price per share, percentage of estimated per-share NAV", "label": "Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV", "documentation": "Stock Repurchase Program, Share Price, Percentage Of Estimated Per-Share NAV" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionBasisCostOfLivingPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionBasisCostOfLivingPercent", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of living percent multiplier", "label": "Related Party Transaction Basis Cost Of Living Percent", "documentation": "Related Party Transaction Basis Cost Of Living Percent" } } }, "auth_ref": [] }, "hct_RealEstateCostMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RealEstateCostMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Cost", "label": "Real Estate Cost [Member]", "documentation": "Real Estate Cost [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r374", "r376", "r705" ] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearTwo", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market leases, amortization income, 2025", "label": "Below Market Lease, Amortization Income, Year Two", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearFour", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market leases, amortization income, 2027", "label": "Below Market Lease, Amortization Income, Year Four", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "hct_TripleNetLeasedHealthcareFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "TripleNetLeasedHealthcareFacilitiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triple-Net Leased Properties", "label": "Triple-Net Leased Healthcare Facilities [Member]", "documentation": "Triple-Net Leased Healthcare Facilities [Member]" } } }, "auth_ref": [] }, "hct_NoncashOrPartNoncashMortgageNotesPayableRepaidWithProceedsFromRealEstateSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NoncashOrPartNoncashMortgageNotesPayableRepaidWithProceedsFromRealEstateSales", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage notes payable repaid with proceeds from real estate sales", "label": "Noncash, Or Part Noncash, Mortgage Notes Payable Repaid With Proceeds From Real Estate Sales", "documentation": "Noncash, Or Part Noncash, Mortgage Notes Payable Repaid With Proceeds From Real Estate Sales" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r569", "r570", "r983" ] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearThree", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market leases, amortization income, 2026", "label": "Below Market Lease, Amortization Income, Year Three", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts of Recognized (Liabilities)", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r26", "r113", "r166", "r245", "r782" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r376", "r705" ] }, "hct_NumberOfRealEstatePropertiesFailedToRecoverCarryingValue": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberOfRealEstatePropertiesFailedToRecoverCarryingValue", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties impaired", "label": "Number Of Real Estate Properties, Failed To Recover Carrying Value", "documentation": "Number Of Real Estate Properties, Failed To Recover Carrying Value" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockDividendsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r547", "r575" ] }, "hct_FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fox Ridge North Little Rock - North Little Rock, AR", "label": "Fox Ridge Senior Living at Parkstone - North Little Rock [Member]", "documentation": "Fox Ridge Senior Living at Parkstone - North Little Rock [Member]" } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market leases, amortization income, remainder 2023 (reminder)", "label": "Below Market Lease, Amortization Income, Remainder of Fiscal Year", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "hct_AmortizationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AmortizationExpenseMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization Expense", "label": "Amortization Expense [Member]", "documentation": "Amortization Expense [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "hct_RestrictedSharePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RestrictedSharePlanMember", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Plan", "label": "Restricted Share Plan [Member]", "documentation": "Restricted Share Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses (including $665 and $47, respectively, due to related parties as of September 30, 2023 and December\u00a031, 2022)", "verboseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r142" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Balance Sheet Location", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "hct_ConsumerPriceIndexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ConsumerPriceIndexMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost Of Living", "label": "Consumer Price Index [Member]", "documentation": "Consumer Price Index [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r344", "r350" ] }, "hct_NoncashOrPartNoncashProceedsFromSaleAndCollectionOfMortgageNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NoncashOrPartNoncashProceedsFromSaleAndCollectionOfMortgageNotesPayable", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from real estate sales used to repay mortgage notes payable", "label": "Noncash, Or Part Noncash, Proceeds From Sale And Collection Of Mortgage Notes Payable", "documentation": "Noncash, Or Part Noncash, Proceeds From Sale And Collection Of Mortgage Notes Payable" } } }, "auth_ref": [] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLeaseLiabilitiesAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLeaseLiabilitiesAcquired", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Market lease liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired" } } }, "auth_ref": [] }, "hct_PlazaDelRioMedicalOfficeCampusPortfolioAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PlazaDelRioMedicalOfficeCampusPortfolioAZMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plaza Del Rio Medical Office Campus Portfolio - Peoria, AZ", "label": "Plaza Del Rio Medical Office Campus Portfolio AZ [Member]", "documentation": "Plaza Del Rio Medical Office Campus Portfolio AZ [Member]" } } }, "auth_ref": [] }, "hct_PreferredUnitIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PreferredUnitIssuanceValue", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of preferred OP Units", "label": "Preferred Unit, Issuance Value", "documentation": "Preferred Unit, Issuance Value" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r321", "r333", "r344", "r348", "r349", "r350", "r351", "r352", "r353", "r356" ] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivatives Included in AOCI", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r117" ] }, "hct_LeaseIntangiblesLeaseupPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LeaseIntangiblesLeaseupPeriod", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangibles, lease-up period", "label": "Lease Intangibles, Lease-up Period", "documentation": "Lease Intangibles, Lease-up Period" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r193", "r279", "r426", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r442", "r526", "r724", "r726", "r758" ] }, "hct_RelatedPartyTransactionReductionofRealEstateCostPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionReductionofRealEstateCostPercent", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction of real estate cost percent", "label": "Related Party Transaction Reduction of Real Estate Cost Percent", "documentation": "Related Party Transaction Reduction of Real Estate Cost Percent" } } }, "auth_ref": [] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states properties are located in", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndOtherIncome", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income", "label": "Interest and Other Income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r67", "r68", "r69", "r71" ] }, "hct_MonthlyBaseManagementFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MonthlyBaseManagementFeeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly Base Management Fee", "label": "Monthly Base Management Fee [Member]", "documentation": "Monthly Base Management Fee [Member]" } } }, "auth_ref": [] }, "hct_MultiPropertyCMBSLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MultiPropertyCMBSLoanMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Multi-Property CMBS Loan", "label": "Multi-Property CMBS Loan [Member]", "documentation": "Multi-Property CMBS Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r67", "r68", "r69", "r71" ] }, "hct_LesseeOperatingLeaseLiabilitytobePaidDueafterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LesseeOperatingLeaseLiabilitytobePaidDueafterYearFour", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionBasisofCoreEarningsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionBasisofCoreEarningsPercent", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of core earnings, percent", "label": "Related Party Transaction, Basis of Core Earnings, Percent", "documentation": "Related Party Transaction, Basis of Core Earnings, Percent" } } }, "auth_ref": [] }, "hct_LIBORBasedInterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LIBORBasedInterestRateSwapMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIBOR", "label": "LIBOR Based Interest Rate Swap [Member]", "documentation": "LIBOR Based Interest Rate Swap" } } }, "auth_ref": [] }, "hct_InplaceLeasesandOtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "InplaceLeasesandOtherIntangibleAssetsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-place Leases and Other Intangible Assets", "label": "In-place Leases and Other Intangible Assets [Member]", "documentation": "In-place Leases and Other Intangible Assets [Member]" } } }, "auth_ref": [] }, "hct_GrossRevenueManagedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "GrossRevenueManagedPropertiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Revenue, Managed Properties", "label": "Gross Revenue, Managed Properties [Member]", "documentation": "Gross Revenue, Managed Properties [Member]" } } }, "auth_ref": [] }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties held for use", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Use", "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Use" } } }, "auth_ref": [] }, "hct_NoncontrollingInterestsInPropertyOwningSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NoncontrollingInterestsInPropertyOwningSubsidiaries", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails": { "parentTag": "us-gaap_MinorityInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests in property owning subsidiaries", "label": "Noncontrolling Interests In Property Owning Subsidiaries", "documentation": "Noncontrolling Interests In Property Owning Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r813", "r814", "r815", "r817", "r818", "r819", "r822", "r926", "r927", "r972", "r1000", "r1006" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r110", "r115" ] }, "hct_EconomicDependencyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "EconomicDependencyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/EconomicDependency" ], "lang": { "en-us": { "role": { "terseLabel": "Economic Dependency", "label": "Economic Dependency [Text Block]", "documentation": "Matters related to services provided by affiliate." } } }, "auth_ref": [] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate investments", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "hct_FinanceLeaseLiabilitytobePaidDueafterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "FinanceLeaseLiabilitytobePaidDueafterYearFour", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, Due after Year Four", "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "hct_SecondAmendedandRestatedAdvisoryAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SecondAmendedandRestatedAdvisoryAgreementMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Amended and Restated Advisory Agreement", "label": "Second Amended and Restated Advisory Agreement [Member]", "documentation": "Second Amended and Restated Advisory Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset in the Consolidated Balance Sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r23", "r31", "r113", "r745", "r746" ] }, "hct_RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subordinated incentive listing distribution", "label": "Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark", "documentation": "Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "hct_EarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "EarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "documentation": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "auth_ref": [] }, "hct_LimitedPartnersCapitalAccountPotentiallyRedeemableAmount": { "xbrltype": "sharesItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LimitedPartnersCapitalAccountPotentiallyRedeemableAmount", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable amount of shares (in shares)", "label": "Limited Partners' Capital Account, Potentially Redeemable Amount", "documentation": "Limited Partners' Capital Account, Potentially Redeemable Amount" } } }, "auth_ref": [] }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividendWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividendWeightedAverageGrantDateFairValue", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock dividend (in usd per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "hct_DebtInstrumentCovenantsMinimumCashCashEquivalentsandBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DebtInstrumentCovenantsMinimumCashCashEquivalentsandBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, covenant requirements, amount", "label": "Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity", "documentation": "Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionPeriodofNoticeforTermination": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionPeriodofNoticeforTermination", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of notice of termination", "label": "Related Party Transaction, Period of Notice for Termination", "documentation": "Related Party Transaction, Period of Notice for Termination" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionPropertyManagementFeesEarnedByRelatedPartyPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionPropertyManagementFeesEarnedByRelatedPartyPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property management fees", "label": "Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark", "documentation": "Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark" } } }, "auth_ref": [] }, "hct_InterestRateCapMaturingApril2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "InterestRateCapMaturingApril2024Member", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Cap Maturing April 2024", "label": "Interest Rate Cap Maturing April 2024 [Member]", "documentation": "Interest Rate Cap Maturing April 2024" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of market least intangibles", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r72", "r75" ] }, "hct_HealthcareTrustSpecialLimitedPartnershipLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "HealthcareTrustSpecialLimitedPartnershipLLCMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare Trust Special Limited Partnership, LLC", "label": "Healthcare Trust Special Limited Partnership, LLC [Member]", "documentation": "Healthcare Trust Special Limited Partnership, LLC [Member]" } } }, "auth_ref": [] }, "hct_DerivativeNotionalAmountTerminatedInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DerivativeNotionalAmountTerminatedInPeriod", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives terminated in period", "label": "Derivative, Notional Amount, Terminated In Period", "documentation": "Derivative, Notional Amount, Terminated In Period" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r171", "r418", "r549", "r920" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number or rights per share (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "hct_PreferredUnitIssuanceValueSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PreferredUnitIssuanceValueSharePrice", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred units issued (in usd per share)", "label": "Preferred Unit, Issuance Value, Share Price", "documentation": "Preferred Unit, Issuance Value, Share Price" } } }, "auth_ref": [] }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesMarketedForSale": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesMarketedForSale", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties marketed for sale", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale", "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Marketed For Sale" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r60", "r62", "r131", "r132", "r356" ] }, "us-gaap_OffMarketLeaseUnfavorable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffMarketLeaseUnfavorable", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Market lease intangible liabilities, net", "label": "Off-Market Lease, Unfavorable", "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition." } } }, "auth_ref": [ "r39" ] }, "hct_DebtInstrumentPrepaymentWrittenNoticeRequirement": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DebtInstrumentPrepaymentWrittenNoticeRequirement", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt prepayment, written notice requirement", "label": "Debt Instrument, Prepayment, Written Notice Requirement", "documentation": "Debt Instrument, Prepayment, Written Notice Requirement" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r18", "r517" ] }, "hct_SeriesAPreferredUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SeriesAPreferredUnitMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Unit", "label": "Series A Preferred Unit [Member]", "documentation": "Series A Preferred Unit" } } }, "auth_ref": [] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Contract", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r776", "r782", "r800" ] }, "hct_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "hct_ContractPurchasePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ContractPurchasePriceMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Purchase Price", "label": "Contract Purchase Price [Member]", "documentation": "Contract Purchase Price [Member]" } } }, "auth_ref": [] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangiblesAcquiredDuringThePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangiblesAcquiredDuringThePeriod", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-place leases, market leases, and other intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_MortgageNotesPayableDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageNotesPayableDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage Notes Payable, Net", "label": "Mortgage Notes Payable Disclosure [Text Block]", "documentation": "The entire disclosure for mortgage notes payable." } } }, "auth_ref": [] }, "hct_QuarterlyVariableManagementFeeBenchmarkOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "QuarterlyVariableManagementFeeBenchmarkOneMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly Variable Management Fee, Benchmark One", "label": "Quarterly Variable Management Fee, Benchmark One [Member]", "documentation": "Quarterly Variable Management Fee, Benchmark One [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r188" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r871" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerAddressMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Former Address", "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r831", "r854" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r194", "r195", "r196", "r241", "r242", "r243", "r315", "r427", "r428", "r429", "r431", "r434", "r439", "r441", "r639", "r640", "r641", "r642", "r798", "r905", "r922" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r167", "r264", "r597", "r613" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r871" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r267" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r410", "r452", "r457", "r532", "r578", "r794", "r795", "r800", "r801", "r802" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r871" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r410", "r452", "r457", "r532", "r577", "r800", "r801", "r802" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from tenants", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r263", "r280", "r322", "r323", "r340", "r345", "r346", "r352", "r354", "r356", "r357", "r383", "r384", "r386", "r387", "r388", "r390", "r392", "r394", "r395", "r539", "r600", "r937" ] }, "us-gaap_MinorityInterestInOperatingPartnerships": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestInOperatingPartnerships", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails": { "parentTag": "us-gaap_MinorityInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Non-controlling Interests in the OP", "label": "Noncontrolling Interest in Operating Partnerships", "documentation": "Carrying amount of the equity interests owned by noncontrolling partners in an operating partnership included in the entity's consolidated financial statements." } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating (loss) income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r321", "r341", "r347", "r350", "r789" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r410", "r452", "r453", "r454", "r455", "r456", "r457", "r532", "r579", "r794", "r795", "r800", "r801", "r802" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r238", "r253", "r256", "r272", "r280", "r289", "r297", "r298", "r321", "r341", "r347", "r350", "r357", "r383", "r384", "r386", "r387", "r388", "r390", "r392", "r394", "r395", "r510", "r513", "r514", "r529", "r539", "r600", "r610", "r647", "r697", "r719", "r720", "r789", "r808", "r809", "r825", "r916", "r937" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r872" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r299", "r310", "r311", "r312" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in usd per share)", "periodEndLabel": "Ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r475", "r476" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r44", "r255", "r257", "r265", "r598", "r614" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r493" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r872" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r479" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/CoverPage", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r233", "r241", "r242", "r243", "r280", "r303", "r304", "r307", "r309", "r315", "r316", "r357", "r383", "r386", "r387", "r388", "r394", "r395", "r427", "r428", "r431", "r434", "r441", "r539", "r639", "r640", "r641", "r642", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r678", "r698", "r721", "r752", "r753", "r754", "r755", "r756", "r905", "r922", "r929" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r760" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r479" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r872" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r60", "r62", "r131", "r132", "r356", "r760", "r907" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and transaction related", "negatedTerseLabel": "Acquisition and transaction related", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r95" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r103", "r200", "r253", "r256", "r297", "r298", "r611", "r916" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r59", "r60", "r62", "r63", "r131", "r203", "r760" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r875" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r874" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r878" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r876" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r145", "r198", "r635", "r636" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r807" ] }, "us-gaap_DerivativeFinancialInstrumentsAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFinancialInstrumentsAssetsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets, at fair value", "label": "Derivative Financial Instruments, Assets [Member]", "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r877" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r877" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r495", "r496", "r497", "r648", "r926", "r927", "r928", "r972", "r1006" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnSecurities", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Not Offset in the Consolidated Balance Sheet, Financial Instruments", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset", "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r29", "r247", "r780" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Base Rent Payments", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r979" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r232", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r775" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r979" ] }, "us-gaap_MortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgagesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsCarryingAmountsandFairValuesofDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgages", "netLabel": "Mortgage Notes Payable", "verboseLabel": "Gross mortgage notes payable and mortgage premium and discounts, net", "label": "Mortgages [Member]", "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r10", "r22" ] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r6", "r22", "r237" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r204", "r240", "r280", "r321", "r342", "r348", "r357", "r383", "r384", "r386", "r387", "r388", "r390", "r392", "r394", "r395", "r511", "r515", "r539", "r603", "r689", "r811", "r826", "r937", "r938", "r984" ] }, "hct_SubjectFeesTransitionFeeNotinExcessoftheProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SubjectFeesTransitionFeeNotinExcessoftheProductMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subject Fees (Transition Fee Not in Excess of the Product)", "label": "Subject Fees (Transition Fee Not in Excess of the Product) [Member]", "documentation": "Subject Fees (Transition Fee Not in Excess of the Product) [Member]" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r161", "r811", "r1003" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r899" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amounts representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r562" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r40", "r234", "r259", "r260", "r261", "r286", "r287", "r288", "r290", "r296", "r298", "r314", "r358", "r359", "r442", "r495", "r496", "r497", "r506", "r507", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r540", "r542", "r543", "r544", "r545", "r546", "r565", "r629", "r630", "r631", "r648", "r721" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from mortgage notes payable", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r46" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total present value of minimum lease payments", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r553", "r562" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions in excess of accumulated earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r234", "r286", "r287", "r288", "r290", "r296", "r298", "r358", "r359", "r495", "r496", "r497", "r506", "r507", "r519", "r521", "r522", "r524", "r527", "r629", "r631", "r648", "r1006" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt financing wrote off", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r178" ] }, "us-gaap_LimitedPartnersCapitalAccountByClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedPartnersCapitalAccountByClassAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited Partners' Capital Account by Class [Axis]", "label": "Limited Partners' Capital Account by Class [Axis]", "documentation": "Information by type or class of limited partnership interests." } } }, "auth_ref": [ "r88" ] }, "us-gaap_LimitedPartnersCapitalAccountClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedPartnersCapitalAccountClassDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited Partners' Capital Account, Class [Domain]", "label": "Limited Partners' Capital Account, Class [Domain]", "documentation": "Description of the type or class of limited partner's capital account." } } }, "auth_ref": [ "r88" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r574", "r576" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r562" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r234", "r259", "r260", "r261", "r286", "r287", "r288", "r290", "r296", "r298", "r314", "r358", "r359", "r442", "r495", "r496", "r497", "r506", "r507", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r540", "r542", "r543", "r544", "r545", "r546", "r565", "r629", "r630", "r631", "r648", "r721" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "verboseLabel": "Unrealized Gain (loss) on Designated Derivative", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r16", "r43", "r520", "r523", "r565", "r629", "r630", "r914", "r915", "r916", "r926", "r927", "r928" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income and franchise taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r220", "r231", "r297", "r298", "r329", "r501", "r508", "r616" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Preferred stock issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r47" ] }, "us-gaap_AboveMarketLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AboveMarketLeasesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Above-market lease assets", "label": "Above Market Leases [Member]", "documentation": "Leases acquired as part of a real property acquisition at above market lease rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares of Common Stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r901" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r977" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r931" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_LeasingCommissionsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasingCommissionsExpense", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasing commissions", "label": "Leasing Commissions Expense", "documentation": "Amount of commissions expense incurred because the lessor of real estate obtained a lessee for a rental property through a real estate agent." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Finance Lease Maturities", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r977" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r458", "r569", "r570", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r672", "r673", "r674", "r675", "r676", "r694", "r696", "r728", "r983" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r803", "r804" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate, percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r561", "r810" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r281", "r282", "r569", "r570", "r571", "r572", "r672", "r673", "r674", "r675", "r676", "r694", "r696", "r728" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r259", "r260", "r540", "r542", "r543", "r544", "r545", "r546" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r898" ] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from minority interests", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r15", "r87", "r199" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r803", "r804" ] }, "hct_CommonOperatingPartnershipUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CommonOperatingPartnershipUnitMember", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsBalanceSheetBreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common OP Unit", "label": "Common Operating Partnership Unit [Member]", "documentation": "Common Operating Partnership Unit" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r562" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Mortgage premiums and discounts, net", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r134", "r135", "r136", "r137", "r138", "r940" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r22", "r34", "r146", "r147", "r148", "r149", "r150", "r151", "r153", "r154", "r155", "r190" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r813", "r814", "r817", "r818", "r819", "r822", "r1000", "r1006" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r696", "r771", "r816", "r942", "r980", "r981", "r983" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 }, "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails": { "parentTag": "hct_LongtermLineofCreditIncludingFinancingCosts", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred financing costs, net of accumulated amortization", "negatedTerseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r136", "r940" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r977" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Operating Lease Maturities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r977" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property operating and maintenance", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r976" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director", "label": "Director [Member]" } } }, "auth_ref": [ "r932", "r1002" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r564" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r564" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r184", "r277" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r564" ] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetAssetLiability", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Fair Value, Net Asset (Liability)", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Issue Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r259", "r260", "r540", "r542", "r543", "r544", "r545", "r546" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r326" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r564" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r564" ] }, "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDerivativeInstrumentFinancingActivities", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from termination of derivative instruments", "label": "Proceeds from Derivative Instrument, Financing Activities", "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [ "r269", "r783" ] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions declared in common stock", "label": "Stock Issued During Period, Value, Stock Dividend", "documentation": "Value of stock issued to shareholders as a dividend during the period." } } }, "auth_ref": [ "r17", "r40", "r196" ] }, "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash from termination", "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities", "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [] }, "hct_OperatingLeaseNetInvestmentinLeaseCreditLossExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "OperatingLeaseNetInvestmentinLeaseCreditLossExpenseReversal", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "label": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal)", "documentation": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal)" } } }, "auth_ref": [] }, "hct_AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Realty Capital Healthcare II Special Limited Partnership, LLC", "label": "American Realty Capital Healthcare II Special Limited Partnership, LLC [Member]", "documentation": "American Realty Capital Healthcare II Special Limited Partnership, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_LeasesAcquiredInPlaceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAcquiredInPlaceMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-place lease assets", "label": "Leases, Acquired-in-Place [Member]", "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired." } } }, "auth_ref": [] }, "hct_LimitedPartnersCapitalAccountUnitsRedemptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LimitedPartnersCapitalAccountUnitsRedemptionPeriod", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited partner units, redemption period", "label": "Limited Partners' Capital Account, Units, Redemption Period", "documentation": "Limited Partners' Capital Account, Units, Redemption Period" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during period, shares, new issues (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r17", "r159", "r160", "r196", "r639", "r721", "r753" ] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total intangible assets and liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain (loss) reclassified from accumulated other comprehensive income into income as interest expense", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r251", "r252" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain recognized in accumulated other comprehensive income on interest rate derivatives", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r30", "r43", "r260", "r540", "r543", "r546", "r914" ] }, "hct_VariableManagementIncentiveFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "VariableManagementIncentiveFeeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Management - Incentive Fee", "label": "Variable Management - Incentive Fee [Member]", "documentation": "Variable Management - Incentive Fee [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r73", "r74", "r583" ] }, "hct_HealthcareTrustOperatingPartnershipL.P.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "HealthcareTrustOperatingPartnershipL.P.Member", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsSummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare Trust Operating Partnership, L.P.", "label": "Healthcare Trust Operating Partnership, L.P. [Member]", "documentation": "Healthcare Trust Operating Partnership, L.P. [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r828" ] }, "hct_CommonShareEquivalentsSharesApprovedforIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CommonShareEquivalentsSharesApprovedforIssuance", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares approved for issuance (in shares)", "label": "Common Share Equivalents, Shares Approved for Issuance", "documentation": "Common Share Equivalents, Shares Approved for Issuance" } } }, "auth_ref": [] }, "hct_AdjustmentstoAdditionalPaidinCapitalRebalancingOfOwnershipPercentage": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AdjustmentstoAdditionalPaidinCapitalRebalancingOfOwnershipPercentage", "crdr": "credit", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Rebalancing of ownership percentage", "label": "Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage", "documentation": "Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on designated derivatives", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r251" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAOCIDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount of gain reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r30", "r43", "r260", "r540", "r545", "r546", "r914" ] }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesDisposed": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesDisposed", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties disposed", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Disposed", "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Disposed" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfTreasuryStockByClassTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cumulative Share Repurchases", "label": "Class of Treasury Stock [Table Text Block]", "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r89", "r90", "r91", "r92" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ] }, "hct_SpecialLimitedPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "SpecialLimitedPartnerMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Special Limited Partner", "label": "Special Limited Partner [Member]", "documentation": "Special Limited Partner [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ] }, "hct_FoxRidgeSeniorLivingatChenalLittleRockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "FoxRidgeSeniorLivingatChenalLittleRockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fox Ridge Chenal - Little Rock, AR", "label": "Fox Ridge Senior Living at Chenal - Little Rock [Member]", "documentation": "Fox Ridge Senior Living at Chenal - Little Rock [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of real estate investments", "label": "Proceeds from Sale, Real Estate, Held-for-Investment", "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period." } } }, "auth_ref": [ "r179" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r258", "r499", "r500", "r502", "r503", "r504", "r505", "r638" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "hct_MOBPropertyIllinoisSkilledNursingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "MOBPropertyIllinoisSkilledNursingFacilitiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Illinois skilled nursing facilities", "label": "M O B Property Illinois Skilled Nursing Facilities [Member]", "documentation": "M O B Property Illinois Skilled Nursing Facilities [Member]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Abstract]", "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "hct_AboveandBelowMarketLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "AboveandBelowMarketLeasesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Above and Below Market Leases", "label": "Above and Below Market Leases [Member]", "documentation": "Above and Below Market Leases [Member]" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Non-controlling Interest", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "terseLabel": "Unvested restricted stock (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r19", "r20" ] }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend": { "xbrltype": "sharesItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock dividend (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionDistributionUponNonrenewalOfAdvisoryAgreementPercentageOfBenchmark": { "xbrltype": "percentItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionDistributionUponNonrenewalOfAdvisoryAgreementPercentageOfBenchmark", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesandParticipationsPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution upon nonrenewal of advisory agreement", "label": "Related Party Transaction, Distribution Upon Nonrenewal of Advisory Agreement, Percentage of Benchmark", "documentation": "Related Party Transaction, Distribution Upon Nonrenewal of Advisory Agreement, Percentage of Benchmark" } } }, "auth_ref": [] }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "crdr": "debit", "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total tangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r70", "r172" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "hct_PreferredStockAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PreferredStockAdditionalSharesAuthorized", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, additional shares authorized (in shares)", "label": "Preferred Stock, Additional Shares Authorized", "documentation": "Preferred Stock, Additional Shares Authorized" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityCumulativeShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average Price per Share (in usd per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r89" ] }, "hct_LaSallePropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LaSallePropertiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LaSalle Properties", "label": "LaSalle Properties [Member]", "documentation": "LaSalle Properties" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued through distribution reinvestment plan (in shares)", "label": "Stock Issued During Period, Shares, Dividend Reinvestment Plan", "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity." } } }, "auth_ref": [ "r17", "r721", "r754" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r898" ] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Mortgage notes payable, net", "label": "Secured Debt", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r33", "r207", "r996" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "hct_ContractTerminationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "ContractTerminationCosts", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination costs incurred", "label": "Contract Termination Costs", "documentation": "Contract Termination Costs" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityCumulativeShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of Shares Repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r17", "r160", "r196" ] }, "hct_RentalIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RentalIncomeMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental Income", "label": "Rental Income [Member]", "documentation": "Rental Income [Member]" } } }, "auth_ref": [] }, "hct_LongtermLineofCreditIncludingFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "LongtermLineofCreditIncludingFinancingCosts", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Term Loan, net", "label": "Long-term Line of Credit, Including Financing Costs", "documentation": "Long-term Line of Credit, Including Financing Costs" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash\u00a0provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "hct_GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties", "label": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member]", "documentation": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "hct_NumberOfSeniorHousingCommunitiesManagedByTerminatedContractor": { "xbrltype": "integerItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "NumberOfSeniorHousingCommunitiesManagedByTerminatedContractor", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of senior housing communities managed by terminated contractor", "label": "Number Of Senior Housing Communities Managed By Terminated Contractor", "documentation": "Number Of Senior Housing Communities Managed By Terminated Contractor" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "hct_QuarterlyVariableManagementFeeBenchmarkTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "QuarterlyVariableManagementFeeBenchmarkTwoMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly Variable Management Fee, Benchmark Two", "label": "Quarterly Variable Management Fee, Benchmark Two [Member]", "documentation": "Quarterly Variable Management Fee, Benchmark Two [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Not Offset in the Consolidated Balance Sheet, Cash Collateral Received", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r29", "r123", "r247", "r780" ] }, "hct_PreferredUnitFaceValueSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "PreferredUnitFaceValueSharePrice", "presentation": [ "http://www.thehealthcarereit2.com/role/NoncontrollingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred unit, face value (in usd per share)", "label": "Preferred Unit, Face Value, Share Price", "documentation": "Preferred Unit, Face Value, Share Price" } } }, "auth_ref": [] }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyCappedReimbursementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyCappedReimbursementAmount", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed component", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount", "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "hct_CommonStockStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "CommonStockStockDividendsPerShareDeclared", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions declared in common stock (in usd per share)", "label": "Common Stock, Stock Dividends, Per Share, Declared", "documentation": "Common Stock, Stock Dividends, Per Share, Declared" } } }, "auth_ref": [] }, "hct_UnencumberedPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "UnencumberedPropertiesMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unencumbered Properties", "label": "Unencumbered Properties [Member]", "documentation": "Unencumbered Properties [Member]" } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Derivative Instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r18", "r104", "r105", "r107", "r108", "r112", "r116", "r120", "r121" ] }, "hct_DerivativeNotionalAmountRenewed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "DerivativeNotionalAmountRenewed", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount renewed", "label": "Derivative, Notional Amount Renewed", "documentation": "Derivative, Notional Amount Renewed" } } }, "auth_ref": [] }, "us-gaap_DerivativePremiumPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativePremiumPaid", "crdr": "debit", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative, premium paid", "terseLabel": "Derivative, premium paid", "label": "Derivative, Premium Paid", "documentation": "Amount of premium paid on derivative." } } }, "auth_ref": [ "r910", "r911", "r1008" ] }, "hct_OperationFeesAndReimbursementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20230930", "localname": "OperationFeesAndReimbursementsMember", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total related party operation fees and reimbursements", "label": "Operation Fees and Reimbursements [Member]", "documentation": "Operation Fees and Reimbursements [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "SubTopic": "10", "Topic": "970", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482170/970-10-05-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-9" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB TOPIC 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "15", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482960/835-20-15-8" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "970", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//970/tableOfContent" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "972", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//972/tableOfContent" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "974", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//974/tableOfContent" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "976", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//976/tableOfContent" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "978", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//978/tableOfContent" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479607/944-360-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-23" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r905": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column G))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 103 0001561032-23-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001561032-23-000020-xbrl.zip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end

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